Third National Report on Human Exposure to Environmental Chemicals

July 2005

Department of Health and Human Services
Centers for Disease Control and Prevention

National Center for Environmental Health
Division of Laboratory Sciences
Atlanta, Georgia 30341-3724

NCEH Pub. No. 05-0570

Selected text revisions appear on pages 201-2
February 2006

About CDC's Environmental Health Laboratory

Using advanced laboratory science and innovative techniques, scientists in CDC's Environmental Health Laboratory at the National Center of Environmental Health (NCEH) have helped change the face of environmental public health in this country. By recognizing chemicals that enter the body from environmental exposure, by responding to terrorism and public health emergencies involving chemicals, and by improving laboratory methods to measure chemical exposure, the laboratory has greatly enhanced the understanding of chemical exposure and related health effects for the nation and around the world.

For more than three decades, laboratory scientists at NCEH have been determining which environmental chemicals enter people's bodies, how much of those chemicals are actually present, and how the amounts of those chemicals may be related to health effects. The highly trained scientists measure levels of chemicals directly in people's blood or urine. Rather than predicting how much of a substance gets into people from estimates based on measurements in food, water, air, and other media, NCEH's laboratory scientists have taken out the guesswork by measuring low levels of chemicals that are actually in people's bodies. And they do so with precision, speed, and accuracy, measuring many chemicals in a very small amount—often a teaspoon or less—of blood or urine.

Contents

Introduction

The *National Report on Human Exposure to Environmental Chemicals* provides an ongoing assessment of the exposure of the U.S. population to environmental chemicals using biomonitoring. The *Second National Report on Human Exposure to Environmental Chemicals (Second Report)* was released in 2003 and presented biomonitoring exposure data for 116 environmental chemicals for the civilian, noninstitutionalized U.S. population over the 2-year period 1999-2000. This *Third Report* presents similar exposure data for the U.S. population for 148 environmental chemicals over the period 2001-2002. The *Third Report* also includes the data from the *Second Report*.

Chemicals or their metabolites were measured in blood and urine samples from a random sample of participants from the National Health and Nutrition Examination Survey (NHANES) conducted by CDC's National Center for Health Statistics. NHANES is a series of surveys designed to collect data on the health and nutritional status of the U.S. population.

For this *Report*, an environmental chemical means a chemical compound or chemical element present in air, water, food, soil, dust or other environmental media (e.g., consumer products). Biomonitoring is the assessment of human exposure to chemicals by measuring the chemicals or their metabolites in human specimens such as blood or urine. A metabolite is chemical alteration of the original compound produced by body tissues. Blood and urine levels reflect the amount of the chemical that actually gets into the body from the environment.

Table 1 lists the chemicals measured in the *Second* and *Third Reports* and the years these chemicals were measured.

The new chemicals for the *Third Report* are—
- Pyrethroid insecticides.
- Additional polycyclic aromatic hydrocarbons (including benzo-[a]-pyrene).
- Aldrin, endrin, dieldrin.
- Additional phthalate metabolites.
- Additional pesticides and herbicides.
- Additional dioxins, furans, and polychlorinated biphenyls (PCBs).

We have not performed any analyses for differences in results between the 1999-2000 and 2001-2002 survey periods. As additional *Reports* are released every 2 years, it will become possible to analyze trends. Details on data analysis are presented in the section titled "Data Sources and Analysis."

Table 1. Chemicals Measured in the *Second* and *Third Reports*

Chemical	1999-2000	2001-2002
Metals		
Antimony	•	•
Barium	•	•
Beryllium	•	•
Cadmium	•	•
Cesium	•	•
Cobalt	•	•
Lead	•	•
Mercury	•	•
Molybdenum	•	•
Platinum	•	•
Tungsten	•	•
Thallium	•	•
Uranium	•	•
Tobacco Smoke		
Cotinine	•	•
Phytoestrogens		
Daidzein	•	•
Enterodiol	•	•
Enterolactone	•	•
Equol	•	•
Genistein	•	•
O-Desmethylangolensin	•	•

Chemical	1999-2000	2001-2002
Polycyclic Aromatic Hydrocarbons		
1-Hydroxybenz[a]anthracene	•	•
3-Hydroxybenz[a]anthracene and 9-Hydroxybenz[a]anthracene	•	•
1-Hydroxybenzo[c]phenanthrene	•	•
2-Hydroxybenzo[c]phenanthrene	•	•
3-Hydroxybenzo[c]phenanthrene	•	•
1-Hydroxychrysene		•
2-Hydroxychrysene		•
3-Hydroxychrysene	•	•
4-Hydroxychrysene		•
6-Hydroxychrysene	•	•
3-Hydroxyfluoranthene	•	
2-Hydroxyfluorene	•	•
3-Hydroxyfluorene	•	•
9-Hydroxyfluorene		•
1-Hydroxyphenanthrene	•	•
2-Hydroxyphenanthrene	•	•
3-Hydroxyphenanthrene	•	•
4-Hydroxyphenanthrene		•
9-Hydroxyphenanthrene		•
1-Hydroxypyrene	•	•
3-Hydroxybenzo[a]pyrene		•
1-Hydroxynapthalene		•
2-Hydroxynapthalene		•

Chemical	1999-2000	2001-2002
Polychlorinated Dibenzo-p-dioxins, Dibenzofurans, Coplanar and Mono-Ortho-Substituted Biphenyls		
1,2,3,4,6,7,8,9-Octachlorodibenzo-*p*-dioxin (OCDD)	•	•
1,2,3,4,6,7,8-Heptachlorodibenzo-*p*-dioxin (HpCDD)	•	•
1,2,3,4,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD)		•
1,2,3,6,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD)	•	•
1,2,3,7,8,9-Hexachlorodibenzo-*p*-dioxin (HxCDD)	•	•
1,2,3,7,8-Pentachlorodibenzo-*p*-dioxin (PeCDD)	•	•
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD)	•	•
1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF)	•	•
1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF)	•	•
1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF)		•
1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF)	•	•
1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF)	•	•
1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF)	•	•
1,2,3,7,8-Pentachlorodibenzofuran (PeCDF)	•	•
2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF)	•	•
2,3,4,7,8-Pentachlorodibenzofuran (PeCDF)	•	•
2,3,7,8-Tetrachlorodibenzofuran (TCDF)	•	•
2,4,4'-Trichlorobiphenyl (PCB 28)	•	
2,3',4,4'-Tetrachlorobiphenyl (PCB 66)	•	•
2,4,4',5-Tetrachlorobiphenyl (PCB 74)	•	•
3,4,4',5-Tetrachlorobiphenyl (PCB 81)	•	•
2,3,3',4,4'-Pentachlorobiphenyl (PCB 105)	•	•
2,3',4,4',5-Pentachlorobiphenyl (PCB 118)	•	•
3,3',4,4',5-Pentachlorobiphenyl (PCB 126)	•	•
2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156)	•	•
2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157)	•	•
2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167)	•	•
3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169)	•	•
2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189)		•
Non-dioxin-like Polychlorinated Biphenyls		
2,2',5,5'-Tetrachlorobiphenyl (PCB 52)	•	•
2,2',3,4,5'-Pentachlorobiphenyl (PCB 87)		•
2,2',4,4',5-Pentachlorobiphenyl (PCB 99)	•	•
2,2',4,5,5'-Pentachlorobiphenyl (PCB 101)	•	•
2,3,3',4',6-Pentachlorobiphenyl (PCB 110)		•
2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128)	•	•
2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138&158)	•	•
2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146)	•	•
2,2',3,4',5',6'-Hexachlorobiphenyl (PCB 149)		•
2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151)		•
2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153)	•	•
2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170)	•	•
2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172)	•	•
2,2',3,3',4,5',6'-Heptachlorobiphenyl (PCB 177)	•	•
2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178)	•	•
2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180)	•	•
2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183)	•	•
2,2',3,4',5,5',6-Heptachlorobiphenyl (PCB 187)	•	•
2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194)		•
2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195)		•
2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB196&203)		•
2,2',3,3',4,5,5',6-Octachlorobiphenyl (PCB 199)		•
2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206)		•
Other Pesticides		
N,N-Diethyl-3-methylbenzamide	•	•
ortho-Phenylphenol	•	•
2,5-Dichlorophenol	•	•
Carbamate Pesticides		
2-Isopropoxyphenol	•	•
Carbofuranphenol	•	•

Chemical	1999-2000	2001-2002
Phthalates		
Mono-methyl phthalate		•
Mono-ethyl phthalate	•	•
Mono-n-butyl phthalate	•	•
Mono-isobutyl phthalate		•
Mono-benzyl phthalate	•	•
Mono-cyclohexyl phthalate	•	•
Mono-2-ethylhexyl phthalate	•	•
Mono-(2-ethyl-5-oxohexyl) phthalate		•
Mono-(2-ethyl-5-hydroxyhexyl) phthalate		•
Mono-n-octyl phthalate	•	•
Mono-(3-carboxypropyl) phthalate		•
Mono-isononyl phthalate	•	•
Organochlorine Pesticides		
Hexachlorobenzene	•	•
Beta-hexachlorocyclohexane	•	•
Gamma-hexachlorocyclohexane	•	•
Pentachlorophenol	•	•
2,4,5-Trichlorophenol	•	•
2,4,6-Trichlorophenol	•	•
p,p'-DDT	•	•
p,p'-DDE	•	•
o,p'-DDT	•	•
Oxychlordane	•	•
trans-Nonachlor	•	•
Heptachlor epoxide	•	•
Mirex	•	•
Aldrin		•
Dieldrin		•
Endrin		•
Organophosphate Insecticides: Dialkyl Phosphate Metabolites		
Dimethylphosphate	•	•
Dimethylthiophosphate	•	•
Dimethyldithiophosphate	•	•
Diethylphosphate	•	•
Diethylthiophosphate	•	•
Diethyldithiophosphate	•	•
Organophosphate Insecticides: Specific Metabolites		
Malathion dicarboxylic acid	•	
para-Nitrophenol	•	•
3,5,6-Trichloro-2-pyridinol	•	•
2-Isopropyl-4-methyl-6-hydroxypyrimidine	•	•
2-(Diethylamino)-6-methylpyrimidin-4-ol/one		•
3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol		•
Herbicides		
2,4,5-Trichlorophenoxyacetic acid	•	•
2,4-Dichlorophenoxyacetic acid	•	•
2,4-Dichlorophenol	•	•
Alachlor mercapturate	•	
Atrazine mercapturate	•	•
Acetochlor mercapturate		•
Metolachlor mercapturate		•
Pyrethroid Pesticides		
4-Fluoro-3-phenoxybenzoic acid		•
cis-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid		•
trans-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid		•
cis-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid		•
3-Phenoxybenzoic acid		•

Public Health Uses of the *Report*

The overall purpose of the *Report* is to provide unique exposure information to scientists, physicians, and health officials to help prevent disease that results from exposure to environmental chemicals. Specific public health uses of the exposure information in the *Third Report* are—

- To determine which chemicals get into Americans and at what concentrations.
- For chemicals with a known toxicity level, to determine the prevalence of people with levels above those toxicity levels.
- To establish reference ranges that can be used by physicians and scientists to determine whether a person or group has an unusually high exposure.
- To assess the effectiveness of public health efforts to reduce exposure of Americans to specific chemicals.
- To determine whether exposure levels are higher among minorities, children, women of childbearing age, or other potentially vulnerable groups.
- To track, over time, trends in levels of exposure of the population.
- To set priorities for research on human health effects.

Data Presented for Each Environmental Chemical

The Report presents tables of descriptive statistics on the distribution of blood or urine levels for each environmental chemical. Statistics include unadjusted geometric means and percentiles with confidence intervals.

Geometric means are calculated by taking the log of each concentration, then calculating the mean of those log values, and finally, taking the antilog of that mean (the calculation can be done using any log base, such as 10 or e). A geometric mean provides a better estimate of central tendency for data that are distributed with a long tail at the upper end of the distribution. This type of distribution is common when measuring environmental chemicals in blood or urine. The geometric mean is influenced less by high values than is the arithmetic mean.

Percentiles (50th, 75th, 90th, and 95th) are given to provide additional information about the shape of the distribution. In the *Third Report*, 10th and 25th percentiles are no longer included in order to provide adequate space in the tables to cover multiple years of data. Many of the tables in the *Report* are heavily filled with data. For tables with data entered for the 50th, 90th, and 95th

percentiles, figures showing these percentiles have also been included to help readers visualize the analytical results. Vertical lines above and below the point estimate of the percentile in these graphs represent the 95% confidence interval, which gives an estimate of uncertainty for that percentile. Percentile estimates for both survey periods are plotted.

For urine measurements, data are shown for the both the concentration in urine and the concentration corrected for urine-creatinine level. Serum measurements for chemicals that concentrate in lipid (e.g., dioxins, furans, PCBs, organochlorine pesticides) are presented per gram of total lipid in the serum and also per whole weight of serum.

General information is provided for each chemical that also aids the interpretation of levels.

A brief overview of information about each chemical is provided in the text to address common uses, sources of human exposure, disposition in the body, and known human health effects or major consistent effects in animals. Additionally, studies from other populations where blood and urine levels are available are presented for comparison.

The text also discusses briefly differences among demographic groups obtained by comparing the geometric means adjusted for the demographic covariates of age, gender, race/ethnicity, and when applicable, urinary creatinine, serum cotinine, or a lipid level. These adjusted geometric means are not shown in the tables. See the section titled "Data Sources and Data Analysis" for more details.

Interpreting *Report* Exposure Data: Important Factors

The survey design provides estimates for the U.S. population.

NHANES is designed to provide estimates for the civilian, noninstitutionalized U.S. population. The NHANES design does not select or exclude participants on the basis of their potential for low or high exposure to a chemical. The current design does not permit examination of exposure levels by locality, state, or region; seasons of the year; proximity to sources of exposure; or use of particular products. For example, it is not possible to extract a subset of the data and examine levels of blood lead that represent levels in a particular state's population.

Data from earlier *Reports* are included in the Third *Report*.

The *Third Report* includes data from the *First* and *Second Report*s in the tables and charts. One exception is that 10th and 25th percentiles are no longer included in the *Report* because of space limitations in the tables. Each chemical has 50th, 75th, 90th, and 95th percentiles included in the tables along with the unadjusted geometric means and sample sizes for the survey periods (i.e., 1999-2000 and 2001-2002) for which that chemical was analyzed. Current plans are to release future *Reports* of the exposure of the U.S. population to cover 2-year periods (e.g., 2003-2004, 2005-2006, 2007-2008).

Statistical tests for significance of trends over time should await additional data from future *Reports*. More detailed research analyses of the data in the *Report* is encouraged.

We have not performed statistical tests for trends over time given that data are available only for the 1999-2000 and 2001-2002 survey periods. New data will be released for the U.S. population every 2 years, with the next release covering the survey period 2003-2004. With additional data points it will be possible to describe patterns over time and in some cases test for trends. We plan to investigate trends in future *Reports* for chemicals that have at least 3 survey periods

More in-depth statistical analysis, including additional covariates, interactions and predictive variables, are beyond the scope of this document. We hope that scientists will be stimulated to examine the data further through analysis of the raw data available at http://www.cdc.gov/nchs/nhanes.htm.

Research studies, separate from the *Report*, are required to determine which blood or urine levels are safe and which are associated with disease.

The measurement of an environmental chemical in a person's blood or urine does not by itself mean that the chemical causes disease. Advances in analytical methods allow us to measure low levels of environmental chemicals in people, but separate studies of varying exposure levels and health effects are needed to determine which blood or urine levels result in disease. These studies must also consider other factors such as duration of exposure. The *Third Report* does not present new data on health risks from different exposures.

For some environmental chemicals, such as lead, research studies have given us a good understanding of the health risks associated with different blood lead levels. However, for many environmental chemicals, we need more research to assess health risks from different blood or urine levels. The results shown in the *Third Report* should help prioritize and foster research on human health risks that result from exposure to environmental chemicals.

Not all the chemicals in the *Report* are measured in the same individuals. Therefore, it is not possible to determine how many of the 148 chemicals were found at detectable levels in a given person. As noted above, the presence of a chemical does not imply disease. The levels or concentrations of the chemical are more important determinants of the relation to disease, when established in appropriate research studies, than the detection or presence of a chemical.

For more information about exposure to environmental chemicals, see the section titled "Toxicology and Health-Risk Information," which includes Internet reference sites. Each environmental chemical can be searched in databases at these Web sites using its chemical name or the Chemical Abstract Service (CAS) number, which is provided in the *Third Report*. The Agency for Toxic Substances and Disease Registry's (ATSDR) Toxicological Profiles and ToxFAQs provide good summaries of toxicology information as well as answers to common questions about exposure and health effects.

Blood and urine levels of a chemical should not be confused with levels of the chemical in air, water, food, soil, or dust.

Concentrations of environmental chemicals in blood or urine are not the same as those in air, water, food, soil, or dust. For example, a chemical concentration of 10 µg/L in water does not produce a level of 10 µg/L in blood or urine. Blood or urine levels may reflect exposure from one or more sources, including air, water, food, soil, and dust.

Levels of a chemical in blood and urine are determined by how much of the chemical has entered the body through all routes of exposure, including ingestion, inhalation, or dermal absorption, and how the chemical is distributed in body tissues, transformed into metabolites, and eliminated from the body. Although the levels in the blood and urine are measures of the amount of a chemical that has entered the body by all routes of exposure, the blood or urine level alone does not determine which exposure source or which route of

exposure has occurred. Except for metals, most measurements in urine quantify chemical metabolites.

Biomonitoring Exposure Measurements

The blood and urine exposure measurements presented in the *Third Report* were made at CDC's Environmental Health Laboratory (Division of Laboratory Sciences, National Center for Environmental Health). The analytical methods used for measuring the environmental chemicals or their metabolites in blood and urine were based on isotope dilution mass spectrometry, inductively coupled plasma mass spectrometry, or graphite furnace atomic absorption spectrometry. References for the analytical methods used to measure the different chemicals are provided in Appendix B. Laboratory measurements undergo extensive quality control and quality assurance review, including tolerance limits for operational parameters, the measurement of quality control samples in each analytical run to detect unacceptable performance in accuracy or precision, and verification of traceable calibration materials.

For chemicals measured in urine, levels are presented two ways: per volume of urine and per gram of creatinine. Levels per gram of creatinine (i.e., creatinine-corrected) adjust for urine dilution. For example, if one person has consumed more fluids than another person, his or her urine output is likely higher and the urine more dilute than that of the latter person. Creatinine is excreted from the body at a relatively constant rate over time, so expressing the result per gram of creatinine helps adjust for the effects of urinary dilution. The range and mean of

Table 2. Units of Measurements and Conversions

Unit	Abbreviation	Value
liter	L	
deciliter	dL	10^{-1} liters
milliliter	mL	10^{-3} liters
gram	g	
milligram	mg	10^{-3} grams
microgram	µg	10^{-6} grams
nanogram	ng	10^{-9} grams
picogram	pg	10^{-12} grams
femtogram	fg	10^{-15} grams
parts-per-million	ppm	1 µg/g, or approximately 1 µg/mL or 1 mg/L
parts-per-billion	ppb	1 ng/g, or approximately 1 ng/mL or 1 µg/L
parts-per-trillion	ppt	1 pg/g, or approximately 1 pg/mL or 1 ng/L
parts-per-quadrillion	ppq	1 fg/g, or approximately 1 fg/mL or 1 pg/L

creatinine levels were 2-650 mg/dL and 136.4 mg/dL in NHANES 1999-2000, and 5-774 mg/dL and 130.6 mg/dL in NHANES 2001-2002, respectively, results that are typical for the general U.S. population (see Barr et al., 2005). Creatinine corrects for urinary dilution in individual specimens, although this dilution variability has little effect on point estimates (e.g., means, percentiles). Interpretation of creatinine corrected results should also recognize that creatinine correction can also partially adjust for differences in lean body mass or renal function among persons.

For dioxins, furans, PCBs, and organochlorine pesticides, serum levels are presented per gram of total lipid and per whole weight of serum. These compounds are lipophilic and concentrate in the body's lipid stores, including the lipid in serum. Serum levels reported per gram of total lipid reflect the amount of these compounds that are stored in body fat. Serum levels per whole weight of serum are also included to facilitate comparison with studies investigating exposure to these chemicals that have published results in these units.

Units of measurement are important. Results are reported here using standard units, generally conforming to those most commonly used in biomonitoring measurements. Useful unit conversions are presented in Table 2.

Selection of Chemicals Included in the *Report*

Chemicals in the *Report* were selected on the basis of scientific data that suggested exposure in the U.S. population; the seriousness of health effects known or suspected to result from some levels of exposure; the need to assess the efficacy of public health actions to reduce exposure to a chemical; the availability of a biomonitoring analytical method with adequate accuracy, precision, sensitivity, specificity, and throughput; the availability of adequate blood or urine samples; and the incremental analytical cost to perform the biomonitoring analysis for the chemical. The availability of biomonitoring methods with adequate performance and acceptable cost was a major consideration.

In October 2002, CDC solicited nominations for candidate chemicals or categories of chemical to include in future *Reports* (*Federal Register*, Vol. 67, No. 194, October 7, 2002) and received nominations for hundreds of chemicals. Details on the prioritization process for scoring the nominated chemicals and the resulting scores are available at www.cdc.gov/exposurereport/chemical_nominations.htm.

Data Sources and Data Analysis

The National Health and Nutrition Examination Survey (NHANES)

Biomonitoring measurements for the *Report* were made in samples from participants in NHANES. NHANES is a series of surveys conducted by CDC's National Center for Health Statistics (NCHS) that is designed to collect data on the health and nutritional status of the U.S. population. NHANES collects information about a wide range of health-related behaviors, performs a physical examination and collects samples for laboratory tests. NHANES is unique in its ability to examine public health issues in the U.S. population, such as risk factors for cardiovascular disease. Beginning in 1999, NHANES became a continuous survey, sampling the U.S. population annually and releasing the data in 2-year cycles. The sampling plan follows a complex, stratified, multistage, probability-cluster design to select a representative sample of the civilian, noninstitutionalized population in the United States.

The NHANES protocol includes a home interview followed by a standardized physical examination in a mobile examination center. As part of the examination component, blood is obtained by venipuncture for participants aged 1 year and older, and urine specimens are collected from people aged 6 years and older. Additional detailed information on the design and conduct of the NHANES survey is available at http://www.cdc.gov/nchs/nhanes.htm.

Environmental chemicals were measured in either blood or urine specimens collected as part of the examination component of NHANES. The age range for which a chemical was measured varied by chemical group. Most of the environmental chemicals were measured in randomly selected subsamples within specific age groups. Randomization of subsample selection is built into the NHANES design before sample collection begins. This subsampling was needed to ensure an adequate quantity of sample for analysis and to accommodate the throughput of the mass spectrometry analytical methods.

Age groups and sample sizes for each exposure measurement are provided in each of the tables of results. Blood lead and cadmium levels were measured in all people aged 1 year and older. Serum cotinine was measured in the entire NHANES sample for ages 3 years and older. Total blood mercury was measured in children aged 1-5 years and in women aged 16-49 years. Urine mercury was measured in women aged 16-49 years.

Metals, phthalates, polycyclic aromatic hydrocarbons (PAHs), and phytoestrogens were measured in urine from a random one-third subsample of people aged 6 years and older.

Urinary levels of herbicides, selected pesticides, and metabolites of organophosphate pesticides were measured in a random one-half subsample of children aged 6-11 years in 1999 and 2000, a random one-quarter subsample of people aged 12-59 years in 1999, and a random one-third subsample of people aged 12 years and older in 2000. These chemicals also were measured in a random one-third subsample of people aged 6 years and older in 2001 and 2002. Dioxins, furans, polychlorinated biphenyls (PCBs), and organochlorine pesticides were measured in serum from a random one-third subsample of people aged 12 years and older in 1999 and 2000. In 2001 and 2002, dioxins, furans, and coplanar PCBs were measured in a random one-third subsample of people aged 20 years and older and organochlorine pesticides and other PCBs were measured in a random one-third subsample of people aged 12 years and older.

Data Analysis

Because the NHANES sample design is complex, sample weights must be used to adjust for the unequal probability of selection into the survey. Sample weights also are used to adjust for possible bias resulting from nonresponse and are post-stratified to U.S. Census Bureau estimates of the U.S. population. Data were analyzed using the statistical software package Statistical Analysis System (SAS) (SAS Institute Inc., 2002) and the statistical software package SUDAAN (SUDAAN Release 8.0, 2001). SUDAAN uses sample weights and calculates variance estimates that account for the complex survey design.

Guidelines for the analysis of NHANES data are provided by NCHS at http://www.cdc.gov/nchs/data/nhanes/nhanes_general_guidelines_june_04.pdf. These guidelines note that the previous analysis of 1999-2000 data used a jackknife method (available within SUDAAN) for variance estimation that was based on replicate weights. To better address multiple 2-year data sets and combining 2-year data sets into 4-year data sets, NCHS developed a new approach based on masked variance units that uses a Taylor series (linearization) method that is also available in SUDAAN. More details on this approach are provided in the analytical guidelines.

In the *Third Report*, all variance estimates (both 1999-2000 and 2001-2002 data) were calculated using the Taylor series (linearization) method within SUDAAN. In the *Second Report*, 1999-2000 variance estimates were calculated using the jackknife method (See Appendix C for details). The two methods produce very similar, but not identical, variance estimates. Consequently, some confidence intervals for 1999-2000 presented in the *Second Report* will differ slightly from confidence intervals for the same time period presented in the *Third Report*.

Selected percentiles and unadjusted geometric means of analyte concentrations are presented in tables and charts. Percentile estimates were calculated using SAS Proc Univariate using weighted data. Results are shown for the total population and also by age group, gender, and race/ethnicity as defined in NHANES. For these analyses, race/ethnicity is categorized as Mexican American, non-Hispanic black, and non-Hispanic white. Other racial/ethnic groups are sampled, but the proportion of the total population represented by other racial/ethnic groups is not large enough to produce valid estimates. Other racial/ethnic groups are included in estimates that are based on the entire population sample. Age groups are shown for each chemical in the results table. Gender is coded as male or female.

In the text (not in the tables), results are presented of comparisons of geometric mean levels for different demographic groups using analysis of covariance (ANCOVA), which included as covariates age, gender, race/ethnicity, urine creatinine and serum cotinine, as appropriate. ANCOVA allows for comparison of geometric means of two demographic groups after adjusting for these covariates. For example, when comparing geometric mean blood lead levels for adolescents to those for adults, the ANCOVA would first adjust the geometric mean blood lead level for adolescents for gender, race/ethnicity, and serum cotinine and also the geometric mean blood lead level for adults for gender, race/ethnicity, and serum cotinine. The ANCOVA was performed using SUDAAN with a significance level for statistical testing of $\alpha = 0.025$. These analyses were conducted separately for each two year survey period and differences for each survey period were not statistically compared.

Urine creatinine is included as a continuous variable in the ANCOVA for chemicals measured in urine to adjust for urinary dilution. Cotinine is a major metabolite of nicotine and a good indicator of smoking status. Therefore, log cotinine is also included as a continuous variable in ANCOVA analyses of dioxins; furans; PCBs;

organochlorine pesiticides; PAHs; and the metals (lead, cadmium, mercury, antimony, barium, molybdenum, thallium) to adjust for known or probable effects of smoking on the levels of these chemicals in blood or urine, including the contribution of chemicals contained in smoke and the effect of chemicals in smoke on the metabolism of other measured chemicals. The decision to adjust for log cotinine was determined by whether log cotinine was a significant predictor of the chemical's concentration and results of research that examined cotinine as a predictive variable.

Concentrations less than the limit of detection (LOD) were assigned a value equal to the LOD divided by the square root of 2 for calculation of geometric means. The LOD is the level at which the measurement has a 95% probability of being greater than zero (Taylor, 1987). Assigning a value of the LOD divided by 2 made little difference in geometric mean estimates. Percentile estimates that are less than the LOD for the chemical analysis are reported as "< LOD." If the proportion of results below the LOD was greater than 40%, geometric means were not calculated. Appendix A contains a table of LOD values for each chemical. For the same chemical, LOD values may change over time as a result of improvements to analytical methods. One possible consequence is that results may be reported as "< LOD" in the 1999-2000 data but be reported as a concentration value above the LOD in 2001-2002 because the analytical method had improved. Thus, for proper interpretation, the LOD values in the tables of descriptive statistics tables should be referenced to the LOD table in Appendix A.

For most chemicals, the LOD is constant for each sample analyzed. For dioxins, furans, PCBs, organochlorine pesticides, and a few other pesticides, each individual sample has its own LOD. These analyses have an individual LOD for each sample, mostly because the sample volume used for analysis differed for each sample. A higher sample volume results in a lower LOD (i.e., a better ability to detect low levels). For these chemicals, the maximum LOD value is provided in the LOD table in Appendix A. The maximum LOD was the highest LOD among all the individual samples analyzed. In general, the mean LOD was about 40-50% of the maximum LOD.

The same procedure for imputing values below the LOD in calculations of geometric means was used for chemicals with individual LODs for each sample. That is, concentrations less than the individual LOD were assigned a value equal to the individual LOD divided by the square root of 2. For chemicals that had individual

sample LODs, a conservative rule was used for reporting percentiles: if any individual sample LOD in the demographic group was above the percentile estimate, the percentile estimate was not reported.

For chemicals measured in urine, separate tables are presented for the chemical concentration expressed per volume of urine (uncorrected table) and the chemical concentration expressed per gram of creatinine (creatinine corrected table). Geometric mean and percentile calculations were performed separately for each of these concentrations. LOD calculations were performed using the chemical concentration expressed per volume of urine, because this concentration determines the analytical sensitivity. For this reason, LOD results for urine measurements in Appendix A are in weight per volume of urine. In the creatinine corrected tables, a result for a geometric mean or percentile was reported as < LOD if the corresponding geometric mean or percentile was < LOD in the uncorrected table. So for example, if the 50th percentile for males was < LOD in the uncorrected table, it would also be < LOD in the creatinine corrected table.

For chemicals measured in serum lipid, separate tables are presented for the chemical concentration expressed per volume of serum (lipid unadjusted table) and the chemical concentration expressed per amount of lipid (lipid adjusted table). Geometric mean and percentile calculations were performed separately for each of these concentrations. LOD calculations were performed using the chemical concentration expressed per amount of lipid, because this concentration determines the analytical sensitivity. For this reason, LOD results for chemicals measured in serum lipid in Appendix A are in weight per amount of lipid. In the lipid unadjusted tables, a result for a geometric mean or percentile was reported as < LOD if the corresponding geometric mean or percentile was < LOD in the lipid adjusted table.

Toxicology and Health-Risk Information

The *Third Report* presents new data on the exposure of the U.S. population to environmental chemicals. The measurement of an environmental chemical in a person's blood or urine does not by itself mean that the chemical causes disease. Advances in analytical methods allow us to measure lower and lower levels of environmental chemicals in people. Separate studies of varying exposure levels and health effects are required to determine which blood and urine levels are safe and which result in disease.

If available, generally recognized guidelines for blood or urine levels for each chemical are presented in the *Third Report* in the text discussion provided for each chemical or chemical group. These guidelines are usually from federal agencies. One exception is the American Conference of Governmental Industrial Hygienists (ACGIH), a private organization that publishes biological exposure indices (BEIs) which "generally indicate a concentration below which nearly all workers should not experience adverse health effects" (ACGIH, 2001). BEIs are blood or urine levels of a chemical that correspond to air-exposure limits for workers set by ACGIH. This organization notes that these values are for workers and that it is not appropriate to apply them to the general population. Information about the BEI level is provided here for comparison, not to imply that the BEI is a safety level for general population exposure. For most chemicals reported here, such guidelines are not available.

The *Report* also provides written information about each chemical or chemical group regarding uses, sources of human exposure, disposition in the body, and major effects, if known. In addition, selected studies have been provided, where possible, to permit comparison of blood and urine levels of a chemical in other population groups. Although the information in the text is provided as a brief overview for each chemical, it is not intended as a comprehensive review of each chemical. Generally, information was retrieved from major texts, consensus documents, and federal agency reviews, and then supplemented with published scientific investigations obtained by electronic searches in national and international databases.

Information Available on the Internet

Links to nonfederal organizations are provided solely as a service to our readers. These links do not constitute an endorsement of these organizations or their programs by CDC or the federal government. CDC is not responsible for the content of an individual organization's Web pages found at these links. For information about toxicology and health risks, see the following sites:

U.S. Government-Related Internet Links

Centers for Disease Control and Prevention (CDC) and Agency for Toxic Substances and Disease Registry (ATSDR)

- NIOSH Pocket Guide to Chemical Hazards: http://www.cdc.gov/niosh/npg/npgd0000.html
- Registry of Toxic Effects of Chemical Substances (RTECS): http://www.cdc.gov/niosh/rtecs
- Tobacco Information and Prevention Source: http://www.cdc.gov/tobacco
- National Center for Health Statistics: http://www.cdc.gov/nchs
- National Health and Nutrition Examination Survey: http://www.cdc.gov/nchs/nhanes.htm
- Childhood Lead Poisoning Prevention Program: http://www.cdc.gov/nceh/lead/lead.htm
- Pesticides and Public Health: Integrated Methods of Mosquito Management: http://www.cdc.gov/ncidod/eid/vol7no1/rose.htm
- National Institute for Occupational Safety and Health (NIOSH), Occupational Health and Safety Guidelines for Chemical Hazards: http://www.cdc.gov/niosh/81-123.html
- Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles and ToxFAQs: http://www.atsdr.cdc.gov/toxprofiles or http://www.atsdr.cdc.gov/toxfaq.html

*U.S. Department of Health and Human Services (*U.S. DHHS*)*
- Environmental Health Policy Committee: http://web.health.gov/environment

U.S. Food and Drug Administration (U.S. FDA)
- Center for Devices and Radiological Health: http://www.fda.gov/cdrh
- Center for Food Safety and Applied Nutrition: http://www.cfsan.fda.gov
- National Center for Toxicological Research: http://www.fda.gov/nctr

National Institutes of Health (NIH)
- National Cancer Institute (NCI): http://www.nci.nih.gov
- National Institute of Child Health and Human Development (NICHD): http://www.nichd.nih.gov
- National Institute for Environmental Health Sciences (NIEHS): http://www.niehs.nih.gov
- National Toxicology Program (NTP) Chemical Health and Safety Data: http://ntp.niehs.nih.gov/index.cfm?objectid=03610FA5-C828-304B-FE31F1182E8F764C
- National Toxicology Program (NTP) Report on Carcinogens: http://ntp.niehs.nih.gov/ntpweb/index.cfm?objectid=72016262-BDB7-CEBA-FA60E922B18C2540
- Chemical Carcinogenesis Research Information System: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS
- Hazardous Susbstances Data Bank (HSDB®): http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB

U.S. Environmental Protection Agency (U.S. EPA)
- Office of Air and Radiation (OAR): http://www.epa.gov/oar
- Office of Environmental Information (OEI): http://www.epa.gov/oei
- Office of Prevention, Pesticides, and Toxic Substances (OPPTS): http://www.epa.gov/opptsmnt/index.htm
- Office of Research and Development (ORD): http://www.epa.gov/ORD
- Office of Water (OW): http://www.epa.gov/OW
- Office of Pesticide Programs: http://www.epa.gov/pesticides
- EPA Integrated Risk-Information System (IRIS): http://www.epa.gov/iris
- EPA Envirofacts: http://www.epa.gov/enviro/index_java.html
- Lead: http://www.epa.gov/OGWDW/dwh/c-ioc/lead.html

U.S. Department of Agriculture (USDA)
- Food Safety and Inspection Service: http://www.fsis.usda.gov
- USDA, Forest Service Pesticide Fact Sheets: http://www.fs.fed.us/foresthealth/pesticide

U.S. Department of Energy (DOE)
- Office of Environment, Safety and Health: http://tis.eh.doe.gov/portal/home.htm

U.S. Department of Housing and Urban Development (HUD)
- Office of Healthy Homes and Lead-Hazard Control: http://www.hud.gov/offices/lead

U.S. Consumer Product Safety Commission (CPSC)
- http://www.cpsc.gov

U.S. Department of Transportation (DOT)
- Hazardous Materials Emergency-Response Guidebook: http://hazmat.dot.gov/pubs/erg/gydebook.htm

U.S. Department of Labor, Occupational Safety and Health Administration (OSHA)
- http://www.osha.gov/index.html

Other Related Internet Sites

- American College of Occupational and Environmental Medicine: http://www.acoem.org
- Association of Occupational and Environmental Clinics: http://www.aoec.org
- Association of Public Health Laboratories: http://www.aphl.org
- Chemfinder: http://www.chemfinder.com
- International Chemical Safety Cards: http://www.ilo.org/public/english/protection/safework/cis/products/icsc/dtasht/index.htm
- International Programme on Chemical Safety (IPCS): http://www.who.int/pcs
- Material Safety Data Sheets (MSDS): www.hazard.com/msds
- National Research Council (NRC) Toxicological Effects of Methylmercury: http://books.nap.edu/books/0309071402/html/index.html

Results by Chemical Group

Metals

Antimony

CAS No. 7440-36-0

General Information

In nature, antimony can be found in ores or other minerals, often combined with oxygen to form antimony trioxide. Elemental antimony can exist in one of four valences in its various chemical and physical forms: -3, 0, +3 and +5. Antimony is used in metal alloys, storage batteries, solder, sheet and pipe metal, ammunition, metal bearings, castings, and pewter. Antimony is used as a fire-retardant in textiles and plastics. It is also used in paints, ceramics, fireworks, enamels, and glass. Stibine is a metal hydride form of antimony used in the semiconductor industry. Two antimony compounds (sodium stibogluconate and antimony potassium tartrate) are used as antiparasitic medications.

Antimony enters the environment from natural sources and from its use in industry. People are exposed to antimony primarily from food and to a lesser extent from air and drinking water. Workplace exposures occur as a result of breathing the air near industries such as smelters, coal-fired plants, and refuse incinerators that process or release antimony. Dermal contact with soil, water, or other substances containing antimony is another means of exposure.

The absorption, distribution, and excretion of antimony vary depending on its oxidation state. Urinary excretion appears to be greater for pentavalent antimony than for trivalent compounds (Elinder and Friberg, 1986). An elimination half-life of about 95 hours has been estimated after occupational exposures (Kentner et al., 1995).

Inorganic antimony salts irritate the mucous membranes, skin, and eyes. Acute inhalational exposure to antimony has been associated with irritation of the respiratory tract

Table 3. Antimony

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.132** (.120-.145)	**.130** (.120-.140)	**.210** (.200-.230)	**.330** (.300-.350)	**.420** (.390-.460)	2276
	01-02	**.134** (.126-.142)	**.130** (.120-.130)	**.180** (.180-.190)	**.260** (.240-.300)	**.340** (.320-.390)	2690
Age group							
6-11 years	99-00	**.176** (.154-.200)	**.190** (.160-.200)	**.260** (.230-.280)	**.350** (.300-.390)	**.400** (.320-.600)	316
	01-02	**.146** (.134-.160)	**.150** (.130-.160)	**.200** (.180-.210)	**.260** (.230-.310)	**.330** (.280-.380)	368
12-19 years	99-00	**.158** (.141-.178)	**.170** (.150-.180)	**.230** (.210-.270)	**.340** (.290-.420)	**.460** (.350-.510)	663
	01-02	**.169** (.156-.184)	**.150** (.140-.180)	**.230** (.220-.250)	**.350** (.320-.400)	**.460** (.360-.480)	762
20 years and older	99-00	**.123** (.112-.137)	**.110** (.100-.120)	**.190** (.180-.220)	**.310** (.280-.330)	**.420** (.390-.470)	1297
	01-02	**.128** (.119-.136)	**.120** (.120-.130)	**.170** (.160-.190)	**.240** (.220-.280)	**.330** (.280-.380)	1560
Gender							
Males	99-00	**.143** (.131-.157)	**.140** (.130-.150)	**.240** (.220-.250)	**.350** (.320-.370)	**.470** (.390-.570)	1132
	01-02	**.145** (.136-.154)	**.130** (.130-.150)	**.200** (.180-.200)	**.310** (.280-.330)	**.390** (.350-.430)	1335
Females	99-00	**.122** (.109-.137)	**.120** (.100-.130)	**.190** (.180-.220)	**.300** (.270-.330)	**.390** (.350-.460)	1144
	01-02	**.125** (.117-.133)	**.110** (.110-.120)	**.180** (.160-.190)	**.240** (.210-.260)	**.310** (.260-.350)	1355
Race/ethnicity							
Mexican Americans	99-00	**.132** (.108-.161)	**.130** (.110-.160)	**.200** (.180-.240)	**.300** (.250-.370)	**.410** (.330-.560)	787
	01-02	**.142** (.130-.154)	**.120** (.110-.130)	**.200** (.160-.220)	**.250** (.230-.300)	**.360** (.300-.390)	683
Non-Hispanic blacks	99-00	**.175** (.148-.207)	**.180** (.150-.200)	**.260** (.220-.290)	**.390** (.310-.470)	**.490** (.400-.620)	554
	01-02	**.180** (.164-.197)	**.160** (.150-.180)	**.250** (.210-.280)	**.350** (.320-.410)	**.450** (.370-.530)	667
Non-Hispanic whites	99-00	**.128** (.115-.144)	**.120** (.110-.140)	**.210** (.180-.220)	**.320** (.280-.350)	**.400** (.350-.500)	768
	01-02	**.126** (.117-.135)	**.120** (.120-.130)	**.180** (.170-.180)	**.240** (.220-.270)	**.340** (.310-.390)	1132

and impaired pulmonary function (Renes, 1953). Pulmonary edema may occur in severe cases (Cordasco et al., 1973). Dysrhythmias and T-wave changes on electrocardiogram have also been noted in people after both therapeutic (Berman, 1988; Ming-Hsin et al., 1958) and occupational exposures (Briegner et al., 1954). Ingestion of antimony may cause people to experience a metallic taste, and gastrointestinal symptoms such as vomiting, diarrhea, abdominal pain, and ulcers (Werrin, 1962). The toxicity of stibine after acute inhalational exposure has been reported to be similar to that of arsine, resulting in hemolysis with abdominal and back pain (Dernehl et al., 1944).

Workplace standards for air exposure to antimony have been established by OSHA and ACGIH. Antimony trioxide is rated as being possibly carcinogenic to humans by IARC. Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Urinary Antimony Reported in the Tables

Urinary antimony levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Previous studies reporting measurements in general populations (Minoia et al., 1990; Paschal et al., 1998) or compiled reference ranges (Hamilton et al., 1994) have found values slightly higher than those reported here, which may be due to methodologic, population, or exposure differences. Several investigations of airborne exposures to antimony in workers show urinary levels that are many times higher than those seen in this *Report*, even when exposure levels were below workplace air standards (Iavicoli et al., 2002; Kentner et al., 1995; Ludersdorf et al., 1987; Bailly et al., 1991).

Table 4. Antimony (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.124** (.108-.143)	**.119** (.102-.143)	**.185** (.163-.213)	**.274** (.233-.333)	**.382** (.333-.430)	2276
	01-02	**.126** (.119-.134)	**.120** (.115-.126)	**.173** (.162-.188)	**.265** (.242-.296)	**.364** (.320-.414)	2689
Age group							
6-11 years	99-00	**.191** (.147-.248)	**.183** (.156-.220)	**.250** (.196-.414)	**.439** (.271-.741)	**.537** (.333-1.30)	316
	01-02	**.178** (.159-.200)	**.173** (.150-.193)	**.228** (.200-.272)	**.338** (.265-.480)	**.469** (.313-.727)	368
12-19 years	99-00	**.121** (.104-.140)	**.119** (.095-.146)	**.176** (.146-.206)	**.259** (.206-.310)	**.310** (.228-.421)	663
	01-02	**.121** (.112-.131)	**.115** (.106-.127)	**.159** (.138-.186)	**.224** (.199-.245)	**.266** (.244-.310)	762
20 years and older	99-00	**.118** (.104-.135)	**.111** (.096-.136)	**.174** (.149-.209)	**.263** (.227-.320)	**.352** (.320-.391)	1297
	01-02	**.122** (.115-.129)	**.115** (.108-.121)	**.167** (.153-.179)	**.265** (.241-.296)	**.364** (.318-.405)	1559
Gender							
Males	99-00	**.112** (.099-.127)	**.108** (.095-.127)	**.164** (.146-.181)	**.226** (.204-.268)	**.319** (.235-.391)	1132
	01-02	**.114** (.107-.123)	**.108** (.103-.115)	**.153** (.138-.171)	**.228** (.205-.250)	**.333** (.272-.421)	1334
Females	99-00	**.137** (.117-.161)	**.131** (.108-.164)	**.212** (.176-.247)	**.318** (.257-.400)	**.425** (.357-.485)	1144
	01-02	**.139** (.131-.148)	**.132** (.124-.140)	**.196** (.178-.211)	**.295** (.267-.317)	**.371** (.333-.444)	1355
Race/ethnicity							
Mexican Americans	99-00	**.120** (.107-.135)	**.114** (.105-.129)	**.167** (.148-.203)	**.249** (.207-.313)	**.333** (.280-.357)	787
	01-02	**.138** (.128-.149)	**.129** (.117-.143)	**.182** (.159-.203)	**.269** (.229-.308)	**.338** (.308-.429)	682
Non-Hispanic blacks	99-00	**.114** (.099-.133)	**.112** (.098-.130)	**.163** (.144-.183)	**.236** (.195-.338)	**.339** (.255-.425)	554
	01-02	**.123** (.113-.134)	**.115** (.106-.126)	**.163** (.150-.181)	**.232** (.208-.267)	**.300** (.248-.373)	667
Non-Hispanic whites	99-00	**.129** (.109-.152)	**.124** (.102-.152)	**.195** (.167-.225)	**.298** (.239-.352)	**.400** (.333-.444)	768
	01-02	**.127** (.117-.138)	**.120** (.113-.130)	**.176** (.159-.198)	**.280** (.241-.317)	**.380** (.318-.471)	1132

Comparing Adjusted Geometric Means

Geometric mean levels of urinary antimony for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary antimony were slightly higher for the group aged 6-11 years than for either groups aged 12-19 years or 20 years and older. The group aged 12-19 years had higher levels than the group aged 20 years and older. Mexican Americans had slightly higher levels than non-Hispanic whites. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of antimony in urine does not mean that the level of antimony causes an adverse health effect. Whether antimony at the levels reported here is a cause for health concern is not yet known; more research is needed. These urine antimony data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of antimony than are found in the general population. These data will also help scientists plan and conduct research about exposure to antimony and health effects.

Figure 1. Antimony (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Barium

CAS No. 7440-39-3

General Information

Elemental barium is a silver-white metal. Barium's abundance in the earth's crust is approximately 0.05%. In nature, it combines with other chemicals such as sulfur or carbon and oxygen to form numerous barium salts. Of the various salts, approximately half are freely soluble in water, whereas the others are practically insoluble (notably barium sulfate and barium carbonate). Barium compounds are used by the oil and gas industries to make drilling muds. These compounds are also produced commercially for use in paint, bricks, tiles, glass, rubber, depilatories, fireworks, and ceramics. Medically, barium sulfate is used as a contrast medium for taking radiographs of the gastrointestinal tract. Barium salts are available for sale as rodenticides.

People can be exposed to barium in air, water, and food.

Small amounts of barium can be released into the air during mining and other industrial processes. Workers employed by industries that make or use barium compounds are exposed to barium dust. Certain foods, such as brazil nuts, are exceptionally high in barium (Genter, 2001).

The health effects of exposure to barium compounds depend on the dose, chemical form, water solubility, and route of exposure. Toxicity from soluble barium salts is rare but occurs after intentional or accidental ingestion of barium carbonate in rodenticides (Genter, 2001). Barium blocks cellular efflux of potassium resulting in extracellular profound hypokalemia. Symptoms include perioral paresthesias, vomiting, diarrhea, weakness, paralysis, hypertension, and cardiac dysrhythmias. The lethal dose of barium by ingestion is reported to be between 0.8-0.9 grams (Jourdan et al., 2001).

Table 5. Barium

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**1.50** (1.35-1.66)	**1.50** (1.30-1.70)	**3.00** (2.70-3.40)	**5.40** (4.60-6.10)	**6.80** (6.20-8.40)	2180
	01-02	**1.52** (1.41-1.65)	**1.63** (1.50-1.75)	**3.12** (2.76-3.51)	**5.22** (4.73-5.74)	**7.48** (6.54-8.12)	2690
Age group							
6-11 years	99-00	**2.15** (1.70-2.72)	**2.20** (1.80-2.30)	**3.90** (2.60-6.10)	**6.40** (5.20-8.30)	**8.30** (5.00-76.2)	297
	01-02	**1.80** (1.44-2.26)	**2.08** (1.74-2.49)	**3.62** (2.86-4.39)	**5.37** (4.26-7.38)	**6.88** (5.37-8.49)	368
12-19 years	99-00	**1.97** (1.78-2.19)	**2.00** (1.60-2.30)	**3.50** (3.10-4.00)	**5.90** (4.80-7.00)	**9.70** (5.90-13.1)	621
	01-02	**2.03** (1.76-2.34)	**2.27** (1.96-2.53)	**4.09** (3.48-4.72)	**6.69** (5.55-7.87)	**9.00** (7.25-11.4)	762
20 years and older	99-00	**1.36** (1.24-1.51)	**1.40** (1.30-1.70)	**2.70** (2.50-3.00)	**5.00** (4.20-5.50)	**6.40** (5.70-8.30)	1262
	01-02	**1.43** (1.32-1.54)	**1.50** (1.39-1.65)	**2.85** (2.55-3.26)	**4.86** (4.53-5.47)	**7.14** (6.08-8.12)	1560
Gender							
Males	99-00	**1.70** (1.54-1.88)	**1.80** (1.70-2.00)	**3.10** (2.80-3.40)	**5.50** (4.20-6.30)	**7.50** (5.90-9.40)	1083
	01-02	**1.64** (1.47-1.82)	**1.80** (1.63-1.98)	**3.15** (2.76-3.73)	**5.52** (4.82-6.35)	**7.87** (6.49-9.32)	1335
Females	99-00	**1.33** (1.15-1.53)	**1.50** (1.20-1.60)	**2.80** (2.30-3.10)	**5.10** (4.20-5.90)	**6.80** (5.60-10.4)	1097
	01-02	**1.43** (1.30-1.56)	**1.43** (1.28-1.63)	**3.10** (2.73-3.43)	**4.86** (4.44-5.88)	**7.15** (6.32-7.86)	1355
Race/ethnicity							
Mexican Americans	99-00	**1.35** (1.25-1.46)	**1.30** (1.20-1.50)	**2.60** (2.30-2.90)	**4.50** (4.00-5.10)	**6.30** (5.50-6.80)	692
	01-02	**1.21** (1.06-1.37)	**1.24** (1.08-1.45)	**2.55** (2.04-2.90)	**4.31** (3.65-5.49)	**6.08** (5.21-8.22)	683
Non-Hispanic blacks	99-00	**1.34** (1.12-1.62)	**1.30** (1.20-1.50)	**2.50** (2.20-2.80)	**5.10** (3.70-6.40)	**7.40** (5.40-13.9)	540
	01-02	**1.30** (1.14-1.48)	**1.41** (1.22-1.62)	**2.61** (2.31-2.82)	**4.28** (3.70-5.18)	**5.99** (4.87-7.26)	667
Non-Hispanic whites	99-00	**1.56** (1.36-1.80)	**1.70** (1.60-2.00)	**3.30** (2.80-3.70)	**5.40** (4.50-6.20)	**7.20** (6.20-8.80)	765
	01-02	**1.61** (1.46-1.77)	**1.67** (1.53-1.82)	**3.30** (2.86-3.73)	**5.66** (4.94-6.30)	**7.70** (6.61-8.49)	1132

Chronic accumulation of inhaled barium dust in the lung tissue may cause baritosis, a benign condition that may occur among barite ore miners. Chronic exposures to natural levels of barium in drinking water have not produced general health effects or evidence of cardiovascular risk (Brenniman and Levy, 1984; Wones et al., 1990). Workplace standards for external air exposure to various barium salts have been established by OSHA and a drinking water standard has been established by U.S. EPA. Barium is not rated for carcinogenicity. Information about external exposure and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Urinary Barium Reported in the Tables

Urinary barium levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Previous studies reporting urinary levels of barium in general populations have found values generally similar to those documented in this *Report* (Minoia et al., 1990; Paschal et al., 1998). In addition, levels determined in clinically submitted specimens are broadly comparable (Komaromy-Hiller et al., 2000). Median urinary levels of barium found in welders of barium-containing electrodes were 60 times higher than the median levels in this *Report* (Zschiesche et al., 1992) without obvious adverse effects. Urinary concentrations in acute poisonings are often hundreds to thousands times higher.

Comparing Adjusted Geometric Means

Geometric mean levels of urinary barium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary barium were higher for the group aged 6-11 years than either groups aged 12-19 years or aged 20 years and

Table 6. Barium (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**1.40** (1.26-1.56)	**1.41** (1.28-1.54)	**2.54** (2.18-2.89)	**4.68** (3.85-5.47)	**6.27** (5.47-8.09)	2180
	01-02	**1.44** (1.31-1.58)	**1.48** (1.35-1.63)	**2.76** (2.51-3.03)	**4.58** (4.14-4.95)	**6.24** (5.28-7.27)	2689
Age group							
6-11 years	99-00	**2.37** (1.68-3.32)	**2.35** (1.83-2.92)	**4.46** (2.55-6.46)	**8.77** (3.75-22.0)	**11.4** (5.45-22.0)	297
	01-02	**2.20** (1.91-2.52)	**2.41** (2.19-2.83)	**3.91** (3.29-4.51)	**4.96** (4.58-6.00)	**6.71** (5.20-8.47)	368
12-19 years	99-00	**1.51** (1.34-1.70)	**1.39** (1.26-1.59)	**2.48** (1.97-3.06)	**4.36** (3.23-5.39)	**6.95** (4.24-11.4)	621
	01-02	**1.45** (1.33-1.59)	**1.56** (1.31-1.77)	**2.88** (2.68-3.12)	**4.50** (3.84-5.20)	**5.55** (4.81-6.10)	762
20 years and older	99-00	**1.30** (1.19-1.42)	**1.33** (1.20-1.45)	**2.32** (2.08-2.62)	**4.29** (3.62-4.91)	**5.65** (5.28-6.33)	1262
	01-02	**1.37** (1.24-1.50)	**1.40** (1.24-1.52)	**2.53** (2.23-2.84)	**4.38** (4.02-5.00)	**6.55** (5.00-7.64)	1559
Gender							
Males	99-00	**1.32** (1.22-1.42)	**1.36** (1.23-1.47)	**2.39** (2.11-2.57)	**4.24** (3.48-5.00)	**5.61** (4.39-10.2)	1083
	01-02	**1.30** (1.16-1.45)	**1.34** (1.19-1.50)	**2.46** (2.14-2.83)	**4.50** (3.73-4.95)	**5.42** (4.81-7.51)	1334
Females	99-00	**1.49** (1.27-1.74)	**1.46** (1.29-1.68)	**2.65** (2.13-3.46)	**4.86** (3.96-6.38)	**7.36** (5.25-11.3)	1097
	01-02	**1.59** (1.45-1.75)	**1.63** (1.48-1.79)	**2.98** (2.75-3.30)	**4.76** (4.38-5.31)	**6.97** (5.86-7.52)	1355
Race/ethnicity							
Mexican Americans	99-00	**1.21** (1.10-1.33)	**1.17** (1.03-1.37)	**2.39** (2.10-2.59)	**4.00** (3.33-4.80)	**5.31** (4.80-6.51)	692
	01-02	**1.18** (1.03-1.34)	**1.16** (1.00-1.38)	**2.33** (1.90-2.61)	**3.68** (3.29-4.10)	**4.95** (4.24-6.80)	682
Non-Hispanic blacks	99-00	**.881** (.703-1.11)	**.904** (.710-1.06)	**1.64** (1.36-2.00)	**3.27** (2.26-4.76)	**4.84** (3.57-10.8)	540
	01-02	**.891** (.777-1.02)	**.920** (.754-1.11)	**1.64** (1.44-2.03)	**2.86** (2.48-3.37)	**3.96** (3.52-4.68)	667
Non-Hispanic whites	99-00	**1.56** (1.38-1.77)	**1.55** (1.36-1.74)	**2.72** (2.27-3.24)	**5.00** (3.81-6.02)	**6.60** (5.52-10.2)	765
	01-02	**1.62** (1.49-1.76)	**1.66** (1.49-1.82)	**3.04** (2.76-3.32)	**4.95** (4.55-5.41)	**6.71** (5.57-7.64)	1132

older. Levels in the group aged 12-19 years were higher than the group aged 20 years and older. Levels in non-Hispanic whites were higher than in non-Hispanic blacks and Mexican Americans. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of barium in urine does not mean that the level of barium causes an adverse health effect. Whether barium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urine barium data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of barium than are found in the general population. These data will also help scientists plan and conduct research about exposure to barium and health effects.

Figure 2. Barium (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Beryllium

CAS No. 7440-41-7

General Information

Pure beryllium is a hard gray metal. The lightest of all metals, beryllium can be found in mineral rocks, coal, soil, and volcanic dust. Beryllium compounds are commercially mined, and the beryllium is refined for use in mirrors and in special metal alloys used in the automobile, computer, nuclear, electrical, aircraft, and machine-parts industries. Beryllium is also used in the production of sports equipment such as golf clubs and bike frames. In medicine, beryllium is used in instruments, x-ray machines, and dental bridges.

Exposure to beryllium occurs mostly in the workplace, near some hazardous waste sites, and from breathing tobacco smoke. Two types of minerals, bertrandite and beryl, are mined for commercial recovery of beryllium. In the workplace, beryllium dust enters the body

primarily through the lungs, where it remains for years, but there are little data available on how the metal accumulates in the lungs. Low-level beryllium exposure occurs through breathing air, eating food, or drinking water containing the metal. Small amounts of beryllium dust can enter air from burning coal and oil.

Beryllium may be harmful if inhaled. The effects depend on the concentration of beryllium in the inhaled air and the duration of air exposure. Air levels greater than 100 µg/m^3 can result in erythema and edema of the lung mucosa, producing pneumonitis. Chronic beryllium disease, or berylliosis, is a granulomatous interstitial lung disease that results from chronic beryllium inhalation and immunologic response. Skin contact with beryllium may also produce dermatitis, and some people demonstrate a hypersensitivity reaction to beryllium. Contact dermatitis and subcutaneous nodules have been reported with skin

Table 7. Beryllium

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2690
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	.140 (<LOD-.160)	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1560
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	.130 (<LOD-.150)	1335
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	683
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

exposure to beryllium.

Workplace air standards for external exposure have been established by OSHA and ACGIH. NTP considers beryllium to be a known carcinogen. IARC states that beryllium is an animal carcinogen, and sufficient evidence exists to consider beryllium and beryllium compounds as carcinogenic in people, causing lung and central nervous system cancers. More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Urinary Beryllium Reported in the Tables

Urinary beryllium levels were measured in a subsample of NHANES participants aged 6 years old and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Comparable to the 1999-2000 subsample analysis, levels of beryllium were mostly undetectable. Previous studies have reported urinary levels for general populations as either undetectable concentrations or have not had comparable detection limits (Komaromy-Hiller et al., 2000; Minoia et al., 1990; Paschal et al., 1998). A summary of reference ranges taken from previous studies suggested that a true reference range for urinary beryllium is below the detection limits in past applications (less than 1 μg/L) (Hamilton et al., 1994). Apostoli and Schaller (2001) suggest that previous detection limits are inadequate to quantitate normal human exposure. In that study, urinary beryllium in workers correlated with air exposure measures, and when air levels were below the recommended threshold limit value, urinary beryllium concentrations ranged from 0.12 to 0.15 μg/L. The 95th percentiles in this *Report* for people aged 12-19 years and for males (0.14 μg/L and 0.13 μg/L, respectively) are similar to those values reported by Apostoli and Schaller (2001). Because the

Table 8. Beryllium (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in μg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2689
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	.231 (.173-.273)	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1559
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	.281 (.237-.333)	1334
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	682
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

detection limit documented in this *Report* was 0.13 μg/L and because most of the samples were undetectable, these NHANES 1999-2002 levels are likely to be lower than levels considered safe for workers.

Finding a measurable amount of beryllium in urine does not mean that the level of beryllium causes an adverse health effect. Whether beryllium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary beryllium data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of beryllium than are found in the general population. These data will also help scientists plan and conduct research about exposure to beryllium and health effects.

Cadmium
CAS No. 7440-43-9

General Information

Cadmium is a soft, malleable, bluish-white metal that is obtained chiefly as a by-product during the processing of zinc-containing ores (principally sphalerite, as zinc sulfide) and to a lesser extent during the refining of lead and copper from sulfide ore. The predominant commercial use of cadmium is in the manufacture of batteries (78% of uses). The use of cadmium in pigments accounts for 12% of consumption; in coatings and plating another 8% is used, and the remainder is used in stabilizers for plastic (1.5%), and nonferrous alloys and other uses (0.5%). From 2001 through 2004, the commercial use of cadmium declined approximately 70% in response to environmental concerns (U.S. Geological

Survey, 2004). Emissions of cadmium into the environment occur mainly via anthropogenic activities, such as secondary lead smelting, primary copper smelting, primary lead production, hazardous and municipal waste incineration, and petroleum refining (U.S. EPA, 1992).

Cadmium is absorbed via inhalation and ingestion. Inhalation of cigarette smoke is a predominant source in smokers. For nonsmokers who are not exposed to cadmium in the workplace, food is the largest source of cadmium intake and absorption. An analysis of food-intake rates and food-cadmium concentrations for the U.S. population recently estimated a geometric mean daily cadmium intake of 18.9 µg/day, or 0.4 µg/kg/day

Table 9. Cadmium in blood

Geometric mean and selected percentiles of blood concentrations (in µg/L) for the U.S. population aged 1 year and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 1 and older	99-00	**.412** (.378-.449)	**.300** (.300-.400)	**.600** (.500-.600)	**1.00** (.900-1.00)	**1.30** (1.20-1.40)	7970
	01-02	*	**.300** (<LOD-.300)	**.400** (.400-.500)	**.900** (.900-1.10)	**1.30** (1.20-1.60)	8945
Age group							
1-5 years	99-00	*	< LOD	**.300** (<LOD-.300)	**.400** (.300-.400)	**.400** (.300-.400)	723
	01-02	*	< LOD	< LOD	< LOD	**.300** (<LOD-.300)	898
6-11 years	99-00	*	< LOD	**.300** (<LOD-.300)	**.400** (.300-.400)	**.400** (.400-.500)	905
	01-02	*	< LOD	< LOD	< LOD	**.400** (.300-.400)	1044
12-19 years	99-00	**.333** (.304-.366)	**.300** (<LOD-.300)	**.300** (.300-.400)	**.800** (.600-.900)	**1.10** (.900-1.10)	2135
	01-02	*	< LOD	**.300** (<LOD-.300)	**.400** (.400-.500)	**.800** (.600-1.10)	2231
20 years and older	99-00	**.468** (.426-.513)	**.400** (.300-.400)	**.600** (.600-.700)	**1.00** (1.00-1.10)	**1.50** (1.40-1.60)	4207
	01-02	*	**.300** (.300-.400)	**.600** (.500-.600)	**1.10** (.900-1.20)	**1.60** (1.30-1.80)	4772
Gender							
Males	99-00	**.403** (.368-.441)	**.400** (.300-.400)	**.600** (.500-.600)	**1.00** (.900-1.10)	**1.30** (1.20-1.50)	3913
	01-02	*	**.300** (<LOD-.300)	**.400** (.400-.500)	**.900** (.900-1.10)	**1.40** (1.20-1.80)	4339
Females	99-00	**.421** (.386-.460)	**.300** (.300-.400)	**.600** (.500-.600)	**1.00** (.800-1.00)	**1.30** (1.10-1.40)	4057
	01-02	*	**.300** (.300-.400)	**.500** (.500-.600)	**1.00** (.900-1.10)	**1.40** (1.20-1.60)	4606
Race/ethnicity							
Mexican Americans	99-00	**.395** (.367-.424)	**.400** (.300-.400)	**.400** (.400-.500)	**.700** (.700-.900)	**1.10** (.900-1.30)	2742
	01-02	*	< LOD	**.300** (.300-.400)	**.600** (.500-.700)	**1.00** (.700-1.30)	2268
Non-Hispanic blacks	99-00	**.393** (.361-.427)	**.300** (.300-.400)	**.600** (.500-.600)	**1.00** (.800-1.10)	**1.40** (1.10-1.50)	1842
	01-02	*	< LOD	**.400** (.400-.500)	**1.00** (.900-1.00)	**1.40** (1.20-1.50)	2219
Non-Hispanic whites	99-00	**.420** (.376-.470)	**.400** (.300-.400)	**.500** (.500-.600)	**1.00** (.900-1.10)	**1.30** (1.20-1.40)	2716
	01-02	*	< LOD	**.500** (.500-.600)	**.900** (.900-1.10)	**1.40** (1.20-1.80)	3806

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

(Choudhury et al., 2001). Although several studies have found that the average gastrointestinal absorption of dietary cadmium is on the order of 5% (Diamond et al., 2003), two balance studies have suggested that this value may be five- to ten-fold greater in young women than in the general population (Kikuchi et al., 2003; Horiguchi et al., 2004*a*). With chronic exposure, cadmium accumulates in the liver and the kidney, with one-third to one half of the total amount accumulating in the kidney (Nordberg and Nordberg, 2001). In both organs, cadmium tightly binds to metallothionein, an inducible metal-binding protein that provides protection against many of cadmium's toxic effects (Klaasen et al., 1999). The estimated half-life of cadmium in the kidney is one to four decades (ATSDR, 1999; Diamond et al., 2003).

The kidney is a critical target for cadmium. Renal tubular damage and glomerular damage can be caused by high-dose chronic exposure, which may occur in people who are occupationally exposed, and is manifested by irreversible proteinuria and progressive reductions in glomerular filtration rate (Roels et al., 1999). Increased urinary excretion of calcium and phosphorus and decreased hydroxylation of vitamin D metabolites that accompany advanced tubular damage may result in overt, and often painful, osteomalacia or osteoporosis, typified by a condition known as "Itai-Itai disease" that afflicted women living in a cadmium-polluted region of Japan. Several recent epidemiological investigations in Belgium (Staessen et al., 1996; Hotz et al., 1999; Staessen et al., 1999), Sweden (Jarup et al., 2000; Alfven et al., 2002; Olsson et al., 2002), Japan (Suwazono et al., 2000; Ezaki et al., 2003; Horiguchi et al., 2004*b*) China (Jin et al., 2004), and the United States (Noonan et al., 2002) have detected an association between relatively low-level environmental cadmium exposure and biomarkers of renal dysfunction or diminished bone mineral density. Environmental exposure from cadmium pollution has been linked to an increased rate of end-stage renal disease in a Swedish population residing in the vincinity of two battery manufacturing plants (Hellstrom et al., 2001). Although all the mechanisms of cadmium toxicity

Table 10. Cadmium in urine

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.193** (.169-.220)	**.232** (.214-.249)	**.475** (.436-.519)	**.858** (.763-.980)	**1.20** (1.06-1.33)	2257
	01-02	**.210** (.189-.235)	**.229** (.207-.255)	**.458** (.423-.482)	**.839** (.753-.919)	**1.20** (1.07-1.28)	2690
Age group							
6-11 years	99-00	*	**.078** (.061-.101)	**.141** (.115-.173)	**.219** (.178-.233)	**.279** (.211-.507)	310
	01-02	**.061** (<LOD-.081)	**.077** (.067-.092)	**.140** (.112-.160)	**.219** (.184-.262)	**.282** (.260-.326)	368
12-19 years	99-00	**.092** (.067-.126)	**.128** (.107-.148)	**.202** (.183-.232)	**.329** (.272-.372)	**.424** (.366-.596)	648
	01-02	**.109** (.087-.136)	**.135** (.114-.157)	**.210** (.189-.247)	**.327** (.289-.366)	**.442** (.366-.480)	762
20 years and older	99-00	**.281** (.253-.313)	**.306** (.261-.339)	**.551** (.510-.621)	**.979** (.836-1.13)	**1.31** (1.13-1.57)	1299
	01-02	**.273** (.249-.299)	**.280** (.261-.308)	**.545** (.493-.607)	**.955** (.855-1.06)	**1.28** (1.20-1.43)	1560
Gender							
Males	99-00	**.199** (.165-.241)	**.227** (.193-.263)	**.462** (.381-.539)	**.892** (.748-1.15)	**1.41** (.980-1.83)	1121
	01-02	**.201** (.177-.229)	**.223** (.191-.257)	**.445** (.393-.481)	**.870** (.741-1.03)	**1.22** (1.12-1.38)	1335
Females	99-00	**.187** (.153-.229)	**.239** (.220-.255)	**.492** (.456-.540)	**.806** (.705-.980)	**1.10** (1.01-1.19)	1136
	01-02	**.219** (.192-.251)	**.234** (.202-.265)	**.466** (.433-.519)	**.817** (.733-.886)	**1.17** (.918-1.36)	1355
Race/ethnicity							
Mexican Americans	99-00	**.191** (.157-.233)	**.202** (.167-.221)	**.438** (.351-.551)	**.813** (.686-.977)	**1.12** (.886-1.38)	780
	01-02	**.160** (.135-.189)	**.181** (.171-.198)	**.321** (.285-.362)	**.559** (.430-.733)	**.766** (.633-1.15)	683
Non-Hispanic blacks	99-00	**.283** (.208-.387)	**.312** (.243-.412)	**.633** (.498-.806)	**1.22** (.892-1.38)	**1.48** (1.30-1.72)	546
	01-02	**.277** (.229-.336)	**.302** (.257-.354)	**.580** (.476-.713)	**1.04** (.843-1.38)	**1.51** (1.28-1.74)	667
Non-Hispanic whites	99-00	**.175** (.148-.206)	**.220** (.194-.246)	**.455** (.388-.510)	**.797** (.714-1.01)	**1.17** (.963-1.47)	760
	01-02	**.204** (.179-.231)	**.221** (.191-.255)	**.445** (.394-.479)	**.813** (.717-.875)	**1.17** (.989-1.24)	1132

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

are uncertain, key factors may involve perturbation of zinc-dependent biochemical processes, induction of oxidative stress, aberrant gene expression, estrogenic effects (Johnson et al., 2003), or altered cell signaling and steroidogenesis (Misra et al., 2003; Waalkes, 2003; Henson and Chedrese, 2004).

Acute and heavy airborne exposure to dusts and fumes, as may occur from welding on cadmium-alloyed metals, may result in severe, potentially fatal pneumonitis (Fernandez et al., 1996). Chronic inhalation exposure to cadmium particulate has been associated with changes in pulmonary function and chest radiography consistent with emphysema (Davison et al., 1988). Among U.S. adult smokers and former smokers studied in NHANES III, increases in urinary cadmium were associated with obstructive changes in pulmonary function (Mannino et al., 2004). Workplace exposure to airborne cadmium particulate has been associated with decrements in olfactory function (Mascagni et al., 2003). Animal studies have demonstrated reproductive and teratogenic

effects. Two recent small epidemiologic studies have noted a positive association of environmental cadmium levels in maternal urine or blood with gestational age (Nishijo et al., 2002) and birth height (Zhang et al., 2004). NTP has determined that cadmium is a known human carcinogen. Potential modes of action have recently been reviewed (Waalkes, 2003). Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Cadmium in Blood and Urine Reported in the Tables

In the NHANES 2001-2002 sample, blood cadmium levels were measured in all participants aged 1 year and older, and urine cadmium levels were measured in a sample of people aged 6 years and older. Participants were selected to be a representative sample of the U.S.

Table 11. Cadmium in urine (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.181** (.157-.209)	**.219** (.199-.238)	**.423** (.391-.446)	**.712** (.645-.757)	**.933** (.826-1.07)	2257
	01-02	**.199** (.181-.218)	**.212** (.194-.232)	**.404** (.377-.440)	**.690** (.630-.754)	**.917** (.813-.998)	2689
Age group							
6-11 years	99-00	*	**.085** (.063-.107)	**.147** (.123-.182)	**.210** (.171-.316)	**.300** (.184-.607)	310
	01-02	**.075** (.059-.094)	**.100** (.083-.112)	**.166** (.136-.192)	**.233** (.206-.281)	**.291** (.221-.440)	368
12-19 years	99-00	**.071** (.051-.098)	**.093** (.084-.106)	**.147** (.130-.163)	**.215** (.204-.240)	**.283** (.222-.404)	648
	01-02	**.078** (.067-.091)	**.091** (.085-.101)	**.136** (.123-.143)	**.191** (.175-.234)	**.280** (.234-.321)	762
20 years and older	99-00	**.267** (.247-.289)	**.288** (.261-.304)	**.484** (.433-.545)	**.769** (.727-.818)	**1.07** (.927-1.17)	1299
	01-02	**.261** (.236-.289)	**.273** (.247-.303)	**.481** (.426-.518)	**.776** (.691-.850)	**.979** (.874-1.12)	1559
Gender							
Males	99-00	**.154** (.131-.182)	**.174** (.158-.191)	**.329** (.293-.382)	**.617** (.537-.700)	**.788** (.696-.929)	1121
	01-02	**.159** (.143-.177)	**.168** (.157-.182)	**.334** (.304-.364)	**.532** (.491-.653)	**.757** (.690-.856)	1334
Females	99-00	**.211** (.170-.261)	**.267** (.239-.308)	**.473** (.423-.551)	**.783** (.690-.917)	**1.09** (.813-1.38)	1136
	01-02	**.245** (.216-.278)	**.263** (.228-.297)	**.479** (.414-.541)	**.792** (.687-.884)	**.985** (.876-1.16)	1355
Race/ethnicity							
Mexican Americans	99-00	**.175** (.137-.223)	**.181** (.144-.225)	**.331** (.266-.418)	**.612** (.441-.828)	**.843** (.674-1.13)	780
	01-02	**.156** (.136-.178)	**.170** (.150-.184)	**.282** (.263-.340)	**.501** (.388-.614)	**.693** (.507-.839)	682
Non-Hispanic blacks	99-00	**.183** (.140-.240)	**.201** (.168-.241)	**.414** (.343-.472)	**.658** (.516-.827)	**.873** (.722-.962)	546
	01-02	**.190** (.156-.232)	**.195** (.174-.225)	**.385** (.336-.449)	**.676** (.559-.850)	**.917** (.725-1.08)	667
Non-Hispanic whites	99-00	**.175** (.146-.209)	**.219** (.191-.250)	**.432** (.387-.470)	**.729** (.666-.783)	**1.00** (.826-1.16)	760
	01-02	**.205** (.184-.229)	**.224** (.208-.242)	**.421** (.382-.470)	**.719** (.668-.784)	**.931** (.806-1.05)	1132

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

population. Blood cadmium reflects both recent and cumulative exposures. During typical environmental exposure, urinary cadmium predominantly reflects cumulative exposure and the concentration of cadmium in the kidney (Nordberg and Nordberg, 2001; Lauwerys and Hoet, 2001 Satarug et al., 2002).

A general population survey of approximately 4,700 adults in Germany in 1998 found levels of cadmium in blood and urine that were also similar or slightly higher than the adult values reported in the 1999-2000 and 2001-2002 samples (Becker et al., 2002; Becker et al., 2003). Creatinine-corrected urine cadmium values obtained in a study of 361 subjects from a U.S. community, where smelting activity had occurred in the past, and an unexposed comparison community were also similar to the corresponding values in this *Report* (Noonan et al., 2002). A general population survey of 10,753 adult Japanese women found geometric mean urinary cadmium levels that were approximately four-to-five-fold higher than the levels found for U.S. adults in this *Report*. (Ezaki et al., 2003). People who are occupationally exposed may have blood and urine levels that are higher than levels in the general population. The 95th percentiles for blood cadmium levels in this *Report* are less than the OSHA criterion (OSHA, 29 CFR 1910.1027) for blood cadmium (5 µg/L), and the 95th percentile for urine cadmium is less than the OSHA criterion for urine cadmium (3 µg/gram of creatinine). Occupational criteria are provided here for comparison only, not to imply a safety level for general population exposure.

In recent studies, levels of urinary cadmium greater than or equal to 1 µg/gram of creatinine have been associated with increases in urinary protein markers of renal tubular function (Jarup et al., 2000; Moriguchi et al., 2004; Noonan et al., 2002). In addition, a decrease in bone density has been correlated with urinary cadmium excretion among middle-aged women with a mean urinary cadmium concentration of approximately 1 µg/gram creatinine (Staessen et al., 1999), and among women older than 60 years, the odds of low bone-mineral density increased by nearly three-fold when the blood cadmium level exceeded 1.1 µg/L (Alfven et al., 2002). In this *Report*, the urinary and blood cadmium levels at the 95th and 90th percentiles, respectively, approach these cited values associated with subclinical changes in renal function and bone mineral density. Further research is needed to address the public health consequences of such exposure in the United States.

Comparing Adjusted Geometric Means

Geometric mean levels of blood cadmium in the NHANES 2001-2002 sample could not be calculated for this *Report* due to an insufficient number of samples with detectable levels of cadmium. The adjusted geometric mean levels of blood cadmium for the demographic groups were compared previously in the NHANES 1999-2000 sample after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). Adjusted geometric mean levels of blood cadmium were slightly higher in the group aged 20 years and older than either of the groups aged 6-11 or the 12-19 years; and the group aged 12-19 years was higher than the group aged 6-11 years. Females had slightly higher blood cadmium levels than males. Mexican Americans had higher adjusted geometric mean levels of blood cadmium than non-Hispanic whites or non-Hispanic blacks; and non-Hispanic blacks had higher blood cadmium levels than non-Hispanic whites. Similar relationships for age and gender were found in a study of NHANES III participants (Paschal et al., 2000).

Due to a recently demonstrated interference from molybdenum oxide when measuring low-level urinary cadmium using the ICP-MS method, both the 1999-2000 and 2001-2002 data were corrected for this interference based on the molybdenum measurement and expected proportion of molybdenum oxide. Geometric mean levels of urinary cadmium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine. In the NHANES 2001-2002 sample, the group aged 20 years and older had higher adjusted geometric mean levels of urinary cadmium than in either of the groups aged 6-11 or 12-19 years. Females had higher urinary cadmium levels than males. Higher urinary cadmium values in females than in males have been observed in other general population studies (Olsson et al., 2002) and, as noted previously, may be a possible consequence of increased gastrointestinal absorption of cadmium in females. It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of cadmium in blood or urine does not mean that the level of cadmium will result in an adverse health effect. These data provide physicians with a reference range so they can determine whether or not people have been exposed to higher levels of cadmium than are found in the general population. These data also will help scientists plan and conduct research about the relation between exposure to cadmium and health effects.

Figure 3. Cadmium in urine (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in μg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Cesium

CAS No. 7440-46-2

General Information

Cesium is a silver-white metal that is found naturally in rock, soil, and clay. Inorganic cesium compounds are commonly used in photomultiplier tubes, vacuum tubes, scintillation counters, infrared lamps, semiconductors, high-power gas-ion devices, and as polymerization catalysts and photographic emulsions. Radioactive ^{137}Cs has been used medically to treat cancer.

Most human exposure to cesium occurs through the diet. For absorbed cesium salts, the body half-life is estimated to be 70-109 days based on ^{137}Cs exposures. Little is known about the health effects of this metal although cesium is generally of low toxicity when given to animals. However, cesium hydroxide is corrosive and irritating when concentrations are high. Workplace air standards for external exposure for certain cesium salts

are recommended by NIOSH on the basis of these irritant effects. It is not known whether cesium compounds are carcinogenic.

Interpreting Levels of Urinary Cesium Reported in the Tables

Urinary cesium levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In one study of clinically submitted specimens (Komaromy-Hiller et al., 2000), mean urinary cesium concentrations were slightly lower than those reported here. In a small population study of Europeans, Minoia et al. (1990) found average urinary cesium levels to be comparable to levels in this *Report*. Median values in the NHANES 1999-2000 and 2001-2002 subsamples are more than

Table 12. Cesium

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**4.35** (4.00-4.74)	**4.80** (4.40-5.30)	**7.10** (6.50-7.70)	**9.60** (8.80-10.3)	**11.4** (10.2-12.9)	2464
	01-02	**4.81** (4.40-5.26)	**5.49** (5.09-5.89)	**7.91** (7.47-8.39)	**10.4** (9.56-11.4)	**12.6** (11.1-13.8)	2690
Age group							
6-11 years	99-00	**4.87** (4.08-5.81)	**5.60** (4.60-6.70)	**7.30** (6.70-8.00)	**9.00** (7.90-10.1)	**9.70** (8.90-10.4)	340
	01-02	**4.87** (4.08-5.82)	**5.61** (4.69-6.52)	**7.96** (6.77-8.84)	**9.79** (8.64-10.6)	**11.1** (10.2-12.4)	368
12-19 years	99-00	**4.55** (4.09-5.05)	**5.10** (4.30-5.60)	**6.80** (6.10-7.70)	**8.80** (8.00-9.40)	**10.4** (8.90-12.3)	718
	01-02	**5.22** (4.57-5.95)	**5.62** (5.13-6.12)	**7.55** (7.13-8.04)	**9.71** (9.12-11.1)	**12.0** (10.0-15.0)	762
20 years and older	99-00	**4.26** (3.94-4.62)	**4.80** (4.40-5.30)	**7.10** (6.50-7.60)	**9.80** (8.80-10.5)	**11.6** (10.2-13.2)	1406
	01-02	**4.74** (4.32-5.20)	**5.43** (5.05-5.87)	**7.96** (7.43-8.52)	**10.6** (9.73-11.5)	**12.8** (11.2-14.2)	1560
Gender							
Males	99-00	**4.84** (4.35-5.38)	**5.50** (4.60-5.90)	**7.50** (6.90-8.20)	**9.70** (8.60-10.7)	**11.6** (10.3-13.0)	1226
	01-02	**5.34** (4.89-5.84)	**6.11** (5.61-6.64)	**8.26** (7.84-9.08)	**10.8** (10.1-12.1)	**12.8** (11.3-15.0)	1335
Females	99-00	**3.95** (3.63-4.29)	**4.50** (4.10-4.80)	**6.60** (6.20-7.30)	**9.10** (8.30-9.90)	**11.1** (9.90-12.9)	1238
	01-02	**4.36** (3.95-4.81)	**4.87** (4.45-5.25)	**7.29** (6.71-8.01)	**9.77** (9.07-11.0)	**12.4** (10.4-13.8)	1355
Race/ethnicity							
Mexican Americans	99-00	**4.32** (3.82-4.89)	**4.70** (4.20-5.10)	**6.60** (6.20-7.10)	**9.10** (8.00-9.80)	**10.9** (9.50-12.6)	884
	01-02	**4.63** (4.10-5.24)	**5.29** (4.59-5.89)	**7.08** (6.42-7.99)	**9.13** (7.86-11.3)	**11.3** (8.81-14.9)	683
Non-Hispanic blacks	99-00	**4.94** (4.33-5.64)	**5.40** (4.80-6.30)	**7.40** (6.80-8.20)	**9.80** (8.80-10.8)	**11.5** (9.80-13.1)	568
	01-02	**4.93** (4.70-5.17)	**5.31** (5.05-5.63)	**7.36** (6.97-7.59)	**9.44** (8.71-9.68)	**10.7** (10.1-12.3)	667
Non-Hispanic whites	99-00	**4.25** (3.83-4.72)	**4.70** (4.20-5.50)	**7.10** (6.50-7.80)	**9.60** (8.80-10.4)	**11.7** (10.3-13.3)	821
	01-02	**4.77** (4.27-5.32)	**5.46** (4.97-6.03)	**7.97** (7.43-8.55)	**10.4** (9.54-11.4)	**12.6** (11.0-13.8)	1132

twice the median values reported in a nonrandom subsample from NHANES III (1988-1994) (Paschal et al., 1998), which may be due to methodologic, population, or exposure differences.

Comparing Adjusted Geometric Means

Geometric mean levels of urinary cesium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary cesium were slightly higher for children aged 6-11 years than for either of the groups aged 12-19 years or 20 years and older. The group aged 12-19 years had lower levels than the 20 year and older group. Mexican Americans had higher levels than non-Hispanic blacks. Non-Hispanic whites had higher levels than non-Hispanic blacks. It is unknown whether these differences associated with age or race/ethnicity represent

differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of cesium in urine does not mean that the level of cesium causes an adverse health effect. Whether cesium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary cesium data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of cesium than levels found in the general population. These data will also help scientists plan and conduct research about exposure to cesium and health effects.

Table 13. Cesium (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**4.10** (3.96-4.25)	**4.12** (3.97-4.27)	**5.41** (5.21-5.70)	**7.14** (6.83-7.50)	**8.64** (8.00-9.30)	2464
	01-02	**4.54** (4.30-4.79)	**4.44** (4.20-4.64)	**6.06** (5.66-6.47)	**8.18** (7.62-8.95)	**10.2** (8.84-11.7)	2689
Age group							
6-11 years	99-00	**5.34** (5.03-5.67)	**5.42** (5.03-6.04)	**6.63** (6.18-7.13)	**8.23** (7.13-9.41)	**9.89** (7.88-10.1)	340
	01-02	**5.95** (5.48-6.46)	**5.91** (5.43-6.53)	**7.77** (7.00-8.28)	**9.19** (8.35-11.9)	**11.9** (9.38-12.3)	368
12-19 years	99-00	**3.43** (3.29-3.58)	**3.52** (3.29-3.68)	**4.35** (4.17-4.56)	**5.31** (4.97-5.79)	**6.56** (5.33-8.09)	718
	01-02	**3.73** (3.41-4.08)	**3.55** (3.36-3.74)	**4.74** (4.40-5.13)	**6.10** (5.35-7.63)	**8.05** (6.44-9.82)	762
20 years and older	99-00	**4.08** (3.88-4.29)	**4.06** (3.85-4.29)	**5.38** (5.04-5.85)	**7.17** (6.84-7.58)	**8.60** (7.91-9.30)	1406
	01-02	**4.54** (4.30-4.78)	**4.42** (4.20-4.59)	**5.94** (5.64-6.40)	**8.15** (7.46-8.97)	**10.2** (8.74-11.7)	1559
Gender							
Males	99-00	**3.78** (3.65-3.91)	**3.78** (3.60-3.96)	**4.96** (4.72-5.20)	**6.45** (6.18-6.70)	**7.71** (7.01-8.64)	1226
	01-02	**4.22** (3.96-4.51)	**4.10** (3.87-4.41)	**5.60** (5.27-6.03)	**7.67** (6.90-8.48)	**9.46** (8.22-11.5)	1334
Females	99-00	**4.43** (4.20-4.68)	**4.44** (4.14-4.77)	**5.92** (5.36-6.47)	**7.70** (7.16-8.06)	**9.38** (8.00-10.4)	1238
	01-02	**4.86** (4.58-5.16)	**4.72** (4.50-5.06)	**6.54** (5.93-7.00)	**8.47** (7.84-9.79)	**10.3** (8.95-12.2)	1355
Race/ethnicity							
Mexican Americans	99-00	**3.99** (3.73-4.25)	**3.95** (3.64-4.13)	**5.09** (4.79-5.38)	**6.64** (6.08-7.10)	**7.96** (7.20-8.95)	884
	01-02	**4.51** (4.00-5.08)	**4.51** (3.82-4.95)	**5.91** (5.31-6.64)	**7.77** (6.60-10.0)	**10.0** (7.60-20.5)	682
Non-Hispanic blacks	99-00	**3.21** (2.90-3.56)	**3.26** (3.05-3.44)	**4.30** (4.00-4.55)	**5.49** (5.00-5.98)	**6.33** (5.91-7.04)	568
	01-02	**3.38** (3.19-3.57)	**3.34** (3.05-3.60)	**4.41** (4.15-4.78)	**5.87** (5.63-6.29)	**6.75** (6.41-7.03)	667
Non-Hispanic whites	99-00	**4.26** (4.07-4.47)	**4.28** (4.05-4.50)	**5.63** (5.26-6.05)	**7.27** (6.84-7.83)	**8.68** (7.93-9.38)	821
	01-02	**4.81** (4.55-5.08)	**4.62** (4.42-4.96)	**6.33** (5.91-6.68)	**8.46** (7.84-9.39)	**10.3** (9.04-11.8)	1132

Figure 4. Cesium in urine (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Cobalt

CAS No. 7440-48-4

General Information

Cobalt is a magnetic element that occurs in nature either as a steel-gray, shiny, hard metal or in combination with other elements. The cobalt used in U.S. industry is imported or obtained by recycling scrap metal that contains cobalt. Among its many uses are the manufacture of superalloys used in gas turbines in aircraft engines, hard-metal alloys (in combination with tungsten carbide), blue-colored pigments, and fertilizers. Cobalt is used as a drying agent in paints, varnishes, and inks. It is also a component of porcelain enamel applied to steel bathroom fixtures, large appliances, and kitchenware. Cobalt compounds are used as catalysts in the production of oil and gas and in the synthesis of polyester and other materials. Cobalt compounds are also used in the manufacture of battery electrodes, steel-belted radial tires, automobile airbags, diamond-polishing

wheels, and magnetic recording media.

Cobalt occurs naturally in airborne dust, seawater, and many types of soil. It is also emitted into the environment from burning coal and oil and from car and truck exhaust. Usual human exposure is from food sources. Cobalt may be released into the systemic circulation of patients who receive joint prostheses that are fabricated from cobalt alloys (Lhotka et al., 2003). Exposure in the workplace may come from electroplating, the refining or processing of alloys, the grinding of tungsten carbide-type, hard-metal cutting tools, and the use of diamond-polishing wheels containing cobalt metal. Workplace standards for external air exposure to cobalt and several of its compounds have been established by OSHA and ACGIH.

Table 14. Cobalt

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.375** (.336-.419)	**.400** (.360-.440)	**.630** (.570-.670)	**.940** (.890-1.03)	**1.32** (1.16-1.48)	2465
	01-02	**.379** (.355-.404)	**.410** (.380-.430)	**.610** (.570-.660)	**.930** (.860-1.00)	**1.27** (1.15-1.44)	2690
Age group							
6-11 years	99-00	**.499** (.427-.583)	**.520** (.430-.600)	**.740** (.610-.900)	**1.03** (.860-1.12)	**1.22** (1.03-1.50)	340
	01-02	**.452** (.377-.543)	**.510** (.430-.610)	**.710** (.660-.810)	**1.07** (.940-1.21)	**1.28** (1.17-1.53)	368
12-19 years	99-00	**.519** (.463-.581)	**.520** (.480-.550)	**.810** (.670-.890)	**1.16** (1.01-1.47)	**1.52** (1.26-2.56)	719
	01-02	**.515** (.469-.564)	**.520** (.470-.570)	**.750** (.690-.840)	**1.23** (1.07-1.32)	**1.59** (1.37-1.99)	762
20 years and older	99-00	**.343** (.305-.386)	**.360** (.320-.410)	**.560** (.510-.640)	**.880** (.800-.950)	**1.28** (1.07-1.39)	1406
	01-02	**.352** (.333-.373)	**.370** (.350-.400)	**.550** (.520-.590)	**.860** (.790-.930)	**1.15** (1.04-1.42)	1560
Gender							
Males	99-00	**.371** (.331-.416)	**.400** (.360-.440)	**.580** (.530-.630)	**.810** (.730-.890)	**1.01** (.900-1.12)	1227
	01-02	**.367** (.338-.399)	**.390** (.360-.410)	**.540** (.510-.590)	**.780** (.740-.840)	**1.05** (.960-1.14)	1335
Females	99-00	**.379** (.333-.431)	**.410** (.340-.460)	**.670** (.590-.790)	**1.17** (.930-1.36)	**1.49** (1.28-1.98)	1238
	01-02	**.390** (.364-.417)	**.430** (.390-.440)	**.660** (.620-.700)	**1.05** (.980-1.16)	**1.44** (1.22-1.81)	1355
Race/ethnicity							
Mexican Americans	99-00	**.418** (.348-.502)	**.470** (.370-.530)	**.660** (.620-.760)	**1.05** (.950-1.19)	**1.47** (1.25-1.67)	884
	01-02	**.398** (.373-.424)	**.420** (.400-.450)	**.640** (.600-.710)	**.950** (.850-1.03)	**1.20** (1.06-1.48)	683
Non-Hispanic blacks	99-00	**.434** (.405-.465)	**.420** (.390-.470)	**.680** (.620-.750)	**1.15** (1.02-1.25)	**1.45** (1.23-2.04)	568
	01-02	**.435** (.388-.487)	**.410** (.380-.440)	**.650** (.540-.810)	**1.15** (.840-1.63)	**1.75** (1.32-2.22)	667
Non-Hispanic whites	99-00	**.369** (.316-.431)	**.400** (.340-.450)	**.620** (.550-.700)	**.930** (.820-1.07)	**1.29** (1.02-1.65)	822
	01-02	**.359** (.327-.394)	**.380** (.350-.430)	**.580** (.520-.650)	**.870** (.800-.930)	**1.16** (1.04-1.32)	1132

Cobalt constitutes 4% by weight of vitamin B-12 (cobalamin), an essential human nutrient. A nutritional requirement for cobalt not contained in dietary cobalamin has not been established. Cobalt is absorbed by oral and pulmonary routes. Human studies with ^{60}Co administered as soluble cobalt chloride have measured oral absorption ranging from approximately 1% to 25% (Smith et al., 1972). Once absorbed and distributed in the body, cobalt is excreted predominantly in the urine and to a lesser extent in the feces. Elimination reflects a multi-compartmental model dominated by compartments with half-lives on the order of several hours to a week, but with a minor fraction (10% to 15%) exhibiting a half-life of several years (Smith et al., 1972; Mosconi et al., 1994). A portion of cobalt retained for long periods is concentrated in the liver. Lung retention of cobalt compounds of low solubility, such as cobalt oxide, may be prolonged, with some fractions exhibiting pulmonary clearance half-lives of 1-2 years (Hedge et al., 1979). Recent inhalation exposure to soluble cobalt compounds may be monitored effectively by measuring cobalt in urine or blood (Lison et al., 1994).

Most toxic effects of cobalt have been encountered in workplace situations. Cobalt compounds are a recognized cause of allergic contact dermatitis (Dickel et al., 2001; Lisi et al., 2003; Thomssen et al., 2001). Occupational exposure to cobalt-containing dusts has caused occupational asthma (Shirakawa et al., 1989; Pisati and Zedda, 1994). "Hard metal disease," an interstitial lung disorder with findings that range from alveolitis to pulmonary fibrosis, has been associated with exposure to dusts that contain cobalt, usually in combination with tungsten carbide (Cugell et al., 1990). The extent to which cobalt exposure alone causes interstitial lung disease is unresolved (Swennen et al., 1993; Linna et al., 2003)

Cobalt was once added as a foaming agent to beer and caused outbreaks of cardiomyopathy among heavy drinkers in the mid-1960s (Alexander et al., 1972). Other case reports have suggested a link between occupational cobalt exposure and cardiomyopathy (Jarvis et al., 1992).

## Table 15. Cobalt (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.353** (.319-.391)	**.328** (.302-.365)	**.515** (.457-.581)	**.810** (.679-.963)	**1.16** (.938-1.50)	2465
	01-02	**.358** (.333-.384)	**.335** (.313-.360)	**.523** (.487-.562)	**.844** (.750-.955)	**1.15** (1.00-1.28)	2689
Age group							
6-11 years	99-00	**.547** (.467-.640)	**.554** (.449-.647)	**.774** (.626-.938)	**1.00** (.830-1.48)	**1.23** (.895-1.50)	340
	01-02	**.552** (.508-.599)	**.548** (.503-.609)	**.756** (.660-.829)	**1.00** (.900-1.25)	**1.30** (1.03-1.73)	368
12-19 years	99-00	**.391** (.353-.433)	**.378** (.329-.407)	**.535** (.469-.595)	**.824** (.632-1.16)	**1.44** (.821-3.54)	719
	01-02	**.368** (.343-.396)	**.352** (.327-.372)	**.534** (.471-.611)	**.851** (.673-.949)	**1.06** (.932-1.24)	762
20 years and older	99-00	**.328** (.297-.362)	**.306** (.280-.328)	**.471** (.428-.522)	**.727** (.632-.905)	**1.12** (.861-1.36)	1406
	01-02	**.337** (.313-.363)	**.312** (.293-.336)	**.474** (.435-.513)	**.792** (.704-.955)	**1.15** (.963-1.33)	1559
Gender							
Males	99-00	**.290** (.259-.324)	**.279** (.248-.301)	**.400** (.365-.449)	**.608** (.534-.728)	**.833** (.667-1.10)	1227
	01-02	**.290** (.272-.310)	**.277** (.256-.297)	**.392** (.361-.425)	**.642** (.574-.707)	**.848** (.786-.929)	1334
Females	99-00	**.426** (.378-.479)	**.407** (.362-.457)	**.605** (.550-.694)	**.955** (.781-1.29)	**1.50** (1.11-1.83)	1238
	01-02	**.435** (.404-.468)	**.408** (.382-.438)	**.635** (.560-.708)	**.993** (.867-1.16)	**1.29** (1.12-1.60)	1355
Race/ethnicity							
Mexican Americans	99-00	**.386** (.339-.439)	**.376** (.333-.419)	**.598** (.500-.669)	**.895** (.826-1.00)	**1.23** (1.11-1.35)	884
	01-02	**.388** (.361-.417)	**.361** (.333-.394)	**.591** (.500-.662)	**.872** (.777-.990)	**1.10** (.990-1.27)	682
Non-Hispanic blacks	99-00	**.282** (.275-.289)	**.257** (.243-.278)	**.417** (.378-.462)	**.707** (.600-.785)	**.975** (.757-1.60)	568
	01-02	**.298** (.275-.323)	**.268** (.251-.294)	**.444** (.392-.511)	**.728** (.582-.917)	**1.03** (.740-1.55)	667
Non-Hispanic whites	99-00	**.369** (.324-.421)	**.351** (.313-.387)	**.533** (.452-.611)	**.861** (.667-1.16)	**1.25** (.895-1.57)	822
	01-02	**.362** (.331-.396)	**.343** (.313-.368)	**.523** (.479-.562)	**.830** (.736-.983)	**1.16** (.983-1.33)	1132

Cobalt compounds were formerly used in the treatment of anemia, a probable consequence of their capacity to stimulate erythropoetin production (Goldberg et al., 1988). A recent study observed elevated serum cobalt levels in association with excessive erythrocytosis among residents of a high-altitude mining community (Jefferson et al., 2002). Pharmaceutical preparations of cobalt used in the past as hematinics have been associated with the development of overt hypothyroidism (Kriss et al., 1955), and a subclinical decrement in thyroid production was observed in a study of cobalt-production workers (Swennen et al., 1993).

Cobalt compounds have elicited numerous genotoxic effects in both *in vitro* and *in vivo* assays (De Boeck et al., 2003) and have produced lung cancer in rats and mice following chronic inhalation (Bucher et al., 1999). An industry-wide study of hard-metal workers in France observed an increased mortality from lung cancer (Moulin et al., 1998). IARC considers cobalt and its compounds as possibly carcinogenic to humans. Information about external exposure (i.e., environmental levels) and health effects is available from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov /toxprofiles.

Interpreting Levels of Urinary Cobalt Reported in the Tables

Urinary cobalt levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. The levels of cobalt measured in the adults in the NHANES 2001-2002 also are similar to those found in recent smaller general population surveys of European adults (Kristiansen et al., 1997; White and Sabbioni, 1998). Because concentrations of cobalt in the urine decline rapidly within 24 hours after an exposure ceases (Alexandersson et al., 1988), urinary measurements mainly reflect recent exposure, although substantial occupational exposure can produce elevated urinary levels for many weeks.

Individuals with occupational exposure to cobalt often have urinary cobalt levels that are many times higher than those of the general population (ATSDR, 2004). The ACGIH biological exposure index (BEI) for inorganic forms of cobalt (except insoluble cobalt oxides) is 15 µg/L (ACGIH, 2001). Information about the BEI is provided here for comparison, not to imply that the BEI is a safety level for general population exposure. For workers exposed to cobalt in the air, a distinction should be made between soluble cobalt and insoluble (oxides and metallic) cobalt (Christensen and Poulsen, 1994; Lison et al., 1994). Exposure to soluble cobalt salts will produce proportionately higher urinary levels because of better absorption. Correlations between air-exposure levels and urinary cobalt levels in hard-metal fabricators are well documented (Ichikawa et al., 1985; Linnainmaa and Kiilunen, 1997; ACGIH 2001; Kraus et al., 2001; Lauwerys and Hoet, 2001).

Comparing Adjusted Geometric Means

Geometric mean levels of urinary cobalt for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary cobalt were slightly higher for children aged 6-11 years than for people aged 12-19 years, with both age groups having higher levels than people aged 20 years and older. Urinary cobalt levels in females were higher than in males, and levels in non-Hispanic blacks were slightly lower than in either Mexican Americans or non-Hispanic whites. Relative higher urinary cobalt levels in females than in males have been noted in other investigations and may reflect increased cobalt uptake by premenopausal women (Kristiansen et al., 1997). It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of cobalt in urine does not mean that the level of cobalt causes an adverse health effect. Whether cobalt at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary cobalt data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of cobalt than are found in the general population. These data will also help scientists plan and conduct research about exposure to cobalt and health effects.

Figure 5. Cobalt (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Lead
CAS No. 7439-92-1

General Information

Elemental lead, a malleable, dense, blue-gray metal, is a naturally occurring element found in soils and rocks. It can be combined to form inorganic and organic molecules, such as lead phosphate and tetraethyl lead. Lead has a variety of uses in the manufacture of storage batteries; solders (particularly for electrical components and automobile radiators); metal alloys (including brass, bronze, and certain types of steel); plastics; leaded glass; ceramic glazes; ammunition; antique-molded or cast ornaments; and shielding used as protection from radiation sources. In the past, lead was added to residential paints and gasoline, and it has been used in plumbing for centuries. Small amounts of lead also may be emitted from the burning of fossil fuels.

Since the elimination of leaded gasoline in the United States and the removal of lead from solder in canned food containers, adult lead exposures tend to be limited to certain occupational and recreational sources. For children, the major sources of exposure are from deteriorated lead-based paint and the resulting dust and soil contamination. However, less common sources of exposure still exist, including lead-glazed ceramic pottery; pewter utensils and drinking vessels; plumbing systems with lead-soldered joints or lead pipes; lead-based painted surfaces undergoing renovation or demolition; lead-containing folk remedies; bullet fragments retained in human tissue; lead-contaminated

Table 16. Lead in blood

Geometric mean and selected percentiles of blood concentrations (in µg/dL) for the U.S. population aged 1 year and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 1 and older	99-00	**1.66** (1.60-1.72)	**1.60** (1.50-1.60)	**2.40** (2.30-2.60)	**3.80** (3.60-3.90)	**4.90** (4.60-5.30)	7970
	01-02	**1.45** (1.39-1.51)	**1.40** (1.30-1.40)	**2.20** (2.10-2.20)	**3.40** (3.10-3.50)	**4.40** (4.20-4.70)	8945
Age group							
1-5 years	99-00	**2.23** (1.96-2.53)	**2.20** (1.90-2.50)	**3.30** (2.80-3.80)	**4.80** (4.00-6.60)	**7.00** (6.10-8.30)	723
	01-02	**1.70** (1.55-1.87)	**1.50** (1.40-1.70)	**2.50** (2.20-2.80)	**4.10** (3.40-5.00)	**5.80** (4.70-6.90)	898
6-11 years	99-00	**1.51** (1.36-1.66)	**1.30** (1.20-1.50)	**2.00** (1.70-2.40)	**3.30** (2.70-3.60)	**4.50** (3.40-6.20)	905
	01-02	**1.25** (1.14-1.36)	**1.10** (1.00-1.30)	**1.60** (1.50-1.80)	**2.70** (2.40-3.00)	**3.70** (3.00-4.70)	1044
12-19 years	99-00	**1.10** (1.04-1.17)	**1.00** (.900-1.10)	**1.40** (1.30-1.60)	**2.30** (2.10-2.30)	**2.80** (2.60-3.00)	2135
	01-02	**.942** (.899-.986)	**.800** (.800-.900)	**1.20** (1.20-1.30)	**1.90** (1.80-2.00)	**2.70** (2.30-2.90)	2231
20 years and older	99-00	**1.75** (1.68-1.81)	**1.70** (1.60-1.70)	**2.50** (2.50-2.60)	**3.90** (3.70-4.00)	**5.20** (4.80-5.50)	4207
	01-02	**1.56** (1.49-1.62)	**1.60** (1.50-1.60)	**2.20** (2.20-2.30)	**3.60** (3.30-3.70)	**4.60** (4.20-4.90)	4772
Gender							
Males	99-00	**2.01** (1.93-2.09)	**1.80** (1.80-1.90)	**2.90** (2.80-3.00)	**4.40** (4.10-4.80)	**6.00** (5.40-6.40)	3913
	01-02	**1.78** (1.71-1.86)	**1.70** (1.70-1.80)	**2.70** (2.50-2.80)	**3.90** (3.70-4.10)	**5.30** (5.00-5.50)	4339
Females	99-00	**1.37** (1.32-1.43)	**1.30** (1.20-1.30)	**1.90** (1.90-2.10)	**3.00** (2.90-3.20)	**4.00** (3.70-4.20)	4057
	01-02	**1.19** (1.14-1.25)	**1.10** (1.10-1.20)	**1.80** (1.70-1.80)	**2.60** (2.40-2.70)	**3.60** (3.00-3.80)	4606
Race/ethnicity							
Mexican Americans	99-00	**1.83** (1.75-1.91)	**1.80** (1.60-1.80)	**2.70** (2.60-2.90)	**4.20** (3.90-4.50)	**5.80** (5.10-6.60)	2742
	01-02	**1.46** (1.34-1.60)	**1.50** (1.30-1.60)	**2.20** (2.00-2.60)	**3.60** (3.30-4.00)	**5.40** (4.40-6.60)	2268
Non-Hispanic blacks	99-00	**1.87** (1.75-2.00)	**1.70** (1.60-1.90)	**2.80** (2.50-2.90)	**4.20** (4.00-4.60)	**5.70** (5.20-6.10)	1842
	01-02	**1.65** (1.52-1.80)	**1.60** (1.40-1.70)	**2.50** (2.30-2.80)	**4.20** (3.80-4.60)	**5.70** (5.30-6.50)	2219
Non-Hispanic whites	99-00	**1.62** (1.55-1.69)	**1.60** (1.50-1.60)	**2.40** (2.30-2.40)	**3.60** (3.40-3.70)	**5.00** (4.40-5.70)	2716
	01-02	**1.43** (1.37-1.48)	**1.40** (1.30-1.40)	**2.10** (2.10-2.20)	**3.10** (3.00-3.40)	**4.10** (3.90-4.50)	3806

dust in indoor firing ranges; and contact with soil, dust, or water contaminated by active or inactive mining or smelting operations. Children may also be exposed to lead brought into the home on the work clothes of adults whose work involves lead.

Following inhalation of fine lead particulate or fume or ingestion of soluble lead compounds, absorbed lead is bound to erythrocytes and is distributed initially to multiple soft tissues, including the brain, kidneys, bone marrow, and gonads, and to a slower extent to the subperiosteal surface and matrix of bone. Lead also undergoes transplacental transport and poses a potential hazard to the fetus. The kinetics of lead clearance from the body are characterized by a multi-compartmental model, predominantly composed of the blood and soft tissues, with a half-life of 1 to 2 months, and the skeleton, with a half-life of years to decades. Approximately 70% of lead excretion occurs via the urine, with lesser amounts eliminated via the feces, and scant amounts through sweat, hair, and nails (Leggett,

1993; O'Flaherty, 1993). The fraction of absorbed lead not undergoing prompt excretion, which is approximately half of the absorbed lead, may be incorporated into bone, the site of about 90% of the body lead burden in most adults.

Lead exerts multisystemic toxic effects through a variety of mechanisms, including interference in the function of essential cations such as calcium, zinc, and iron; inhibition of certain enzymes; binding to ion channels and regulatory proteins; generation of reactive oxygen species; and alteration in gene expression. Large amounts of lead in the body can cause clinical anemia, kidney injury, abdominal pain, seizures, encephalopathy, and paralysis. An increased prevalence of anemia has been observed with blood lead levels (BLLs) in excess of 25 µg/dL in children (Schwartz et al., 1990), or higher than 50 µg/dL in adults (Lilis et al., 1977). Kidney toxicity associated with chronic high-dose lead exposure includes interstitial and peritubular fibrosis, but low-level environmental lead exposure also can be associated with

Table 17. Lead in urine

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.766** (.708-.828)	**.800** (.700-.800)	**1.30** (1.30-1.40)	**2.10** (2.00-2.30)	**2.90** (2.60-3.20)	2465
	01-02	**.677** (.637-.718)	**.600** (.600-.700)	**1.20** (1.10-1.20)	**2.00** (1.80-2.00)	**2.60** (2.50-2.80)	2690
Age group							
6-11 years	99-00	**1.07** (.955-1.20)	**1.00** (.900-1.20)	**1.50** (1.40-1.60)	**2.40** (1.80-3.00)	**3.40** (2.40-5.00)	340
	01-02	**.753** (.661-.857)	**.800** (.600-.800)	**1.20** (1.00-1.30)	**2.00** (1.60-2.40)	**2.60** (2.10-3.60)	368
12-19 years	99-00	**.659** (.579-.749)	**.600** (.500-.800)	**1.10** (.900-1.20)	**1.70** (1.40-2.10)	**2.20** (1.90-2.50)	719
	01-02	**.564** (.526-.605)	**.600** (.500-.600)	**.900** (.800-1.10)	**1.50** (1.40-1.70)	**1.90** (1.70-2.10)	762
20 years and older	99-00	**.752** (.691-.818)	**.700** (.700-.800)	**1.40** (1.20-1.50)	**2.10** (1.90-2.30)	**2.90** (2.50-3.20)	1406
	01-02	**.688** (.641-.738)	**.700** (.600-.700)	**1.20** (1.10-1.20)	**1.90** (1.80-2.10)	**2.80** (2.50-2.90)	1560
Gender							
Males	99-00	**.923** (.822-1.04)	**.900** (.800-.900)	**1.60** (1.40-1.80)	**2.40** (2.20-2.90)	**3.40** (2.90-3.70)	1227
	01-02	**.808** (.757-.862)	**.700** (.700-.800)	**1.30** (1.30-1.50)	**2.40** (2.20-2.70)	**3.20** (2.90-3.50)	1335
Females	99-00	**.642** (.589-.701)	**.600** (.600-.700)	**1.20** (1.10-1.30)	**1.90** (1.60-2.10)	**2.40** (2.00-2.90)	1238
	01-02	**.573** (.535-.613)	**.500** (.500-.600)	**1.00** (1.00-1.10)	**1.50** (1.40-1.70)	**2.20** (1.90-2.40)	1355
Race/ethnicity							
Mexican Americans	99-00	**1.02** (.915-1.13)	**1.00** (.900-1.20)	**1.70** (1.60-1.90)	**2.80** (2.50-3.40)	**4.10** (3.10-5.40)	884
	01-02	**.833** (.745-.931)	**.900** (.700-1.00)	**1.50** (1.20-1.70)	**2.40** (2.00-2.90)	**3.20** (2.70-3.70)	683
Non-Hispanic blacks	99-00	**1.11** (1.00-1.23)	**1.10** (1.00-1.20)	**1.90** (1.50-2.00)	**2.90** (2.40-3.50)	**4.20** (3.30-5.70)	568
	01-02	**.940** (.833-1.06)	**.900** (.800-.900)	**1.50** (1.30-1.80)	**2.60** (2.00-3.20)	**3.70** (2.90-4.80)	667
Non-Hispanic whites	99-00	**.695** (.625-.773)	**.700** (.600-.700)	**1.30** (1.10-1.40)	**1.90** (1.70-2.20)	**2.60** (2.30-3.00)	822
	01-02	**.610** (.572-.651)	**.600** (.600-.700)	**1.00** (1.00-1.10)	**1.80** (1.70-2.00)	**2.40** (2.10-2.50)	1132

small decrements in renal function (Payton et al., 1994; Kim et al., 1996; Muntner et al., 2003).

Low-level environmental lead exposure has been associated with subclinical decrements in neurocognitive function in young children and elevated blood pressure in adults. Although in 1991 the Centers for Disease Control and Prevention (CDC) established 10 µg/dL as a blood lead concentration of concern in children, no threshold for lead's effects has yet been identified (National Research Council, 1993). Recent studies have suggested possible neurodevelopmental effects at blood lead concentrations of less than 10 µg/dL (Lanphear et al., 2000; Canfield et al., 2003); further assessment is ongoing. In adults, subtle, nonspecific neurocognitive effects may occur at BLLs as low as 20-60 µg/dL (Mantere et al., 1984; Schwartz et al., 2001), with overt encephalopathy, seizures, and peripheral neuropathy at higher levels (e.g., levels greater than 100 µg/dL). Results of studies of adults with occupational or environmental lead exposure have shown consistent

associations between increased BLLs and increased blood pressure (Schwartz, 1995; Staessen et al., 1995; Nash et al., 2003) and associations between increased bone lead concentrations and blood pressure (Hu et al., 1996; Korrick et al., 1999).

The potential adverse effects of lead on reproduction are an area of ongoing research and may include increased spontaneous abortion in women (Borja-Aburto et al., 1999) and problems with sperm formation in men (Alexander et al., 1996; Telisman et al., 2000). The International Agency for Research on Cancer (IARC) considers lead as a possible human carcinogen, and the National Toxicology Program (NTP) considers lead and its compounds as reasonably anticipated to be human carcinogens (NTP, 2005), but further study is needed on the relation between lead exposure and cancer in people (Jemal et al., 2002).

Table 18. Lead in urine (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.721** (.700-.742)	**.700** (.677-.725)	**1.11** (1.06-1.15)	**1.70** (1.62-1.85)	**2.37** (2.21-2.76)	2465
	01-02	**.639** (.603-.677)	**.634** (.586-.676)	**1.03** (.962-1.08)	**1.52** (1.42-1.60)	**2.03** (1.89-2.22)	2689
Age group							
6-11 years	99-00	**1.17** (.975-1.41)	**1.06** (.918-1.22)	**1.55** (1.22-1.97)	**2.71** (1.67-4.66)	**4.66** (1.97-18.0)	340
	01-02	**.918** (.841-1.00)	**.870** (.798-.933)	**1.26** (1.12-1.43)	**2.33** (1.59-3.64)	**3.64** (1.83-5.56)	368
12-19 years	99-00	**.496** (.460-.535)	**.469** (.408-.508)	**.702** (.655-.828)	**1.10** (.981-1.28)	**1.65** (1.15-2.78)	719
	01-02	**.404** (.380-.428)	**.373** (.342-.400)	**.602** (.541-.702)	**.990** (.882-1.18)	**1.41** (1.07-1.63)	762
20 years and older	99-00	**.720** (.683-.758)	**.712** (.667-.739)	**1.10** (1.02-1.18)	**1.69** (1.53-1.87)	**2.31** (2.11-2.62)	1406
	01-02	**.658** (.617-.703)	**.649** (.608-.702)	**1.04** (.992-1.11)	**1.51** (1.40-1.61)	**2.00** (1.85-2.19)	1559
Gender							
Males	99-00	**.720** (.679-.763)	**.693** (.645-.734)	**1.10** (.991-1.22)	**1.68** (1.50-2.09)	**2.43** (2.15-3.03)	1227
	01-02	**.639** (.607-.673)	**.638** (.586-.684)	**1.01** (.957-1.08)	**1.55** (1.41-1.61)	**2.06** (1.88-2.43)	1334
Females	99-00	**.722** (.681-.765)	**.706** (.667-.746)	**1.11** (1.05-1.16)	**1.74** (1.50-2.02)	**2.38** (2.03-2.88)	1238
	01-02	**.639** (.594-.688)	**.625** (.571-.670)	**1.03** (.938-1.11)	**1.50** (1.39-1.61)	**1.98** (1.85-2.15)	1355
Race/ethnicity							
Mexican Americans	99-00	**.940** (.876-1.01)	**.882** (.796-1.02)	**1.43** (1.36-1.56)	**2.38** (2.08-2.77)	**3.31** (2.78-4.18)	884
	01-02	**.810** (.731-.898)	**.769** (.702-.893)	**1.28** (1.09-1.44)	**2.05** (1.75-2.50)	**2.78** (2.55-3.33)	682
Non-Hispanic blacks	99-00	**.722** (.659-.790)	**.667** (.583-.753)	**1.11** (.988-1.20)	**1.98** (1.56-2.51)	**2.83** (2.20-3.88)	568
	01-02	**.644** (.559-.742)	**.606** (.510-.710)	**.962** (.853-1.19)	**1.79** (1.36-2.33)	**2.75** (2.04-3.98)	667
Non-Hispanic whites	99-00	**.696** (.668-.725)	**.677** (.645-.718)	**1.07** (.997-1.14)	**1.66** (1.50-1.83)	**2.31** (1.94-2.82)	822
	01-02	**.615** (.579-.654)	**.621** (.571-.667)	**1.00** (.930-1.06)	**1.46** (1.37-1.52)	**1.88** (1.61-2.00)	1132

Interpreting Levels of Lead in Blood and Urine Reported in the Tables

Levels of lead in blood were measured in all participants aged 1 year and older and urine lead levels were measured in a sample of people aged 6 years and older. Participants were selected to be a representative sample of the U.S. population. Blood lead measurement is the preferred method of evaluating lead exposure and its health effects in people. BLLs are contributed to by both recent intake and an equilibration with stored lead in other tissues, particularly in the skeleton. Urinary lead measurements are more variable than blood lead levels for a given individual.

The U.S. adult population has similar or slightly lower BLLs than adults in other developed nations. A general population survey of 4,646 adults in Germany in 1998 reported a geometric mean blood lead concentration of 3.07 µg/dL (Becker et al., 2002), a value nearly twice that found for U.S. adults in the 2001-2002 NHANES sample. A general population survey of 1,164 adults in Italy in 2000 found blood lead values slightly more than double those reported for U.S. adults in the 2001-2002 NHANES sample (Apostoli et al., 2002*a*).

In 1991, CDC designated 10 µg/dL as the blood lead level of concern in children, a level associated with the risk for subtle neurodevelopmental impairments. For children 1- 5 years old sampled over the four year period 1999-2002, the geometric mean BLL was 1.9 µg/dL (1.8-2.1), with 1.6% (1.1-2.3) of the children having BLLs greater than or equal to 10 µg/dL. Data from NHANES III, (phase 2, 1991-1994) showed that 4.4% of children aged 1-5 years had BLLs greater than or equal to 10 µg/dL, and the geometric mean BLL for children aged 1-5 years was 2.7 µg/dL (Pirkle et al., 1998). State childhood blood lead surveillance systems reported blood lead results for 2.4 million children to CDC in 2001. Of these children, 3.09% had a confirmed BLL of greater than or equal to 10 µg/dL (CDC, 2003*a*). Among a predominantly non-white population of U.S. children aged 0 to 17 years who were screened at an urban medical center in Washington, D.C. in 2001 and 2002, the geometric mean BLL in males was 3.2 µg/dL (n = 5,584) and 3.0 µg/dL in females (n = 5,562) (Soldin et al., 2003). These levels are higher than levels in similar age groups in the 2001-2002 NHANES sample and may reflect a higher prevalence of elevated BLLs that occur among children who 1) are non-Hispanic black and Mexican American; 2) live in urban settings; 3) are from lower socioeconomic groups; 4) are immigrants, refugees, or 5) reside in housing built before 1950 (CDC, 2003*a*; CDC, 2002; Geltman et al., 2001). In places where leaded gasoline is still used, such as in

Bangladesh, BLLs among school children are similar to BLLs measured in the United States before lead was removed from gasoline (i.e., a mean BLL of 15.0 µg/dL and 87.4% of children with levels in excess of 10 µg/dL [Kaiser et al., 2001]).

The U.S. Department of Labor, Occupational Safety and Health Administration (OSHA) requires monitoring of blood lead levels when occupational exposure to airborne levels of lead exceeds the established action level of greater than 30 micrograms per cubic meter of air (OSHA, 29 CFR 1910.1025). First established in the late 1970s, OSHA regulations have required medical removal of workers from workplace lead exposure when blood lead concentrations exceed 50 µg/dL or at lower levels per a physician's discretion. The American Conference of Governmental Industrial Hygienists (ACGIH, 2001) established a Biological Exposure Index (BEI) for inorganic lead in 1995 which recommended that BLL in workers remain less than 30 µg/dL. Levels for adults in the NHANES 1999-2000 and 2001-2002 samples are generally below these worker thresholds (four adult NHANES participants were above 30 µg/dL).

Comparing Adjusted Geometric Means

Geometric mean BLLs for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and log serum cotinine (data not shown). In NHANES 2001-2002, adjusted geometric mean BLLs were higher in children aged 1-5 years than in children aged 6-11 years, and both these age groups had higher levels than did those aged 12-19 years. BLLs in adults aged 20 years and older were higher than BLLs in the group aged 12-19 years. BLLs for males were higher than those for females. Non-Hispanic whites had lower BLLs than non-Hispanic blacks.

For urinary lead in NHANES 2001-2002, adjusted geometric mean levels of urinary lead in the group aged 6-11 years were higher than either the group aged 12-19 years or the group aged 20 years and older. The group aged 20 years and older had higher levels than the group aged 12-19 years. Mexican Americans had higher urinary levels than either non-Hispanic blacks or whites. Non-Hispanic blacks had higher levels than non-Hispanic whites. Males had slightly higher levels than females.

It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight. For instance, to account for the decreasing BLLs observed with increasing ages during childhood, several explanations are possible, including

decreasing exposure, dilution of lead by growth of body mass, or changing equilibria with bone turnover.

These blood and urine levels of lead provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of lead than are found in the general population. These data will also help scientists plan and conduct research about exposure to lead and health effects.

Figure 6. Lead in blood

Selected percentiles with 95% confidence intervals of blood concentrations (in µg/dL) for the U.S. population aged 1 year and older, National Health and Nutrition Examination Survey, 1999-2002.

Figure 7. Lead in urine (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Mercury

CAS No. 7439-97-6

General Information

Mercury is a naturally occurring metal that has elemental (metallic), inorganic, and organic forms. Elemental mercury is a shiny, silver-white liquid (quicksilver) obtained predominantly from the refining of mercuric sulfide in cinnabar ore. Elemental mercury is used to produce chlorine gas and caustic soda for industrial applications. Other major uses include electrical equipment (e.g., thermostats and switches), electrical lamps, thermometers, sphygmomanometers and barometers, and dental amalgam. Inorganic mercury exists in two oxidative states (mercurous and mercuric) that combine with other elements, such as chlorine (e.g., mercuric chloride), sulfur, or oxygen, to form inorganic mercury compounds or salts. Inorganic mercury compounds such as mercuric oxide are used in the production of batteries and pigments. Pharmaceutical applications of mercury have been declining, although certain organomercury compounds are still used as preservatives (e.g., thimerosal, phenylmercuric acetate) or topical antiseptics (e.g.,

merbromin). Some cosmetic skin creams from countries other than the U.S. may contain mercury. Folk medicines may contain mercury compounds, and elemental mercury is used ritually in some Latin American and Caribbean communities.

Elemental mercury is released into the air from the combustion of fossil fuels (primarily coal), solid-waste incineration, and mining and smelting. Through biogeochemical cycling, some atmospheric elemental mercury is deposited on land and water. In addition, water can be contaminated by the direct release of elemental and inorganic mercury from industrial processes. Metabolism of mercury by microorganisms in sediments creates methyl mercury, an organomercurial compound, which can bioaccumulate in terrestrial and especially aquatic food chains. The ingestion of methyl mercury, predominantly from fish and other seafood, constitutes the main source of dietary mercury exposure in the general population. Using the 1999-2000 NHANES data, it was estimated that women 16 to 49 years of age ingest a geometric

Table 19. Mercury in blood

Geometric mean and selected percentiles of blood concentrations (in µg/L) for males and females aged 1 to 5 years and females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Age Group							
1-5 years (females and males)	99-00	**.343** (.297-.395)	**.300** (.200-.300)	**.500** (.500-.600)	**1.40** (1.00-2.30)	**2.30** (1.20-3.50)	705
	01-02	**.318** (.268-.377)	**.300** (.200-.300)	**.700** (.500-.800)	**1.20** (.900-1.60)	**1.90** (1.40-2.90)	872
Females	99-00	**.377** (.299-.475)	**.200** (.200-.300)	**.800** (.500-1.10)	**1.60** (1.00-2.80)	**2.70** (1.30-5.50)	318
	01-02	**.329** (.265-.407)	**.300** (.200-.300)	**.700** (.500-.800)	**1.30** (1.00-2.10)	**2.60** (1.30-4.90)	432
Males	99-00	**.317** (.269-.374)	**.200** (.200-.300)	**.500** (.500-.600)	**1.10** (.800-1.60)	**2.10** (1.10-3.50)	387
	01-02	**.307** (.256-.369)	**.300** (.200-.300)	**.600** (.400-.700)	**1.30** (.900-1.70)	**1.70** (1.40-2.00)	440
16-49 years (females only)	99-00	**1.02** (.825-1.27)	**.900** (.800-1.20)	**2.00** (1.50-3.00)	**4.90** (3.70-6.30)	**7.10** (5.30-11.3)	1709
	01-02	**.833** (.738-.940)	**.700** (.700-.800)	**1.70** (1.40-1.90)	**3.00** (2.70-3.50)	**4.60** (3.70-5.90)	1928
Race/ethnicity (females, 16-49 years)							
Mexican Americans	99-00	**.820** (.664-1.01)	**.900** (.700-1.00)	**1.40** (1.20-2.00)	**2.60** (2.00-3.60)	**4.00** (2.70-5.50)	579
	01-02	**.667** (.541-.824)	**.700** (.500-.800)	**1.10** (1.00-1.40)	**2.10** (1.70-3.00)	**3.50** (2.30-4.40)	527
Non-hispanic blacks	99-00	**1.35** (1.06-1.73)	**1.30** (1.10-1.70)	**2.60** (1.80-3.40)	**4.80** (3.30-6.60)	**5.90** (4.20-11.7)	370
	01-02	**1.06** (.871-1.29)	**1.10** (.800-1.20)	**1.80** (1.50-2.20)	**3.20** (2.20-3.90)	**4.10** (3.30-6.00)	436
Non-hispanic whites	99-00	**.944** (.726-1.23)	**.900** (.700-1.10)	**1.90** (1.30-3.30)	**5.00** (3.00-6.90)	**6.90** (4.50-12.0)	588
	01-02	**.800** (.697-.919)	**.800** (.700-.800)	**1.50** (1.30-2.00)	**3.00** (2.20-3.70)	**4.60** (3.30-6.80)	806

Table 20. Mercury in urine

Geometric mean and selected percentiles of urine concentrations (in µg/L) for females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Age group (females)							
16-49 years	99-00	**.719** (.622-.831)	**.760** (.610-.910)	**1.62** (1.43-1.94)	**3.15** (2.55-3.92)	**5.00** (3.59-5.79)	1748
	01-02	**.606** (.553-.665)	**.580** (.500-.670)	**1.37** (1.23-1.55)	**2.91** (2.53-3.17)	**3.99** (3.50-4.63)	1960
Race/ethnicity (females, 16-49 years)							
Mexican Americans	99-00	**.724** (.656-.799)	**.650** (.560-.810)	**1.69** (1.45-2.07)	**3.68** (3.10-4.45)	**5.62** (4.91-7.38)	595
	01-02	**.592** (.502-.699)	**.560** (.420-.710)	**1.35** (1.09-1.76)	**2.84** (2.32-3.85)	**4.13** (2.81-6.24)	531
Non-Hispanic blacks	99-00	**1.06** (.832-1.35)	**1.03** (.850-1.51)	**2.30** (1.83-3.03)	**4.81** (3.41-6.18)	**6.98** (5.04-10.3)	381
	01-02	**.772** (.616-.966)	**.740** (.540-.930)	**1.76** (1.30-2.37)	**3.50** (2.57-4.97)	**5.18** (3.61-6.92)	442
Non-Hispanic whites	99-00	**.657** (.557-.774)	**.710** (.520-.870)	**1.50** (1.31-1.77)	**2.84** (2.39-3.32)	**4.05** (3.16-5.52)	594
	01-02	**.565** (.501-.637)	**.540** (.450-.650)	**1.31** (1.09-1.56)	**2.70** (2.22-3.16)	**3.62** (3.13-4.54)	826

mean of 1.22 micrograms of mercury per day from fish/seafood (approximately 85% as methyl mercury) (Mahaffey et al., 2004). Inhalation of mercury volatilized from dental amalgam is another major source of mercury exposure in the general population and is estimated to result in a daily intake of 1-5 µg per day (U.S. DHHS, 1993). Accidental spills of elemental mercury, which create the potential for subsequent volatization and inhalation of mercury vapor, have often required public health intervention (Zeitz et al., 2002).

The kinetics of the different forms of mercury vary considerably. Elemental mercury, absorbed mainly through inhalation of volatilized vapor, undergoes distribution to most tissues, with the highest concentrations occurring in the kidney (Hursh et al., 1980; Barregard et al., 1999). After absorption of elemental mercury, blood concentrations decline initially with a rapid half-life of approximately 1-3 days followed by a slower half-life of approximately 1 week to 3 weeks (Barregard et al., 1992; Sandborgh-Englund et al., 1998). The slow-phase half-life may be several weeks longer in people with chronic occupational exposure (Sallsten et al., 1993). After exposure to elemental mercury, excretion of mercury occurs predominantly through the kidney (Sandborgh-Englund et al., 1998), and peak urine mercury levels can lag behind peak blood levels by days to a few weeks (Barregard et al., 1992); thereafter, for both acute and chronic exposures, urinary mercury levels

decline with a half-life of approximately 1-3 months (Roels et al., 1991; Jonsson et al., 1999).

About 15% of inorganic mercury is absorbed from the human gastrointestinal tract (Rahola et al., 1973). Lesser penetration of inorganic mercury occurs through the blood-brain barrier than occurs with either elemental or methyl mercury (Hattula and Rahola, 1975; Vahter et al., 1994). The half-life of inorganic mercury in blood is similar to the slow-phase half-life of mercury after inhalation of elemental mercury. Excretion occurs by renal and fecal routes.

The fraction of methyl mercury absorbed from the gastrointestinal tract is about 95% (Aberg et al., 1969; Miettinen et al., 1971). Methyl mercury enters the brain and other tissues (Vahter et al., 1994) and then undergoes slow dealkylation to inorganic mercury. Human pharmacokinetic studies indicate that methyl mercury declines in blood and the whole body with a half-life of approximately 50 days (Sherlock et al., 1984; Smith et al., 1994; Smith and Farris, 1996). After exposure to methyl mercury, greater than two-thirds of the mercury is excreted via the feces, with a relatively minor amount eliminated as inorganic mercury in the urine (Smith et al., 1994; Smith and Farris, 1996). Small fractions of inorganic mercury and methyl mercury are incorporated into hair (Suzuki et al., 1993), which has been used in epidemiologic studies as a biomarker of exposure to methyl mercury (McDowell et al., 2004).

Table 21. Mercury in urine (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Age group (females)							
16-49 years	99-00	**.710** (.624-.806)	**.723** (.636-.833)	**1.41** (1.24-1.65)	**2.48** (2.10-2.97)	**3.27** (2.85-3.92)	1748
	01-02	**.620** (.579-.664)	**.650** (.582-.709)	**1.27** (1.15-1.42)	**2.30** (2.07-2.45)	**3.00** (2.68-3.39)	1960
Race/ethnicity (females, 16-49 years)							
Mexican Americans	99-00	**.685** (.580-.809)	**.639** (.508-.790)	**1.45** (1.27-1.61)	**2.89** (2.21-3.42)	**4.51** (3.07-5.68)	595
	01-02	**.600** (.526-.686)	**.596** (.426-.709)	**1.32** (1.04-1.47)	**2.41** (2.14-2.77)	**3.21** (2.65-4.46)	531
Non-Hispanic blacks	99-00	**.658** (.520-.831)	**.615** (.475-.892)	**1.22** (.909-1.79)	**2.56** (1.69-3.99)	**3.99** (2.76-5.14)	381
	01-02	**.522** (.410-.665)	**.516** (.387-.664)	**1.03** (.742-1.47)	**1.97** (1.42-3.25)	**3.21** (1.87-4.44)	442
Non-Hispanic whites	99-00	**.706** (.605-.824)	**.721** (.631-.846)	**1.41** (1.23-1.72)	**2.46** (1.99-2.97)	**3.05** (2.46-4.00)	594
	01-02	**.632** (.578-.691)	**.655** (.569-.744)	**1.28** (1.14-1.45)	**2.30** (2.03-2.56)	**2.95** (2.45-3.53)	826

Inorganic mercury and methyl mercury are also distributed into human breast milk, although the process may be more efficient for inorganic mercury (Grandjean et al., 1995; Oskarsson et al., 1996). Transplacental transport of methyl mercury and elemental mercury has been demonstrated in animal models. In a recent human study, concentrations of mercury in umbilical cord blood were correlated with mercury concentrations in maternal hair, maternal fish/seafood consumption, and maternal dental amalgam (Bjornberg et al., 2003). A recent meta-analysis of human studies of the ratio of mercury in umbilical cord blood to maternal blood produced an estimate of 1.7 (Stern and Smith, 2003).

The health effects of mercury are diverse and can depend on the form of the mercury to which a person is exposed and the severity and length of exposure. Acute, high-dose exposure to elemental mercury vapor may cause severe pneumonitis. At levels below those that cause acute lung injury, overt signs and symptoms of chronic inhalation may include tremor; gingivitis; and neurocognitive and behavioral disturbances, particularly irritability, depression, short-term memory loss, fatigue, anorexia, and sleep disturbance (Bidstrup et al., 1951; Smith et al., 1970; Smith et al., 1983). Subclinical neurological effects of low-level occupational exposure to elemental mercury have been found in some investigations (Chapman et al., 1990; Bittner et al., 1998), but an impact of low-level environmental exposure, such as that resulting from

dental amalgam, has not been established (Factor-Litvak et al., 2003; Bates et al., 2004a).

Exposure to inorganic mercury usually occurs by ingestion. The most prominent effect is on the kidneys, where mercury accumulates, and leads to tubular necrosis. In addition, there may be an irritant or corrosive effect on the gastrointestinal tract (Sanchez-Sicilia et al., 1963). Occupational exposure to elemental mercury vapor has been associated with subclinical effects on biomarkers of renal dysfunction (Cardenas et al., 1993). Acrodynia, a sporadic and predominantly pediatric syndrome in which the constellation of findings may include anorexia, insomnia, irritability, hypertension, maculopapular rash, pain in the extremities and pinkish discoloration of the hands and feet, has been associated with a variety of exposures to elemental mercury and inorganic mercury compounds (Tunnessen et al., 1987).

Overt poisoning from methyl mercury primarily affects the central nervous system, causing parasthesias, ataxia, dysarthria, hearing impairment, and progressive constriction of the visual fields, typically after a latent period of weeks to months. Methyl mercury has well-characterized adverse reproductive effects. High-level prenatal exposure may result in a constellation of developmental deficits that include mental retardation, cerebellar ataxia, dysarthria, limb deformities, altered physical growth, sensory impairments, and cerebral

palsy (National Research Council, 2000). In recent epidemiologic studies, lower levels of prenatal exposure due to maternal seafood consumption have been associated with an increased risk for abnormal neurocognitive test results in children (National Research Council, 2000; Rice et al., 2003). Although recent investigations have suggested a possible link between chronic ingestion of methyl mercury and an increased risk for myocardial infarction (Guallar et al., 2002; National Research Council, 2000), the existence of a causal relation is unresolved. Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris, the U.S. EPA's mercury homepage at http://www.epa.gov/mercury, and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Mercury in Blood and Urine Reported in the Tables

Blood mercury levels were measured in a subsample of NHANES participants aged 1-5 years and in females aged 16-49 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. The measurement of total blood mercury includes both inorganic and organic forms. In the general population, the total blood mercury concentration is due mostly to the dietary intake of organic forms, particularly of methyl mercury. Little organic mercury is excreted in the urine. Urinary mercury consists mostly of inorganic mercury (Cianciola et al., 1997; Kingman et al., 1998). These distinctions can assist in interpreting mercury blood levels in people. Total blood mercury levels are known to increase with greater fish consumption (Grandjean et al., 1995; Mahaffey and Mergler, 1998; Sanzo et al., 2001; Dewailly et al., 2001), and urine levels will increase with the number of teeth filled with mercury-containing amalgams (Becker et al., 2003).

The data in this *Report* are similar or slightly lower than levels found in other population studies. In Germany, for example, the geometric mean for blood mercury was 0.58 µg/L for 4,645 adults aged 18 to 69 years participating in a 1998 representative population survey (Becker et al., 2002). During the years 1996 through 1998, Benes et al. (2000) studied 1,216 blood donors in the Czech Republic (896 men and 320 women; average age 33 years) and 758 children (average age 9.9 years). The median concentration of blood mercury for adults was 0.78 µg/L and 0.46 µg/L for the juvenile population. A cohort of 1,127 U.S. men

(mean age 52.8 years, range 40 years to 78 years) with no occupational exposure to mercury, but who received dental care at military facilities during the mid to late 1990s, had an average blood mercury concentration of 2.55 µg/L (Kingman et al., 1998).

Blood mercury levels in both the 1999-2000 and 2001-2002 subsamples are below levels considered associated with known health effects. When blood mercury levels rise to about 100 µg/L following recent inorganic or elemental mercury poisoning, abnormal renal function tests may occur with low frequency. Total blood mercury levels in this *Report* were also well below levels established as occupational exposure guidelines. ACGIH recommends that the blood levels of inorganic mercury in workers not exceed 15 µg/L (six participants in the survey had higher levels, although these levels were unlikely to be due to inorganic forms of mercury). Information about the biological exposure indices (BEIs) is provided here for comparison, not to imply that the BEI is a safety level for general population exposure.

Clinically observable signs of ataxia and paresthesias occur with low frequency when blood mercury levels rise to about 100 µg/L following recent methyl mercury poisoning. However, the developing fetus may be the most susceptible to the effects of ongoing methyl mercury exposure (National Research Council, 2000). A cord blood mercury level of 85 µg/L (lower 95% confidence bound = 58 µg/L) is associated with a 5% increase in the prevalence of an abnormal Boston Naming Test (NRC, 2000). *Report* data for the period 1999-2002 show that all women of childbearing age had levels below 58 µg/L, a concentration associated with neurologic effects in the fetus. These data show that 5.7% of women of childbearing age had levels between 5.8 and 58 µg/L; that is, levels within a factor of 10 of those associated with neurological effects. Better defining safe levels of mercury in maternal blood is a priority area for additional research. EPA has set an oral reference dose (RfD, a daily dose considered to be safe) for methyl mercury of 0.1µg/kg/day, derived in part from this and other associated blood levels in outcome studies. A specific value for the blood mercury concentration that corresponds to the RfD has not been established (Rice, 2004).

Urinary mercury levels in recent German (Becker et al., 2003), Czech (Benes et al., 2002), and Italian (Apostoli et al., 2002*b*) adult population surveys were roughly similar to the values found for women in the 2001–2002 NHANES subsample. An expert-panel

report recently prepared for the U.S. Department of Health and Human Services (U.S. DHHS) noted that several studies have observed a modest, reversible increase in urinary N-acetyl-glucosaminidase, a biomarker of perturbation in renal tubular function, among workers with urinary mercury concentrations of greater than or equal to 25-35 µg/L (Life Sciences Research Office, 2004). The ACGIH (2001) currently recommends that urinary inorganic mercury in workers not exceed 35 µg/gram of creatinine.

Comparing Adjusted Geometric Means

Geometric mean levels of blood mercury for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). In NHANES 2001-2002, non-Hispanic black females aged 16-49 years had higher levels than non-Hispanic white and Mexican-American females aged 16-49 years. Non-Hispanic white females aged 16-49 years had higher levels than Mexican American females aged 16-49 years. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

For urinary mercury levels, there were no differences of the adjusted geometric means among the three race/ethnicity groups.

Finding a measurable amount of mercury in blood or urine does not mean that the level of mercury causes an adverse health effect. These data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of mercury than are found in the general population. These data will also help scientists plan and conduct research about mercury exposure and health effects.

Figure 8. Mercury in blood

Selected percentiles with 95% confidence intervals of blood concentrations (in µg/L) for males and females aged 1 to 5 years and females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

Figure 9. Mercury in urine (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

Molybdenum

CAS No. 7439-98-7

General Information

Elemental molybdenum is a silver-white, hard metal with many commercial uses, including the production of metal alloys. Compounds of molybdenum are used as corrosion inhibitors; hydrogenation catalysts; lubricants; alloys in steel; chemical reagents in hospital laboratories; and in pigments for ceramics, inks and paints.

Molybdenum is a nutritionally essential trace element and enters the body primarily from dietary sources. Molybdenum is a cofactor for a limited number of human enzymes, principally sulfite oxidase and xanthine oxidase (Kisker et al., 1997). The recommended dietary allowance for adult men and women is 45 µg/day (Institute of Medicine, 2001), and the average dietary daily intake of molybdenum is approximately 100 µg/day (WHO, 1996; Institute of Medicine, 2001). Molybdenum

occurs in natural waters and may be present in concentrations of several hundred micrograms per liter or higher in ground and surface water in the vicinity of mining operations or ore deposits. In industry, dust and other fine particles produced during the refining or shaping of molybdenum or molybdenum-containing alloys are sources of exposure.

Gastrointestinal absorption of molybdenum averages 88-93% for dietary intakes of 22 to 1490 µg/day. Excretion occurs predominantly via the kidney, which exerts homestatic regulation over molybdenum balance. At a daily oral molybdenum dose of 24 µg, urinary excretion over a six day period was 18% of the ingested dose, but at daily oral doses of 95 µg and 428 µg, urinary excretion over a six day period rose to 50% and 67% of the ingested dose, respectively (Turnlund et al., 1995).

Table 22. Molybdenum

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**45.9** (40.1-52.6)	**50.7** (44.6-58.4)	**84.9** (78.7-92.3)	**134** (125-146)	**178** (154-216)	2257
	01-02	**45.0** (42.1-48.0)	**52.4** (48.9-55.5)	**83.3** (79.1-88.5)	**124** (117-130)	**165** (145-176)	2690
Age group							
6-11 years	99-00	**78.2** (61.0-100)	**83.4** (67.7-105)	**126** (106-147)	**174** (147-242)	**267** (159-840)	310
	01-02	**63.3** (53.4-75.0)	**69.2** (63.0-77.6)	**109** (94.5-124)	**169** (138-197)	**197** (161-291)	368
12-19 years	99-00	**54.3** (47.6-62.0)	**60.6** (52.2-70.3)	**93.3** (79.9-109)	**146** (112-171)	**183** (146-216)	648
	01-02	**60.6** (55.5-66.2)	**65.7** (58.7-73.1)	**96.9** (91.8-108)	**145** (129-159)	**179** (155-227)	762
20 years and older	99-00	**41.7** (36.7-47.4)	**46.5** (40.5-52.3)	**76.7** (73.4-82.2)	**125** (114-134)	**167** (143-206)	1299
	01-02	**41.1** (38.3-44.1)	**47.4** (43.7-51.2)	**79.0** (71.9-83.6)	**114** (103-124)	**150** (130-166)	1560
Gender							
Males	99-00	**52.7** (45.7-60.7)	**57.4** (48.5-68.4)	**93.2** (83.8-106)	**150** (128-187)	**213** (161-278)	1121
	01-02	**51.0** (46.6-55.7)	**56.9** (51.8-62.6)	**88.5** (81.6-96.5)	**130** (120-141)	**169** (145-194)	1335
Females	99-00	**40.4** (34.8-46.8)	**45.5** (40.4-52.0)	**77.2** (71.0-85.7)	**118** (105-138)	**154** (132-180)	1136
	01-02	**39.9** (37.2-42.9)	**45.7** (42.7-49.0)	**78.4** (72.6-82.9)	**114** (104-128)	**158** (130-177)	1355
Race/ethnicity							
Mexican Americans	99-00	**47.0** (42.1-52.4)	**53.2** (49.0-59.0)	**80.3** (73.7-91.7)	**120** (103-139)	**152** (120-217)	780
	01-02	**49.3** (46.5-52.3)	**55.7** (50.4-61.0)	**86.3** (80.8-94.1)	**133** (113-155)	**177** (142-207)	683
Non-Hispanic blacks	99-00	**57.7** (51.0-65.2)	**61.8** (55.0-71.5)	**97.7** (85.0-110)	**151** (126-188)	**202** (150-274)	546
	01-02	**53.2** (49.9-56.7)	**60.3** (54.2-63.1)	**89.9** (81.0-101)	**130** (121-147)	**166** (147-170)	667
Non-Hispanic whites	99-00	**44.5** (37.0-53.4)	**48.5** (41.1-59.8)	**85.0** (76.7-95.9)	**135** (119-154)	**178** (146-223)	760
	01-02	**42.2** (38.5-46.2)	**48.9** (44.2-53.2)	**80.7** (71.9-85.8)	**117** (108-129)	**152** (134-180)	1132

Molybdenum is generally considered to be of low toxicity to people, and clinical or epidemiological evidence of adverse effects is limited. Chronic exposure to high levels may possibly result in higher serum uric acid levels and gout-like illness (Koval'skiy et al., 1961; U.S. EPA, 1993). Based on studies finding adverse reproductive effects in rats and mice, the Panel on Micronutrients of the Institute of Medicine identified a no observed adverse effect level (NOAEL) of 0.9 mg/kg/day and established a tolerable upper intake level of 0.03 mg/kg/day in humans (Institute of Medicine, 2001). A long term inhalation bioassay of molybdenum trioxide in mice yielded "some evidence" of carcinogenicity (NTP, 1997). A recent case-control study suggested a possible link between occupational exposure to molybdenum and lung cancer (Droste et al., 1999) but the available epidemiological data are scant and molybdenum has not been systematically evaluated for carcinogenicity by U.S. EPA or IARC.

Interpreting Levels of Urinary Molybdenum Reported in the Tables

Urinary molybdenum levels were measured in a subsample of NHANES participants aged 6 years and older. Subsamples were randomly selected within the specified age range to be a representative sample of the U.S. population. Because molybdenum is an essential element for good health, intake and loss in the urine is expected. The levels documented for adults in the NHANES 2001-2002 subsample are broadly comparable to levels reported for adults in recent smaller European population surveys (Minoia et al., 2002; White and Sabbioni, 1998; Iversen et al., 1998). Among infants, urinary molybdenum concentrations may be slightly lower than other age groups (Sievers et al., 2001).

Table 23. Moylbdenum (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**43.2** (40.0-46.6)	**41.5** (38.5-45.2)	**63.5** (59.3-68.8)	**108** (97.3-115)	**144** (125-171)	2257
	01-02	**42.5** (39.9-45.2)	**42.2** (40.1-45.2)	**62.0** (58.4-66.4)	**98.8** (90.1-109)	**130** (120-149)	2689
Age group							
6-11 years	99-00	**85.9** (73.7-100)	**78.9** (71.6-88.4)	**122** (107-133)	**173** (130-243)	**213** (154-1040)	310
	01-02	**77.2** (73.1-81.5)	**77.5** (71.8-84.5)	**109** (99.4-120)	**154** (129-170)	**185** (165-219)	368
12-19 years	99-00	**41.9** (39.3-44.6)	**40.5** (37.7-44.4)	**57.3** (51.5-62.5)	**85.0** (67.4-107)	**109** (78.4-185)	648
	01-02	**43.4** (40.8-46.1)	**44.1** (40.8-47.2)	**60.6** (57.6-63.7)	**85.5** (79.7-93.8)	**106** (94.8-118)	762
20 years and older	99-00	**39.6** (36.9-42.6)	**38.5** (36.1-41.0)	**56.4** (53.5-60.7)	**92.5** (83.1-100)	**120** (116-147)	1299
	01-02	**39.3** (36.8-42.0)	**39.6** (36.4-42.1)	**57.2** (52.9-61.0)	**86.7** (75.2-96.8)	**122** (109-139)	1559
Gender							
Males	99-00	**40.8** (37.5-44.3)	**38.5** (37.2-40.4)	**62.4** (55.9-68.4)	**101** (83.9-118)	**131** (112-179)	1121
	01-02	**40.3** (37.1-43.8)	**40.2** (36.3-43.3)	**60.4** (54.8-66.3)	**91.3** (83.4-106)	**123** (107-155)	1334
Females	99-00	**45.5** (41.5-50.0)	**43.7** (39.5-48.8)	**64.4** (59.5-70.5)	**111** (95.2-121)	**149** (122-181)	1136
	01-02	**44.6** (42.2-47.1)	**45.1** (42.2-46.9)	**63.6** (59.5-69.4)	**107** (92.5-119)	**136** (117-169)	1355
Race/ethnicity							
Mexican Americans	99-00	**42.9** (40.6-45.4)	**43.2** (40.9-45.6)	**61.6** (57.2-65.5)	**89.0** (80.0-103)	**115** (93.7-137)	780
	01-02	**48.1** (44.3-52.2)	**48.4** (44.8-52.3)	**71.5** (66.4-76.0)	**103** (90.0-120)	**129** (109-155)	682
Non-Hispanic blacks	99-00	**37.2** (33.4-41.6)	**37.0** (33.0-41.2)	**55.9** (49.6-63.3)	**88.2** (69.1-112)	**117** (88.3-141)	546
	01-02	**36.5** (34.1-39.0)	**37.5** (35.1-38.9)	**57.1** (49.7-62.4)	**78.3** (71.5-92.0)	**109** (81.1-127)	667
Non-Hispanic whites	99-00	**44.5** (40.2-49.2)	**42.1** (38.8-47.3)	**65.3** (58.9-71.3)	**116** (101-126)	**172** (131-195)	760
	01-02	**42.5** (39.3-46.0)	**41.9** (39.3-45.6)	**61.2** (57.1-67.2)	**104** (88.7-120)	**138** (120-163)	1132

Comparing Adjusted Geometric Means

Geometric mean levels of urinary molybdenum for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary molybdenum were higher for children aged 6-11 years than for people aged 12-19 years or aged 20 years and older. The group aged 12-19 years had higher levels than the group aged 20 years and older. Non-Hispanic blacks had slightly lower levels than non-Hispanic whites and Mexican Amercians. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

These urinary molybdenum data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of molybdenum than are found in the general population. These data will also help scientists plan and conduct research about molybdenum exposure and health effects.

Figure 10. Molybdenum (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older,National Health and Nutrition Examination Survey, 1999-2002.

Platinum

CAS No. 7440-06-4

General Information

Platinum is a silver-gray, lustrous metal found naturally in extremely low amounts in the earth's crust and typically is associated with sulfide-ore bodies of nickel, copper, and iron. Important properties of platinum are its resistance to corrosion, strength at high temperatures, and high catalytic activity.

Platinum compounds are also used in electrodes and jewelry, as oxidation catalysts in chemical manufacturing, in thick-film circuits printed on ceramic substrates, and as drugs (e.g., cisplatin, carboplatin) in the treatment of cancer. Platinum-rhodium and platinum-palladium crystals are used as catalysts in petroleum refining and in the control of automobile-exhaust emissions. Platinum-rhodium compounds are also used in glass and glass-fiber manufacture and in high-

temperature thermocouples. Higher environmental soil concentrations of platinum have been associated with nearby roadways due to vehicular emissions (Farago et al., 1998), although the ambient air concentrations of platinum associated with its use in automotive engine catalytic converters are estimated to be 10,000 times lower than occupational exposure limits.

The acute and chronic toxic effects of exposure to platinum are highly dependent on the type of compound (e.g., metallic, inorganic salt, or organometallic), the route of exposure (e.g., intravenous (medicinal use), inhalational, cutaneous, oral), and duration of exposure. Platinum metal is considered biologically inert, whereas platinum compounds (e.g., salts) can cause acute and chronic irritant and immune-mediated hypersensitivity reactions, such as bronchitis and asthma following inhalational exposure. Also, contact dermatitis following

Table 24. Platinum

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2690
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	< LOD	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1560
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	< LOD	1335
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	683
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

topical exposure may occur in occupational exposure settings (e.g., platinum refining plants).

Workplace air standards for external exposure are generally established for soluble salts of platinum by OSHA and ACGIH, or recommended for the metal form by NIOSH (Czerczak & Gromiec, 2000). The pharmaceutical cisplatin is an animal carcinogen as determined by NTP and a possible human carcinogen. The carcinogenicity of other platinum compounds remains uncertain. Information about external exposure (i.e., environmental levels) and health effects is available on line (W.H.O. International Programme on Chemical Safety at http://www.inchem.org).

Interpreting Levels of Urinary Platinum Reported in the Tables

Urinary platinum levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range

to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, as in the previously tested 1999-2000 subsample, urinary platinum levels were detectable in only a few percent of the sample (detection limit was 0.04 µg/L). Older studies reporting measurements in general populations have found detectable and higher values than the value of the detection limit reported in this *Report* (Vaughan et al., 1992; Paschal et al., 1998), which may be due to methodologic, population, or exposure differences. Recently, several studies have shown that background concentrations in general populations are usually less than 0.005 µg/L (Iavicoli et al., 2004; Wilhelm et al., 2003) or less than 0.01 µg/L (Becker et al., 2003; Herr et al., 2003).

One study found that traffic-control police had no greater urinary platinum concentrations than office-based control subjects (Iavicoli et al., 2004). Gold-platinum alloys used for dental fillings also may contribute to urinary platinum concentrations (Schierl, 2001; Herr et al., 2003).

Table 25. Platinum (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	50th	75th	90th	95th	Sample size
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2689
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	< LOD	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1559
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	< LOD	1334
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	682
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Platinum-industry and precious-metal workers can have urinary concentrations 1,000 times higher than general populations (Schierl et al., 1998). The handling of cisplatin and carboplatin by pharmacy and other hospital personnel has been associated with modest (ten-fold or less) elevations in urinary platinum concentrations (Ensslin et al., 1997; Pethran et al., 2003).

Finding a measurable amount of platinum in urine does not mean that the level of platinum causes an adverse health effect. Whether platinum at the levels reported here is a cause for health concern is not yet known; more research is needed. These urine platinum data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of platinum than are found in the general population. These data will also help scientists plan and conduct research about exposure to platinum and health effects.

Thallium

CAS No. 7440-28-0

General Information

Elemental thallium is a blue-white metal found in small amounts in soil and in sulfide-based minerals. In the past, thallium was obtained as a by-product of the smelting of other metals; however, it has not been specifically mined or refined in the United States since 1984. It is still used in relatively small amounts in pharmaceutical and electronics manufacturing, the latter being the current major industrial consumer of thallium in this country. In the United States, thallium has been restricted from pesticidal (rodenticidal, insecticidal, and fungicidal) or cosmetic (depilatory) uses.

Thallium exposure occurs primarily from industrial processes such as coal-burning and smelting. From these and other sources, thallium is produced in a fine particulate form that can be absorbed through inhalation or ingestion. Thallium disappears from the blood with a half-life of several days representing distribution into other tissues. In addition, thallium readily crosses the placenta and also distributes into breast milk. Elimination from the body tissues is slow, occurring via urine and feces.

Thallium produces toxicity by replacing intracellular potassium in the body, though additional mechanisms of action are possible. Since thallium salts are colorless, odorless, and tasteless, there is potential for undetected malevolent use. Severe accidental thallium poisoning has involved the ingestion of rat poisons that contain water-soluble thallium salts. Relatively high-dose intentional or accidental ingestion can result in gastrointestinal symptoms followed by multi-organ failure, neurologic injury, and death. Peripheral neuropathy and alopecia are well-documented effects of acute and chronic exposures.

Table 26. Thallium

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.176** (.162-.192)	**.200** (.180-.210)	**.280** (.260-.310)	**.400** (.370-.420)	**.450** (.420-.470)	2413
	01-02	**.165** (.154-.177)	**.180** (.170-.200)	**.270** (.260-.290)	**.360** (.350-.380)	**.440** (.410-.470)	2653
Age group							
6-11 years	99-00	**.201** (.167-.243)	**.200** (.150-.260)	**.300** (.250-.350)	**.410** (.330-.450)	**.440** (.350-.590)	336
	01-02	**.172** (.147-.202)	**.200** (.160-.220)	**.290** (.230-.330)	**.340** (.330-.360)	**.380** (.360-.420)	362
12-19 years	99-00	**.202** (.181-.225)	**.210** (.200-.240)	**.290** (.270-.340)	**.410** (.390-.430)	**.460** (.430-.510)	697
	01-02	**.200** (.182-.220)	**.210** (.190-.240)	**.300** (.290-.320)	**.360** (.340-.390)	**.460** (.400-.500)	746
20 years and older	99-00	**.170** (.157-.183)	**.180** (.170-.200)	**.290** (.260-.310)	**.400** (.370-.420)	**.450** (.420-.470)	1380
	01-02	**.159** (.147-.173)	**.190** (.170-.200)	**.270** (.250-.290)	**.380** (.350-.400)	**.440** (.400-.490)	1545
Gender							
Males	99-00	**.197** (.179-.217)	**.220** (.190-.240)	**.310** (.280-.350)	**.390** (.360-.440)	**.440** (.420-.480)	1200
	01-02	**.184** (.173-.196)	**.200** (.190-.220)	**.290** (.270-.290)	**.380** (.350-.390)	**.420** (.390-.460)	1313
Females	99-00	**.159** (.145-.175)	**.180** (.150-.200)	**.270** (.240-.290)	**.380** (.340-.410)	**.450** (.410-.490)	1213
	01-02	**.149** (.137-.163)	**.150** (.150-.170)	**.250** (.230-.280)	**.370** (.330-.400)	**.430** (.400-.500)	1340
Race/ethnicity							
Mexican Americans	99-00	**.172** (.150-.196)	**.190** (.160-.220)	**.260** (.240-.290)	**.370** (.320-.420)	**.450** (.370-.520)	861
	01-02	**.160** (.148-.173)	**.180** (.150-.190)	**.250** (.240-.270)	**.330** (.310-.360)	**.400** (.350-.440)	675
Non-Hispanic blacks	99-00	**.217** (.197-.239)	**.220** (.200-.240)	**.340** (.300-.380)	**.440** (.390-.510)	**.550** (.460-.620)	561
	01-02	**.202** (.187-.218)	**.210** (.200-.230)	**.290** (.270-.330)	**.400** (.380-.440)	**.520** (.440-.590)	657
Non-Hispanic whites	99-00	**.170** (.153-.188)	**.200** (.160-.220)	**.280** (.250-.320)	**.400** (.360-.420)	**.440** (.420-.480)	801
	01-02	**.159** (.147-.172)	**.180** (.160-.190)	**.270** (.250-.290)	**.350** (.320-.380)	**.430** (.390-.460)	1114

Workplace air standards for external exposure are generally established by OSHA and ACGIH. Chronic high-level exposures have been associated with weight loss, arthralgias, and polyneuropathy. IARC and NTP consider the evidence for the carcinogenicity of thallium as inadequate or unclassifiable. Information about external exposure (i.e., environmental levels) and health effects is available from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Urinary Thallium Reported in the Tables

Urinary thallium levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Previous studies have suggested that normal background urinary thallium concentrations are less than 1 µg/L (Schaller et al., 1980; Brockhaus et al., 1981; Minoia et al., 1990), which are consistent with levels documented

in this NHANES 2001-2002 subsample and the previous 1999-2000 subsample. Other population surveys have demonstrated urinary levels of roughly similar magnitude (White and Sabbioni, 1998; Minoia et al., 1990; Paschal et al., 1998).

Urinary concentrations of 100 µg/L in asymptomatic workers (500 times higher than median levels observed in this *Report*) are thought to correspond to workplace exposures at the threshold limit value of 0.1 mg/m^3 (Marcus, 1985). Brockhaus et al. (1981) studied 1,265 people living near a thallium-emitting cement plant in Germany. Nearby residents were exposed by eating garden plants on which thallium had been deposited. Seventy-eight percent of the urine specimens in that study contained more than 1 µg/L, with concentrations ranging up to 76.5 µg/L. There was no increase in the prevalence of symptoms at levels less than 20 µg/L and only a slight increase in nonspecific symptoms above 20 µg/L.

Table 27. Thallium (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval) 50th	75th	90th	95th	Sample size
Total, age 6 and older	99-00	**.166** (.159-.173)	**.168** (.162-.176)	**.224** (.217-.233)	**.297** (.273-.319)	**.366** (.338-.387)	2413
	01-02	**.156** (.151-.162)	**.156** (.148-.164)	**.215** (.208-.222)	**.287** (.278-.300)	**.348** (.337-.365)	2652
Age group							
6-11 years	99-00	**.221** (.197-.248)	**.221** (.196-.236)	**.292** (.229-.356)	**.375** (.318-.469)	**.424** (.356-.600)	336
	01-02	**.211** (.198-.226)	**.207** (.198-.221)	**.286** (.257-.321)	**.370** (.333-.402)	**.411** (.389-.456)	362
12-19 years	99-00	**.153** (.146-.160)	**.154** (.146-.162)	**.205** (.191-.219)	**.257** (.231-.278)	**.321** (.265-.364)	697
	01-02	**.143** (.137-.150)	**.145** (.135-.152)	**.196** (.184-.207)	**.269** (.250-.289)	**.307** (.299-.333)	746
20 years and older	99-00	**.162** (.153-.171)	**.167** (.154-.176)	**.217** (.207-.230)	**.285** (.271-.300)	**.364** (.325-.389)	1380
	01-02	**.153** (.147-.159)	**.152** (.144-.161)	**.210** (.200-.217)	**.277** (.263-.292)	**.342** (.313-.362)	1544
Gender							
Males	99-00	**.154** (.147-.161)	**.156** (.149-.164)	**.202** (.192-.214)	**.269** (.254-.297)	**.338** (.300-.364)	1200
	01-02	**.146** (.140-.153)	**.148** (.141-.156)	**.192** (.184-.204)	**.259** (.245-.278)	**.307** (.291-.342)	1312
Females	99-00	**.178** (.167-.189)	**.182** (.169-.196)	**.244** (.226-.259)	**.313** (.281-.366)	**.380** (.333-.462)	1213
	01-02	**.167** (.158-.176)	**.167** (.153-.179)	**.233** (.217-.250)	**.313** (.282-.348)	**.375** (.348-.402)	1340
Race/ethnicity							
Mexican Americans	99-00	**.158** (.147-.170)	**.159** (.148-.175)	**.212** (.200-.234)	**.282** (.266-.304)	**.338** (.306-.389)	861
	01-02	**.156** (.145-.169)	**.155** (.145-.167)	**.204** (.190-.221)	**.286** (.250-.315)	**.361** (.301-.424)	674
Non-Hispanic blacks	99-00	**.142** (.133-.152)	**.140** (.129-.151)	**.200** (.184-.214)	**.277** (.244-.307)	**.383** (.286-.462)	561
	01-02	**.138** (.128-.150)	**.136** (.125-.146)	**.194** (.170-.212)	**.256** (.238-.278)	**.321** (.271-.387)	657
Non-Hispanic whites	99-00	**.169** (.160-.179)	**.173** (.167-.181)	**.226** (.215-.240)	**.300** (.271-.325)	**.364** (.333-.377)	801
	01-02	**.161** (.155-.167)	**.161** (.153-.171)	**.220** (.214-.231)	**.291** (.278-.304)	**.347** (.327-.375)	1114

Comparing Adjusted Geometric Means

Geometric mean levels of urinary thallium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary thallium were slightly higher for people aged 6-11 years than for the other two age groups. It is unknown whether these differences associated with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding low amounts of thallium in urine does not mean that the level of thallium causes adverse health effects. Whether thallium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary thallium data provide physicians with a reference range so that they can determine whether individuals or groups have been exposed to higher levels of thallium than are found in the general population. These data will also help scientists plan and conduct research about thallium exposure and health effects.

Figure 11. Thallium (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Tungsten

CAS No. 7440-33-7

General Information

Tungsten is a steel-gray to tin-white metal naturally occurring in the earth's crust, mainly as scheelite (CaWO$_4$). A major use of tungsten is in the production of hard metals, such as tungsten carbide, which is used in rock drills and metal-cutting tools, and ferrotungsten, which is used in the steel industry. Additionally, tungsten compounds are used as lubricating agents, filaments for incandescent lamps, bronzes in pigments, and as catalysts in the petroleum industry.

Most background environmental exposures to tungsten are from the soluble forms, such as tungstate salts, whereas occupational exposure is from tungsten metal dusts released during the grinding or drilling of metals. Drinking water also can be a source of exposure. Workplace air standards for external exposure have been

established by ACGIH or recommended by NIOSH. Evidence is lacking for the carcinogenicity of tungsten; it has not been classified with respect to its carcinogenicity by either IARC or NTP.

Only limited information is available on the toxicity of tungsten. Human illness from low-level environmental or occupational exposure has not been well established. Although workers occupationally exposed to tungsten carbide may develop serious lung disease ("hard metal" disease), their illness may stem from co-exposure to cobalt mixed with tungsten carbide rather than to tungsten itself.

Table 28. Tungsten

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.093** (.087-.100)	**.090** (.080-.090)	**.180** (.160-.190)	**.320** (.280-.360)	**.500** (.420-.550)	2338
	01-02	**.082** (.073-.092)	**.060** (.060-.080)	**.150** (.130-.180)	**.300** (.260-.340)	**.450** (.370-.560)	2652
Age group							
6-11 years	99-00	**.158** (.123-.204)	**.160** (.100-.200)	**.260** (.210-.330)	**.490** (.380-.560)	**.590** (.510-.950)	320
	01-02	**.137** (.110-.170)	**.140** (.100-.160)	**.250** (.200-.340)	**.450** (.360-.690)	**.770** (.510-1.53)	363
12-19 years	99-00	**.113** (.097-.132)	**.110** (.090-.120)	**.200** (.170-.230)	**.360** (.300-.430)	**.530** (.380-.800)	679
	01-02	**.113** (.095-.135)	**.100** (.090-.130)	**.210** (.180-.240)	**.390** (.310-.520)	**.570** (.430-.710)	744
20 years and older	99-00	**.084** (.078-.091)	**.070** (.060-.080)	**.150** (.130-.180)	**.270** (.250-.320)	**.440** (.360-.520)	1339
	01-02	**.073** (.065-.082)	**.060** (.050-.060)	**.130** (.110-.160)	**.250** (.210-.300)	**.370** (.300-.490)	1545
Gender							
Males	99-00	**.107** (.096-.120)	**.100** (.080-.110)	**.210** (.180-.230)	**.380** (.310-.470)	**.530** (.470-.650)	1160
	01-02	**.088** (.074-.105)	**.080** (.060-.090)	**.160** (.130-.210)	**.330** (.260-.390)	**.490** (.380-.580)	1307
Females	99-00	**.082** (.077-.087)	**.070** (.060-.070)	**.140** (.130-.160)	**.270** (.240-.290)	**.390** (.320-.470)	1178
	01-02	**.076** (.069-.084)	**.060** (.050-.060)	**.140** (.120-.170)	**.280** (.230-.320)	**.430** (.330-.530)	1345
Race/ethnicity							
Mexican Americans	99-00	**.113** (.095-.133)	**.100** (.090-.120)	**.190** (.160-.240)	**.390** (.300-.520)	**.550** (.420-.830)	790
	01-02	**.101** (.093-.109)	**.090** (.080-.110)	**.180** (.170-.200)	**.370** (.310-.430)	**.560** (.450-.670)	680
Non-Hispanic blacks	99-00	**.113** (.101-.126)	**.090** (.080-.110)	**.200** (.170-.240)	**.360** (.290-.460)	**.550** (.420-.810)	562
	01-02	**.096** (.080-.116)	**.080** (.060-.110)	**.150** (.120-.230)	**.310** (.270-.400)	**.460** (.390-.580)	649
Non-Hispanic whites	99-00	**.092** (.084-.100)	**.070** (.060-.090)	**.170** (.150-.190)	**.310** (.270-.380)	**.460** (.380-.520)	802
	01-02	**.076** (.066-.088)	**.050** (.040-.070)	**.150** (.120-.170)	**.290** (.230-.350)	**.430** (.330-.560)	1117

Interpreting Levels of Urinary Tungsten Reported in the Tables

Urinary tungsten levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. A nonrandom subsample from NHANES III demonstrated higher values than those in this *Report* (Paschal et al., 1998), possibly due to methodologic, population, or exposure differences. One small study of unexposed individuals (n = 14) yielded values similar to those reported here (Schramel et al., 1997). Median urinary tungsten levels may be increased as much as 15-fold over median levels in this *Report* due to natural increases in drinking water sources (CDC, 2003b). During grinding operations that release tungsten metal into the air, workers had elevated urinary tungsten levels that were more than 900 times higher than the overall geometric mean in the NHANES 1999-2000 subsample (Kraus et al., 2001). The application of the technique of neutron activation analysis to a control group of non-metal workers showed mean urinary tungsten levels similar to levels at the 95th percentile of the NHANES 1999-2000 subsample, whereas the tungsten-worker group had mean urine levels 35 times higher (Nicolaou et al., 1987). Patients with medically-inserted tungsten embolization coils showed elevated tungsten levels in blood, urine, and hair (Bachthaler et al., 2004). Urinary tungsten levels in these patients were often hundreds-fold higher than demonstrated in this *Report*.

Comparing Adjusted Geometric Means

Geometric mean levels of urinary tungsten for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2002-2002, the group aged 6-11 years had higher adjusted geometric mean levels of urinary tungsten than either of the groups aged 12-19 years or 20 years and older. The group aged 12-19 years had higher

Table 29. Tungsten (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.087** (.080-.095)	**.080** (.075-.086)	**.146** (.136-.158)	**.270** (.206-.333)	**.381** (.302-.459)	2338
	01-02	**.078** (.069-.087)	**.074** (.064-.084)	**.138** (.122-.154)	**.255** (.216-.300)	**.359** (.315-.436)	2651
Age group							
6-11 years	99-00	**.174** (.150-.201)	**.169** (.136-.198)	**.293** (.216-.333)	**.438** (.331-.667)	**.614** (.452-.880)	320
	01-02	**.168** (.144-.197)	**.158** (.139-.188)	**.275** (.231-.326)	**.412** (.333-.554)	**.634** (.436-1.28)	363
12-19 years	99-00	**.084** (.078-.091)	**.079** (.074-.084)	**.138** (.124-.158)	**.231** (.180-.287)	**.339** (.237-.465)	679
	01-02	**.081** (.071-.092)	**.081** (.072-.091)	**.147** (.122-.167)	**.250** (.208-.301)	**.359** (.272-.431)	744
20 years and older	99-00	**.080** (.072-.089)	**.074** (.067-.082)	**.130** (.115-.143)	**.218** (.179-.301)	**.339** (.245-.426)	1339
	01-02	**.070** (.063-.079)	**.067** (.057-.075)	**.119** (.099-.139)	**.214** (.176-.267)	**.321** (.250-.429)	1544
Gender							
Males	99-00	**.083** (.074-.094)	**.073** (.063-.086)	**.146** (.126-.165)	**.279** (.198-.386)	**.439** (.329-.605)	1160
	01-02	**.071** (.060-.083)	**.064** (.056-.077)	**.125** (.098-.152)	**.255** (.203-.306)	**.364** (.300-.431)	1306
Females	99-00	**.091** (.085-.098)	**.084** (.080-.091)	**.145** (.136-.158)	**.265** (.200-.301)	**.339** (.300-.381)	1178
	01-02	**.085** (.077-.094)	**.083** (.075-.091)	**.143** (.128-.162)	**.258** (.216-.317)	**.353** (.317-.538)	1345
Race/ethnicity							
Mexican Americans	99-00	**.106** (.093-.120)	**.100** (.086-.115)	**.184** (.152-.214)	**.327** (.267-.392)	**.493** (.354-.727)	790
	01-02	**.098** (.090-.108)	**.089** (.081-.100)	**.163** (.143-.187)	**.294** (.256-.370)	**.554** (.410-.797)	679
Non-Hispanic blacks	99-00	**.073** (.064-.083)	**.071** (.061-.081)	**.124** (.109-.154)	**.201** (.188-.222)	**.360** (.217-.465)	562
	01-02	**.066** (.056-.077)	**.060** (.049-.079)	**.109** (.090-.125)	**.199** (.153-.285)	**.340** (.250-.414)	649
Non-Hispanic whites	99-00	**.091** (.083-.100)	**.081** (.077-.088)	**.149** (.135-.167)	**.278** (.200-.354)	**.383** (.302-.462)	802
	01-02	**.078** (.068-.088)	**.073** (.061-.085)	**.138** (.120-.156)	**.253** (.209-.308)	**.353** (.286-.453)	1117

levels than the group aged 20 years and older. Levels in Mexican Americans were higher than in non-Hispanic blacks and non-Hispanic whites. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of tungsten in urine does not mean that the level of tungsten causes an adverse health effect. Whether tungsten at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary tungsten data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of tungsten than are found in the general population. These data will also help scientists plan and conduct research about exposure to tungsten and health effects.

Figure 12. Tungsten (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Uranium

CAS No. 7440-61-1

General Information

Uranium is a silver-white, extremely dense, and weakly radioactive metal. It is typically extracted from ores containing less than 1% natural uranium. Natural uranium is a mixture of three isotopes: ^{238}U (99.2739%), ^{235}U (0.7204%), and ^{234}U (0.0057%). It usually occurs as an inorganic compound with oxygen, chlorine, or other elements. Uranium has many commercial uses, including its use in nuclear weapons, nuclear fuel, in some ceramics, and as an aid in electron microscopy and photography. Depleted uranium (DU) refers to uranium in which the proportion of ^{235}U and ^{234}U isotopes have been reduced, compared with the proportion in natural uranium. DU is used in the production of armor-piercing projectiles.

Human exposure to uranium occurs primarily in the workplace by inhaling dust and other small particles. Exposure to insoluble uranium oxides and uranium metal via inhalation results in retention of these forms of uranium in the lungs and other tissues with little excretion in the urine. Soluble forms of uranium salts are poorly absorbed in the gastrointestinal tract, but these small amounts can be reflected in urinary measurements. Some uranium can be absorbed from food and water, especially in areas where large amounts of uranium occur naturally. Soluble uranium compounds may exhibit some dermal absorption. Exposure to DU can occur after internal contact with DU-containing shrapnel or dust.

After absorption, soluble uranium is predominantly distributed to the kidneys and the bones. Approximately 50% of uranium is eliminated in the urine within the first

Table 30. Uranium

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.008** (.007-.009)	**.007** (.006-.007)	**.013** (.010-.016)	**.026** (.021-.038)	**.046** (.036-.054)	2464
	01-02	**.009** (.007-.010)	**.008** (.006-.009)	**.014** (.011-.016)	**.029** (.022-.037)	**.046** (.034-.062)	2690
Age group							
6-11 years	99-00	**.009** (.007-.011)	**.007** (.005-.007)	**.013** (.009-.019)	**.032** (.018-.048)	**.046** (.033-.066)	340
	01-02	**.008** (.007-.010)	**.008** (.006-.010)	**.014** (.010-.020)	**.025** (.020-.036)	**.037** (.025-.049)	368
12-19 years	99-00	**.009** (.008-.011)	**.009** (.008-.010)	**.014** (.012-.018)	**.025** (.020-.043)	**.043** (.028-.072)	719
	01-02	**.010** (.008-.012)	**.009** (.008-.012)	**.017** (.012-.023)	**.030** (.021-.042)	**.041** (.027-.088)	762
20 years and older	99-00	**.008** (.006-.009)	**.007** (.005-.008)	**.012** (.009-.016)	**.026** (.021-.038)	**.045** (.035-.054)	1405
	01-02	**.009** (.007-.010)	**.007** (.006-.009)	**.014** (.011-.016)	**.030** (.022-.039)	**.046** (.034-.059)	1560
Gender							
Males	99-00	**.009** (.008-.011)	**.007** (.007-.010)	**.015** (.012-.020)	**.036** (.024-.046)	**.053** (.040-.067)	1227
	01-02	**.009** (.008-.011)	**.008** (.007-.010)	**.014** (.012-.019)	**.033** (.023-.043)	**.046** (.035-.065)	1335
Females	99-00	**.007** (.006-.008)	**.006** (.005-.007)	**.011** (.009-.014)	**.023** (.016-.032)	**.035** (.026-.050)	1237
	01-02	**.008** (.007-.010)	**.008** (.006-.009)	**.013** (.011-.016)	**.027** (.018-.037)	**.040** (.029-.062)	1355
Race/ethnicity							
Mexican Americans	99-00	**.017** (.012-.023)	**.015** (.011-.021)	**.032** (.019-.053)	**.059** (.040-.127)	**.113** (.054-.279)	883
	01-02	**.013** (.010-.016)	**.011** (.009-.015)	**.022** (.016-.027)	**.039** (.031-.054)	**.054** (.045-.067)	683
Non-Hispanic blacks	99-00	**.009** (.007-.011)	**.007** (.006-.010)	**.013** (.010-.019)	**.028** (.018-.045)	**.049** (.030-.067)	568
	01-02	**.008** (.007-.009)	**.007** (.007-.009)	**.012** (.010-.013)	**.020** (.017-.027)	**.030** (.023-.037)	667
Non-Hispanic whites	99-00	**.007** (.006-.009)	**.007** (.005-.007)	**.012** (.008-.014)	**.023** (.016-.033)	**.041** (.027-.051)	822
	01-02	**.008** (.007-.009)	**.006** (.006-.008)	**.012** (.010-.014)	**.026** (.018-.034)	**.036** (.028-.049)	1132

24 hours after exposure. Following exposure to soluble uranium salts, the initial half-life of uranium is considered to be about 15 days (Bhattacharyya et al., 1992), representing distribution and excretion, with a much slower elimination from bone. After inhalation exposure of insoluble uranium, the half-life for disappearance from the lung is several years (Durakovic et al., 2003).

Health effects from uranium exposure occur from chemical toxicity. Radiation risks from exposure to natural uranium are very low. Nephrotoxicity, the primary toxic effect attributed to chronic uranium exposure in people, manifests as tubular damage and appears reversible with decreasing exposure. Workplace air standards for external exposure to soluble and insoluble uranium compounds have been established by OSHA and ACGIH. Although older evaluations suggested the carcinogenicity of uranium among smokers, the U.S. EPA has withdrawn its classification for carcinogenicity; IARC and NTP have no ratings.

Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Urinary Uranium Reported in the Tables

Urine uranium levels were measured in a subsample of NHANES participants aged 6 years old and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. The analytical method measures only levels of the ^{238}U isotope and not levels of the ^{235}U isotope (^{235}U is higher in enriched uranium used as nuclear fuel). More than 99% of naturally occurring uranium is ^{238}U.

A previous nonrandom subsample from NHANES III (n = 499) showed concentrations that are essentially similar to those in this *Report* (Ting et al., 1999). Dang et

Table 31. Uranium (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.007** (.006-.009)	**.007** (.006-.009)	**.013** (.010-.016)	**.024** (.019-.030)	**.034** (.027-.053)	2464
	01-02	**.008** (.007-.010)	**.007** (.006-.009)	**.014** (.011-.018)	**.026** (.020-.033)	**.040** (.028-.054)	2689
Age group							
6-11 years	99-00	**.009** (.007-.012)	**.008** (.006-.010)	**.015** (.010-.024)	**.030** (.016-.044)	**.037** (.030-.077)	340
	01-02	**.010** (.008-.011)	**.010** (.008-.012)	**.015** (.013-.019)	**.027** (.018-.032)	**.033** (.027-.048)	368
12-19 years	99-00	**.007** (.006-.008)	**.006** (.005-.008)	**.010** (.009-.014)	**.020** (.014-.030)	**.030** (.019-.074)	719
	01-02	**.007** (.006-.008)	**.007** (.006-.008)	**.012** (.009-.016)	**.020** (.014-.026)	**.026** (.020-.042)	762
20 years and older	99-00	**.007** (.006-.009)	**.007** (.005-.008)	**.013** (.010-.016)	**.024** (.019-.029)	**.034** (.025-.051)	1405
	01-02	**.008** (.007-.010)	**.007** (.006-.009)	**.014** (.011-.019)	**.027** (.020-.039)	**.043** (.030-.063)	1559
Gender							
Males	99-00	**.007** (.006-.009)	**.006** (.005-.008)	**.011** (.009-.015)	**.021** (.017-.028)	**.035** (.024-.056)	1227
	01-02	**.007** (.006-.008)	**.007** (.006-.008)	**.012** (.010-.015)	**.022** (.018-.028)	**.033** (.025-.047)	1334
Females	99-00	**.008** (.007-.010)	**.007** (.006-.009)	**.013** (.010-.017)	**.024** (.019-.033)	**.034** (.027-.054)	1237
	01-02	**.009** (.008-.011)	**.009** (.007-.011)	**.016** (.012-.021)	**.029** (.021-.042)	**.045** (.031-.067)	1355
Race/ethnicity							
Mexican Americans	99-00	**.015** (.011-.022)	**.015** (.011-.020)	**.028** (.016-.058)	**.059** (.027-.146)	**.100** (.042-.270)	883
	01-02	**.012** (.010-.016)	**.012** (.009-.016)	**.021** (.015-.028)	**.033** (.024-.053)	**.049** (.033-.077)	682
Non-Hispanic blacks	99-00	**.006** (.004-.007)	**.005** (.004-.006)	**.008** (.006-.013)	**.017** (.011-.028)	**.028** (.018-.048)	568
	01-02	**.005** (.005-.006)	**.005** (.005-.006)	**.008** (.007-.010)	**.013** (.011-.014)	**.017** (.014-.029)	667
Non-Hispanic whites	99-00	**.007** (.006-.009)	**.007** (.006-.009)	**.012** (.010-.015)	**.021** (.017-.027)	**.030** (.024-.050)	822
	01-02	**.008** (.007-.009)	**.007** (.006-.009)	**.013** (.011-.016)	**.025** (.018-.032)	**.034** (.025-.051)	1132

al. (1992), Karpas et al. (1996), and Galletti (2003) reported urinary levels for small groups of normal individuals in a range similar to those values seen in both the 1999-2000 and 2001-2002 subsamples. In addition, other studies have demonstrated urinary uranium concentrations that are consistent with levels documented in this *Report*, in that the reported levels were below their respective detection limits (Hamilton et al., 1994; Komaromy-Hiller et al., 2000; Byrne et al., 1991).

In one study, 105 people exposed to well water containing natural uranium in the range of 1.8 to 7770 μg/L (median 157 μg/L) had urinary levels of uranium as high as 9.55 μg/L (median 0.162 μg/L)(Orloff et al., 2003). Eighty-five percent of the levels were above the 95th percentile of the NHANES 1999-2000 subsample. In another study of people drinking well water with high natural uranium concentrations, the median urinary concentration was 0.078 μg/L (ranging up to 5.65 μg/L), and a subtle effect of uranium on calcium and phosphate fractional clearance was indicated (within the normal range of these measures), but without effects on other biochemical or traditional markers of renal function (Kurttio et al., 2002). The urinary uranium levels reported here for the NHANES 2001-2002 subsample are well below any of these aforementioned levels.

The U.S. Nuclear Regulatory Commission (U.S. NRC) has set an action level of 15 μg/L for uranium in urine to protect people who are occupationally exposed to uranium (U.S. NRC, 1978). Six workers in a depleted uranium program had concentrations of 0.110 to 45 μg/L (Ejnik et al., 2000). Several recent studies have investigated urinary uranium levels in veterans who served during the 1991 Gulf War. In one study, 17 soldiers with embedded shrapnel had a median urinary uranium concentration of 2.61 μg/g creatinine and 28 soldiers who may have been exposed to DU by inhalation, ingestion, or wound contamination, but in whom no shrapnel was embedded, had a mean urinary uranium concentration of 0.066 μg/g creatinine (Gwiazda et al., 2004). In a much larger study of a group of 446 Gulf War veterans who were concerned about past exposure to DU, the geometric mean urinary uranium concentration was 0.011 μg/L (McDiarmid, et al., 2004).

Comparing Adjusted Geometric Means

Geometric mean levels of urinary uranium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary uranium in the group aged 6-11 years were

higher than the groups aged 12-19 years. Mexican Americans had higher levels than either non-Hispanic blacks or non-Hispanic whites, and non-Hispanic whites had higher levels than non-Hispanic blacks. Females had slightly higher adjusted geometric mean levels of urinary uranium than males. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of uranium in urine does not mean that the level of uranium causes an adverse health effect. Whether uranium at the levels reported here is cause for health concern is unknown; more research is needed. These urinary uranium data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of uranium than are found in the general population. These data will also help scientists plan and conduct research about uranium exposure and health effects.

Figure 13. Uranium (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Results by Chemical Group

Tobacco Smoke

Cotinine

CAS No. 486-56-6

General Information

Tobacco use is the most important preventable cause of premature morbidity and mortality in the United States. The consequences of smoking and of using smokeless tobacco products are well known and include an increased risk for cancer, emphysema, cardiovascular disease, and possibly other disorders.

Inhalation of tobacco smoke is the main source of nicotine exposure for the general population. Cigarettes contain about 1.5% nicotine by weight (Kozlowski et al., 1998), producing roughly 1-2 mg of bioavailable nicotine per cigarette (Institute of Medicine, 2001). Nicotine can also be absorbed from the gastrointestinal tract and skin as a result of chewing tobacco or chewing gum or using skin patches that contain nicotine. Workers who harvest

tobacco can be exposed to nicotine and intoxicated as a result of the transdermal absorption of nicotine contained in the plant. Some other plants also contain nicotine in smaller amounts. Nicotine has been used previously as an insecticide and is still available for that purpose in its sulfate and alkaloid forms.

Up to 92% of the nicotine delivered in smoke is absorbed from the lungs into the blood stream (Armitage et al., 1975; Iwase et al., 1991). Air concentrations of nicotine in public spaces where smoking is allowed are about 1-10 $\mu g/m^3$. Once absorbed, nicotine has a half-life in blood plasma of several hours (Benowitz, 1996). Cotinine is a metabolite of nicotine and is currently regarded as the best biomarker in active smokers and in nonsmokers exposed to environmental tobacco smoke (ETS). Measuring cotinine is preferred over measuring

Table 32. Cotinine

Geometric mean and selected percentiles of serum concentrations (in ng/mL) for the non-smoking U.S. population aged 3 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 3 and older	99-00	*	**.059** (<LOD-.070)	**.236** (.190-.300)	**1.02** (.750-1.25)	**1.96** (1.60-2.62)	5999
	01-02	**.062** (.050-.077)	†	**.163** (.123-.224)	**.932** (.737-1.17)	**2.19** (1.83-2.44)	6813
Age group							
3-11 years	99-00	*	**.109** (.063-.180)	**.500** (.259-1.09)	**1.88** (.997-3.44)	**3.37** (1.42-4.79)	1174
	01-02	**.110** (.076-.160)	**.071** (<LOD-.124)	**.570** (.306-1.01)	**2.23** (1.60-2.78)	**3.21** (2.53-4.01)	1414
12-19 years	99-00	*	**.107** (.080-.160)	**.540** (.428-.660)	**1.65** (1.48-1.92)	**2.56** (2.09-3.39)	1773
	01-02	**.086** (.059-.126)	**.051** (<LOD-.109)	**.352** (.189-.580)	**1.53** (1.09-2.12)	**3.12** (2.47-3.99)	1902
20 years and older	99-00	*	< LOD	**.167** (.140-.193)	**.630** (.530-.810)	**1.48** (1.28-1.66)	3052
	01-02	**.052** (<LOD-.063)	†	**.113** (.090-.150)	**.623** (.465-.770)	**1.38** (1.11-1.84)	3497
Gender							
Males	99-00	*	**.080** (.059-.109)	**.302** (.220-.394)	**1.20** (.950-1.49)	**2.39** (1.66-3.22)	2789
	01-02	**.075** (.059-.095)	†	**.230** (.165-.316)	**1.17** (.932-1.42)	**2.44** (2.23-2.97)	3149
Females	99-00	*	< LOD	**.179** (.148-.220)	**.850** (.597-1.14)	**1.85** (1.33-2.45)	3210
	01-02	**.053** (<LOD-.066)	†	**.123** (.092-.180)	**.711** (.537-.990)	**1.76** (1.32-2.16)	3664
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	**.138** (.110-.176)	**.506** (.370-.726)	**1.21** (.900-1.70)	2241
	01-02	**.060** (<LOD-.084)	†	**.157** (.080-.308)	**.727** (.452-1.19)	**2.11** (1.14-2.98)	1877
Non-Hispanic blacks	99-00	*	**.131** (.111-.150)	**.505** (.400-.625)	**1.43** (1.18-1.75)	**2.34** (1.84-3.50)	1333
	01-02	**.164** (.136-.197)	**.132** (.106-.161)	**.570** (.436-.760)	**1.77** (1.54-2.01)	**3.12** (2.47-4.25)	1599
Non-Hispanic whites	99-00	*	**.050** (<LOD-.070)	**.210** (.150-.310)	**.950** (.621-1.40)	**1.92** (1.48-3.02)	1950
	01-02	**.052** (<LOD-.068)	†	**.119** (.087-.180)	**.800** (.571-1.11)	**1.88** (1.49-2.30)	2845

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† 83% of measurements had a LOD of 0.015 ng/mL and 17% of measurements had a LOD of 0.050 ng/mL. See note in text.

nicotine because cotinine persists longer in the body (plasma half-life is about 16 hours) (Benowitz and Jacob, 1994). Cotinine can be measured in serum, urine, saliva, and hair. Nonsmokers exposed to typical levels of ETS have serum cotinine levels of less than 1 ng/mL, with heavy exposure to ETS producing levels in the 1-10 ng/mL range. Active smokers almost always have levels higher than 10 ng/mL and sometimes higher than 500 ng/mL.

Nicotine stimulates preganglionic cholinergic receptors within peripheral sympathetic autonomic ganglia and at cholinergic sites within the central nervous system. Nicotine indirectly causes a release of dopamine in the brain regions that control pleasure and motivation, a process leading to addiction. Acute tobacco or nicotine intoxication can produce dizziness, nausea, vomiting, diaphoresis, salivation, diarrhea, variable changes in blood pressure and heart rate, seizures, and death. Symptoms of nicotine withdrawal include irritability, craving, cognitive and sleep disturbances, and increased appetite.

Tobacco smoke is considered a human carcinogen by IARC and NTP. Lung cancer is the leading cancer-related killer of both men and women in the United States, and smoking is by far the leading cause of lung cancer. Persistent exposure to ETS is associated with an increased risk for lung cancer. More recently, coronary heart disease (Whincup et al., 2004) and prothrombotic risk factors (Bazzano et al., 2003) have been associated with ETS exposure. ETS may exacerbate asthma among susceptible children and increase the risk for lower respiratory-tract illnesses, such as bronchitis and pneumonia, among young children. Exposure to ETS has also been associated recently with decrements in pulmonary function in adults with asthma (Eisner, 2002). More information about the effects of smoking and nicotine can be found at: http://www.nida.nih.gov/researchreports/nicotine/nicotine.html.

Interpreting Levels of Serum Cotinine Reported in the Table

Serum cotinine levels were measured in a subsample of nonsmoking NHANES participants aged 3 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Nonsmoking is defined as a serum cotinine level of less than or equal to 10 ng/mL. Choosing a cutoff of 15 ng/mL makes little difference in the results. Serum cotinine has been measured in many studies of non-smoking populations, and such levels are similar or

slightly higher than those reported here, depending on the degree of ETS exposure.

From 1988 through 1991, as part of NHANES III, CDC determined that the median level (50th percentile) of cotinine among nonsmokers in the United States was 0.20 ng/mL (Pirkle et al., 1996). Since that 1988-1991 survey period, median levels of cotinine (as measured in NHANES 1999-2002) have decreased 68% in children, 69% in adolescents, and about 75% in adults. This reduction in cotinine levels suggests a major reduction in exposure of the general U.S. population to ETS since the period 1988-1991.

Note: Results are reported as less than the limit of detection (LOD) if they are less than the LOD of the individual sample, which could be either 0.015 ng/mL or 0.050 ng/mL for the 2001-2002 subsample (more sensitive instrumentation was introduced during 2001-2002 analyses). The reporting requirement for a geometric mean is that 60% of the serum cotinine levels must be greater than or equal to the respective specimen-specific LOD. To calculate geometric means and percentiles, measurements below their LOD are assigned values of LOD/square root of 2.

The reporting requirement for percentiles is that they must be greater than the maximum LOD (i.e., greater than 0.050 ng/mL). This requirement avoids confusion in interpretation that could result if a percentile estimate was lower than one of the two LODs. These two reporting requirements (one for geometric means and one for percentiles) occasionally result in a geometric mean being reported with no estimate being reported for the 50th percentile (as is the case for cotinine). For completeness, we list here, for 2001-2002, the computed 50th percentiles (with 95% confidence limits), recognizing that these estimates are in between the two LODs; that is, between 0.015 ng/mL-0.050 ng/mL.

Age 3 years and older	0.035	(0.032-0.052)
Age 20 years and older	0.034	(0.024-0.038)
Males	0.045	(0.035-0.063)
Females	0.034	(0.023-0.038)
Mexican Americans	0.036	(0.025-0.060)
Non-Hispanic whites	0.034	(0.022-0.043)

Comparing Adjusted Geometric Means

Geometric mean levels of serum cotinine for the demographic groups in the NHANES 2001-2002 subsample were compared after adjusting for the covariates of age, race/ethnicity, and gender (data not

shown). Both groups aged 3-11 years and 12-19 years had higher adjusted geometric mean levels of cotinine than the group aged 20 years and older. Males had higher levels than females. Non-Hispanic whites and Mexican Americans both had lower levels than non-Hispanic blacks. Higher levels of cotinine have previously been reported for non-Hispanic blacks (Caraballo et al., 1998). It is unknown whether these age, gender, and race/ethnicity differences represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

These serum cotinine data will help public health officials determine whether or not people have been exposed to higher levels of ETS than are found in the general population. These data will also help scientists plan and conduct research about exposure to ETS and health effects.

Results by Chemical Group

Polycyclic Aromatic Hydrocarbons

Polycyclic Aromatic Hydrocarbons

General Information

Polycyclic aromatic hydrocarbons (PAHs) are a class of chemicals that result from the incomplete burning of coal, oil, gas, wood, garbage, or other organic substances, such as tobacco and charbroiled meat. Exposure to these chemicals usually occurs as exposure to mixtures and not to individual chemicals. Exposure can occur through air, water, soil, or food. PAHs enter the air from motor vehicle exhaust, residential and industrial furnaces, tobacco smoke, volcanoes, agricultural burning, residential wood burning, and wildfires. Seasonal variations in exposure to PAHs are known to occur. The soil and water near industrialized areas can contain elevated concentrations of PAHs. Foods that contain PAHs include smoked, charcoal-broiled, and roasted foods and plant foods that become contaminated by atmospheric deposition. Cereal products (e.g., wheat, corn, oats, and barley) may contain PAHs because of methods used to dry them.

Workers in certain occupational settings are exposed to PAHs from the burning or coking of petroleum products. Workplace situations include coke production, coal gasification and gas refinery, iron or steel production, roofing tar and asphalt application, chimney sweeping,

waste incineration, and aluminum smelting. Coal tar is composed of PAHs and can be used as a medical therapy for psoriasis. OSHA have developed criteria on the allowable levels of these chemicals in the workplace. The U.S. EPA and The U.S. Food and Drug Administration (U.S. FDA) have only limited or preliminary standards for a few PAHs in water or food.

PAHs can be absorbed through the skin, respiratory tract, and gastrointestinal tract (Ramesh et al., 2004). In cells, some PAHs can bind and stimulate the Ah receptor, which in turn induces a greater metabolism of the PAHs themselves to products that can interact with DNA and promote cancer (Nebert et al., 2004) Lung, genito-urinary, and skin cancers have been reported in occupational settings, where the amount of exposure is greater than it is in the general population (Lloyd, 1971; Redmond et al., 1976; Boffetta et al., 1997; Bostrom et al., 2002; Armstrong et al., 2004). Additionally, PAH exposure may affect the immune system (Li et al., 2003) and reduce fetal growth (Dejmek et al., 2000; Perera et al., 2003). Early studies have been limited by the inability to evaluate the isolated effects of individual PAHs and other contributing carcinogens, such as those in tobacco smoke. IARC classifies benz[a]anthracene and benzo[a]pyrene as probable human carcinogens, and

Table 33. Polycyclic Aromatic Hydrocarbons (PAHs) and their metabolites

PAH (CAS number)	Urinary hydroxylated metabolite (CAS number)
Benz[a]anthracene (56-55-3)	1-Hydroxybenz[a]anthracene (69847-26-3) 3-Hydroxybenz[a]anthracene (4834-35-9) and 9-Hydroxybenz[a]anthracene
Benzo[c]phenanthrene (195-19-7)	1-Hydroxybenzo[c]phenanthrene 2-Hydroxybenzo[c]phenanthrene (22717-94-8) 3-Hydroxybenzo[c]phenanthrene
Chrysene (218-01-9)	1-Hydroxychrysene(63019-38-5) 2-Hydroxychrysene (65945-06-4) 3-Hydroxychrysene (63019-39-6) 4-Hydroxychrysene (63019-40-9) 6-Hydroxychrysene (37515-51-8)
Fluoranthene (206-44-0)	3-Hydroxyfluoranthrene
Fluorene (86-73-7)	2-Hydroxyfluorene (2443-58-5) 3-Hydroxyfluorene (6344-67-8) 9-Hydroxyfluorene (484-17-3)
Phenanthrene (85-01-8)	1-Hydroxyphenanthrene (2433-56-9) 2-Hydroxyphenanthrene 3-Hydroxyphenanthrene (605-87-8) 4-Hydroxyphenanthrene (7651-86-7) 9-Hydroxyphenanthrene (484-17-3)
Pyrene (129-00-0)	1-Hydroxypyrene (5315-79-7)
Benzo[a]pyrene (50-32-8)	3-Hydroxybenzo[a]pyrene (13345-21-6)
Naphthalene (91-20-3)	1-Hydroxynapthalene (90-15-3) 2-Hydroxynapthalene (135-19-3)

benzo[b]fluoranthene, benzo[j]fluoranthene, benzo[k]fluoranthene, and indeno[1,2,3,cd]pyrene as possible human carcinogens. The NTP lists the following chemicals as reasonably anticipated to be human carcinogens: benz[a]anthracene, benzo[b]fluor-anthene, benzo[j]fluoranthene, benzo[k]fluoranthene, benzo[a]pyrene, dibenz[a,h]acridine, dibenz[a,j]acridine, dibenz[a,h]anthracene, 7H-dibenzo-[c,g]carbazole, dibenzo[a,e]pyrene, dibenzo[a,h]pyrene, dibenzo[a,i]-pyrene, dibenzo[a,l]pyrene, indeno[1,2,3-cd]pyrene, and 5-methylchrysene (NTP, 2002). The U.S. EPA has classified as probable carcinogens the following: benz[a]anthracene, benzo[a]pyrene, benzo[b]fluor-anthene, benzo[k]fluoranthene, chrysene, dibenz[a,h]-anthracene, and indeno[1,2,3-cd]pyrene. Pyrene was reviewed by IARC and determined it not to be classi-fiable as to its human carcinogenicity. In 2005, NTP listed naphthalene as reasonably anticipated to be a human carcinogen (NTP, 2005). IARC, NTP, and U.S. EPA also list chemical mixtures (e.g., soot, coke-oven emissions, coal tars), which contain PAH chemicals, as known carcinogens.

Information about external exposure (i.e., environmental levels) and health effects is available in several reviews (Bostrom et al., 2002, Armstrong et al., 2004) as well as from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Urinary PAH Metabolites Reported in the Tables

Urinary levels of hydroxylated metabolites of PAHs were measured in a subsample of NHANES participants aged 6 years old and older. Participants were selected within the specified age range to be a representative sample of the U.S. population.

Measurement of these 22 metabolites reflects exposure to PAHs that has occurred within the previous few days. Some of the parent PAHs can produce more than one measureable urinary metabolite. Table 34 shows the relation between PAHs and their metabolites. The hydroxylated metabolites of the PAHs are excreted in human urine both as free hydroxylated metabolites and as hydroxylated metabolites conjugated to glucuronic acid and sulfate. Measurements provided in this *Report* include both free and conjugated forms of the hydroxylated metabolites.

Finding a measurable amount of one or more metabolites in the urine does not mean that the levels of the PAHs metabolites cause an adverse health effect. Whether levels of PAH metabolites at the levels reported here are

cause for health concern is not known; more research is needed. These data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of PAHs than are found in the general population. These data will help scientists plan and conduct research on exposure to PAHs and health effects.

1-Hydroxybenz[a]anthracene and 3- and 9-Hydroxybenz[a]anthracene

Metabolites of Benz[a]anthracene, CAS No. 56-55-3

Interpreting Levels of Urinary Benz[a]anthracene Metabolites Reported in the Tables

Urinary levels of 1-hydroxybenz[a]anthracene and combined levels of 3-hydroxybenz[a]-anthracene and 9-hydroxybenz[a]anthracene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels of 1- and 3-hydroxy-benz[a]anthracene have been reported in a small sample of pre-school children (Wilson et al., 2003). A sampling of 24 adults and 24 children from low income households in North Carolina found higher urinary levels of urinary 1-hydroxybenz[a]anthracene and 3-hydroxybenz[a]-anthracene, exceeding five- to ten-fold the concentrations measured in the NHANES 1999-2002 subsamples (Chuang et al., 1999). Workers manufacturing fireproof stone had 3-hydroxybenz[a]anthracene levels that were

10-100 times higher than the levels that were found in the NHANES 1999-2002 subsamples (Gundel et al., 2000).

Table 34. 1-Hydroxybenz[a]anthracene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2084
	01-02	*	< LOD	< LOD	< LOD	**30.0** (22.0-36.0)	2748
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	276
	01-02	*	< LOD	< LOD	**13.0** (<LOD-30.0)	**45.0** (19.0-56.0)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	626
	01-02	*	< LOD	< LOD	**4.00** (<LOD-19.0)	**38.0** (10.0-68.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1182
	01-02	*	< LOD	< LOD	< LOD	**26.0** (21.0-34.0)	1626
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1004
	01-02	*	< LOD	< LOD	**10.0** (<LOD-20.0)	**30.0** (23.0-39.0)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1080
	01-02	*	< LOD	< LOD	< LOD	**30.0** (15.0-40.0)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**6.80** (<LOD-10.9)	667
	01-02	*	< LOD	< LOD	< LOD	**21.0** (<LOD-38.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	**5.20** (<LOD-7.20)	465
	01-02	*	< LOD	< LOD	**30.0** (13.0-42.0)	**59.0** (30.0-89.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	779
	01-02	*	< LOD	< LOD	< LOD	**27.0** (20.0-37.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 35. 1-Hydroxybenz[a]anthracene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2084
	01-02	*	< LOD	< LOD	< LOD	**27.0** (19.6-32.4)	2748
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	276
	01-02	*	< LOD	< LOD	**21.5** (10.0-28.0)	**34.0** (27.0-50.5)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	626
	01-02	*	< LOD	< LOD	**12.4** (6.83-24.8)	**28.0** (14.8-38.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1182
	01-02	*	< LOD	< LOD	< LOD	**24.5** (18.4-31.1)	1626
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1004
	01-02	*	< LOD	< LOD	**12.7** (10.2-17.0)	**24.8** (18.4-33.8)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1080
	01-02	*	< LOD	< LOD	< LOD	**27.0** (17.5-33.9)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**15.7** (9.43-18.3)	667
	01-02	*	< LOD	< LOD	< LOD	**21.5** (14.1-33.3)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	**7.36** (5.41-11.0)	465
	01-02	*	< LOD	< LOD	**17.5** (10.7-28.1)	**33.9** (17.5-61.6)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	779
	01-02	*	< LOD	< LOD	< LOD	**28.0** (18.7-32.7)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 36. 3- and 9-Hydroxybenz[a]anthracene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	**7.50** (6.00-9.90)	**11.6** (8.40-15.6)	2152
	01-02	*	< LOD	< LOD	**11.0** (<LOD-15.0)	**24.0** (19.0-31.0)	2748
Age group							
6-11 years	99-00	*	< LOD	**7.70** (<LOD-11.9)	**14.4** (7.70-49.8)	**32.0** (9.50-71.0)	285
	01-02	*	< LOD	< LOD	< LOD	**14.0** (11.0-21.0)	387
12-19 years	99-00	*	< LOD	**6.20** (<LOD-7.50)	**10.5** (8.80-13.8)	**14.9** (11.4-16.8)	652
	01-02	*	< LOD	< LOD	**14.0** (<LOD-18.0)	**28.0** (18.0-42.0)	735
20 years and older	99-00	*	< LOD	< LOD	**5.80** (<LOD-7.20)	**8.80** (6.50-11.8)	1215
	01-02	*	< LOD	< LOD	**11.0** (<LOD-16.0)	**23.0** (18.0-31.0)	1626
Gender							
Males	99-00	*	< LOD	< LOD	**7.90** (5.70-12.6)	**13.5** (9.20-18.8)	1033
	01-02	*	< LOD	< LOD	**15.0** (12.0-18.0)	**25.0** (20.0-31.0)	1349
Females	99-00	*	< LOD	< LOD	**7.10** (6.00-9.10)	**10.3** (8.90-11.9)	1119
	01-02	*	< LOD	< LOD	< LOD	**21.0** (14.0-35.0)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	**7.70** (6.80-8.90)	**11.1** (8.10-14.2)	688
	01-02	*	< LOD	< LOD	**11.0** (<LOD-16.0)	**23.0** (16.0-31.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**7.60** (5.80-11.5)	**11.6** (7.30-19.0)	488
	01-02	*	< LOD	< LOD	**18.0** (15.0-25.0)	**35.0** (22.0-46.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	**7.60** (5.60-10.3)	**11.8** (7.70-18.0)	793
	01-02	*	< LOD	< LOD	**11.0** (<LOD-18.0)	**23.0** (18.0-36.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 37. 3- and 9-Hydroxybenz[a]anthracene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	12.2 (10.1-14.6)	17.6 (15.7-21.1)	2152
	01-02	*	< LOD	< LOD	21.4 (19.2-23.7)	31.8 (28.4-35.5)	2748
Age group							
6-11 years	99-00	*	< LOD	9.61 (6.63-14.6)	18.1 (10.3-29.6)	23.6 (12.8-40.5)	285
	01-02	*	< LOD	< LOD	< LOD	29.6 (23.7-39.8)	387
12-19 years	99-00	*	< LOD	5.09 (4.42-5.94)	7.69 (6.44-8.64)	10.0 (8.50-11.9)	652
	01-02	*	< LOD	< LOD	18.2 (15.2-24.8)	29.1 (21.5-50.7)	735
20 years and older	99-00	*	< LOD	< LOD	12.2 (10.2-14.3)	17.4 (15.2-21.1)	1215
	01-02	*	< LOD	< LOD	21.5 (20.3-24.5)	32.3 (28.1-35.5)	1626
Gender							
Males	99-00	*	< LOD	< LOD	9.77 (8.09-12.7)	14.7 (10.7-19.0)	1033
	01-02	*	< LOD	< LOD	18.7 (15.6-21.9)	26.3 (21.5-35.3)	1349
Females	99-00	*	< LOD	< LOD	14.1 (12.3-16.5)	21.1 (16.5-22.4)	1119
	01-02	*	< LOD	< LOD	< LOD	33.8 (29.8-39.8)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	10.8 (8.84-15.5)	18.1 (11.9-21.6)	688
	01-02	*	< LOD	< LOD	21.5 (17.2-28.4)	32.3 (27.3-36.3)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	6.77 (5.76-9.05)	10.9 (7.45-14.1)	488
	01-02	*	< LOD	< LOD	17.6 (14.5-22.2)	28.4 (21.5-41.2)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	13.1 (10.3-16.5)	19.0 (16.5-22.4)	793
	01-02	*	< LOD	< LOD	23.7 (20.9-25.6)	33.8 (29.6-37.4)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

1-Hydroxybenzo[c]phenanthrene, 2-Hydroxybenzo[c]phenanthrene, and 3-Hydroxybenzo[c]phenanthrene

Metabolites of Benzo[c]phenanthrene, CAS No. 195-19-7

Urinary levels of 1-hydroxybenzo[c]phenanthrene, 2-hydroxybenzo-[c]phenanthrene, and 3-hydroxybenzo[c]phenanthrene were measured in a subsample of NHANES participants aged 6 years and older.

Table 38. 1-Hydroxybenzo[c]phenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	8.20 (<LOD-13.1)	17.2 (10.8-31.3)	31.0 (19.0-47.2)	2200
	01-02	*	< LOD	< LOD	< LOD	34.0 (16.0-54.0)	2732
Age group							
6-11 years	99-00	*	< LOD	9.10 (<LOD-17.5)	17.0 (9.20-40.1)	32.1 (13.8-254)	297
	01-02	*	< LOD	< LOD	< LOD	15.0 (<LOD-35.0)	385
12-19 years	99-00	*	< LOD	9.50 (7.10-13.2)	18.0 (12.4-31.2)	31.2 (16.9-48.1)	665
	01-02	*	< LOD	< LOD	< LOD	29.0 (11.0-64.0)	728
20 years and older	99-00	*	< LOD	8.10 (<LOD-12.8)	16.9 (10.5-31.0)	30.3 (19.4-47.2)	1238
	01-02	*	< LOD	< LOD	4.00 (<LOD-19.0)	37.0 (16.0-79.0)	1619
Gender							
Males	99-00	*	< LOD	8.40 (<LOD-13.8)	18.0 (11.5-33.6)	35.4 (25.2-47.2)	1054
	01-02	*	< LOD	< LOD	< LOD	19.0 (5.00-33.0)	1340
Females	99-00	*	< LOD	8.20 (<LOD-13.3)	16.5 (9.80-25.8)	24.7 (15.2-47.2)	1146
	01-02	*	< LOD	< LOD	13.0 (<LOD-37.0)	51.0 (26.0-94.0)	1392
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	12.9 (7.40-20.2)	21.9 (15.2-32.4)	32.4 (23.3-47.5)	716
	01-02	*	< LOD	< LOD	11.0 (<LOD-84.0)	52.0 (9.00-105)	659
Non-Hispanic blacks	99-00	*	< LOD	7.60 (<LOD-9.90)	12.8 (8.20-32.4)	30.3 (11.0-49.2)	497
	01-02	*	< LOD	< LOD	< LOD	21.0 (<LOD-72.0)	687
Non-Hispanic whites	99-00	*	< LOD	8.40 (<LOD-14.4)	17.0 (10.0-32.9)	29.4 (16.7-58.7)	806
	01-02	*	< LOD	< LOD	< LOD	35.0 (15.0-83.0)	1205

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 39. 1-Hydroxybenzo[c]phenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	**< LOD**	**10.1** (7.69-13.3)	**22.8** (15.7-30.0)	**36.1** (23.5-62.3)	2200
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**41.3** (21.0-70.8)	2732
Age group							
6-11 years	99-00	*	**< LOD**	**9.73** (7.29-17.7)	**22.7** (10.7-39.6)	**32.8** (20.5-80.5)	297
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**28.3** (7.00-114)	385
12-19 years	99-00	*	**< LOD**	**7.69** (5.73-10.2)	**16.3** (11.5-22.0)	**24.3** (16.3-34.0)	665
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**21.5** (15.0-46.7)	728
20 years and older	99-00	*	**< LOD**	**10.5** (7.88-13.8)	**23.5** (15.4-33.3)	**37.4** (23.5-80.7)	1238
	01-02	*	**< LOD**	**< LOD**	**12.4** (8.50-20.7)	**45.9** (20.7-76.5)	1619
Gender							
Males	99-00	*	**< LOD**	**8.61** (6.67-11.1)	**18.6** (12.7-26.7)	**28.8** (22.8-37.1)	1054
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**18.7** (12.2-37.2)	1340
Females	99-00	*	**< LOD**	**11.8** (8.24-17.5)	**25.1** (15.4-41.1)	**40.4** (21.1-93.3)	1146
	01-02	*	**< LOD**	**< LOD**	**19.3** (9.55-45.5)	**69.6** (33.3-103)	1392
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**12.3** (9.47-17.0)	**26.7** (19.0-36.3)	**37.1** (27.1-50.0)	716
	01-02	*	**< LOD**	**< LOD**	**16.2** (5.12-54.5)	**42.0** (12.4-106)	659
Non-Hispanic blacks	99-00	*	**< LOD**	**5.75** (4.32-7.86)	**11.8** (7.80-20.5)	**21.1** (11.4-40.5)	497
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**14.0** (5.38-78.5)	687
Non-Hispanic whites	99-00	*	**< LOD**	**10.4** (7.84-14.3)	**23.9** (15.4-36.4)	**37.4** (22.8-86.9)	806
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**45.7** (19.1-87.5)	1205

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 40. 2-Hydroxybenzo[c]phenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	14.3 (9.60-19.6)	21.2 (16.5-28.1)	2175
	01-02	*	< LOD	< LOD	< LOD	13.0 (6.00-20.0)	2748
Age group							
6-11 years	99-00	*	< LOD	7.00 (<LOD-16.2)	19.9 (11.6-34.9)	30.2 (14.2-47.2)	285
	01-02	*	< LOD	< LOD	< LOD	< LOD	387
12-19 years	99-00	*	< LOD	< LOD	14.0 (8.90-20.0)	20.0 (14.6-32.3)	657
	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	99-00	*	< LOD	< LOD	13.5 (8.50-21.2)	20.1 (14.0-29.4)	1233
	01-02	*	< LOD	< LOD	< LOD	16.0 (9.00-24.0)	1626
Gender							
Males	99-00	*	< LOD	7.00 (<LOD-10.9)	16.9 (12.2-23.8)	29.0 (22.2-34.9)	1046
	01-02	*	< LOD	< LOD	< LOD	13.0 (6.00-20.0)	1349
Females	99-00	*	< LOD	< LOD	11.9 (8.20-17.5)	17.0 (12.8-22.0)	1129
	01-02	*	< LOD	< LOD	< LOD	13.0 (<LOD-27.0)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	12.2 (8.10-17.1)	17.0 (12.2-28.9)	686
	01-02	*	< LOD	< LOD	< LOD	15.0 (<LOD-42.0)	665
Non-Hispanic blacks	99-00	*	< LOD	10.0 (<LOD-16.6)	20.0 (14.4-34.3)	34.3 (19.0-51.6)	495
	01-02	*	< LOD	< LOD	< LOD	18.0 (<LOD-23.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	13.5 (8.40-20.5)	21.2 (15.0-29.4)	810
	01-02	*	< LOD	< LOD	< LOD	15.0 (<LOD-22.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.
* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 41. 2-Hydroxybenzo[c]phenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	**20.0** (16.0-23.7)	**28.2** (23.1-30.9)	2175
	01-02	*	< LOD	< LOD	< LOD	**20.3** (15.9-23.3)	2748
Age group							
6-11 years	99-00	*	< LOD	**11.4** (9.53-13.0)	**23.1** (12.3-32.0)	**34.3** (20.0-67.3)	285
	01-02	*	< LOD	< LOD	< LOD	< LOD	387
12-19 years	99-00	*	< LOD	< LOD	**11.7** (8.77-15.0)	**16.4** (11.7-26.1)	657
	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	99-00	*	< LOD	< LOD	**20.9** (16.0-26.7)	**28.6** (25.3-32.8)	1233
	01-02	*	< LOD	< LOD	< LOD	**21.4** (16.7-29.1)	1626
Gender							
Males	99-00	*	< LOD	**8.42** (6.96-10.9)	**17.3** (13.3-23.1)	**25.3** (19.3-34.3)	1046
	01-02	*	< LOD	< LOD	< LOD	**17.5** (13.5-23.3)	1349
Females	99-00	*	< LOD	< LOD	**20.9** (16.6-26.7)	**30.0** (26.7-30.9)	1129
	01-02	*	< LOD	< LOD	< LOD	**21.9** (16.7-35.0)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	**15.5** (11.7-20.8)	**22.9** (16.6-25.0)	686
	01-02	*	< LOD	< LOD	< LOD	**23.3** (14.0-53.7)	665
Non-Hispanic blacks	99-00	*	< LOD	**7.38** (5.57-11.7)	**16.7** (11.7-22.3)	**23.3** (18.0-33.0)	495
	01-02	*	< LOD	< LOD	< LOD	**13.2** (10.9-18.4)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	**20.8** (16.1-25.3)	**28.6** (25.3-32.0)	810
	01-02	*	< LOD	< LOD	< LOD	**21.9** (16.7-28.2)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 42. 3-Hydroxybenzo[c]phenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2172
	01-02	*	< LOD	< LOD	< LOD	**11.0** (8.00-16.0)	2748
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	287
	01-02	*	< LOD	< LOD	**8.00** (<LOD-13.0)	**13.0** (8.00-24.0)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	*	< LOD	< LOD	< LOD	**12.0** (<LOD-21.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	< LOD	**11.0** (8.00-16.0)	1626
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1045
	01-02	*	< LOD	< LOD	**7.00** (<LOD-11.0)	**11.0** (9.00-15.0)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1127
	01-02	*	< LOD	< LOD	< LOD	**12.0** (6.00-18.0)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	689
	01-02	*	< LOD	< LOD	< LOD	**14.0** (8.00-21.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	491
	01-02	*	< LOD	< LOD	< LOD	**14.0** (<LOD-26.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	< LOD	< LOD	**11.0** (8.00-15.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 43. 3-Hydroxybenzo[c]phenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2172
	01-02	*	< LOD	< LOD	< LOD	15.9 (14.6-16.7)	2748
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	287
	01-02	*	< LOD	< LOD	10.9 (8.75-14.0)	14.6 (12.5-15.9)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	*	< LOD	< LOD	< LOD	13.1 (10.0-17.5)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	< LOD	15.9 (14.3-17.1)	1626
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1045
	01-02	*	< LOD	< LOD	9.46 (8.54-10.5)	12.5 (11.3-15.9)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1127
	01-02	*	< LOD	< LOD	< LOD	16.7 (15.9-19.6)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	689
	01-02	*	< LOD	< LOD	< LOD	17.5 (14.0-23.3)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	491
	01-02	*	< LOD	< LOD	< LOD	13.4 (10.7-18.4)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	< LOD	< LOD	15.9 (14.3-16.7)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

1-Hydroxychrysene, 2-Hydroxychrysene 3-Hydroxychrysene, 4-Hydroxychrysene, and 6-Hydroxychrysene

Metabolites of Chrysene, CAS No. 218-01-9

Interpreting Levels of Urinary Chrysene Metabolites Reported in the Tables

Urinary levels of 1-hydroxychrysene, 2-hydroxychrysene 3-hydroxychrysene, 4-hydroxychrysene, and 6-hydroxychrysene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels of 6-hydroxychrysene have been reported in preschool children (Wilson et al., 2003). A sampling of 24 adults and 24 children from low income households in North Carolina found higher levels of urinary 6-hydroxychrysene, exceeding five- to ten-fold the concentrations measured in the NHANES 1999-2002 subsamples (Chuang et al., 1999).

Table 44. 1-Hydroxychrysene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	13.0 (<LOD-27.0)	64.0 (46.0-78.0)	105 (85.0-138)	2748
Age group							
6-11 years	01-02	*	< LOD	< LOD	35.0 (19.0-52.0)	69.0 (37.0-83.0)	387
12-19 years	01-02	*	< LOD	8.00 (<LOD-23.0)	46.0 (31.0-62.0)	71.0 (50.0-119)	735
20 years and older	01-02	*	< LOD	17.0 (<LOD-30.0)	71.0 (53.0-87.0)	116 (92.0-147)	1626
Gender							
Males	01-02	*	< LOD	23.0 (<LOD-38.0)	73.0 (55.0-89.0)	107 (87.0-152)	1349
Females	01-02	*	< LOD	5.00 (<LOD-20.0)	49.0 (31.0-71.0)	92.0 (74.0-134)	1399
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	62.0 (31.0-102)	104 (74.0-206)	665
Non-Hispanic blacks	01-02	*	< LOD	19.0 (<LOD-47.0)	78.0 (53.0-103)	135 (81.0-190)	692
Non-Hispanic whites	01-02	*	< LOD	12.0 (<LOD-28.0)	60.0 (42.0-79.0)	105 (75.0-143)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 45. 1-Hydroxychrysene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	**17.1** (11.3-25.0)	**50.0** (41.2-59.7)	**89.2** (71.4-104)	2748
Age group							
6-11 years	01-02	*	< LOD	< LOD	**42.6** (22.2-54.7)	**58.1** (47.0-74.2)	387
12-19 years	01-02	*	< LOD	**13.3** (7.61-18.6)	**35.0** (28.3-41.0)	**49.3** (37.4-65.7)	735
20 years and older	01-02	*	< LOD	**18.1** (11.7-28.5)	**55.9** (42.8-70.2)	**103** (78.9-120)	1626
Gender							
Males	01-02	*	< LOD	**19.4** (11.7-28.8)	**50.0** (41.1-57.7)	**86.4** (59.7-109)	1349
Females	01-02	*	< LOD	**15.9** (10.6-23.3)	**50.0** (38.9-66.0)	**91.5** (69.2-126)	1399
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	**58.2** (36.3-92.5)	**108** (61.8-147)	665
Non-Hispanic blacks	01-02	*	< LOD	**18.3** (6.48-33.9)	**56.6** (37.9-83.0)	**106** (62.4-154)	692
Non-Hispanic whites	01-02	*	< LOD	**16.5** (10.9-24.7)	**47.3** (38.4-59.4)	**91.5** (68.6-107)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 46. 2-Hydroxychrysene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	11.0 (<LOD-26.0)	31.0 (14.0-45.0)	2748
Age group							
6-11 years	01-02	*	< LOD	< LOD	22.0 (<LOD-43.0)	39.0 (13.0-49.0)	387
12-19 years	01-02	*	< LOD	< LOD	9.00 (<LOD-32.0)	32.0 (<LOD-49.0)	735
20 years and older	01-02	*	< LOD	< LOD	10.0 (<LOD-23.0)	32.0 (12.0-46.0)	1626
Gender							
Males	01-02	*	< LOD	< LOD	12.0 (<LOD-28.0)	34.0 (13.0-50.0)	1349
Females	01-02	*	< LOD	< LOD	9.00 (<LOD-22.0)	31.0 (12.0-43.0)	1399
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	15.0 (<LOD-39.0)	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	20.0 (<LOD-43.0)	43.0 (17.0-65.0)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	9.00 (<LOD-24.0)	27.0 (11.0-45.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 47. 2-Hydroxychrysene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	**17.5** (12.1-24.5)	**27.8** (20.9-35.0)	2748
Age group							
6-11 years	01-02	*	< LOD	< LOD	**21.9** (17.2-29.0)	**29.9** (22.0-34.2)	387
12-19 years	01-02	*	< LOD	< LOD	**14.3** (8.14-18.5)	**24.1** (15.2-35.0)	735
20 years and older	01-02	*	< LOD	< LOD	**17.6** (11.7-25.2)	**27.8** (20.6-38.9)	1626
Gender							
Males	01-02	*	< LOD	< LOD	**17.3** (9.72-24.9)	**26.3** (18.2-34.2)	1349
Females	01-02	*	< LOD	< LOD	**18.2** (14.0-24.5)	**30.2** (21.7-39.4)	1399
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	**21.8** (15.9-31.3)	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	**19.5** (7.50-32.4)	**30.8** (18.4-45.5)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	**17.3** (11.7-25.0)	**27.1** (20.3-35.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 49. 3-Hydroxychrysene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	2233
	01-02	*	< LOD	< LOD	35.0 (27.1-41.5)	56.8 (47.4-62.5)	2748
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	26.9 (17.5-46.2)	300
	01-02	*	< LOD	< LOD	36.8 (23.8-62.5)	67.3 (36.7-89.9)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	17.3 (13.7-21.9)	674
	01-02	*	< LOD	< LOD	28.2 (20.0-40.7)	43.8 (33.8-57.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	35.8 (26.7-44.6)	57.8 (50.0-63.6)	1626
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	20.6 (17.5-29.2)	1067
	01-02	*	< LOD	< LOD	28.2 (24.1-35.0)	47.6 (40.9-57.0)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1166
	01-02	*	< LOD	< LOD	40.9 (30.2-50.0)	65.0 (51.6-83.0)	1399
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	33.3 (21.9-37.1)	722
	01-02	*	< LOD	< LOD	28.4 (24.4-35.8)	42.0 (30.0-54.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	515
	01-02	*	< LOD	< LOD	22.8 (15.1-30.5)	35.0 (23.0-62.5)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	16.3 (13.9-18.4)	40.6 (31.8-47.4)	61.8 (51.5-70.2)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 50. 4-Hydroxychrysene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2748
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	5.00 (<LOD-11.0)	387
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1626
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1349
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1399
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	13.0 (4.00-18.0)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 51. 4-Hydroxychrysene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2748
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	9.55 (7.24-12.4)	387
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1626
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1349
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1399
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	9.00 (7.49-12.2)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 52. 6-Hydroxychrysene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	4.50 (<LOD-5.30)	6.00 (5.30-6.80)	2279
	01-02	*	< LOD	7.00 (<LOD-13.0)	43.0 (32.0-55.0)	77.0 (57.0-101)	2736
Age group							
6-11 years	99-00	*	< LOD	< LOD	5.00 (<LOD-5.90)	6.10 (5.70-7.60)	298
	01-02	*	< LOD	10.0 (<LOD-20.0)	32.0 (25.0-52.0)	68.0 (34.0-115)	386
12-19 years	99-00	*	< LOD	< LOD	5.70 (4.30-7.50)	7.70 (5.00-11.2)	689
	01-02	*	< LOD	10.0 (6.00-16.0)	46.0 (29.0-59.0)	79.0 (59.0-105)	728
20 years and older	99-00	*	< LOD	< LOD	4.40 (<LOD-5.10)	5.80 (4.90-6.60)	1292
	01-02	*	< LOD	7.00 (<LOD-13.0)	44.0 (32.0-60.0)	77.0 (57.0-103)	1622
Gender							
Males	99-00	*	< LOD	< LOD	4.80 (<LOD-5.70)	6.40 (5.40-7.70)	1091
	01-02	*	< LOD	13.0 (7.00-18.0)	55.0 (41.0-67.0)	101 (67.0-123)	1341
Females	99-00	*	< LOD	< LOD	4.20 (<LOD-5.10)	5.80 (4.50-7.30)	1188
	01-02	*	< LOD	< LOD	33.0 (22.0-46.0)	59.0 (44.0-78.0)	1395
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	4.70 (3.70-5.10)	6.00 (4.90-8.10)	749
	01-02	*	< LOD	16.0 (7.00-20.0)	48.0 (38.0-63.0)	84.0 (63.0-117)	664
Non-Hispanic blacks	99-00	*	< LOD	< LOD	4.90 (<LOD-6.60)	6.80 (4.70-9.50)	515
	01-02	*	< LOD	9.00 (<LOD-14.0)	61.0 (40.0-88.0)	112 (77.0-134)	683
Non-Hispanic whites	99-00	*	< LOD	< LOD	4.50 (<LOD-5.50)	5.90 (5.50-6.60)	827
	01-02	*	< LOD	9.00 (<LOD-15.0)	42.0 (29.0-58.0)	73.0 (52.0-107)	1206

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 53. 6-Hydroxychrysene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	8.05 (7.06-9.15)	12.6 (10.4-13.3)	2279
	01-02	*	< LOD	9.26 (6.36-13.8)	36.9 (28.0-46.0)	61.5 (47.7-76.4)	2736
Age group							
6-11 years	99-00	*	< LOD	< LOD	7.74 (5.11-13.1)	11.0 (8.09-24.5)	298
	01-02	*	< LOD	12.2 (5.00-18.9)	39.4 (24.5-62.7)	80.6 (40.0-115)	386
12-19 years	99-00	*	< LOD	< LOD	6.32 (4.61-9.35)	9.23 (5.83-11.7)	689
	01-02	*	< LOD	9.05 (6.49-12.7)	36.0 (21.1-46.9)	62.7 (44.3-97.6)	728
20 years and older	99-00	*	< LOD	< LOD	8.18 (7.07-9.60)	13.3 (11.4-14.1)	1292
	01-02	*	< LOD	8.65 (5.19-14.2)	36.4 (26.7-46.2)	60.7 (46.0-76.0)	1622
Gender							
Males	99-00	*	< LOD	< LOD	6.67 (5.22-8.51)	9.23 (8.28-11.7)	1091
	01-02	*	< LOD	12.0 (8.24-15.5)	41.5 (30.4-56.1)	64.4 (52.2-97.2)	1341
Females	99-00	*	< LOD	< LOD	9.88 (8.00-11.4)	14.1 (12.6-17.1)	1188
	01-02	*	< LOD	< LOD	32.5 (22.6-44.6)	50.8 (42.6-68.8)	1395
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	8.05 (5.45-11.4)	13.3 (7.74-24.2)	749
	01-02	*	< LOD	14.8 (8.29-20.8)	48.5 (33.6-63.4)	75.0 (50.3-123)	664
Non-Hispanic blacks	99-00	*	< LOD	< LOD	4.62 (3.81-6.00)	7.50 (5.71-7.93)	515
	01-02	*	< LOD	7.04 (3.89-11.6)	41.6 (29.9-55.5)	68.8 (46.0-113)	683
Non-Hispanic whites	99-00	*	< LOD	< LOD	8.57 (7.75-10.4)	13.1 (11.4-15.5)	827
	01-02	*	< LOD	9.42 (6.09-14.7)	38.2 (26.5-47.7)	62.4 (45.5-85.4)	1206

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

3-Hydroxyfluoranthene

Metabolite of Fluoranthene, CAS No. 206-44-0

Data for 3-hydroxyfluoranthene are not available for the current survey period 2001-2002. The table shown here reports data from 1999-2000 only.

Comparing Adjusted Geometric Means

For the 1999-2000 subsample, geometric mean levels of urinary fluorene metabolites in the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). There were no differences between the demographic groups in adjusted geometric mean levels of urinary 3-hydroxyfluoranthene.

Table 54. 3-Hydroxyfluoranthene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**13.4** (9.43-19.0)	**17.5** (7.90-25.9)	**32.3** (27.4-40.2)	**58.6** (49.4-73.0)	**98.8** (78.9-147)	2236
Age group							
6-11 years	99-00	**12.6** (8.82-17.9)	**15.8** (3.90-24.7)	**37.6** (24.7-45.1)	**65.7** (44.6-146)	**138** (66.3-216)	308
12-19 years	99-00	**15.0** (9.47-23.9)	**20.3** (5.10-31.8)	**38.7** (29.6-48.8)	**60.6** (47.6-91.4)	**98.9** (75.4-162)	675
20 years and older	99-00	**13.2** (9.39-18.6)	**17.3** (8.20-24.5)	**31.1** (26.8-38.5)	**58.2** (48.9-74.0)	**90.7** (71.7-151)	1253
Gender							
Males	99-00	**13.5** (9.55-19.0)	**17.4** (8.80-25.1)	**32.6** (27.1-42.1)	**58.2** (47.6-74.0)	**98.8** (64.7-190)	1074
Females	99-00	**13.3** (9.26-19.1)	**17.5** (6.80-26.1)	**31.8** (26.9-39.1)	**58.7** (48.9-77.2)	**88.4** (68.4-146)	1162
Race/ethnicity							
Mexican Americans	99-00	**14.0** (8.96-21.9)	**17.1** (6.90-26.8)	**30.4** (22.7-44.4)	**52.1** (42.9-73.8)	**96.6** (60.8-312)	715
Non-Hispanic blacks	99-00	**13.9** (8.32-23.2)	**17.7** (<LOD-29.3)	**38.2** (25.0-57.6)	**89.3** (56.8-174)	**185** (95.5-291)	527
Non-Hispanic whites	99-00	**13.2** (8.64-20.2)	**17.3** (6.50-28.1)	**32.0** (25.8-41.6)	**56.7** (43.6-74.0)	**87.3** (64.7-127)	803

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

Table 55. 3-Hydroxyfluoranthene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**12.3** (8.39-18.2)	**14.7** (7.90-24.9)	**36.3** (25.0-47.8)	**67.9** (54.4-84.7)	**102** (86.0-127)	2236
Age group							
6-11 years	99-00	**12.8** (8.49-19.4)	**13.7** (5.32-27.2)	**44.3** (21.3-66.5)	**77.0** (54.7-115)	**131** (67.3-254)	308
12-19 years	99-00	**10.1** (5.86-17.4)	**13.4** (4.90-24.1)	**29.1** (19.0-44.3)	**54.9** (39.2-84.6)	**92.1** (66.6-134)	675
20 years and older	99-00	**12.7** (8.76-18.4)	**14.8** (8.03-25.7)	**36.5** (25.6-46.8)	**68.9** (54.4-85.0)	**102** (82.9-128)	1253
Gender							
Males	99-00	**10.7** (7.16-15.9)	**12.1** (6.41-20.7)	**32.9** (20.7-45.3)	**62.5** (44.3-82.4)	**91.3** (72.6-122)	1074
Females	99-00	**14.2** (9.70-20.7)	**17.5** (9.10-28.0)	**39.6** (28.9-49.9)	**75.5** (61.3-89.1)	**107** (90.5-172)	1162
Race/ethnicity							
Mexican Americans	99-00	**12.7** (7.69-21.1)	**13.8** (6.76-23.0)	**30.7** (20.8-48.2)	**64.1** (48.2-97.4)	**107** (67.7-312)	715
Non-Hispanic blacks	99-00	**9.14** (5.44-15.4)	**10.4** (2.98-21.3)	**30.2** (19.8-42.6)	**72.6** (47.6-116)	**133** (84.2-216)	527
Non-Hispanic whites	99-00	**13.1** (8.31-20.7)	**16.0** (6.45-29.7)	**36.9** (25.0-52.1)	**68.8** (51.2-86.0)	**90.6** (77.0-127)	803

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

2-Hydroxyfluorene, 3-Hydroxyfluorene, and 9-Hydroxyfluorene

Metabolites of Fluorene, CAS No. 86-73-7

Interpreting Levels of Urinary Fluorene Metabolites Reported in the Tables

Urinary levels of 2-hydroxyfluorene, 3-hydroxyfluorene, 9-hydroxyfluorene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Levels of 2-hydroxyfluorene have been shown to be higher in smokers than non-smokers (Toriba et al., 2003).

Comparing Adjusted Geometric Means

Geometric mean levels of urinary fluorene metabolites for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of 2- and 3-fluorene were higher for the group aged 6-11 years than either of the groups aged 12-19 years or 20 years and older.

For adjusted geometric mean levels of 9-fluorene in NHANES 2001-2002, the group aged 12-19 years had lower levels than either of the groups aged 6-11 years or 20 years and older.

It is unknown whether these differences associated with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 56. 2-Hydroxyfluorene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**441** (287-678)	**422** (237-826)	**1350** (895-2290)	**3710** (2620-5250)	**6450** (4630-9470)	2315
	01-02	**318** (277-366)	**293** (252-328)	**619** (515-779)	**1700** (1330-2090)	**2820** (2340-3450)	2745
Age group							
6-11 years	99-00	**294** (181-477)	**262** (157-563)	**780** (447-1360)	**1800** (1140-2000)	**2010** (1810-3260)	306
	01-02	**246** (219-277)	**262** (212-298)	**417** (357-492)	**679** (530-926)	**979** (773-1180)	387
12-19 years	99-00	**469** (301-729)	**421** (243-933)	**1410** (932-2190)	**2810** (2180-4130)	**4980** (3540-6610)	694
	01-02	**295** (244-357)	**267** (237-319)	**548** (427-652)	**1190** (712-2090)	**2190** (1290-3250)	733
20 years and older	99-00	**461** (300-709)	**456** (251-857)	**1510** (973-2620)	**4280** (2750-6090)	**7270** (4720-10300)	1315
	01-02	**333** (287-385)	**300** (254-343)	**716** (546-893)	**1950** (1520-2310)	**3140** (2540-3660)	1625
Gender							
Males	99-00	**474** (294-765)	**468** (223-923)	**1450** (875-2460)	**3780** (2440-6350)	**6920** (4160-12500)	1106
	01-02	**377** (324-439)	**329** (287-377)	**773** (579-1010)	**2060** (1480-2690)	**3210** (2340-3930)	1346
Females	99-00	**412** (276-616)	**385** (246-755)	**1330** (866-2150)	**3600** (2700-4660)	**5790** (4350-9470)	1209
	01-02	**272** (232-317)	**250** (211-296)	**512** (425-614)	**1270** (1120-1700)	**2310** (1990-2920)	1399
Race/ethnicity							
Mexican Americans	99-00	**296** (217-404)	**268** (164-454)	**807** (485-1290)	**1870** (1230-2530)	**2930** (1900-5400)	750
	01-02	**267** (212-337)	**270** (200-344)	**491** (368-620)	**951** (652-1190)	**1350** (1080-2130)	662
Non-Hispanic blacks	99-00	**646** (337-1240)	**680** (258-1520)	**2140** (983-4570)	**5790** (2680-11800)	**10800** (4830-19300)	534
	01-02	**459** (401-526)	**433** (377-474)	**1020** (725-1400)	**2200** (1760-3110)	**3480** (2520-4770)	692
Non-Hispanic whites	99-00	**418** (249-704)	**402** (211-860)	**1320** (825-2550)	**3990** (2590-5150)	**6450** (4600-9470)	842
	01-02	**310** (259-372)	**282** (234-332)	**599** (477-817)	**1710** (1210-2260)	**2920** (2260-3640)	1207

Table 57. 2-Hydroxyfluorene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**408** (259-642)	**382** (233-713)	**1160** (756-1660)	**2880** (1960-4350)	**5270** (3540-6860)	2315
	01-02	**298** (261-340)	**240** (209-266)	**530** (432-681)	**1310** (1100-1490)	**1890** (1590-2290)	2745
Age group							
6-11 years	99-00	**307** (180-525)	**336** (140-724)	**787** (520-1200)	**1380** (1030-2180)	**1740** (1410-2880)	306
	01-02	**275** (238-319)	**256** (224-289)	**387** (319-508)	**695** (527-989)	**1040** (724-1470)	387
12-19 years	99-00	**314** (190-519)	**369** (153-619)	**785** (543-1300)	**1880** (1260-2550)	**2570** (2220-3360)	694
	01-02	**228** (194-268)	**187** (164-220)	**358** (278-479)	**852** (537-1100)	**1170** (885-2150)	733
20 years and older	99-00	**443** (283-692)	**400** (259-739)	**1260** (806-2080)	**3480** (2290-5200)	**6040** (3990-7970)	1315
	01-02	**314** (275-358)	**245** (213-277)	**597** (491-766)	**1430** (1270-1590)	**2080** (1700-2530)	1625
Gender							
Males	99-00	**376** (225-628)	**378** (195-702)	**1070** (657-1750)	**2440** (1550-4870)	**4870** (2630-6870)	1106
	01-02	**305** (263-353)	**248** (209-290)	**563** (449-717)	**1330** (1030-1590)	**1900** (1460-2460)	1346
Females	99-00	**441** (291-667)	**393** (250-741)	**1260** (841-1680)	**3300** (2200-4410)	**5490** (3580-7720)	1209
	01-02	**291** (255-332)	**227** (207-260)	**497** (399-649)	**1220** (1060-1490)	**1890** (1590-2290)	1399
Race/ethnicity							
Mexican Americans	99-00	**275** (187-405)	**252** (155-443)	**597** (394-999)	**1350** (960-1720)	**2090** (1410-3110)	750
	01-02	**250** (206-303)	**221** (176-279)	**375** (306-501)	**711** (517-1040)	**1350** (787-2060)	662
Non-Hispanic blacks	99-00	**425** (219-823)	**541** (174-1070)	**1190** (679-2650)	**3090** (1500-7100)	**6040** (3080-8500)	534
	01-02	**323** (281-373)	**273** (220-334)	**660** (496-856)	**1290** (1050-1700)	**1880** (1590-2460)	692
Non-Hispanic whites	99-00	**414** (241-711)	**387** (215-762)	**1240** (756-1910)	**3110** (2050-4880)	**5620** (3670-7370)	842
	01-02	**306** (260-360)	**243** (208-273)	**546** (435-741)	**1400** (1140-1590)	**2080** (1530-2620)	1207

Figure 14. 2-Hydroxyfluorene (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 58. 3-Hydroxyfluorene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**170** (114-254)	**151** (86.3-280)	**572** (341-956)	**1840** (1260-2530)	**3390** (2290-4680)	2312
	01-02	**134** (115-155)	**111** (96.0-125)	**253** (207-349)	**959** (666-1300)	**1620** (1390-1900)	2745
Age group							
6-11 years	99-00	**105** (70.3-157)	**92.8** (57.2-166)	**247** (137-439)	**615** (328-851)	**851** (647-1290)	306
	01-02	**106** (94.8-119)	**106** (90.0-124)	**174** (145-200)	**287** (235-358)	**377** (306-455)	387
12-19 years	99-00	**192** (126-293)	**198** (119-295)	**621** (358-903)	**1330** (978-1910)	**2110** (1550-2400)	692
	01-02	**129** (103-161)	**113** (97.0-137)	**221** (177-266)	**542** (325-1070)	**1210** (680-2130)	733
20 years and older	99-00	**178** (117-269)	**156** (89.1-306)	**639** (375-1160)	**2080** (1450-3350)	**4060** (2600-5020)	1314
	01-02	**138** (119-161)	**110** (94.0-128)	**311** (228-429)	**1130** (823-1400)	**1840** (1470-2080)	1625
Gender							
Males	99-00	**189** (119-299)	**167** (85.4-319)	**689** (341-1230)	**2060** (1320-3160)	**3520** (2090-6060)	1105
	01-02	**163** (137-194)	**134** (114-154)	**352** (242-481)	**1100** (721-1500)	**1810** (1390-2190)	1346
Females	99-00	**154** (106-224)	**141** (85.2-250)	**478** (333-742)	**1710** (986-2490)	**3010** (1900-4610)	1207
	01-02	**111** (95.0-130)	**93.0** (83.0-108)	**203** (167-248)	**796** (498-1040)	**1390** (1230-1660)	1399
Race/ethnicity							
Mexican Americans	99-00	**105** (75.6-145)	**96.7** (53.8-167)	**313** (203-432)	**862** (493-1370)	**1490** (941-1650)	748
	01-02	**108** (87.1-134)	**98.0** (80.0-118)	**190** (144-255)	**476** (302-641)	**668** (476-1140)	662
Non-Hispanic blacks	99-00	**266** (145-489)	**257** (116-572)	**954** (441-1750)	**2800** (1320-5800)	**5290** (2390-8600)	534
	01-02	**203** (169-244)	**161** (135-188)	**444** (308-830)	**1420** (1130-1780)	**2350** (1520-3000)	692
Non-Hispanic whites	99-00	**161** (99.9-259)	**137** (72.9-298)	**552** (318-964)	**1910** (1160-2720)	**3590** (2290-4730)	842
	01-02	**130** (108-157)	**108** (93.0-127)	**246** (202-352)	**948** (621-1320)	**1610** (1320-1990)	1207

Table 59. 3-Hydroxyfluorene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**157** (102-241)	**135** (79.9-234)	**482** (306-766)	**1510** (918-2540)	**2710** (1780-4060)	2312
	01-02	**125** (108-144)	**94.4** (83.3-106)	**219** (174-303)	**754** (622-873)	**1060** (909-1290)	2745
Age group							
6-11 years	99-00	**110** (69.8-173)	**111** (62.4-204)	**268** (175-418)	**504** (324-832)	**832** (480-1540)	306
	01-02	**119** (103-137)	**110** (96.7-121)	**153** (135-197)	**264** (206-377)	**382** (254-631)	387
12-19 years	99-00	**129** (79.4-209)	**140** (68.7-253)	**374** (228-496)	**799** (536-1120)	**1130** (917-1390)	692
	01-02	**99.3** (81.6-121)	**81.5** (74.2-92.6)	**144** (109-197)	**390** (214-700)	**700** (372-1380)	733
20 years and older	99-00	**170** (111-262)	**138** (83.9-244)	**613** (329-978)	**1820** (1130-2730)	**3020** (2140-4290)	1314
	01-02	**131** (113-151)	**94.0** (81.0-108)	**279** (195-367)	**853** (727-923)	**1210** (1010-1350)	1625
Gender							
Males	99-00	**150** (90.9-246)	**128** (72.9-253)	**496** (270-807)	**1390** (777-2710)	**2710** (1440-4170)	1105
	01-02	**132** (111-156)	**99.4** (87.3-116)	**260** (194-361)	**745** (560-914)	**1130** (862-1380)	1346
Females	99-00	**164** (111-243)	**138** (86.6-228)	**477** (311-792)	**1650** (1050-2400)	**2860** (2000-3790)	1207
	01-02	**119** (104-136)	**88.9** (78.6-103)	**179** (156-227)	**777** (604-888)	**1030** (923-1270)	1399
Race/ethnicity							
Mexican Americans	99-00	**97.5** (65.6-145)	**89.2** (52.4-147)	**220** (146-338)	**665** (380-854)	**987** (709-1600)	748
	01-02	**101** (84.2-121)	**84.0** (74.8-97.2)	**158** (124-214)	**364** (227-598)	**598** (357-1230)	662
Non-Hispanic blacks	99-00	**175** (94.1-325)	**176** (74.3-364)	**550** (313-1060)	**1590** (828-2830)	**2710** (1590-3950)	534
	01-02	**143** (118-173)	**110** (90.7-133)	**316** (186-525)	**849** (622-1230)	**1240** (882-1430)	692
Non-Hispanic whites	99-00	**159** (96.6-262)	**138** (73.4-260)	**505** (314-832)	**1650** (967-2700)	**2920** (1830-4210)	842
	01-02	**128** (108-152)	**94.7** (83.4-109)	**223** (171-323)	**816** (642-914)	**1150** (910-1410)	1207

Figure 15. 3-Hydroxyfluorene (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 60. 9-Hydroxyfluorene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**219** (191-251)	**219** (186-258)	**429** (363-510)	**779** (690-897)	**1090** (950-1300)	2745
Age group							
6-11 years	01-02	**169** (142-201)	**168** (144-202)	**295** (255-369)	**487** (415-683)	**720** (546-994)	387
12-19 years	01-02	**197** (161-242)	**200** (153-266)	**370** (319-445)	**666** (527-784)	**883** (679-1270)	733
20 years and older	01-02	**230** (199-265)	**231** (201-270)	**452** (376-568)	**839** (726-965)	**1150** (995-1360)	1625
Gender							
Males	01-02	**251** (217-292)	**249** (207-296)	**475** (396-578)	**858** (698-1080)	**1240** (990-1520)	1346
Females	01-02	**192** (164-225)	**194** (164-238)	**387** (328-462)	**701** (617-881)	**1020** (913-1100)	1399
Race/ethnicity							
Mexican Americans	01-02	**199** (147-269)	**202** (155-273)	**347** (277-506)	**701** (451-1080)	**1080** (603-1690)	662
Non-Hispanic blacks	01-02	**327** (287-373)	**324** (289-348)	**609** (538-708)	**1060** (884-1430)	**1570** (1130-2350)	692
Non-Hispanic whites	01-02	**213** (182-250)	**214** (176-260)	**414** (347-508)	**772** (676-868)	**1060** (884-1300)	1207

Table 61. 9-Hydroxyfluorene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**205** (183-229)	**206** (181-232)	**353** (312-393)	**585** (507-697)	**852** (736-1120)	2745
Age group							
6-11 years	01-02	**189** (156-228)	**197** (162-238)	**330** (285-372)	**542** (426-660)	**740** (568-1010)	387
12-19 years	01-02	**152** (130-179)	**145** (120-183)	**256** (212-313)	**432** (348-584)	**642** (497-970)	733
20 years and older	01-02	**217** (194-243)	**219** (189-245)	**373** (331-412)	**608** (525-736)	**933** (747-1250)	1625
Gender							
Males	01-02	**203** (180-230)	**198** (173-227)	**348** (300-408)	**607** (526-722)	**843** (745-1070)	1346
Females	01-02	**206** (182-234)	**213** (183-245)	**361** (306-395)	**541** (488-697)	**894** (702-1160)	1399
Race/ethnicity							
Mexican Americans	01-02	**186** (143-243)	**182** (142-250)	**302** (233-416)	**515** (375-724)	**724** (515-1380)	662
Non-Hispanic blacks	01-02	**231** (201-265)	**224** (199-240)	**359** (324-388)	**605** (453-929)	**1190** (674-1680)	692
Non-Hispanic whites	01-02	**211** (186-239)	**211** (178-245)	**367** (324-411)	**605** (521-719)	**896** (747-1160)	1207

1-Hydroxyphenanthrene, 2-Hydroxyphenanthrene, 3-Hydroxyphenanthrene, 4-Hydroxyphenanthrene, and 9-Hydroxyphenanthrene

Metabolites of Phenanthrene, CAS No. 85-01-8

Interpreting Levels of Urinary Phenanthrene Metabolites Reported in the Tables

Urinary levels of 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenanthrene, 4-hydroxyphenanthrene, and 9-hydroxyphenanthrene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Residents of homes with PAH contaminated parquet flooring had higher mean urinary 1-, 2-, 3- and 4-hydroxy-phenanthrene levels than were found in this NHANES 1999-2002 subsample (Heudorf and Angerer, 2001*a*). Workers manufacturing fireproof stone had urinary levels of 1-, 2-, 3- and 4-hydroxy-phenanthrene levels that were about ten times higher than the levels that were found in this NHANES 1999-2002 subsample (Gundel et al., 2000).

Tobacco smoking increased levels of 2-, 3- and 4-hydroxyphenanthrene levels (Heudorf and Angerer, 2001*b*).

Comparing Adjusted Geometric Means

Geometric means levels of urinary phenanthrene metabolites for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary 1-hydroxyphenanthrene were higher in females than males, higher in non-Hispanic whites than non-Hispanic blacks, and higher in the group aged 6-11 years than either of the groups aged 12-19 years or 20 years and older.

Table 62. 1-Hydroxyphenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**154** (115-206)	**160** (105-236)	**367** (280-483)	**698** (609-836)	**1070** (851-1390)	2246
	01-02	**140** (125-158)	**140** (128-152)	**266** (229-312)	**476** (426-539)	**684** (581-763)	2741
Age group							
6-11 years	99-00	**121** (85.4-172)	**102** (74.2-204)	**257** (184-389)	**513** (360-666)	**666** (535-1080)	294
	01-02	**119** (104-137)	**121** (98.0-142)	**228** (182-249)	**357** (265-501)	**493** (367-661)	387
12-19 years	99-00	**167** (128-218)	**175** (137-229)	**353** (266-443)	**688** (580-865)	**1080** (721-1560)	680
	01-02	**133** (110-162)	**130** (109-152)	**238** (198-303)	**429** (376-546)	**579** (439-820)	733
20 years and older	99-00	**157** (116-212)	**163** (105-247)	**400** (295-523)	**739** (623-899)	**1100** (859-1530)	1272
	01-02	**145** (127-164)	**145** (132-163)	**273** (237-326)	**498** (440-565)	**712** (582-789)	1621
Gender							
Males	99-00	**153** (112-209)	**147** (99.8-236)	**351** (262-498)	**680** (588-836)	**1020** (735-1590)	1072
	01-02	**150** (133-169)	**145** (132-164)	**284** (235-348)	**499** (424-593)	**713** (575-845)	1344
Females	99-00	**156** (118-205)	**172** (119-236)	**372** (290-480)	**753** (610-946)	**1100** (855-1530)	1174
	01-02	**132** (115-152)	**136** (120-151)	**254** (221-297)	**462** (390-520)	**654** (538-769)	1397
Race/ethnicity							
Mexican Americans	99-00	**113** (94.9-134)	**113** (98.9-137)	**230** (180-314)	**447** (328-557)	**618** (459-745)	727
	01-02	**117** (90.8-152)	**115** (88.0-147)	**214** (157-294)	**364** (254-583)	**514** (342-847)	664
Non-Hispanic blacks	99-00	**162** (100-262)	**170** (82.7-303)	**441** (252-680)	**821** (574-1300)	**1210** (790-2290)	516
	01-02	**150** (127-179)	**145** (126-170)	**287** (243-327)	**493** (423-629)	**713** (568-975)	690
Non-Hispanic whites	99-00	**154** (109-218)	**156** (102-248)	**378** (267-533)	**704** (604-891)	**1060** (867-1450)	815
	01-02	**144** (125-166)	**143** (130-160)	**276** (241-330)	**489** (436-552)	**649** (550-793)	1204

For adjusted geometric mean levels of urinary 2-hydroxyphenanthrene in the NHANES 2001-2002, there were no demographic differences observed.

For adjusted geometric mean levels of urinary 3-hydroxyphenanthrene, in NHANES 2001-2002, higher levels were observed in the group aged 6-11 years than either of the groups age 12-19 years or 20 years and older. Non-Hispanic whites had higher levels than Mexican Americans.

For adjusted geometric mean levels of urinary 4-hydroxyphenanthrene, in NHANES 2001-2002, no demographic group differences were observed.

For adjusted geometric mean levels of urinary 9-hydroxyphenanthrene, in NHANES 2001-2002, non-Hispanic whites had higher levels than either non-Hispanic blacks or Mexican Americans. Also, Mexican Americans had higher levels than non-Hispanic blacks.

It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 63. 1-Hydroxyphenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**142** (103-195)	**143** (102-204)	**299** (240-379)	**571** (450-693)	**907** (652-1270)	2246
	01-02	**132** (118-147)	**125** (113-141)	**210** (191-231)	**344** (310-385)	**464** (404-539)	2741
Age group							
6-11 years	99-00	**127** (86.4-187)	**135** (85.8-206)	**265** (185-372)	**457** (372-577)	**622** (503-913)	294
	01-02	**133** (116-153)	**125** (110-147)	**188** (165-225)	**344** (245-437)	**452** (364-598)	387
12-19 years	99-00	**112** (79.9-156)	**121** (93.5-154)	**207** (164-283)	**406** (293-632)	**661** (421-972)	680
	01-02	**103** (87.9-121)	**97.2** (81.4-117)	**158** (131-192)	**237** (198-322)	**354** (235-531)	733
20 years and older	99-00	**150** (109-207)	**150** (104-220)	**321** (254-397)	**603** (462-828)	**973** (671-1530)	1272
	01-02	**137** (122-153)	**131** (117-145)	**223** (200-243)	**351** (319-395)	**476** (421-541)	1621
Gender							
Males	99-00	**120** (85.0-170)	**124** (81.4-187)	**260** (195-328)	**479** (362-641)	**692** (497-1090)	1072
	01-02	**122** (108-137)	**116** (104-131)	**194** (173-218)	**314** (262-395)	**450** (348-642)	1344
Females	99-00	**166** (122-225)	**166** (120-219)	**351** (276-418)	**631** (474-969)	**1120** (643-2180)	1174
	01-02	**142** (125-160)	**136** (118-156)	**226** (199-256)	**353** (323-399)	**473** (421-541)	1397
Race/ethnicity							
Mexican Americans	99-00	**104** (81.4-133)	**104** (78.8-141)	**192** (154-234)	**327** (241-456)	**474** (372-672)	727
	01-02	**110** (88.6-136)	**101** (85.5-131)	**162** (138-203)	**275** (187-452)	**396** (268-755)	664
Non-Hispanic blacks	99-00	**107** (65.5-174)	**109** (56.6-209)	**269** (173-395)	**548** (358-847)	**887** (534-1410)	516
	01-02	**106** (88.7-127)	**102** (92.4-111)	**172** (141-203)	**272** (224-356)	**384** (308-598)	690
Non-Hispanic whites	99-00	**151** (104-220)	**153** (99.9-236)	**323** (249-395)	**580** (468-820)	**1010** (643-1510)	815
	01-02	**142** (126-161)	**137** (119-153)	**226** (206-247)	**363** (321-406)	**476** (411-552)	1204

Figure 16. 1-Hydroxyphenanthrene (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 64. 2-Hydroxyphenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**98.3** (76.6-126)	**107** (79.7-141)	**240** (194-335)	**545** (448-689)	**828** (714-937)	2179
	01-02	**54.0** (46.0-63.5)	**57.0** (49.0-68.0)	**117** (102-140)	**240** (200-271)	**332** (299-377)	2742
Age group							
6-11 years	99-00	**79.6** (57.3-111)	**74.1** (45.8-113)	**189** (113-289)	**401** (283-585)	**698** (383-1140)	291
	01-02	**40.5** (34.3-47.7)	**45.0** (37.0-57.0)	**87.0** (71.0-101)	**170** (133-207)	**257** (195-320)	387
12-19 years	99-00	**109** (90.0-132)	**112** (92.6-139)	**233** (183-296)	**529** (427-615)	**767** (570-1250)	650
	01-02	**49.5** (37.3-65.7)	**51.0** (41.0-68.0)	**107** (90.0-122)	**210** (145-270)	**281** (214-524)	733
20 years and older	99-00	**99.3** (76.4-129)	**108** (81.2-148)	**253** (203-345)	**571** (454-721)	**864** (721-945)	1238
	01-02	**56.8** (48.1-66.9)	**60.0** (51.0-73.0)	**126** (104-152)	**249** (207-292)	**342** (308-398)	1622
Gender							
Males	99-00	**107** (81.9-140)	**109** (82.2-158)	**263** (199-382)	**592** (448-778)	**928** (702-1340)	1048
	01-02	**62.1** (53.3-72.5)	**67.0** (58.0-80.0)	**135** (109-161)	**274** (245-303)	**359** (329-414)	1345
Females	99-00	**90.6** (70.7-116)	**105** (72.7-132)	**226** (183-307)	**514** (402-632)	**797** (579-915)	1131
	01-02	**47.4** (39.1-57.5)	**50.0** (40.0-59.0)	**105** (88.0-128)	**200** (171-240)	**292** (236-357)	1397
Race/ethnicity							
Mexican Americans	99-00	**86.0** (69.6-106)	**92.3** (68.9-124)	**217** (163-285)	**432** (325-482)	**583** (433-913)	698
	01-02	**46.8** (32.7-66.8)	**51.0** (35.0-72.0)	**95.0** (72.0-137)	**191** (122-332)	**303** (187-652)	665
Non-Hispanic blacks	99-00	**131** (84.6-202)	**141** (69.6-250)	**370** (214-562)	**698** (476-1080)	**1080** (782-2310)	509
	01-02	**71.1** (58.0-87.1)	**74.0** (66.0-90.0)	**152** (123-182)	**260** (217-311)	**374** (284-560)	690
Non-Hispanic whites	99-00	**91.7** (67.2-125)	**103** (70.6-139)	**231** (177-339)	**514** (409-712)	**810** (680-906)	792
	01-02	**53.1** (43.6-64.6)	**57.0** (47.0-66.0)	**116** (98.0-144)	**242** (199-286)	**333** (303-385)	1204

Table 65. 2-Hydroxyphenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**90.3** (69.3-118)	**89.8** (67.8-119)	**188** (147-255)	**368** (310-439)	**521** (426-748)	2179
	01-02	**50.6** (43.3-59.2)	**52.5** (46.4-59.6)	**91.4** (78.7-108)	**164** (138-200)	**231** (206-275)	2742
Age group							
6-11 years	99-00	**83.8** (59.6-118)	**74.4** (58.8-98.3)	**173** (98.3-289)	**350** (275-402)	**413** (350-702)	291
	01-02	**45.3** (38.8-52.8)	**49.7** (39.8-57.8)	**85.9** (69.6-100)	**144** (105-217)	**234** (138-397)	387
12-19 years	99-00	**74.0** (57.7-94.8)	**75.0** (58.8-91.4)	**133** (105-196)	**295** (214-377)	**441** (319-611)	650
	01-02	**38.4** (29.6-49.7)	**38.5** (30.6-48.7)	**64.9** (52.4-84.0)	**116** (86.7-167)	**173** (128-305)	733
20 years and older	99-00	**94.3** (71.8-124)	**94.9** (68.0-131)	**197** (157-263)	**392** (310-486)	**573** (466-810)	1238
	01-02	**53.7** (46.2-62.4)	**55.6** (49.4-62.0)	**94.2** (84.1-112)	**173** (145-201)	**241** (209-287)	1622
Gender							
Males	99-00	**85.2** (64.7-112)	**80.6** (63.0-110)	**175** (135-231)	**375** (293-438)	**544** (413-810)	1048
	01-02	**50.4** (43.3-58.5)	**52.5** (47.2-59.2)	**91.4** (78.6-103)	**176** (140-208)	**245** (206-349)	1345
Females	99-00	**95.5** (72.5-126)	**97.1** (71.5-133)	**207** (163-262)	**367** (310-448)	**536** (393-816)	1131
	01-02	**50.9** (42.7-60.7)	**52.4** (45.5-61.0)	**91.6** (75.0-115)	**158** (133-183)	**213** (200-245)	1397
Race/ethnicity							
Mexican Americans	99-00	**78.8** (62.0-100)	**77.3** (61.9-101)	**155** (113-202)	**310** (222-370)	**382** (303-618)	698
	01-02	**43.7** (31.9-59.8)	**43.9** (34.3-58.8)	**80.5** (59.8-115)	**146** (103-245)	**242** (144-394)	665
Non-Hispanic blacks	99-00	**86.9** (55.8-135)	**93.3** (48.8-159)	**207** (131-318)	**408** (291-664)	**664** (470-993)	509
	01-02	**50.2** (40.5-62.2)	**49.6** (44.3-56.0)	**87.6** (72.5-103)	**173** (127-224)	**251** (178-459)	690
Non-Hispanic whites	99-00	**89.4** (64.9-123)	**87.8** (65.8-122)	**188** (141-261)	**366** (300-439)	**536** (411-810)	792
	01-02	**52.5** (43.8-62.9)	**54.7** (47.7-61.9)	**92.5** (80.5-113)	**170** (140-204)	**231** (202-293)	1204

Figure 17. 2-Hydroxyphenanthrene (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 66. 3-Hydroxyphenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**127** (106-152)	**138** (113-165)	**256** (225-297)	**464** (399-547)	**657** (594-721)	2299
	01-02	**105** (92.5-118)	**105** (90.0-118)	**200** (178-225)	**400** (336-480)	**649** (542-747)	2741
Age group							
6-11 years	99-00	**136** (102-181)	**140** (102-197)	**247** (185-334)	**383** (280-632)	**622** (336-794)	302
	01-02	**105** (91.1-122)	**108** (81.0-136)	**193** (160-231)	**298** (245-346)	**412** (319-545)	387
12-19 years	99-00	**147** (126-173)	**163** (137-196)	**281** (240-322)	**417** (363-536)	**611** (457-725)	700
	01-02	**104** (87.3-125)	**106** (90.0-122)	**201** (165-231)	**329** (255-444)	**447** (331-631)	733
20 years and older	99-00	**122** (102-146)	**133** (108-155)	**254** (223-295)	**477** (410-554)	**671** (594-760)	1297
	01-02	**105** (91.7-119)	**105** (89.0-118)	**200** (178-228)	**433** (366-515)	**683** (597-806)	1621
Gender							
Males	99-00	**141** (114-174)	**149** (119-185)	**287** (225-357)	**495** (409-626)	**658** (552-802)	1100
	01-02	**122** (107-138)	**117** (105-131)	**224** (187-277)	**474** (372-597)	**734** (597-1010)	1344
Females	99-00	**114** (96.2-135)	**130** (102-152)	**242** (215-270)	**399** (346-506)	**624** (554-718)	1199
	01-02	**90.8** (77.7-106)	**92.0** (80.0-106)	**184** (155-207)	**328** (287-386)	**518** (429-649)	1397
Race/ethnicity							
Mexican Americans	99-00	**113** (103-123)	**120** (99.7-139)	**231** (193-244)	**353** (296-438)	**495** (369-635)	763
	01-02	**83.5** (64.1-109)	**83.0** (63.0-111)	**144** (116-193)	**259** (189-421)	**454** (253-1140)	664
Non-Hispanic blacks	99-00	**174** (124-245)	**182** (116-292)	**390** (289-470)	**671** (477-1060)	**1110** (775-2750)	522
	01-02	**145** (122-172)	**135** (120-163)	**281** (228-346)	**507** (407-684)	**957** (609-1410)	690
Non-Hispanic whites	99-00	**120** (95.3-151)	**135** (107-167)	**248** (217-292)	**448** (356-554)	**632** (515-721)	821
	01-02	**104** (90.8-120)	**105** (91.0-119)	**199** (177-224)	**401** (331-495)	**649** (518-747)	1204

Table 67. 3-Hydroxyphenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**116** (94.5-143)	**121** (101-144)	**198** (171-235)	**365** (312-400)	**480** (402-574)	2299
	01-02	**98.0** (87.4-110)	**86.5** (78.8-97.1)	**158** (142-174)	**299** (252-342)	**428** (360-621)	2741
Age group							
6-11 years	99-00	**143** (106-192)	**155** (114-197)	**226** (183-331)	**416** (326-436)	**440** (418-499)	302
	01-02	**118** (103-135)	**114** (94.9-131)	**173** (150-201)	**289** (238-368)	**408** (308-544)	387
12-19 years	99-00	**99.3** (78.5-126)	**112** (92.9-124)	**173** (134-213)	**261** (213-317)	**317** (273-402)	700
	01-02	**81.1** (70.1-93.8)	**78.0** (66.7-89.4)	**116** (96.5-144)	**205** (153-275)	**275** (198-511)	733
20 years and older	99-00	**116** (94.9-143)	**118** (99.2-140)	**201** (167-241)	**374** (316-444)	**502** (410-675)	1297
	01-02	**98.9** (88.3-111)	**85.2** (78.3-96.6)	**164** (147-183)	**320** (273-356)	**488** (379-774)	1621
Gender							
Males	99-00	**111** (86.9-143)	**122** (97.6-143)	**189** (157-240)	**355** (240-466)	**470** (387-633)	1100
	01-02	**98.6** (87.7-111)	**87.1** (79.5-98.2)	**159** (138-188)	**310** (245-368)	**505** (356-761)	1344
Females	99-00	**121** (99.8-147)	**120** (101-150)	**214** (168-265)	**369** (326-401)	**487** (400-675)	1199
	01-02	**97.5** (84.9-112)	**86.3** (76.7-100)	**157** (139-178)	**292** (245-333)	**410** (352-583)	1397
Race/ethnicity							
Mexican Americans	99-00	**105** (93.2-118)	**107** (96.6-118)	**161** (147-174)	**244** (209-302)	**368** (279-425)	763
	01-02	**78.2** (62.4-98.0)	**70.5** (56.2-87.4)	**130** (92.9-171)	**224** (173-321)	**333** (224-656)	664
Non-Hispanic blacks	99-00	**115** (80.8-163)	**120** (90.4-167)	**213** (162-300)	**410** (300-549)	**652** (482-850)	522
	01-02	**102** (85.8-122)	**91.8** (79.8-108)	**160** (133-202)	**296** (234-475)	**589** (347-1260)	690
Non-Hispanic whites	99-00	**117** (91.4-151)	**124** (99.2-150)	**203** (173-253)	**373** (292-442)	**480** (389-671)	821
	01-02	**103** (91.5-117)	**89.4** (80.2-102)	**167** (148-193)	**324** (272-368)	**447** (365-738)	1204

Figure 18. 3-Hydroxyphenanthrene (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 68. 4-Hydroxyphenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**41.9** (31.3-56.0)	**67.0** (46.0-92.0)	**141** (119-170)	**225** (196-254)	**280** (250-339)	2741
Age group							
6-11 years	01-02	**34.5** (24.3-48.9)	**51.0** (30.0-77.0)	**118** (87.0-155)	**201** (155-256)	**250** (184-284)	387
12-19 years	01-02	**38.8** (28.9-52.1)	**66.0** (38.0-85.0)	**131** (112-156)	**223** (188-261)	**306** (257-358)	733
20 years and older	01-02	**43.4** (32.0-58.9)	**70.0** (46.0-96.0)	**146** (124-173)	**228** (196-264)	**292** (249-346)	1621
Gender							
Males	01-02	**45.3** (33.6-61.0)	**73.0** (46.0-99.0)	**142** (117-176)	**226** (192-250)	**287** (247-346)	1344
Females	01-02	**38.9** (28.8-52.5)	**64.0** (43.0-88.0)	**141** (118-165)	**222** (190-265)	**278** (249-350)	1397
Race/ethnicity							
Mexican Americans	01-02	**42.8** (23.7-77.4)	**72.0** (25.0-120)	**144** (92.0-215)	**227** (183-268)	**289** (243-398)	664
Non-Hispanic blacks	01-02	**48.6** (33.8-69.9)	**78.0** (51.0-113)	**159** (129-186)	**233** (194-276)	**277** (240-335)	690
Non-Hispanic whites	01-02	**41.1** (29.6-57.0)	**66.0** (41.0-96.0)	**140** (116-171)	**225** (186-266)	**287** (247-356)	1204

Table 69. 4-Hydroxyphenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**39.2** (29.6-52.0)	**56.5** (39.3-76.3)	**121** (97.3-147)	**236** (196-273)	**347** (293-411)	2741
Age group							
6-11 years	01-02	**38.5** (26.4-56.2)	**56.7** (25.5-91.0)	**123** (92.6-168)	**239** (169-278)	**314** (243-371)	387
12-19 years	01-02	**30.1** (22.5-40.4)	**47.8** (29.1-61.4)	**89.6** (73.9-112)	**165** (132-194)	**236** (164-540)	733
20 years and older	01-02	**41.0** (30.7-54.9)	**58.8** (41.1-79.5)	**127** (105-154)	**245** (200-292)	**371** (300-447)	1621
Gender							
Males	01-02	**36.7** (27.6-48.8)	**54.5** (34.4-71.6)	**109** (88.0-130)	**189** (161-224)	**282** (252-307)	1344
Females	01-02	**41.8** (31.0-56.2)	**60.4** (42.4-80.4)	**135** (106-170)	**268** (227-332)	**418** (346-488)	1397
Race/ethnicity							
Mexican Americans	01-02	**40.1** (22.8-70.4)	**60.7** (26.2-100)	**134** (97.5-173)	**236** (176-314)	**323** (242-408)	664
Non-Hispanic blacks	01-02	**34.3** (24.7-47.7)	**56.8** (36.8-71.4)	**98.8** (84.1-123)	**157** (138-176)	**230** (193-256)	690
Non-Hispanic whites	01-02	**40.6** (29.8-55.4)	**58.1** (37.8-81.4)	**126** (100-157)	**252** (198-297)	**387** (293-470)	1204

Table 70. 9-Hydroxyphenanthrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**33.9** (29.7-38.6)	**41.0** (36.0-46.0)	**87.0** (75.0-103)	**205** (169-254)	**343** (291-396)	2741
Age group							
6-11 years	01-02	**24.7** (21.0-29.1)	**32.0** (28.0-39.0)	**59.0** (50.0-68.0)	**95.0** (70.0-125)	**124** (90.0-225)	387
12-19 years	01-02	**30.2** (25.1-36.4)	**34.0** (31.0-40.0)	**70.0** (60.0-86.0)	**151** (101-204)	**250** (161-312)	733
20 years and older	01-02	**35.9** (30.9-41.6)	**44.0** (38.0-49.0)	**100** (81.0-117)	**244** (183-292)	**392** (314-476)	1621
Gender							
Males	01-02	**39.4** (33.8-46.0)	**47.0** (42.0-53.0)	**93.0** (76.0-123)	**236** (170-290)	**381** (269-487)	1344
Females	01-02	**29.4** (25.1-34.5)	**36.0** (32.0-42.0)	**78.0** (69.0-97.0)	**179** (151-244)	**337** (247-392)	1397
Race/ethnicity							
Mexican Americans	01-02	**26.7** (21.2-33.7)	**34.0** (26.0-43.0)	**62.0** (49.0-78.0)	**132** (86.0-202)	**202** (124-396)	664
Non-Hispanic blacks	01-02	**34.7** (28.5-42.4)	**41.0** (36.0-47.0)	**104** (81.0-127)	**269** (170-391)	**399** (285-550)	690
Non-Hispanic whites	01-02	**34.6** (30.2-39.7)	**43.0** (37.0-48.0)	**91.0** (78.0-108)	**207** (160-269)	**344** (281-421)	1204

Table 71. 9-Hydroxyphenanthrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**31.7** (28.1-35.8)	**36.3** (32.3-40.4)	**72.1** (63.2-85.9)	**156** (139-179)	**240** (213-290)	2741
Age group							
6-11 years	01-02	**27.6** (23.7-32.2)	**35.0** (30.3-40.2)	**56.4** (46.3-66.7)	**89.5** (72.0-101)	**120** (88.9-152)	387
12-19 years	01-02	**23.5** (19.9-27.7)	**26.7** (22.8-30.6)	**44.8** (38.5-55.9)	**101** (77.8-118)	**158** (107-270)	733
20 years and older	01-02	**33.9** (29.7-38.7)	**38.8** (34.1-42.9)	**80.5** (69.4-102)	**175** (148-212)	**268** (216-321)	1621
Gender							
Males	01-02	**31.9** (27.7-36.8)	**36.0** (32.0-40.4)	**71.0** (58.6-91.6)	**163** (131-187)	**218** (182-290)	1344
Females	01-02	**31.6** (27.3-36.5)	**36.7** (31.7-41.5)	**73.1** (63.6-86.6)	**151** (133-187)	**271** (216-308)	1397
Race/ethnicity							
Mexican Americans	01-02	**25.0** (20.7-30.3)	**28.2** (24.8-31.8)	**52.7** (42.7-68.9)	**110** (74.8-160)	**166** (107-346)	664
Non-Hispanic blacks	01-02	**24.5** (20.0-30.1)	**29.4** (25.8-32.7)	**63.4** (44.2-84.9)	**143** (96.9-209)	**233** (153-313)	690
Non-Hispanic whites	01-02	**34.3** (30.6-38.4)	**39.1** (34.0-43.3)	**78.7** (65.2-96.4)	**167** (144-199)	**268** (216-313)	1204

1-Hydroxypyrene

Metabolite of Pyrene, CAS No. 129-00-0

Interpreting Levels of Urinary 1-Hydroxypyrene Reported in the Tables

Pyrene is commonly found in PAH mixtures, and its urinary metabolite has been used as an indicator of exposure to PAH chemicals. Urinary 1-hydroxypyrene levels were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. The geometric mean levels of 1-hydroxypyrene in the NHANES 2001-2002 subsample is similar to that of other general populations residing in an urban setting (Goen et al., 1995; Chuang et al., 1999, Heudorf and Angerer, 2001*b*; Roggi et al., 1997; Yang et al., 2003). Higher levels have been noted for residents of industrialized urban areas compared with rural or suburban settings (Adonis et al., 2003; Kanoh et al., 1993; Kuo et al., 2004).

Many-fold higher levels can be found in workers from certain occupations (Jacob and Seidel, 2002) including aluminum smelting (Alexandrie et al., 2000); diesel engine mechanics (Adonis et al., 2003, Kuusimaki et al., 2004); taxi, bus, and truck drivers (Chuang et al., 2003, Hansen et al., 2004; Kuusimaki et al., 2004); painters (Lee et al., 2003), boilermakers (Mukherjee et al., 2004); toll booth operators (Tsai et al., 2004); traffic police (Merlo et al., 1998) and coke oven plant workers (Lu et al., 2002; Serdar et al., 2003*a*; Siwinska et al., 2004). Tobacco smoking leads to higher levels in smokers (Chuang et al., 2003; Adonis et al., 2003, Heudorf and Angerer, 2001*b*) as well as the non-smoking children of smokers (Tsai et al., 2003). Coal stove exposure or consumption of broiled, fried or grilled meat contribute to higher levels of 1-hydroxypyrene (Siwinska et al., 1999; Scheepers et al., 2002, Yang et al., 2003).

Table 72. 1-Hydroxypyrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**79.8** (66.9-95.1)	**78.0** (67.9-92.6)	**187** (164-229)	**434** (372-506)	**730** (571-926)	2312
	01-02	**49.6** (43.4-56.7)	**47.0** (42.0-56.0)	**103** (90.0-116)	**214** (184-245)	**349** (290-400)	2747
Age group							
6-11 years	99-00	**90.8** (71.4-115)	**94.1** (77.9-120)	**170** (136-201)	**300** (197-413)	**419** (257-757)	310
	01-02	**59.7** (52.8-67.5)	**59.0** (48.0-66.0)	**109** (86.0-150)	**212** (164-257)	**272** (224-453)	387
12-19 years	99-00	**105** (87.8-125)	**108** (83.0-130)	**226** (188-264)	**473** (336-596)	**642** (468-1170)	693
	01-02	**57.8** (47.4-70.6)	**60.0** (44.0-71.0)	**111** (89.0-148)	**230** (179-273)	**329** (267-489)	735
20 years and older	99-00	**74.8** (61.5-91.1)	**70.1** (61.5-86.1)	**187** (155-235)	**446** (379-547)	**795** (596-940)	1309
	01-02	**47.3** (41.1-54.6)	**45.0** (40.0-53.0)	**100** (88.0-115)	**216** (182-246)	**361** (290-416)	1625
Gender							
Males	99-00	**90.1** (73.2-111)	**85.2** (70.5-105)	**227** (178-287)	**496** (413-577)	**747** (577-1020)	1106
	01-02	**57.8** (49.8-67.1)	**55.0** (46.0-64.0)	**120** (97.0-149)	**246** (203-312)	**416** (299-528)	1348
Females	99-00	**71.2** (59.4-85.3)	**70.9** (63.1-87.3)	**163** (152-188)	**361** (300-412)	**669** (387-940)	1206
	01-02	**43.0** (36.7-50.4)	**43.0** (35.0-52.0)	**92.0** (76.0-107)	**178** (150-199)	**278** (219-349)	1399
Race/ethnicity							
Mexican Americans	99-00	**74.2** (67.1-82.0)	**68.1** (62.7-76.8)	**161** (143-179)	**344** (284-460)	**545** (372-714)	766
	01-02	**51.0** (38.0-68.4)	**51.0** (40.0-68.0)	**99.0** (69.0-133)	**163** (125-269)	**269** (154-666)	665
Non-Hispanic blacks	99-00	**108** (83.9-140)	**99.7** (72.2-159)	**245** (202-352)	**586** (428-778)	**839** (496-1480)	528
	01-02	**66.2** (56.9-77.0)	**63.0** (49.0-82.0)	**134** (112-171)	**305** (236-386)	**442** (337-561)	692
Non-Hispanic whites	99-00	**73.7** (58.5-92.9)	**72.9** (63.3-86.1)	**178** (155-213)	**399** (333-506)	**747** (477-977)	832
	01-02	**46.9** (40.0-55.1)	**45.0** (38.0-56.0)	**98.0** (87.0-115)	**214** (179-249)	**343** (271-431)	1207

Comparing Adjusted Geometric Means

Geometric mean levels of urinary 1-hydroxypyrene for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, children aged 6-11 years had higher adjusted geometric mean levels of 1-hydroxy-pyrene than the two other age groups. This age-related difference also has been found by other investigators (Heudorf and Angerer, 2001*b*; Chuang et al., 1999). In addition, the levels for children in this *Report* are similar to levels measured in other studies (van Wijnen et al., 1996; Chuang et al., 1999; Heudorf and Angerer, 2001*a*; Kanoh et al., 1993; Tsai et al., 2003). No differences were observed for race/ethnicity or gender, and several previous studies have also not found differences. It is unknown whether these differences associated with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 73. 1-Hydroxypyrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**74.2** (61.6-89.3)	**73.3** (63.1-84.4)	**158** (139-178)	**362** (286-415)	**500** (436-607)	2312
	01-02	**46.4** (40.9-52.8)	**43.8** (37.8-50.7)	**80.8** (72.9-90.1)	**159** (137-188)	**243** (206-269)	2747
Age group							
6-11 years	99-00	**94.1** (75.3-118)	**91.2** (76.5-114)	**168** (126-234)	**333** (269-378)	**474** (371-571)	310
	01-02	**66.8** (57.5-77.7)	**60.6** (52.9-74.1)	**105** (83.3-137)	**195** (140-320)	**320** (209-399)	387
12-19 years	99-00	**71.5** (59.0-86.5)	**70.7** (55.6-90.0)	**137** (120-170)	**240** (189-341)	**413** (240-663)	693
	01-02	**44.7** (37.8-52.9)	**43.1** (33.3-51.7)	**71.4** (59.0-87.9)	**151** (107-195)	**233** (186-250)	735
20 years and older	99-00	**72.3** (58.8-88.8)	**68.8** (58.9-81.9)	**159** (131-188)	**377** (286-447)	**541** (433-648)	1309
	01-02	**44.7** (39.4-50.7)	**41.2** (36.7-48.4)	**79.5** (72.2-87.5)	**156** (131-185)	**233** (199-252)	1625
Gender							
Males	99-00	**72.1** (56.8-91.6)	**69.9** (58.9-89.7)	**167** (130-189)	**349** (265-420)	**525** (384-793)	1106
	01-02	**46.8** (40.8-53.7)	**46.2** (39.6-51.4)	**83.8** (74.1-96.4)	**169** (138-199)	**249** (207-303)	1348
Females	99-00	**76.1** (63.1-91.9)	**77.2** (59.9-89.7)	**148** (127-183)	**370** (244-450)	**500** (413-613)	1206
	01-02	**46.1** (40.0-53.1)	**42.5** (36.7-51.0)	**77.3** (68.5-89.5)	**152** (122-185)	**218** (199-247)	1399
Race/ethnicity							
Mexican Americans	99-00	**68.2** (61.8-75.3)	**59.6** (53.8-68.1)	**124** (110-141)	**252** (204-333)	**462** (325-557)	766
	01-02	**47.6** (36.9-61.5)	**43.1** (33.3-58.7)	**76.6** (58.7-106)	**149** (95.2-265)	**208** (155-353)	665
Non-Hispanic blacks	99-00	**70.5** (55.6-89.4)	**68.6** (54.1-93.9)	**156** (121-177)	**346** (264-412)	**474** (365-691)	528
	01-02	**46.6** (40.1-54.2)	**43.9** (36.7-51.8)	**87.1** (75.0-108)	**157** (138-194)	**231** (196-269)	692
Non-Hispanic whites	99-00	**73.2** (58.1-92.2)	**72.3** (60.6-85.2)	**163** (133-184)	**377** (286-447)	**547** (447-636)	832
	01-02	**46.4** (40.1-53.6)	**43.5** (37.0-51.9)	**82.7** (73.7-91.2)	**163** (139-195)	**245** (211-288)	1207

Figure 19. 1-Hydroxypyrene (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

3-Hydroxybenzo[a]pyrene

CAS No. 13345-21-6

Metabolite of Benzo[a]pyrene, CAS No. 129-00-0

Interpreting Levels of Urinary
3-Hydroxybenzo[a]pyrene Reported in the Tables

Benzo[a]pyrene is considered a probable carcinogen by the NTP and U.S. EPA. 3-hydroxybenzo[a]pyrene is a metabolite of benzo[a]pyrene and urinary levels were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels of 3-hydroxybenzo[a] pyrene have been reported in a small sample of pre-school children (Wilson et al., 2003) and in workers manufacturing fireproof stone (Gundel et al., 2000).

Table 74. 3-Hydroxybenzo[a]pyrene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	**75th**	**90th**	**95th**	
Total, age 6 and older	01-02	*	< LOD	33.0 (28.0-39.0)	95.0 (73.0-121)	179 (137-251)	2748
Age group							
6-11 years	01-02	*	< LOD	26.0 (18.0-41.0)	73.0 (44.0-126)	139 (79.0-273)	387
12-19 years	01-02	*	< LOD	28.0 (20.0-37.0)	77.0 (46.0-129)	139 (82.0-284)	735
20 years and older	01-02	*	< LOD	36.0 (30.0-41.0)	97.0 (72.0-126)	206 (135-285)	1626
Gender							
Males	01-02	*	< LOD	34.0 (29.0-41.0)	98.0 (72.0-126)	167 (133-273)	1349
Females	01-02	*	< LOD	31.0 (26.0-37.0)	86.0 (67.0-117)	206 (134-251)	1399
Race/ethnicity							
Mexican Americans	01-02	*	13.0 (<LOD-16.0)	41.0 (30.0-55.0)	125 (80.0-199)	253 (165-648)	665
Non-Hispanic blacks	01-02	*	11.0 (<LOD-16.0)	29.0 (25.0-37.0)	68.0 (53.0-106)	136 (76.0-240)	692
Non-Hispanic whites	01-02	*	< LOD	32.0 (26.0-40.0)	96.0 (69.0-126)	167 (124-251)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 75. 3-Hydroxybenzo[a]pyrene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	32.3 (27.3-38.9)	84.7 (69.2-120)	184 (147-248)	2748
Age group							
6-11 years	01-02	*	< LOD	28.8 (22.7-45.5)	91.4 (59.0-171)	207 (91.3-348)	387
12-19 years	01-02	*	< LOD	24.0 (16.7-35.8)	69.8 (43.4-86.7)	103 (77.0-201)	735
20 years and older	01-02	*	< LOD	34.3 (28.4-42.0)	91.7 (69.0-134)	186 (148-263)	1626
Gender							
Males	01-02	*	< LOD	28.9 (23.8-37.8)	72.9 (62.1-99.1)	167 (110-226)	1349
Females	01-02	*	< LOD	35.3 (29.6-43.9)	99.0 (75.0-135)	198 (148-285)	1399
Race/ethnicity							
Mexican Americans	01-02	*	15.3 (12.9-18.3)	41.6 (30.0-58.3)	135 (74.9-188)	225 (157-345)	665
Non-Hispanic blacks	01-02	*	9.86 (8.47-11.1)	21.7 (18.3-26.5)	49.4 (36.2-91.1)	116 (58.6-190)	692
Non-Hispanic whites	01-02	*	< LOD	34.1 (27.3-41.4)	85.7 (68.0-127)	190 (147-263)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

1-Hydroxynaphthalene and 2-Hydroxynaphthalene

Metabolite of Naphthalene, CAS No. 91-20-3

Interpreting Levels of Urinary 1-Hydroxynaphthalene and 2-Hydroxynaphthalene Reported in the Tables

Urinary levels of 1-hydroxynaphthalene and 2-hydroxynaphthalene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels have been reported in pre-school chidlren (Wilson et al., 2003), middle school students living in major cities (Kang et al., 2002) and adults (Kim et al.,2003, Kuusimaki et al., 2004, Serdar et al., 2003b). Bus mechanics and truck drivers (Kuusimaki et al., 2004), coke oven workers (Nan et al., 2001; Serdar et al., 2003a), air force personnel exposed to jet fuel (Serdar 2003b), and tobacco smokers (Serdar et al., 2003a; Nan et al., 2001) had higher levels.

Comparing Adjusted Geometric Means

Geometric means levels of urinary 1-hydroxynaphthalene and 2-hydroxynaphthalene for demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). For adjusted geometric mean levels of urinary 1-hydroxynaphthalene in NHANES 2001-2002, non-Hispanic whites had higher levels than Mexican-Americans, while the group aged 12-19 years had lower levels than either of the groups 6-11 years or 20 years and older.

For adjusted geometric mean levels of urinary 2-hydroxynaphthalene in NHANES 2001-2002 , females had higher levels than males, Mexican Americans had higher levels than either non-Hispanic whites or blacks, and the group aged 12-19 years had lower levels than the group aged 20 years and older. It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Note: 1-hydroxynaphthalene is sometimes called 1-naphthol and 2-hydroxynapthalene is also referred to as 2-naphthol.

Table 76. 1-Hydroxynaphthalene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**2050** (1790-2340)	**1720** (1490-2030)	**4760** (3890-5930)	**12500** (10600-15900)	**22300** (18000-26600)	2748
Age group							
6-11 years	01-02	**1430** (1170-1730)	**1190** (1010-1560)	**2740** (1770-3630)	**6670** (4340-11300)	**12400** (9410-16500)	387
12-19 years	01-02	**1750** (1440-2130)	**1380** (1210-1690)	**3560** (2840-4570)	**9270** (6760-17200)	**21400** (10400-28500)	735
20 years and older	01-02	**2190** (1900-2530)	**1890** (1580-2280)	**5280** (4250-6520)	**13600** (11100-18000)	**23300** (18100-28600)	1626
Gender							
Males	01-02	**2270** (1940-2650)	**1980** (1640-2440)	**5580** (4000-6950)	**12200** (9650-16700)	**21500** (15100-28500)	1349
Females	01-02	**1860** (1600-2160)	**1560** (1320-1760)	**4120** (3380-5030)	**13300** (11100-16300)	**22300** (19400-25500)	1399
Race/ethnicity							
Mexican Americans	01-02	**1590** (1300-1960)	**1440** (1180-1860)	**3010** (2240-4080)	**6750** (4990-9270)	**11900** (7670-20600)	665
Non-Hispanic blacks	01-02	**2700** (2160-3370)	**2190** (1630-2930)	**7170** (4400-10900)	**14900** (11900-22100)	**24700** (17000-44100)	692
Non-Hispanic whites	01-02	**2030** (1720-2390)	**1740** (1470-2150)	**4680** (3630-5990)	**12300** (10200-16300)	**22300** (16600-27200)	1207

Table 77. 1-Hydroxynaphthalene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**1910** (1700-2160)	**1560** (1370-1810)	**4160** (3550-5170)	**10500** (8470-12600)	**17800** (14500-20800)	2748
Age group							
6-11 years	01-02	**1600** (1320-1930)	**1370** (1040-1780)	**2880** (2140-3840)	**5280** (4450-9720)	**12900** (7960-26400)	387
12-19 years	01-02	**1350** (1140-1600)	**1130** (973-1360)	**2520** (2090-3160)	**6920** (3790-11000)	**11200** (8240-16100)	735
20 years and older	01-02	**2070** (1830-2350)	**1720** (1480-2000)	**4980** (3930-6120)	**11600** (9370-14200)	**18600** (15000-22000)	1626
Gender							
Males	01-02	**1830** (1580-2120)	**1550** (1300-1880)	**4050** (3380-5360)	**9440** (7550-11400)	**14200** (12200-16500)	1349
Females	01-02	**1990** (1760-2250)	**1620** (1360-1900)	**4190** (3560-5190)	**12400** (9810-15000)	**20500** (17100-26700)	1399
Race/ethnicity							
Mexican Americans	01-02	**1490** (1240-1780)	**1310** (1070-1630)	**2590** (2140-3370)	**5710** (4280-7530)	**10300** (6120-18300)	665
Non-Hispanic blacks	01-02	**1900** (1500-2410)	**1640** (1340-1980)	**4400** (2830-6450)	**10100** (6560-15900)	**18900** (11700-32700)	692
Non-Hispanic whites	01-02	**2000** (1740-2300)	**1660** (1410-1940)	**4410** (3660-5790)	**10900** (8640-13400)	**17300** (13400-19600)	1207

Table 78. 2-Hydroxynaphthalene

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older,
National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**2470** (2110-2890)	**2280** (1920-2640)	**5680** (4580-6830)	**14700** (12800-19500)	**26000** (22500-29700)	2748
Age group							
6-11 years	01-02	**1690** (1560-1840)	**1700** (1400-1950)	**3000** (2580-3470)	**5350** (3890-6700)	**7720** (6300-9540)	387
12-19 years	01-02	**2220** (1700-2900)	**2150** (1740-2530)	**4390** (3150-6110)	**11000** (6990-20400)	**22500** (13900-28400)	735
20 years and older	01-02	**2620** (2220-3100)	**2440** (1940-2950)	**6380** (5110-8110)	**17600** (14000-21100)	**28100** (23300-33700)	1626
Gender							
Males	01-02	**2750** (2360-3210)	**2510** (2090-2970)	**6040** (4820-7810)	**16400** (11900-23000)	**28100** (20800-35600)	1349
Females	01-02	**2220** (1860-2660)	**2060** (1650-2480)	**5240** (3890-6440)	**13900** (12300-17700)	**25100** (19700-28300)	1399
Race/ethnicity							
Mexican Americans	01-02	**2700** (2360-3080)	**2690** (2350-3260)	**5140** (4360-6150)	**9600** (8150-10600)	**13600** (10400-18700)	665
Non-Hispanic blacks	01-02	**3970** (3470-4540)	**3460** (3100-4020)	**9250** (6820-13200)	**22800** (16000-29100)	**33000** (25900-38700)	692
Non-Hispanic whites	01-02	**2190** (1760-2720)	**1910** (1610-2420)	**4880** (3710-6780)	**14100** (10700-20200)	**25900** (20700-30000)	1207

Table 79. 2-Hydroxynaphthalene (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**2310** (1980-2680)	**1940** (1670-2300)	**4730** (3820-5860)	**11500** (9980-13100)	**16700** (14100-19200)	2748
Age group							
6-11 years	01-02	**1890** (1740-2070)	**1830** (1720-1940)	**3110** (2510-3470)	**5040** (4380-5540)	**6490** (5270-12400)	387
12-19 years	01-02	**1720** (1350-2190)	**1510** (1340-1830)	**2750** (2080-4070)	**7060** (4070-10900)	**10900** (7860-17400)	735
20 years and older	01-02	**2480** (2130-2880)	**2080** (1680-2600)	**5630** (4460-6940)	**12400** (10900-13900)	**17700** (15200-20600)	1626
Gender							
Males	01-02	**2230** (1900-2610)	**1850** (1630-2100)	**4750** (3510-6120)	**11400** (8950-14300)	**15800** (13100-19200)	1349
Females	01-02	**2380** (2050-2770)	**1970** (1660-2560)	**4730** (3790-6000)	**11500** (10300-12800)	**17400** (13700-21500)	1399
Race/ethnicity							
Mexican Americans	01-02	**2520** (2230-2850)	**2350** (2010-2950)	**4650** (3970-5210)	**7120** (6050-8090)	**12000** (7820-15300)	665
Non-Hispanic blacks	01-02	**2790** (2390-3270)	**2390** (2040-2770)	**5980** (4840-6980)	**11600** (9090-15300)	**17400** (12200-23400)	692
Non-Hispanic whites	01-02	**2160** (1780-2620)	**1740** (1440-2180)	**4340** (3320-6090)	**11900** (9930-14300)	**16900** (13800-20600)	1207

Polychlorinated Dibenzo-p-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls

Polychlorinated Dibenzo-p-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls

General Information

Polychlorinated dibenzo-*p*-dioxins and dibenzofurans are two similar classes of chlorinated aromatic chemicals that are produced as contaminants or byproducts. They have no known commercial or natural use. Dioxins are primarily produced during the incineration or burning of waste; the bleaching processes used in pulp and paper mills; and the chemical syntheses of trichlorophenoxyacetic acid, hexachlorophene, vinyl chloride, trichlorophenol, and pentachlorophenol. Synthesis and heat-related degradation of polychlorinated biphenyls (PCBs) will produce furan byproducts. As a result of man-made environmental release and contamination, most soil and water samples reveal trace amounts of polychlorinated dibenzo-*p*-dioxins and dibenzofurans when advanced analytical techniques are applied. Releases from industrial sources have decreased approximately 80% since the 1980s. Today, the largest release of these chemicals occurs as a result of the open burning of household trash and municipal trash, landfill fires, and agricultural and forest fires.

The coplanar and mono-ortho-substituted polychlorinated biphenyls belong to the class of chlorinated aromatic hydrocarbon chemicals that once were used as electrical insulating and heat-exchange fluids. Production of PCBs peaked in the early 1970s and was banned in the United States after 1979. Together with the polychlorinated dioxins and furans, these two classes of PCBs are often referred to as "dioxin-like" chemicals because they act through a similar mechanism. In the environment, these dioxin-like chemicals are persistent and usually occur as a mixture of congeners (i.e., compounds that differ by numbers and positions of chlorine atoms attached to the dibenzo-*p*-dioxin, dibenzofuran, or biphenyl structures). Structural nomenclature is available at http://www.epa.gov/toxteam/pcbid/consistent.htm.

People in the general population are exposed primarily through ingestion of foods that are contaminated with polychlorinated dibenzo-*p*-dioxins and dibenzofurans as a result of the accumulation of these substances in the food chain including high-fat foods, such as dairy products, eggs, and animal fats, and some fish and wildlife. Breast feeding is a substantial source for infants (Beck et al., 1994). People have also been exposed as a result of industrial accidents (e.g., after an explosion in a factory in Seveso, Italy), the use of accidentally contaminated cooking oils (e.g., as occurred in Yusho in

Japan and Yucheng in Taiwan), the spraying of herbicides contaminated with 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD, as Agent Orange in Vietnam), and the burning of PCBs contaminated with polychlorinated dibenzofurans, such as in old electrical transformers. Workplace exposures are rare today, and generally recognized standards for external exposure have not been established.

Because exposure to these chemicals is from a mixture of varying congeners, the effects due to specific individual congeners are difficult to determine (Masuda et al., 1998; Masuda 2001). However, these four groups of chemicals (polychlorinated dibenzo-*p*-dioxins, polychlorinated dibenzofurans, and the coplanar and mono-ortho-substituted polychlorinated biphenyls) are considered to act through a similar mechanism to produce toxic effects. These dioxin-like effects are thought to be mediated through an interaction with the aryl hydrocarbon receptor (AhR), particularly the induction of gene expression for cytochromes P450, CYP1A1 and CYP1A2. Dioxins and furans require four lateral chlorine atoms on the dibenzo-*p*-dioxin or dibenzofuran backbone to bind this receptor. The rank order of interaction with the AhR receptor by degree and position of chlorination is similar for both the dioxin and furan series, with greater effect exhibited with four or five chlorine atoms and with substitution at all four lateral positions. The coplanar polychlorinated biphenyls (unsubstituted at ortho positions) and the mono-ortho-substituted polychlorinated biphenyls (which contain a chlorine atom at one of the ortho positions) can achieve a planar configuration and also interact with the AhR receptor.

The variation in the effect on AhR among the dioxin-like chemicals is 10,000-fold, with TCDD and 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin being the most potent. To compare potency, each of these congeners has been assigned a potency value relative to TCDD (toxic equivalency factor [TEF]). When a TEF is multiplied by the concentration of the congener, a toxic equivalency (TEQ) value is obtained. Thus, the dioxin-like toxicity contributed by each of the polychlorinated dibenzo-*p*-dioxins, dibenzofurans, and coplanar PCBs can then be compared. The sum of all congener TEQs in a specimen (total TEQ) can be used to compare dioxin-like activity among specimens. Many co-planar PCBs have lesser potency, but their concentrations are often much higher than concentrations of TCDD (Kang et al., 1997; Patterson et al., 1994), so their relative contribution to the total TEQ is potentially sizable.

Health effects of exposure to dioxins and furans in people have been observed as a result of industrial or accidental exposures involving large quantities of these chemicals. Chloracne, biochemical liver test abnormalities, elevated blood lipids, fetal injury, and porphyria cutanea tarda have been reported in many of the studies. In some of these exposures, endocrine, reproductive, and immunologic effects have also been suggested although with varying consistency (Baccarelli et al., 2002; Fierens et al., 2003; Kogevinas, 2001; Halperin et al., 1998; Michalek et al., 1999; Jung et al., 1998; Matsuura et al., 2001; Schnorr et al., 2001; Institute of Medicine, 2003). Congenital anomalies and intrauterine growth retardation were observed in offspring of Yucheng mothers exposed to cooking oil contaminated with electrical oil containing PCBs and dibenzofurans. Background levels of PCBs, and possibly dioxins, have been associated with impaired neurological development in newborns and children (Koopman-

Esseboom et al., 1997; Jacobsen and Jacobsen, 1996; Longnecker et al., 2003). A possible dioxin-induced neuropathy may occur in highly exposed adults (Michalek et al., 2001). Many organochlorine-type chemicals, including the dioxins, furans, and PCBs, are also considered to interact with estrogen receptors. Although human studies have yielded inconsistent findings for associations between dioxin exposure and disorders such as endometriosis (Eskenazi et al., 2002; Fierens et al., 2003; Johnson et al., 2001), animal studies have suggested a relationship (Rier and Foster, 2003). The mono-ortho-substituted PCBs (see Table 81) may also interact with estrogen-receptors in addition to their dioxin-like effects, and have been demonstrated to elevate liver enzymes in experimental animals (Parkinson et al., 1983).

Carcinogenic, genetic, reproductive, and developmental effects have been observed in many animal studies although species differ dramatically in sensitivity to these

Table 80. Polychlorinated Dibenzo-p-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls

Polychlorinated dibenzo-*p*-dioxins	CAS number
1,2,3,4,6,7,8,9-Octachlorodibenzo-*p*-dioxin (OCDD)	3268-87-9
1,2,3,4,6,7,8-Heptachlorodibenzo-*p*-dioxin (HpCDD)	35822-46-9
1,2,3,4,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD)	39227-28-6
1,2,3,6,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD)	57653-85-7
1,2,3,7,8,9-Hexachlorodibenzo-*p*-dioxin (HxCDD)	19408-74-3
1,2,3,7,8-Pentachlorodibenzo-p-dioxin (PeCDD)	40321-76-4
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	1746-01-6
Polychlorinated dibenzofurans	**CAS number**
1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF)	39001-02-0
1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF)	67562-39-4
1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF)	55673-89-7
1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF)	70648-26-9
1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF)	57117-44-9
1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF)	72918-21-9
1,2,3,7,8-Pentachlorodibenzofuran (PeCDF)	57117-41-6
2,3,4,6,7,8-Hexchlorodibenzofuran (HxCDF)	60851-34-5
2,3,4,7,8-Pentachlorodibenzofuran (PeCDF)	57117-31-4
2,3,7,8-Tetrachlorodibenzofuran (TCDF)	51207-31-9
Coplanar polychlorinated biphenyls (IUPAC number)	**CAS number**
3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169)	32774-16-6
3,3',4,4',5-Pentachlorobiphenyl (PCB 126)	57465-28-8
3,4,4',5-Tetrachlorobiphenyl (PCB 81)	70362-50-4
Mono-ortho-substituted polychlorinated biphenyls (IUPAC number)	**CAS number**
2,4,4'-Trichlorobiphenyl (PCB 28)	7012-37-5
2,3',4,4'-Tetrachlorobiphenyl (PCB 66)	32598-10-0
2,4,4',5-Tetrachlorobiphenyl (PCB 74)	32690-93-0
2,3,3',4,4'-Pentachlorobiphenyl (PCB 105)	32598-14-4
2,3',4,4',5-Pentachlorobiphenyl (PCB 118)	31508-00-6
2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156)	38380-08-4
2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157)	69782-90-7
2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167)	52663-72-6
2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189)	39635-31-9

chemicals. The Institute of Medicine (2003) has determined that human epidemologic evidence is sufficient for causally linking exposure from herbicides contaminated with TCDD to an increased risk for non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, and soft tissue sarcoma. Generally, the increased risk for these cancers occurs in association with large exposures encountered in contaminated occupational settings or massive unintentional releases. Because of its exceptional potency and because it is the most studied dioxin or furan, TCDD is separately classified by the IARC as a known human carcinogen (Group 1) and by NTP as a known human carcinogen. Other polychlorinated dibenzo-*p*-dioxins and dibenzofurans have not been studied sufficiently for IARC to determine their carcinogenicity. Information about environmental levels and health effects is available online from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles. The U.S. EPA provides updated exposure and health assessments online at http://www.epa.gov/ncea/pdfs/dioxin.

Interpreting Levels of Lipid-Adjusted Serum Polychlorinated Dibenzo-*p*-dioxins, Polychlorinated Dibenzofurans, Coplanar Polychlorinated Biphenyls, and Mono-ortho-substituted Polychlorinated Biphenyls Reported in the Tables

Lipid-adjusted serum measurements and whole weight-based measurements of polychlorinated dibenzo-*p*-dioxins, dibenzofurans, and coplanar PCBs were measured in a subsample of NHANES 2001-2002 participants aged 20 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. (Note: The NHANES 1999-2000 subsample included people aged 12-19 years and people aged 20 years and older. The NHANES 2001-2002 subsample does not include the 12-19 year-old age group). The generally low values reported here support the observation that human serum levels of polychlorinated dibenzo-*p*-dioxins, dibenzofurans, and PCBs have decreased by more than 80% since the 1980s (Aylward and Hays, 2002; Lorber, 2002).

Only the following polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar and mono-ortho-substituted polychlorinated biphenyls (IUPAC nomenclature) had demonstrable 90th percentile levels in the NHANES 2001-2002 subsample, and those in bold letters had sufficient data for calculating geometric means:

- **1,2,3,4,6,7,8,9-octachlorodibenzo-*p*-dioxin**
- **1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin**
- 1,2,3,4,7,8-hexachlorodibenzo-*p*-dioxin

- **1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin***
- 1,2,3,7,8,9-hexachlorodibenzo-*p*-dioxin
- 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin*
- **1,2,3,4,6,7,8-heptachlorodibenzofuran**
- 1,2,3,4,7,8-hexachlorodibenzofuran
- 1,2,3,6,7,8-hexachlorodibenzofuran
- 2,3,4,7,8-pentachlorodibenzofuran*
- **coplanar polychlorinated biphenyls 126* and 169**
- mono-ortho substituted PCBs 74, 118* and 156*

About 80%-90% of the total TEQ can be estimated from six of the congeners (indicated by asterisks) listed above, plus an estimate of the TCDD level. Though the mono-ortho-substituted PCBs are less potent (i.e., lower TEFs), their contribution to the total TEQ is substantial since they are present in much higher concentrations than are the coplanar PCBs, dioxins, and furans. In keeping with results from reports from Germany (Papke et al., 1998), New Zealand (Bates et al., 2004*b*) and elsewhere, the NHANES 1999-2000 and 2001-2002 data show that the highly chlorinated and laterally substituted congeners are frequently detected. The presence of many of these congeners in human sera is probably due to their greater solubility in body fat and slower elimination (Geyer et al., 2002), but can also be due to their greater presence in the food chain. For example, people consuming fish from the Great Lakes had mean concentrations of dioxins and furans that are several times background values in the population (Falk et al., 1999; Anderson et al., 1998; Hanrahan et al., 1999).

Of the dioxins and furans, octachlorodibenzo-*p*-dioxin typically is present in the highest concentration but contributes little to the TEQ, with the other commonly detected dioxin and furan congeners being more than eight-fold lower in concentration. Similar levels of octachlorodibenzo-*p*-dioxin are seen in a representative pooled sampling of New Zealanders aged 15 years and older who were studied during 1997-1998. The weighted mean octachlorodibenzo-*p*-dioxin level in the New Zealand study was 361 picograms per gram (pg/g) lipid (Bates et al., 2004*b*) compared with the NHANES 2001-2002 median level of 349 pg/g lipid for non-Hispanic whites aged 20 years and older. On the other hand, 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin concentrations in this *Report* are about 60-fold lower than octachlorodibenzo-*p*-dioxin levels (at the comparable percentiles), but because of a 10,000-fold greater TEF (equal to that of TCDD), the contribution of 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin to the TEQ is about 160 times greater than the octachlorodibenzo-*p*-dioxin. In 1996, a small convenience sample of German residents aged 18-71 years showed that levels of 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin at the 95th percentile were

9.9 pg/g lipid (Papke et al., 1998). Levels at the 95th percentile in the NHANES 2001-2002 subsample reported here were 15.8 pg/g.

The three major hexachlorodibenzo-*p*-dioxins are assigned equal TEF values, but the 1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin often demonstrates multifold higher concentrations than the other two hexachlorodibenzo-*p*-dioxins, about six-fold higher in the NHANES 2001-2002 subsample. The geometric mean levels of 1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin in the 2001-2002 subsample are slightly higher than levels in either the German or New Zealand study mentioned above (Papke et al., 1998; Bates et al., 2004*b*). A small convenience sample of Japanese men and women aged 20-76 years studied during 1996-1997 also showed lower median levels of 17 pg/g and 18 pg/g lipid, respectively, than levels in the NHANES 2001-2002 subsample (Arisawa et al., 2003).

For TCDD levels in the NHANES 2001-2002 subsample, only the 95th percentiles in women and non-Hispanic blacks could be characterized, which were 6.4 and 7.4, picograms/gram (pg/g) of lipid, respectively (detection limit of 5.8 pg/g of lipid). The remainder of the U.S. population is likely to be below these levels of this hallmark dioxin. In 1996, the 95th percentile for lipid-adjusted serum TCDD levels in 139 Germans aged 18-71 years was 4.3 pg/g of lipid, with that percentile comprising mainly older individuals (Papke, 1998). The TCDD levels in this *Report* are much lower than those for chemical-production workers even when they were examined 15 years after workplace exposure had ceased (median serum TCDD concentration = 68 pg/g of lipid) (Calvert et al., 1996). TCDD levels of chemical-plant workers exposed to high concentrations have ranged as high as 2,000 pg/g lipid (World Health Organization/ IARC, 1997).

In the NHANES 2001-2002 subsample, the geometric mean levels of coplanar PCBs 126 and 169 for participants aged 20 years and older were similar or slightly lower than those reported from a representative pooled sample of New Zealanders in 1996-1997 (Bates et al., 2004*b*) and of a smaller sample of non-occupationally exposed men and women aged 20-76 years in Japan in 1999 (Arisawa et al., 2003). Of the mono-ortho-chlorine-substituted PCB congeners, the most frequently detected in general population studies are PCBs 118 and 156. Of these, PCB 118 levels were higher than PCB 156 in the NHANES 1999-2000 and 2001-2002 subsamples although PCB 156 contributes more to the TEQ because its TEF is five-fold greater than the TEF of PCB 118. Compared with levels in a convenience sample of the

U.S. population in 1988 (Patterson et al., 1994), levels of PCB 118 are at least five-fold lower in the NHANES 1999-2002 subsamples. The PCB 156 levels in the NHANES data for 1999-2002 are slightly lower than those reported for a Canadian population study in 1994 (Longnecker et al., 2000). Levels of PCB 156 and PCB 118 were slightly higher in a Swedish study of 150 men than in the NHANES 1999-2002 subsample possibly due to higher fish intake in the Swedish population (Glynn et al., 2000). However, in fish-consuming Japanese men and women studied during 1996-1997, PCB 118 levels were similar to levels in the NHANES 2001-2002 subsample at the comparable 75th percentiles (Arisawa et al., 2003).

As was the case for TCDD, levels of other polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar and mono-ortho- substituted biphenyls in this *Report* are below levels associated with occupational or unintentional exposures that produce health effects. There are no firmly established relationships between serum lipid-based concentrations (mainly considering TCDD) and effects in people. Studies of industrial and accidental exposures suggest that concentrations of at least 800 pg/g of lipid might be necessary to induce chloracne, a specific effect, although levels in the thousands of pg/g of lipid do not always produce this effect (Mocarelli et al., 1991). The studies showing clinical effects in people after large unintentional exposures have demonstrated concentrations ranging from several hundred to the tens of thousands of pg/g of lipid (Masuda 2001; Masuda et al., 1998; Mocarelli et al., 1991).

Comparing Adjusted Geometric Means

For comparison of demographic groups in the NHANES 2001-2002 subsample, geometric means of whole weight-based serum measurements were adjusted for age, gender, race/ethnicity, log serum cotinine, and lipid level (data not shown). In NHANES 2001-2002, females had higher adjusted geometric mean levels than males for 1,2,3,4,6,7,8-heptachlorodibenzo-*p*-dioxin, and 3,3,4,4,5-pentachlorobiphenyl (PCB 126). However, males had higher levels than females for 3,3,4,4,5,5-hexachlorobiphenyl (PCB 169). In the previously mentioned study of Japanese adults, women demonstrated higher levels than men for the octachlorodibenzo-*p*-dioxin, 1,2,3,4,6,7,8-heptachlorodibenzo-*p*-dioxin and 1,2,3,7,8,9-hexachlorodibenzo-*p*-dioxin, but men had higher levels for PCBs 169, 156, and 189 (Arisawa et al., 2003). In NHANES 2001-2002, Mexican Americans had lower adjusted geometric mean levels than non-Hispanic blacks

and whites for 1,2,3,4,6,7,8-heptachlorodibenzofuran, 1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin, and 3,3,4,4,5,-hexachlorobiphenyl (PCB 126). Also, non-Hispanic whites had lower levels than non-Hispanic blacks for 1,2,3,4,6,7,8-heptachlorodibenzofuran.

Differences in levels of specific polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar and mono-ortho-substituted polychlorinated biphenyls are due in part to exposure but also result from differences in absorption, tissue distribution, metabolism, and elimination. Half-lives for all the dioxins and furans vary from 3 years to 19 years, with the half-life of TCDD estimated at around 7 years (Geyer et al., 2002). Current levels may be influenced by both past (stored in body fat) and recent exposures. Several studies have shown that levels of dioxins and furans in serum or fat increase with the age of the individual (Falk et al., 1999; Kang et al., 1997; Luotamo et al., 1991; Patterson et al., 1986). Most of the dioxins, furans and PCBs measured in the previously mentioned New Zealand representative sample showed an increasing trend with age (Bates et al., 2004*b*). In part, this age trend was noticeable at the higher percentiles for the more highly chlorinated congeners in the NHANES 1999-2000 subsample which included both the groups aged 12-19 years and 20 and older.

Finding a measurable amount of one or more of the polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar or mono-ortho-substituted biphenyls in serum does not mean that the level of one or more of these causes an adverse health effect. Whether the concentrations reported here are a cause for health concern is not yet known; more research is needed. These levels provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar or mono-ortho-substituted biphenyls than levels found in the general population. These data will also help scientists plan and conduct research on exposure and health effects.

Notes: 1) As seen in other recent population studies, pooling of approximately 50 or more specimens is sometimes required to have adequate amounts of specimen to to properly estimate a TEQ of dioxin-like compounds in the general population. Because of limited availability of serum volumes and the low levels detected in the NHANES 1999-2002 population, TEQ values are not estimated from this analysis of individual samples. Future plans include an analysis of pooled specimens to improve the LOD for these compounds and allow calculation of TEQ values. 2) PCB analyses by GC-high resolution mass spectrometry are usually specific for the

stated PCB congener. However, in some cases, multiple congeners of the same molecular weight could potentially contribute to the analytical result for a stated congener. Such potentially contributing congeners are not present in significant proportions in the environment or in the body and are unlikely to affect the stated results. Known situations would include: PCBs 158, 160, 163, and 164 contributing to the result for PCB 138; PCB 132 contributing to the result for PCB 153; PCB 190 contributing to the result for PCB 170; and PCB 203 contributing to the result for PCB 196.

Table 81. 1,2,3,4,6,7,8,9-Octachlorodibenzo-*p*-dioxin (OCDD) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	**445** (389-496)	**704** (624-802)	**948** (822-1080)	1254
	01-02	**346** (<LOD-394)	**333** (<LOD-399)	**571** (498-668)	**939** (780-1090)	**1260** (997-1610)	1171
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	**421** (363-517)	667
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	**445** (389-496)	**704** (624-802)	**948** (822-1080)	1254
	01-02	**346** (<LOD-394)	**333** (<LOD-399)	**571** (498-668)	**939** (780-1090)	**1260** (997-1610)	1171
Gender (20 years and older)							
Males	99-00	*	< LOD	**331** (<LOD-378)	**541** (453-639)	**710** (572-873)	575
	01-02	*	< LOD	**438** (346-579)	**745** (593-968)	**1030** (837-1240)	517
Females	99-00	*	< LOD	**525** (475-608)	**846** (689-982)	**1050** (948-1290)	679
	01-02	**410** (356-472)	**405** (333-498)	**643** (574-731)	**1020** (858-1360)	**1450** (1060-1780)	654
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	**471** (374-572)	**703** (608-916)	**940** (746-1190)	333
	01-02	*	< LOD	**432** (394-545)	**754** (578-1220)	**1150** (696-1640)	250
Non-Hispanic blacks	99-00	*	< LOD	**493** (405-566)	**820** (727-1070)	**1170** (820-1680)	226
	01-02	**421** (352-503)	**420** (339-509)	**669** (537-907)	**1110** (956-1520)	**1640** (1130-1900)	210
Non-Hispanic whites	99-00	*	< LOD	**427** (369-484)	**671** (581-800)	**913** (731-1080)	578
	01-02	**349** (<LOD-409)	**333** (<LOD-421)	**574** (493-670)	**945** (764-1170)	**1290** (971-1650)	632

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 82. 1,2,3,4,6,7,8,9-Octachlorodibenzo-*p*-dioxin (OCDD) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	**2800** (2480-3110)	**4570** (4100-5020)	**6200** (5340-7300)	1254
	01-02	**2230** (1970-2540)	**2170** (1870-2550)	**3860** (3180-4520)	**6460** (5140-8290)	**9110** (6940-11400)	1171
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	**1910** (1600-2340)	667
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	**2800** (2480-3110)	**4570** (4100-5020)	**6200** (5340-7300)	1254
	01-02	**2230** (1970-2540)	**2170** (1870-2550)	**3860** (3180-4520)	**6460** (5140-8290)	**9110** (6940-11400)	1171
Gender (20 years and older)							
Males	99-00	*	< LOD	**2210** (1860-2480)	**3270** (2880-3900)	**4620** (3630-6870)	575
	01-02	*	< LOD	**3100** (2410-4070)	**5270** (4070-7140)	**7410** (6020-9760)	517
Females	99-00	*	< LOD	**3370** (2990-3830)	**5270** (4780-6050)	**7070** (6150-9280)	679
	01-02	**2590** (2250-2980)	**2620** (2160-3000)	**4340** (3880-4860)	**6990** (5870-9040)	**9460** (7070-12300)	654
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	**2880** (2400-3390)	**4450** (3870-6010)	**6690** (5340-7990)	333
	01-02	*	< LOD	**3410** (2760-3860)	**5810** (4250-7670)	**8050** (5760-11800)	250
Non-Hispanic blacks	99-00	*	< LOD	**2780** (2480-3660)	**5080** (4310-6550)	**7550** (4900-11600)	226
	01-02	**2480** (2050-3000)	**2460** (2060-2970)	**4170** (3160-5560)	**7140** (5470-9920)	**9460** (7990-12000)	210
Non-Hispanic whites	99-00	*	< LOD	**2800** (2400-3150)	**4270** (3790-4980)	**5960** (4930-7390)	578
	01-02	**2270** (1930-2660)	**2200** (1840-2770)	**3860** (3090-4720)	**6460** (4890-8860)	**9120** (6630-12300)	632

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 83. 1,2,3,4,6,7,8-Heptachlorodibenzo-*p*-dioxin (HpCDD) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	**61.9** (57.1-66.7)	**92.0** (81.2-101)	**119** (102-139)	1237
	01-02	**39.0** (33.7-45.0)	**40.2** (34.9-46.7)	**68.7** (56.7-82.2)	**115** (88.2-138)	**147** (126-177)	1220
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	**63.6** (<LOD-75.6)	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	**61.9** (57.1-66.7)	**92.0** (81.2-101)	**119** (102-139)	1237
	01-02	**39.0** (33.7-45.0)	**40.2** (34.9-46.7)	**68.7** (56.7-82.2)	**115** (88.2-138)	**147** (126-177)	1220
Gender (20 years and older)							
Males	99-00	*	< LOD	**56.2** (<LOD-63.6)	**75.5** (69.9-85.2)	**95.0** (84.0-103)	572
	01-02	**36.6** (31.7-42.3)	**38.7** (33.3-42.6)	**61.6** (49.7-75.0)	**101** (75.6-131)	**138** (103-169)	553
Females	99-00	*	< LOD	**67.1** (59.7-73.6)	**105** (94.8-122)	**137** (120-169)	665
	01-02	**41.2** (34.9-48.7)	**43.6** (35.3-52.4)	**76.0** (59.5-90.1)	**123** (92.6-143)	**157** (130-191)	667
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	**66.8** (60.7-74.1)	**102** (83.6-115)	**135** (108-169)	330
	01-02	**39.6** (35.7-43.9)	**39.7** (33.6-47.4)	**64.0** (55.8-74.7)	**107** (82.4-128)	**148** (111-171)	262
Non-Hispanic blacks	99-00	*	< LOD	**62.2** (<LOD-75.1)	**101** (81.8-114)	**137** (106-187)	224
	01-02	**43.7** (35.4-54.0)	**42.0** (32.2-59.8)	**80.6** (60.9-106)	**134** (101-166)	**166** (130-230)	218
Non-Hispanic whites	99-00	*	< LOD	**62.2** (<LOD-67.1)	**88.7** (74.0-102)	**116** (97.0-134)	567
	01-02	**39.3** (33.0-46.8)	**40.5** (34.0-50.1)	**70.9** (56.3-87.5)	**117** (85.9-145)	**147** (125-186)	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 84. 1,2,3,4,6,7,8-Heptachlorodibenzo-*p*-dioxin (HpCDD) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	**385** (354-418)	**610** (534-677)	**802** (681-936)	1237
	01-02	**252** (219-289)	**265** (232-303)	**440** (376-529)	**779** (591-989)	**1030** (840-1290)	1220
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	**287** (239-340)	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	**385** (354-418)	**610** (534-677)	**802** (681-936)	1237
	01-02	**252** (219-289)	**265** (232-303)	**440** (376-529)	**779** (591-989)	**1030** (840-1290)	1220
Gender (20 years and older)							
Males	99-00	*	< LOD	**363** (310-397)	**501** (446-578)	**642** (543-716)	572
	01-02	**243** (211-279)	**244** (213-291)	**422** (349-527)	**765** (536-976)	**983** (766-1260)	553
Females	99-00	*	< LOD	**414** (354-462)	**707** (597-867)	**945** (825-1100)	665
	01-02	**260** (221-306)	**281** (236-324)	**464** (386-551)	**782** (621-997)	**1140** (849-1330)	667
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	**404** (364-472)	**646** (585-785)	**906** (677-1090)	330
	01-02	**254** (232-278)	**249** (229-286)	**403** (360-521)	**789** (643-929)	**988** (817-1240)	262
Non-Hispanic blacks	99-00	*	< LOD	**373** (297-428)	**592** (480-752)	**966** (610-1220)	224
	01-02	**258** (208-319)	**262** (180-339)	**469** (343-600)	**852** (578-1170)	**1160** (821-1660)	218
Non-Hispanic whites	99-00	*	< LOD	**391** (353-430)	**610** (511-679)	**758** (676-871)	567
	01-02	**255** (216-302)	**276** (228-328)	**442** (374-547)	**779** (551-1010)	**1020** (803-1290)	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 85. 1,2,3,4,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	01-02	*	< LOD	< LOD	**10.7** (<LOD-13.8)	**14.9** (11.7-20.0)	1239
Age group							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	**10.7** (<LOD-13.8)	**14.9** (11.7-20.0)	1239
Gender							
(20 years and older)							
Males	01-02	*	< LOD	< LOD	**10.9** (<LOD-14.3)	**14.7** (11.4-16.5)	566
Females	01-02	*	< LOD	< LOD	**10.6** (<LOD-14.1)	**14.9** (11.1-23.0)	673
Race/ethnicity							
(20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	**9.20** (<LOD-11.7)	263
Non-Hispanic blacks	01-02	*	< LOD	< LOD	**13.9** (<LOD-17.6)	**18.3** (13.9-23.0)	220
Non-Hispanic whites	01-02	*	< LOD	< LOD	**11.2** (<LOD-14.4)	**15.1** (12.0-20.5)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 86. 1,2,3,4,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	01-02	*	< LOD	< LOD	**73.8** (54.3-90.7)	**105** (81.2-139)	1239
Age group							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	**73.8** (54.3-90.7)	**105** (81.2-139)	1239
Gender (20 years and older)							
Males	01-02	*	< LOD	< LOD	**73.4** (52.6-90.7)	**105** (77.9-134)	566
Females	01-02	*	< LOD	< LOD	**73.8** (53.2-90.7)	**102** (78.0-152)	673
Race/ethnicity (20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	**70.2** (48.0-118)	263
Non-Hispanic blacks	01-02	*	< LOD	< LOD	**82.1** (53.3-130)	**125** (75.7-184)	220
Non-Hispanic whites	01-02	*	< LOD	< LOD	**77.5** (53.2-97.1)	**105** (78.8-143)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 87. 1,2,3,6,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	**36.1** (31.5-40.5)	**62.8** (53.6-69.1)	**75.6** (70.5-84.2)	1237
	01-02	**34.6** (29.6-40.6)	**39.2** (32.7-44.7)	**60.7** (50.3-74.2)	**95.2** (76.2-120)	**127** (99.4-153)	1234
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	**26.7** (20.2-29.6)	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	**36.1** (31.5-40.5)	**62.8** (53.6-69.1)	**75.6** (70.5-84.2)	1237
	01-02	**34.6** (29.6-40.6)	**39.2** (32.7-44.7)	**60.7** (50.3-74.2)	**95.2** (76.2-120)	**127** (99.4-153)	1234
Gender (20 years and older)							
Males	99-00	*	< LOD	**34.4** (27.2-40.5)	**59.2** (47.1-68.5)	**73.0** (64.4-81.9)	569
	01-02	**34.1** (28.3-41.1)	**38.8** (31.5-44.6)	**61.3** (50.0-79.5)	**94.7** (70.8-131)	**128** (88.5-181)	564
Females	99-00	*	< LOD	**37.9** (32.5-41.6)	**65.6** (55.1-70.5)	**82.8** (69.3-98.9)	668
	01-02	**35.1** (29.9-41.2)	**40.1** (32.4-46.3)	**59.8** (49.8-72.3)	**97.0** (77.1-114)	**126** (108-142)	670
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	**24.2** (<LOD-32.4)	**46.8** (38.1-56.1)	**59.5** (52.7-67.9)	332
	01-02	**18.3** (15.6-21.4)	**21.2** (19.4-25.0)	**31.9** (27.0-40.3)	**51.5** (40.3-69.9)	**67.9** (48.0-111)	260
Non-Hispanic blacks	99-00	*	< LOD	**35.1** (28.4-44.9)	**62.8** (48.0-79.2)	**84.9** (72.2-98.1)	223
	01-02	**38.9** (33.6-45.0)	**40.2** (33.5-47.3)	**63.2** (54.6-76.9)	**93.9** (78.5-132)	**133** (92.6-185)	219
Non-Hispanic whites	99-00	*	< LOD	**38.2** (34.4-42.0)	**64.4** (54.3-69.3)	**77.7** (69.9-84.9)	567
	01-02	**37.8** (31.5-45.4)	**42.6** (33.9-51.1)	**65.0** (52.3-82.2)	**99.6** (78.4-130)	**130** (103-165)	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 88. 1,2,3,6,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	**232** (196-268)	**403** (349-458)	**520** (458-607)	1237
	01-02	**224** (192-261)	**246** (219-287)	**410** (347-498)	**663** (549-785)	**870** (696-1100)	1234
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	**122** (93.2-155)	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	**232** (196-268)	**403** (349-458)	**520** (458-607)	1237
	01-02	**224** (192-261)	**246** (219-287)	**410** (347-498)	**663** (549-785)	**870** (696-1100)	1234
Gender (20 years and older)							
Males	99-00	*	< LOD	**211** (170-255)	**380** (297-440)	**460** (398-571)	569
	01-02	**226** (190-270)	**262** (223-301)	**425** (347-540)	**677** (547-794)	**883** (666-1180)	564
Females	99-00	*	< LOD	**246** (196-298)	**424** (350-521)	**579** (492-672)	668
	01-02	**222** (190-260)	**237** (207-281)	**397** (338-474)	**643** (526-771)	**863** (720-1060)	670
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	**154** (102-213)	**307** (272-359)	**392** (357-445)	332
	01-02	**117** (99.4-139)	**128** (107-157)	**233** (198-270)	**401** (278-524)	**524** (384-731)	260
Non-Hispanic blacks	99-00	*	< LOD	**212** (167-275)	**389** (302-477)	**522** (399-627)	223
	01-02	**229** (199-264)	**226** (190-284)	**371** (333-477)	**643** (480-799)	**799** (596-1260)	219
Non-Hispanic whites	99-00	*	< LOD	**251** (207-293)	**421** (353-481)	**526** (472-617)	567
	01-02	**246** (206-293)	**272** (233-325)	**440** (365-552)	**679** (549-870)	**897** (718-1150)	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 89. 1,2,3,7,8,9-Hexachlorodibenzo-*p*-dioxin (HxCDD) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	**12.4** (10.4-15.1)	**16.9** (14.3-20.0)	1238
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	642
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	**12.4** (10.4-15.1)	**16.9** (14.3-20.0)	1238
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	565
	01-02	*	< LOD	< LOD	**12.0** (<LOD-14.5)	**14.8** (12.9-18.0)	567
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	**12.9** (10.7-16.7)	**18.3** (15.3-20.9)	671
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	328
	01-02	*	< LOD	< LOD	**9.40** (<LOD-11.2)	**12.1** (<LOD-20.0)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	223
	01-02	*	< LOD	< LOD	**14.4** (11.2-20.0)	**19.9** (14.6-23.9)	220
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	562
	01-02	*	< LOD	< LOD	**12.6** (9.90-15.9)	**17.2** (14.7-20.6)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 90. 1,2,3,7,8,9-Hexachlorodibenzo-*p*-dioxin (HxCDD) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	**86.5** (68.8-108)	**121** (99.5-146)	1238
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	642
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	**86.5** (68.8-108)	**121** (99.5-146)	1238
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	565
	01-02	*	< LOD	< LOD	**84.1** (62.7-104)	**108** (90.6-142)	567
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	**89.7** (67.9-121)	**123** (102-150)	671
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	328
	01-02	*	< LOD	< LOD	**74.7** (50.5-104)	**104** (74.7-167)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	223
	01-02	*	< LOD	< LOD	**92.6** (62.8-126)	**123** (82.6-169)	220
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	562
	01-02	*	< LOD	< LOD	**88.1** (67.9-119)	**124** (96.6-152)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 91. 1,2,3,7,8-Pentachlorodibenzo-*p*-dioxin (PeCDD) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	**11.2** (9.30-13.3)	**15.8** (13.3-19.8)	1236
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	659
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	**11.2** (9.30-13.3)	**15.8** (13.3-19.8)	1236
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	**10.5** (9.10-13.3)	**14.3** (11.7-19.4)	564
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	678
	01-02	*	< LOD	**6.10** (<LOD-7.80)	**11.6** (9.30-13.9)	**16.4** (13.7-20.8)	672
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	338
	01-02	*	< LOD	< LOD	< LOD	**8.70** (<LOD-12.7)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	**7.70** (<LOD-9.30)	**13.8** (9.60-18.4)	**18.4** (14.2-24.0)	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	**11.6** (9.40-14.1)	**16.7** (13.6-20.2)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 92. 1,2,3,7,8-Pentachlorodibenzo-*p*-dioxin (PeCDD) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	**77.8** (62.8-95.1)	**117** (90.3-133)	1236
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	659
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	**77.8** (62.8-95.1)	**117** (90.3-133)	1236
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	**76.1** (54.7-93.7)	**107** (83.5-133)	564
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	678
	01-02	*	< LOD	**37.8** (25.0-50.2)	**80.1** (62.9-107)	**121** (85.7-167)	672
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	338
	01-02	*	< LOD	< LOD	< LOD	**66.0** (43.3-111)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	**43.0** (27.0-53.8)	**81.9** (58.2-117)	**123** (81.9-169)	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	**80.8** (61.6-107)	**119** (88.6-142)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 93. 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	572
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	6.40 (<LOD-9.10)	669
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	336
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	222
	01-02	*	< LOD	< LOD	< LOD	7.40 (<LOD-10.0)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 94. 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	572
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	**50.7** (29.2-74.3)	669
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	336
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	222
	01-02	*	< LOD	< LOD	< LOD	**52.1** (27.4-72.0)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 95. 1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	< LOD	< LOD	< LOD	541
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	329
	01-02	*	< LOD	< LOD	< LOD	< LOD	257
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	224
	01-02	*	< LOD	< LOD	< LOD	< LOD	212
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	653

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 96. 1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	< LOD	< LOD	< LOD	541
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	329
	01-02	*	< LOD	< LOD	< LOD	< LOD	257
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	224
	01-02	*	< LOD	< LOD	< LOD	< LOD	212
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	653

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 97. 1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	**14.2** (<LOD-17.5)	**18.4** (15.0-23.8)	1109
	01-02	**9.64** (8.53-10.9)	**10.3** (8.80-11.7)	**14.5** (12.7-16.6)	**21.3** (18.0-25.5)	**27.1** (22.5-32.0)	1219
Age group							
12-19 years	99-00	*	< LOD	< LOD	**17.7** (16.2-20.9)	**24.0** (20.9-28.1)	600
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	**14.2** (<LOD-17.5)	**18.4** (15.0-23.8)	1109
	01-02	**9.64** (8.53-10.9)	**10.3** (8.80-11.7)	**14.5** (12.7-16.6)	**21.3** (18.0-25.5)	**27.1** (22.5-32.0)	1219
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	**15.9** (<LOD-20.0)	**19.9** (16.4-26.9)	508
	01-02	**10.1** (8.74-11.6)	**10.9** (9.00-12.5)	**15.2** (12.9-17.2)	**20.8** (17.2-27.8)	**28.9** (22.0-34.8)	557
Females	99-00	*	< LOD	< LOD	< LOD	**17.0** (14.0-25.2)	601
	01-02	**9.28** (8.20-10.5)	**9.30** (8.10-11.0)	**14.1** (12.3-15.9)	**21.0** (17.4-25.5)	**26.5** (22.3-31.9)	662
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**17.3** (<LOD-23.1)	299
	01-02	**7.73** (7.19-8.31)	**8.20** (7.80-8.60)	**11.1** (10.6-12.5)	**16.5** (14.5-19.6)	**20.2** (17.2-26.8)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**22.4** (14.0-28.3)	**28.2** (25.3-29.8)	202
	01-02	**12.3** (10.6-14.4)	**12.8** (10.9-15.2)	**17.2** (15.4-21.0)	**25.5** (22.4-31.2)	**32.1** (25.7-37.6)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	**16.8** (14.2-18.5)	503
	01-02	**9.50** (8.30-10.9)	**10.0** (8.20-11.8)	**14.4** (12.6-16.2)	**20.5** (16.9-25.3)	**25.5** (20.5-31.7)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 98. 1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	85.7 (74.7-97.7)	108 (93.6-127)	1109
	01-02	62.2 (55.4-69.9)	64.4 (58.0-71.6)	94.1 (82.3-110)	134 (119-165)	181 (147-206)	1219
Age group							
12-19 years	99-00	*	< LOD	< LOD	79.3 (69.5-84.2)	99.0 (83.4-120)	600
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	85.7 (74.7-97.7)	108 (93.6-127)	1109
	01-02	62.2 (55.4-69.9)	64.4 (58.0-71.6)	94.1 (82.3-110)	134 (119-165)	181 (147-206)	1219
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	89.0 (74.7-111)	111 (93.6-138)	508
	01-02	66.3 (58.2-75.6)	70.0 (59.8-81.8)	99.3 (85.5-120)	143 (120-181)	181 (146-237)	557
Females	99-00	*	< LOD	< LOD	< LOD	101 (85.7-149)	601
	01-02	58.8 (52.0-66.4)	60.2 (53.5-67.6)	89.1 (74.7-107)	130 (108-164)	169 (131-225)	662
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	112 (81.1-121)	299
	01-02	49.5 (46.0-53.4)	50.2 (45.7-57.2)	76.5 (67.1-82.1)	97.2 (90.9-124)	133 (94.8-202)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	124 (92.0-153)	157 (114-214)	202
	01-02	72.6 (61.9-85.2)	70.5 (62.4-85.2)	107 (91.5-128)	146 (131-177)	192 (154-259)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	97.8 (89.3-105)	503
	01-02	61.8 (54.3-70.4)	64.5 (57.4-72.2)	94.3 (78.1-112)	133 (114-166)	180 (137-222)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 99. 1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
Age group							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
Gender							
(20 years and older)							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	666
Race/ethnicity							
(20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	661

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 100. 1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
Age group							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
Gender (20 years and older)							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	666
Race/ethnicity (20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	661

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 101. 1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	8.00 (6.90-9.30)	12.1 (9.40-14.9)	15.4 (12.9-18.6)	1223
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	8.00 (6.90-9.30)	12.1 (9.40-14.9)	15.4 (12.9-18.6)	1223
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	8.20 (7.10-9.70)	12.6 (9.50-15.9)	15.9 (12.2-20.9)	562
Females	99-00	*	< LOD	< LOD	< LOD	13.0 (<LOD-17.1)	666
	01-02	*	< LOD	7.90 (6.60-9.00)	11.7 (9.40-13.8)	14.1 (12.1-18.6)	661
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	7.20 (<LOD-8.00)	8.00 (6.90-10.7)	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	14.5 (<LOD-18.1)	221
	01-02	*	< LOD	8.90 (7.70-10.1)	13.6 (11.1-17.1)	18.6 (14.6-22.6)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	563
	01-02	*	< LOD	8.20 (7.10-10.2)	12.5 (9.90-15.5)	15.9 (13.1-19.0)	664

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 102. 1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population
National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002,
aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	**54.0** (46.5-63.6)	**82.3** (65.5-104)	**108** (88.0-138)	1223
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	**54.0** (46.5-63.6)	**82.3** (65.5-104)	**108** (88.0-138)	1223
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	**56.9** (48.6-71.4)	**90.1** (71.1-108)	**108** (87.4-144)	562
Females	99-00	*	< LOD	< LOD	< LOD	**86.1** (72.5-105)	666
	01-02	*	< LOD	**51.6** (43.7-59.6)	**76.1** (62.6-97.0)	**104** (80.1-139)	661
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	**48.4** (42.2-56.3)	**65.3** (48.6-79.4)	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	**96.5** (75.9-120)	221
	01-02	*	< LOD	**52.7** (45.0-62.7)	**85.2** (63.7-108)	**122** (85.2-147)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	563
	01-02	*	< LOD	**56.0** (48.5-66.1)	**84.2** (64.5-115)	**112** (88.6-142)	664

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 103. 1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	**7.10** (<LOD-8.20)	**10.3** (9.00-13.1)	**14.0** (11.0-17.1)	1236
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	**7.10** (<LOD-8.20)	**10.3** (9.00-13.1)	**14.0** (11.0-17.1)	1236
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	573
	01-02	*	< LOD	**7.10** (<LOD-8.50)	**11.3** (8.50-13.8)	**14.8** (11.3-18.7)	566
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	**7.00** (6.10-7.90)	**9.90** (9.20-11.2)	**13.1** (10.5-15.6)	670
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	**6.80** (<LOD-11.1)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	**7.60** (6.10-9.10)	**11.9** (10.0-14.1)	**15.6** (12.3-21.0)	219
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	**7.30** (6.20-9.00)	**10.7** (9.00-14.0)	**14.8** (11.6-17.2)	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 104. 1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	**46.0** (38.6-56.5)	**70.2** (58.3-90.2)	**101** (77.6-120)	1236
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	**46.0** (38.6-56.5)	**70.2** (58.3-90.2)	**101** (77.6-120)	1236
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	573
	01-02	*	< LOD	**47.6** (38.3-60.5)	**72.3** (57.5-105)	**104** (73.5-133)	566
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	**45.0** (37.0-54.3)	**66.2** (58.3-79.1)	**90.2** (71.9-115)	670
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	**52.7** (41.2-65.9)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	**44.4** (37.2-57.3)	**71.5** (59.8-90.9)	**107** (70.7-142)	219
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	**49.6** (41.9-57.9)	**72.8** (58.4-102)	**103** (82.6-121)	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 105. 1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	664
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	< LOD	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	221
	01-02	*	< LOD	< LOD	< LOD	< LOD	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	560
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 106. 1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	664
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	< LOD	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	221
	01-02	*	< LOD	< LOD	< LOD	< LOD	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	560
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 107. 1,2,3,7,8-Pentachlorodibenzofuran (PeCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	681
	01-02	*	< LOD	< LOD	< LOD	< LOD	670
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	< LOD	< LOD	263
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	< LOD	< LOD	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 108. 1,2,3,7,8-Pentachlorodibenzofuran (PeCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	681
	01-02	*	< LOD	< LOD	< LOD	< LOD	670
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	< LOD	< LOD	263
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	< LOD	< LOD	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 109. 2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	665
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	326
	01-02	*	< LOD	< LOD	< LOD	< LOD	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 110. 2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population
National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002,
aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	665
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	326
	01-02	*	< LOD	< LOD	< LOD	< LOD	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 111. 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	**16.1** (13.9-17.2)	1239
	01-02	*	< LOD	**9.10** (7.40-11.0)	**14.3** (12.3-16.2)	**18.0** (16.1-21.1)	1230
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	**16.1** (13.9-17.2)	1239
	01-02	*	< LOD	**9.10** (7.40-11.0)	**14.3** (12.3-16.2)	**18.0** (16.1-21.1)	1230
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	**14.1** (12.9-15.7)	569
	01-02	*	< LOD	**9.30** (7.30-11.6)	**14.1** (11.6-16.7)	**16.7** (13.9-21.4)	560
Females	99-00	*	< LOD	< LOD	**13.7** (<LOD-16.1)	**17.1** (15.5-19.3)	670
	01-02	*	< LOD	**9.10** (7.50-10.7)	**14.3** (13.0-16.1)	**18.5** (16.4-21.2)	670
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	**7.80** (6.00-9.60)	**9.80** (7.80-12.5)	264
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**12.9** (<LOD-15.0)	**16.6** (13.7-21.0)	220
	01-02	*	< LOD	**8.30** (6.80-9.30)	**13.9** (11.7-16.4)	**18.9** (15.1-23.0)	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	**12.8** (<LOD-14.1)	**16.1** (14.1-17.5)	564
	01-02	*	**5.80** (<LOD-6.80)	**10.3** (8.10-11.9)	**15.5** (13.0-17.6)	**18.4** (16.5-22.2)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 112. 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	**107** (98.3-125)	1239
	01-02	*	< LOD	**60.8** (51.3-70.5)	**98.5** (83.4-114)	**134** (113-152)	1230
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	**107** (98.3-125)	1239
	01-02	*	< LOD	**60.8** (51.3-70.5)	**98.5** (83.4-114)	**134** (113-152)	1230
Gender							
(20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	**98.2** (80.7-109)	569
	01-02	*	< LOD	**61.7** (49.3-76.6)	**98.4** (76.6-134)	**135** (105-160)	560
Females	99-00	*	< LOD	< LOD	**93.5** (79.1-104)	**115** (103-129)	670
	01-02	*	< LOD	**59.7** (52.0-67.6)	**99.6** (90.5-105)	**126** (107-146)	670
Race/ethnicity							
(20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	**55.8** (48.7-69.7)	**76.3** (61.9-92.4)	264
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**79.4** (68.3-95.6)	**107** (86.9-143)	220
	01-02	*	< LOD	**50.0** (41.3-60.4)	**89.5** (72.3-107)	**121** (92.0-154)	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	**88.8** (78.2-97.2)	**109** (98.2-128)	564
	01-02	*	**37.3** (30.1-44.1)	**65.4** (52.9-78.2)	**104** (90.7-118)	**135** (118-154)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 113. 2,3,7,8-Tetrachlorodibenzofuran (TCDF) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	574
	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	671
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	335
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	667

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 114. 2,3,7,8-Tetrachlorodibenzofuran (TCDF) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	574
	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	671
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	335
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	667

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 115. 2,4,4'-Trichlorobiphenyl (PCB 28) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1849
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	647
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1202
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	886
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	963
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	618
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	392
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	687

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 116. 2,4,4'-Trichlorobiphenyl (PCB 28) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1849
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	647
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1202
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	886
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	963
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	618
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	392
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	687

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 117. 2,3',4,4'-Tetrachlorobiphenyl (PCB 66) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1931
	01-02	*	< LOD	< LOD	< LOD	< LOD	2250
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	671
	01-02	*	< LOD	< LOD	< LOD	< LOD	724
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1526
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1012
	01-02	*	< LOD	< LOD	< LOD	< LOD	1203
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	548
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	414
	01-02	*	< LOD	< LOD	< LOD	< LOD	495
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	723
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 118. 2,3',4,4'-Tetrachlorobiphenyl (PCB 66) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1931
	01-02	*	< LOD	< LOD	< LOD	< LOD	2250
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	671
	01-02	*	< LOD	< LOD	< LOD	< LOD	724
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1526
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1012
	01-02	*	< LOD	< LOD	< LOD	< LOD	1203
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	548
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	414
	01-02	*	< LOD	< LOD	< LOD	< LOD	495
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	723
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 119. 2,4,4',5-Tetrachlorobiphenyl (PCB 74) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**20.7** (17.8-23.4)	**29.0** (24.5-32.3)	1924
	01-02	*	**< LOD**	**13.1** (11.0-15.7)	**23.3** (20.1-27.4)	**32.6** (26.9-38.7)	2307
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	671
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**12.6** (<LOD-14.4)	**22.3** (19.5-25.6)	**30.0** (26.2-35.8)	1253
	01-02	*	**< LOD**	**14.6** (12.4-17.1)	**25.2** (21.4-28.9)	**34.8** (28.5-41.1)	1549
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**15.3** (12.9-17.5)	**21.5** (18.3-24.4)	915
	01-02	*	**< LOD**	**10.5** (<LOD-12.1)	**20.2** (15.1-24.9)	**28.5** (20.8-38.2)	1075
Females	99-00	*	**< LOD**	**13.9** (<LOD-16.3)	**24.5** (21.9-28.5)	**31.6** (28.8-40.3)	1009
	01-02	*	**< LOD**	**15.7** (13.5-18.6)	**26.1** (23.1-29.3)	**35.9** (31.4-41.4)	1232
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**15.8** (12.8-18.2)	636
	01-02	*	**< LOD**	**< LOD**	**13.0** (<LOD-18.1)	**19.6** (16.2-23.0)	567
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**29.0** (18.6-38.4)	**43.5** (35.4-64.0)	411
	01-02	*	**< LOD**	**12.0** (<LOD-14.2)	**21.7** (16.4-26.9)	**31.5** (24.5-41.0)	515
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**21.6** (18.9-24.0)	**29.0** (24.1-32.0)	719
	01-02	*	**< LOD**	**14.6** (12.2-17.3)	**25.7** (21.3-30.1)	**35.5** (29.0-42.5)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 120. 2,4,4',5-Tetrachlorobiphenyl (PCB 74) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**.139** (.120-.151)	**.183** (.162-.218)	1924
	01-02	*	**< LOD**	**.084** (.073-.099)	**.150** (.134-.174)	**.212** (.181-.263)	2307
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	671
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**.084** (.072-.096)	**.148** (.137-.158)	**.203** (.174-.232)	1253
	01-02	*	**< LOD**	**.094** (.081-.110)	**.166** (.140-.192)	**.226** (.196-.279)	1549
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**.098** (.088-.118)	**.151** (.128-.168)	915
	01-02	*	**< LOD**	**.069** (.057-.078)	**.131** (.101-.171)	**.189** (.138-.241)	1075
Females	99-00	*	**< LOD**	**.096** (.077-.109)	**.158** (.143-.184)	**.223** (.186-.254)	1009
	01-02	*	**< LOD**	**.101** (.088-.112)	**.168** (.149-.190)	**.236** (.205-.285)	1232
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**.111** (.083-.126)	636
	01-02	*	**< LOD**	**< LOD**	**.087** (.067-.123)	**.144** (.107-.157)	567
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**.169** (.109-.246)	**.277** (.218-.418)	411
	01-02	*	**< LOD**	**.070** (.058-.083)	**.131** (.104-.166)	**.192** (.152-.251)	515
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**.145** (.126-.157)	**.185** (.163-.212)	719
	01-02	*	**< LOD**	**.096** (.078-.111)	**.167** (.139-.196)	**.229** (.194-.282)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 121. 3,4,4',5-Tetrachlorobiphenyl (PCB 81) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	651
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	554
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	< LOD	< LOD	259
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	557
	01-02	*	< LOD	< LOD	< LOD	< LOD	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 122. 3,4,4',5-Tetrachlorobiphenyl (PCB 81) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population
National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002,
aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	**75th**	**90th**	**95th**	
Total, age 20 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	651
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	554
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	< LOD	< LOD	259
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	557
	01-02	*	< LOD	< LOD	< LOD	< LOD	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 123. 2,3,3',4,4'-Pentachlorobiphenyl (PCB 105) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis)
for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1915
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	665
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1250
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	913
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1002
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	12.8 (<LOD-18.0)	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	714
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 124. 2,3,3',4,4'-Pentachlorobiphenyl (PCB 105) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1915
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	665
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1250
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	913
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1002
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	.076 (.058-.112)	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	714
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 125. 2,3',4,4',5-Pentachlorobiphenyl (PCB 118) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**13.1** (<LOD-15.1)	**27.0** (22.1-30.3)	**40.3** (32.8-47.4)	1926
	01-02	*	**< LOD**	**15.1** (13.0-17.5)	**29.0** (26.1-33.7)	**44.6** (39.6-48.9)	2307
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	667
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**14.7** (12.8-17.4)	**28.0** (24.4-33.5)	**43.6** (35.6-52.3)	1259
	01-02	*	**< LOD**	**16.9** (15.1-18.8)	**32.4** (28.3-37.3)	**46.4** (41.1-51.0)	1549
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**19.6** (16.6-24.4)	**28.0** (24.4-38.1)	919
	01-02	*	**< LOD**	**11.9** (<LOD-14.6)	**22.0** (17.6-27.1)	**32.7** (25.4-47.5)	1075
Females	99-00	*	**< LOD**	**16.7** (13.5-19.5)	**32.0** (27.0-40.3)	**46.8** (41.0-57.0)	1007
	01-02	*	**< LOD**	**18.7** (16.3-20.5)	**35.9** (31.6-40.9)	**48.7** (44.5-54.3)	1232
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**17.0** (14.1-18.3)	**23.7** (20.9-27.1)	636
	01-02	*	**< LOD**	**< LOD**	**16.8** (12.5-21.7)	**26.4** (19.3-33.2)	567
Non-Hispanic blacks	99-00	*	**< LOD**	**18.9** (12.9-21.7)	**38.6** (28.4-54.4)	**59.7** (45.7-80.8)	413
	01-02	*	**< LOD**	**15.6** (12.6-19.9)	**37.3** (26.1-46.4)	**54.9** (40.0-66.6)	515
Non-Hispanic whites	99-00	*	**< LOD**	**13.1** (<LOD-15.6)	**25.6** (20.7-32.0)	**40.3** (30.4-46.8)	720
	01-02	*	**< LOD**	**15.8** (13.6-18.1)	**31.1** (27.1-35.7)	**45.3** (38.7-50.1)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 126. 2,3',4,4',5-Pentachlorobiphenyl (PCB 118) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	**.085** (.077-.097)	**.179** (.151-.196)	**.259** (.217-.322)	1926
	01-02	*	< LOD	**.095** (.084-.111)	**.192** (.163-.224)	**.293** (.267-.322)	2307
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	**.099** (.087-.111)	**.189** (.168-.220)	**.281** (.230-.360)	1259
	01-02	*	< LOD	**.109** (.095-.124)	**.212** (.183-.245)	**.310** (.282-.367)	1549
Gender							
Males	99-00	*	< LOD	< LOD	**.128** (.114-.142)	**.188** (.159-.217)	919
	01-02	*	< LOD	**.080** (.065-.095)	**.139** (.116-.167)	**.208** (.162-.289)	1075
Females	99-00	*	< LOD	**.110** (.088-.133)	**.210** (.181-.259)	**.321** (.261-.408)	1007
	01-02	*	< LOD	**.125** (.102-.141)	**.237** (.213-.262)	**.356** (.302-.384)	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	**.112** (.093-.128)	**.143** (.129-.183)	636
	01-02	*	< LOD	< LOD	**.120** (.082-.155)	**.180** (.128-.224)	567
Non-Hispanic blacks	99-00	*	< LOD	**.111** (.079-.146)	**.223** (.182-.322)	**.399** (.259-.503)	413
	01-02	*	< LOD	**.094** (.073-.121)	**.213** (.165-.271)	**.322** (.231-.457)	515
Non-Hispanic whites	99-00	*	< LOD	**.086** (.077-.102)	**.176** (.145-.199)	**.250** (.202-.331)	720
	01-02	*	< LOD	**.101** (.089-.119)	**.205** (.172-.239)	**.301** (.269-.364)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 127. 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	30.8 (27.2-36.3)	57.1 (50.5-65.8)	89.5 (66.1-110)	1238
	01-02	22.7 (20.9-24.7)	24.5 (22.0-26.5)	40.8 (36.1-47.5)	69.3 (61.6-80.8)	108 (92.7-116)	1226
Age group							
12-19 years	99-00	*	< LOD	< LOD	23.8 (<LOD-27.5)	30.6 (26.2-36.0)	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	30.8 (27.2-36.3)	57.1 (50.5-65.8)	89.5 (66.1-110)	1238
	01-02	22.7 (20.9-24.7)	24.5 (22.0-26.5)	40.8 (36.1-47.5)	69.3 (61.6-80.8)	108 (92.7-116)	1226
Gender (20 years and older)							
Males	99-00	*	< LOD	27.1 (<LOD-30.6)	44.6 (38.0-50.5)	65.0 (50.5-82.8)	572
	01-02	20.3 (18.5-22.3)	23.0 (20.8-25.4)	36.5 (32.8-39.4)	52.6 (46.2-61.6)	81.9 (61.0-101)	561
Females	99-00	*	< LOD	36.6 (30.4-44.4)	67.8 (55.7-83.8)	99.1 (75.9-122)	666
	01-02	25.1 (22.9-27.4)	26.0 (22.8-28.8)	48.6 (41.4-54.4)	82.7 (71.1-96.8)	116 (98.6-128)	665
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	27.5 (<LOD-34.3)	49.0 (38.7-59.9)	70.0 (57.2-82.4)	337
	01-02	17.8 (15.5-20.4)	19.6 (17.8-20.9)	28.4 (26.2-33.9)	47.9 (39.7-54.9)	69.2 (49.3-103)	262
Non-Hispanic blacks	99-00	*	< LOD	38.4 (29.4-46.0)	75.1 (50.2-136)	136 (71.4-279)	223
	01-02	22.2 (18.2-27.0)	22.1 (19.4-25.3)	44.3 (37.9-51.5)	76.5 (59.0-111)	115 (96.1-153)	217
Non-Hispanic whites	99-00	*	< LOD	29.6 (24.2-35.6)	53.0 (43.2-61.2)	75.0 (59.1-98.6)	562
	01-02	23.1 (20.9-25.4)	24.7 (22.0-27.6)	42.0 (35.4-49.6)	72.3 (63.9-82.9)	114 (88.3-124)	663

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 128. 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	**75th**	**90th**	**95th**	
Total, age 20 and older	99-00	*	< LOD	**204** (173-232)	**381** (319-451)	**591** (479-709)	1238
	01-02	**147** (135-160)	**158** (143-175)	**270** (249-298)	**482** (436-541)	**730** (625-840)	1226
Age group							
12-19 years	99-00	*	< LOD	< LOD	**108** (94.0-126)	**144** (116-196)	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	**204** (173-232)	**381** (319-451)	**591** (479-709)	1238
	01-02	**147** (135-160)	**158** (143-175)	**270** (249-298)	**482** (436-541)	**730** (625-840)	1226
Gender (20 years and older)							
Males	99-00	*	< LOD	**173** (147-194)	**271** (250-319)	**422** (319-560)	572
	01-02	**134** (121-149)	**152** (130-169)	**249** (233-267)	**399** (346-467)	**566** (467-693)	561
Females	99-00	*	< LOD	**237** (182-297)	**470** (402-586)	**684** (586-804)	666
	01-02	**159** (146-172)	**160** (149-184)	**298** (270-348)	**548** (483-637)	**818** (658-958)	665
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	**184** (123-242)	**327** (271-381)	**512** (364-576)	337
	01-02	**114** (97.8-133)	**125** (106-150)	**214** (175-257)	**335** (272-460)	**585** (354-784)	262
Non-Hispanic blacks	99-00	*	< LOD	**236** (162-308)	**547** (356-779)	**941** (517-1600)	223
	01-02	**131** (106-161)	**128** (110-158)	**266** (214-304)	**532** (361-662)	**779** (585-1060)	217
Non-Hispanic whites	99-00	*	< LOD	**188** (157-237)	**329** (285-424)	**554** (424-666)	562
	01-02	**150** (136-164)	**160** (146-179)	**276** (249-301)	**486** (431-553)	**746** (600-937)	663

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 129. 2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**12.5** (<LOD-13.8)	**16.5** (15.5-18.0)	1907
	01-02	*	**< LOD**	**< LOD**	**14.2** (12.1-15.8)	**18.2** (15.6-20.9)	2296
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	665
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	756
20 years and older	99-00	*	**< LOD**	**< LOD**	**13.5** (<LOD-14.7)	**17.5** (16.0-19.7)	1242
	01-02	*	**< LOD**	**< LOD**	**14.9** (13.2-16.6)	**19.7** (17.0-22.1)	1540
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**12.6** (<LOD-14.0)	**16.0** (14.6-18.0)	912
	01-02	*	**< LOD**	**< LOD**	**13.6** (11.2-16.4)	**18.2** (14.3-22.1)	1069
Females	99-00	*	**< LOD**	**< LOD**	**12.8** (<LOD-14.7)	**16.3** (14.7-20.1)	995
	01-02	*	**< LOD**	**< LOD**	**14.7** (13.2-15.5)	**18.1** (16.2-21.0)	1227
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	631
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	566
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**14.6** (<LOD-20.5)	**21.6** (17.2-32.1)	412
	01-02	*	**< LOD**	**< LOD**	**15.5** (12.6-20.0)	**23.5** (16.4-29.4)	511
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**13.6** (<LOD-15.2)	**17.4** (16.0-18.9)	711
	01-02	*	**< LOD**	**< LOD**	**15.0** (13.0-17.1)	**19.3** (16.2-22.1)	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 130. 2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**.085** (.075-.092)	**.109** (.098-.129)	1907
	01-02	*	**< LOD**	**< LOD**	**.094** (.082-.107)	**.126** (.110-.140)	2296
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	665
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	756
20 years and older	99-00	*	**< LOD**	**< LOD**	**.090** (.081-.099)	**.116** (.104-.139)	1242
	01-02	*	**< LOD**	**< LOD**	**.104** (.089-.114)	**.132** (.118-.144)	1540
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**.085** (.072-.098)	**.109** (.094-.130)	912
	01-02	*	**< LOD**	**< LOD**	**.092** (.078-.113)	**.123** (.105-.151)	1069
Females	99-00	*	**< LOD**	**< LOD**	**.085** (.075-.093)	**.108** (.092-.141)	995
	01-02	*	**< LOD**	**< LOD**	**.096** (.086-.104)	**.134** (.111-.140)	1227
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	631
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	566
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**.094** (.071-.124)	**.151** (.113-.188)	412
	01-02	*	**< LOD**	**< LOD**	**.096** (.079-.131)	**.144** (.104-.179)	511
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**.089** (.081-.098)	**.111** (.101-.129)	711
	01-02	*	**< LOD**	**< LOD**	**.104** (.089-.115)	**.131** (.117-.140)	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 131. 2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1897
	01-02	*	< LOD	< LOD	< LOD	< LOD	2294
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	654
	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1539
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	901
	01-02	*	< LOD	< LOD	< LOD	< LOD	1068
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	996
	01-02	*	< LOD	< LOD	< LOD	< LOD	1226
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	405
	01-02	*	< LOD	< LOD	< LOD	< LOD	510
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	716
	01-02	*	< LOD	< LOD	< LOD	< LOD	1055

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 132. 2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1897
	01-02	*	< LOD	< LOD	< LOD	< LOD	2294
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	654
	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1539
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	901
	01-02	*	< LOD	< LOD	< LOD	< LOD	1068
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	996
	01-02	*	< LOD	< LOD	< LOD	< LOD	1226
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	405
	01-02	*	< LOD	< LOD	< LOD	< LOD	510
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	716
	01-02	*	< LOD	< LOD	< LOD	< LOD	1055

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 133. 2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1908
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	908
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1000
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	627
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	411
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	715
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 134. 2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1908
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	908
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1000
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	627
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	411
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	715
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 135. 3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	**36.4** (33.8-40.3)	**47.8** (42.8-51.0)	1240
	01-02	**17.9** (16.0-19.9)	**19.0** (16.8-21.9)	**33.1** (27.5-38.6)	**50.0** (43.9-55.0)	**60.7** (55.8-65.8)	1223
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	**36.4** (33.8-40.3)	**47.8** (42.8-51.0)	1240
	01-02	**17.9** (16.0-19.9)	**19.0** (16.8-21.9)	**33.1** (27.5-38.6)	**50.0** (43.9-55.0)	**60.7** (55.8-65.8)	1223
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	**38.1** (33.8-42.3)	**45.7** (40.8-52.8)	572
	01-02	**20.2** (17.8-22.8)	**22.0** (18.5-25.3)	**36.0** (29.5-43.2)	**53.0** (45.8-56.9)	**60.6** (55.7-69.0)	559
Females	99-00	*	< LOD	< LOD	**34.6** (30.9-40.6)	**48.3** (39.4-52.0)	668
	01-02	**16.0** (14.2-18.1)	**16.8** (14.7-19.2)	**30.1** (24.5-36.5)	**46.0** (40.7-51.9)	**60.9** (52.2-70.0)	664
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**33.6** (29.5-38.1)	335
	01-02	*	< LOD	**15.0** (11.3-18.3)	**24.6** (18.3-32.3)	**32.3** (26.3-39.6)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**41.3** (34.6-52.2)	**53.2** (44.3-65.6)	224
	01-02	**17.2** (15.4-19.1)	**18.3** (15.7-20.0)	**31.7** (25.8-35.4)	**47.3** (41.1-53.9)	**54.8** (48.3-64.5)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	**36.6** (33.5-41.8)	**48.1** (41.8-51.6)	568
	01-02	**19.5** (17.2-22.2)	**21.4** (17.4-24.7)	**36.0** (29.6-41.1)	**53.5** (47.0-58.3)	**64.3** (59.2-72.8)	662

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 136. 3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 20 and older	99-00	*	< LOD	< LOD	240 (227-261)	303 (281-339)	1240
	01-02	115 (103-129)	125 (108-146)	217 (189-253)	343 (299-374)	416 (379-490)	1223
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	240 (227-261)	303 (281-339)	1240
	01-02	115 (103-129)	125 (108-146)	217 (189-253)	343 (299-374)	416 (379-490)	1223
Gender (20 years and older)							
Males	99-00	*	< LOD	< LOD	245 (223-276)	298 (274-341)	572
	01-02	133 (117-152)	151 (130-168)	244 (198-293)	363 (309-409)	446 (372-529)	559
Females	99-00	*	< LOD	< LOD	240 (214-264)	310 (273-347)	668
	01-02	102 (90.0-115)	107 (91.0-123)	194 (170-234)	318 (282-368)	391 (373-462)	664
Race/ethnicity (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	235 (190-295)	335
	01-02	*	< LOD	97.6 (79.3-138)	184 (143-250)	262 (179-341)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	262 (192-334)	334 (265-505)	224
	01-02	101 (91.2-113)	103 (88.0-118)	190 (147-234)	295 (261-328)	361 (309-423)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	244 (226-273)	298 (276-347)	568
	01-02	127 (112-144)	145 (124-157)	229 (195-275)	368 (317-388)	438 (388-515)	662

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

Table 137. 2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	752
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1546
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1070
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	514
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 138. 2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	752
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1546
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1070
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	514
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Results by Chemical Group

Non-dioxin-like Polychlorinated Biphenyls

Non-dioxin-like Polychlorinated Biphenyls

(The coplanar and mono-ortho-substituted PCBs are reported and specifically discussed in the section titled "Polychlorinated Dibenzo-p-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls.")

General Information

Polychlorinated biphenyls (PCBs) are a class of chlorinated aromatic hydrocarbon chemicals that once were used as electrical insulating and heat-exchange fluids. Peak production occurred in the early 1970s, and production was banned in the United States after 1979. The continued concern about these chemicals is because of their release into and persistence in the environment.

Food is the main source of exposure for the general population. PCBs enter the food chain by a variety of routes, including migration into food from packaging materials, contamination of animal feeds, and accumulation in the fatty tissues of animals. PCBs are found at higher concentrations in fatty foods. Diets that contain PCB-contaminated fats (e.g., milk and dairy products; fish, including whales) will increase exposure to PCBs. The transfer of PCBs from mother to infants via breast milk is another source of exposure. Other sources for the general population include the

release of these chemicals from PCB-containing waste sites and fires involving transformers and capacitors. Additionally, the heat from fires can result in the production of polychlorinated Dibenzo furans from PCBs. In certain occupational settings workers can be exposed to PCBs, including when repairing or manufacturing transformers, capacitors, and hydraulic systems, and when remediating hazardous-waste sites. Both U.S. FDA and OSHA have developed criteria on the allowable levels of these chemicals in foods and the workplace. The U.S. EPA has also set criteria for water and for storing and removing waste that contains PCBs. The Stockholm Treaty, signed in May 2001, will put into effect the most stringent guidelines to date regarding elimination, restriction and unintentional production of PCBs and selected pesticides (Porta and Zumeta, 2002).

Exposure to these chemicals nearly always occurs from mixtures rather than from individual PCBs. The different types of PCB chemicals are known as congeners, compounds that are distinguished by the number of

Table 139. Non-dioxin-like Polychlorinated Biphenyls (PCBs) and their classification

Non-dioxin-like polychlorinated biphenyls (IUPAC number)	CAS number
Polychlorinated biphenyls (general class)	1336-36-3
2,2',5,5'-Tetrachlorobiphenyl (PCB 52)	35693-99-3
2,2',3,4,5'-Pentachlorobiphenyl (PCB 87)	38380-02-8
2,2',4,4',5-Pentachlorobiphenyl (PCB 99)	38380-01-7
2,2',4,5,5'-Pentachlorobiphenyl (PCB 101)	37680-73-2
2,3,3',4',6-Pentachlorobiphenyl (PCB 110)	38380-03-9
2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128)	38380-07-3
2,2',3,4,4',5'-Hexachlorobiphenyl (PCB 138)	35065-28-2
2,3,3',4,4',6-Hexachlorobiphenyl (PCB 158)	74472-42-7
2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146)	51908-16-8
2,2',3,4',5',6-Hexachlorobiphenyl (PCB 149)	38380-04-0
2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151)	52663-63-5
2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153)	35065-27-1
2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170)	35065-30-6
2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172)	52663-74-8
2,2',3,3',4,5',6'-Heptachlorobiphenyl (PCB 177)	52663-70-4
2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178)	52663-67-9
2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180)	35065-29-3
2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183)	52663-69-1
2,2',3,4',5,5',6-Heptachlorobiphenyl (PCB 187)	52663-68-0
2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194)	35694-08-7
2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195)	52663-78-2
2,2',3,3',4,4',5,6'-Octachlorobiphenyl (PCB 196)	42740-50-1
2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199)	52663-75-9
2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB 203)	52663-76-0
2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206)	40186-72-9

chlorine atoms and their location on the biphenyl structure. PCB congeners can be divided into the coplanar, the mono-ortho-substituted PCBs, and other PCBs. The significance of this designation is that the coplanar and the mono-ortho-substituted PCBs have dioxin-like toxicologic effects. The coplanar and mono-ortho-substituted PCBs are discussed in the section titled "Polychlorinated Dibenzo-p-dioxins, Polychlorinated Dibenzofurans, and the Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls." Table 138 gives the nomenclature for the PCBs in this section.

Human health effects that have been reported after investigations of occupational and accidental exposures to PCBs include elevations of serum hepatic enzymes, dermal changes, and inconsistent evidence for altered serum lipid levels and some types of cancer (e.g., breast, liver, biliary) (ATSDR, 2000; Negri et al., 2003; Pavuk, et al., 2003; Charles et al., 2001; Lucena et al., 2001; Charlier et al., 2003; Warner et al., 2002). Reproductive and developmental effects demonstrated in animals may also be of concern. Background levels of PCBs from transplacental transfer after environmental exposure have been reported to be associated with impaired neurological development in newborns and children (Koopman-Essenboom et al., 1997; Jacobson and Jacobson, 1996; Longnecker et al., 2003; Sala et al., 2001), though several other studies have reported that these effects do not persist into school age (Gladen and Rogan, 1991; Gray et al., 2005). PCBs are classified as probable human carcinogens by IARC and are classified by NTP as reasonably anticipated to be carcinogens. Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov /toxprofiles.

Interpreting Levels of Lipid-Adjusted Serum Non-dioxin-like PCBs Reported in the Tables

Lipid-adjusted serum levels of PCBs were measured in a subsample of NHANES participants aged 12 years and older. Participants were randomly selected within the specified age range to be a representative sample of the U.S. population. Measurement of serum PCBs can reflect either recent or past exposure to PCBs. Some PCBs can persist in the body for years after exposure. The contribution of individual PCB congeners to the sum of PCB measurements in the body may vary by exposure source and differences in pharmacokinetics. Some of the PCBs measured may represent exposure to the breakdown of other PCBs in a person's environment.

The most frequently detected di-ortho-chlorine-substituted PCBs in general populations are 138, 153, and 180 (Patterson et al., 1994; Heudorf et al., 2002). These congeners also were found to contribute a substantial portion of the total PCB concentration observed in pooled specimens representative of a New Zealand population (Bates et al., 2004*b*) and in a smaller population of Swedish men (Glynn et al., 2000). Because of its predominance, PCB 153 has been used as a marker of exposure for the other PCBs. In 1994, levels of PCBs 138, 153, and 180 in pooled, banked serum were generally three to four times lower than levels reported in 1988 (Longnecker et al., 2000; Patterson et al., 1994). The concentrations of the di-ortho-substituted PCBs are generally higher than the mono-ortho-substituted PCBs, which in turn are higher than the coplanar PCBs (Glynn et al., 2000; Longnecker et al., 2000; Patterson et al., 1994). In a convenience sample of 624 urban Germans aged 0-65 years conducted during 1998 (Heudorf et al., 2002), 95th percentile levels for PCBs 138, 153, and 180 were similar or up to two-fold higher than 95th percentile levels in this *Report*. A representative pooled sampling of New Zealanders showed slightly lower levels than those in this *Report* (Bates et al., 2004*b*). Heavy fish consumption is considered to contribute to about a two-fold increase in the concentration of these PCB congeners (Patterson et al., 1994).

The tri-ortho-chlorine-substituted PCBs are 177, 178, 183, and 187. The levels for PCB 187 shown in this *Report* are similar to the levels measured in a convenience sample of the general Canadian population in 1994 (Longnecker et al., 2000).

Comparing Adjusted Geometric Means

For comparison of demographic groups in the NHANES 2001-2002 subsample, geometric means of whole weight-based serum measurements were adjusted for age, gender, race/ethnicity, serum cotinine, and lipid level (data not shown). Due to improved limits of detection in NHANES 2001-2002, PCB 138 & 158, PCB 153, and PCB 180 had sufficient detection rates to allow comparison of adjusted geometric means of the demographic groups, which were not possible in the 1999-2000 subssample. For PCB 138 & 158, no differences between the demographic groups were found. For PCB 153, males had slightly higher levels than females, and Mexican Americans had two-fold lower levels than either non-Hispanic blacks or non-Hispanic whites. For PCB 180, males had slightly higher adjusted geometric mean levels than females. It is unknown whether these differences associated with gender or race/ethnicity represent differences in exposure,

pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of one or more PCBs in the blood does not indicate that the levels of the PCBs cause an adverse health effect. These data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of PCBs than levels found in the general population. Whether PCBs at the levels reported here are cause for health concern is not known; more research is needed.

Table 140. 2,2',5,5'-Tetrachlorobiphenyl (PCB 52) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1912
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**16.2** (14.3-17.2)	1537
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	664
	01-02	*	**< LOD**	**< LOD**	**16.2** (<LOD-23.8)	**22.9** (16.9-32.3)	291
20 years and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1248
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**16.0** (13.5-16.9)	1246
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	908
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**16.0** (<LOD-17.5)	716
Females	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1004
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**16.5** (14.0-18.2)	821
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	631
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**16.9** (<LOD-20.6)	366
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	408
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**16.1** (<LOD-20.9)	282
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	716
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**16.5** (14.3-17.5)	773

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 141. 2,2',5,5'-Tetrachlorobiphenyl (PCB 52) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1912
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.089** (.081-.097)	1537
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	664
	01-02	*	**< LOD**	**< LOD**	**.079** (.048-.101)	**.104** (.083-.135)	291
20 years and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1248
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.086** (.076-.092)	1246
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	908
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.085** (.071-.104)	716
Females	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1004
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.088** (.083-.094)	821
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	631
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.083** (.051-.102)	366
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	408
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.092** (.068-.112)	282
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	716
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.088** (.081-.099)	773

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 142. 2,2',3,4,5'-Pentachlorobiphenyl (PCB 87) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 143. 2,2',3,4,5'-Pentachlorobiphenyl (PCB 87) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 144. 2,2',4,4',5-Pentachlorobiphenyl (PCB 99) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**13.1** (<LOD-14.6)	**19.1** (16.2-20.6)	1897
	01-02	*	**< LOD**	**< LOD**	**17.6** (15.3-20.8)	**26.3** (22.1-30.5)	2281
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	654
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**< LOD**	**13.9** (<LOD-16.0)	**19.9** (17.0-21.1)	1243
	01-02	*	**< LOD**	**10.8** (<LOD-12.3)	**19.4** (16.6-22.3)	**28.8** (23.2-32.1)	1523
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**16.7** (13.8-20.5)	905
	01-02	*	**< LOD**	**< LOD**	**16.7** (13.8-21.0)	**24.9** (19.8-30.1)	1061
Females	99-00	*	**< LOD**	**< LOD**	**13.9** (<LOD-16.2)	**20.0** (17.3-23.5)	992
	01-02	*	**< LOD**	**< LOD**	**18.0** (15.8-22.2)	**28.5** (22.5-33.2)	1220
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	624
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**13.4** (10.7-17.4)	562
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**20.3** (17.0-31.1)	**31.5** (22.9-57.4)	400
	01-02	*	**< LOD**	**11.6** (10.6-13.1)	**22.4** (18.8-25.8)	**28.8** (23.0-37.2)	510
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**12.5** (<LOD-14.5)	**18.1** (14.3-20.8)	715
	01-02	*	**< LOD**	**< LOD**	**18.5** (15.3-22.3)	**28.5** (22.1-32.4)	1046

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 145. 2,2',4,4',5-Pentachlorobiphenyl (PCB 99) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**.085** (.075-.098)	**.114** (.102-.145)	1897
	01-02	*	**< LOD**	**< LOD**	**.117** (.100-.139)	**.183** (.149-.208)	2281
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	654
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**< LOD**	**.093** (.082-.104)	**.126** (.106-.151)	1243
	01-02	*	**< LOD**	**.070** (.063-.079)	**.131** (.109-.157)	**.193** (.161-.212)	1523
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**.107** (.086-.127)	905
	01-02	*	**< LOD**	**< LOD**	**.107** (.090-.137)	**.161** (.120-.197)	1061
Females	99-00	*	**< LOD**	**< LOD**	**.098** (.078-.108)	**.133** (.102-.165)	992
	01-02	*	**< LOD**	**< LOD**	**.129** (.106-.157)	**.200** (.159-.212)	1220
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	624
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**.100** (.068-.120)	562
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**.135** (.106-.175)	**.213** (.151-.395)	400
	01-02	*	**< LOD**	**.071** (.063-.084)	**.129** (.106-.151)	**.187** (.139-.232)	510
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**.085** (.070-.098)	**.111** (.094-.145)	715
	01-02	*	**< LOD**	**< LOD**	**.124** (.098-.159)	**.187** (.156-.211)	1046

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 146. 2,2',4,5,5'-Pentachlorobiphenyl (PCB 101) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1929
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	918
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1011
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	634
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 147. 2,2',4,5,5'-Pentachlorobiphenyl (PCB 101) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1929
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	918
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1011
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	634
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 148. 2,3,3',4',6-Pentachlorobiphenyl (PCB 110) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 149. 2,3,3',4',6-Pentachlorobiphenyl (PCB 110) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 150. 2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1927
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	917
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1010
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	725
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 151. 2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1927
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	917
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1010
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	725
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 152. 2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138 & 158) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	**49.2** (42.9-55.8)	**70.8** (59.8-82.7)	1930
	01-02	**19.9** (18.0-22.0)	**20.0** (18.0-22.8)	**40.4** (35.3-44.9)	**70.1** (61.8-78.8)	**94.6** (82.5-107)	2293
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	**17.0** (13.7-20.2)	**23.1** (17.7-41.2)	748
20 years and older	99-00	*	< LOD	< LOD	**54.7** (47.4-60.8)	**72.8** (66.0-88.9)	1261
	01-02	**23.3** (21.1-25.8)	**23.9** (21.4-26.8)	**44.6** (40.4-49.2)	**73.8** (66.2-83.0)	**99.5** (88.7-109)	1545
Gender							
Males	99-00	*	< LOD	< LOD	**47.2** (<LOD-55.7)	**68.2** (55.7-83.8)	918
	01-02	**20.1** (17.9-22.6)	**20.4** (17.5-23.5)	**39.2** (32.2-46.0)	**68.6** (58.1-82.5)	**94.5** (77.8-109)	1066
Females	99-00	*	< LOD	< LOD	**52.8** (44.7-61.2)	**72.0** (61.1-88.4)	1012
	01-02	**19.7** (17.8-21.7)	**20.2** (18.2-23.1)	**41.8** (37.5-45.9)	**69.6** (63.4-78.5)	**93.9** (80.2-109)	1227
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	**18.6** (13.6-23.4)	**33.3** (26.5-44.2)	**51.6** (42.3-57.6)	559
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**72.1** (61.7-89.4)	**122** (86.5-185)	412
	01-02	**22.3** (19.3-25.6)	**21.8** (18.4-27.1)	**46.5** (38.0-55.6)	**91.5** (70.1-112)	**122** (91.5-169)	513
Non-Hispanic whites	99-00	*	< LOD	< LOD	**49.3** (41.4-55.8)	**70.1** (55.7-85.2)	727
	01-02	**21.5** (19.2-24.0)	**21.9** (19.4-24.8)	**43.0** (37.7-48.0)	**70.6** (62.3-79.7)	**96.1** (79.1-110)	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 153. 2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138 & 158) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	**.338** (.301-.369)	**.457** (.385-.532)	1930
	01-02	**.122** (.110-.135)	**.124** (.112-.139)	**.265** (.231-.292)	**.457** (.405-.508)	**.649** (.558-.698)	2293
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	**.085** (.064-.107)	**.113** (.086-.205)	748
20 years and older	99-00	*	< LOD	< LOD	**.357** (.323-.385)	**.489** (.399-.556)	1261
	01-02	**.148** (.133-.163)	**.152** (.136-.166)	**.292** (.264-.323)	**.505** (.453-.554)	**.676** (.605-.718)	1545
Gender							
Males	99-00	*	< LOD	< LOD	**.323** (.286-.370)	**.422** (.371-.528)	918
	01-02	**.125** (.112-.140)	**.125** (.111-.139)	**.262** (.228-.292)	**.456** (.374-.542)	**.627** (.509-.711)	1066
Females	99-00	*	< LOD	< LOD	**.344** (.303-.373)	**.485** (.385-.540)	1012
	01-02	**.119** (.107-.132)	**.123** (.111-.143)	**.265** (.231-.294)	**.457** (.418-.496)	**.656** (.588-.703)	1227
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	**.114** (.089-.151)	**.233** (.173-.334)	**.349** (.267-.431)	559
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**.473** (.362-.666)	**.828** (.525-1.22)	412
	01-02	**.125** (.108-.146)	**.129** (.093-.157)	**.286** (.231-.347)	**.546** (.424-.675)	**.764** (.564-1.06)	513
Non-Hispanic whites	99-00	*	< LOD	< LOD	**.339** (.296-.371)	**.438** (.372-.532)	727
	01-02	**.133** (.119-.149)	**.136** (.119-.156)	**.280** (.254-.303)	**.464** (.420-.527)	**.647** (.548-.717)	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 154. 2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**13.3** (<LOD-15.2)	1923
	01-02	*	**< LOD**	**< LOD**	**11.0** (<LOD-12.4)	**15.3** (13.6-16.9)	2299
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	667
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**14.2** (<LOD-17.1)	1256
	01-02	*	**< LOD**	**< LOD**	**11.8** (10.7-13.5)	**16.5** (14.6-17.9)	1541
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	915
	01-02	*	**< LOD**	**< LOD**	**11.0** (<LOD-12.9)	**15.3** (12.9-17.2)	1069
Females	99-00	*	**< LOD**	**< LOD**	**< LOD**	**13.4** (<LOD-16.3)	1008
	01-02	*	**< LOD**	**< LOD**	**11.0** (<LOD-12.2)	**15.2** (13.2-17.3)	1230
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	633
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	567
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**16.9** (13.4-22.9)	**28.1** (20.2-42.2)	412
	01-02	*	**< LOD**	**< LOD**	**16.6** (12.7-21.4)	**23.8** (16.9-31.6)	515
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	723
	01-02	*	**< LOD**	**< LOD**	**10.8** (<LOD-12.0)	**15.2** (12.8-16.8)	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 155. 2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**.082** (.074-.101)	1923
	01-02	*	**< LOD**	**< LOD**	**.073** (.067-.082)	**.104** (.092-.118)	2299
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	667
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**.090** (.077-.116)	1256
	01-02	*	**< LOD**	**< LOD**	**.079** (.071-.087)	**.112** (.100-.123)	1541
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	915
	01-02	*	**< LOD**	**< LOD**	**.071** (.061-.083)	**.102** (.090-.123)	1069
Females	99-00	*	**< LOD**	**< LOD**	**< LOD**	**.085** (.074-.114)	1008
	01-02	*	**< LOD**	**< LOD**	**.073** (.066-.083)	**.112** (.089-.121)	1230
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	633
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	567
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**.101** (.082-.129)	**.175** (.117-.274)	412
	01-02	*	**< LOD**	**< LOD**	**.103** (.079-.133)	**.148** (.114-.195)	515
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	723
	01-02	*	**< LOD**	**< LOD**	**.071** (.066-.081)	**.100** (.087-.115)	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 156. 2,2',3,4',5',6-Hexachlorobiphenyl (PCB 149) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 158. 2,2',3,4',5',6-Hexachlorobiphenyl (PCB 149) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 159. 2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 160. 2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 161. 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	77.8 (70.2-87.3)	112 (91.8-130)	1926
	01-02	27.2 (24.7-30.1)	30.1 (26.1-34.1)	57.7 (52.1-63.2)	94.7 (86.5-104)	126 (107-142)	2306
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	12.4 (11.1-14.1)	21.2 (17.4-26.7)	30.3 (23.1-64.7)	757
20 years and older	99-00	*	< LOD	< LOD	83.2 (75.9-91.8)	122 (98.7-139)	1258
	01-02	32.6 (29.5-36.1)	35.0 (31.1-39.0)	62.8 (57.6-68.0)	99.5 (90.7-110)	132 (116-146)	1549
Gender							
Males	99-00	*	< LOD	< LOD	75.0 (66.7-86.2)	111 (87.7-128)	917
	01-02	28.5 (25.5-32.0)	31.5 (26.7-35.2)	57.7 (48.2-65.5)	97.5 (82.1-110)	124 (104-146)	1074
Females	99-00	*	< LOD	< LOD	79.0 (70.2-92.0)	118 (91.4-142)	1009
	01-02	26.1 (23.6-28.8)	29.0 (25.1-33.4)	57.8 (51.9-62.6)	94.2 (87.8-98.2)	126 (105-145)	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	67.5 (59.5-71.8)	634
	01-02	12.5 (10.8-14.4)	10.9 (<LOD-13.0)	24.2 (18.2-33.9)	47.4 (35.7-58.1)	66.7 (55.2-72.3)	567
Non-Hispanic blacks	99-00	*	< LOD	59.1 (<LOD-82.0)	121 (90.3-159)	176 (130-287)	412
	01-02	30.0 (26.2-34.4)	31.0 (25.8-36.4)	64.5 (54.2-82.7)	126 (97.1-152)	170 (126-246)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	76.4 (69.3-83.9)	102 (87.7-125)	725
	01-02	29.9 (26.8-33.4)	32.9 (28.7-36.8)	61.2 (55.8-66.7)	96.3 (86.5-109)	126 (104-142)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 162. 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	**.530** (.493-.561)	**.749** (.613-.843)	1926
	01-02	**.167** (.151-.185)	**.186** (.166-.207)	**.378** (.337-.407)	**.621** (.563-.693)	**.851** (.754-.954)	2306
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	**.064** (.054-.072)	**.104** (.084-.138)	**.147** (.111-.311)	757
20 years and older	99-00	*	< LOD	< LOD	**.561** (.505-.605)	**.786** (.670-.879)	1258
	01-02	**.206** (.187-.228)	**.218** (.197-.250)	**.407** (.379-.446)	**.667** (.595-.742)	**.898** (.815-1.04)	1549
Gender							
Males	99-00	*	< LOD	< LOD	**.531** (.474-.562)	**.691** (.576-.846)	917
	01-02	**.177** (.159-.198)	**.194** (.166-.214)	**.380** (.333-.429)	**.611** (.506-.726)	**.851** (.704-1.04)	1074
Females	99-00	*	< LOD	< LOD	**.530** (.480-.592)	**.759** (.612-.875)	1009
	01-02	**.158** (.142-.175)	**.176** (.150-.205)	**.375** (.335-.395)	**.626** (.565-.712)	**.860** (.756-.954)	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**.468** (.384-.543)	634
	01-02	**.075** (.063-.089)	**.064** (.050-.078)	**.153** (.118-.207)	**.330** (.269-.415)	**.466** (.374-.541)	567
Non-Hispanic blacks	99-00	*	< LOD	**.368** (.273-.514)	**.749** (.619-.894)	**1.27** (.816-1.64)	412
	01-02	**.169** (.146-.195)	**.179** (.144-.202)	**.392** (.331-.486)	**.776** (.578-.954)	**1.04** (.831-1.43)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	**.519** (.480-.563)	**.702** (.583-.846)	725
	01-02	**.185** (.165-.207)	**.207** (.182-.231)	**.393** (.367-.425)	**.637** (.563-.720)	**.838** (.738-.987)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 163. 2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	**23.6** (22.0-25.4)	**30.9** (28.1-35.1)	1798
	01-02	*	< LOD	**17.5** (15.6-19.3)	**26.7** (24.9-29.0)	**35.0** (32.4-37.3)	2301
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	**24.9** (23.3-26.4)	**33.9** (29.6-37.5)	1153
	01-02	*	**11.1** (<LOD-12.0)	**19.1** (17.2-20.9)	**28.2** (26.2-30.9)	**36.8** (33.4-39.4)	1545
Gender							
Males	99-00	*	< LOD	< LOD	**23.8** (22.0-26.3)	**32.6** (28.1-37.0)	863
	01-02	*	**10.7** (<LOD-11.9)	**18.4** (16.3-20.9)	**27.9** (24.7-31.9)	**36.1** (32.1-38.3)	1073
Females	99-00	*	< LOD	< LOD	**22.4** (20.7-25.4)	**29.7** (25.8-36.3)	935
	01-02	*	< LOD	**16.4** (15.0-17.9)	**25.9** (24.0-28.4)	**34.0** (30.4-38.1)	1228
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**23.2** (20.3-26.5)	606
	01-02	*	< LOD	< LOD	**15.4** (11.1-18.6)	**21.1** (17.1-25.1)	565
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**30.9** (23.1-36.3)	**39.6** (33.7-59.1)	382
	01-02	*	< LOD	**18.7** (14.8-23.1)	**32.4** (25.5-43.9)	**44.1** (32.5-61.7)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	**24.0** (22.0-25.8)	**31.0** (26.8-37.3)	658
	01-02	*	**10.9** (<LOD-11.8)	**18.4** (16.8-20.4)	**27.7** (25.4-30.2)	**35.0** (32.3-38.1)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 164. 2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	**.158** (.141-.183)	**.212** (.199-.225)	1798
	01-02	*	< LOD	**.114** (.104-.122)	**.183** (.167-.202)	**.246** (.214-.271)	2301
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	**.172** (.154-.192)	**.221** (.204-.252)	1153
	01-02	*	**.070** (.065-.077)	**.122** (.114-.133)	**.197** (.177-.213)	**.254** (.227-.286)	1545
Gender							
Males	99-00	*	< LOD	< LOD	**.169** (.140-.200)	**.215** (.199-.254)	863
	01-02	*	**.067** (.057-.074)	**.119** (.107-.134)	**.194** (.166-.207)	**.245** (.206-.281)	1073
Females	99-00	*	< LOD	< LOD	**.149** (.130-.167)	**.205** (.186-.229)	935
	01-02	*	< LOD	**.110** (.100-.117)	**.175** (.157-.196)	**.245** (.211-.281)	1228
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**.166** (.126-.187)	606
	01-02	*	< LOD	< LOD	**.104** (.082-.125)	**.154** (.116-.188)	565
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**.188** (.147-.205)	**.258** (.194-.372)	382
	01-02	*	< LOD	**.112** (.094-.141)	**.211** (.151-.271)	**.276** (.209-.394)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	**.164** (.139-.197)	**.214** (.197-.242)	658
	01-02	*	**.067** (.058-.074)	**.119** (.112-.129)	**.187** (.171-.204)	**.247** (.207-.274)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 165. 2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1901
	01-02	*	< LOD	< LOD	< LOD	< LOD	2199
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	*	< LOD	< LOD	< LOD	< LOD	679
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1241
	01-02	*	< LOD	< LOD	< LOD	< LOD	1520
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	911
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	990
	01-02	*	< LOD	< LOD	< LOD	< LOD	1172
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	630
	01-02	*	< LOD	< LOD	< LOD	< LOD	519
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	494
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	706
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 166. 2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1901
	01-02	*	< LOD	< LOD	< LOD	< LOD	2199
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	*	< LOD	< LOD	< LOD	< LOD	679
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1241
	01-02	*	< LOD	< LOD	< LOD	< LOD	1520
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	911
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	990
	01-02	*	< LOD	< LOD	< LOD	< LOD	1172
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	630
	01-02	*	< LOD	< LOD	< LOD	< LOD	519
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	494
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	706
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 167. 2,2',3,3',4,5',6'-Heptachlorobiphenyl (PCB 177) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1873
	01-02	*	< LOD	< LOD	< LOD	< LOD	2287
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	653
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1220
	01-02	*	< LOD	< LOD	< LOD	< LOD	1531
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	887
	01-02	*	< LOD	< LOD	< LOD	< LOD	1065
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	986
	01-02	*	< LOD	< LOD	< LOD	< LOD	1222
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	562
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	399
	01-02	*	< LOD	< LOD	< LOD	10.6 (<LOD-12.3)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	698
	01-02	*	< LOD	< LOD	< LOD	< LOD	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 168. 2,2',3,3',4,5',6'-Heptachlorobiphenyl (PCB 177) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1873
	01-02	*	< LOD	< LOD	< LOD	< LOD	2287
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	653
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1220
	01-02	*	< LOD	< LOD	< LOD	< LOD	1531
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	887
	01-02	*	< LOD	< LOD	< LOD	< LOD	1065
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	986
	01-02	*	< LOD	< LOD	< LOD	< LOD	1222
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	562
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	399
	01-02	*	< LOD	< LOD	< LOD	.064 (.042-.099)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	698
	01-02	*	< LOD	< LOD	< LOD	< LOD	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 169. 2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1932
	01-02	*	< LOD	< LOD	< LOD	< LOD	2299
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1263
	01-02	*	< LOD	< LOD	< LOD	< LOD	1541
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1013
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	415
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 170. 2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1932
	01-02	*	< LOD	< LOD	< LOD	< LOD	2299
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1263
	01-02	*	< LOD	< LOD	< LOD	< LOD	1541
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1013
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	415
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 171. 2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	37.4 (32.7-41.8)	62.0 (56.6-66.6)	79.0 (72.1-89.2)	1924
	01-02	19.2 (17.4-21.1)	21.8 (19.0-24.6)	42.2 (38.3-47.5)	69.7 (63.7-75.9)	87.0 (83.3-93.0)	2302
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	12.2 (<LOD-14.8)	21.3 (14.2-26.0)	755
20 years and older	99-00	*	< LOD	41.0 (37.6-45.2)	65.5 (60.6-69.4)	83.8 (75.6-96.1)	1257
	01-02	23.0 (20.8-25.5)	26.4 (22.7-28.5)	46.7 (41.4-51.1)	74.0 (66.7-79.8)	90.7 (85.0-99.5)	1547
Gender							
Males	99-00	*	< LOD	40.5 (34.5-45.0)	65.1 (58.6-71.4)	83.8 (75.8-96.3)	919
	01-02	21.1 (18.8-23.7)	25.1 (21.2-30.0)	46.7 (39.8-51.8)	73.8 (63.2-79.8)	86.9 (78.0-99.4)	1073
Females	99-00	*	< LOD	34.4 (29.8-39.3)	56.7 (52.2-62.6)	74.6 (66.6-90.5)	1005
	01-02	17.5 (15.9-19.3)	18.3 (16.0-21.6)	39.6 (34.8-43.9)	64.0 (57.9-72.0)	87.9 (79.1-98.1)	1229
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	41.7 (33.2-50.5)	56.6 (49.7-63.8)	633
	01-02	*	< LOD	18.0 (11.4-22.2)	36.9 (28.2-45.7)	54.2 (42.2-60.0)	566
Non-Hispanic blacks	99-00	*	< LOD	39.1 (32.2-48.4)	78.4 (64.3-93.7)	117 (89.6-144)	414
	01-02	19.5 (16.5-23.1)	20.7 (16.9-23.8)	48.4 (36.7-57.9)	89.6 (73.7-101)	116 (96.1-167)	514
Non-Hispanic whites	99-00	*	< LOD	39.9 (34.5-45.3)	62.0 (56.5-68.6)	79.0 (71.3-91.4)	719
	01-02	21.4 (19.1-23.9)	24.8 (21.4-27.9)	45.6 (40.2-51.0)	72.3 (63.8-78.0)	87.9 (83.8-94.3)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 172 2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	.245 (.224-.266)	.414 (.373-.452)	.535 (.493-.604)	1924
	01-02	.118 (.106-.130)	.140 (.120-.155)	.278 (.253-.304)	.458 (.401-.508)	.605 (.541-.692)	2302
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	.061 (.053-.075)	.092 (.068-.135)	755
20 years and older	99-00	*	< LOD	.266 (.244-.296)	.441 (.407-.482)	.558 (.503-.617)	1257
	01-02	.146 (.131-.162)	.168 (.150-.188)	.302 (.275-.337)	.490 (.429-.555)	.637 (.572-.738)	1547
Gender							
Males	99-00	*	< LOD	.257 (.224-.300)	.459 (.365-.506)	.568 (.501-.648)	919
	01-02	.131 (.117-.147)	.165 (.137-.197)	.296 (.258-.339)	.479 (.405-.554)	.616 (.526-.716)	1073
Females	99-00	*	< LOD	.231 (.195-.266)	.377 (.344-.413)	.510 (.430-.557)	1005
	01-02	.106 (.096-.117)	.113 (.100-.135)	.261 (.228-.281)	.415 (.375-.470)	.604 (.519-.701)	1229
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	.275 (.198-.324)	.390 (.316-.452)	633
	01-02	*	< LOD	.110 (.079-.157)	.259 (.198-.307)	.353 (.279-.419)	566
Non-Hispanic blacks	99-00	*	< LOD	.245 (.188-.298)	.497 (.349-.656)	.727 (.534-1.04)	414
	01-02	.110 (.092-.131)	.119 (.091-.142)	.287 (.215-.345)	.560 (.436-.651)	.719 (.523-1.01)	514
Non-Hispanic whites	99-00	*	< LOD	.263 (.234-.299)	.430 (.377-.470)	.537 (.483-.604)	719
	01-02	.132 (.118-.148)	.160 (.142-.180)	.292 (.262-.327)	.471 (.405-.532)	.617 (.526-.730)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 173. 2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1928
	01-02	*	< LOD	< LOD	< LOD	< LOD	2306
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	757
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1074
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1009
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	12.7 (<LOD-14.9)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	722
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 174. 2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1928
	01-02	*	< LOD	< LOD	< LOD	< LOD	2306
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	757
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1074
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1009
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	.082 (.057-.105)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	722
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 175. 2,2',3,4',5,5',6-Heptachlorobiphenyl (PCB 187) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**17.7** (15.6-20.0)	**24.6** (22.0-27.6)	1930
	01-02	*	**< LOD**	**12.1** (10.5-13.7)	**21.7** (19.6-23.7)	**27.9** (26.8-29.7)	2307
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	667
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**< LOD**	**19.2** (16.8-21.8)	**25.9** (24.1-29.0)	1263
	01-02	*	**< LOD**	**13.3** (12.0-15.2)	**23.0** (20.9-24.7)	**29.2** (27.3-32.0)	1549
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**17.7** (15.7-19.6)	**25.9** (21.6-29.0)	917
	01-02	*	**< LOD**	**12.7** (<LOD-15.8)	**22.3** (19.4-24.1)	**27.7** (25.1-30.1)	1075
Females	99-00	*	**< LOD**	**< LOD**	**17.7** (15.1-21.7)	**24.2** (21.6-27.0)	1013
	01-02	*	**< LOD**	**11.9** (<LOD-13.0)	**21.3** (18.5-23.5)	**28.5** (26.2-31.3)	1232
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**17.3** (15.1-19.1)	636
	01-02	*	**< LOD**	**< LOD**	**10.5** (<LOD-13.4)	**15.7** (12.5-18.0)	567
Non-Hispanic blacks	99-00	*	**< LOD**	**15.3** (<LOD-21.1)	**31.1** (26.0-39.0)	**47.1** (36.6-72.1)	412
	01-02	*	**< LOD**	**16.3** (12.3-21.0)	**30.0** (22.9-40.6)	**43.5** (30.3-61.9)	515
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**16.8** (14.9-18.6)	**22.0** (19.1-25.2)	727
	01-02	*	**< LOD**	**12.5** (10.7-14.5)	**21.7** (18.9-23.7)	**27.4** (25.2-29.2)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 176. 2,2',3,4',5,5',6-Heptachlorobiphenyl (PCB 187) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	**.120** (.108-.134)	**.166** (.143-.181)	1930
	01-02	*	< LOD	**.080** (.072-.090)	**.140** (.128-.159)	**.198** (.177-.218)	2307
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	**.128** (.112-.141)	**.176** (.155-.191)	1263
	01-02	*	< LOD	**.090** (.077-.100)	**.149** (.132-.174)	**.210** (.186-.231)	1549
Gender							
Males	99-00	*	< LOD	< LOD	**.123** (.099-.139)	**.178** (.141-.198)	917
	01-02	*	< LOD	**.082** (.072-.098)	**.144** (.130-.163)	**.187** (.165-.230)	1075
Females	99-00	*	< LOD	< LOD	**.116** (.106-.130)	**.162** (.136-.179)	1013
	01-02	*	< LOD	**.076** (.067-.086)	**.134** (.119-.150)	**.202** (.178-.217)	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	**.118** (.100-.134)	636
	01-02	*	< LOD	< LOD	**.078** (.058-.098)	**.104** (.091-.121)	567
Non-Hispanic blacks	99-00	*	< LOD	**.090** (.070-.132)	**.203** (.164-.226)	**.290** (.207-.531)	412
	01-02	*	< LOD	**.102** (.074-.119)	**.192** (.149-.258)	**.286** (.187-.382)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	**.112** (.099-.127)	**.147** (.134-.168)	727
	01-02	*	< LOD	**.081** (.072-.092)	**.136** (.123-.157)	**.191** (.167-.217)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 177. 2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	11.1 (<LOD-11.9)	18.1 (16.5-19.5)	23.7 (20.9-27.0)	2279
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	746
20 years and older	01-02	*	< LOD	11.9 (11.0-13.2)	18.9 (17.7-20.5)	25.3 (22.7-28.0)	1533
Gender							
Males	01-02	*	< LOD	12.2 (10.6-13.9)	19.1 (17.1-21.1)	25.2 (21.2-28.3)	1059
Females	01-02	*	< LOD	< LOD	17.0 (14.7-18.8)	21.7 (19.3-26.2)	1220
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	13.9 (10.5-17.6)	561
Non-Hispanic blacks	01-02	*	< LOD	12.2 (<LOD-15.3)	22.6 (18.0-27.5)	29.8 (23.7-41.1)	508
Non-Hispanic whites	01-02	*	< LOD	11.9 (10.9-13.1)	18.7 (17.1-20.2)	24.1 (20.9-28.0)	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 178. 2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	50th	75th	90th	95th	Sample size
Total, age 12 and older	01-02	*	< LOD	**.070** (.064-.078)	**.123** (.104-.139)	**.162** (.146-.187)	2279
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	746
20 years and older	01-02	*	< LOD	**.079** (.070-.086)	**.132** (.109-.147)	**.174** (.149-.197)	1533
Gender							
Males	01-02	*	< LOD	**.078** (.069-.087)	**.132** (.106-.152)	**.169** (.147-.206)	1059
Females	01-02	*	< LOD	< LOD	**.109** (.094-.132)	**.147** (.133-.176)	1220
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	**.099** (.080-.114)	561
Non-Hispanic blacks	01-02	*	< LOD	**.079** (.059-.089)	**.138** (.101-.175)	**.195** (.138-.253)	508
Non-Hispanic whites	01-02	*	< LOD	**.076** (.069-.085)	**.129** (.109-.146)	**.165** (.146-.193)	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 179. 2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2230
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	716
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1514
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1035
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1195
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	544
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	490
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1037

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 180. 2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2230
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	716
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1514
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1035
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1195
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	544
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	490
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1037

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 181. 2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB 196 & 203) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	**14.1** (13.0-15.7)	**19.2** (17.4-20.9)	2299
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	01-02	*	< LOD	< LOD	**15.0** (13.7-16.9)	**19.9** (18.2-21.4)	1544
Gender							
Males	01-02	*	< LOD	< LOD	**14.6** (13.3-16.5)	**19.4** (16.3-21.2)	1071
Females	01-02	*	< LOD	< LOD	**13.8** (11.9-15.9)	**19.0** (17.0-21.3)	1228
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	**11.1** (<LOD-12.5)	565
Non-Hispanic blacks	01-02	*	< LOD	< LOD	**17.5** (14.0-21.0)	**22.8** (19.6-30.2)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	**14.6** (13.5-16.2)	**19.5** (18.1-21.3)	1058

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 182. 2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB 196 & 203) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	.095 (.086-.105)	.127 (.113-.140)	2299
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	01-02	*	< LOD	< LOD	.103 (.092-.111)	.133 (.114-.150)	1544
Gender							
Males	01-02	*	< LOD	< LOD	.100 (.086-.115)	.126 (.110-.150)	1071
Females	01-02	*	< LOD	< LOD	.092 (.078-.101)	.126 (.110-.138)	1228
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	.071 (.060-.089)	565
Non-Hispanic blacks	01-02	*	< LOD	< LOD	.108 (.086-.135)	.148 (.108-.208)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	.099 (.090-.110)	.131 (.112-.143)	1058

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 183. 2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	**17.0** (15.4-18.1)	**22.4** (19.9-25.9)	2292
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	01-02	*	< LOD	**10.5** (<LOD-11.8)	**17.8** (16.2-19.2)	**24.4** (20.7-27.4)	1536
Gender							
Males	01-02	*	< LOD	< LOD	**17.3** (15.4-18.7)	**21.2** (19.2-24.5)	1066
Females	01-02	*	< LOD	< LOD	**16.1** (14.5-17.9)	**22.7** (19.4-27.3)	1226
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	**12.1** (<LOD-14.2)	565
Non-Hispanic blacks	01-02	*	< LOD	**12.4** (<LOD-15.2)	**21.9** (17.0-28.1)	**30.7** (22.4-37.4)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	**17.2** (15.9-18.9)	**22.6** (19.8-26.3)	1051

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 184. 2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	.108 (.100-.126)	.151 (.135-.168)	2292
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	01-02	*	< LOD	.069 (.060-.079)	.122 (.105-.136)	.158 (.139-.184)	1536
Gender							
Males	01-02	*	< LOD	< LOD	.108 (.098-.133)	.150 (.133-.179)	1066
Females	01-02	*	< LOD	< LOD	.111 (.098-.125)	.151 (.132-.167)	1226
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	.087 (.066-.107)	565
Non-Hispanic blacks	01-02	*	< LOD	.069 (.054-.087)	.135 (.104-.179)	.182 (.133-.301)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	.114 (.102-.130)	.150 (.132-.170)	1051

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 185. 2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206) (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2208
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	723
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1485
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1033
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1175
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	533
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	483
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1034

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 186. 2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206) (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2208
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	723
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1485
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1033
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1175
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	533
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	483
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1034

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Third National Report on Human Exposure to Environmental Chemicals

Results by Chemical Group

Phthalates

Phthalates

General Information

Phthalates are industrial chemicals that can act as plasticizers, which, when added to plastic, impart flexibility and resilience. Many consumer products contain phthalates. Among these products are vinyl flooring; adhesives; detergents; lubricating oils; solvents; automotive plastics; plastic clothing, such as raincoats; and personal-care products, such as soap, shampoo, deodorants, fragrances, hair spray, nail polish; and some medical pharmaceuticals. Phthalates are widely used in flexible polyvinyl chloride plastics, such as plastic bags, food packaging, garden hoses, inflatable recreational toys, blood-storage bags, intravenous medical tubing, and children's toys. Soil and water contamination can be greatest in areas of industrial use and waste disposal.

People are exposed through direct contact with products that contain phthalates or through food that is in contact with packaging that contains phthalates. For the general population, the oral route of exposure has been considered a major route. However, both population studies (Adibi et al., 2003) and occupational studies (Dirven et al., 1993; Liss et al., 1985; Nielsen et al., 1985) have shown that personal air-sample levels of phthalate diesters correlate modestly well with concentrations of urinary metabolites, suggesting that inhalation is an important route of exposure (Otake et al., 2004). In contrast, urinary levels in children did not correlate with home- dust measurements of phthalate content (Becker et al., 2004). Generally, phthalates are metabolized and excreted quickly and do not accumulate in the body (Anderson et al., 2001). Ingested phthalate diesters are initially hydrolyzed in the intestine to their corresponding monoester, which is then absorbed. (Albro et al., 1982; Albro and Lavenhar, 1989). Absorbed

monoester metabolites may be further oxidized in the body. Table 188 shows the monoester metabolites and other oxidized metabolites of phthalates measured in this *Report* and also includes their commonly used abbreviations.

Several of the phthalates produce testicular injury, liver injury, liver cancer, and teratogenicity in rodent studies, but these effects either have not been demonstrated when tested in non-human primates or people or have not been investigated. The monoester metabolites are thought to mediate toxic effects for some of the phthalates. Phthalates have weak or no estrogenic, antiestrogenic, or androgenic activity *in vitro*, although not all metabolites have been tested (Jobling et al., 1995; Coldham et al., 1997; Harris et al., 1997; Parks et al., 2000; Okubo et al., 2003) and have shown no estrogenic activity *in vivo* (Zacharewski et al., 1998; Milligan et al., 1998). However, in animal studies, several phthalates show antiandrogenic activity and exposure to high doses of di-2-ethylhexyl phthalate (DEHP), dibutyl phthalate (DBP), and benzylbutyl phthalate (BzBP) during the fetal period have produced lowered testosterone levels, testicular atrophy, and Sertoli cell abnormalities in male animals and, at higher doses, ovarian abnormalities in female animals (see reviews by the Center for the Evaluation of Risks to Human Reproduction, 2000; McKee et al., 2004; and Jarfelt et al., 2005). Such effects may also be mediated through an inhibition of testicular, adrenal, or ovarian steroidogenesis. Phthalate levels in men from an infertility clinic have been associated with several parameters of sperm analysis (Duty et al., 2003; Duty et al., 2004; Duty et al., 2005).

Differences between human and rodent studies in the timing of dosages relative to critical developmental

Table 187. Phthalates and their metabolites

Phthalate name (CAS number)	Abbreviation	Urinary metabolite (CAS number)	Abbreviation
Dimethyl phthalate (131-11-3)	DMP	Mono-methyl phthalate (4376-18-5)	MMP
Diethyl phthalate (84-66-2)	DEP	Mono-ethyl phthalate (2306-33-4)	MEP
Dibutyl phthalates (84-74-2)	DBP	Mono-n-butyl phthalate (131-70-4)	MnBP
		Mono-isobutyl phthalate	MiBP
Benzylbutyl phthalate (85-68-7)	BzBP	Mono-benzyl phthalate (2528-16-7) (some mono-n-butyl phthalate)	MBzP
Dicyclohexyl phthalate (84-61-7)	DCHP	Mono-cyclohexyl phthalate (7517-36-4)	MCHP
Di-2-ethylhexyl phthalate (117-81-7)	DEHP	Mono-2-ethylhexyl phthalate (4376-20-9)	MEHP
		Mono-(2-ethyl-5-oxohexyl) phthalate	MEOHP
		Mono-(2-ethyl-5-hydroxyhexyl) phthalate	MEHHP
Di-n-octyl phthalate (117-84-0)	DOP	Mono-n-octyl phthalate (5393-19-1)	MOP
		Mono-(3-carboxypropyl) phthalate	MCPP
Di-isononyl phthalate (28553-12-0)	DiNP	Mono-isononyl phthalate	MiNP

periods and in the amounts of putative metabolites generated in animals versus humans, as well as the large doses given to test animals, make it difficult to translate the effects observed in animals to health effects in people. For instance, blood levels of phthalate monoesters can be higher in rodents than in non-human primates that are given equivalent doses due to the greater absorption in rodents or possibly greater hydrolysis to the monoester metabolite (Kessler et al., 2004; Lake et al., 1977). In addition, phthalates cause peroxisomal proliferation, which may be a pathway to the development of liver cancers in animals. However, peroxisomal proliferation may be a less relevant pathway in people (Melnick, 2001).

The Center for the Evaluation of Risks to Human Reproduction of the NTP has reviewed the reproductive effects for many of the phthalates (see http://cerhr.niehs. nih.gov/news/phthalates/monographs.html). Information about external exposure (i.e., environmental levels) and health effects is also available for some phthalates from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/ toxprofiles.

Interpreting Levels of Urinary Phthalate Metabolites Reported in the Tables

Urinary levels of phthalate metabolites were measured in a subsample of NHANES participants aged 6 years and older. Participants were randomly selected within the specified age range to be a representative sample of the U.S. population. The concentrations for the monoester phthalate metabolites in the NHANES 2001-2002 subsample appear roughly similar to concentrations to those seen in an earlier survey of U.S. residents (Blount et al., 2000), pregnant women in New York City (Adibi et al., 2003), and in men from a Boston infertility clinic (Duty et al., 2004). In a small sample of Germans aged 7-64 years, median levels of mono-2-ethylhexyl phthalate (MEHP), mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP) and mono-benzyl phthalate (MBzP) were about two-fold higher than median levels in the NHANES 2001-2002 subsample; the median level of mono-butyl phthalate (MBP) was about six-fold higher; and the median level of mono-ethyl phthalate (MEP) was slightly lower than the median levels of these metabolites in the NHANES 1999-2002 subsamples (Koch et al., 2003).

With the exception of MEP, the NHANES 1999-2000 and 2001-2002 subsamples showed that children aged 6-11 years excreted higher concentrations of metabolites than did older age groups, a finding that has been noted in other studies of German adults and children for DEHP metabolites (Koch et al., 2004; Becker et al., 2004). The 1999-2000 and 2001-2002 NHANES subsamples also showed other differences in concentrations of specific phthalate metabolites by age, gender, and race/ethnicity (see data on individual phthalates). It is known that there is variation from person to person in the proportions or amounts of the metabolite excreted after people received similar doses (Anderson et al., 2001) as well as variation in the same person during repetitive monitoring (Hauser et al., 2004; Hoppin et al., 2002). The proportions of each metabolite for a given phthalate may vary also by differing routes of exposure (Liss et al., 1985; Peck and Albro, 1982).

Differences among the levels of various phthalate metabolites within a person may be due to differences in either exposure or pharmacokinetics for each of those phthalates. For instance, DEHP has been one of the more widely used phthalates, yet levels of MEHP are found in lower concentrations than MEP, MBP, or MBzP. It is now known that a greater proportion of the dose is accounted by other DEHP urinary metabolites (e.g., MEOHP and MEHHP), which demonstrate higher urinary concentrations than MEHP (Barr et al., 2003; Koch et al., 2003). Likewise, the low detection rates for some of the monoester metabolites of the long alkyl chain phthalates (di-isononyl and dioctyl) may be due to lower exposure to these compounds, to less of the parent compound being metabolized to the measured monoester metabolite, or, as seen with DEHP, to further oxidation to other unmeasured metabolites.

Finding a measurable amount of one or more phthalate metabolites in urine does not mean that they cause an adverse health effect. Whether these levels of phthalate metabolites are cause for health concern is not yet known; more research is needed. These levels of phthalate metabolites in urine provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of phthalates than levels found in the general population. These data will also help scientists plan and conduct research on phthalate exposure and health effects.

Mono-methyl Phthalate

CAS No. 4376-18-5

Metabolite of Dimethyl Phthalate, CAS No.131-11-3

General Information

Dimethyl phthalate (DMP) is used to manufacture solid rocket propellant and some consumer products such as insect repellants and plastics. People exposed to DMP will excrete mono-methyl phthalate (MMP) in their urine. The amount of MMP is an indicator of how much contact with DMP has occurred. Workplace air standards for external exposure to dimethyl phthalate have been established by NIOSH and ACGIH. DMP has not been completely classified with respect to carcinogenicity by IARC and NTP.

Comparing Adjusted Geometric Means

MMP was not measured in NHANES 1999-2000. For NHANES 2001-2002, geometric mean levels of urinary MMP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). Adjusted geometric mean levels of urinary MMP were found to be higher in children aged 6-11 years than in either of the groups aged 12-19 years and 20 years and older and levels in the group aged 12-19 years were higher than in the group aged 20 years and older. Females had higher levels than males. It is unknown whether these differences associated with age and gender represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 188. Mono-methyl phthalate

Geometric mean and selected percentiles of urine concentrations (in μg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**1.15** (.985-1.34)	**1.50** (1.30-1.70)	**3.30** (2.80-3.70)	**6.00** (5.10-7.40)	**9.80** (8.00-12.5)	2782
Age group							
6-11 years	01-02	**1.45** (1.13-1.87)	**1.80** (1.40-2.60)	**4.00** (3.30-4.70)	**6.90** (6.00-8.00)	**11.6** (7.60-20.8)	393
12-19 years	01-02	**1.59** (1.28-1.96)	**2.10** (1.80-2.50)	**3.80** (3.30-4.70)	**8.50** (5.30-10.5)	**12.7** (9.60-17.8)	742
20 years and older	01-02	**1.06** (.904-1.25)	**1.40** (1.10-1.60)	**3.10** (2.40-3.50)	**5.60** (4.60-6.90)	**9.10** (7.10-11.8)	1647
Gender							
Males	01-02	**1.17** (.962-1.43)	**1.50** (1.20-1.80)	**3.30** (2.80-3.80)	**5.90** (4.80-7.90)	**9.10** (7.10-12.7)	1371
Females	01-02	**1.13** (.973-1.31)	**1.30** (1.10-1.60)	**3.30** (2.80-3.70)	**6.40** (4.90-7.80)	**10.3** (8.00-15.2)	1411
Race/ethnicity							
Mexican Americans	01-02	**1.21** (1.02-1.45)	**1.50** (1.30-1.70)	**3.30** (2.70-3.90)	**5.50** (4.70-7.30)	**8.30** (6.40-15.2)	677
Non-Hispanic blacks	01-02	**1.64** (1.37-1.98)	**2.00** (1.70-2.50)	**4.40** (3.50-5.10)	**8.30** (6.20-10.1)	**10.8** (9.50-13.4)	703
Non-Hispanic whites	01-02	**1.08** (.906-1.29)	**1.40** (1.10-1.60)	**3.10** (2.50-3.60)	**5.60** (4.60-6.60)	**9.70** (7.10-14.0)	1216

Table 189. Mono-methyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**1.08** (.935-1.24)	**1.33** (1.13-1.54)	**2.62** (2.36-2.95)	**5.00** (3.96-6.00)	**7.97** (6.07-10.9)	2772
Age group							
6-11 years	01-02	**1.65** (1.28-2.13)	**2.32** (1.72-2.86)	**3.93** (3.27-4.71)	**6.77** (5.75-9.41)	**12.5** (7.60-22.5)	392
12-19 years	01-02	**1.23** (1.01-1.48)	**1.51** (1.32-1.81)	**2.84** (2.52-3.33)	**5.36** (3.68-6.39)	**7.27** (5.64-11.4)	742
20 years and older	01-02	**1.00** (.866-1.16)	**1.21** (1.04-1.40)	**2.44** (2.14-2.65)	**4.49** (3.49-5.88)	**7.72** (5.54-11.7)	1638
Gender							
Males	01-02	**.953** (.792-1.15)	**1.17** (1.01-1.40)	**2.38** (2.03-2.78)	**4.12** (3.45-5.64)	**6.42** (4.94-9.32)	1367
Females	01-02	**1.21** (1.06-1.38)	**1.45** (1.24-1.82)	**2.86** (2.60-3.04)	**5.45** (4.55-7.07)	**10.0** (7.20-15.3)	1405
Race/ethnicity							
Mexican Americans	01-02	**1.14** (.969-1.34)	**1.47** (1.29-1.63)	**2.48** (2.19-2.94)	**4.19** (3.75-5.79)	**7.53** (4.76-15.2)	674
Non-Hispanic blacks	01-02	**1.15** (.945-1.40)	**1.39** (1.28-1.67)	**2.69** (2.35-2.93)	**4.86** (4.20-5.88)	**8.02** (5.85-10.9)	702
Non-Hispanic whites	01-02	**1.07** (.913-1.25)	**1.30** (1.05-1.58)	**2.60** (2.32-2.97)	**5.23** (3.72-6.82)	**8.29** (6.08-12.6)	1211

Mono-ethyl Phthalate

CAS No. 2306-33-4

Metabolite of Diethyl Phthalate, CAS No. 84-66-2

General Information

Diethyl phthalate (DEP) is an industrial solvent used in many consumer products, particularly those containing fragrances. Products that may contain DEP include perfume, cologne, deodorant, soap, shampoo, and hand lotion. People exposed to DEP will excrete monoethyl phthalate (MEP) in their urine. Workplace air standards for external exposure to DEP have been established by ACGIH or recommended by NIOSH. It has not been completely classified with respect to its carcinogenicity by IARC and NTP.

Interpreting Levels of Urinary Mono-ethyl Phthalate in the Tables

MEP levels in the NHANES 2001-2002 subsample appear similar to levels in a small sample of pregnant women in New York City (Adibi et al., 2003). MEP levels found in a small sample of German residents (Koch et al., 2003) are slightly lower than levels documented in this *Report*.

Table 190. Mono-ethyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**179** (156-204)	**164** (136-201)	**450** (370-538)	**1260** (1010-1480)	**2840** (2150-3770)	2536
	01-02	**178** (159-199)	**169** (141-194)	**465** (415-527)	**1230** (1040-1440)	**2500** (1860-3220)	2782
Age group							
6-11 years	99-00	**91.3** (74.8-111)	**74.7** (62.1-93.7)	**197** (129-249)	**378** (290-730)	**756** (379-1070)	328
	01-02	**85.1** (71.2-102)	**71.9** (61.9-92.5)	**181** (142-217)	**444** (315-636)	**808** (572-1090)	393
12-19 years	99-00	**211** (160-278)	**193** (141-256)	**558** (419-818)	**1510** (1050-2150)	**3260** (1550-4420)	752
	01-02	**197** (159-243)	**184** (148-227)	**479** (387-651)	**1260** (983-1480)	**2060** (1470-3050)	742
20 years and older	99-00	**190** (164-219)	**180** (140-220)	**482** (390-590)	**1340** (1010-1660)	**3480** (2230-4640)	1456
	01-02	**191** (171-214)	**181** (152-212)	**498** (441-567)	**1350** (1060-1660)	**2720** (2160-3670)	1647
Gender							
Males	99-00	**179** (149-215)	**154** (119-197)	**523** (372-650)	**1430** (1020-2280)	**3480** (2130-4560)	1214
	01-02	**182** (157-211)	**171** (139-199)	**502** (419-603)	**1450** (1060-2110)	**3050** (2110-4390)	1371
Females	99-00	**178** (154-206)	**174** (138-210)	**425** (350-508)	**977** (880-1230)	**2230** (1370-3880)	1322
	01-02	**174** (153-198)	**167** (139-194)	**427** (387-498)	**1050** (879-1310)	**1840** (1490-2500)	1411
Race/ethnicity							
Mexican Americans	99-00	**181** (157-209)	**174** (146-210)	**441** (390-541)	**1250** (851-1510)	**1720** (1460-2130)	813
	01-02	**226** (195-262)	**220** (190-264)	**530** (444-660)	**1490** (1050-2110)	**2590** (1540-4460)	677
Non-Hispanic blacks	99-00	**322** (275-377)	**306** (256-350)	**789** (635-949)	**1880** (1410-2270)	**3600** (2130-4640)	603
	01-02	**352** (324-384)	**357** (290-407)	**839** (709-1090)	**2160** (1620-2470)	**3540** (2810-5070)	703
Non-Hispanic whites	99-00	**152** (133-175)	**133** (108-157)	**366** (287-482)	**977** (798-1340)	**2470** (1590-3880)	908
	01-02	**158** (141-178)	**147** (119-177)	**413** (366-451)	**1020** (905-1230)	**2310** (1560-2720)	1216

Comparing Adjusted Geometric Means

Geometric mean levels of urinary MEP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2001-2002, the adjusted geometric mean levels of urinary MEP were lower in the group aged 6-11 years than either of the other age groups and the group aged 12-19 was had lower levels than the group 20 years and older. This age-related trend is opposite the direction shown for other phthalates. Non-Hispanic whites had lower levels than non-Hispanic blacks or Mexican Americans. Levels in non-Hispanic blacks were not significantly higher than in Mexican Americans. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 191. Mono-ethyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**163** (149-178)	**141** (129-157)	**360** (307-422)	**898** (753-1180)	**1950** (1670-2310)	2536
	01-02	**167** (150-185)	**147** (133-161)	**388** (333-435)	**975** (804-1180)	**1860** (1430-2200)	2772
Age group							
6-11 years	99-00	**92.6** (77.9-110)	**79.4** (65.7-110)	**165** (127-208)	**341** (219-554)	**625** (400-784)	328
	01-02	**96.9** (82.4-114)	**81.2** (66.3-105)	**171** (135-224)	**494** (290-802)	**837** (512-1320)	392
12-19 years	99-00	**142** (119-169)	**122** (93.0-156)	**361** (275-495)	**879** (676-1260)	**1550** (1000-2000)	752
	01-02	**152** (126-184)	**140** (111-180)	**325** (249-409)	**808** (590-1100)	**1330** (868-1840)	742
20 years and older	99-00	**179** (161-199)	**154** (136-177)	**390** (336-452)	**1010** (803-1460)	**2170** (1790-3350)	1456
	01-02	**181** (164-200)	**159** (143-182)	**419** (363-486)	**1060** (883-1320)	**2080** (1490-2790)	1638
Gender							
Males	99-00	**141** (124-159)	**120** (107-134)	**324** (249-415)	**996** (693-1480)	**1940** (1460-2900)	1214
	01-02	**147** (129-168)	**126** (110-147)	**347** (279-418)	**1160** (843-1480)	**2080** (1490-3030)	1367
Females	99-00	**187** (165-211)	**157** (142-179)	**377** (307-495)	**821** (697-1170)	**1920** (1170-3410)	1322
	01-02	**187** (166-210)	**171** (148-187)	**410** (356-476)	**860** (712-1100)	**1430** (1190-2010)	1405
Race/ethnicity							
Mexican Americans	99-00	**164** (142-190)	**154** (136-174)	**382** (314-472)	**814** (673-974)	**1330** (974-1920)	813
	01-02	**214** (183-250)	**199** (166-242)	**472** (396-572)	**1070** (862-1650)	**1900** (1330-2630)	674
Non-Hispanic blacks	99-00	**208** (183-236)	**196** (166-228)	**443** (390-505)	**1030** (762-1700)	**1880** (1230-2590)	603
	01-02	**247** (225-271)	**227** (185-270)	**557** (478-618)	**1230** (961-1480)	**2070** (1550-2800)	702
Non-Hispanic whites	99-00	**149** (135-165)	**128** (111-142)	**313** (239-387)	**834** (655-1390)	**1950** (1480-2740)	908
	01-02	**156** (141-173)	**136** (124-149)	**337** (288-402)	**911** (712-1160)	**1590** (1320-2170)	1211

Figure 20. Mono-ethyl phthalate (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Mono-n-butyl Phthalate

CAS No. 131-70-4

Metabolite of Di-n-butyl Phthalate, CAS No. 84-74-2 and Benzylbutyl Phthalate, CAS No. 85-68-7

Mono-isobutyl Phthalate

Metabolite of Di-isobutyl Phthalates, CAS No. 84-74-2

General Information

Dibutyl phthalates (di-n-butyl, di-isobutyl) are industrial solvents or additives used in many consumer products such as nail polish, cosmetics, some printing inks, pharmaceutical coatings, and insecticides. People exposed to dibutyl phthalates will excrete mono-butyl phthalates (n-butyl, iso-butyl) in their urine. Small amounts of mono-3-carboxypropyl phthalate are also produced from di-n-butyl phthalate. In addition, exposure to benzylbutyl phthalate (BzBP) will also result in small amounts of mono-n-butyl phthalate appearing in the urine (Anderson et al., 2001).

Workplace air standards for external exposure to dibutyl phthalate have been established by NIOSH and ACGIH. Dibutyl phthalates can produce reproductive toxicity in animals (Center for the Evaluation of Risks to Human Reproduction, 2003). Dibutyl phthalates have not been completely classified with respect to carcinogenicity by IARC or NTP.

Interpreting Levels of Urinary Mono-n-butyl and Mono-isobutyl Phthalates in the Tables

Mono-butyl phthalate (MBP) levels in the NHANES 1999-2000 subsample represented the sum of both

Table 192. Mono-n-butyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)								Sample size
			50th		75th		90th		95th		
Total, age 6 and older	99-00	**24.6** (22.1-27.4)	**26.0** (23.6-29.2)		**51.6** (44.4-59.8)		**98.6** (90.2-114)		**149** (121-169)		2541
	01-02	**18.9** (17.4-20.6)	**20.4** (19.1-21.7)		**40.4** (36.5-44.2)		**73.6** (65.3-85.4)		**108** (94.1-122)		2782
Age group											
6-11 years	99-00	**41.4** (35.6-48.0)	**40.0** (36.2-49.2)		**75.5** (59.1-92.8)		**124** (98.4-159)		**163** (127-279)		328
	01-02	**31.1** (26.6-36.5)	**32.4** (25.5-36.4)		**62.1** (51.3-76.9)		**107** (84.3-136)		**157** (110-290)		393
12-19 years	99-00	**36.0** (30.8-42.1)	**36.1** (30.6-44.9)		**67.7** (55.9-79.7)		**119** (90.2-159)		**165** (121-227)		752
	01-02	**25.1** (21.6-29.2)	**26.4** (22.0-32.6)		**52.2** (48.1-60.4)		**92.4** (72.3-119)		**147** (105-183)		742
20 years and older	99-00	**21.6** (19.0-24.5)	**23.0** (19.7-26.0)		**46.1** (36.6-53.5)		**95.0** (78.7-111)		**142** (117-161)		1461
	01-02	**17.0** (15.4-18.8)	**19.1** (17.1-20.4)		**35.1** (31.6-40.2)		**64.8** (57.3-79.7)		**95.4** (84.6-113)		1647
Gender											
Males	99-00	**22.0** (20.1-24.1)	**23.1** (20.3-26.1)		**43.1** (36.6-49.5)		**83.9** (71.3-96.2)		**115** (97.8-132)		1215
	01-02	**17.7** (16.0-19.6)	**19.3** (17.0-20.6)		**34.4** (30.3-40.6)		**62.1** (54.1-75.5)		**95.2** (75.5-117)		1371
Females	99-00	**27.3** (23.6-31.5)	**30.0** (25.9-33.3)		**59.5** (51.6-69.6)		**119** (98.3-145)		**167** (143-223)		1326
	01-02	**20.2** (18.2-22.4)	**21.6** (19.7-24.3)		**46.7** (43.1-51.1)		**85.0** (72.7-92.5)		**120** (106-136)		1411
Race/ethnicity											
Mexican Americans	99-00	**23.4** (21.8-25.1)	**26.3** (23.9-28.1)		**48.1** (41.2-56.7)		**92.2** (78.9-101)		**116** (104-131)		814
	01-02	**20.1** (16.6-24.5)	**23.0** (17.9-26.3)		**41.9** (34.0-51.2)		**76.9** (62.9-92.5)		**112** (84.6-143)		677
Non-Hispanic blacks	99-00	**37.0** (31.9-42.9)	**38.7** (33.4-44.5)		**78.2** (58.7-91.8)		**117** (107-143)		**167** (143-197)		603
	01-02	**29.6** (26.6-33.1)	**31.5** (28.7-34.1)		**58.0** (49.3-62.5)		**91.7** (79.5-121)		**138** (110-184)		703
Non-Hispanic whites	99-00	**21.8** (19.3-24.6)	**23.1** (19.5-27.5)		**45.9** (37.5-53.3)		**90.2** (74.7-106)		**138** (111-161)		912
	01-02	**17.6** (16.0-19.3)	**19.1** (17.0-20.9)		**36.5** (32.4-42.6)		**69.2** (59.2-87.6)		**107** (89.8-123)		1216

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value.

For 01-02, mono-n-butyl phthalate levels were measured separately, and only mono-n-butyl phthalate levels are given in this table.

mono-isobutyl phthalate (MiBP) and mono-n-butyl phthalate (MnBP), whereas in NHANES 2001-2002 it was possible to measure the concentrations of these two phthalates separately. Levels in the 1999-2000 and 2001-2002 subsamples appear roughly similar when the sum of the MiBP and MnBP levels in 2001-2002 are compared with the 1999-2000 MBP levels. Concentrations reported in these two subsamples are generally similar to those reported in U.S. residents (Blount et al., 2000) and in men from an infertility clinic (Duty et al., 2004). Levels reported for 1999-2002 are six-fold lower than levels reported in German residents (Koch et al., 2003) and slightly lower than levels found in a small sample of pregnant women in New York City (Adibi et al.,2003).

Comparing Adjusted Geometric Means

Geometric mean levels of urinary monobutyl phthalates for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary MnBP were higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older, and the group aged 12-19 years had higher levels than the group aged 20 years and older. Levels were higher in females than in males.

In NHANES 2001-2002, adjusted geometric mean levels of urinary MiBP were higher in children aged 6-11 years than in people aged 12-19 years and 20 years. Levels were higher in females than in males. Non-Hispanic whites had lower levels than non-Hispanic blacks or Mexican Americans. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 193. Mono-n-butyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**22.4** (20.6-24.4)	**21.9** (19.8-24.3)	**38.9** (35.0-41.8)	**68.3** (60.3-78.3)	**97.5** (81.4-131)	2541
	01-02	**17.8** (16.7-18.9)	**17.4** (16.3-18.3)	**30.4** (28.2-32.4)	**52.4** (47.3-61.1)	**81.3** (71.0-92.5)	2772
Age group							
6-11 years	99-00	**41.9** (37.4-47.1)	**38.9** (34.3-49.0)	**65.7** (56.7-80.0)	**107** (71.2-179)	**159** (102-263)	328
	01-02	**35.5** (31.7-39.6)	**35.1** (29.3-38.9)	**55.4** (50.1-62.3)	**84.0** (69.0-113)	**146** (93.8-235)	392
12-19 years	99-00	**24.3** (21.2-27.8)	**23.6** (20.6-27.4)	**37.6** (31.6-43.8)	**62.3** (52.4-76.4)	**88.1** (61.4-142)	752
	01-02	**19.4** (17.3-21.7)	**20.3** (17.5-22.3)	**34.9** (30.5-37.9)	**53.4** (45.2-73.9)	**88.6** (60.3-106)	742
20 years and older	99-00	**20.4** (18.6-22.4)	**19.5** (18.1-21.4)	**34.9** (30.3-40.0)	**62.4** (53.4-72.1)	**91.0** (70.3-135)	1461
	01-02	**16.1** (15.0-17.3)	**15.4** (14.2-16.5)	**26.3** (24.2-28.6)	**44.3** (38.7-51.1)	**71.6** (61.2-85.6)	1638
Gender							
Males	99-00	**17.3** (16.1-18.6)	**17.0** (15.5-18.8)	**28.6** (25.8-32.1)	**49.1** (42.6-53.5)	**63.6** (57.3-71.5)	1215
	01-02	**14.4** (13.5-15.4)	**13.7** (13.0-14.9)	**22.9** (20.8-24.9)	**39.9** (35.6-44.0)	**60.0** (50.5-78.0)	1367
Females	99-00	**28.6** (25.3-32.3)	**28.6** (25.5-30.5)	**50.6** (41.9-56.3)	**84.3** (69.2-106)	**131** (93.6-155)	1326
	01-02	**21.7** (19.6-23.9)	**21.5** (19.7-23.6)	**35.9** (33.0-39.2)	**64.9** (58.9-70.2)	**91.5** (81.4-103)	1405
Race/ethnicity							
Mexican Americans	99-00	**21.2** (19.3-23.3)	**20.0** (18.2-22.9)	**40.1** (32.6-44.3)	**63.6** (57.5-70.1)	**81.6** (73.9-100)	814
	01-02	**19.0** (16.2-22.2)	**19.2** (16.3-21.4)	**33.3** (28.3-39.6)	**61.0** (43.9-84.0)	**86.7** (60.6-128)	674
Non-Hispanic blacks	99-00	**23.9** (21.3-26.8)	**25.0** (20.7-28.0)	**42.2** (35.9-49.6)	**69.6** (61.1-83.9)	**94.4** (83.9-105)	603
	01-02	**20.8** (18.7-23.0)	**20.2** (19.2-22.8)	**34.5** (30.8-36.6)	**61.9** (50.0-73.9)	**85.6** (71.6-99.0)	702
Non-Hispanic whites	99-00	**21.3** (19.1-23.8)	**20.5** (18.6-23.2)	**36.4** (31.5-41.0)	**67.1** (56.7-78.4)	**97.6** (73.5-142)	912
	01-02	**17.4** (16.3-18.6)	**16.5** (15.3-17.8)	**29.0** (26.6-32.2)	**50.7** (45.5-59.0)	**81.4** (68.5-103)	1211

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value.

For 01-02, mono-n-butyl phthalate levels were measured separately, and only mono-n-butyl phthalate levels are given in this table.

Table 194. Mono-isobutyl phthalate

Geometric mean and selected percentiles of urine concentrations (in μg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**2.71** (2.49-2.94)	**2.60** (2.40-2.90)	**5.70** (5.30-6.00)	**11.9** (11.3-12.6)	**17.9** (16.3-19.8)	2782
Age group							
6-11 years	01-02	**4.22** (3.28-5.43)	**4.40** (3.10-6.10)	**10.7** (7.30-13.4)	**18.6** (14.2-22.0)	**23.4** (20.4-27.8)	393
12-19 years	01-02	**3.48** (2.90-4.17)	**3.80** (2.90-4.40)	**7.30** (6.00-9.00)	**14.5** (11.7-18.6)	**22.2** (16.2-33.4)	742
20 years and older	01-02	**2.46** (2.30-2.63)	**2.40** (2.10-2.50)	**5.00** (4.70-5.30)	**10.4** (9.40-12.0)	**16.3** (13.6-18.5)	1647
Gender							
Males	01-02	**2.73** (2.50-2.97)	**2.70** (2.40-3.10)	**5.60** (5.00-6.10)	**11.6** (10.1-12.6)	**16.6** (13.6-20.1)	1371
Females	01-02	**2.68** (2.44-2.96)	**2.50** (2.20-2.90)	**5.70** (5.20-6.20)	**12.6** (11.0-14.7)	**18.7** (16.3-24.0)	1411
Race/ethnicity							
Mexican Americans	01-02	**3.26** (2.72-3.91)	**3.40** (2.60-4.10)	**7.10** (6.10-9.00)	**12.1** (11.1-14.5)	**18.3** (14.1-25.6)	677
Non-Hispanic blacks	01-02	**4.90** (4.46-5.37)	**5.30** (4.50-6.00)	**10.6** (9.20-12.0)	**18.3** (15.7-18.9)	**25.4** (20.5-30.8)	703
Non-Hispanic whites	01-02	**2.33** (2.10-2.59)	**2.20** (1.90-2.60)	**4.90** (4.40-5.30)	**9.60** (8.30-11.4)	**15.6** (13.0-18.6)	1216

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value.

For 01-02, mono-isobutyl phthalate levels were measured separately, and only mono-isobutyl phthalate levels are given in this table.

Table 195. Mono-isobutyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**2.53** (2.35-2.72)	**2.44** (2.26-2.67)	**4.50** (4.12-4.83)	**8.02** (7.60-8.66)	**12.0** (10.8-13.5)	2772
Age group							
6-11 years	01-02	**4.80** (3.89-5.93)	**5.17** (4.13-6.32)	**9.17** (7.03-11.6)	**15.0** (11.1-24.3)	**24.3** (13.8-40.3)	392
12-19 years	01-02	**2.68** (2.29-3.15)	**2.83** (2.39-3.33)	**4.79** (4.04-5.51)	**7.60** (6.18-10.2)	**12.8** (8.76-15.6)	742
20 years and older	01-02	**2.31** (2.18-2.45)	**2.24** (2.06-2.43)	**3.79** (3.64-4.22)	**7.13** (6.88-7.63)	**10.6** (9.46-11.3)	1638
Gender							
Males	01-02	**2.21** (2.08-2.35)	**2.16** (1.97-2.35)	**3.71** (3.58-4.04)	**7.18** (6.44-7.95)	**10.9** (10.0-12.5)	1367
Females	01-02	**2.87** (2.59-3.17)	**2.83** (2.51-3.18)	**5.10** (4.61-5.83)	**8.66** (8.02-10.1)	**13.5** (11.1-15.0)	1405
Race/ethnicity							
Mexican Americans	01-02	**3.05** (2.55-3.66)	**2.98** (2.50-3.79)	**5.73** (4.86-6.99)	**10.5** (8.04-13.3)	**16.0** (12.2-19.4)	674
Non-Hispanic blacks	01-02	**3.43** (3.20-3.68)	**3.52** (2.95-3.81)	**6.10** (5.03-7.04)	**10.5** (8.80-12.6)	**15.6** (12.6-19.7)	702
Non-Hispanic whites	01-02	**2.29** (2.09-2.51)	**2.20** (1.99-2.43)	**3.77** (3.50-4.34)	**7.13** (6.67-7.78)	**10.7** (9.62-12.6)	1211

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value.
For 01-02, mono-isobutyl phthalate levels were measured separately, and only mono-isobutyl phthalate levels are given in this table.

Mono-benzyl Phthalate

CAS No. 2528-16-7

Metabolite of benzylbutyl phthalate, CAS No. 85-68-7

General Information

Benzylbutyl phthalate (BzBP) is an industrial solvent and additive used in products such as adhesives, vinyl-flooring products, sealants, car-care products, and to a lesser extent, some personal-care products. People exposed to BzBP will excrete MBzP and small amounts of mono-n-butyl phthalate in their urine. Workplace air standards for external exposures have not been established for BzBP. Like other phthalates, BzBP has low acute toxicity. It can produce reproductive toxicity in animals (Center for the Evaluation of Risks to Human Reproduction, 2000). BzBP is classified as a possible human carcinogen by U.S. EPA, but is considered not classifiable by IARC and unlisted by NTP.

Interpreting Levels of Urinary Mono-benzyl Phthalate in the Tables

The levels of MBzP in the NHANES 2001-2002 subsample appear generally similar to levels reported previously for U.S. residents (Blount et al., 2000), in a small sample of pregnant women in New York City (Adibi et al., 2003), in men from an infertility clinic (Duty et al., 2004), and in a small sample of German residents (Koch et al., 2003).

Table 196. Mono-benzyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**15.3** (13.7-17.1)	**17.0** (15.3-18.9)	**35.3** (32.6-39.6)	**67.1** (55.3-82.0)	**103** (94.6-116)	2541
	01-02	**15.1** (13.9-16.3)	**15.7** (14.8-17.4)	**38.0** (34.5-41.2)	**80.8** (71.3-88.2)	**122** (102-142)	2782
Age group							
6-11 years	99-00	**39.4** (32.9-47.2)	**40.3** (33.8-48.6)	**82.0** (55.8-98.1)	**128** (98.1-214)	**214** (108-399)	328
	01-02	**33.4** (29.1-38.4)	**37.0** (26.6-43.4)	**68.5** (61.6-92.8)	**166** (116-191)	**226** (183-330)	393
12-19 years	99-00	**25.6** (21.9-30.0)	**28.3** (22.2-34.8)	**51.1** (43.7-58.5)	**87.9** (67.2-115)	**125** (93.7-170)	752
	01-02	**23.2** (19.9-27.2)	**24.7** (21.2-31.0)	**55.5** (47.4-62.9)	**113** (91.8-133)	**169** (134-198)	742
20 years and older	99-00	**12.4** (10.9-14.2)	**13.8** (12.1-15.6)	**28.9** (25.2-33.1)	**52.0** (43.9-62.5)	**86.3** (54.7-119)	1461
	01-02	**12.7** (11.7-13.9)	**13.8** (12.8-14.9)	**31.8** (28.5-33.5)	**65.4** (53.8-76.3)	**99.7** (82.8-121)	1647
Gender							
Males	99-00	**16.2** (14.1-18.6)	**17.7** (15.0-19.9)	**35.4** (31.5-40.3)	**69.4** (59.9-87.2)	**108** (96.3-130)	1215
	01-02	**15.6** (13.6-17.9)	**16.0** (14.2-18.3)	**37.0** (33.1-43.0)	**78.4** (63.5-97.4)	**122** (88.1-178)	1371
Females	99-00	**14.6** (12.7-16.6)	**16.0** (14.2-19.2)	**35.8** (30.8-41.4)	**63.7** (53.7-82.4)	**103** (84.2-116)	1326
	01-02	**14.6** (13.1-16.3)	**15.4** (13.7-17.9)	**38.1** (32.2-42.9)	**81.4** (68.3-91.6)	**122** (102-143)	1411
Race/ethnicity							
Mexican Americans	99-00	**13.9** (12.1-16.1)	**15.7** (13.4-16.8)	**33.0** (27.5-36.1)	**67.5** (55.5-84.0)	**98.3** (80.6-150)	814
	01-02	**13.2** (10.8-16.2)	**14.7** (10.8-18.5)	**29.5** (25.5-38.0)	**70.3** (53.0-85.4)	**91.6** (70.3-161)	677
Non-Hispanic blacks	99-00	**23.0** (20.7-25.5)	**23.0** (20.5-25.6)	**49.3** (43.4-55.6)	**94.0** (80.0-130)	**138** (106-241)	603
	01-02	**23.8** (21.0-26.9)	**24.2** (19.9-28.0)	**50.6** (41.5-62.9)	**101** (86.4-127)	**139** (127-179)	703
Non-Hispanic whites	99-00	**14.3** (12.7-16.1)	**16.1** (14.2-18.5)	**33.9** (30.6-38.4)	**58.7** (51.3-74.1)	**103** (74.1-116)	912
	01-02	**14.0** (12.7-15.4)	**14.6** (13.3-15.5)	**35.3** (32.2-39.5)	**76.6** (66.1-90.3)	**121** (93.2-155)	1216

Comparing Adjusted Geometric Means

Geometric mean levels of urinary mono-benzyl phthalate for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary mono-benzyl phthalate were higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older, and the group aged 12-19 years had higher levels than the group aged 20 years and older. Levels in females were higher than in males. Mexican Amercians had lower levels than non-Hispanic whites, but were not significantly different from non-Hispanic blacks. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 197. Mono-benzyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**14.0** (13.0-15.0)	**13.3** (12.8-14.3)	**25.1** (23.4-27.2)	**50.1** (41.5-58.8)	**77.4** (69.6-86.3)	2541
	01-02	**14.1** (13.2-15.1)	**13.5** (12.7-14.4)	**26.6** (24.9-29.3)	**55.1** (49.2-59.0)	**90.4** (73.6-102)	2772
Age group							
6-11 years	99-00	**40.0** (33.6-47.6)	**38.4** (30.2-51.3)	**73.2** (56.6-99.1)	**104** (89.4-142)	**142** (99.8-173)	328
	01-02	**38.1** (34.5-42.1)	**37.2** (33.8-42.2)	**67.9** (55.8-80.4)	**134** (116-176)	**195** (121-305)	392
12-19 years	99-00	**17.3** (15.4-19.4)	**17.0** (14.6-20.3)	**28.3** (24.3-34.8)	**49.7** (38.8-69.2)	**69.3** (49.6-81.9)	752
	01-02	**17.9** (15.7-20.5)	**18.1** (15.7-20.8)	**33.9** (29.3-38.6)	**67.7** (55.8-85.9)	**99.7** (80.7-123)	742
20 years and older	99-00	**11.8** (10.7-12.9)	**12.1** (11.1-12.9)	**20.1** (18.4-23.3)	**34.3** (30.5-40.8)	**57.2** (41.3-73.9)	1461
	01-02	**12.0** (11.2-12.9)	**11.8** (11.2-12.5)	**21.6** (19.9-23.7)	**42.2** (35.7-48.3)	**64.9** (54.5-78.3)	1638
Gender							
Males	99-00	**12.7** (11.8-13.6)	**12.3** (11.6-13.0)	**23.7** (21.5-26.1)	**44.5** (35.5-57.0)	**73.5** (48.5-99.8)	1215
	01-02	**12.7** (11.4-14.2)	**11.9** (10.9-13.2)	**24.0** (21.2-26.4)	**49.2** (44.3-55.9)	**80.3** (60.9-104)	1367
Females	99-00	**15.3** (13.8-16.8)	**14.7** (13.3-16.0)	**25.9** (24.1-29.3)	**56.4** (46.8-60.6)	**80.0** (60.1-117)	1326
	01-02	**15.7** (14.2-17.3)	**15.1** (13.8-16.5)	**29.5** (25.9-34.3)	**58.2** (50.2-69.4)	**95.8** (69.4-116)	1405
Race/ethnicity							
Mexican Americans	99-00	**12.6** (11.4-14.0)	**11.9** (10.9-13.2)	**24.1** (21.5-26.5)	**46.5** (42.0-53.8)	**68.1** (56.4-93.8)	814
	01-02	**12.4** (10.7-14.4)	**11.9** (9.97-14.8)	**23.7** (19.7-29.3)	**46.0** (36.5-61.6)	**72.0** (53.5-120)	674
Non-Hispanic blacks	99-00	**14.8** (13.5-16.3)	**13.6** (12.2-15.2)	**26.9** (22.5-31.8)	**55.5** (39.5-76.0)	**86.8** (64.4-99.8)	603
	01-02	**16.7** (14.7-19.0)	**15.7** (13.7-19.3)	**33.4** (26.5-38.0)	**60.1** (53.7-69.4)	**101** (75.6-116)	702
Non-Hispanic whites	99-00	**14.0** (12.7-15.3)	**13.4** (12.8-14.8)	**25.2** (23.1-27.4)	**51.5** (38.8-64.8)	**77.9** (67.4-90.3)	912
	01-02	**13.9** (12.9-15.0)	**13.0** (12.1-14.3)	**25.7** (24.0-28.1)	**53.0** (46.5-58.5)	**89.2** (69.4-109)	1211

Figure 21. Mono-benzyl phthalate (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Mono-cyclohexyl Phthalate

CAS No. 7517-36-4

Metabolite of Dicyclohexyl Phthalate, CAS No. 84-61-7

General Information

Dicyclohexyl phthalate (DCHP) is Used to stabilize some rubbers, resins, and polymers, including nitrocellulose, polyvinyl acetate, and polyvinyl chloride. People exposed to DCHP will excrete mono-cyclohexyl phthalate in their urine. Workplace air standards for external exposure have not been established for DCHP. It has not been completely classified as to its carcinogenicity by IARC and NTP.

In both the NHANES 1999-2000 and 2001-2002 subsamples, mono-cyclohexyl phthalate was characterized only at the 90th and 95th percentiles.

Table 198. Mono-cyclohexyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	1.00 (<LOD-1.60)	2541
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.400 (.400-.500)	2782
Age group							
6-11 years	99-00	*	< LOD	< LOD	1.00 (<LOD-1.10)	1.70 (1.00-3.80)	328
	01-02	*	< LOD	< LOD	.300 (.300-.500)	.600 (.500-.700)	393
12-19 years	99-00	*	< LOD	< LOD	1.00 (<LOD-1.50)	1.70 (1.00-2.40)	752
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.600)	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1461
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1647
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	1.00 (<LOD-2.00)	1215
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1371
Females	99-00	*	< LOD	< LOD	< LOD	1.00 (<LOD-1.70)	1326
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1411
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	814
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.300-.600)	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	1.00 (.900-1.20)	603
	01-02	*	< LOD	< LOD	.300 (<LOD-.400)	.400 (.400-.600)	703
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	.900 (<LOD-1.30)	912
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1216

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 199. Mono-cyclohexyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	**3.00** (2.60-3.33)	2541
	01-02	*	< LOD	< LOD	**.588** (.513-.667)	**.854** (.769-.952)	2772
Age group							
6-11 years	99-00	*	< LOD	< LOD	**1.50** (1.20-1.94)	**2.82** (1.54-6.44)	328
	01-02	*	< LOD	< LOD	**.667** (.513-.741)	**.909** (.690-1.17)	392
12-19 years	99-00	*	< LOD	< LOD	**1.22** (.952-1.46)	**1.67** (1.36-1.82)	752
	01-02	*	< LOD	< LOD	**.465** (.385-.659)	**.769** (.526-1.02)	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1461
	01-02	*	< LOD	< LOD	**.606** (.513-.669)	**.870** (.755-.952)	1638
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	**2.14** (1.62-3.16)	1215
	01-02	*	< LOD	< LOD	**.500** (.417-.625)	**.800** (.667-1.00)	1367
Females	99-00	*	< LOD	< LOD	< LOD	**3.28** (2.86-3.51)	1326
	01-02	*	< LOD	< LOD	**.667** (.588-.755)	**.870** (.769-.952)	1405
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	814
	01-02	*	< LOD	< LOD	**.556** (.476-.669)	**.882** (.690-1.04)	674
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	**1.43** (1.09-1.71)	603
	01-02	*	< LOD	< LOD	**.408** (.357-.465)	**.588** (.500-.723)	702
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	**3.00** (2.60-3.53)	912
	01-02	*	< LOD	< LOD	**.606** (.492-.690)	**.870** (.690-.952)	1211

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Mono-2-ethylhexyl Phthalate

CAS No. 4376-20-9

Mono-(2-ethyl-5-hydroxyhexyl) Phthalate

Mono-(2-ethyl-5-oxohexyl) Phthalate

CAS No. 40321-98-0

Metabolites of Di-2-ethylhexyl Phthalate, CAS No. 117-81-7

General Information

Di-2-ethylhexyl phthalate (DEHP) is primarily used to produce flexible plastics, mainly polyvinyl chloride, which is used for many home and garden products, food containers, toys, packaging film, and blood-product storage and intravenous delivery systems. Concentrations in plastic materials may reach 40% by weight. DEHP has been removed from or replaced in most children's toys and food packaging in the United States. Other sources of exposure include foods and foods in contact with

plastic containing DEHP.

DEHP is metabolized into various metabolites (Albro et al., 1982; Dirven et al., 1993; Kato et al., 2004; Barr et al., 2003; Koch et al., 2003). Three of these metabolites, measured for this *Report* are mono-(2-ethyl-5-hexyl) phthalate (MEHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP).

MEHP is primarily formed by the hydrolysis of DEHP in

Table 200. Mono-2-ethylhexyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**3.43** (3.19-3.69)	**3.20** (2.90-3.50)	**7.60** (6.80-8.20)	**14.8** (13.5-17.4)	**23.8** (19.2-28.6)	2541
	01-02	**4.27** (3.80-4.79)	**4.10** (3.60-4.90)	**9.80** (8.40-11.6)	**22.8** (18.9-27.4)	**38.9** (31.8-50.0)	2782
Age group							
6-11 years	99-00	**5.12** (4.42-5.92)	**4.90** (3.30-5.80)	**11.1** (8.30-13.6)	**19.0** (13.8-36.1)	**34.5** (15.6-130)	328
	01-02	**4.41** (3.90-5.00)	**4.40** (4.10-5.30)	**9.20** (7.80-11.7)	**19.3** (14.6-25.9)	**29.9** (20.7-47.4)	393
12-19 years	99-00	**3.75** (3.24-4.35)	**3.70** (2.80-4.60)	**8.10** (6.40-9.40)	**15.0** (11.4-20.5)	**22.8** (19.1-29.2)	752
	01-02	**4.57** (3.96-5.27)	**4.50** (3.70-5.10)	**11.0** (9.50-13.5)	**23.0** (17.6-31.7)	**42.5** (25.9-57.5)	742
20 years and older	99-00	**3.21** (2.94-3.51)	**3.00** (2.70-3.30)	**7.20** (6.40-8.00)	**14.2** (12.1-16.8)	**22.4** (17.5-27.0)	1461
	01-02	**4.20** (3.63-4.86)	**4.10** (3.40-4.80)	**9.40** (8.10-11.9)	**23.5** (18.0-29.8)	**39.5** (30.3-57.1)	1647
Gender							
Males	99-00	**3.68** (3.31-4.10)	**3.40** (2.90-3.90)	**8.00** (7.30-8.80)	**16.0** (14.0-19.0)	**25.3** (19.5-36.7)	1215
	01-02	**4.31** (3.84-4.83)	**4.30** (3.70-5.10)	**9.60** (8.20-11.1)	**23.0** (16.9-29.8)	**37.9** (29.9-48.4)	1371
Females	99-00	**3.21** (2.91-3.54)	**3.00** (2.80-3.40)	**7.00** (5.70-8.20)	**13.5** (11.4-15.3)	**21.6** (15.6-28.5)	1326
	01-02	**4.23** (3.67-4.86)	**4.10** (3.40-4.80)	**9.70** (8.40-12.2)	**23.0** (19.4-28.4)	**42.5** (31.4-53.7)	1411
Race/ethnicity							
Mexican Americans	99-00	**3.49** (3.16-3.85)	**3.50** (2.90-3.80)	**7.00** (5.70-8.60)	**13.3** (10.7-18.7)	**23.9** (17.4-27.3)	814
	01-02	**4.32** (3.75-4.98)	**4.70** (3.80-5.70)	**10.1** (8.30-11.0)	**19.4** (16.6-23.0)	**28.4** (24.2-39.9)	677
Non-Hispanic blacks	99-00	**4.82** (3.92-5.93)	**5.10** (4.10-5.80)	**9.40** (7.60-11.4)	**19.5** (12.9-26.5)	**29.2** (18.6-60.3)	603
	01-02	**6.60** (5.57-7.82)	**6.70** (5.40-8.10)	**15.4** (13.0-18.7)	**32.7** (26.5-41.4)	**52.1** (41.0-84.0)	703
Non-Hispanic whites	99-00	**3.16** (2.89-3.46)	**2.80** (2.50-3.10)	**7.30** (6.30-8.20)	**14.4** (12.2-17.0)	**22.4** (16.9-28.5)	912
	01-02	**3.85** (3.37-4.40)	**3.60** (3.10-4.30)	**8.60** (7.70-9.90)	**20.9** (17.3-25.9)	**37.9** (29.9-49.5)	1216

the gastrointestinal tract and then absorbed. MEOHP and MEHHP are produced by the oxidative metabolism of MEHP and are present at roughly three- to ten-fold higher concentrations than MEHP in urine (Barr et al., 2003; Koch et al., 2003).

MEHP is considered a toxic metabolite of DEHP. Liver toxicity, decreased testicular weight, and testicular atrophy have been observed in animal studies at high or chronic doses (Center for the Evaluation of Risks to Human Reproduction, 2003). DEHP has also been observed to suppress estradiol production in female rats (Lovecamp-Swan and Davis, 2003). Recently, the U.S. Food and Drug Administration (U.S. FDA) considered the amounts of DEHP or MEHP received from intravenous delivery systems or blood transfusions (MEHP is formed in situ in blood from DEHP) to be below thresholds likely to cause injury in adults. However, in lifesaving instances during which neonates would receive exchange blood transfusions, relatively higher exposures might occur (http://www.fda.gov/cdrh/

ost/dehp-pvc.pdf; Calafat et al., 2004).

Workplace air standards for external exposure to DEHP are generally established by OSHA and ACGIH. It is classified as a probable human carcinogen by the U.S. EPA, reasonably anticipated to be a human carcinogen by NTP, but considered not classifiable by IARC.

Interpreting Levels of Urinary Di-2-ethylhexyl Phthalate Metabolites in the Tables

The levels of MEHP in the NHANES 2001-2002 subsample appear roughly comparable to those reported previously for U.S. residents (Blount et al., 2000) and in a small sample of pregnant women in New York City (Adibi et al., 2003), and in men from an infertility clinic (Duty et al., 2004). Levels of MEHP, MEOHP, and MHHP were similar or up to two-fold higher in a sample of German residents (Koch et al., 2003) and German children (Koch et al., 2004; Becker et al., 2004).

Table 201. Mono-2-ethylhexyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**3.12** (2.95-3.31)	**3.08** (2.82-3.27)	**5.88** (5.38-6.25)	**10.8** (9.62-12.5)	**18.5** (15.0-21.8)	2541
	01-02	**3.99** (3.57-4.46)	**3.89** (3.42-4.44)	**7.94** (7.14-9.02)	**18.2** (15.4-21.6)	**32.8** (25.2-42.9)	2772
Age group							
6-11 years	99-00	**5.19** (4.55-5.93)	**5.37** (4.52-5.95)	**9.11** (8.06-11.4)	**21.6** (11.5-41.9)	**41.9** (13.5-86.2)	328
	01-02	**5.02** (4.47-5.64)	**5.38** (4.51-6.21)	**9.82** (7.87-11.0)	**20.9** (13.7-28.8)	**31.2** (24.3-40.7)	392
12-19 years	99-00	**2.53** (2.14-2.99)	**2.31** (2.05-2.76)	**5.83** (4.38-6.29)	**9.63** (7.41-11.5)	**12.1** (10.5-17.3)	752
	01-02	**3.53** (3.09-4.03)	**3.62** (2.89-4.48)	**7.45** (6.51-8.67)	**15.2** (11.7-21.9)	**25.2** (17.7-32.8)	742
20 years and older	99-00	**3.03** (2.83-3.25)	**2.98** (2.73-3.23)	**5.55** (4.90-6.06)	**10.0** (8.60-12.9)	**17.5** (13.8-22.1)	1461
	01-02	**3.96** (3.48-4.50)	**3.81** (3.24-4.37)	**7.77** (6.88-9.00)	**18.4** (15.3-22.1)	**33.3** (23.1-47.9)	1638
Gender							
Males	99-00	**2.89** (2.60-3.22)	**2.76** (2.52-2.96)	**5.58** (4.71-6.08)	**10.3** (9.35-12.4)	**21.6** (14.1-27.7)	1215
	01-02	**3.49** (3.06-3.98)	**3.32** (2.76-3.90)	**7.00** (6.46-7.77)	**16.2** (12.9-20.9)	**31.2** (20.1-49.9)	1367
Females	99-00	**3.36** (3.11-3.63)	**3.33** (2.90-3.80)	**6.15** (5.55-6.77)	**11.1** (9.02-14.0)	**16.3** (12.4-24.6)	1326
	01-02	**4.53** (4.01-5.11)	**4.43** (3.79-5.13)	**9.17** (7.93-10.3)	**20.4** (16.6-24.8)	**35.1** (27.7-42.0)	1405
Race/ethnicity							
Mexican Americans	99-00	**3.16** (2.72-3.68)	**3.15** (2.52-3.81)	**5.88** (4.86-7.24)	**11.6** (9.63-13.1)	**15.7** (12.6-23.1)	814
	01-02	**4.05** (3.57-4.61)	**4.16** (3.75-4.89)	**7.76** (6.47-9.60)	**16.4** (13.5-18.9)	**24.5** (19.8-28.7)	674
Non-Hispanic blacks	99-00	**3.11** (2.59-3.73)	**3.13** (2.50-3.61)	**5.84** (4.43-7.32)	**10.2** (8.05-15.6)	**18.4** (11.6-35.2)	603
	01-02	**4.63** (3.95-5.42)	**4.59** (3.97-5.02)	**9.89** (7.95-12.5)	**21.2** (16.0-33.2)	**39.8** (27.1-48.1)	702
Non-Hispanic whites	99-00	**3.09** (2.84-3.36)	**3.08** (2.73-3.47)	**5.87** (5.11-6.67)	**10.6** (8.95-13.5)	**20.0** (13.7-23.9)	912
	01-02	**3.80** (3.33-4.33)	**3.63** (3.11-4.32)	**7.71** (6.63-9.17)	**17.0** (13.8-21.8)	**32.8** (21.5-46.9)	1211

Comparing Adjusted Geometric Means

Geometric mean levels of urinary MEHP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary MEHP were higher in children aged 6-11 years than in people aged 12-19 years and 20 years. Females had slightly higher levels than in males. Adjusted geometric mean levels in non-Hispanic blacks were higher than levels in non-Hispanic whites.

Geometric mean levels of urinary MEOHP and MEHHP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine. In the NHANES 2001-2002 subsample (not measured in NHANES 1999-2000), levels of MEOHP and MEHHP were found to be higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older. For MEOHP, females had slightly higher levels than males. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight. Koch et al. (2004) showed that levels of MEHP, MEOHP, and MEHHP were higher in nursery school children (aged 2-6 years) than in their teachers or parents. In another study of children (Becker et al., 2004), boys showed higher levels of all three DEHP metabolites than girls, and lower concentrations of MEHHP and MEOHP were seen in children aged 13-14 years compared with younger children.

Figure 22. Mono-2-ethylhexyl phthalate (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older
National Health and Nutrition Examination Survey, 1999-2002.

Table 202. Mono-(2-ethyl-5-hydroxyhexyl) phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**20.0** (17.8-22.5)	**20.1** (17.8-22.4)	**43.6** (38.0-49.7)	**91.3** (77.0-108)	**192** (131-256)	2782
Age group							
6-11 years	01-02	**33.6** (29.7-37.9)	**32.9** (26.9-39.1)	**66.9** (49.7-74.0)	**126** (103-148)	**210** (137-280)	393
12-19 years	01-02	**24.9** (21.3-29.1)	**25.2** (22.9-31.3)	**50.6** (40.7-64.5)	**107** (78.5-148)	**202** (114-280)	742
20 years and older	01-02	**18.1** (15.7-20.9)	**17.7** (14.7-20.7)	**39.8** (32.5-47.8)	**86.2** (65.7-107)	**175** (110-279)	1647
Gender							
Males	01-02	**22.0** (19.5-24.7)	**21.2** (19.4-23.9)	**47.8** (40.9-54.3)	**94.2** (80.8-110)	**212** (130-256)	1371
Females	01-02	**18.3** (15.7-21.4)	**18.2** (14.9-22.1)	**39.8** (34.2-46.0)	**86.0** (69.4-115)	**170** (119-273)	1411
Race/ethnicity							
Mexican Americans	01-02	**18.5** (16.2-21.1)	**19.0** (16.2-21.6)	**36.3** (31.6-44.0)	**79.9** (66.4-93.9)	**123** (100-161)	677
Non-Hispanic blacks	01-02	**29.8** (26.1-34.1)	**30.9** (27.2-34.3)	**61.9** (52.6-68.3)	**126** (108-157)	**276** (157-339)	703
Non-Hispanic whites	01-02	**19.1** (16.7-21.9)	**19.2** (16.8-21.3)	**41.7** (35.3-50.7)	**91.1** (75.6-110)	**212** (130-275)	1216

Table 203. Mono-(2-ethyl-5-hydroxyhexyl) phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	**75th**	**90th**	**95th**	
Total, age 6 and older	01-02	**18.8** (17.0-20.8)	**16.6** (14.9-18.6)	**32.3** (27.8-37.2)	**70.8** (58.4-88.3)	**147** (101-200)	2772
Age group							
6-11 years	01-02	**38.3** (34.3-42.6)	**34.2** (29.9-38.9)	**60.4** (51.9-76.4)	**107** (96.3-147)	**211** (122-313)	392
12-19 years	01-02	**19.2** (17.0-21.8)	**17.7** (15.6-20.0)	**34.9** (29.2-42.6)	**73.4** (58.4-80.7)	**102** (86.6-160)	742
20 years and older	01-02	**17.2** (15.2-19.4)	**15.0** (13.3-16.7)	**27.7** (23.2-34.7)	**63.2** (48.3-88.3)	**134** (84.7-207)	1638
Gender							
Males	01-02	**17.9** (16.2-19.7)	**15.4** (13.8-17.8)	**32.4** (28.0-37.2)	**73.4** (55.3-91.8)	**136** (97.7-224)	1367
Females	01-02	**19.7** (17.3-22.5)	**17.6** (15.4-19.5)	**32.3** (26.8-38.9)	**69.3** (57.6-93.7)	**160** (93.7-201)	1405
Race/ethnicity							
Mexican Americans	01-02	**17.5** (15.9-19.2)	**15.7** (14.6-17.6)	**30.7** (26.1-35.7)	**65.3** (50.6-83.9)	**106** (76.3-130)	674
Non-Hispanic blacks	01-02	**21.0** (18.8-23.3)	**19.7** (17.5-21.8)	**38.3** (32.1-46.0)	**93.5** (69.2-124)	**161** (130-183)	702
Non-Hispanic whites	01-02	**19.0** (17.1-21.1)	**16.3** (14.8-18.4)	**32.4** (27.6-37.3)	**71.5** (57.8-94.3)	**178** (99.3-242)	1211

Table 204. Mono-(2-ethyl-5-oxohexyl) phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**13.5** (12.0-15.0)	**14.0** (12.5-15.1)	**29.6** (25.2-34.0)	**59.9** (50.4-70.9)	**120** (87.2-156)	2782
Age group							
6-11 years	01-02	**23.3** (20.9-26.1)	**22.6** (18.5-28.1)	**46.5** (38.1-52.0)	**80.5** (64.7-109)	**142** (93.9-178)	393
12-19 years	01-02	**17.5** (15.1-20.3)	**18.5** (16.0-20.7)	**35.0** (27.6-42.1)	**69.9** (52.2-104)	**118** (74.0-174)	742
20 years and older	01-02	**12.0** (10.5-13.9)	**12.2** (10.4-14.1)	**25.9** (21.3-32.1)	**52.3** (41.8-68.3)	**115** (74.9-160)	1647
Gender							
Males	01-02	**14.5** (13.0-16.2)	**14.6** (13.0-16.1)	**31.6** (25.6-34.7)	**60.4** (52.3-71.4)	**129** (84.4-167)	1371
Females	01-02	**12.5** (10.8-14.6)	**13.0** (10.9-14.9)	**28.1** (23.7-33.5)	**57.5** (45.8-72.7)	**115** (81.8-147)	1411
Race/ethnicity							
Mexican Americans	01-02	**13.1** (11.6-14.9)	**13.2** (11.6-15.0)	**25.3** (21.6-30.8)	**56.6** (40.6-70.3)	**76.5** (70.5-101)	677
Non-Hispanic blacks	01-02	**19.6** (17.1-22.5)	**20.0** (17.9-22.4)	**39.0** (34.8-44.2)	**80.5** (71.4-97.4)	**148** (102-228)	703
Non-Hispanic whites	01-02	**12.8** (11.2-14.6)	**13.1** (11.6-14.6)	**28.5** (23.6-34.0)	**58.6** (48.8-70.9)	**126** (83.7-172)	1216

Table 205. Mono-(2-ethyl-5-oxohexyl) phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**12.6** (11.5-13.9)	**11.2** (10.2-12.3)	**21.3** (18.3-23.9)	**45.1** (37.1-58.1)	**87.5** (69.0-124)	2772
Age group							
6-11 years	01-02	**26.6** (24.0-29.4)	**22.8** (20.3-25.0)	**43.3** (33.6-48.2)	**74.4** (69.0-91.9)	**130** (83.0-187)	392
12-19 years	01-02	**13.5** (12.0-15.2)	**12.0** (10.8-14.3)	**23.4** (19.9-28.5)	**48.4** (39.2-54.9)	**70.5** (55.0-97.2)	742
20 years and older	01-02	**11.4** (10.2-12.8)	**10.1** (8.90-11.4)	**17.5** (15.2-21.9)	**39.0** (30.3-53.9)	**84.3** (53.1-134)	1638
Gender							
Males	01-02	**11.8** (10.7-13.0)	**10.2** (8.93-11.7)	**21.0** (18.5-23.0)	**46.1** (34.9-58.7)	**83.1** (69.7-104)	1367
Females	01-02	**13.5** (11.9-15.3)	**12.0** (10.8-13.7)	**21.5** (18.0-25.9)	**44.8** (36.8-61.9)	**92.3** (59.3-139)	1405
Race/ethnicity							
Mexican Americans	01-02	**12.4** (11.4-13.5)	**10.8** (10.5-12.4)	**20.8** (18.5-24.4)	**46.4** (33.4-56.5)	**65.8** (53.1-83.1)	674
Non-Hispanic blacks	01-02	**13.8** (12.3-15.4)	**13.0** (12.0-14.1)	**23.9** (20.0-29.2)	**58.3** (45.3-77.7)	**101** (81.3-124)	702
Non-Hispanic whites	01-02	**12.7** (11.4-14.1)	**11.2** (9.91-12.3)	**21.0** (18.0-24.0)	**45.8** (36.2-66.0)	**96.0** (68.5-161)	1211

Mono-3-carboxypropyl Phthalate

Mono-n-octyl Phthalate
CAS No. 5393-19-1

Metabolites of di-n-octyl phthalate, CAS No. 117-84-0

General Information

Di-n-octylphthalate (DOP) is used primarily to produce flexible plastics. People exposed to DOP will excrete primarily mono-3-carboxypropyl phthalate (MCPP) and smaller amounts of mono-n-octyl phthalate (MOP) in their urine. Workplace air standards for external exposure are established for DOP by OSHA. Like other phthalates, DOP has low acute toxicity. It has not been classified with respect to carcinogenicity by IARC and NTP.

Interpreting Levels of Urinary Mono-3-carboxypropyl and Mono-n-octyl Phthalates in the Tables

In both the NHANES 1999-2000 and 2001-2002 subsamples, MOP was only detectable at the 90th and 95th percentiles. A low detection rate was also reported in a small sample of German residents (Koch et al., 2003). MCPP levels were measured only in the 2001-2002

subsample and were higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older; the group aged 12-19 years had higher levels than in the group aged 20 years and older. Females had slightly higher levels than males. Additionally, levels of MCPP were lower in non-Hispanic blacks than in either non-Hispanic whites or Mexican Americans. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Table 206. Mono-3-carboxypropyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**2.75** (2.49-3.04)	**3.00** (2.80-3.30)	**5.70** (5.00-6.30)	**10.0** (8.80-11.2)	**14.6** (12.7-17.5)	2782
Age group							
6-11 years	01-02	**6.11** (5.46-6.84)	**6.60** (5.40-7.50)	**11.8** (10.2-13.2)	**20.1** (17.8-23.1)	**24.7** (22.2-31.6)	393
12-19 years	01-02	**3.71** (3.18-4.33)	**4.00** (3.40-4.70)	**7.00** (6.10-8.10)	**11.5** (9.50-12.7)	**13.9** (11.8-19.0)	742
20 years and older	01-02	**2.37** (2.11-2.66)	**2.60** (2.20-3.00)	**4.80** (4.20-5.30)	**8.10** (7.10-9.20)	**12.0** (10.0-14.2)	1647
Gender							
Males	01-02	**2.89** (2.64-3.17)	**3.10** (2.80-3.30)	**5.60** (4.90-6.70)	**9.80** (8.70-12.0)	**14.2** (12.4-18.0)	1371
Females	01-02	**2.62** (2.29-2.99)	**3.00** (2.40-3.30)	**5.60** (4.90-6.30)	**10.0** (8.30-11.2)	**14.7** (11.2-20.3)	1411
Race/ethnicity							
Mexican Americans	01-02	**2.67** (2.26-3.16)	**3.00** (2.30-3.40)	**5.30** (4.40-5.90)	**9.10** (7.30-12.4)	**13.6** (10.4-18.7)	677
Non-Hispanic blacks	01-02	**3.09** (2.81-3.40)	**3.20** (2.90-3.50)	**6.30** (5.50-6.50)	**10.8** (9.10-13.0)	**14.9** (13.5-22.4)	703
Non-Hispanic whites	01-02	**2.72** (2.40-3.08)	**2.90** (2.50-3.30)	**5.70** (4.80-6.70)	**10.3** (8.90-11.9)	**15.8** (12.6-19.5)	1216

Table 207. Mono-3-carboxypropyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**2.57** (2.34-2.82)	**2.45** (2.23-2.76)	**4.07** (3.85-4.46)	**7.25** (6.59-8.01)	**11.4** (10.1-12.6)	2772
Age group							
6-11 years	01-02	**6.96** (6.29-7.71)	**7.07** (5.77-7.87)	**11.3** (9.27-14.0)	**20.7** (15.5-22.3)	**26.4** (20.7-27.0)	392
12-19 years	01-02	**2.86** (2.52-3.25)	**2.93** (2.50-3.36)	**4.57** (4.03-5.23)	**6.69** (6.30-7.25)	**9.44** (8.03-10.7)	742
20 years and older	01-02	**2.24** (2.03-2.47)	**2.19** (1.99-2.39)	**3.49** (3.10-3.93)	**5.32** (4.79-6.18)	**7.71** (6.71-9.28)	1638
Gender							
Males	01-02	**2.35** (2.16-2.56)	**2.20** (2.01-2.42)	**3.76** (3.45-4.20)	**7.16** (6.03-7.98)	**11.6** (9.28-15.4)	1367
Females	01-02	**2.80** (2.47-3.18)	**2.75** (2.44-3.01)	**4.37** (3.97-4.86)	**7.65** (6.17-8.69)	**11.1** (8.66-15.9)	1405
Race/ethnicity							
Mexican Americans	01-02	**2.51** (2.20-2.87)	**2.36** (2.05-2.73)	**4.24** (3.65-5.00)	**7.42** (5.58-10.3)	**11.2** (8.18-14.5)	674
Non-Hispanic blacks	01-02	**2.17** (2.02-2.33)	**2.07** (1.88-2.28)	**3.64** (3.24-4.07)	**6.73** (5.46-7.70)	**10.0** (8.27-13.1)	702
Non-Hispanic whites	01-02	**2.69** (2.41-3.00)	**2.56** (2.23-2.92)	**4.16** (3.87-4.76)	**7.66** (6.59-8.47)	**11.8** (10.0-14.7)	1211

Table 208. Mono-n-octyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	**1.60** (1.20-2.00)	**2.90** (2.20-3.30)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2782
Age group							
6-11 years	99-00	*	< LOD	< LOD	**2.00** (.900-3.50)	**3.20** (1.70-4.30)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	393
12-19 years	99-00	*	< LOD	< LOD	**1.60** (.900-2.50)	**2.80** (2.00-4.20)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	**1.50** (1.10-1.90)	**2.90** (2.00-3.50)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1647
Gender							
Males	99-00	*	< LOD	< LOD	**1.60** (1.10-2.10)	**2.80** (2.00-3.40)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1371
Females	99-00	*	< LOD	< LOD	**1.40** (1.10-2.00)	**3.10** (2.20-3.70)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1411
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	**1.00** (<LOD-1.40)	**1.50** (1.40-2.60)	814
	01-02	*	< LOD	< LOD	< LOD	< LOD	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**1.80** (<LOD-3.00)	**3.00** (2.20-3.70)	603
	01-02	*	< LOD	< LOD	< LOD	< LOD	703
Non-Hispanic whites	99-00	*	< LOD	< LOD	**1.50** (1.20-2.10)	**3.00** (2.30-3.50)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1216

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 209. Mono-n-octyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	**2.40** (2.07-2.61)	**3.51** (2.86-4.29)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2772
Age group							
6-11 years	99-00	*	< LOD	< LOD	**2.22** (1.60-3.75)	**3.75** (1.97-10.3)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	392
12-19 years	99-00	*	< LOD	< LOD	**1.49** (1.29-1.71)	**1.82** (1.54-3.33)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	**2.56** (2.07-2.91)	**3.47** (2.86-4.29)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1638
Gender							
Males	99-00	*	< LOD	< LOD	**1.82** (1.54-2.05)	**2.52** (1.94-3.45)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1367
Females	99-00	*	< LOD	< LOD	**2.95** (2.50-3.55)	**4.00** (3.33-5.56)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1405
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	**1.82** (1.43-2.61)	**3.16** (2.60-4.00)	814
	01-02	*	< LOD	< LOD	< LOD	< LOD	674
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**1.36** (1.03-1.94)	**2.18** (1.50-3.27)	603
	01-02	*	< LOD	< LOD	< LOD	< LOD	702
Non-Hispanic whites	99-00	*	< LOD	< LOD	**2.60** (2.07-3.00)	**3.60** (3.00-4.62)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1211

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Mono-isononyl Phthalate

Metabolite of Di-isononyl Phthalate, CAS No. 28553-12-0

General Information

Di-isononyl phthalate (DiNP) is actually a mixture of phthalates with branched alkyl side chains of varying length (C8, C9, and C10). DINP is primarily used to produce flexible plastics and has been used to replace di-2-ethylhexyl phthalate (DEHP) in some plastics. DiNP is now widely used in such products as children's toys, flooring, gloves, food-packaging material, drinking straws, and garden hoses. People exposed to DiNP will excrete small amounts of mono-isononyl phthalate (MiNP) in their urine. As with DEHP, other oxidative metabolites of DiNP are probably the most abundant urinary metabolites (McKee et al., 2002). Because DiNP is a complex mixture, MiNP may not reflect total exposure to all DiNP components.

Workplace air standards for external exposure have not been established for DiNP, which although considered an animal carcinogen, has not been completely classified as to human carcinogenicity (IARC, NTP).

In both the NHANES 1999-2000 and 2001-2002 subsamples, MiNP was detectable only at the 95th percentiles.

Table 210. Mono-isononyl phthalate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	3.50 (<LOD-13.8)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2782
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	5.70 (<LOD-22.5)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	393
12-19 years	99-00	*	< LOD	< LOD	< LOD	2.30 (<LOD-20.3)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	3.10 (<LOD-13.2)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1647
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	4.90 (<LOD-18.9)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1371
Females	99-00	*	< LOD	< LOD	< LOD	2.50 (<LOD-6.80)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1411
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	1.40 (<LOD-2.70)	814
	01-02	*	< LOD	< LOD	< LOD	1.00 (<LOD-1.20)	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	2.30 (<LOD-13.8)	6.80 (<LOD-30.2)	603
	01-02	*	< LOD	< LOD	< LOD	1.00 (<LOD-1.70)	703
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	3.50 (<LOD-16.0)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1216

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 211. Mono-isononyl phthalate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	4.29 (2.86-7.88)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2772
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	6.00 (2.77-14.2)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	392
12-19 years	99-00	*	< LOD	< LOD	< LOD	1.94 (1.30-7.65)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	4.62 (3.16-7.93)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1638
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	4.24 (1.94-10.2)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1367
Females	99-00	*	< LOD	< LOD	< LOD	4.29 (3.33-5.79)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1405
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	3.51 (2.86-5.00)	814
	01-02	*	< LOD	< LOD	< LOD	2.31 (1.76-2.73)	674
Non-Hispanic blacks	99-00	*	< LOD	< LOD	2.03 (.759-5.31)	4.26 (1.43-14.3)	603
	01-02	*	< LOD	< LOD	< LOD	1.62 (1.25-1.88)	702
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	5.00 (3.00-10.0)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1211

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Results by Chemical Group

Phytoestrogens

Phytoestrogens

General Information

Phytoestrogens are naturally occurring chemical constituents of certain plants that may interact with estrogen receptors to produce estrogenic effects. Two major groups of phytoestrogens found in people's diets are isoflavones and lignans.

The major isoflavones include daidzein, genistein, O-desmethylangolensin, glycitein, and equol. Plant sources of isoflavones include legumes, with the largest contribution coming from soybeans and soy-based products. Soy flour and soy protein isolates are often added to processed meats, meat substitutes, breads, and protein food bars and can be a major source of isoflavones (Grace et al., 2004, Lampe et al., 1999). Formononectin and biochanin A are methylated isoflavones found in clovers and are metabolized in the body to daidzein and genistein. Daidzein is further metabolized to O-desmethylangolensin in the body and to equol by intestinal bacteria. The richest source of total isoflavones is mature red clover leaf (containing mainly biochanin A and formononetin, with lesser amounts of genistein, daidzein, and other related molecules), followed by kudzu root, and soy (richest source of the isoflavone genistein). Naringenin (precursor to genistein) and hesperetin are flavonoids found in higher amounts in citrus fruits.

Lignans include matairesinol, secoisolariciresinol, enterolactone, and enterodiol. The dietary lignans matairesinol and secoisolariciresinol are transformed by gut flora into enterolactone and enterodiol, respectively. Enterodiol may also interconvert with enterolactone. Lignans are found in flax seeds (richest source of secoisolariciresinol and matairesinol), and cereal grains. Other phytoestrogens are found in other plants. For example, the phytoestrogens resveratrol and *trans*-resveratrol are both found in grape skins and wine.

Diet is the major source of human exposure to phytoestrogens. The absorption and metabolism of phytoestrogens demonstrate large interindividual variability, which may relate to differences in both in human pharmacokinetics and metabolism by gut flora. Phytoestrogens are ingested in their natural beta-glycosidic forms, with the bioavailability of the glycosides exceeding the bioavailability of free aglycones. The beta-glycosidic forms are hydrolyzed to their aglycones in the intestine, absorbed, and then glucuronidated in the intestinal wall. The glucuronidated

Table 212. Phytoestrogens

Phytoestrogen	CAS number
Daidzein	486-66-8
Enterodiol	80226-00-2
Enterolactone	78473-71-9
Equol	531-95-3
Genistein	446-72-0
O-Desmethylangolensin	21255-69-6

metabolites of isoflavones predominate in blood and urine (Setchell et al., 2001, Adlercreutz et al., 1995*b*).

Phytoestrogens persist in plasma for about 24 hours. The isoflavones are excreted in both urine and feces. (Setchell et al., 2001). Results of studies with flax seed show that plasma and urine concentrations increased in a dose-dependent manner (Nesbitt et al., 1999). Equol excretion may depend on diet and the type of intestinal flora present (Hutchins et al., 1995*a,b*; Karr et al., 1997; Setchell et al., 2001; Setchell and Cassidy, 1999).

Phytoestrogens preferentially bind to estrogen-beta receptors (ER-beta). Genistein binding to ER-beta produces a conformational change similar to that produced by the drug reloxifene (a selective estrogen receptor modulator prescribed for osteoporosis) but dissimilar to the binding of estradiol. Phytoestrogens decrease (by down-regulation) the number of ER-alpha receptors on breast and uterine tissue (Nikov et al., 2001). Generally, phytoestrogens are much less potent than the endogenously produced estrogens, but phytoestrogens can be present in much greater quantities (100 to 1000 times the concentration of endogenous estrogens). Additionally, phytoestrogens bind less tightly to steroid-hormone serum-transport proteins than do endogenous estrogens (Nagel et al., 1998). Soy-based infant formula can result in plasma concentrations of isoflavones in infants that are13,000-22,000 times higher than endogenous estrogen concentrations in infants (Setchell et al., 1997). Equol has more potent estrogen activity than its precursor, daidzein, and has been proposed to be most important in explaining the mechanism of action of isoflavones in disease prevention (Setchell et al., 2002).

Some actions of phytoestrogens are thought to occur through pathways other than interaction with estrogen receptors. These actions include inhibiting the transformation of estrone to estradiol and inhibiting enzymes important for steroid biosynthesis, as well as having antioxidant and anti-angiogenesis activity. (Adlercreutz et al., 1995*a*; Dixon and Ferreira, 2002).

Studies of the effects of dietary phytoestrogens or soy protein on the incidence of breast and prostate cancer vary in outcome but suggest a protective effect (Knowles et al., 2000; den Tonkelaar et al., 2001; Stattin et al., 2002; Ingram et al., 1997; Murkies et al., 2000; Howe et al., 1990; Lee et al., 1991). In such studies, many unmeasured non-phytoestrogen flavonoid chemicals, vitamins, and other nutrients that also are present in plant foods may also contribute to observed health outcomes. *In vitro* experiments have shown both anti-cancer and stimulatory effects on cell growth of target cells. Many of the different phytoestrogens have been tested for mutagenic activity *in vitro* and do not appear to be mutagenic, but studies assessing the carcinogenicity of phytoestrogens have not been conducted. Cornwell et al. (2004) have summarized the potential anti-cancer benefits of phytoestrogens.

Comparisons of Western diets with Asian diets, which include higher intakes of soy-based foods, suggest that the higher isoflavone intake in Asian diets may account for the lower incidence of menopausal symptoms such as hot flashes and osteoporosis. The ingestion of isoflavones by pre- and post-menopausal women produces varying effects on the menstrual cycle, sex-hormone protein binding, pituitary responses, and bone density, depending on dose, the type of phytoestrogen used, the hormonal state of the subjects, and the design of the studies (see, for example, Teede et al., 2001; Murkies et al., 2000; Xu et al., 2000; Hodgert et al., 2000; Safe et al., 2001; Nicholls et al., 2002; Kotsopoulos et al., 2000; Cassidy et al., 1994; Adlercreutz et al., 1995*a*; Kim et al., 2002; Kreijkamp-Kaspers et al., 2004).

Adverse reproductive effects have been observed in animals that graze on clover. Although the results of these studies are conflicting, results of some chronic feeding studies suggest that high doses of phytoestrogens alter the fetal hormonal environment when consumed during gestation (Cornwell et al., 2004). Results of studies of children who had been fed soy-based formula as infants and who were followed up through adolescence (Klein, 1998) and young adulthood (Strom et al., 2001) found no adverse reproductive or endocrine effects.

Interpreting Levels of Urinary Phytoestrogens Reported in the Tables

Urinary levels of phytoestrogens were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S.

population. In general, the concentrations observed in the NHANES 1999-2000 and 2000-2001 subsamples reflect a diet lower in isoflavones than lignans, consistent with consumption of a Western diet in which whole grains and cereals rather than soybean products contribute the bulk of phytoestrogens. Enterolactone levels were highest followed by daidzein, genistein, enterodiol, equol, and O-desmethylangolensin. Isoflavone levels at the higher percentiles may reflect dietary supplementation with soy products. The relationship between the dose and urinary excretion is linear for many phytoestrogens, except for equol (Karr et al., 1997; Slavin et al 1998; Lampe et al., 1999). Because excretory half-lives are reported to be in the range of 3-10 hours (Lu et al., 1995, Setchell et al., 2001), urinary concentrations reflect recent consumption.

Levels of lignans (enterolactone, enterodiol) in the 1999-2000 and 2001-2002 subsamples appeared broadly similar to levels found in studies of postmenopausal women in the United Kingdom (Grace et al., 2004); men and women in the United States (Valentin-Blasini et al., 2003); men and women in Minnesota (Lampe et al., 1999); postmenopausal Dutch women (den Tonkelaar et al., 2001); young African-American, Latina; and Japanese women in the San Francisco Bay Area (Horn-Ross et al., 1997); Japanese men and women (Adlercreutz et al.,1991; Uehara et al., 2000*a*); premenopausal omnivorous women in Boston (Adlercreutz et al., 1986); and healthy postmenopausal Finnish omnivore and vegetarians (Uehara et al., 2000*a,b*). Vegetarian women in Boston and Helsinki (Adlercreutz et al., 1986); men and women consuming an experimental cruciferous diet (Kirkman et al.,1995); and Boston women consuming a macrobiotic diet excrete significantly higher levels of these lignans (Hutchins, 1995*a*).

Levels of isoflavones (daidzein, genistein, equol, and O-desmethylangolensin) in the NHANES 1999-2000 and 2001-2002 subsamples appear broadly similar to those seen in young Caucasian, African-American, Latina, and Japanese women in the San Francisco Bay Area (Horn-Ross et al., 1997); men and women in the United States (Valentin-Blasini et al., 2003, Lampe et al., 1999); Caucasian and Filipino women living in Hawaii (Maskarinec et al.,1998); postmenopausal women from Holland (den Tonkelaar et al., 2001) and the United Kingdom (Grace et al., 2004); omnivorous and vegetarian Helsinki women (Uehara et al., 2000 *a,b*); and premenopausal omnivorous Boston women (Hutchins, 1995 *a,b*).

Isoflavone levels seen in the NHANES 1999-2000 and 2001-2002 subsamples were 4 to 50 times lower than

levels observed in Japanese men and women (Adlercreutz et al.,1991; Uehara et al., 2000*a*); Japanese women (Arai et al., 2000); postmenopausal Chinese women (Zheng et al., 1999); Singaporean women (Seow et al., 1998, Chen et al., 1999); and Japanese women living in Hawaii (Maskarinec et al., 1998). Genistein and daidzein levels in this *Report* were two-fold higher than levels reported in people consuming a carotenoid diet but lower than levels found in people consuming a cruciferous diet, and O-desmethylangolensin levels were seven times lower (Kirkman et al., 1995). Levels of genistein, daidzein, and O-desmethylangolensin for people consuming a soy diet were 6 to 100 times higher than levels in either NHANES subsample. Supplementing an omnivorous American diet over a three month period with 60 grams of soy powder for female subjects increased isoflavone levels by more than 13-fold. (Albertazzi et al.,1999).

Comparing Adjusted Geometric Means

Geometric means of urinary phytoestrogen levels for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown).

In NHANES 2001-2002, both urinary enterodiol and enterolactone levels were higher in the group aged 6-11 years than in the group aged 12-19 years. Levels of the lignans previously have been reported to differ by race (Horn-Ross et al., 1997), and in an NHANES III statistical analysis, to differ by income, gender, and age (Valentin-Blasini et al., 2003).

In NHANES 2001-2002, both urinary genistein and daizein levels were higher in the group aged 6-11 years than in either of the groups aged 12-19 years or 20 years and older, and females had higher levels than males. One study found that levels were higher in males for all phytoestrogens except equol (Lampe et al., 1999).

In NHANES 2001-2002, adjusted geometric mean levels of urinary equol were higher for non-Hispanic whites than for Mexican Americans or non-Hispanic blacks. Adjusted geometric mean levels of urinary equol were higher in the group aged 6-11 years than in either of the other two age groups.

In NHANES 2001-2002, adjusted geometric mean levels of urinary O-desmethylangolensin were higher in non-Hispanic whites than in Mexican Americans. The group aged 20 years and older had lower adjusted geometric mean levels of urinary O-desmethylangolensin than either of the other two age groups.

It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

These urinary phytoestrogens data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of phytoestrogens than those levels found in the general population. These data will also help scientists plan and conduct research about the relation between exposure to phytoestrogens and health effects.

Table 213. Daidzein

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**75.1** (61.9-91.1)	**69.7** (57.8-82.6)	**229** (184-298)	**538** (471-702)	**1310** (990-1540)	2553
	01-02	**51.7** (46.6-57.5)	**52.3** (48.9-57.4)	**192** (151-226)	**577** (447-725)	**1250** (863-1640)	2794
Age group							
6-11 years	99-00	**90.5** (75.1-109)	**101** (70.3-138)	**257** (172-430)	**505** (437-840)	**1130** (657-1740)	330
	01-02	**84.9** (71.6-101)	**72.7** (56.3-97.0)	**257** (155-385)	**571** (437-989)	**1030** (628-1470)	396
12-19 years	99-00	**123** (91.4-166)	**123** (85.6-168)	**325** (227-454)	**833** (445-1490)	**1460** (861-2410)	753
	01-02	**69.3** (52.6-91.3)	**70.2** (52.5-87.5)	**251** (185-344)	**769** (573-984)	**1360** (922-1950)	744
20 years and older	99-00	**67.6** (55.4-82.4)	**60.9** (49.3-74.1)	**215** (167-239)	**518** (459-573)	**1320** (978-1540)	1470
	01-02	**46.4** (41.4-52.0)	**49.1** (40.8-53.4)	**176** (133-216)	**520** (396-703)	**1210** (771-1900)	1654
Gender							
Males	99-00	**88.9** (71.4-111)	**80.6** (66.6-112)	**261** (198-355)	**573** (501-989)	**1540** (989-2080)	1220
	01-02	**49.8** (42.8-57.9)	**50.7** (46.0-55.0)	**189** (137-237)	**498** (386-694)	**906** (717-1380)	1375
Females	99-00	**64.1** (52.9-77.6)	**57.8** (45.0-73.2)	**199** (150-244)	**476** (389-722)	**1220** (566-1700)	1333
	01-02	**53.6** (48.1-59.8)	**55.7** (49.8-62.7)	**197** (148-231)	**642** (511-816)	**1470** (1170-1980)	1419
Race/ethnicity							
Mexican Americans	99-00	**78.9** (59.8-104)	**66.2** (48.4-87.1)	**254** (170-402)	**800** (534-1020)	**1360** (968-2780)	816
	01-02	**39.2** (28.5-54.0)	**39.9** (28.8-59.9)	**168** (100-287)	**515** (388-669)	**896** (613-1480)	679
Non-Hispanic blacks	99-00	**91.9** (71.9-118)	**102** (81.6-133)	**286** (243-377)	**553** (459-824)	**1190** (640-1900)	607
	01-02	**66.1** (48.2-90.7)	**72.2** (52.8-97.3)	**255** (176-393)	**757** (448-1400)	**1400** (757-2480)	706
Non-Hispanic whites	99-00	**74.4** (61.5-89.9)	**66.9** (56.2-78.2)	**216** (157-298)	**512** (438-745)	**1360** (989-1710)	917
	01-02	**48.6** (43.8-54.0)	**49.5** (42.7-54.1)	**171** (137-204)	**504** (389-658)	**1140** (774-1620)	1222

Table 214. Daidzein (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**68.5** (55.9-83.9)	**65.1** (52.8-80.8)	**204** (156-249)	**555** (471-629)	**944** (836-1150)	2553
	01-02	**48.6** (43.7-54.0)	**48.5** (43.3-56.6)	**166** (140-196)	**497** (395-614)	**957** (801-1180)	2784
Age group							
6-11 years	99-00	**92.6** (76.3-112)	**92.9** (71.2-114)	**251** (157-324)	**529** (363-838)	**1030** (781-2150)	330
	01-02	**96.6** (79.2-118)	**86.3** (60.8-127)	**275** (159-395)	**649** (452-733)	**930** (679-1140)	395
12-19 years	99-00	**83.1** (58.4-118)	**83.9** (53.8-126)	**207** (138-386)	**628** (295-1060)	**1000** (628-2380)	753
	01-02	**53.4** (40.8-70.0)	**50.9** (38.3-77.6)	**181** (142-248)	**549** (385-718)	**1030** (622-1360)	744
20 years and older	99-00	**63.8** (51.5-79.1)	**59.3** (48.7-75.0)	**194** (151-234)	**554** (471-624)	**908** (783-1180)	1470
	01-02	**43.9** (39.4-48.9)	**43.8** (37.4-53.3)	**153** (127-188)	**441** (348-599)	**939** (788-1220)	1645
Gender							
Males	99-00	**69.7** (54.7-88.8)	**70.2** (51.3-84.3)	**197** (147-276)	**620** (494-836)	**1050** (884-1290)	1220
	01-02	**40.5** (34.8-47.1)	**41.7** (34.5-47.9)	**140** (108-179)	**348** (260-553)	**788** (585-946)	1371
Females	99-00	**67.4** (54.8-82.9)	**61.4** (51.1-80.9)	**207** (152-250)	**495** (356-624)	**838** (610-1410)	1333
	01-02	**57.7** (50.8-65.5)	**60.1** (48.6-73.4)	**191** (159-228)	**616** (536-722)	**1180** (924-1430)	1413
Race/ethnicity							
Mexican Americans	99-00	**72.5** (59.1-88.9)	**64.2** (47.1-91.1)	**243** (176-310)	**674** (468-1080)	**1360** (753-2690)	816
	01-02	**36.8** (27.7-48.9)	**36.9** (24.8-56.9)	**148** (101-225)	**441** (307-585)	**722** (578-1160)	676
Non-Hispanic blacks	99-00	**59.1** (46.5-75.1)	**66.9** (52.1-87.1)	**171** (134-207)	**377** (316-533)	**797** (562-1010)	607
	01-02	**46.4** (33.7-63.8)	**51.0** (35.5-70.8)	**167** (105-249)	**499** (263-794)	**939** (542-1530)	705
Non-Hispanic whites	99-00	**72.8** (60.3-88.0)	**67.5** (55.3-81.5)	**207** (160-249)	**560** (442-659)	**908** (742-1350)	917
	01-02	**48.1** (43.4-53.4)	**47.5** (42.4-56.1)	**163** (138-191)	**463** (375-627)	**957** (805-1220)	1217

Figure 23. Daidzein (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 215. Enterodiol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**26.6** (21.9-32.3)	**34.0** (29.4-38.7)	**78.7** (62.6-95.5)	**165** (135-215)	**266** (215-335)	2527
	01-02	**35.7** (32.5-39.3)	**39.4** (36.3-43.4)	**89.0** (80.7-96.9)	**180** (162-205)	**252** (223-295)	2794
Age group							
6-11 years	99-00	**26.5** (17.1-41.0)	**29.4** (21.2-44.2)	**77.6** (44.2-109)	**193** (91.1-279)	**276** (131-458)	327
	01-02	**33.6** (29.8-37.8)	**35.4** (29.4-43.7)	**78.1** (63.8-87.0)	**150** (113-171)	**201** (167-327)	396
12-19 years	99-00	**29.8** (23.8-37.2)	**33.9** (27.4-42.0)	**83.9** (59.1-101)	**166** (112-234)	**247** (182-337)	744
	01-02	**35.3** (30.5-40.9)	**37.7** (34.8-43.4)	**84.2** (72.1-96.9)	**162** (128-206)	**238** (169-343)	744
20 years and older	99-00	**26.1** (21.8-31.3)	**34.3** (29.8-38.7)	**78.2** (63.5-94.8)	**160** (132-196)	**261** (189-335)	1456
	01-02	**36.1** (31.8-41.0)	**40.4** (36.0-45.7)	**91.2** (79.3-105)	**190** (161-220)	**254** (224-311)	1654
Gender							
Males	99-00	**25.3** (19.5-32.7)	**33.0** (28.0-38.0)	**72.6** (54.7-94.3)	**149** (109-219)	**258** (167-280)	1206
	01-02	**35.2** (31.8-39.1)	**40.5** (36.8-44.8)	**90.6** (82.3-103)	**182** (158-198)	**263** (223-338)	1375
Females	99-00	**27.9** (23.4-33.3)	**36.0** (29.9-40.3)	**84.4** (71.8-97.9)	**174** (146-219)	**279** (219-375)	1321
	01-02	**36.2** (32.2-40.7)	**38.3** (35.3-43.4)	**87.0** (75.6-98.5)	**174** (152-212)	**245** (220-283)	1419
Race/ethnicity							
Mexican Americans	99-00	**21.7** (19.5-24.1)	**28.0** (24.7-34.7)	**70.4** (60.8-78.8)	**143** (117-169)	**213** (169-256)	791
	01-02	**30.5** (25.7-36.3)	**34.0** (29.0-39.2)	**75.2** (58.8-89.7)	**159** (119-202)	**244** (192-298)	679
Non-Hispanic blacks	99-00	**25.8** (21.7-30.7)	**31.2** (24.4-35.9)	**66.0** (50.2-86.7)	**157** (122-193)	**260** (185-336)	608
	01-02	**35.0** (28.9-42.3)	**38.7** (33.2-49.0)	**83.6** (70.0-103)	**168** (132-186)	**218** (175-339)	706
Non-Hispanic whites	99-00	**29.2** (24.0-35.4)	**37.5** (31.3-43.8)	**85.8** (68.3-99.4)	**171** (138-228)	**270** (187-375)	915
	01-02	**35.6** (31.8-40.0)	**40.4** (36.0-44.4)	**89.6** (78.4-101)	**174** (153-198)	**254** (214-337)	1222

Table 216. Enterodiol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**24.2** (20.3-28.9)	**29.9** (25.0-34.7)	**70.5** (59.6-82.1)	**146** (124-177)	**240** (199-320)	2527
	01-02	**33.4** (30.6-36.6)	**37.5** (33.0-42.0)	**78.3** (71.8-87.0)	**147** (135-163)	**224** (193-246)	2784
Age group							
6-11 years	99-00	**27.0** (18.6-39.3)	**33.7** (21.8-43.7)	**62.7** (43.0-108)	**150** (81.6-290)	**290** (150-411)	327
	01-02	**38.1** (32.5-44.7)	**39.3** (30.8-53.0)	**78.3** (66.6-101)	**188** (147-244)	**304** (242-389)	395
12-19 years	99-00	**20.1** (16.7-24.2)	**24.1** (19.6-30.1)	**55.0** (42.6-71.7)	**99.5** (91.5-116)	**158** (121-177)	744
	01-02	**27.2** (23.3-31.8)	**28.6** (24.9-34.9)	**62.7** (54.9-71.0)	**104** (84.2-139)	**152** (111-225)	744
20 years and older	99-00	**24.7** (20.6-29.5)	**30.6** (26.0-34.8)	**72.7** (62.5-84.5)	**155** (129-184)	**240** (199-344)	1456
	01-02	**34.0** (30.2-38.3)	**39.4** (32.5-44.8)	**83.3** (74.0-92.5)	**150** (136-166)	**223** (188-250)	1645
Gender							
Males	99-00	**19.8** (15.4-25.4)	**25.4** (20.0-31.4)	**55.1** (46.4-64.2)	**121** (94.6-168)	**197** (145-282)	1206
	01-02	**28.7** (26.0-31.7)	**31.4** (27.0-36.7)	**71.2** (64.2-78.0)	**138** (117-160)	**212** (179-259)	1371
Females	99-00	**29.3** (25.0-34.4)	**34.9** (29.5-41.6)	**85.2** (74.5-92.3)	**164** (141-201)	**321** (226-370)	1321
	01-02	**38.6** (34.6-43.1)	**43.5** (39.3-48.7)	**88.3** (74.7-102)	**157** (137-172)	**225** (179-298)	1413
Race/ethnicity							
Mexican Americans	99-00	**19.6** (17.3-22.2)	**23.5** (19.7-28.7)	**59.6** (49.8-77.7)	**134** (114-154)	**193** (154-227)	791
	01-02	**28.7** (24.5-33.6)	**31.0** (27.0-36.8)	**64.1** (55.0-77.5)	**130** (94.4-182)	**223** (143-331)	676
Non-Hispanic blacks	99-00	**16.6** (13.9-19.7)	**18.8** (14.4-22.9)	**47.3** (37.7-55.8)	**113** (85.9-145)	**165** (131-272)	608
	01-02	**24.5** (19.7-30.6)	**26.8** (22.6-33.3)	**57.5** (48.1-73.2)	**117** (92.2-141)	**157** (118-246)	705
Non-Hispanic whites	99-00	**28.6** (24.3-33.6)	**33.8** (28.9-39.3)	**75.8** (65.3-87.2)	**162** (130-197)	**252** (203-363)	915
	01-02	**35.1** (31.5-39.2)	**40.8** (33.7-46.5)	**82.7** (74.3-90.3)	**151** (136-169)	**224** (187-275)	1217

Figure 24. Enterodiol (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 217. Enterolactone

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**239** (200-286)	**315** (245-381)	**726** (595-879)	**1970** (1440-2370)	**2790** (2480-3070)	2548
	01-02	**259** (233-287)	**348** (314-389)	**807** (739-873)	**1590** (1420-1820)	**2720** (1870-3430)	2794
Age group							
6-11 years	99-00	**308** (219-432)	**353** (243-474)	**721** (520-1320)	**1730** (973-2840)	**2840** (1700-3590)	331
	01-02	**288** (245-339)	**329** (271-412)	**680** (566-775)	**1380** (929-1620)	**2160** (1420-2550)	396
12-19 years	99-00	**250** (191-327)	**317** (242-410)	**670** (454-888)	**1760** (973-2480)	**2900** (1950-4330)	746
	01-02	**267** (231-308)	**321** (255-399)	**729** (617-856)	**1480** (1230-1800)	**2180** (1560-3310)	744
20 years and older	99-00	**230** (193-274)	**310** (242-375)	**728** (599-888)	**1980** (1490-2390)	**2790** (2510-3540)	1471
	01-02	**254** (223-289)	**355** (310-394)	**835** (760-914)	**1660** (1460-1890)	**2840** (1890-3610)	1654
Gender							
Males	99-00	**254** (212-304)	**351** (265-417)	**778** (579-1050)	**1980** (1580-2400)	**2730** (2430-3350)	1219
	01-02	**262** (233-295)	**340** (314-387)	**873** (769-957)	**1800** (1490-2470)	**3050** (1990-4070)	1375
Females	99-00	**226** (180-284)	**287** (236-339)	**684** (554-795)	**1880** (1200-2460)	**2830** (2100-4330)	1329
	01-02	**255** (226-288)	**355** (293-397)	**759** (680-840)	**1440** (1190-1700)	**2200** (1710-2950)	1419
Race/ethnicity							
Mexican Americans	99-00	**212** (169-265)	**281** (230-335)	**631** (539-732)	**1650** (950-2210)	**2690** (2380-3350)	813
	01-02	**275** (221-342)	**347** (312-395)	**777** (671-913)	**1520** (1090-1920)	**2280** (1610-2990)	679
Non-Hispanic blacks	99-00	**262** (196-349)	**360** (293-440)	**759** (629-925)	**1710** (1000-2420)	**2500** (1870-3280)	605
	01-02	**278** (226-342)	**417** (341-479)	**769** (686-853)	**1450** (1110-1710)	**1960** (1540-2420)	706
Non-Hispanic whites	99-00	**247** (196-311)	**317** (240-403)	**751** (616-955)	**2040** (1600-2450)	**2950** (2460-3880)	917
	01-02	**267** (235-303)	**354** (307-397)	**834** (750-923)	**1630** (1420-1890)	**2780** (1820-3740)	1222

Table 218. Enterolactone (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**218** (184-260)	**284** (247-336)	**733** (613-869)	**1570** (1290-1830)	**2240** (1860-2830)	2548
	01-02	**242** (219-267)	**322** (293-358)	**755** (668-857)	**1430** (1240-1590)	**2120** (1690-2450)	2784
Age group							
6-11 years	99-00	**315** (238-416)	**384** (266-435)	**703** (495-1110)	**1570** (1110-2010)	**2100** (1580-3040)	331
	01-02	**327** (273-391)	**349** (262-478)	**725** (603-994)	**1400** (1140-1800)	**1970** (1420-2940)	395
12-19 years	99-00	**169** (133-214)	**208** (172-264)	**484** (371-615)	**1150** (742-1540)	**1850** (1310-2350)	746
	01-02	**206** (178-239)	**254** (223-293)	**619** (466-753)	**1110** (869-1480)	**1490** (1140-2080)	744
20 years and older	99-00	**217** (181-261)	**288** (249-350)	**785** (653-923)	**1610** (1330-1890)	**2300** (1890-3110)	1471
	01-02	**240** (212-270)	**330** (300-375)	**784** (672-915)	**1460** (1300-1630)	**2180** (1890-2470)	1645
Gender							
Males	99-00	**199** (170-234)	**263** (228-309)	**664** (490-828)	**1380** (1200-1710)	**2010** (1780-2480)	1219
	01-02	**213** (191-238)	**288** (256-317)	**682** (602-764)	**1340** (1090-1580)	**1940** (1560-2550)	1371
Females	99-00	**238** (191-297)	**302** (260-379)	**819** (662-954)	**1690** (1390-2010)	**2550** (1940-3390)	1329
	01-02	**273** (240-311)	**356** (313-407)	**824** (698-1010)	**1490** (1320-1670)	**2150** (1900-2410)	1413
Race/ethnicity							
Mexican Americans	99-00	**194** (165-228)	**254** (225-282)	**605** (519-695)	**1340** (969-1740)	**2100** (1620-2790)	813
	01-02	**258** (213-313)	**356** (296-408)	**725** (590-905)	**1240** (1010-1470)	**1610** (1240-2540)	676
Non-Hispanic blacks	99-00	**168** (125-226)	**212** (173-274)	**539** (411-732)	**1130** (874-1450)	**1590** (1120-2560)	605
	01-02	**195** (155-245)	**302** (257-332)	**561** (477-629)	**972** (821-1130)	**1490** (1080-1730)	705
Non-Hispanic whites	99-00	**241** (194-300)	**323** (279-388)	**828** (674-997)	**1780** (1390-2020)	**2480** (1930-3340)	917
	01-02	**264** (231-301)	**339** (299-393)	**828** (716-944)	**1520** (1320-1850)	**2410** (1950-2800)	1217

Figure 25. Enterolactone (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 219. Equol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**8.37** (7.21-9.72)	**8.02** (6.27-9.90)	**17.2** (15.2-19.8)	**35.0** (28.9-41.6)	**53.5** (40.1-74.2)	2182
	01-02	**9.17** (7.76-10.8)	**9.00** (7.40-10.5)	**19.6** (16.6-23.5)	**42.1** (34.3-51.5)	**72.2** (53.6-89.2)	2794
Age group							
6-11 years	99-00	**10.5** (7.65-14.3)	**11.2** (5.43-18.6)	**24.9** (17.5-29.5)	**34.4** (29.5-53.3)	**54.8** (30.1-149)	272
	01-02	**12.2** (10.2-14.6)	**13.6** (11.1-16.0)	**26.2** (17.9-36.3)	**50.0** (35.0-84.3)	**85.4** (50.4-159)	396
12-19 years	99-00	**10.9** (8.64-13.8)	**10.7** (8.52-13.4)	**22.0** (16.0-34.9)	**42.9** (34.1-71.3)	**71.6** (48.1-210)	657
	01-02	**10.2** (8.50-12.1)	**10.4** (8.20-12.5)	**20.4** (16.8-24.8)	**43.1** (30.1-56.1)	**64.4** (46.3-99.2)	744
20 years and older	99-00	**7.79** (6.79-8.94)	**7.43** (5.71-8.85)	**16.0** (13.6-18.1)	**33.1** (24.4-39.7)	**52.2** (36.3-93.9)	1253
	01-02	**8.70** (7.29-10.4)	**8.00** (6.20-10.1)	**18.6** (15.0-22.3)	**41.2** (34.1-47.4)	**73.5** (53.9-89.0)	1654
Gender							
Males	99-00	**9.15** (7.37-11.4)	**8.44** (6.36-11.2)	**19.0** (15.9-24.0)	**35.6** (29.2-54.8)	**71.3** (39.7-166)	1042
	01-02	**9.41** (7.99-11.1)	**9.10** (7.60-10.7)	**20.1** (16.7-26.1)	**43.1** (32.4-53.1)	**61.7** (51.8-81.5)	1375
Females	99-00	**7.70** (6.79-8.75)	**7.57** (5.79-9.04)	**15.6** (12.7-18.9)	**33.5** (26.7-37.7)	**48.2** (37.1-62.9)	1140
	01-02	**8.94** (7.38-10.8)	**8.50** (6.70-10.7)	**19.0** (15.6-22.9)	**41.5** (33.3-51.5)	**79.8** (56.6-122)	1419
Race/ethnicity							
Mexican Americans	99-00	**5.24** (4.77-5.76)	**4.49** (3.65-5.18)	**9.44** (7.96-10.3)	**18.5** (14.5-22.6)	**30.9** (21.6-48.4)	726
	01-02	**7.22** (6.04-8.62)	**6.40** (4.40-9.00)	**14.2** (11.3-20.1)	**31.2** (21.1-41.0)	**42.4** (37.2-49.2)	679
Non-Hispanic blacks	99-00	**6.73** (5.20-8.71)	**6.24** (3.86-10.0)	**15.1** (12.7-17.6)	**27.6** (19.4-35.6)	**36.4** (28.9-49.4)	514
	01-02	**7.15** (6.06-8.43)	**6.00** (4.60-7.60)	**14.7** (11.8-18.7)	**30.9** (22.8-41.9)	**45.7** (36.1-90.5)	706
Non-Hispanic whites	99-00	**9.26** (7.80-11.0)	**8.95** (6.73-11.9)	**19.0** (16.1-22.7)	**36.1** (30.1-45.4)	**56.1** (42.1-89.4)	758
	01-02	**9.91** (7.95-12.4)	**9.90** (7.30-12.6)	**22.0** (17.4-27.4)	**44.4** (35.1-57.5)	**74.4** (55.1-107)	1222

Table 220. Equol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**7.70** (6.82-8.70)	**7.96** (6.87-9.35)	**16.2** (13.2-18.6)	**30.6** (26.9-35.1)	**50.3** (41.8-67.3)	2182
	01-02	**8.55** (7.22-10.1)	**7.94** (6.52-9.71)	**17.4** (14.6-21.5)	**37.1** (30.1-46.3)	**62.6** (50.0-85.0)	2784
Age group							
6-11 years	99-00	**10.3** (7.83-13.5)	**11.4** (7.46-16.3)	**22.6** (14.7-27.2)	**31.5** (25.5-46.0)	**47.8** (32.7-150)	272
	01-02	**13.8** (11.2-17.2)	**14.0** (10.6-17.0)	**28.7** (19.6-39.8)	**54.4** (34.9-99.8)	**88.2** (56.8-186)	395
12-19 years	99-00	**7.61** (6.17-9.39)	**8.02** (6.72-9.29)	**13.9** (11.4-20.4)	**27.3** (20.8-38.3)	**47.4** (27.5-149)	657
	01-02	**7.83** (6.68-9.17)	**7.77** (6.29-9.13)	**17.3** (14.9-19.2)	**31.9** (25.3-41.7)	**50.6** (33.0-76.7)	744
20 years and older	99-00	**7.45** (6.60-8.41)	**7.63** (6.34-9.22)	**15.3** (12.7-17.7)	**30.8** (25.0-37.2)	**51.6** (41.2-71.8)	1253
	01-02	**8.17** (6.88-9.72)	**7.50** (5.97-9.32)	**16.3** (13.7-20.2)	**36.3** (28.2-43.3)	**58.7** (47.9-85.0)	1645
Gender							
Males	99-00	**7.01** (5.93-8.29)	**7.31** (5.63-8.78)	**13.8** (11.7-17.6)	**29.3** (21.4-41.8)	**54.1** (35.8-81.0)	1042
	01-02	**7.62** (6.35-9.14)	**7.38** (5.80-9.13)	**16.0** (13.9-19.2)	**32.4** (27.5-41.2)	**54.3** (37.7-66.2)	1371
Females	99-00	**8.41** (7.33-9.66)	**8.65** (7.33-10.1)	**17.4** (15.1-19.9)	**31.6** (27.5-37.2)	**46.0** (41.0-56.5)	1140
	01-02	**9.55** (7.95-11.5)	**8.65** (6.85-10.6)	**19.0** (15.7-23.3)	**41.7** (32.3-56.8)	**77.1** (61.7-115)	1413
Race/ethnicity							
Mexican Americans	99-00	**4.89** (4.36-5.47)	**4.73** (3.90-5.27)	**8.83** (8.18-9.91)	**22.3** (16.5-26.8)	**36.8** (25.3-57.6)	726
	01-02	**6.73** (5.71-7.92)	**6.78** (5.47-8.04)	**14.9** (11.6-17.8)	**28.2** (22.3-35.3)	**40.6** (29.5-55.2)	676
Non-Hispanic blacks	99-00	**4.36** (3.41-5.57)	**4.57** (2.94-6.23)	**10.2** (7.96-12.0)	**17.1** (14.8-19.8)	**25.6** (19.6-32.0)	514
	01-02	**5.00** (4.25-5.89)	**4.48** (3.76-5.42)	**10.9** (8.74-13.0)	**22.4** (16.5-29.3)	**35.3** (24.5-46.7)	705
Non-Hispanic whites	99-00	**9.13** (7.85-10.6)	**9.38** (7.63-11.2)	**18.0** (15.2-21.6)	**35.1** (29.5-41.3)	**56.5** (46.0-73.0)	758
	01-02	**9.76** (7.89-12.1)	**9.03** (6.87-12.1)	**19.5** (15.3-25.4)	**41.4** (30.6-56.8)	**67.0** (56.8-85.0)	1217

Figure 26. Equol (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 221. Genistein

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**24.4** (19.7-30.3)	**27.0** (22.5-32.8)	**93.6** (75.8-118)	**284** (244-331)	**562** (413-709)	2557
	01-02	**33.0** (30.1-36.2)	**28.9** (26.8-31.7)	**92.5** (77.9-109)	**306** (240-372)	**613** (523-719)	2794
Age group							
6-11 years	99-00	**27.6** (21.1-36.1)	**31.9** (18.1-42.6)	**104** (67.6-151)	**218** (151-315)	**376** (272-725)	331
	01-02	**39.2** (33.4-46.0)	**31.5** (25.8-39.6)	**94.1** (61.8-158)	**258** (188-399)	**502** (258-830)	396
12-19 years	99-00	**43.7** (34.2-55.7)	**45.4** (34.3-60.5)	**137** (93.7-179)	**319** (245-464)	**547** (321-777)	754
	01-02	**34.1** (27.2-42.8)	**28.9** (25.7-32.8)	**90.1** (69.2-110)	**278** (216-363)	**467** (360-687)	744
20 years and older	99-00	**21.9** (17.6-27.2)	**24.0** (21.7-28.4)	**86.2** (67.5-108)	**284** (235-343)	**566** (412-744)	1472
	01-02	**32.1** (28.8-35.8)	**28.8** (25.4-33.4)	**93.4** (77.3-110)	**312** (235-389)	**627** (530-788)	1654
Gender							
Males	99-00	**29.8** (22.2-40.0)	**31.8** (26.3-37.2)	**108** (79.1-151)	**335** (257-440)	**709** (437-981)	1222
	01-02	**32.2** (27.9-37.2)	**29.5** (25.4-33.7)	**90.7** (73.4-103)	**239** (190-331)	**470** (335-719)	1375
Females	99-00	**20.3** (17.0-24.2)	**23.1** (20.1-26.3)	**84.7** (59.6-105)	**235** (203-288)	**427** (339-619)	1335
	01-02	**33.7** (30.9-36.8)	**28.7** (26.0-32.3)	**97.0** (79.9-118)	**385** (253-500)	**666** (598-807)	1419
Race/ethnicity							
Mexican Americans	99-00	**31.1** (25.1-38.5)	**30.0** (25.1-37.3)	**117** (83.9-179)	**328** (248-479)	**570** (419-1180)	819
	01-02	**28.3** (22.0-36.4)	**25.6** (19.2-32.4)	**74.5** (48.8-111)	**225** (174-314)	**424** (323-523)	679
Non-Hispanic blacks	99-00	**26.7** (19.2-37.0)	**32.8** (24.4-41.5)	**103** (84.8-137)	**252** (209-364)	**495** (329-926)	608
	01-02	**37.6** (27.4-51.6)	**35.2** (23.6-49.5)	**95.5** (71.1-142)	**375** (188-523)	**596** (375-1120)	706
Non-Hispanic whites	99-00	**23.6** (19.1-29.3)	**25.3** (21.7-32.0)	**91.4** (68.0-122)	**284** (227-353)	**566** (395-734)	917
	01-02	**30.9** (27.8-34.4)	**27.6** (24.6-30.8)	**89.7** (70.7-105)	**276** (226-365)	**626** (485-755)	1222

## Table 222. Genistein (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**22.3** (17.7-28.1)	**23.8** (18.8-28.9)	**84.7** (67.2-105)	**222** (182-279)	**380** (334-497)	2557
	01-02	**30.9** (28.5-33.6)	**25.9** (23.7-29.1)	**83.1** (72.2-96.4)	**257** (211-296)	**427** (374-490)	2784
Age group							
6-11 years	99-00	**28.3** (21.1-37.9)	**27.8** (15.8-41.3)	**94.3** (60.5-145)	**206** (148-317)	**490** (279-895)	331
	01-02	**44.6** (37.1-53.6)	**37.7** (29.7-49.0)	**110** (76.5-146)	**250** (173-371)	**487** (252-713)	395
12-19 years	99-00	**29.4** (22.3-38.8)	**32.0** (23.8-41.6)	**83.2** (64.1-104)	**181** (130-295)	**336** (184-816)	754
	01-02	**26.3** (21.3-32.5)	**21.0** (17.8-26.5)	**66.2** (47.9-91.5)	**200** (149-298)	**321** (261-435)	744
20 years and older	99-00	**20.6** (16.3-26.2)	**21.6** (17.7-26.2)	**83.1** (64.9-107)	**234** (190-287)	**381** (325-562)	1472
	01-02	**30.4** (27.6-33.4)	**24.7** (21.9-30.0)	**83.1** (68.5-99.0)	**269** (208-328)	**435** (374-518)	1645
Gender							
Males	99-00	**23.3** (16.8-32.3)	**23.8** (17.5-32.2)	**86.1** (64.7-115)	**234** (178-330)	**523** (323-889)	1222
	01-02	**26.2** (23.1-29.8)	**22.0** (19.4-26.0)	**67.6** (57.5-77.0)	**186** (145-237)	**350** (278-418)	1371
Females	99-00	**21.3** (17.5-26.0)	**22.9** (17.5-29.3)	**83.1** (57.2-106)	**209** (154-283)	**357** (283-398)	1335
	01-02	**36.2** (32.8-39.8)	**29.6** (25.5-33.8)	**107** (87.9-129)	**321** (269-356)	**571** (427-729)	1413
Race/ethnicity							
Mexican Americans	99-00	**28.4** (23.3-34.7)	**27.9** (22.5-35.0)	**109** (91.5-137)	**257** (209-380)	**562** (257-981)	819
	01-02	**26.6** (21.6-32.7)	**20.8** (16.1-28.5)	**60.1** (50.5-73.4)	**208** (162-270)	**371** (271-479)	676
Non-Hispanic blacks	99-00	**17.1** (12.4-23.7)	**19.5** (15.7-26.1)	**59.0** (43.1-93.7)	**178** (132-245)	**299** (222-446)	608
	01-02	**26.4** (19.3-36.1)	**22.7** (16.4-33.6)	**69.4** (42.2-115)	**206** (140-317)	**384** (217-747)	705
Non-Hispanic whites	99-00	**23.2** (18.5-29.0)	**24.9** (19.0-31.7)	**86.1** (68.4-105)	**232** (178-295)	**381** (325-523)	917
	01-02	**30.6** (28.3-33.2)	**25.4** (22.7-29.6)	**82.0** (68.3-96.3)	**248** (204-320)	**426** (365-518)	1217

Figure 27. Genistein (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 223. O-Desmethylangolensin

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**4.39** (3.37-5.73)	**4.98** (3.65-6.77)	**22.7** (18.7-30.2)	**100** (74.8-141)	**222** (182-250)	2271
	01-02	**4.08** (3.53-4.73)	**3.30** (2.60-4.00)	**19.7** (16.6-24.6)	**96.0** (70.1-135)	**260** (153-435)	2794
Age group							
6-11 years	99-00	**5.60** (3.85-8.15)	**7.52** (3.43-15.2)	**36.1** (20.3-45.0)	**78.5** (43.4-191)	**168** (74.8-264)	287
	01-02	**6.19** (4.51-8.49)	**5.70** (3.80-9.30)	**26.2** (15.7-52.1)	**116** (61.5-215)	**281** (161-466)	396
12-19 years	99-00	**6.04** (3.76-9.70)	**7.58** (5.13-13.5)	**36.4** (22.0-57.3)	**106** (63.4-165)	**194** (107-238)	667
	01-02	**5.92** (4.46-7.87)	**5.20** (3.60-7.50)	**33.6** (18.0-56.8)	**125** (91.2-172)	**249** (172-435)	744
20 years and older	99-00	**4.05** (3.12-5.26)	**4.46** (3.31-5.64)	**19.8** (16.0-26.5)	**101** (80.8-150)	**228** (179-259)	1317
	01-02	**3.65** (3.08-4.32)	**2.70** (2.20-3.60)	**17.0** (13.9-22.4)	**81.5** (63.0-128)	**259** (135-493)	1654
Gender							
Males	99-00	**4.97** (3.71-6.66)	**5.62** (4.12-8.73)	**29.1** (19.8-42.9)	**121** (74.1-190)	**235** (177-332)	1087
	01-02	**3.81** (3.08-4.71)	**3.20** (2.50-4.00)	**17.4** (13.2-24.6)	**82.2** (58.4-116)	**194** (123-324)	1375
Females	99-00	**3.92** (2.97-5.16)	**4.21** (3.18-5.51)	**19.4** (14.1-26.1)	**83.8** (61.1-114)	**192** (123-250)	1184
	01-02	**4.36** (3.64-5.23)	**3.40** (2.50-4.50)	**21.2** (16.8-29.2)	**106** (70.6-199)	**394** (230-746)	1419
Race/ethnicity							
Mexican Americans	99-00	**2.41** (1.55-3.73)	**2.14** (1.31-3.37)	**21.0** (10.6-30.5)	**96.6** (59.7-140)	**191** (122-320)	721
	01-02	**2.44** (1.51-3.94)	**1.40** (.500-3.40)	**12.6** (5.80-27.6)	**65.2** (33.5-102)	**152** (75.8-265)	679
Non-Hispanic blacks	99-00	**5.74** (4.55-7.24)	**8.43** (5.82-10.9)	**33.5** (22.1-52.4)	**106** (78.3-156)	**192** (149-255)	538
	01-02	**5.35** (4.00-7.14)	**5.30** (2.80-7.20)	**32.7** (21.8-52.4)	**119** (75.9-216)	**303** (150-436)	706
Non-Hispanic whites	99-00	**4.50** (3.26-6.22)	**4.99** (3.43-7.10)	**22.5** (17.1-34.4)	**100** (72.0-152)	**228** (177-259)	826
	01-02	**4.13** (3.43-4.96)	**3.40** (2.60-4.20)	**17.9** (15.5-23.8)	**98.7** (67.4-153)	**260** (148-493)	1222

Table 224. O-Desmethylangolensin (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	50th	75th	90th	95th	Sample size
Total, age 6 and older	99-00	**4.03** (2.97-5.45)	**4.43** (3.10-6.34)	**21.8** (15.3-31.6)	**90.4** (62.9-122)	**167** (140-218)	2271
	01-02	**3.81** (3.31-4.39)	**3.20** (2.53-4.00)	**18.8** (16.1-22.9)	**85.2** (65.1-116)	**289** (153-421)	2784
Age group							
6-11 years	99-00	**6.00** (4.04-8.91)	**7.09** (3.94-16.6)	**28.8** (14.3-45.0)	**83.3** (45.0-167)	**167** (88.2-262)	287
	01-02	**7.03** (5.05-9.78)	**6.49** (4.24-11.6)	**29.9** (16.3-54.1)	**101** (75.3-199)	**305** (134-464)	395
12-19 years	99-00	**4.13** (2.33-7.35)	**5.67** (2.82-11.5)	**26.0** (14.7-44.4)	**71.4** (40.8-122)	**115** (75.2-262)	667
	01-02	**4.57** (3.44-6.07)	**3.88** (2.82-5.32)	**26.0** (18.0-35.9)	**95.0** (61.4-129)	**259** (129-331)	744
20 years and older	99-00	**3.82** (2.84-5.13)	**3.90** (2.69-5.73)	**20.2** (12.9-29.2)	**96.5** (61.8-133)	**172** (140-252)	1317
	01-02	**3.43** (2.94-4.00)	**2.71** (2.00-3.57)	**16.4** (13.5-19.6)	**78.5** (58.2-124)	**289** (149-470)	1645
Gender							
Males	99-00	**3.95** (2.79-5.58)	**4.46** (2.88-6.50)	**24.5** (13.8-40.5)	**96.5** (62.4-122)	**209** (125-265)	1087
	01-02	**3.09** (2.48-3.86)	**2.86** (2.00-4.07)	**15.1** (10.4-19.9)	**60.0** (42.1-90.2)	**151** (93.6-311)	1371
Females	99-00	**4.10** (3.00-5.61)	**4.14** (2.91-6.34)	**20.4** (14.4-27.2)	**86.0** (49.1-145)	**155** (100-205)	1184
	01-02	**4.64** (3.83-5.63)	**3.67** (2.73-4.81)	**25.8** (18.1-34.0)	**116** (71.3-205)	**421** (175-739)	1413
Race/ethnicity							
Mexican Americans	99-00	**2.19** (1.49-3.24)	**1.88** (1.15-3.10)	**14.7** (11.3-25.8)	**71.2** (52.3-113)	**135** (90.5-251)	721
	01-02	**2.29** (1.47-3.57)	**1.38** (.748-3.17)	**11.8** (4.91-23.6)	**47.4** (31.4-87.8)	**113** (54.7-242)	676
Non-Hispanic blacks	99-00	**3.65** (2.90-4.60)	**5.22** (3.58-6.75)	**23.8** (17.6-32.1)	**65.2** (52.1-79.7)	**116** (81.9-239)	538
	01-02	**3.75** (2.76-5.10)	**3.56** (2.14-5.56)	**22.8** (15.3-30.4)	**75.6** (46.5-175)	**207** (98.5-339)	705
Non-Hispanic whites	99-00	**4.42** (3.12-6.27)	**4.65** (3.05-7.23)	**22.3** (15.3-37.9)	**96.5** (57.6-148)	**177** (140-215)	826
	01-02	**4.05** (3.39-4.84)	**3.50** (2.43-4.57)	**20.2** (16.1-25.9)	**93.7** (69.8-125)	**301** (153-482)	1217

Figure 28. O-Desmethylangolensin (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Results by Chemical Group

Organochlorine Pesticides

Organochlorine Pesticides

General Information

Organochlorine pesticides, including DDT, are effective against a variety of insects. Some organochlorines, including hexachlorobenzene and pentachlorophenol, have been used primarily as fungicides and antimicrobials. These chemicals were introduced in the 1940s, and many of their uses have been restricted by the U.S. EPA because of their persistence in the environment. Although many of these chemicals are no longer widely used in the United States, other countries continue to use them.

Organochlorine pesticides can enter the environment from direct application and runoff, disposal of contaminated wastes into landfills, emissions from waste incinerators, and releases from manufacturing plants that produce these chemicals. Some organochlorine pesticides are volatile or can adhere to soil or particles in the air. In aquatic systems, organochlorine pesticides are adsorbed onto sediments in water that can then bioaccumulate in fish and other marine mammals. Because these chemicals are soluble in fat, they are found at higher concentrations in fatty foods. In the general population, the diet is the main source of exposure to organochlorine pesticides, primarily through the ingestion of fatty foods (such as milk, dairy products, and fish). Minor sources of exposure for the general population include contaminated drinking water and air. Infants can be exposed to these chemicals through breast milk and the fetus can be exposed in utero via the placenta. Workers can be exposed to organochlorine chemicals in the manufacture, formulation, or application of these chemicals. The U.S. FDA, U.S. EPA, and OSHA have developed criteria on the allowable levels of certain organochlorine chemicals in foods, the environment, and the workplace.

Organochlorine pesticides vary in their chemical structures and mechanisms of toxicity. They can be classified into four categories: dichlorodiphenylethanes (e.g., DDT), cyclodienes (e.g., heptachlor, dieldrin), chlorinated benzenes (e.g., hexachlorobenzene [HCB]), and cyclohexanes (e.g., hexachlorocyclohexane [HCH]). Table 226 shows the parent organochlorine pesticides and their metabolites that were measured for this *Report*. For example, DDT metabolizes to DDE. Measurements of these chemicals can reflect either recent or accumulated chronic exposures or both. Some of the metabolites can be produced from the metabolism of more than one pesticide. In addition to reflecting exposure to the parent pesticide, the level of the metabolite in a person's blood or urine may also reflect exposure to the metabolite itself if it was present in the person's environment. The health effects of exposure to organochlorine pesticides on the general population at current levels of exposure are unknown.

Table 225. Organochlorine pesticides and their metabolites

Organochlorine pesticide (CAS number)	Serum pesticide or metabolite(s) (CAS number)	Urinary pesticide or metabolite(s) (CAS number)
Hexachlorobenzene (118-74-1)	Hexachlorobenzene (118-74-1)	Pentachlorophenol (87-86-5) 2,4,6-Trichlorophenol (88-06-2) 2,4,5-Trichlorophenol (95-95-4)
Hexachlorocyclohexanes	Hexachlorocyclohexane (608-73-1) including beta-HCH (319-85-7) and gamma-HCH (58-89-9) isomers	Pentachlorophenol (87-86-5) 2,4,6-Trichlorophenol (88-06-2) 2,4,5-Trichlorophenol (95-95-4)
Pentachlorophenol (87-86-5)		Pentachlorophenol (87-86-5)
Trichlorophenols Including 2,4,5-Trichlorophenol (95-95-4) and 2,4,6-Trichlorophenol (88-06-2)		2,4,5-Trichlorophenol (95-95-4) 2,4,6-Trichlorophenol (88-06-2)
DDT (50-29-3) *p,p'*-DDT (50-29-3) *o,p'*-DDT (789-02-6)	*p,p'*-DDE (72-55-9)	
Heptachlor (76-44-8)	Heptachlor epoxide (1024-57-3)	
Chlordane (12789-03-6)	Oxychlordane (27304-13-8)	
Mirex (2385-85-5)	Mirex (2385-85-5)	
Aldrin (309-00-02)	Aldrin (309-00-02) Dieldrin (60-57-1)	
Dieldrin (60-57-1)	Dieldrin (60-57-1)	
Endrin (72-20-8)	Endrin (72-20-8)	

Hexachlorobenzene

CAS No. 118-74-1

General Information

Hexachlorobenzene (HCB) is an organochlorine pesticide that was once used in the United States as a fungicide to pretreat grain. The U.S. EPA cancelled the use of HCB as a fungicide in 1984. Hexachlorobenzene may also be produced as a byproduct in the manufacturing process for certain chemicals.

Hexachlorobenzene is a relatively persistent compound in the environment. Because HCB does not dissolve easily in water, it is usually not present in high concentrations in drinking water. The U.S. EPA has issued an advisory for safe levels of HCB in drinking water. In the general population, the diet, including foods high in fats, is a significant source of exposure to HCB. Small amounts of HCB have also been detected in outdoor air. Workers in chemical manufacturing industries may be exposed to higher levels of HCB via inhalation or dermal pathways of exposure.

HCB interferes with the normal synthesis of heme in the body, resulting in the accumulation of abnormal heme precursors. This interference can adversely affect the skin as well as other organ systems. Chronic dietary overexposure to HCB also has caused serious health effects. For example, during the years 1955-1959, HCB-treated grain was processed into bread and consumed by people living in southeastern Turkey. Those with significant exposures developed porphyria cutanea tarda; hyperpigmentation of the skin; and other manifestations, including weakness, paresthesia, thyromegaly, and arthritis. Children born to mothers exposed during that time developed sores on their skin, and many died within the first 2 years of life (Peters et al., 1982). HCB has been associated with reproductive and developmental disorders in experimental animal studies. IARC classifies hexachlorobenzene as possibly carcinogenic to humans, and NTP classifies hexachlorobenzene as reasonably anticipated to be a human carcinogen.

Table 226. Hexachlorobenzene (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1702
	01-02	*	< LOD	< LOD	< LOD	< LOD	2277
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	591
	01-02	*	< LOD	< LOD	< LOD	< LOD	747
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1111
	01-02	*	< LOD	< LOD	< LOD	< LOD	1530
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	< LOD	< LOD	< LOD	1058
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	895
	01-02	*	< LOD	< LOD	< LOD	< LOD	1219
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	583
	01-02	*	< LOD	< LOD	< LOD	< LOD	554
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	350
	01-02	*	< LOD	< LOD	< LOD	< LOD	511
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	1052

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Once exposure to HCB occurs, the chemical is distributed throughout the body and accumulates in fatty tissues. HCB can persist in body fat for many years and is eliminated very slowly from the body. Age-dependent increases of HCB in body fat have been consistently reported in studies of general populations (Bertram et al., 1986; Glynn et al., 2003; Becker et al.; 2002). Grimalt et al. (1994) reported that residents living near an HCB chemical plant had serum HCB levels that were about five-fold greater than levels of residents from a reference community. In another study, serum HCB levels in workers at an HCB plant were about five-fold greater than levels in the local population (Herrero et al., 1999).

Pentachlorophenol (PCP), 2,4,5-trichlorophenol (2,4,5-TCP), and 2,4,6-trichlorophenol (2,4,6-TCP) are urinary metabolites of HCB (To-Figueras et al., 1997). Urinary PCP can also result from exposure to other chlorinated hydrocarbons, such as pentachlorobenzene, hexachloro-cyclohexane, or pentachloronitrobenzene. Similarly, urinary 2,4,5-TCP and 2,4,6-TCP can result from exposure to other chlorinated hydrocarbons such as hexachlorocyclohexane. Because urinary PCP, 2,4,5-

TCP, and 2,4,6-TCP can occur from exposures to chemicals other than HCB, measuring HCB in serum is a more specific indicator of exposure to HCB.

More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc. gov/toxprofiles.

Interpreting Levels of Lipid-Adjusted Serum HCB Reported in the Tables

Serum hexachlorobenzene levels were measured in a subsample of NHANES participants aged 12 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the NHANES 1999-2000 and 2001-2002 subsamples, hexachlorobenzene levels in serum were below the limit of detection. In a probability sample of the German population aged 18-69 years, the mean concentration of HCB in blood was 0.44 µg/L (Becker et al., 2002), which is slightly lower than the limit of

Table 227. Hexachlorobenzene (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1702
	01-02	*	< LOD	< LOD	< LOD	< LOD	2277
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	591
	01-02	*	< LOD	< LOD	< LOD	< LOD	747
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1111
	01-02	*	< LOD	< LOD	< LOD	< LOD	1530
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	< LOD	< LOD	< LOD	1058
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	895
	01-02	*	< LOD	< LOD	< LOD	< LOD	1219
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	583
	01-02	*	< LOD	< LOD	< LOD	< LOD	554
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	350
	01-02	*	< LOD	< LOD	< LOD	< LOD	511
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	1052

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

detection (on a lipid adjusted basis) in this *Report*. HCB was detected in only 4.9% of people in the 1976-1980 NHANES subsample (Stehr-Green et al., 1989). Mean levels in small sample of males and females in Spain were about 100 and 20 fold higher, respectively, than the detection limit in this *Report* (To-Figueras et al., 1997).

Finding a measurable amount of hexachlorobenzene in serum does not mean that the level of the hexachlorobenzene will result in an adverse health effect. These data will help scientists plan and conduct research about exposure to hexachlorobenzene and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of hexachlorobenzene than levels found in the general population.

Hexachlorocylclohexane

CAS No. 608-73-1

General Information

Hexachlorocylclohexane (HCH) is an organochlorine pesticide with several isomeric forms: alpha, beta, gamma, and delta. The gamma isomer, commonly known as lindane, is the only isomer with insecticidal activity. The other isomers are used either as fungicides or to synthesize other chemicals and also may be formed during the synthesis of lindane. Technical-grade HCH contains all four isomers but mostly the alpha isomer. In 1985, many agricultural uses of lindane were cancelled in the United States. Lindane has had limited registration for use in the preplanting treatment of seeds although the U.S. EPA has recently required additional studies about and restrictions on these uses. Agricultural workers may be exposed to lindane via dermal, inhalation, or ingestion routes when applying the chemical. Lindane is also approved for use by the U.S. FDA in topical pharmaceutical products to treat human scabies and lice.

At high doses, gamma-HCH (lindane) blocks inhibitory neurotransmitters in the central nervous system. Seizures and deaths among children have resulted from excess dermal application of 1% lindane lotions and from accidental ingestion of lindane vaporizer tablets used in the past. Workers who directly handled HCH have complained of headache, paresthesias, tremors, and memory loss (Nigam et al., 1986). Blood dyscrasias (anemia, leukopenia) have been reported after accidental or large exposures (Morgan et al., 1980; Rugman et al., 1990). Lindane and other HCH isomers are mainly metabolized to chlorophenols such as 2,4,6-trichlorophenol, 2,4,5-trichlorophenol, and 2,3,5-trichlorophenol. Beta-HCH has a blood elimination half-life of 7 years, whereas gamma-HCH has a shorter blood elimination half-life of only 20 hours.

IARC classifies hexachlorocyclohexane isomers as possibly carcinogenic to humans, and NTP classifies

Table 228. beta-Hexachlorocylclohexane (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	**9.68** (<LOD-10.9)	**< LOD**	**19.0** (16.0-21.6)	**42.0** (33.4-50.6)	**68.9** (50.6-87.6)	1893
	01-02	*	**< LOD**	**10.3** (9.08-11.0)	**23.6** (19.4-29.4)	**43.3** (32.4-55.2)	2291
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**11.4** (<LOD-16.1)	653
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**8.44** (<LOD-12.2)	758
20 years and older	99-00	**10.9** (9.61-12.4)	**< LOD**	**21.0** (18.9-24.0)	**46.0** (35.9-56.8)	**73.4** (52.7-96.0)	1240
	01-02	*	**< LOD**	**11.2** (10.3-13.2)	**25.5** (21.2-33.5)	**46.2** (34.6-62.0)	1533
Gender							
Males	99-00	*	**< LOD**	**14.5** (10.7-19.1)	**29.8** (23.3-38.7)	**44.6** (32.8-68.9)	901
	01-02	*	**< LOD**	**8.24** (7.15-10.1)	**17.7** (15.5-22.2)	**29.2** (22.7-35.8)	1067
Females	99-00	**11.1** (9.56-12.8)	**< LOD**	**22.0** (19.1-27.6)	**51.3** (42.2-67.6)	**81.1** (64.4-111)	992
	01-02	*	**< LOD**	**11.8** (10.4-14.5)	**30.6** (24.2-39.9)	**54.5** (39.9-71.5)	1224
Race/ethnicity							
Mexican Americans	99-00	**16.7** (13.7-20.2)	**15.5** (11.6-20.4)	**37.5** (29.6-47.3)	**97.9** (62.6-135)	**139** (99.8-199)	632
	01-02	*	**7.60** (<LOD-8.63)	**16.6** (13.4-21.1)	**44.0** (32.7-56.4)	**84.4** (55.2-107)	563
Non-Hispanic blacks	99-00	*	**< LOD**	**14.7** (12.0-23.1)	**36.6** (30.0-41.7)	**48.9** (40.9-81.1)	403
	01-02	*	**< LOD**	**7.73** (<LOD-10.4)	**23.3** (11.8-47.3)	**45.9** (20.5-115)	513
Non-Hispanic whites	99-00	*	**< LOD**	**17.5** (14.1-20.5)	**34.4** (25.2-46.0)	**51.3** (40.0-70.8)	702
	01-02	*	**< LOD**	**9.27** (7.60-10.8)	**20.4** (17.1-24.3)	**33.5** (24.3-44.7)	1051

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

hexachlorocyclohexane isomers as reasonably anticipated to be human carcinogens. More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov /toxprofiles.

Interpreting Levels of Lipid-Adjusted Serum beta-HCH and gamma-HCH Reported in the Tables

Serum beta-HCH and gamma-HCH levels were measured in a subsample of NHANES participants aged 12 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Because of its longer half-life, beta-HCH is usually the isomer with the highest concentration in the general population.

The 95th percentile level of beta-HCH for the current 2001-2002 NHANES subsample is similar to the corresponding 95th percentile values reported in a study of adults in Germany (Wilhelm et al., 2003). Another

study of New Zealand adults older than age 15 years that recently reported beta-HCH mean levels to be 19.7 ng/gram of lipid (Bates et al., 2004*b*), which are slightly higher than mean levels reported for the 1999-2000 subsample. The levels of beta-HCH in serum shown in this *Report* are far below a biological tolerance level of 25 μg/L (approximately 4,200 ng/gram of serum lipid) in serum or plasma for workers at the end of their shifts as defined by the Deutsche Forschungsgemeinchaft (2000).

Beta-HCH levels in the U.S. population have been declining since 1970 (Radomski et al., 1971; Stehr-Green et al., 1989; Kutz et al., 1991; Sturgeon et al., 1998). Kutz et al. (1991) estimated that in 1970 nearly 100% of the U.S. population had detectable beta-HCH in adipose tissue and that 80% had detectable concentrations in 1980, with the mean adipose beta-HCH level decreasing from 0.37 μg/gram of lipid (370 ng/gram) in 1971 to 0.10 μg/gram of lipid (100 ng/gram) in 1983. In 1976, the median serum lipid-adjusted level of beta-HCH was 119 ng/gram for a control population of 7,712 Danish females (Hoyer et al., 1998). The large difference between these 1976 levels and current U.S. levels may represent a

Table 229. beta-Hexachlorocylclohexane (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	**.058** (.051-.066)	< LOD	**.124** (.103-.146)	**.286** (.223-.359)	**.447** (.359-.558)	1893
	01-02	*	< LOD	**.066** (.058-.076)	**.160** (.132-.196)	**.296** (.218-.388)	2291
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	**.055** (.047-.070)	653
	01-02	*	< LOD	< LOD	< LOD	**.048** (.030-.066)	758
20 years and older	99-00	**.067** (.059-.077)	< LOD	**.140** (.120-.162)	**.324** (.243-.412)	**.477** (.406-.616)	1240
	01-02	*	< LOD	**.077** (.067-.093)	**.175** (.145-.226)	**.312** (.240-.446)	1533
Gender							
Males	99-00	*	< LOD	**.093** (.077-.117)	**.206** (.157-.249)	**.286** (.215-.474)	901
	01-02	*	< LOD	**.054** (.046-.061)	**.131** (.099-.166)	**.200** (.164-.254)	1067
Females	99-00	**.065** (.056-.077)	< LOD	**.149** (.122-.189)	**.383** (.303-.447)	**.556** (.422-.679)	992
	01-02	*	< LOD	**.082** (.070-.098)	**.204** (.165-.254)	**.368** (.290-.455)	1224
Race/ethnicity							
Mexican Americans	99-00	**.098** (.080-.119)	**.093** (.073-.110)	**.245** (.203-.307)	**.582** (.386-.844)	**.905** (.582-1.37)	632
	01-02	*	**.043** (.034-.052)	**.104** (.083-.129)	**.301** (.211-.453)	**.612** (.400-.851)	563
Non-Hispanic blacks	99-00	*	< LOD	**.104** (.072-.142)	**.243** (.186-.293)	**.359** (.284-.465)	403
	01-02	*	< LOD	**.044** (.030-.070)	**.138** (.076-.265)	**.226** (.125-.674)	513
Non-Hispanic whites	99-00	*	< LOD	**.118** (.095-.142)	**.244** (.172-.339)	**.390** (.283-.508)	702
	01-02	*	< LOD	**.060** (.051-.070)	**.137** (.113-.169)	**.220** (.164-.310)	1051

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

global change in levels over time.

Age-related increases in the levels of beta-HCH have previously been observed by the German Commission on Biological Monitoring (Ewers et al., 1999). In addition, such an age relationship was observed previously in both a nonrandom subsample from the NHANES II (1976-1980) and for beta-HCH levels in adipose tissue (Stehr-Green et al., 1989; Kutz et al., 1991). Also, higher levels in females than in males also had been observed for beta-HCH levels in serum (Stehr-Green et al., 1989), but not in adipose tissue (Burns, 1974).

In the NHANES 1999-2000 and 2001-2002 subsamples, serum levels of gamma-HCH were generally below the limit of detection, and detection limits were lower than values reported in studies of people in other countries including Spain (Botella et al., 2004) and India (Bhatnagar et al., 2004). Levels of lindane in the general population of other countries can be higher than levels in the U.S. population (Radomski et al., 1971), probably because of regional variations in the use of the pesticide.

Serum lindane levels in workers involved in the

manufacture, processing, application, or formulation of HCH were found to be several-fold higher than levels in people with no known occupational exposure to the pesticide (Nigam et al., 1986; Radomski et al., 1971; Angerer et al., 1983). The United Kingdom's benchmark guidance value for workers with lindane exposure is 35 nanomoles per liter (approximately 1,700 ng/gram of lipid) in whole blood or 70 nanomoles per liter in plasma (Wilson, 1999). The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area sets the biological tolerance value for lindane as 20 µg/L (approximately 3,300 ng/gram of lipid) (Deutsche Forschungsgemeinchaft, 2000).

Finding a measurable amount of HCH isomers in serum does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to HCH isomers and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of HCH isomers than levels found in the general population.

Table 230. gamma Hexachlorocylclohexane (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1799
	01-02	*	< LOD	< LOD	< LOD	< LOD	2280
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1139
	01-02	*	< LOD	< LOD	< LOD	< LOD	1522
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	863
	01-02	*	< LOD	< LOD	< LOD	< LOD	1060
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	936
	01-02	*	< LOD	< LOD	< LOD	< LOD	1220
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	631
	01-02	*	< LOD	< LOD	< LOD	< LOD	563
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	380
	01-02	*	< LOD	< LOD	< LOD	< LOD	509
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	646
	01-02	*	< LOD	< LOD	< LOD	< LOD	1045

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 231. gamma Hexachlorocylclohexane (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1799
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	2280
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	660
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	758
20 years and older	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1139
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1522
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	863
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1060
Females	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	936
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1220
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	631
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	563
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	380
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	509
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	646
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1045

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Pentachlorophenol

CAS No. 87-86-5

General Information

Pentachlorophenol (PCP) is used primarily as a fungicide to preserve wood in the United States. The use of PCP has decreased over the years as a result of regulations issued by the U.S. EPA in 1984. Compared with other organochlorine pesticides, PCP is not a highly persistent chemical in the environment. The general population may be exposed through food and water sources, which can be contaminated from either PCP releases or waste-site runoffs or from breakdown products of other organochlorine chemicals (e.g., hexachlorocyclohexane, hexachlorobenzene). Homes containing PCP-treated wood are another source of exposure. Workers who manufacture or apply PCP may inhale it or absorb the chemical through their skin. The U.S. EPA and OSHA have developed criteria for allowable levels of PCP in the environment and in workplaces.

PCP is not extensively metabolized and is eliminated from the body relatively rapidly over the course of hours to days. Some PCP is metabolized to tetrachlorhydroquinone and excreted to a minor extent as glucuronidated conjugates (Braun et al., 1979; Ahlborg et al., 1974). PCP in the body may also be the result of metabolism from HCB (To-Figueras et al., 1997). Acute overexposure to PCP can lead to the uncoupling of oxidative phosphorylation, resulting in severe hyperthermia. These effects have been observed when people ingest or inhale PCP or absorb it through the skin. IARC has determined that pentachlorophenol is possibly carcinogenic to humans. More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Table 232. Pentachlorophenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	.360 (<LOD-.930)	1.30 (.480-2.10)	1994
	01-02	*	< LOD	< LOD	1.23 (.590-1.76)	1.94 (1.58-2.53)	2528
Age group							
6-11 years	99-00	*	< LOD	< LOD	.760 (<LOD-1.51)	1.65 (.990-2.00)	482
	01-02	*	< LOD	< LOD	1.37 (.890-1.70)	2.08 (1.58-2.75)	577
12-19 years	99-00	*	< LOD	< LOD	.650 (<LOD-2.60)	2.00 (.510-5.90)	681
	01-02	*	< LOD	< LOD	1.48 (.850-2.30)	2.30 (1.47-5.04)	826
20-59 years	99-00	*	< LOD	< LOD	< LOD	1.10 (.250-1.70)	831
	01-02	*	< LOD	< LOD	1.01 (<LOD-1.76)	1.86 (1.45-2.53)	1125
Gender							
Males	99-00	*	< LOD	< LOD	.630 (<LOD-1.30)	1.40 (.400-2.20)	973
	01-02	*	< LOD	< LOD	1.31 (.680-1.80)	1.94 (1.47-3.09)	1190
Females	99-00	*	< LOD	< LOD	< LOD	.860 (.280-2.00)	1021
	01-02	*	< LOD	< LOD	1.10 (<LOD-1.78)	1.92 (1.54-2.42)	1338
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	.650 (<LOD-1.90)	696
	01-02	*	< LOD	< LOD	.990 (<LOD-2.37)	1.60 (<LOD-3.14)	680
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.970 (<LOD-2.50)	1.64 (.860-2.70)	521
	01-02	*	< LOD	< LOD	1.73 (1.25-2.29)	2.75 (2.02-3.67)	696
Non-Hispanic whites	99-00	*	< LOD	< LOD	.350 (<LOD-1.10)	1.30 (<LOD-2.30)	603
	01-02	*	< LOD	< LOD	1.16 (<LOD-1.76)	1.91 (1.48-2.42)	951

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Interpreting Levels of Urinary Pentachlorophenol Reported in the Tables

Urinary levels of PCP were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In NHANES 2001-2002, urinary PCP levels at the 95th percentile were approximately five-fold lower than 95th percentile values measured in a nonrandom subsample from NHANES III participants (Hill et al., 1995). Urinary PCP levels at the 95th percentile in this *Report* were approximately two-fold lower than the corresponding 95th percentile values reported in a study of German adults aged 18-69 years (Becker et al., 2003) and approximately seven-fold lower than the 95th percentile levels for children aged 6-14 years (Seifert et al., 2000). Urinary levels of pentachlorophenol in the NHANES 2001-2002 subsample are far below allowable workplace BEIs (ACGIH, 2001).

Finding a measurable amount of PCP in urine does not mean that the level of the PCP will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to PCP and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of PCP than levels found in the general population.

Table 233. Pentachlorophenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	.720 (.643-.857)	1.12 (.892-1.26)	1994
	01-02	*	< LOD	< LOD	1.52 (1.25-1.75)	2.26 (1.67-3.09)	2527
Age group							
6-11 years	99-00	*	< LOD	< LOD	.930 (.581-1.13)	1.39 (.985-1.83)	482
	01-02	*	< LOD	< LOD	1.83 (1.29-3.18)	3.18 (1.83-3.89)	577
12-19 years	99-00	*	< LOD	< LOD	.525 (.277-1.53)	1.26 (.400-2.75)	681
	01-02	*	< LOD	< LOD	1.19 (.904-1.53)	1.82 (1.25-2.82)	825
20-59 years	99-00	*	< LOD	< LOD	< LOD	1.06 (.857-1.20)	831
	01-02	*	< LOD	< LOD	1.52 (1.25-1.75)	2.06 (1.67-2.99)	1125
Gender							
Males	99-00	*	< LOD	< LOD	.750 (.450-.947)	1.13 (.857-1.80)	973
	01-02	*	< LOD	< LOD	1.12 (.946-1.40)	1.73 (1.25-2.92)	1190
Females	99-00	*	< LOD	< LOD	< LOD	1.10 (.857-1.14)	1021
	01-02	*	< LOD	< LOD	1.67 (1.52-1.99)	2.69 (1.93-3.50)	1337
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	.947 (.643-1.68)	696
	01-02	*	< LOD	< LOD	1.09 (.745-2.10)	1.94 (1.06-3.55)	680
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.713 (.390-1.18)	1.34 (.816-1.38)	521
	01-02	*	< LOD	< LOD	1.30 (.780-1.66)	1.94 (1.46-2.59)	695
Non-Hispanic whites	99-00	*	< LOD	< LOD	.750 (.614-.857)	1.13 (.857-1.20)	603
	01-02	*	< LOD	< LOD	1.52 (1.27-1.67)	2.10 (1.67-3.08)	951

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

2,4,5-Trichlorophenol
CAS No. 95-95-4

2,4,6-Trichlorophenol
CAS No. 88-06-2

Metabolites of Organochlorine Pesticides and Other Environmental Chemicals

General Information

The chemicals 2,4,5-trichlorophenol (2,4,5-TCP) and 2,4,6-trichlorophenol (2,4,6-TCP) are metabolites of several organochlorine chemicals, including hexachlorobenzene and hexachlorocyclohexane. Trichlorophenols are no longer intentionally manufactured, but they may be produced as byproducts of the manufacture of other chlorinated aromatic compounds. Small amounts of trichlorophenols can be produced during combustion of natural materials and from the chlorination of waste water that contains phenols. IARC classifies polychlorophenols (including

trichlorophenols) as possibly carcinogenic to humans, and NTP classifies 2,4,6-TCP as reasonably anticipated to be a human carcinogen. More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Urinary Trichlorphenol Reported in the Tables

Urinary levels of 2,4,5-TCP and 2,4,6-TCP were measured in a subsample of NHANES participants aged

Table 234. 2,4,5-Trichlorophenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	**< LOD**	**1.40** (.970-2.70)	**5.40** (2.50-14.0)	**16.0** (4.30-39.0)	1998
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**2.31** (<LOD-7.81)	2526
Age group							
6-11 years	99-00	*	**< LOD**	**1.30** (1.00-2.70)	**4.60** (2.30-11.0)	**11.0** (4.10-36.0)	483
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**2.42** (<LOD-13.3)	577
12-19 years	99-00	*	**< LOD**	**1.60** (.940-3.72)	**5.40** (2.50-24.0)	**24.0** (3.80-41.0)	682
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**1.90** (<LOD-6.10)	826
20-59 years	99-00	*	**< LOD**	**1.40** (.950-2.60)	**5.30** (2.30-15.0)	**18.0** (4.30-44.0)	833
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**2.71** (<LOD-8.27)	1123
Gender							
Males	99-00	*	**< LOD**	**1.40** (.950-3.40)	**5.30** (2.60-8.20)	**9.30** (5.30-27.0)	974
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**5.57** (<LOD-15.8)	1187
Females	99-00	*	**< LOD**	**1.50** (.980-3.10)	**6.50** (2.30-27.0)	**21.0** (3.20-48.0)	1024
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	1339
Race/ethnicity							
Mexican Americans	99-00	*	**.940** (<LOD-1.30)	**1.70** (1.40-3.50)	**8.50** (4.60-18.0)	**21.0** (8.90-33.0)	697
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**14.2** (<LOD-121)	680
Non-Hispanic blacks	99-00	*	**< LOD**	**1.20** (.900-2.20)	**4.80** (2.00-8.40)	**8.60** (3.50-63.0)	524
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**2.31** (<LOD-9.03)	696
Non-Hispanic whites	99-00	*	**< LOD**	**1.40** (.920-3.60)	**4.50** (2.30-9.20)	**9.20** (4.30-27.0)	603
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**2.42** (<LOD-8.27)	949

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the current NHANES 2001-2002 subsample, urinary 2,4,6-TCP levels at the 95th percentile were several times higher than a nonrandom subsample from NHANES III during 1988-1994 (Hill et al., 1995) and several times higher than 95th percentile values reported in a study of German adults aged 18-69 years (Becker et al., 2003). Urinary levels of 2,4,5-TCP at the 95th percentile were similar to values reported in a nonrandom subsample from NHANES III during 1988-1994 (Hill et al., 1995) and several times higher than 95th percentile values reported in a study of German adults aged 18-69 years (Becker et al., 2003).

Comparing Adjusted Geometric Means

Geometric mean levels of urinary 2,4,5-TCP in the 1999-2000 and 2001-2002 subsamples and 2,4,6-TCP in the 2001-2002 subsample could not be calculated due to an insufficient detection rate. Geometric mean levels of urinary 2,4,6-TCP for the demographic groups in 1999-2000 were compared after adjusting for the covariates of race/ethnicity, age, gender and urinary creatinine (data not shown). Adjusted geometric mean levels of urinary 2,4,6-TCP were slightly higher for children aged 6-11 years than for either groups aged 12-19 or 20-59 years, and the group aged 12-19 had higher levels than the group aged 20-59 years. It is unknown whether these differences associated with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of 2,4,5-TCP or 2,4,6-TCP in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to 2,4,5-TCP or 2,4,6-TCP and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of 2,4,5-TCP or 2,4,6-TCP than levels found in the general population.

Table 235. 2,4,5-Trichlorophenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	2.36 (1.54-3.16)	5.50 (3.24-11.2)	11.9 (4.96-19.6)	1998
	01-02	*	< LOD	< LOD	< LOD	4.57 (3.18-7.11)	2525
Age group							
6-11 years	99-00	*	< LOD	2.27 (1.19-4.78)	5.79 (3.83-12.4)	12.8 (5.28-25.4)	483
	01-02	*	< LOD	< LOD	< LOD	5.64 (2.56-13.8)	577
12-19 years	99-00	*	< LOD	1.44 (.923-2.50)	3.77 (1.93-11.2)	11.2 (2.62-20.1)	682
	01-02	*	< LOD	< LOD	< LOD	2.67 (2.21-5.82)	825
20-59 years	99-00	*	< LOD	2.46 (1.60-3.20)	5.71 (3.37-11.5)	11.7 (4.78-19.6)	833
	01-02	*	< LOD	< LOD	< LOD	4.57 (3.37-7.11)	1123
Gender							
Males	99-00	*	< LOD	1.67 (1.01-3.15)	4.24 (3.05-8.02)	9.55 (4.13-13.6)	974
	01-02	*	< LOD	< LOD	< LOD	4.31 (2.56-8.37)	1187
Females	99-00	*	< LOD	2.57 (1.79-4.00)	7.73 (3.05-17.8)	16.2 (5.00-29.3)	1024
	01-02	*	< LOD	< LOD	< LOD	< LOD	1338
Race/ethnicity							
Mexican Americans	99-00	*	.980 (.726-1.33)	2.49 (1.68-4.24)	6.89 (4.17-12.4)	11.8 (6.88-16.9)	697
	01-02	*	< LOD	< LOD	< LOD	11.9 (1.83-48.9)	680
Non-Hispanic blacks	99-00	*	< LOD	1.16 (.790-2.29)	3.39 (2.15-6.32)	6.79 (2.69-18.2)	524
	01-02	*	< LOD	< LOD	< LOD	2.81 (1.33-9.17)	695
Non-Hispanic whites	99-00	*	< LOD	2.44 (1.53-3.24)	4.72 (3.47-8.43)	9.55 (4.27-17.8)	603
	01-02	*	< LOD	< LOD	< LOD	4.31 (3.20-7.21)	949

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 236. 2,4,6-Trichlorophenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years,
National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**2.85** (2.55-3.18)	**2.45** (2.40-2.60)	**4.80** (3.80-7.60)	**14.8** (7.70-25.0)	**25.0** (15.0-39.0)	1989
	01-02	*	**1.68** (<LOD-2.43)	**5.94** (4.89-6.63)	**10.8** (9.98-11.7)	**14.9** (13.4-17.9)	2503
Age group							
6-11 years	99-00	**4.47** (3.36-5.95)	**3.72** (2.70-5.90)	**11.0** (4.71-18.0)	**24.0** (14.0-38.0)	**32.0** (20.5-46.0)	481
	01-02	*	**2.99** (1.91-4.32)	**7.79** (5.73-9.99)	**13.4** (10.6-17.3)	**19.2** (14.1-25.3)	574
12-19 years	99-00	**3.56** (3.00-4.23)	**3.00** (2.60-3.60)	**6.00** (4.20-11.0)	**20.0** (9.60-37.0)	**37.0** (20.0-54.0)	678
	01-02	*	**3.26** (2.32-4.37)	**7.49** (6.45-9.40)	**13.5** (11.0-18.2)	**19.4** (17.3-26.6)	820
20-59 years	99-00	**2.52** (2.23-2.85)	**2.40** (2.10-2.40)	**4.20** (3.50-5.20)	**11.6** (6.00-21.0)	**21.0** (11.0-37.0)	830
	01-02	*	**< LOD**	**4.83** (3.70-6.28)	**9.60** (8.72-10.7)	**13.2** (11.8-15.2)	1109
Gender							
Males	99-00	**2.92** (2.58-3.31)	**2.60** (2.40-2.80)	**5.10** (3.90-7.90)	**15.0** (8.30-23.0)	**26.0** (15.0-38.0)	970
	01-02	*	**2.36** (1.68-3.02)	**6.65** (5.98-7.53)	**12.1** (10.8-13.1)	**17.0** (13.6-22.2)	1178
Females	99-00	**2.78** (2.35-3.28)	**2.40** (2.10-2.45)	**4.80** (3.40-7.59)	**16.0** (6.00-32.0)	**25.0** (13.0-47.0)	1019
	01-02	*	**< LOD**	**4.69** (3.59-6.09)	**9.71** (8.25-11.6)	**13.1** (11.7-16.6)	1325
Race/ethnicity							
Mexican Americans	99-00	**2.70** (2.20-3.32)	**2.60** (2.10-3.10)	**4.80** (4.10-6.50)	**14.0** (8.20-23.0)	**22.0** (13.0-34.0)	694
	01-02	*	**2.07** (<LOD-3.23)	**5.31** (3.95-6.54)	**11.3** (8.51-12.8)	**15.6** (12.6-19.8)	677
Non-Hispanic blacks	99-00	**3.14** (2.40-4.12)	**2.80** (2.10-3.40)	**6.40** (3.40-14.0)	**18.0** (9.30-33.0)	**32.0** (16.0-68.0)	519
	01-02	*	**2.58** (1.32-4.02)	**6.45** (5.04-7.55)	**11.1** (8.87-14.9)	**17.9** (11.8-24.7)	696
Non-Hispanic whites	99-00	**2.74** (2.46-3.06)	**2.45** (2.30-2.70)	**4.60** (3.80-6.60)	**12.0** (6.40-21.0)	**20.0** (12.0-37.0)	602
	01-02	*	**1.57** (<LOD-2.20)	**6.10** (5.01-6.65)	**10.7** (9.67-12.3)	**14.6** (13.3-17.9)	931

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 237. 2,4,6-Trichlorophenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**2.54** (2.30-2.81)	**2.38** (2.14-2.68)	**4.91** (3.83-6.49)	**12.1** (8.67-17.0)	**21.2** (13.6-31.5)	1989
	01-02	*	**2.43** (2.09-2.75)	**4.36** (4.14-4.70)	**8.33** (7.10-9.26)	**11.6** (9.25-15.6)	2502
Age group							
6-11 years	99-00	**4.82** (3.87-6.00)	**4.71** (3.41-6.53)	**11.5** (7.63-15.3)	**21.8** (14.1-32.6)	**31.5** (22.7-36.8)	481
	01-02	*	**4.00** (3.29-4.81)	**8.26** (6.16-10.4)	**13.9** (9.51-21.5)	**21.2** (12.9-64.1)	574
12-19 years	99-00	**2.40** (2.08-2.78)	**2.33** (1.95-2.68)	**4.27** (3.13-6.00)	**11.6** (6.94-13.6)	**14.4** (11.3-23.6)	678
	01-02	*	**2.76** (2.09-3.17)	**4.52** (3.83-5.92)	**8.28** (6.81-9.89)	**12.3** (8.73-22.8)	819
20-59 years	99-00	**2.32** (2.04-2.63)	**2.22** (1.89-2.56)	**4.25** (3.38-5.63)	**9.95** (6.64-15.9)	**19.6** (10.9-34.4)	830
	01-02	*	**< LOD**	**4.05** (3.66-4.38)	**7.08** (6.43-7.72)	**9.77** (8.53-11.9)	1109
Gender							
Males	99-00	**2.24** (1.99-2.53)	**2.15** (1.82-2.42)	**4.41** (3.56-5.88)	**10.8** (7.04-16.4)	**17.5** (11.5-28.5)	970
	01-02	*	**2.23** (1.91-2.65)	**4.22** (3.77-4.73)	**8.05** (6.70-9.17)	**12.2** (8.79-17.7)	1178
Females	99-00	**2.88** (2.49-3.33)	**2.63** (2.24-2.95)	**5.53** (3.88-7.23)	**13.3** (9.65-21.9)	**24.7** (13.3-37.0)	1019
	01-02	*	**< LOD**	**4.53** (4.19-5.11)	**8.40** (7.27-9.51)	**10.9** (9.26-13.6)	1324
Race/ethnicity							
Mexican Americans	99-00	**2.43** (2.06-2.87)	**2.50** (2.22-2.82)	**5.43** (3.87-7.10)	**10.8** (8.46-14.9)	**18.3** (12.1-21.8)	694
	01-02	*	**2.22** (1.64-2.88)	**4.25** (3.47-5.76)	**8.05** (6.21-11.1)	**11.6** (9.63-13.9)	677
Non-Hispanic blacks	99-00	**2.13** (1.65-2.76)	**1.90** (1.60-2.52)	**3.97** (2.76-8.02)	**11.6** (5.32-19.7)	**19.4** (10.9-29.5)	519
	01-02	*	**2.00** (1.48-2.76)	**3.83** (3.15-4.81)	**6.52** (5.50-8.06)	**9.87** (7.14-13.2)	695
Non-Hispanic whites	99-00	**2.59** (2.33-2.88)	**2.41** (2.20-2.77)	**4.87** (3.83-6.06)	**11.0** (7.62-15.5)	**19.6** (12.9-32.8)	602
	01-02	*	**2.63** (2.27-2.88)	**4.60** (4.29-4.98)	**8.56** (7.22-9.65)	**12.0** (9.25-17.1)	931

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Figure 29. 2,4,6-Trichlorophenol (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

^a Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Dichlorodiphenyltrichloroethane

CAS No. 50-29-3

General Information

Dichlorodiphenyltrichloroethane (DDT) is an insecticide that was used in the 1940s by the military against mosquitoes that carried vector-borne diseases (e.g., malaria). The U.S. EPA banned the use of DDT in the United States in 1973, and it is no longer being applied in this country. However, DDT is still used in other countries. Commercially available DDT (technical grade) contains three chemical forms of DDT: *p,p'*-DDT, *o,o'*-DDT, and *o,p'*-DDT.

DDT is converted in the environment to other more stable chemical forms, including 1,1'-(2,2-dichloro-ethenylidene)-bis[4-chlorobenzene] (DDE) and 1,1'-dichloro-(2,2-bis(p-chlorophenyl) ethane (DDD). All of these chemicals are highly persistent in the environment and can be found in soil, air, and water. The biodegradation half-life of DDT in soil varies from 2 years to 15 years, depending on conditions.

In the general population, food is the primary source of exposure to DDT. Many foods and commodities contain detectable residues of DDT or its degradation products. The estimated food intake of DDT in the United States has decreased since the 1950s (Walker et al., 1954; Durham et al., 1965; Duggan and Corneliussen, 1972). However, food imported into the United States from other countries that still use DDT may contain DDT or DDE residues. In addition, local spraying with DDT can add greatly to body burdens. For example, after a single application of DDT for malaria control, DDT levels were seven-fold higher in people tested 1 year after the application than in a comparison population (Dua et al., 1996).

After DDT enters the body, it is metabolized to DDE. DDT and DDE are widely distributed to different organs in the body, particularly fatty tissues. The concentration of DDT and metabolites in fatty tissues may be several

Table 238. *p,p'*-DDT (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	**28.0** (21.9-34.0)	1679
	01-02	*	< LOD	< LOD	< LOD	**26.5** (22.4-32.7)	2305
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	677
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	**30.5** (23.0-37.3)	1002
	01-02	*	< LOD	< LOD	< LOD	**28.1** (23.8-39.0)	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	**25.1** (<LOD-39.3)	799
	01-02	*	< LOD	< LOD	< LOD	**21.6** (<LOD-25.8)	1073
Females	99-00	*	< LOD	< LOD	< LOD	**29.4** (23.0-35.8)	880
	01-02	*	< LOD	< LOD	**18.1** (<LOD-21.9)	**36.3** (25.5-54.3)	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	**61.3** (27.0-155)	**150** (59.3-590)	635
	01-02	*	< LOD	< LOD	**83.1** (33.3-236)	**236** (104-541)	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	**22.2** (<LOD-31.5)	**31.5** (23.2-65.0)	356
	01-02	*	< LOD	< LOD	**22.1** (<LOD-40.9)	**40.9** (21.2-95.8)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	**17.7** (<LOD-20.7)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

hundred times greater than concentrations in other tissues. DDE persists longer in the body than DDT. Previous studies have reported that levels of DDT and DDE increase as a person ages.

DDT and its metabolites can cause adverse effects through different mechanisms—by interfering with the movement of ions through cells in the nervous system or by mimicking or blocking the action of reproductive hormones. The toxic effects of DDT demonstrated in experimental animals include infertility (Jonsson et al., 1975); a decrease in the number of implanted ova (Lundberg, 1974); intrauterine growth retardation (Fabro et al., 1984); cancer (Cabral et al., 1982); neurologic developmental disorders (Eriksson et al., 1990); and fetal death (Clement and Okey, 1974). In people, elevations of liver enzymes in serum have been observed after large accidental or workplace exposures; acute overdoses may cause tremors, gait disturbances, fatigue, headache, and vomiting (Hayes, 1976). The association of DDT with breast cancer has been studied, and a causal link is uncertain (Lebel et al., 1998; Hoyer et al., 1998; Helzlsouer et al., 1999; Hunter et al., 1997). IARC

classifies DDT (*p,p*'-DDT) as a possible human carcinogen; NTP considers that DDT is reasonably anticipated to be a human carcinogen.

More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc. gov/toxprofiles.

Interpreting Levels of Lipid-Adjusted Serum DDT and DDE Reported in the Tables

Serum levels of *p,p*'-DDT, *o,p*'-DDT and *p,p*'-DDE were measured in a subsample of NHANES participants aged 12 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Geometric mean levels of *p,p*'-DDE in the NHANES 2001-2002 subsample were similar to measurements reported in a previous study of adults in Germany (Becker et al., 2002). The *p,p*'-DDE levels in the NHANES 2001-2002 subsample were approximately three-fold lower than serum *p,p*'-DDE measurements

## Table 239. *p,p'*-DDT (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	.172 (.131-.218)	1679
	01-02	*	< LOD	< LOD	< LOD	.184 (.161-.221)	2305
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	677
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	.187 (.147-.228)	1002
	01-02	*	< LOD	< LOD	< LOD	.201 (.167-.257)	1549
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	.147 (.107-.188)	799
	01-02	*	< LOD	< LOD	< LOD	.153 (.121-.184)	1073
Females	99-00	*	< LOD	< LOD	< LOD	.190 (.142-.232)	880
	01-02	*	< LOD	< LOD	.131 (.110-.146)	.239 (.175-.398)	1232
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	.393 (.188-.998)	.998 (.331-4.26)	635
	01-02	*	< LOD	< LOD	.512 (.253-1.34)	1.56 (.569-4.01)	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.123 (.090-.168)	.170 (.141-.420)	356
	01-02	*	< LOD	< LOD	.134 (.079-.285)	.229 (.121-.532)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	.125 (.103-.141)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

reported in studies of adults in New Zealand (Bates et al., 2004*b*) and ten times lower than serum measurements reported in adults in Slovakia (Pavuk et al., 2004).

The 95th percentile value for serum levels of *p,p*'-DDT and *p,p*'-DDE in the NHANES 2001-2002 subsample were approximately 15-fold and three-fold lower, respectively, than measurements reported in a nonrandom subsample from NHANES II (1976-1980) participants (Stehr-Green et al., 1989). Serum *p,p*'-DDT levels in the NHANES 2001-2002 subsample were many times lower than levels in women in Spain (Botella et al., 2004), or in men in India (Bhatnagar et al., 2004).

In the NHANES 1999-2000 and 2001-2002 subsamples, serum levels of *o,p*'-DDT were below the limit of detection.

Comparing Adjusted Geometric Means

Geometric mean levels of serum *p,p*'-DDE for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and lipid level (data not shown). In NHANES 2001-2002, adjusted geometric mean levels in the group aged 20 years and older were more than a two-fold higher level of *p,p*'-DDE than the group aged 12-19 years. These findings are consistent with previous measurements in NHANES II (1976-1980) participants, in whom levels of *p,p*'-DDE were also observed to be higher in older age groups (Stehr-Green et al., 1989). The adjusted geometric mean levels of *p,p*'-DDE in Mexican Americans was approximately two-fold higher than in non-Hispanic blacks and approximately three-fold higher in than in non-Hispanic whites. Non-Hispanic blacks had higher levels than non-Hispanic whites. Other studies have also reported higher serum levels of *p,p*'-DDE in Mexican Americans (Akkina et al., 2004). In a study of African-American farmers, Martin et al. (2002) reported higher median lipid-adjusted levels of DDE than the median values that appear in this *Report*. It is unknown

Table 240. *p,p'*-DDE (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	**260** (226-298)	**226** (184-278)	**537** (476-631)	**1150** (976-1350)	**1780** (1410-2300)	1964
	01-02	**295** (267-327)	**250** (227-277)	**597** (521-699)	**1400** (1210-1500)	**2320** (1830-2780)	2298
Age group							
12-19 years	99-00	**118** (102-135)	**108** (97.7-119)	**185** (141-237)	**339** (243-479)	**528** (339-812)	686
	01-02	**124** (106-146)	**112** (98.5-138)	**213** (172-253)	**319** (282-389)	**456** (343-722)	758
20 years and older	99-00	**297** (256-344)	**267** (213-323)	**608** (530-693)	**1250** (1030-1550)	**2020** (1520-2620)	1278
	01-02	**338** (303-376)	**285** (249-337)	**689** (590-798)	**1470** (1310-1700)	**2550** (1980-3080)	1540
Gender							
Males	99-00	**249** (220-283)	**222** (182-262)	**493** (380-578)	**992** (789-1130)	**1430** (1080-2160)	937
	01-02	**285** (252-323)	**245** (222-285)	**520** (441-619)	**1160** (937-1360)	**1900** (1570-2390)	1069
Females	99-00	**270** (226-322)	**234** (184-302)	**601** (490-707)	**1350** (1040-1720)	**2170** (1570-2810)	1027
	01-02	**305** (273-341)	**256** (219-297)	**704** (567-844)	**1480** (1400-1690)	**2630** (1940-3300)	1229
Race/ethnicity							
Mexican Americans	99-00	**674** (574-792)	**623** (545-701)	**1350** (1090-1660)	**3090** (2040-4950)	**4940** (3070-9350)	657
	01-02	**652** (569-747)	**551** (455-690)	**1380** (1050-1950)	**4110** (2520-6550)	**7030** (3080-15600)	566
Non-Hispanic blacks	99-00	**295** (241-362)	**251** (199-313)	**651** (492-874)	**1850** (1040-2220)	**2300** (1560-5680)	416
	01-02	**324** (262-400)	**248** (223-296)	**744** (583-999)	**1580** (1180-2980)	**3260** (1270-6900)	515
Non-Hispanic whites	99-00	**217** (189-249)	**191** (162-238)	**438** (355-507)	**825** (647-1010)	**1160** (1010-1350)	732
	01-02	**253** (226-284)	**224** (203-254)	**463** (402-558)	**1140** (878-1340)	**1640** (1410-1940)	1053

whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

There were no significant differences in serum *p,p'*-DDE levels between males and females in NHANES 2001-2002; however others have reported differences in levels of DDT or its metabolites between females and males (Waliszewski et al., 1996; Stehr-Green et al., 1989; Finklea et al., 1972; Sala et al., 1999).

Finding a measurable amount of *p,p'*-DDT or *p,p'*-DDE in serum does not mean that the level of the *p,p'*-DDT or *p,p'*-DDE will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to DDT or DDE and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of DDT or DDE than levels found in the general population.

Table 241. *p,p'*-DDE (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	**1.54** (1.33-1.79)	**1.31** (1.09-1.66)	**3.49** (2.97-4.27)	**7.49** (6.14-9.25)	**11.6** (9.25-14.8)	1964
	01-02	**1.81** (1.64-2.01)	**1.57** (1.37-1.72)	**3.97** (3.43-4.59)	**8.81** (7.85-10.1)	**15.4** (12.9-17.6)	2298
Age group							
12-19 years	99-00	**.561** (.488-.646)	**.518** (.433-.603)	**.872** (.682-1.18)	**1.52** (1.13-2.25)	**2.31** (1.76-3.56)	686
	01-02	**.623** (.534-.726)	**.592** (.495-.727)	**.997** (.819-1.22)	**1.65** (1.39-2.07)	**2.30** (1.91-3.14)	758
20 years and older	99-00	**1.83** (1.56-2.14)	**1.61** (1.26-2.07)	**4.17** (3.48-4.66)	**8.12** (6.37-10.6)	**12.3** (9.87-16.7)	1278
	01-02	**2.14** (1.91-2.39)	**1.76** (1.61-2.04)	**4.59** (4.10-5.26)	**9.75** (8.34-11.5)	**16.8** (13.7-19.1)	1540
Gender							
Males	99-00	**1.49** (1.30-1.70)	**1.25** (1.10-1.44)	**3.01** (2.56-3.74)	**6.43** (5.40-8.00)	**9.63** (6.63-15.6)	937
	01-02	**1.77** (1.57-2.01)	**1.59** (1.36-1.76)	**3.40** (3.03-4.10)	**7.48** (6.43-8.75)	**13.1** (9.66-17.6)	1069
Females	99-00	**1.59** (1.32-1.92)	**1.38** (1.03-1.99)	**4.05** (3.15-4.79)	**8.12** (6.36-11.5)	**13.2** (9.81-18.5)	1027
	01-02	**1.85** (1.66-2.06)	**1.49** (1.32-1.75)	**4.57** (3.81-5.47)	**10.1** (9.01-11.9)	**16.8** (13.4-19.7)	1229
Race/ethnicity							
Mexican Americans	99-00	**3.92** (3.40-4.51)	**3.52** (3.17-3.91)	**8.20** (7.26-10.4)	**22.0** (12.2-32.2)	**31.5** (19.7-48.1)	657
	01-02	**3.92** (3.37-4.57)	**3.53** (2.68-4.34)	**9.33** (7.31-12.5)	**26.6** (17.9-38.3)	**40.9** (26.8-90.5)	566
Non-Hispanic blacks	99-00	**1.63** (1.31-2.02)	**1.34** (1.11-1.66)	**3.80** (3.01-5.69)	**11.1** (6.57-13.2)	**14.6** (8.88-35.2)	416
	01-02	**1.82** (1.46-2.28)	**1.38** (1.22-1.72)	**4.39** (3.52-6.06)	**10.5** (7.24-17.6)	**19.3** (8.51-49.3)	515
Non-Hispanic whites	99-00	**1.32** (1.14-1.53)	**1.13** (1.01-1.35)	**2.85** (2.34-3.36)	**5.71** (4.62-6.53)	**8.04** (6.32-9.81)	732
	01-02	**1.57** (1.39-1.76)	**1.41** (1.27-1.58)	**3.10** (2.56-3.68)	**7.00** (6.02-8.34)	**11.3** (8.60-13.7)	1053

Figure 30. *p,p'*-DDE (lipid adjusted)

Selected percentiles with 95% confidence intervals of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

Table 242. *o,p'*-DDT (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1669
	01-02	*	< LOD	< LOD	< LOD	< LOD	2279
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1002
	01-02	*	< LOD	< LOD	< LOD	< LOD	1523
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	796
	01-02	*	< LOD	< LOD	< LOD	< LOD	1059
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	873
	01-02	*	< LOD	< LOD	< LOD	< LOD	1220
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	632
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	354
	01-02	*	< LOD	< LOD	< LOD	< LOD	507
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	560
	01-02	*	< LOD	< LOD	< LOD	< LOD	1045

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 243. *o,p'*-DDT (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1669
	01-02	*	< LOD	< LOD	< LOD	< LOD	2279
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1002
	01-02	*	< LOD	< LOD	< LOD	< LOD	1523
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	796
	01-02	*	< LOD	< LOD	< LOD	< LOD	1059
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	873
	01-02	*	< LOD	< LOD	< LOD	< LOD	1220
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	632
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	354
	01-02	*	< LOD	< LOD	< LOD	< LOD	507
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	560
	01-02	*	< LOD	< LOD	< LOD	< LOD	1045

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Chlordane
CAS No.12789-03-6 and 57-74-9

Heptachlor
CAS No. 76-44-8

General Information

Chlordane is an organochlorine pesticide that was once used on agricultural crops and lawns and in buildings to kill termites and other insects. In 1988, the U.S. EPA cancelled registration for the production and use of chlordane in the United States. Heptachlor is another organochlorine pesticide that has a chemical structure and mechanism of toxicity similar to that of chlordane. The use of heptachlor in the United States is restricted to include limited applications for controlling fire ants.

The technical-grade formulation of chlordane may consist of more than 50 related chemicals. The main components are *cis-* and *trans-*chlordane, *trans-*nonachlor, and heptachlor. Chlordane is metabolized in

the environment and in the body to oxychlordane. Heptachlor is metabolized to heptachlor epoxide. Chlordane is an unlikely source of exposure if heptachlor epoxide is found in the absence of either oxychlordane or *trans-*nonachlor.

Heptachlor, chlordane, and their metabolites are highly persistent chemicals in the environment as well as in the body. Fatty foods are the most likely source of exposure to these chemicals in the general population. In Hawaii during 1981 and 1982, heptachlor was used on pineapples, and the remnant pineapple tops (chops) were fed to milk-producing cows, resulting in human exposure when people drank the milk. (Takahashi and Parks, 1982). Consequently, increased levels of heptachlor epoxide were found in the breast milk of lactating

Table 244. Oxychlordane (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	20.6 (17.8-23.0)	34.4 (30.5-38.6)	44.8 (40.2-49.6)	1661
	01-02	11.4 (<LOD-12.5)	11.1 (<LOD-12.5)	21.7 (19.2-24.4)	36.3 (31.4-41.4)	49.7 (42.0-61.2)	2249
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	< LOD	11.4 (<LOD-12.6)	752
20 years and older	99-00	*	< LOD	23.3 (21.0-25.9)	37.7 (32.3-43.5)	47.7 (43.1-50.8)	998
	01-02	12.9 (11.7-14.3)	13.2 (11.4-14.9)	23.9 (21.2-26.6)	38.4 (33.4-45.7)	53.1 (44.1-65.9)	1497
Gender							
Males	99-00	*	< LOD	17.8 (16.1-19.5)	31.2 (25.8-37.5)	42.3 (35.3-49.6)	793
	01-02	11.1 (<LOD-12.6)	11.1 (<LOD-12.5)	20.6 (16.5-24.5)	33.1 (27.5-43.8)	48.1 (40.2-56.9)	1049
Females	99-00	*	< LOD	22.3 (20.1-25.9)	36.7 (31.4-39.1)	46.1 (39.1-51.8)	868
	01-02	11.7 (10.7-12.7)	11.0 (<LOD-12.9)	23.1 (20.7-25.0)	37.4 (34.5-42.1)	52.5 (42.7-70.0)	1200
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	16.2 (<LOD-19.7)	28.9 (18.8-42.0)	39.8 (26.8-61.0)	628
	01-02	*	< LOD	13.9 (11.0-18.4)	27.1 (21.0-33.1)	37.9 (29.9-42.0)	557
Non-Hispanic blacks	99-00	*	< LOD	18.5 (<LOD-32.2)	39.9 (26.5-47.3)	47.5 (43.5-65.5)	350
	01-02	11.7 (<LOD-13.6)	< LOD	22.6 (17.2-28.3)	41.2 (30.6-53.7)	55.3 (41.8-73.5)	501
Non-Hispanic whites	99-00	*	< LOD	21.8 (18.6-24.6)	34.1 (28.9-40.9)	43.5 (37.2-49.8)	559
	01-02	12.1 (11.0-13.3)	11.7 (10.5-13.9)	22.9 (20.0-25.6)	37.4 (31.5-44.1)	50.8 (41.0-67.4)	1031

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

women. Indoor inhalational exposure to chlordane may occur for decades after the termite treatment of a residence. It is estimated that 80 million homes have been treated with chlordane. Indoor-air concentrations of chlordane have been measured that are higher than outdoor-air concentrations (U.S. EPA, 1990; Whitemore et al., 1994).

Chlordane, heptachlor, and their metabolites distribute widely in the body and accumulate in fatty tissues. The metabolites of chlordane and heptachlor are eliminated from the body very slowly over the course of months to years. At high doses, chlordane and heptachlor block inhibitory neurotransmitters in the central nervous system. In cases of human poisoning , headache, nausea, gastrointestinal inflammation, confusion, tremors, and seizures have been reported. For this class of chemicals, animal studies demonstrate liver, hematologic, and developmental toxicities and immunological effects. IARC considers chlordane and heptachlor as possibly carcinogenic to humans.

Information about external exposure (i.e., environmental

levels) and health effects of chlordane is available from ATSDR's Toxicological Profiles at http://www.atsdr.cdc. gov/toxprofiles/tp31.html and for heptachlor at http://www.atsdr.cdc.gov/tfacts12.html.

Interpreting Levels of Lipid-Adjusted Serum Oxychlordane, *trans*-Nonachlor, and Heptachlor Epoxide Reported in the Tables

Serum levels of oxychlordane, *trans*-nonachlor, and heptachlor epoxide were measured in a subsample of NHANES participants aged 12 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population.

Serum oxychlordane levels in both the NHANES 1999-2000 and the 2001-2002 subsamples are comparable to levels measured in Swedish men and women (Glynn et al., 2003). Levels of oxychlordane exceeding the 95th percentile in this *Report* were reported in a study of an Inuit population in Greenland (Van Oostdam et al., 2004). Serum *trans*-nonachlor levels in the NHANES 2001-2002 subsample were similar to levels in adult

Table 245. Oxychlordane (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	.134 (.119-.150)	.255 (.202-.287)	.310 (.290-.343)	1661
	01-02	.070 (.063-.077)	.069 (.058-.078)	.143 (.126-.160)	.248 (.215-.297)	.352 (.289-.441)	2249
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	< LOD	.058 (.050-.068)	752
20 years and older	99-00	*	< LOD	.154 (.136-.179)	.279 (.228-.304)	.328 (.299-.398)	998
	01-02	.082 (.074-.091)	.084 (.074-.094)	.157 (.137-.180)	.267 (.225-.318)	.370 (.307-.449)	1497
Gender							
Males	99-00	*	< LOD	.122 (.101-.135)	.216 (.182-.279)	.303 (.264-.343)	793
	01-02	.069 (.061-.079)	.067 (.058-.082)	.133 (.116-.160)	.231 (.189-.299)	.319 (.252-.426)	1049
Females	99-00	*	< LOD	.143 (.126-.173)	.267 (.202-.306)	.319 (.291-.401)	868
	01-02	.071 (.065-.077)	.069 (.059-.078)	.146 (.132-.163)	.258 (.228-.308)	.365 (.278-.513)	1200
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	.100 (.082-.130)	.203 (.127-.317)	.282 (.186-.413)	628
	01-02	*	< LOD	.097 (.065-.126)	.194 (.144-.238)	.278 (.210-.363)	557
Non-Hispanic blacks	99-00	*	< LOD	.113 (.070-.174)	.237 (.171-.288)	.311 (.244-.426)	350
	01-02	.066 (.055-.077)	< LOD	.127 (.094-.168)	.259 (.181-.349)	.349 (.241-.560)	501
Non-Hispanic whites	99-00	*	< LOD	.139 (.124-.165)	.264 (.198-.296)	.316 (.281-.376)	559
	01-02	.075 (.068-.083)	.076 (.066-.086)	.151 (.131-.172)	.253 (.219-.312)	.365 (.280-.449)	1031

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

females in Sweden (Glynn et al., 2003), and two-fold lower than levels reported for women in New York (Wolff et al., 2000). Compared with serum levels in the NHANES 2001-2002 subsample, higher serum levels of *trans*-nonachlor were reported in an Inuit population in Greenland (Van Oostdam et al., 2004). Levels of heptachlor epoxide in both the 1999-2000 and the 2001-2002 subsamples approximately ten-fold lower at the corresponding 90th percentile for a historical cohort of women studied during the period 1963-1967 (James et al., 2002).

Comparing Adjusted Geometric Means

Geometric means levels of serum *trans*-nonachlor and oxychlordane in the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and lipid level (data not shown). Some comparisons are not possible due to a low detection rate for some demographic groups. For the adjusted geometric means levels of *trans*-nonachlor in NHANES 2001-2002, Mexican Americans were lower than non-Hispanic blacks and non-Hispanic whites. For

the adjusted geometric means levels of oxychlordane in NHANES 2001-2002, improved detections limits permitted comparison of several demographic groups, but no differences were found.

Finding a measurable amount of oxychlordane, *trans*-nonachlor, or heptachlor epoxide in serum does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to heptachlor or chlordane and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of heptachlor and chlordane than levels found in the general population.

Table 246. *trans*-Nonachlor (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	**18.3** (16.7-20.0)	**17.8** (16.0-19.8)	**31.9** (28.9-36.0)	**55.1** (48.4-62.6)	**79.4** (67.6-88.1)	1933
	01-02	**17.0** (15.2-18.9)	**17.9** (15.5-20.5)	**33.7** (30.2-37.2)	**56.3** (49.6-65.9)	**78.2** (63.6-111)	2286
Age group							
12-19 years	99-00	*	< LOD	< LOD	**18.8** (<LOD-20.2)	**23.4** (19.1-28.4)	664
	01-02	*	< LOD	< LOD	**13.3** (11.8-16.2)	**18.9** (15.2-23.5)	758
20 years and older	99-00	**20.8** (19.0-22.8)	**20.6** (18.0-23.5)	**35.2** (30.9-40.0)	**59.9** (51.8-67.6)	**82.2** (74.9-89.6)	1269
	01-02	**19.8** (17.6-22.3)	**20.8** (18.8-23.0)	**36.6** (32.8-40.9)	**60.6** (52.5-69.9)	**84.9** (66.0-123)	1528
Gender							
Males	99-00	**17.7** (16.5-19.1)	**17.1** (14.6-19.6)	**30.0** (27.7-34.2)	**51.1** (47.3-58.6)	**78.2** (60.2-88.1)	922
	01-02	**17.0** (14.8-19.5)	**18.3** (14.8-21.1)	**34.4** (28.3-38.9)	**54.8** (45.0-68.9)	**77.2** (58.9-105)	1062
Females	99-00	**18.8** (16.7-21.1)	**18.4** (16.1-22.2)	**32.9** (29.0-38.3)	**58.7** (48.4-67.6)	**80.8** (71.5-95.5)	1011
	01-02	**17.0** (15.4-18.7)	**17.5** (15.0-20.3)	**32.8** (30.2-36.4)	**56.4** (51.9-65.5)	**76.8** (65.5-111)	1224
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	**25.0** (22.7-29.5)	**40.7** (35.1-51.8)	**55.9** (45.8-77.2)	650
	01-02	**11.9** (<LOD-14.6)	**10.6** (<LOD-14.4)	**26.0** (19.3-30.4)	**47.9** (36.3-57.2)	**59.8** (49.3-74.1)	558
Non-Hispanic blacks	99-00	**20.3** (17.0-24.1)	**17.5** (14.7-22.7)	**35.7** (28.3-45.4)	**77.0** (60.8-90.7)	**106** (84.0-143)	404
	01-02	**18.8** (15.4-22.9)	**19.2** (14.7-22.0)	**36.8** (28.2-50.3)	**72.9** (50.8-110)	**112** (68.7-160)	514
Non-Hispanic whites	99-00	**19.1** (17.2-21.1)	**18.8** (16.8-21.9)	**32.8** (28.0-37.6)	**52.5** (44.9-64.4)	**74.0** (62.3-86.7)	722
	01-02	**17.5** (15.6-19.7)	**18.8** (16.1-21.1)	**34.0** (29.7-38.1)	**55.5** (45.9-69.4)	**78.5** (59.1-126)	1052

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 247. *trans*-Nonachlor (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	**.109** (.099-.119)	**.105** (.093-.123)	**.212** (.187-.233)	**.369** (.325-.418)	**.544** (.468-.628)	1933
	01-02	**.104** (.093-.116)	**.112** (.097-.124)	**.217** (.191-.243)	**.389** (.328-.470)	**.589** (.432-.797)	2286
Age group							
12-19 years	99-00	*	< LOD	< LOD	**.089** (.063-.106)	**.111** (.100-.128)	664
	01-02	*	< LOD	< LOD	**.067** (.059-.083)	**.093** (.075-.125)	758
20 years and older	99-00	**.128** (.116-.141)	**.126** (.107-.147)	**.233** (.212-.255)	**.401** (.360-.461)	**.573** (.494-.686)	1269
	01-02	**.125** (.111-.141)	**.133** (.118-.148)	**.241** (.213-.278)	**.418** (.347-.537)	**.642** (.469-.843)	1528
Gender							
Males	99-00	**.106** (.098-.114)	**.103** (.089-.118)	**.207** (.179-.224)	**.353** (.305-.401)	**.514** (.401-.628)	922
	01-02	**.105** (.091-.122)	**.112** (.091-.134)	**.224** (.192-.263)	**.379** (.310-.495)	**.579** (.390-.828)	1062
Females	99-00	**.111** (.099-.125)	**.112** (.093-.131)	**.220** (.185-.250)	**.383** (.310-.452)	**.573** (.463-.694)	1011
	01-02	**.103** (.093-.113)	**.109** (.094-.123)	**.214** (.184-.241)	**.395** (.341-.448)	**.589** (.429-.825)	1224
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	**.165** (.124-.205)	**.300** (.244-.344)	**.387** (.318-.520)	650
	01-02	**.071** (.056-.091)	**.064** (.044-.094)	**.156** (.123-.209)	**.328** (.272-.394)	**.465** (.354-.594)	558
Non-Hispanic blacks	99-00	**.112** (.093-.134)	**.101** (.082-.134)	**.215** (.174-.297)	**.481** (.340-.595)	**.748** (.511-.955)	404
	01-02	**.106** (.085-.131)	**.107** (.080-.125)	**.218** (.162-.313)	**.485** (.316-.680)	**.680** (.408-1.19)	514
Non-Hispanic whites	99-00	**.116** (.104-.129)	**.119** (.100-.137)	**.214** (.185-.244)	**.366** (.302-.437)	**.513** (.435-.632)	722
	01-02	**.108** (.096-.122)	**.117** (.101-.133)	**.220** (.191-.250)	**.388** (.305-.494)	**.596** (.402-.927)	1052

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Figure 31. *trans*-Nonachlor (lipid adjusted)

Selected percentiles with 95% confidence intervals of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

 a Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Table 248. Heptachlor epoxide (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	**< LOD**	**< LOD**	**15.3** (<LOD-19.8)	**23.9** (15.1-38.8)	1589
	01-02	*	**< LOD**	**< LOD**	**14.8** (13.0-17.8)	**21.6** (18.1-26.2)	2259
Age group							
12-19 years	99-00	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	638
	01-02	*	**< LOD**	**< LOD**	**< LOD**	**< LOD**	741
20 years and older	99-00	*	**< LOD**	**< LOD**	**17.8** (<LOD-23.9)	**27.1** (16.8-46.1)	951
	01-02	*	**< LOD**	**< LOD**	**15.7** (13.6-18.8)	**23.1** (19.1-29.1)	1518
Gender							
Males	99-00	*	**< LOD**	**< LOD**	**< LOD**	**19.2** (<LOD-27.2)	760
	01-02	*	**< LOD**	**< LOD**	**13.9** (12.0-17.3)	**20.8** (15.9-25.3)	1047
Females	99-00	*	**< LOD**	**< LOD**	**18.2** (<LOD-25.2)	**27.0** (16.0-54.3)	829
	01-02	*	**< LOD**	**< LOD**	**15.5** (13.3-18.2)	**23.2** (18.9-29.8)	1212
Race/ethnicity							
Mexican Americans	99-00	*	**< LOD**	**< LOD**	**15.2** (<LOD-23.6)	**21.6** (<LOD-62.3)	598
	01-02	*	**< LOD**	**< LOD**	**13.2** (<LOD-16.3)	**16.6** (13.8-23.1)	553
Non-Hispanic blacks	99-00	*	**< LOD**	**< LOD**	**< LOD**	**19.4** (<LOD-32.4)	336
	01-02	*	**< LOD**	**< LOD**	**14.6** (11.7-19.0)	**21.0** (18.2-27.3)	503
Non-Hispanic whites	99-00	*	**< LOD**	**< LOD**	**16.5** (<LOD-21.8)	**25.2** (<LOD-54.3)	539
	01-02	*	**< LOD**	**< LOD**	**15.3** (12.9-19.1)	**22.8** (18.9-29.8)	1041

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 249. Heptachlor epoxide (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	.110 (.091-.144)	.177 (.109-.220)	1589
	01-02	*	< LOD	< LOD	.102 (.089-.121)	.153 (.125-.179)	2259
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	638
	01-02	*	< LOD	< LOD	< LOD	< LOD	741
20 years and older	99-00	*	< LOD	< LOD	.125 (.097-.170)	.188 (.125-.273)	951
	01-02	*	< LOD	< LOD	.107 (.092-.141)	.166 (.135-.187)	1518
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	.149 (.108-.184)	760
	01-02	*	< LOD	< LOD	.099 (.088-.114)	.148 (.106-.179)	1047
Females	99-00	*	< LOD	< LOD	.118 (.091-.192)	.196 (.116-.310)	829
	01-02	*	< LOD	< LOD	.103 (.084-.122)	.166 (.126-.197)	1212
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	.103 (.079-.170)	.170 (.085-.318)	598
	01-02	*	< LOD	< LOD	.089 (.069-.109)	.114 (.098-.240)	553
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	.112 (.055-.192)	336
	01-02	*	< LOD	< LOD	.092 (.069-.114)	.129 (.102-.180)	503
Non-Hispanic whites	99-00	*	< LOD	< LOD	.116 (.090-.162)	.184 (.109-.310)	539
	01-02	*	< LOD	< LOD	.103 (.089-.128)	.165 (.128-.187)	1041

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Mirex

CAS No. 2385-85-5

General Information

Mirex has not been produced or used in the United States since 1977. This chemical was formerly used in southern regions of the United States to control fire ants. It was also used as a flame-retardant additive. Mirex binds strongly to soil and is a highly persistent chemical in the environment. The most likely source of exposure to mirex in the general population is the diet. Some states and U.S. EPA have issued public advisories or warnings that fish from contaminated lakes and rivers may contain mirex.

After people are exposed to mirex, it accumulates in fatty tissues in the body and is not metabolized. At high doses, mirex blocks the action of inhibitory neurotransmitters in the central nervous system. This blocking action can cause abnormal excitation of the brain. Studies of workers exposed to chlordecone, an organochlorine insecticide structurally related to mirex, have reported

adverse effects on the liver, nervous system, and reproductive system. IARC classifies mirex as possibly carcinogenic to humans, and NTP classifies mirex as reasonably anticipated to be a human carcinogen.

More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from the ATSDR's Toxicological Profiles at http://www.atsdr.cdc. gov/toxprofiles.

Interpreting Levels of Lipid-Adjusted Serum Mirex Reported in the Tables

Levels of mirex in serum were measured in a subsample of NHANES participants aged 12 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population.

In the NHANES 1999-2000 and 2001-2002 subsamples,

Table 250. Mirex (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1853
	01-02	*	< LOD	< LOD	15.8 (<LOD-73.7)	57.1 (13.2-230)	2257
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	659
	01-02	*	< LOD	< LOD	< LOD	< LOD	728
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1194
	01-02	*	< LOD	< LOD	19.6 (<LOD-108)	71.0 (14.6-305)	1529
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	887
	01-02	*	< LOD	< LOD	16.1 (<LOD-65.6)	50.8 (12.3-225)	1052
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	966
	01-02	*	< LOD	< LOD	14.6 (<LOD-90.4)	63.0 (12.0-374)	1205
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	617
	01-02	*	< LOD	< LOD	< LOD	< LOD	548
Non-Hispanic blacks	99-00	*	< LOD	< LOD	15.5 (<LOD-42.2)	39.5 (<LOD-115)	398
	01-02	*	< LOD	13.5 (<LOD-44.2)	48.2 (15.4-230)	153 (30.5-425)	500
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	688
	01-02	*	< LOD	< LOD	15.0 (<LOD-103)	66.7 (12.5-291)	1049

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

as well as in a subsample of NHANES II (1976-1980) participants, serum mirex levels were generally below the limits of detection (Stehr-Green, 1989). In the NHANES 2001-2002 subsample, only mirex levels at the 90th and 95th percentiles were characterized. In a study of fishermen in New York who consumed sport fish, median levels of lipid-adjusted serum mirex were lower than the 95th percentile values in this 2001-2002 subsample (Bloom et al., 2005).

Finding a measurable amount of mirex in serum does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to mirex and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of mirex than levels found in the general population.

Table 251. Mirex (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1853
	01-02	*	< LOD	< LOD	.101 (.049-.468)	.414 (.080-1.73)	2257
Age group							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	659
	01-02	*	< LOD	< LOD	< LOD	< LOD	728
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1194
	01-02	*	< LOD	< LOD	.137 (.053-.687)	.468 (.089-1.92)	1529
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	887
	01-02	*	< LOD	< LOD	.111 (.055-.468)	.368 (.089-1.37)	1052
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	966
	01-02	*	< LOD	< LOD	.087 (.043-.513)	.419 (.072-1.79)	1205
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	617
	01-02	*	< LOD	< LOD	< LOD	< LOD	548
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.087 (.044-.221)	.221 (.124-.449)	398
	01-02	*	< LOD	.085 (.031-.240)	.293 (.092-1.41)	.826 (.166-3.02)	500
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	688
	01-02	*	< LOD	< LOD	.098 (.047-.609)	.449 (.077-1.79)	1049

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Aldrin
CAS No. 309-00-02

Dieldrin
CAS No. 60-57-1

General Information

Aldrin and dieldrin are organochlorine pesticides that are no longer produced or used in the United States. From the 1950s to 1970, both chemicals were widely used insecticides on agricultural commodities including cotton and corn. These agricultural uses were cancelled in 1970. Aldrin and dieldrin were also registered for use to control termites, but this use was cancelled in 1987. Dieldrin was also used as a sheep-dip pesticide.

Aldrin is rapidly converted to dieldrin in the environment. Aldrin volatilizes from soil after agricultural application or is converted to dieldrin, which volatilizes more slowly. The most likely source of exposure to aldrin and dieldrin in the general population is the diet. Inhalation exposure may also occur among people living in residences where aldrin was previously applied as a pesticide. The U.S. EPA, OSHA, and U.S. FDA have developed criteria on the allowable levels of aldrin in drinking water, workplaces, and foods, respectively.

After aldrin enters the body, it is metabolized to dieldrin.

Dieldrin will accumulate in fatty tissues and its metabolites are excreted in bile and feces. It is also excreted in breast milk. The elimination half-life of dieldrin is approximately 1 year. At high doses, aldrin and dieldrin block inhibitory neurotransmitters in the central nervous system. This blocking action can cause abnormal excitation of the brain, leading to symptoms such as headache, confusion, muscle twitching, nausea, vomiting, and seizures.

More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc. gov/toxprofiles.

Interpreting Levels of Lipid-Adjusted Serum Aldrin and Dieldrin Reported in the Tables

Serum aldrin and dieldrin levels were measured in a subsample of NHANES participants aged 12 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population.

Table 252. Aldrin (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2275
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1519
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1057
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1218
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	512
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1045

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

In the NHANES 2001-2002 subsample, serum levels of aldrin were below the limit of detection, which is consistent with findings of NHANES II (1976-1980) (Stehr-Green, 1989). As well, levels of aldrin were not detectable in a study of New Zealand adults aged 15 years and older (Bates et al., 2004*b*).

In the NHANES 2001-2002 subsample, the 95th percentile value for serum dieldrin was approximately ten times lower than levels measured in a subsample from NHANES II (1976-1980). In New Zealanders aged 15 years and older (Bates et al., 2004*b*) and in Norwegian women (Ward et al., 2000), levels of lipid-adjusted serum dieldrin were lower than the 95th percentile value for dieldrin in this NHANES 2001-2002 subsample.

Finding a measurable amount of aldrin or dieldrin in serum does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to aldrin or dieldrin and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of aldrin and dieldrin than levels found in the general population.

Table 253. Aldrin (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2275
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1519
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1057
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1218
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	512
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1045

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 254. Dieldrin (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	**15.2** (14.3-17.0)	**20.3** (18.7-22.4)	2159
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	716
20 years and older	01-02	*	< LOD	**10.5** (<LOD-11.6)	**16.4** (15.1-18.2)	**21.3** (19.1-24.0)	1443
Gender							
Males	01-02	*	< LOD	< LOD	**15.7** (14.4-18.7)	**20.2** (18.5-23.6)	1007
Females	01-02	*	< LOD	< LOD	**15.2** (13.4-17.0)	**19.8** (18.0-21.6)	1152
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	**11.6** (<LOD-15.1)	**15.4** (12.6-17.6)	539
Non-Hispanic blacks	01-02	*	< LOD	< LOD	**15.0** (11.8-19.1)	**20.2** (15.8-25.2)	484
Non-Hispanic whites	01-02	*	< LOD	< LOD	**15.5** (14.8-17.7)	**20.7** (18.9-23.6)	980

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 255. Dieldrin (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	.109 (.099-.121)	.146 (.129-.164)	2159
Age group							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	716
20 years and older	01-02	*	< LOD	.067 (.062-.075)	.117 (.105-.127)	.158 (.141-.178)	1443
Gender							
Males	01-02	*	< LOD	< LOD	.114 (.102-.129)	.156 (.126-.190)	1007
Females	01-02	*	< LOD	< LOD	.097 (.089-.111)	.141 (.123-.157)	1152
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	.083 (.068-.103)	.119 (.086-.144)	539
Non-Hispanic blacks	01-02	*	< LOD	< LOD	.085 (.071-.113)	.118 (.086-.190)	484
Non-Hispanic whites	01-02	*	< LOD	< LOD	.109 (.100-.124)	.153 (.131-.175)	980

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Endrin
CAS No. 72-20-8

General Information

Endrin, a stereoisomer of dieldrin, is an organochlorine pesticide that is no longer registered for use in the United States. Production and use of endrin was discontinued in 1986. In contrast to aldrin and dieldrin, endrin was not extensively used for termite control in residences. Endrin is a persistent chemical in the environment, particularly in soils. It is transformed in the environment and the human body to metabolites including endrin aldehyde and endrin ketone. The main sources of human exposure to endrin come from residues on food items imported from countries where endrin is still used and living or working near hazardous waste sites where the chemical was produced.

After a person is exposed to endrin, most of the chemical is metabolized and eliminated from the body relatively quickly compared with length of time it takes for other organochlorine pesticides to be metabolized and excreted. Endrin does not accumulate in body tissues, and elimination occurs via its metabolites, which are excreted in the feces. At high doses, endrin blocks inhibitory neurotransmitters in the central nervous system. This blocking action can cause an abnormal excitation of the brain, producing seizures.

Information about external exposure (i.e., environmental

levels) and health effects of endrin is available from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Interpreting Levels of Lipid-Adjusted Serum Endrin Reported in the Tables

Serum endrin levels were measured in a subsample of NHANES participants aged 12 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, serum levels of endrin were below the limit of detection. This finding is consistent the study of New Zealanders aged 15 years and older in whom levels of endrin were also below the limit of detection (Bates et al., 2004*b*). In another study of women in Spain, endrin was detected in 9% of serum samples at a mean concentration of 2.25 ng/mL (about 2.25 ng/g of serum) (Botella et al., 2004).

Finding a measurable amount of endrin in serum does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to endrin and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of endrin than levels found in the general population.

Table 256. Endrin (lipid adjusted)

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	5.10 (<LOD-5.20)	2187
Age group							
12-19 years	01-02	*	< LOD	< LOD	5.10 (<LOD-5.30)	5.60 (5.40-5.70)	730
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1457
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	5.20 (<LOD-5.20)	1022
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1165
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	5.20 (<LOD-6.50)	547
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	5.30 (<LOD-6.10)	487
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	5.10 (<LOD-5.30)	1000

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 257. Endrin (whole weight)

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 12 and older	01-02	*	< LOD	< LOD	< LOD	**.021** (.020-.021)	2187
Age group							
12-19 years	01-02	*	< LOD	< LOD	**.021** (.020-.021)	**.021** (.020-.021)	730
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1457
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	**.020** (.020-.021)	1022
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1165
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	**.021** (.020-.021)	547
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	**.021** (.020-.021)	487
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	**.021** (.020-.021)	1000

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Results by Chemical Group

Organophosphate Pesticides: Dialkyl Phosphate Metabolites

Organophosphate Pesticides: Dialkyl Phosphate Metabolites

General Information

Organophosphate pesticides, which are active against a broad spectrum of insects, account for about half of all insecticides used in the United States. Although organophosphates are still used for insect control on many food crops, most residential uses are being phased out in the United States as a result of implementation of the Food Quality Protection Act of 1996. Certain organophosphates (i.e., malathion, naled) are registered for public health applications (mosquito control) in the United States. About 73 million pounds of organophosphate pesticides were used in the United States in 2001 (70% of all insecticides) (U.S. EPA, 2004). Approximately 40 organophosphate insecticides are registered for use in the United States by the U.S. EPA. Some chemicals in this class are also used in plastics manufacturing, but they do not have insecticidal properties.

Exposure to organophosphates may occur by ingestion, inhalation, or dermal contact. Farm workers, pesticide applicators, and manufacturers of these pesticides may have higher levels of exposure. The acute effects of the organophosphates from intentional and unintentional overdoses or from high-dose exposure are well known and include neurologic dysfunction that results from inhibition of acetylcholine breakdown in the central and peripheral nervous systems. This dysfunction results from the inhibitory effect of organophosphates on the enzyme acetylcholinesterase. Symptoms may include nausea, vomiting, cholinergic effects, weakness, paralysis, and seizures.

About 75% of registered organophosphate pesticides will be metabolized to measurable dialkyl phosphate metabolites. In contrast to the organophosphates, the dialkyl phosphate metabolites do not inhibit acetylcholinesterase enzymes. Dialkyl phosphates themselves are not considered toxic, but they are markers of exposure to organophosphates. Dialkyl phosphate metabolites can be present in urine after low-level organophosphate exposures that do not cause clinical symptoms (Davies and Peterson, 1997; Franklin et al., 1981). Measurement of these metabolites reflects recent exposure that has occurred predominantly in the last few days.

Dialkyl phosphates may also be present in the environment from the degradation of organophosphates (Lu et al., 2005). Therefore, in addition to reflecting exposure to the parent pesticides, the level of the metabolite in a person's urine may reflect exposure to the metabolite itself, if it was present in the person's environment. Generally, health-related guidelines for urinary levels of these metabolites have not been established.

This *Report* provides measurements in urine for the following six dialkyl phosphate metabolites of organophosphate pesticides:

- Dimethylphosphate (DMP)
- Dimethylthiophosphate (DMTP)
- Dimethyldithiophosphate (DMDTP)
- Diethylphosphate (DEP)
- Diethylthiophosphate (DETP)
- Diethyldithiophosphate (DEDTP)

Table 259 shows the six urinary metabolites and their parent organophosphate pesticides. For example, chlorpyrifos is metabolized to both diethylphosphate and diethythiophosphate. Each of the six urinary dialkyl phosphate metabolites can be produced from the metabolism of more than one organophosphate pesticide. Therefore, without other information, the presence of dialkyl phosphate metabolites cannot be linked to exposure to a specific organophosphate pesticide.

Interpreting Levels of Urinary Dialkyl Phosphate Metabolites Reported in the Tables

Urinary organophosphate metabolite levels were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the 2001-2002 NHANES subsample, mean urinary dialkyl phosphate levels were generally lower than levels reported in smaller studies of children (Aprea et al., 2000) and adults (Aprea et al., 1996) in Italy. In those studies, DMTP and DMP were most frequently detected. Urinary dialkyl phosphate levels in the 2001-2002 NHANES subsample were also significantly lower than levels reported in a large study of children and adults in Germany (Heudorf and Angerer, 2001*c*). The measurement of dialkyl phosphates in urine has been used to document exposure of farmers, agricultural workers and their families, pest-control workers, and others to organophosphorus pesticides (Curl et al., 2002; Krieger and Dinoff, 2000; Takamiya, 1994; Davies and Peterson, 1997; Franklin et al., 1981). In occupational studies, reported levels of dialkyl phosphates often exceed levels seen in the general population by up to 50-fold.

Table 258. Organophosphate pesticides and their metabolites

Pesticide (CAS number)	Dimethyl-phosphate (813-79-5)	Dimethylthio-phosphate (1112-38-5)	Dimethyldithio-phosphate (756-80-9)	Diethyl-phosphate (598-02-7)	Diethylthio-phosphate (2465-65-8)	Diethyldithio-phosphate (298-06-6)
Azinphos methyl	•	•	•			
Chlorethoxyphos				•	•	
Chlorpyrifos				•	•	
Chlorpyrifos methyl	•	•				
Coumaphos				•	•	
Dichlorvos (DDVP)	•					
Diazinon				•	•	
Dicrotophos	•					
Dimethoate	•	•	•			
Disulfoton				•	•	•
Ethion				•	•	•
Fenitrothion	•	•				
Fenthion	•	•				
Isazaphos-methyl	•	•				
Malathion	•	•	•			
Methidathion	•	•	•			
Methyl parathion	•	•				
Naled	•					
Oxydemeton-methyl	•	•				
Parathion				•	•	
Phorate				•	•	•
Phosmet	•	•	•			
Pirimiphos-methyl	•	•				
Sulfotepp				•	•	
Temephos	•	•				
Terbufos				•	•	•
Tetrachlorvinphos	•					

Comparing Adjusted Geometric Means

Geometric mean levels of urinary dialkyl phosphate metabolite for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). Due to insufficient detection rates in the two NHANES surveys, only a few comparisons could be made. For adjusted geometric mean levels of DMTP and DEP in NHANES 1999-2000, the groups aged 6-11 years were about twofold higher than the groups aged 20-59 years and for only DMTP, males had slightly higher levels than females. For adjusted geometric mean levels of DETP in NHANES 2001-2002, non-Hispanic blacks had slightly higher levels than non-Hispanic whites. Studies in other countries have reported higher levels of urinary dialkyl phosphate metabolites in children than in adults (Aprea et al., 2000). It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of organophosphate metabolites in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to organophosphates and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of organophosphates than levels found in the general population.

Table 259. Dimethylphosphate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	**.740** (<LOD-1.40)	**2.80** (2.10-3.80)	**7.90** (6.20-8.90)	**13.0** (10.0-18.0)	1949
	01-02	*	**< LOD**	**3.25** (2.76-3.67)	**8.22** (6.95-9.27)	**13.4** (10.9-15.6)	2519
Age group							
6-11 years	99-00	*	**1.00** (.580-2.20)	**4.40** (2.80-6.80)	**10.0** (6.80-15.0)	**21.0** (13.0-26.0)	471
	01-02	*	**.970** (<LOD-2.00)	**5.03** (3.31-7.66)	**12.2** (9.10-15.1)	**18.2** (12.6-41.7)	576
12-19 years	99-00	*	**.650** (<LOD-1.80)	**3.80** (2.50-4.90)	**9.90** (6.10-18.0)	**22.0** (12.0-29.0)	664
	01-02	*	**.670** (<LOD-1.31)	**4.27** (3.41-5.35)	**9.27** (7.80-12.3)	**14.6** (11.8-21.3)	822
20-59 years	99-00	*	**.680** (<LOD-1.30)	**2.60** (1.80-3.60)	**6.50** (5.60-8.10)	**9.70** (8.80-14.0)	814
	01-02	*	**< LOD**	**2.93** (2.35-3.41)	**6.89** (5.80-8.82)	**11.5** (9.66-13.7)	1121
Gender							
Males	99-00	*	**.650** (<LOD-1.30)	**2.80** (2.10-3.90)	**7.90** (6.00-9.30)	**18.0** (10.0-24.0)	952
	01-02	*	**< LOD**	**3.40** (2.49-4.30)	**8.22** (6.67-10.3)	**12.6** (10.9-14.7)	1187
Females	99-00	*	**.780** (<LOD-1.50)	**2.80** (1.80-4.00)	**7.60** (5.70-9.00)	**10.0** (8.90-15.0)	997
	01-02	*	**< LOD**	**3.05** (2.59-3.63)	**8.34** (6.70-9.64)	**13.7** (10.9-17.2)	1332
Race/ethnicity							
Mexican Americans	99-00	*	**1.00** (<LOD-1.80)	**3.80** (2.70-5.10)	**9.50** (6.00-15.0)	**15.0** (8.60-28.0)	672
	01-02	*	**.660** (<LOD-1.51)	**3.22** (2.46-4.27)	**9.28** (7.10-10.7)	**14.4** (10.7-21.0)	678
Non-Hispanic blacks	99-00	*	**.980** (.620-1.40)	**3.60** (2.50-5.50)	**8.90** (6.70-14.0)	**21.0** (14.0-23.0)	509
	01-02	*	**.910** (<LOD-2.20)	**5.45** (3.81-6.78)	**11.5** (8.77-14.9)	**19.4** (14.1-23.3)	695
Non-Hispanic whites	99-00	*	**< LOD**	**2.90** (1.80-4.20)	**7.90** (5.90-9.00)	**10.0** (9.00-18.0)	595
	01-02	*	**< LOD**	**3.01** (2.33-3.49)	**7.39** (5.98-9.22)	**12.3** (9.63-14.6)	948

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 260. Dimethylphosphate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	**.809** (.569-1.15)	**2.93** (2.11-3.92)	**8.46** (6.96-10.4)	**16.1** (13.3-17.6)	1949
	01-02	*	**< LOD**	**3.00** (2.59-3.33)	**7.83** (6.47-9.04)	**12.7** (10.3-15.0)	2518
Age group							
6-11 years	99-00	*	**1.38** (.889-2.38)	**4.48** (2.88-7.89)	**15.9** (8.21-21.2)	**21.7** (19.2-30.1)	471
	01-02	*	**1.93** (1.11-2.97)	**5.99** (4.32-8.28)	**12.6** (9.34-18.5)	**20.6** (13.3-34.8)	576
12-19 years	99-00	*	**.586** (.451-.952)	**2.27** (1.70-2.80)	**7.70** (4.16-14.4)	**14.5** (8.70-35.3)	664
	01-02	*	**.913** (.584-1.27)	**3.28** (2.75-3.78)	**6.29** (5.51-7.30)	**9.70** (7.94-14.2)	821
20-59 years	99-00	*	**.759** (.554-1.12)	**2.87** (1.89-3.99)	**8.11** (5.89-10.3)	**14.6** (10.4-16.8)	814
	01-02	*	**< LOD**	**2.55** (2.05-3.03)	**6.92** (5.85-8.00)	**11.5** (9.38-13.6)	1121
Gender							
Males	99-00	*	**.623** (.442-.942)	**2.38** (1.83-3.18)	**7.58** (4.64-11.6)	**15.2** (9.74-19.5)	952
	01-02	*	**< LOD**	**2.61** (2.07-3.07)	**6.25** (4.82-8.42)	**10.5** (8.28-12.7)	1187
Females	99-00	*	**1.00** (.641-1.68)	**3.53** (2.30-5.19)	**9.12** (7.82-11.7)	**16.4** (11.7-19.7)	997
	01-02	*	**< LOD**	**3.43** (2.74-4.27)	**9.00** (7.51-10.1)	**15.0** (11.9-17.8)	1331
Race/ethnicity							
Mexican Americans	99-00	*	**1.06** (.704-1.55)	**3.78** (2.54-5.45)	**9.41** (7.69-11.5)	**15.9** (11.7-23.6)	672
	01-02	*	**.913** (.575-1.27)	**3.01** (2.52-3.72)	**8.03** (6.09-11.3)	**14.6** (11.4-16.2)	678
Non-Hispanic blacks	99-00	*	**.686** (.527-1.06)	**2.67** (1.89-3.77)	**7.07** (5.09-11.3)	**13.9** (10.6-19.0)	509
	01-02	*	**.833** (.530-1.34)	**3.36** (2.68-4.29)	**7.56** (6.25-9.45)	**13.2** (9.50-17.2)	694
Non-Hispanic whites	99-00	*	**< LOD**	**3.15** (1.97-4.32)	**8.73** (5.89-13.3)	**15.8** (10.0-21.2)	595
	01-02	*	**< LOD**	**2.74** (2.20-3.37)	**7.94** (5.91-9.86)	**12.9** (9.85-17.7)	948

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Figure 32. Dimethylphosphate (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

[a] Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Table 261. Dimethylthiophosphate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**1.82** (1.36-2.44)	**2.70** (1.20-4.00)	**10.0** (8.10-15.0)	**38.0** (17.0-38.0)	**46.0** (38.0-62.0)	1948
	01-02	*	**.450** (<LOD-1.41)	**4.02** (2.90-5.60)	**16.2** (12.4-22.9)	**32.6** (26.6-45.3)	2518
Age group							
6-11 years	99-00	**2.72** (1.93-3.85)	**4.10** (2.40-7.00)	**20.0** (13.0-28.0)	**40.0** (38.0-52.0)	**62.0** (40.0-92.0)	471
	01-02	*	**1.44** (.600-2.69)	**8.33** (5.75-14.0)	**28.2** (19.7-41.4)	**45.7** (28.5-74.5)	575
12-19 years	99-00	**2.53** (1.64-3.92)	**3.60** (1.60-6.50)	**16.0** (8.80-24.0)	**37.0** (21.0-38.0)	**69.0** (38.0-260)	664
	01-02	*	**1.03** (<LOD-2.10)	**4.83** (3.35-6.48)	**20.8** (12.2-27.9)	**33.9** (23.6-54.7)	822
20-59 years	99-00	**1.59** (1.17-2.16)	**2.20** (.830-3.80)	**9.10** (7.10-13.0)	**38.0** (15.0-38.0)	**38.0** (38.0-49.0)	813
	01-02	*	**< LOD**	**3.32** (2.28-4.87)	**13.6** (9.50-20.0)	**29.5** (20.5-45.3)	1121
Gender							
Males	99-00	**2.10** (1.48-2.98)	**3.40** (2.10-4.60)	**13.0** (8.00-22.0)	**38.0** (15.0-38.0)	**41.0** (38.0-53.0)	952
	01-02	*	**.610** (<LOD-1.41)	**4.21** (3.07-5.97)	**18.3** (12.2-27.2)	**30.4** (25.0-43.3)	1187
Females	99-00	**1.59** (1.23-2.06)	**2.00** (.570-3.60)	**9.70** (7.30-14.0)	**38.0** (20.0-38.0)	**52.0** (38.0-110)	996
	01-02	*	**< LOD**	**3.76** (2.50-5.71)	**15.9** (10.6-22.0)	**34.3** (23.2-47.3)	1331
Race/ethnicity							
Mexican Americans	99-00	**1.79** (1.05-3.05)	**2.00** (.530-4.40)	**10.0** (6.60-17.0)	**38.0** (32.0-62.0)	**130** (46.0-230)	671
	01-02	*	**< LOD**	**3.74** (2.66-5.18)	**15.1** (11.1-19.1)	**35.2** (19.1-46.0)	678
Non-Hispanic blacks	99-00	**2.13** (1.57-2.88)	**3.60** (2.10-4.70)	**11.0** (8.40-17.0)	**37.0** (19.0-41.0)	**39.0** (37.0-100)	509
	01-02	*	**1.25** (.650-2.05)	**5.54** (3.29-9.41)	**20.6** (15.6-27.7)	**42.2** (27.2-62.8)	695
Non-Hispanic whites	99-00	**1.77** (1.23-2.53)	**2.60** (.720-4.40)	**11.0** (7.50-17.0)	**38.0** (13.0-38.0)	**45.0** (38.0-69.0)	595
	01-02	*	**< LOD**	**3.99** (2.46-6.14)	**17.0** (10.1-25.0)	**32.6** (25.0-50.2)	947

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 262. Dimethylthiophosphate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**1.64** (1.22-2.20)	**2.12** (1.22-3.35)	**9.57** (6.59-15.8)	**32.0** (23.8-41.1)	**51.0** (39.0-70.1)	1948
	01-02	*	**.854** (.571-1.33)	**3.79** (2.50-5.19)	**13.2** (10.9-18.8)	**27.2** (21.7-37.7)	2517
Age group							
6-11 years	99-00	**2.95** (2.25-3.86)	**5.25** (3.75-6.33)	**18.7** (12.1-28.0)	**45.2** (32.1-60.3)	**65.9** (50.9-95.0)	471
	01-02	*	**2.16** (1.32-3.12)	**10.6** (7.84-13.6)	**28.7** (18.8-45.0)	**47.2** (33.4-71.1)	575
12-19 years	99-00	**1.71** (1.07-2.75)	**2.14** (.886-4.83)	**13.4** (6.46-22.6)	**36.0** (25.6-51.4)	**61.5** (41.7-109)	664
	01-02	*	**.933** (.519-1.56)	**3.56** (2.38-5.57)	**12.2** (8.96-16.0)	**22.4** (13.2-34.7)	821
20-59 years	99-00	**1.47** (1.07-2.02)	**1.90** (.867-3.11)	**8.09** (5.19-14.6)	**27.0** (19.8-37.6)	**47.4** (34.2-70.1)	813
	01-02	*	**< LOD**	**3.16** (1.99-4.62)	**11.8** (7.79-17.2)	**25.2** (15.9-37.0)	1121
Gender							
Males	99-00	**1.61** (1.11-2.34)	**2.28** (1.27-3.51)	**9.27** (6.00-16.9)	**28.9** (19.0-40.4)	**41.1** (34.9-52.9)	952
	01-02	*	**.753** (.466-1.08)	**3.35** (2.26-4.60)	**12.4** (8.54-15.9)	**24.0** (14.6-38.9)	1187
Females	99-00	**1.66** (1.26-2.18)	**2.01** (.866-3.33)	**10.0** (6.67-16.0)	**34.5** (26.2-47.1)	**69.5** (39.0-118)	996
	01-02	*	**< LOD**	**4.22** (2.40-7.00)	**15.6** (11.3-22.6)	**29.6** (24.8-43.8)	1330
Race/ethnicity							
Mexican Americans	99-00	**1.60** (.899-2.86)	**1.83** (.684-4.23)	**10.4** (5.95-16.9)	**37.0** (23.1-63.1)	**112** (40.5-190)	671
	01-02	*	**< LOD**	**3.55** (2.52-4.93)	**13.2** (9.61-22.7)	**30.2** (22.7-47.7)	678
Non-Hispanic blacks	99-00	**1.45** (1.03-2.06)	**1.75** (1.17-3.06)	**8.21** (4.36-13.4)	**25.5** (15.4-39.3)	**52.1** (25.5-97.6)	509
	01-02	*	**1.02** (.667-1.35)	**3.58** (2.33-5.18)	**13.4** (9.69-18.8)	**22.6** (17.5-43.8)	694
Non-Hispanic whites	99-00	**1.68** (1.16-2.43)	**2.22** (.867-3.51)	**9.27** (5.58-17.0)	**32.5** (20.5-49.4)	**51.0** (39.0-71.1)	595
	01-02	*	**< LOD**	**3.82** (2.19-6.38)	**14.1** (10.1-22.1)	**27.4** (21.7-43.8)	947

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Figure 33. Dimethylthiophosphate (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

[a] Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Table 263. Dimethyldithiophosphate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

|	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	**2.30** (1.30-3.90)	**12.0** (5.00-17.0)	**19.0** (17.0-38.0)	1949
	01-02	*	< LOD	**.890** (.210-1.30)	**2.49** (1.88-3.40)	**4.95** (3.55-8.35)	2518
Age group							
6-11 years	99-00	*	**.730** (.080-1.80)	**4.30** (2.30-7.90)	**16.0** (5.30-19.0)	**32.0** (17.0-44.0)	471
	01-02	*	< LOD	**1.30** (.680-2.07)	**3.53** (2.20-4.50)	**7.33** (4.32-9.74)	575
12-19 years	99-00	*	< LOD	**2.20** (1.30-4.50)	**12.0** (5.40-19.0)	**19.0** (17.0-30.0)	664
	01-02	*	< LOD	**.810** (.400-1.14)	**2.51** (1.85-3.07)	**4.63** (3.59-5.83)	821
20-59 years	99-00	*	< LOD	**2.10** (.830-3.60)	**10.0** (3.80-17.0)	**16.0** (5.90-22.0)	814
	01-02	*	< LOD	**.840** (<LOD-1.31)	**2.32** (1.70-3.40)	**4.90** (2.90-9.52)	1122
Gender							
Males	99-00	*	**.110** (<LOD-.610)	**2.30** (1.10-4.80)	**16.0** (5.30-17.0)	**18.0** (17.0-38.0)	952
	01-02	*	< LOD	**.840** (.180-1.26)	**2.40** (1.83-3.28)	**5.13** (3.53-7.86)	1187
Females	99-00	*	< LOD	**2.10** (1.00-3.60)	**10.0** (4.00-17.0)	**20.0** (13.0-40.0)	997
	01-02	*	< LOD	**.950** (.170-1.38)	**2.52** (1.94-3.68)	**5.10** (3.31-10.6)	1331
Race/ethnicity							
Mexican Americans	99-00	*	**.240** (<LOD-.850)	**1.80** (1.10-2.80)	**5.70** (4.10-9.70)	**12.0** (5.80-28.0)	672
	01-02	*	< LOD	**.960** (.750-1.37)	**2.66** (2.07-3.41)	**4.47** (3.70-7.01)	678
Non-Hispanic blacks	99-00	*	**.330** (<LOD-1.20)	**3.20** (1.40-7.00)	**14.0** (5.50-24.0)	**18.0** (16.0-39.0)	509
	01-02	*	< LOD	**.750** (<LOD-1.67)	**2.11** (1.52-4.08)	**4.38** (2.51-8.66)	695
Non-Hispanic whites	99-00	*	< LOD	**2.00** (.800-4.00)	**13.0** (3.80-18.0)	**20.0** (14.0-40.0)	595
	01-02	*	< LOD	**.940** (<LOD-1.42)	**2.49** (1.83-3.65)	**5.74** (3.28-9.74)	947

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 264. Dimethyldithiophosphate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	1.86 (.974-3.86)	10.1 (5.31-18.3)	21.7 (12.8-33.7)	1949
	01-02	*	< LOD	.667 (.333-1.07)	2.60 (1.85-3.69)	5.80 (4.23-7.75)	2517
Age group							
6-11 years	99-00	*	.788 (.186-1.60)	4.07 (2.31-7.18)	16.2 (8.22-27.0)	30.8 (20.2-38.9)	471
	01-02	*	< LOD	1.35 (.805-2.31)	3.76 (2.67-6.24)	6.98 (4.40-12.8)	575
12-19 years	99-00	*	< LOD	1.52 (.623-3.47)	9.42 (4.04-16.8)	18.5 (9.48-42.3)	664
	01-02	*	< LOD	.543 (.306-.773)	1.99 (1.49-2.40)	3.13 (2.51-4.67)	820
20-59 years	99-00	*	< LOD	1.71 (.847-3.56)	8.46 (4.00-19.1)	19.2 (8.57-40.7)	814
	01-02	*	< LOD	.595 (.292-1.05)	2.56 (1.64-4.03)	6.03 (3.96-8.17)	1122
Gender							
Males	99-00	*	.150 (.085-.351)	1.64 (.840-3.97)	11.0 (4.62-17.4)	17.8 (7.51-44.7)	952
	01-02	*	< LOD	.583 (.269-.824)	2.01 (1.40-2.67)	4.43 (2.90-6.80)	1187
Females	99-00	*	< LOD	1.99 (.940-4.00)	9.30 (4.96-25.5)	27.0 (9.66-47.5)	997
	01-02	*	< LOD	.820 (.368-1.43)	2.91 (2.29-4.56)	6.93 (4.44-11.9)	1330
Race/ethnicity							
Mexican Americans	99-00	*	.265 (.087-.658)	1.35 (.857-2.53)	6.55 (3.83-11.8)	16.7 (6.25-38.8)	672
	01-02	*	< LOD	.800 (.543-1.11)	2.59 (1.88-3.22)	4.86 (3.32-6.37)	678
Non-Hispanic blacks	99-00	*	.235 (.071-.698)	2.39 (.690-5.44)	9.41 (4.81-17.8)	17.8 (11.4-40.7)	509
	01-02	*	< LOD	.426 (.140-.933)	1.79 (.828-3.50)	3.65 (2.33-5.91)	694
Non-Hispanic whites	99-00	*	< LOD	1.75 (.778-4.02)	11.3 (4.07-21.5)	21.5 (11.3-34.8)	595
	01-02	*	< LOD	.711 (.304-1.31)	2.85 (1.91-4.96)	6.98 (4.25-9.47)	947

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 265. Diethylphosphate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**1.03** (.670-1.58)	**1.20** (.720-1.60)	**3.10** (2.30-4.70)	**7.50** (5.00-12.0)	**13.0** (7.60-22.0)	1949
	01-02	*	**< LOD**	**2.76** (2.41-3.15)	**6.33** (5.64-7.46)	**11.4** (9.15-12.5)	2520
Age group							
6-11 years	99-00	**1.32** (.757-2.29)	**1.40** (.800-2.50)	**4.50** (1.90-7.50)	**10.0** (4.80-16.0)	**15.0** (8.50-35.0)	471
	01-02	*	**.290** (<LOD-.990)	**3.41** (2.36-4.47)	**9.56** (6.33-18.0)	**20.0** (9.44-38.2)	576
12-19 years	99-00	**1.21** (.758-1.94)	**1.30** (.950-2.00)	**3.70** (2.30-5.40)	**7.90** (4.70-19.0)	**20.0** (8.00-27.0)	664
	01-02	*	**< LOD**	**2.86** (1.96-3.95)	**7.58** (5.71-9.15)	**11.0** (9.35-12.4)	822
20-59 years	99-00	**.955** (.623-1.47)	**1.00** (.650-1.50)	**3.00** (1.70-4.70)	**7.20** (4.70-11.0)	**10.0** (6.80-21.0)	814
	01-02	*	**< LOD**	**2.71** (2.34-3.12)	**5.79** (5.05-7.21)	**10.4** (7.43-12.3)	1122
Gender							
Males	99-00	**1.11** (.717-1.73)	**1.10** (.750-1.70)	**3.80** (2.50-5.00)	**8.00** (5.00-19.0)	**18.0** (7.00-30.0)	952
	01-02	*	**< LOD**	**3.13** (2.44-3.53)	**6.99** (5.79-7.80)	**11.5** (8.98-12.4)	1187
Females	99-00	**.954** (.599-1.52)	**1.10** (.570-1.70)	**2.90** (1.80-4.70)	**7.50** (4.60-11.0)	**11.0** (7.00-15.0)	997
	01-02	*	**.260** (<LOD-.750)	**2.58** (2.17-3.02)	**5.93** (4.55-8.19)	**10.4** (7.27-15.1)	1333
Race/ethnicity							
Mexican Americans	99-00	**1.22** (.740-2.01)	**1.10** (.770-1.60)	**4.10** (2.20-7.00)	**11.0** (5.80-14.0)	**17.0** (12.0-23.0)	672
	01-02	*	**.600** (<LOD-1.63)	**3.10** (2.27-3.72)	**6.22** (5.00-7.82)	**11.2** (7.82-12.3)	678
Non-Hispanic blacks	99-00	**1.56** (1.13-2.14)	**1.60** (1.30-1.70)	**4.20** (2.90-5.80)	**10.0** (5.50-18.0)	**18.0** (8.00-27.0)	509
	01-02	*	**.890** (<LOD-2.42)	**4.59** (3.30-6.52)	**10.2** (7.40-14.0)	**15.4** (9.93-24.2)	696
Non-Hispanic whites	99-00	**.981** (.579-1.66)	**1.10** (.380-1.80)	**3.30** (2.20-4.90)	**7.60** (4.70-14.0)	**14.0** (7.60-25.0)	595
	01-02	*	**< LOD**	**2.44** (2.06-2.91)	**5.48** (4.51-6.33)	**10.0** (7.52-11.9)	948

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 266. Diethylphosphate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.924** (.608-1.41)	**.924** (.574-1.40)	**2.73** (1.68-4.60)	**7.94** (4.40-12.2)	**12.1** (8.00-19.6)	1949
	01-02	*	**< LOD**	**2.39** (2.06-2.69)	**5.23** (4.64-5.98)	**8.53** (6.94-10.2)	2519
Age group							
6-11 years	99-00	**1.43** (.870-2.34)	**1.47** (1.02-2.41)	**3.94** (2.20-8.57)	**10.3** (4.49-20.8)	**16.2** (10.5-32.7)	471
	01-02	*	**.886** (.368-1.76)	**4.02** (2.87-5.25)	**8.84** (6.88-15.6)	**17.0** (9.40-28.8)	576
12-19 years	99-00	**.818** (.533-1.26)	**.786** (.557-1.25)	**2.29** (1.37-3.75)	**5.38** (2.82-14.4)	**12.3** (4.66-34.2)	664
	01-02	*	**< LOD**	**2.05** (1.54-2.67)	**4.40** (3.40-5.28)	**7.16** (5.28-9.75)	821
20-59 years	99-00	**.883** (.574-1.36)	**.857** (.500-1.35)	**2.63** (1.54-4.95)	**7.37** (4.32-12.1)	**12.1** (8.00-17.5)	814
	01-02	*	**< LOD**	**2.28** (2.01-2.56)	**4.74** (3.92-5.83)	**7.31** (5.93-9.72)	1122
Gender							
Males	99-00	**.855** (.566-1.29)	**.811** (.508-1.34)	**2.61** (1.76-4.03)	**7.69** (4.41-12.1)	**12.2** (6.94-23.8)	952
	01-02	*	**< LOD**	**2.04** (1.71-2.52)	**4.31** (3.62-5.00)	**6.88** (5.60-9.42)	1187
Females	99-00	**.996** (.620-1.60)	**.956** (.541-1.62)	**2.80** (1.45-5.85)	**8.00** (4.00-13.0)	**12.1** (6.67-19.6)	997
	01-02	*	**.750** (.438-1.27)	**2.66** (2.24-3.23)	**6.28** (4.75-7.37)	**9.57** (6.61-13.6)	1332
Race/ethnicity							
Mexican Americans	99-00	**1.09** (.633-1.89)	**1.05** (.645-1.98)	**3.78** (2.11-6.46)	**9.84** (5.66-15.7)	**15.6** (8.61-29.0)	672
	01-02	*	**.877** (.341-1.38)	**2.38** (1.79-3.13)	**5.00** (4.04-6.53)	**7.66** (5.88-10.9)	678
Non-Hispanic blacks	99-00	**1.07** (.773-1.47)	**1.17** (.828-1.54)	**2.55** (1.89-3.47)	**5.98** (3.94-9.56)	**11.7** (5.98-22.2)	509
	01-02	*	**.778** (.219-1.56)	**2.78** (2.40-3.40)	**7.19** (4.90-8.84)	**9.75** (7.82-14.9)	695
Non-Hispanic whites	99-00	**.932** (.549-1.58)	**.900** (.426-1.68)	**2.82** (1.51-5.88)	**8.46** (4.40-14.4)	**13.0** (8.21-23.8)	595
	01-02	*	**< LOD**	**2.29** (1.92-2.74)	**4.91** (3.93-5.93)	**7.80** (6.15-10.7)	948

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Figure 34. Diethylphosphate (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

a Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Table 267. Diethylthiophosphate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	**.490** (<LOD-.680)	**.760** (.610-1.10)	**1.30** (1.10-1.70)	**2.20** (1.70-2.80)	1949
	01-02	**.457** (.353-.592)	**.570** (.390-.860)	**1.48** (1.25-1.79)	**2.46** (2.22-3.02)	**3.94** (3.17-4.95)	2519
Age group							
6-11 years	99-00	*	**.590** (<LOD-.800)	**.900** (.710-1.30)	**1.70** (1.10-2.90)	**3.13** (1.70-7.30)	471
	01-02	**.453** (.350-.585)	**.540** (.350-.850)	**1.58** (1.32-2.01)	**2.74** (2.22-3.38)	**4.08** (2.95-5.16)	575
12-19 years	99-00	*	**.210** (<LOD-.710)	**.780** (.600-1.20)	**1.40** (1.10-2.20)	**2.20** (1.60-3.10)	664
	01-02	**.505** (.388-.657)	**.690** (.440-.960)	**1.61** (1.31-1.93)	**2.57** (2.23-3.39)	**4.08** (2.73-5.86)	822
20-59 years	99-00	*	**.480** (<LOD-.660)	**.740** (.600-.930)	**1.30** (.960-1.60)	**2.00** (1.50-2.50)	814
	01-02	**.449** (.340-.592)	**.540** (.380-.880)	**1.44** (1.19-1.77)	**2.46** (2.11-3.17)	**3.79** (2.96-5.34)	1122
Gender							
Males	99-00	*	**.500** (<LOD-.680)	**.790** (.680-1.10)	**1.40** (1.20-1.90)	**2.70** (1.90-4.10)	952
	01-02	**.459** (.359-.587)	**.560** (.370-.850)	**1.49** (1.28-1.76)	**2.54** (2.16-3.34)	**3.83** (2.76-5.86)	1187
Females	99-00	*	**< LOD**	**.720** (.560-1.00)	**1.24** (.910-1.60)	**1.70** (1.30-2.70)	997
	01-02	**.455** (.336-.618)	**.550** (.370-.940)	**1.48** (1.14-1.89)	**2.44** (2.11-3.21)	**3.91** (2.68-5.49)	1332
Race/ethnicity							
Mexican Americans	99-00	*	**.560** (<LOD-.780)	**.840** (.740-.980)	**1.40** (1.20-1.80)	**2.20** (1.90-2.70)	672
	01-02	**.549** (.398-.759)	**.700** (.460-.950)	**1.38** (1.01-1.98)	**2.59** (1.97-3.35)	**3.98** (2.74-5.21)	678
Non-Hispanic blacks	99-00	*	**.560** (<LOD-.750)	**.810** (.690-1.20)	**1.80** (1.30-3.20)	**3.50** (2.00-4.80)	509
	01-02	**.749** (.592-.949)	**1.18** (.740-1.49)	**1.85** (1.74-1.99)	**3.54** (3.01-3.91)	**5.27** (3.89-6.74)	695
Non-Hispanic whites	99-00	*	**.160** (<LOD-.700)	**.730** (.580-1.10)	**1.30** (.880-1.60)	**1.80** (1.50-2.80)	595
	01-02	**.425** (.303-.597)	**.500** (.270-.900)	**1.46** (1.10-1.83)	**2.41** (2.05-3.17)	**3.73** (2.59-6.15)	948

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 268. Diethylthiophosphate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	.254 (.079-.478)	.706 (.456-1.07)	1.70 (1.17-2.32)	2.64 (2.08-3.06)	1949
	01-02	.453 (.348-.590)	.515 (.332-.760)	1.33 (1.04-1.66)	2.84 (2.22-3.76)	4.61 (3.42-6.65)	2518
Age group							
6-11 years	99-00	*	.470 (.136-.869)	1.08 (.797-1.32)	1.73 (1.44-2.36)	2.45 (2.04-5.32)	471
	01-02	.591 (.471-.742)	.628 (.389-1.00)	1.63 (1.31-1.94)	3.20 (2.72-4.16)	5.70 (3.84-6.80)	575
12-19 years	99-00	*	.176 (.051-.404)	.509 (.318-.821)	1.07 (.723-1.61)	1.97 (1.07-3.92)	664
	01-02	.393 (.300-.515)	.534 (.313-.735)	1.23 (.978-1.53)	2.11 (1.61-3.07)	3.14 (2.25-3.97)	821
20-59 years	99-00	*	.250 (.081-.462)	.685 (.443-1.08)	1.79 (1.08-2.39)	2.75 (2.02-3.22)	814
	01-02	.447 (.335-.597)	.494 (.316-.742)	1.31 (.986-1.71)	2.87 (2.08-3.95)	4.61 (3.20-7.81)	1122
Gender							
Males	99-00	*	.267 (.077-.471)	.672 (.515-.835)	1.34 (1.08-2.17)	2.66 (1.67-3.23)	952
	01-02	.372 (.285-.485)	.454 (.268-.692)	1.11 (.939-1.33)	2.05 (1.55-3.11)	3.31 (2.47-4.71)	1187
Females	99-00	*	< LOD	.790 (.382-1.50)	1.89 (1.07-2.52)	2.52 (1.89-3.75)	997
	01-02	.552 (.412-.739)	.580 (.368-.906)	1.60 (1.18-2.42)	3.67 (2.77-4.99)	6.57 (3.92-8.82)	1331
Race/ethnicity							
Mexican Americans	99-00	*	.335 (.063-.786)	.829 (.545-1.20)	1.69 (1.20-2.43)	2.71 (1.75-3.78)	672
	01-02	.509 (.377-.688)	.551 (.376-.844)	1.27 (1.03-1.67)	2.55 (1.77-3.72)	3.67 (2.58-6.30)	678
Non-Hispanic blacks	99-00	*	.300 (.076-.579)	.717 (.514-.848)	1.35 (1.03-2.10)	2.89 (1.49-4.24)	509
	01-02	.535 (.444-.645)	.705 (.553-.925)	1.43 (1.32-1.60)	2.69 (2.30-2.98)	3.89 (3.05-4.99)	694
Non-Hispanic whites	99-00	*	.230 (.062-.548)	.705 (.387-1.22)	1.88 (1.05-2.58)	2.58 (2.08-3.07)	595
	01-02	.448 (.318-.630)	.508 (.269-.800)	1.38 (.995-1.88)	3.08 (2.29-4.23)	5.77 (3.42-8.44)	948

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Figure 35. Diethylthiophosphate (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

a Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Table 269. Diethyldithiophosphate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	**.080** (<LOD-.130)	**.200** (.130-.290)	**.470** (.380-.640)	**.870** (.640-1.10)	1949
	01-02	*	**< LOD**	**< LOD**	**.610** (.410-.760)	**.830** (.700-1.19)	2516
Age group							
6-11 years	99-00	*	**.080** (<LOD-.140)	**.190** (.130-.280)	**.430** (.300-.600)	**.850** (.470-1.00)	471
	01-02	*	**< LOD**	**< LOD**	**.630** (.380-.870)	**.940** (.690-1.42)	576
12-19 years	99-00	*	**.080** (<LOD-.150)	**.260** (.120-.350)	**.640** (.420-.840)	**.900** (.720-1.30)	664
	01-02	*	**< LOD**	**< LOD**	**.560** (.330-.730)	**.820** (.610-.990)	822
20-59 years	99-00	*	**.080** (<LOD-.130)	**.210** (.130-.290)	**.450** (.350-.640)	**.900** (.610-1.10)	814
	01-02	*	**< LOD**	**< LOD**	**.610** (.430-.760)	**.830** (.700-1.32)	1118
Gender							
Males	99-00	*	**.090** (<LOD-.130)	**.220** (.140-.310)	**.470** (.360-.650)	**.870** (.680-1.10)	952
	01-02	*	**< LOD**	**< LOD**	**.600** (.370-.730)	**.770** (.680-1.03)	1187
Females	99-00	*	**.080** (<LOD-.130)	**.190** (.110-.310)	**.450** (.320-.820)	**.850** (.440-1.40)	997
	01-02	*	**< LOD**	**< LOD**	**.660** (.460-.850)	**.990** (.700-1.42)	1329
Race/ethnicity							
Mexican Americans	99-00	*	**.100** (<LOD-.180)	**.310** (.230-.390)	**.650** (.530-.860)	**1.10** (.760-1.20)	672
	01-02	*	**< LOD**	**< LOD**	**.720** (.400-1.13)	**1.12** (.700-1.58)	678
Non-Hispanic blacks	99-00	*	**.090** (<LOD-.160)	**.270** (.130-.390)	**.560** (.400-.830)	**.850** (.650-1.20)	509
	01-02	*	**< LOD**	**< LOD**	**.630** (.410-.820)	**.820** (.730-.970)	694
Non-Hispanic whites	99-00	*	**.080** (<LOD-.150)	**.190** (.120-.280)	**.420** (.310-.720)	**.870** (.500-1.10)	595
	01-02	*	**< LOD**	**< LOD**	**.610** (.360-.780)	**.810** (.650-1.36)	947

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 270. Diethyldithiophosphate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	**.074** (.053-.111)	**.196** (.143-.286)	**.549** (.385-.698)	**.859** (.667-1.14)	1949
	01-02	*	**< LOD**	**< LOD**	**.583** (.380-.733)	**1.01** (.705-1.43)	2515
Age group							
6-11 years	99-00	*	**.102** (.067-.136)	**.193** (.148-.271)	**.571** (.409-.763)	**1.03** (.571-1.58)	471
	01-02	*	**< LOD**	**< LOD**	**.753** (.606-1.12)	**1.36** (1.02-1.86)	576
12-19 years	99-00	*	**.051** (.038-.078)	**.167** (.098-.222)	**.435** (.225-.731)	**.731** (.382-1.09)	664
	01-02	*	**< LOD**	**< LOD**	**.355** (.250-.537)	**.667** (.375-.987)	821
20-59 years	99-00	*	**.075** (.055-.114)	**.205** (.143-.313)	**.549** (.361-.733)	**.859** (.654-1.20)	814
	01-02	*	**< LOD**	**< LOD**	**.583** (.369-.740)	**1.03** (.699-1.60)	1118
Gender							
Males	99-00	*	**.066** (.042-.106)	**.186** (.135-.232)	**.415** (.339-.500)	**.719** (.524-.936)	952
	01-02	*	**< LOD**	**< LOD**	**.383** (.300-.650)	**.740** (.583-1.03)	1187
Females	99-00	*	**.087** (.057-.121)	**.219** (.143-.360)	**.667** (.407-.875)	**.886** (.656-1.62)	997
	01-02	*	**< LOD**	**< LOD**	**.686** (.492-1.00)	**1.24** (.798-1.86)	1328
Race/ethnicity							
Mexican Americans	99-00	*	**.094** (.061-.171)	**.302** (.192-.409)	**.812** (.573-.989)	**1.16** (.859-2.66)	672
	01-02	*	**< LOD**	**< LOD**	**.845** (.444-1.24)	**1.29** (.875-1.78)	678
Non-Hispanic blacks	99-00	*	**.067** (.042-.114)	**.175** (.114-.275)	**.450** (.302-.577)	**.692** (.504-1.02)	509
	01-02	*	**< LOD**	**< LOD**	**.446** (.326-.583)	**.723** (.507-.962)	693
Non-Hispanic whites	99-00	*	**.074** (.049-.118)	**.204** (.139-.308)	**.554** (.380-.733)	**.875** (.596-1.38)	595
	01-02	*	**< LOD**	**< LOD**	**.538** (.352-.746)	**1.03** (.636-1.67)	947

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Organophosphate Pesticides: Specific Metabolites

Organophosphate Pesticides: Specific Metabolites

General Information

These metabolites differ from the dialkyl phosphates because each specific metabolite derives from one or only a few parent pesticides. Table 272 shows the parent organophosphate pesticides and their metabolites. For example, malathion is metabolized to malathion dicarboxylic acid. *Para*-nitrophenol is a metabolite of parathion and methyl parathion and other chemicals. Chlorpyrifos and chlorpyrifos methyl are metabolized to 3,5,6-trichloro-2-pyridinol. In addition to reflecting exposure to the parent insecticide, the level of these metabolites in a person's urine may also reflect exposure to the metabolite if it was present in the person's food or environment.

Sources of potential exposure to organophosphates vary, depending on the chemical. Some organophosphates (including malathion and chlorpyrifos) are commonly used in agriculture, whereas the use of other organophosphates (such as parathion and methyl parathion) have been restricted significantly in the United States. Some organophosphates (malathion, naled) are used for the public health control of mosquitoes The U.S. FDA, USDA, U.S. EPA, and OSHA have developed criteria on allowable levels of these chemicals in foods, the environment, and the workplace, respectively.

The organophosphates share a common mechanism of toxicity that occurs through inhibition of the enzyme acetylcholinesterase in the nervous system. Symptoms of an acute overexposure may include nausea, vomiting, cholinergic effects, weakness, paralysis, and seizures. The specific metabolites reported in this section do not inhibit acetylcholinesterase enzymes but rather are an indicator of exposure to the parent compounds.

This *Report* provides measurements for the metabolites of six organophosphate pesticides. Information about external exposure (i.e., environmental levels) and health effects of specific organophosphate pesticides is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles.

Table 271. Organophosphate pesticides: specific metabolites

Organophosphate pesticide (CAS number)	Primary urinary metabolite (CAS number)
Malathion (121-75-5)	Malathion dicarboxylic acid (1190-28-9)
Parathion (56-38-2)	*para*-Nitrophenol (100-02-7)
Methyl parathion (298-00-0)	*para*-Nitrophenol (100-02-7)
Chlorpyrifos (2921-88-2)	3,5,6-Trichloro-2-pyridinol (6515-38-4)
Chlorpyrifos methyl (5598-13-0)	3,5,6-Trichloro-2-pyridinol (6515-38-4)
Diazinon (333-41-5)	2-Isopropyl-4-methyl-6-hydroxypyrimidine (2814-20-2)
Pirimiphos methyl (29232-93-7)	2-(Diethylamino)-6-methylpyrimidin-4-ol/one
Coumaphos (56-72-4)	3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol

Malathion Dicarboxylic Acid

CAS No. 1190-28-9

Metabolite of Malathion, CAS No. 121-75-5

General Information

Malathion dicarboxylic acid is a metabolite of malathion, which is an organophosphate insecticide that is used on a variety of agricultural crops. There are also non-agricultural uses of this insecticide on lawns, gardens, ornamental trees, shrubs, and plants. Malathion is registered for use in public health mosquito control and in government programs such as the USDA's Boll Weevil Eradication Program. Approximately 16.7 million pounds of malathion, most of which is applied to cotton, are used annually in the United States. Malathion is also used medically in lotion form (0.5%) to kill body lice.

In addition to being a metabolite of malathion in the body, malathion dicarboxylic acid can also occur in the environment from the breakdown of the parent compound. Thus, the detection of malathion dicarboxylic acid in a person's urine may also reflect exposure to the metabolite if it was present in a person's food or environment.

Malathion is slowly absorbed through the skin but is more rapidly and efficiently absorbed via ingestion. It is metabolized in the body to malaoxon, malathion monocarboxylic acid, malathion dicarboxylic acid, and dialkylphosphate metabolites (see section titled "Organophosphate Pesticides: Dialkyl Phosphate Metabolites"). Malathion is rapidly eliminated from the body within 12-24 hours (Bouchard et al., 2003).

Symptoms of an acute overdose of malathion may include nausea, vomiting, cholinergic effects, weakness, paralysis, and seizures. Compared with other organophosphate insecticides, malathion has low acute toxicity. Malathion does not appear to produce human reproductive or teratogenic effects at environmental levels of exposure in human populations (Thomas et al., 1990; Grether et al., 1987). IARC considers malathion not classifiable as a human carcinogen.

Interpreting Levels of Urinary Malathion Dicarboxylic Acid Reported in the Tables

Levels of urinary malathion dicarboxylic acid were measured in a subsample of NHANES participants aged 6-59 years. Note that no data are available for the NHANES 2001-2002 subsample. Participants were selected within the specified age range to be a

Table 272. Malathion dicarboxylic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1920
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	2.80 (<LOD-5.50)	453
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	807
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	937
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	983
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	498
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	580

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

representative sample of the U.S. population. For the NHANES 1999-2000 subsample, urinary levels of malathion dicarboxylic acid at the 95th percentile in children aged 6-11 years are several-fold lower than levels that were measured in Minnesota children (aged 3-13 years, adjusted for sociodemographic variables) in 1997 (Adgate, 2001). In this Minnesota study, children from an urban setting had urinary levels of malathion dicarboxylic acid that were similar to levels in children from a nonurban setting. Of 382 pregnant women living in an agricultural community, 30% had detectable levels of malathion dicarboxylic acid at a detection limit about ten-fold lower than the detection limit used in the NHANES 1999-2000 analyses (Eskenazi et al., 2004). A study of agricultural workers reported urinary levels of malathion dicarboxylic acid ranging from 4-10 µg/gram creatinine, and no effect on cholinesterase activity was observed in these workers (Krieger and Dinoff, 2000). Such worker values are only slightly higher than those detected in the NHANES 1999-2000 subsample.

Finding a measurable amount of malathion dicarboxylic acid in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to malathion and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of malathion than those levels found in the general population.

Table 273. Malathion dicarboxylic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1920
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	3.74 (2.11-5.50)	453
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	807
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	937
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	983
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	498
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	580

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

para-Nitrophenol

CAS No. 100-02-7

Metabolite of Methyl Parathion, CAS No.298-00-0 and Ethyl Parathion, CAS No. 56-38-2

General Information

Para-nitrophenol is a metabolite of the pesticides methyl parathion, ethyl parathion, O-ethyl 4-nitrophenyl phenylphosphonothioate, and of nitrobenzene, which is not a pesticide. Methyl parathion is a restricted-use pesticide with limited applications in agriculture, and many agricultural uses of methyl parathion have been cancelled. Past peak domestic use was once as high as 4 million pounds per year. Methyl parathion is not registered for residential use in the United States. Ethyl parathion had been a restricted-use pesticide with limited applications on certain agricultural crops, but in 2002 voluntary cancellation of all registrations occurred.

In addition to being a metabolite of methyl and ethyl parathion in the body, *para*-nitrophenol can also occur in the environment from the breakdown of the parent compounds. Thus, the detection of *para*-nitrophenol in a person's urine may also reflect exposure to the metabolite if it was present in a person's food or environment

In animal studies, methyl parathion is rapidly absorbed after ingestion, more slowly absorbed through the skin, and is eliminated rapidly after exposure (Kramer et al., 2002). In addition to being metabolized to *para*-nitrophenol, parathion and methyl parathion are metabolized to dialkyl phosphates (see section titled "Organophosphate Pesticides: Dialkyl Phosphate Metabolites").

Table 274. *para*-Nitrophenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	2.40 (1.40-4.50)	5.00 (2.90-11.0)	1989
	01-02	*	< LOD	1.32 (1.20-1.48)	2.70 (2.40-3.02)	3.70 (3.38-3.93)	2477
Age group							
6-11 years	99-00	*	< LOD	.910 (<LOD-2.40)	2.63 (1.70-3.80)	4.20 (2.70-6.40)	479
	01-02	*	.790 (<LOD-.910)	1.48 (1.34-1.61)	2.83 (2.22-3.58)	3.90 (3.01-4.74)	565
12-19 years	99-00	*	< LOD	< LOD	3.40 (1.60-5.70)	5.70 (2.60-19.0)	680
	01-02	*	.720 (<LOD-.910)	1.44 (1.32-1.61)	2.61 (2.15-3.11)	3.34 (3.11-4.01)	813
20-59 years	99-00	*	< LOD	< LOD	2.30 (1.20-5.30)	4.50 (2.20-9.50)	830
	01-02	*	< LOD	1.27 (1.08-1.45)	2.69 (2.32-3.10)	3.72 (3.37-4.24)	1099
Gender							
Males	99-00	*	< LOD	< LOD	2.40 (1.40-4.20)	4.40 (2.50-12.0)	971
	01-02	*	.760 (.300-.910)	1.49 (1.30-1.66)	2.99 (2.59-3.23)	4.00 (3.37-4.91)	1164
Females	99-00	*	< LOD	< LOD	2.50 (1.30-5.70)	5.20 (2.90-9.50)	1018
	01-02	*	< LOD	1.18 (.990-1.37)	2.26 (1.92-2.69)	3.46 (3.18-3.71)	1313
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	1.60 (<LOD-3.40)	5.80 (2.60-23.0)	21.0 (3.50-36.0)	695
	01-02	*	.690 (<LOD-.840)	1.32 (1.08-1.54)	2.62 (1.91-3.44)	3.85 (2.70-6.05)	660
Non-Hispanic blacks	99-00	*	< LOD	1.17 (<LOD-2.50)	2.90 (1.70-6.00)	4.80 (2.50-9.20)	518
	01-02	*	.860 (<LOD-1.12)	1.80 (1.37-2.16)	3.21 (2.55-4.38)	5.60 (4.02-6.79)	679
Non-Hispanic whites	99-00	*	< LOD	< LOD	2.10 (<LOD-4.70)	4.20 (2.10-11.0)	603
	01-02	*	< LOD	1.27 (1.11-1.42)	2.71 (2.30-3.10)	3.70 (3.28-4.01)	941

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Symptoms of an acute overdose of methyl or ethyl parathion may include nausea, vomiting, cholinergic effects, weakness, paralysis, and seizures. Delayed peripheral neuropathy has been reported after chronic occupational exposure and acute overdose. The metabolite, *para*-nitrophenol, does not inhibit acetylcholinesterase enzymes. IARC does not consider ethyl parathion and methyl parathion classifiable as human carcinogens.

Interpreting Levels of Urinary *para*-Nitrophenol Reported in the Tables

Urinary levels of *para*-nitrophenol were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. In general, urinary *para*-nitrophenol levels in the NHANES 2001-2002 subsample appeared roughly similar to values in a nonrandom subsample of NHANES III (1988-1994) participants (Hill et al., 1995).

Considerably higher levels of *para*-nitrophenol have been measured in urine samples obtained from children and adults living in residences where methyl parathion was illegally applied indoors (Barr et al., 2002). The geometric mean concentration of *para*-nitrophenol in these individuals was approximately nine times higher than the 95th percentile values for the 2001-2002 NHANES subsample. In a study of workers who handle parathion, end-of-shift urinary *para*-nitrophenol levels ranged from 190-410 µg/gram of creatinine (Leng and Lewalter, 1999), a range of values that is much higher than the 95th percentile values in this *Report*. ACGIH (2001) recommends a BEI of 0.5 mg (500 µg)/g creatinine for workers at the end of shift.

Finding a measurable amount of *para*-nitrophenol in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to methyl or ethyl parathion and health effects.

Table 275. *para*-Nitrophenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	**75th**	**90th**	**95th**	
Total, age 6 and older	99-00	*	< LOD	< LOD	2.08 (1.33-3.91)	4.20 (2.15-10.2)	1989
	01-02	*	< LOD	.968 (.826-1.10)	1.91 (1.72-2.03)	2.89 (2.44-3.23)	2476
Age group							
6-11 years	99-00	*	< LOD	.938 (.609-1.95)	2.80 (1.94-4.00)	4.20 (3.33-6.70)	479
	01-02	*	.715 (.543-.870)	1.59 (1.30-1.82)	2.74 (2.31-3.11)	3.67 (3.11-4.61)	565
12-19 years	99-00	*	< LOD	< LOD	1.79 (1.08-3.04)	4.00 (1.57-7.29)	680
	01-02	*	.372 (.250-.503)	.839 (.790-.951)	1.59 (1.37-1.78)	2.09 (1.78-2.43)	812
20-59 years	99-00	*	< LOD	< LOD	2.00 (1.17-4.08)	4.29 (2.13-12.3)	830
	01-02	*	< LOD	.875 (.693-1.07)	1.79 (1.56-2.05)	2.89 (2.35-3.33)	1099
Gender							
Males	99-00	*	< LOD	< LOD	1.90 (1.01-3.39)	3.39 (1.77-7.55)	971
	01-02	*	.430 (.307-.535)	.983 (.854-1.08)	1.87 (1.57-2.09)	2.97 (2.14-3.57)	1164
Females	99-00	*	< LOD	< LOD	2.22 (1.48-4.88)	6.90 (2.76-14.1)	1018
	01-02	*	< LOD	.933 (.735-1.23)	1.96 (1.78-2.15)	2.81 (2.44-3.06)	1312
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	1.53 (.759-3.17)	4.80 (2.21-21.9)	17.4 (3.94-47.7)	695
	01-02	*	.402 (.219-.543)	.928 (.717-1.20)	1.87 (1.41-2.60)	3.04 (2.38-3.84)	660
Non-Hispanic blacks	99-00	*	< LOD	.667 (.314-1.79)	2.07 (1.33-3.71)	3.71 (1.98-7.20)	518
	01-02	*	.436 (.167-.636)	1.01 (.801-1.31)	1.71 (1.60-2.21)	2.97 (2.16-4.30)	678
Non-Hispanic whites	99-00	*	< LOD	< LOD	1.94 (1.07-4.29)	3.75 (1.97-10.2)	603
	01-02	*	< LOD	.967 (.786-1.13)	1.96 (1.67-2.26)	2.93 (2.35-3.45)	941

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of methyl and ethyl parathion than those levels found in the general population.

3,5,6-Trichloro-2-pyridinol

CAS No. 6515-38-4

Metabolite of Chlorpyrifos, CAS No. 2921-88-2 and Chlorpyrifos-methyl, CAS No. 5598-13-0

General Information

The chemical 3,5,6-trichloro-2-pyridinol (TCPy) is a specific metabolite of chlorpyrifos and chlorpyrifos-methyl. Chlorpyrifos is an organophosphate insecticide that is used to control insect pests on a variety of agricultural crops in the United States. Approximately 10 million pounds have been applied annually in agriculture. Chlorpyrifos is no longer registered for most indoor residential uses in the United States. Not registered for residential use, chlorpyrifos-methyl is an organo phosphate pesticide used in agriculture. Approximately 80,000 pounds are used per year.

In addition to being a metabolite of chlorpyrifos and chlorpyrifos-methyl in the body, TCPy can also occur in the environment from the breakdown of the parent compounds. Thus, the detection of TCPy in a person's urine may also reflect exposure to the metabolite if it was present in a person's food or environment. In 142 urban homes and preschools of North Carolina, chlorpyrifos and TCPy were detected in all indoor air and dust samples (Morgan et al., 2004)

Chlorpyrifos is not well absorbed through the skin but is rapidly absorbed once ingested. Nolan et al. (1984) found that TCPy is eliminated from the body in the urine with a half-life of approximately 27 hours. Chlorpyrifos, chlorpyrifos-methyl, and other organophosphate pesticides share a common mechanism of toxicity, inhibiting the activity of acetylcholinesterase enzymes in the nervous system. The metabolite TCPy does not inhibit acetylcholinesterase enzymes.

Table 276. 3,5,6-Trichloro-2-pyridinol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**1.77** (1.46-2.14)	**1.70** (1.40-2.10)	**3.50** (2.50-5.10)	**7.30** (4.80-10.0)	**9.90** (7.60-14.0)	1994
	01-02	**1.76** (1.52-2.03)	**2.20** (1.86-2.61)	**4.95** (4.55-5.29)	**8.80** (7.74-9.77)	**12.4** (10.4-15.3)	2509
Age group							
6-11 years	99-00	**2.88** (1.99-4.16)	**2.70** (1.60-4.80)	**6.90** (3.40-10.0)	**11.0** (7.70-17.0)	**16.0** (10.0-26.0)	481
	01-02	**2.67** (2.13-3.35)	**3.08** (2.46-4.22)	**6.36** (4.97-7.97)	**10.7** (7.98-15.3)	**14.9** (11.5-24.0)	573
12-19 years	99-00	**2.37** (1.89-2.97)	**2.10** (1.60-2.90)	**4.50** (2.90-6.70)	**8.00** (5.50-14.0)	**12.5** (8.00-24.0)	681
	01-02	**2.71** (2.19-3.35)	**3.57** (2.60-4.30)	**6.57** (5.61-7.59)	**11.2** (8.66-15.1)	**18.0** (13.7-23.7)	823
20-59 years	99-00	**1.53** (1.29-1.82)	**1.50** (1.20-1.70)	**2.80** (2.20-4.10)	**5.90** (3.90-8.90)	**8.60** (6.70-11.0)	832
	01-02	**1.51** (1.32-1.72)	**1.91** (1.44-2.26)	**4.42** (3.90-4.80)	**7.78** (7.00-8.91)	**10.9** (9.52-12.4)	1113
Gender							
Males	99-00	**1.92** (1.60-2.32)	**1.90** (1.50-2.40)	**3.50** (2.70-5.60)	**7.30** (5.04-10.0)	**9.90** (7.40-14.0)	972
	01-02	**2.13** (1.81-2.51)	**2.66** (2.19-3.16)	**5.37** (4.83-6.25)	**9.63** (8.20-11.3)	**14.9** (10.9-18.9)	1183
Females	99-00	**1.63** (1.31-2.02)	**1.50** (1.20-1.80)	**3.30** (2.30-5.30)	**7.20** (4.30-12.0)	**10.0** (7.10-15.0)	1022
	01-02	**1.45** (1.24-1.70)	**1.72** (1.39-2.21)	**4.38** (3.72-4.95)	**7.71** (6.30-9.20)	**10.4** (8.47-13.2)	1326
Race/ethnicity							
Mexican Americans	99-00	**1.61** (1.31-2.00)	**1.67** (1.30-2.20)	**3.20** (2.60-3.80)	**5.00** (3.80-7.30)	**7.40** (5.10-17.0)	697
	01-02	**2.02** (1.79-2.28)	**2.63** (2.24-3.01)	**4.55** (4.05-5.39)	**9.02** (7.04-10.8)	**12.2** (10.8-15.7)	660
Non-Hispanic blacks	99-00	**2.17** (1.59-2.97)	**1.90** (1.40-2.70)	**4.20** (2.50-8.30)	**9.40** (6.30-12.9)	**13.0** (9.40-26.0)	521
	01-02	**2.19** (1.68-2.84)	**2.89** (2.28-3.47)	**5.47** (4.77-6.96)	**9.27** (7.47-11.6)	**12.3** (10.1-16.8)	701
Non-Hispanic whites	99-00	**1.76** (1.51-2.05)	**1.60** (1.50-2.00)	**3.40** (2.50-4.80)	**7.10** (4.30-10.5)	**10.0** (7.20-14.0)	602
	01-02	**1.71** (1.43-2.03)	**2.15** (1.62-2.64)	**4.94** (4.41-5.31)	**8.68** (7.47-9.97)	**12.3** (9.77-15.9)	947

Interpreting Levels of Urinary TCPy Reported in the Tables

Urinary TCPy levels were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the current NHANES 2001-2002 subsample, TCPy levels appeared roughly similar to values reported for a nonrandom subsample of NHANES III (1988-1994) participants (Hill et al., 1995) and to levels reported in a studies of healthy adults in Germany (Koch et al., 2001) and Italy (Aprea et al., 1999). In a probability-based sample of 102 Minnesota children aged 3-13 years, the weighted population mean of TCPy measurements was approximately three times higher (Adgate, 2001) than the corresponding values reported for the group aged 6-11 years in this *Report*. In another study of adults in Maryland, MacIntosh et al. (1999) found that mean urinary TCPy levels were about three times higher than the levels for adults documented in this *Report*. Of 482 pregnant women living in an agricultural community,

76% had detectable levels of TCPy, and levels were similar to those reported for NHANES 1999-2000 (Eskenazi et al., 2004). Higher levels of TCPy have been measured in urine samples obtained from pesticide applicators. In one study of male pesticide applicators, the geometric mean levels of TCPy in urine samples ranged from 169-262 µg/g creatinine (Hines et al., 2001). These levels are more than 100-fold higher than the geometric mean values for males documented in this *Report*.

Comparing Adjusted Geometric Means

Geometric mean levels of urinary TCPy for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2002-2002, the group aged 6-11 years had higher adjusted geometric mean levels of urinary TCPy than the other two age groups, and the group aged 12-19 years had slightly higher urinary levels of TCPy than the group aged 20-59 years. It is unknown whether these differences associated

Table 277. 3,5,6-Trichloro-2-pyridinol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval) 50th	75th	90th	95th	Sample size
Total, age 6 and older	99-00	**1.58** (1.35-1.85)	**1.47** (1.24-1.74)	**2.85** (2.11-3.59)	**5.43** (4.22-6.68)	**8.42** (6.25-11.6)	1994
	01-02	**1.73** (1.49-2.01)	**1.88** (1.64-2.24)	**3.76** (2.91-4.62)	**6.15** (4.99-8.31)	**9.22** (6.94-12.3)	2508
Age group							
6-11 years	99-00	**3.11** (2.31-4.19)	**3.20** (2.05-4.80)	**6.37** (4.14-8.19)	**10.1** (7.26-14.0)	**14.0** (10.1-21.0)	481
	01-02	**3.48** (2.80-4.32)	**3.76** (3.17-4.36)	**6.21** (4.88-8.57)	**12.1** (7.24-24.4)	**16.9** (12.1-38.0)	573
12-19 years	99-00	**1.60** (1.34-1.91)	**1.45** (1.21-1.81)	**2.58** (1.97-3.92)	**4.82** (3.44-6.16)	**6.16** (4.43-10.6)	681
	01-02	**2.09** (1.72-2.55)	**2.24** (1.92-2.66)	**3.97** (3.30-4.72)	**6.33** (5.62-7.89)	**10.3** (7.65-15.2)	822
20-59 years	99-00	**1.41** (1.23-1.62)	**1.33** (1.11-1.56)	**2.37** (1.87-3.01)	**4.25** (3.53-5.56)	**6.42** (5.11-9.02)	832
	01-02	**1.49** (1.30-1.71)	**1.64** (1.39-1.88)	**3.11** (2.60-3.91)	**5.43** (4.33-7.23)	**7.44** (5.80-11.0)	1113
Gender							
Males	99-00	**1.48** (1.27-1.72)	**1.44** (1.19-1.68)	**2.52** (2.05-3.38)	**4.95** (3.84-6.54)	**7.63** (5.65-11.0)	972
	01-02	**1.71** (1.47-2.00)	**1.87** (1.57-2.22)	**3.46** (2.82-4.28)	**5.93** (4.90-9.24)	**10.3** (6.94-14.3)	1183
Females	99-00	**1.69** (1.42-2.01)	**1.51** (1.25-1.85)	**2.96** (2.24-4.01)	**5.63** (4.26-7.19)	**8.44** (5.79-13.3)	1022
	01-02	**1.75** (1.49-2.07)	**1.93** (1.59-2.33)	**3.91** (3.06-4.85)	**6.47** (5.00-8.11)	**8.98** (6.83-11.8)	1325
Race/ethnicity							
Mexican Americans	99-00	**1.46** (1.20-1.77)	**1.44** (1.05-1.93)	**2.38** (2.09-2.96)	**3.82** (3.24-5.08)	**5.79** (3.88-9.57)	697
	01-02	**1.86** (1.63-2.12)	**2.06** (1.83-2.35)	**3.81** (3.17-4.56)	**6.52** (5.64-7.58)	**9.00** (7.66-11.8)	660
Non-Hispanic blacks	99-00	**1.47** (1.09-1.99)	**1.33** (.936-1.94)	**2.86** (1.58-5.05)	**5.88** (4.05-8.93)	**8.93** (5.91-13.7)	521
	01-02	**1.56** (1.19-2.03)	**1.92** (1.57-2.40)	**3.52** (2.85-4.28)	**5.58** (4.80-6.08)	**7.06** (5.88-8.82)	700
Non-Hispanic whites	99-00	**1.66** (1.45-1.90)	**1.54** (1.31-1.83)	**2.93** (2.09-3.97)	**5.56** (4.21-6.75)	**8.44** (6.25-12.3)	602
	01-02	**1.78** (1.49-2.14)	**1.93** (1.56-2.35)	**3.82** (2.70-4.97)	**6.55** (4.88-10.5)	**9.98** (7.00-13.7)	947

with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of TCPy in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to chlorpyrifos or chlorpyrifos-methyl and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of chlorpyrifos or chlorpyrifos-methyl than those levels found in the general population.

Figure 36. 3,5,6-Trichloro-2-pyridinol (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

[a] Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

2-Isopropyl-4-methyl-6-hydroxypyrimidine

CAS No. 2814-20-2

Metabolite of Diazinon, CAS No. 333-41-5

General Information

The specific metabolite of diazinon is 2-isopropyl-4-methyl-6-hydroxypyrimidine. Diazinon is an organophosphate insecticide that is used to control pests on certain agricultural commodities (including almonds and fruits that contain stones or pits). It is also used as a veterinary insecticide on cattle. Approximately 13 million pounds of diazinon are used annually on agricultural sites in the United States, but diazinon is no longer registered for indoor residential use.

In addition to being a metabolite of diazinon in the body, 2-isopropyl-4-methyl-6-hydroxypyrimidine can also occur in the environment from the breakdown of the parent compound. Thus, the detection of 2-isopropyl-4-methyl-6 hydroxypyrimidine in a person's urine may also reflect exposure to the metabolite if it was present in a person's food or environment.

Diazinon is not well-absorbed through the skin but is rapidly absorbed in the body once ingested. Experimental diazinon exposure in people has shown a rapid elimination from the body, as inferred from dialkyl phosphate excretion (Garfitt et al., 2002). Diazinon and other organophosphates share a common mechanism of toxicity, inhibiting the activity of acetylcholinesterase enzymes in the nervous system. The metabolite 2-isopropyl-4-methyl-6-hydroxypyrimidine does not inhibit acetylcholinesterase enzymes.

Table 278. 2-Isopropyl-4-methyl-6-hydroxypyrimidine

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1842
	01-02	*	< LOD	< LOD	< LOD	< LOD	2535
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	454
	01-02	*	< LOD	< LOD	< LOD	1.45 (<LOD-3.11)	580
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	632
	01-02	*	< LOD	< LOD	< LOD	< LOD	829
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	756
	01-02	*	< LOD	< LOD	< LOD	< LOD	1126
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	894
	01-02	*	< LOD	< LOD	< LOD	< LOD	1191
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	948
	01-02	*	< LOD	< LOD	< LOD	< LOD	1344
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	644
	01-02	*	< LOD	< LOD	< LOD	< LOD	678
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	484
	01-02	*	< LOD	< LOD	< LOD	1.35 (<LOD-1.98)	700
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	554
	01-02	*	< LOD	< LOD	< LOD	< LOD	956

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Interpreting Levels of Urinary 2-Isopropyl-4-methyl-6-hydroxypyrimidine Reported in the Tables

Urinary levels of 2-isopropyl-4-methyl-6-hydroxypyrimidine were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, most of the measurements of 2-isopropyl-4-methyl-6-hydroxypyrimidine in urine were below the limit of detection. In a previous nonrandom sample of adults and children in the United States, 2-isopropyl-4-methyl-6-

hydroxypyrimidine levels in urine ranged from non-detectable to 10 µg/L (Baker et al., 2000).

Finding a measurable amount of 2-isopropyl-4-methyl-6-hydroxypyrimidine in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to diazinon and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of diazinon than those levels found in the general population.

Table 279. 2-Isopropyl-4-methyl-6-hydroxypyrimidine (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1842
	01-02	*	< LOD	< LOD	< LOD	< LOD	2534
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	454
	01-02	*	< LOD	< LOD	< LOD	2.58 (1.75-4.45)	580
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	632
	01-02	*	< LOD	< LOD	< LOD	< LOD	828
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	756
	01-02	*	< LOD	< LOD	< LOD	< LOD	1126
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	894
	01-02	*	< LOD	< LOD	< LOD	< LOD	1191
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	948
	01-02	*	< LOD	< LOD	< LOD	< LOD	1343
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	644
	01-02	*	< LOD	< LOD	< LOD	< LOD	678
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	484
	01-02	*	< LOD	< LOD	< LOD	1.76 (1.07-3.48)	699
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	554
	01-02	*	< LOD	< LOD	< LOD	< LOD	956

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

2-(Diethylamino)-6-methylpyrimidin-4-ol/one

Metabolite of Pirimiphos-methyl, CAS No. 29232-93-7

General Information

The chemical 2-(diethylamino)-6-methylpyrimidin-4-ol/one is a specific metabolite of the organophosphate insecticide pirimiphos-methyl. Pirimiphos-methyl has limited applications in agriculture but is used as a veterinary insecticide. It is not registered for residential use in the United States.

In addition to being a metabolite of pirimiphos-methyl in the body, 2-(diethylamino)-6-methylpyrimidin-4-ol/one can also occur in the environment. Thus, the detection of 2-(diethylamino)-6-methylpyrimidin-4-ol/one may also reflect exposure to the metabolite if it was present in a person's food or environment. Pirimiphos-methyl and other organophosphate pesticides share a common mechanism of toxicity, inhibiting the activity of acetylcholinesterase enzymes in the nervous system. Pirimiphos-methyl has generally been shown to be of low acute toxicity. The metabolite 2-(diethylamino)-6-methylpyrimidin-4-ol/one does not inhibit acetylcholinesterase enzymes.

Interpreting Levels of Urinary 2-(Diethylamino)-6-methylpyrimidin-4-ol/one Reported in the Tables

Urinary levels of 2-(diethylamino)-6-methylpyrimidin-4-ol/one were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, most urinary levels of 2-(diethylamino)-6-methylpyrimidin-4-ol/one were below the limit of detection. In a study of urine specimens obtained from a nonrandom sample of adults and children in the United States, Olsson et al. (2003) found that the geometric mean concentration of 2-(diethylamino)-6-methylpyrimidin-4-ol/one was 4.1 ng/mL urine, with values ranging from non-detectable to 37 ng/mL.

Finding a measurable amount of 2-(diethylamino)-6-methylpyrimidin-4-ol/one in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to pirimiphos-methyl and health effects. These data also provide physicians with a

Table 280. 2-(Diethylamino)-6-methylpyrimidin-4-ol/one

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	.470 (.210-.730)	2481
Age group							
6-11 years	01-02	*	< LOD	< LOD	.230 (<LOD-.820)	.820 (.210-1.64)	567
12-19 years	01-02	*	< LOD	< LOD	< LOD	.610 (<LOD-1.94)	810
20-59 years	01-02	*	< LOD	< LOD	< LOD	.430 (<LOD-.670)	1104
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	.840 (.300-1.55)	1165
Females	01-02	*	< LOD	< LOD	< LOD	.200 (<LOD-.460)	1316
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	.400 (<LOD-1.15)	669
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	687
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	.490 (.200-.840)	929

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

reference range so that they can determine whether or not other people have been exposed to higher levels of pirimiphos-methyl than levels found in the general population.

Table 281. 2-(Diethylamino)-6-methylpyrimidin-4-ol/one (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	.778 (.700-.933)	2481
Age group							
6-11 years	01-02	*	< LOD	< LOD	.680 (.560-.953)	1.17 (.737-1.27)	567
12-19 years	01-02	*	< LOD	< LOD	< LOD	.667 (.467-1.31)	810
20-59 years	01-02	*	< LOD	< LOD	< LOD	.764 (.667-.875)	1104
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	.732 (.572-.986)	1165
Females	01-02	*	< LOD	< LOD	< LOD	.778 (.667-1.00)	1316
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	.778 (.556-1.21)	669
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	687
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	.778 (.700-.933)	929

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol

Metabolite of Coumaphos
CAS No.56-72-4

General Information

The chemical 3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol is a specific metabolite of coumaphos. Coumaphos is an organophosphate insecticide that is used to control insects on beef cattle, dairy cows, swine, and certain other farm animals. It is not registered for residential use in the United States.

Coumaphos and other organophosphate pesticides share a common mechanism of toxicity, inhibiting the activity of acetylcholinesterase enzymes in the nervous system. Coumaphos is considered to be an organophosphate of moderate-to-high acute toxicity. Its metabolite, 3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol, does not inhibit acetylcholinesterase enzymes.

Interpreting Levels of 3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol Reported in the Tables

Urinary levels of 3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range

to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, urinary levels of 3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol were below the limit of detection. In a previous nonrandom study of urine specimens obtained from adults and children in the United States, Olsson et al. (2003) found that levels of 3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol were also below the limit of detection.

Finding a measurable amount of 3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to coumaphos and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of coumaphos than levels found in the general population.

Table 282. 3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2481
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	567
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	815
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1099
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1169
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1312
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	659
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	.200 (<LOD-.270)	701
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	920

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 283. 3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2480
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	567
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	814
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1099
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1169
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1311
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	659
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	.373 (.255-.560)	700
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	920

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Results by Chemical Group

Herbicides

Third National Report on Human Exposure to Environmental Chemicals

Herbicides

General Information

Herbicides are chemicals used to control undesirable weeds and plants in agricultural, residential, and aquatic environments. More herbicides are used annually than insecticides, with about 553 million pounds used in the U.S. during 2001 (U.S. EPA, 2004). The herbicides measured in this *Report* can be classified into these categories: chlorophenoxy acids (2, 4, 5-trichlorophenoxyacetic acid, 2, 4-dichlorophenoxyacetic acid); triazines (atrazine); and chloroacetanilides (alachlor, metolachlor, and acetochlor).

The general population may be exposed to herbicides from their use in residential, forestry, or agricultural applications, or from their diet or drinking water. Workers who manufacture, formulate, or apply these chemicals also may be exposed to herbicides. The U.S. FDA, U.S. EPA, and OSHA have developed criteria for the allowable levels for some of these chemicals in foods, drinking water, and the workplace, respectively.

Table 285 shows the various urinary metabolites and their parent herbicides. For example, atrazine is metabolized to atrazine mercapture. The presence of these chemicals in a person generally reflects recent exposure to herbicides. In addition to reflecting exposure to the parent herbicide, the level of certain metabolites (such as 2, 4-dichlorphenol) in a person's blood or urine may also reflect exposure to the metabolite itself if it was present in the person's environment.

Table 284. Herbicides and their metabolites

Herbicide	CAS number	Urine metabolite
Salts and esters of 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)	93-76-5	2,4,5-Trichlorophenoxyacetic acid
Salts and esters of 2,4-Dichlorophenoxyacetic acid (2,4-D)	94-75-7 120-83-2	2,4-Dichlorophenoxyacetic acid 2,4-Dichlorophenol (minor)
Alachlor	15972-60-8	Alachlor mercpaturate
Atrazine	1912-24-9	Atrazine mercpaturate
Acetochlor	34256-82-1	Acetochlor mercpaturate
Metolachlor	51218-45-2	Metolachlor mercpaturate

2,4,5-Trichlorophenoxyacetic Acid

CAS No. 93-76-5

General Information

The herbicide 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) is a chlorophenoxy acid herbicide that was once registered for use in the United States. Concern about its contamination with 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) led to the discontinuation of 2,4,5-T in 1985.

Although 2,4,5-T is rapidly absorbed via oral and inhalation routes, it is not well absorbed through the skin. Once absorbed into the body, 2,4,5-T distributes widely and then is rapidly eliminated unchanged in the urine, with an elimination half-life of approximately 19 hours (Kohli et al., 1974*a*).

Chlorophenoxyacetic acid herbicides have been associated with weakness, headache, dizziness, nausea, and abdominal pain as a result of overexposure in occupational settings. Some epidemiological studies have reported associations between herbicides containing 2,4,5-T and certain forms of cancer, as well as with other health effects, although it is unclear whether or not these associations indicate a causal relationship (Institute of Medicine, 2003). It is also unclear whether these associations are related to 2,4,5-T or contaminants in the herbicide formulation itself (specifically 2,3,7,8-tetrachlordibenzodioxin). IARC considers the chlorophenoxyacetic acids group of chemicals as possibly carcinogenic to humans.

Interpreting Levels of Urinary 2,4,5-T Reported in the Table

Urinary levels of 2,4,5-T were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population.

Table 285. 2,4,5-Trichlorophenoxyacetic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1814
	01-02	*	< LOD	< LOD	< LOD	< LOD	2538
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	430
	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	618
	01-02	*	< LOD	< LOD	< LOD	< LOD	831
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	766
	01-02	*	< LOD	< LOD	< LOD	< LOD	1127
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	891
	01-02	*	< LOD	< LOD	< LOD	< LOD	1192
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	923
	01-02	*	< LOD	< LOD	< LOD	< LOD	1346
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	*	< LOD	< LOD	< LOD	< LOD	679
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	483
	01-02	*	< LOD	< LOD	< LOD	< LOD	701
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	531
	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

In the NHANES 2001-2002 subsample, urinary levels of 2,4,5-T were generally below the limit of detection. This finding is similar to the findings in the NHANES 1999-2000 subsample and is consistent with results of NHANES II (1976-1980), which showed that urinary levels of 2,4,5-T were below the limit of detection (Kutz et al., 1992). In contrast, detectable levels of 2,4,5-T were reported among asymptomatic herbicide applicators when measured after a day of exposure, with urinary levels ranging 1-11 µg/mL (Kolmodin-Hedman and Erne, 1980).

Finding a measurable amount of 2,4,5-T in urine does not mean that the level of the 2,4,5-T will result in an adverse health effect. These data will help scientists plan and conduct research about the relation of exposure to 2,4,5-T and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of 2,4,5-T than levels found in the general population.

Table 286. 2,4,5-Trichlorophenoxyacetic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1814
	01-02	*	< LOD	< LOD	< LOD	< LOD	2537
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	430
	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	618
	01-02	*	< LOD	< LOD	< LOD	< LOD	830
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	766
	01-02	*	< LOD	< LOD	< LOD	< LOD	1127
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	891
	01-02	*	< LOD	< LOD	< LOD	< LOD	1192
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	923
	01-02	*	< LOD	< LOD	< LOD	< LOD	1345
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	*	< LOD	< LOD	< LOD	< LOD	679
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	483
	01-02	*	< LOD	< LOD	< LOD	< LOD	700
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	531
	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

2,4-Dichlorophenoxyacetic Acid

CAS No. 94-75-7

General Information

Widely used throughout the United States, the chlorophenoxy herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) controls broadleaf weeds in residential, agricultural, and aquatic environments. Approximately 28-33 million pounds of 2,4-D were used in the U.S. in 2001 (U.S. EPA, 2004). The general population may be exposed to 2,4-D by using it on lawns, crops, or in forests as well as by consuming food or drinking water that contains 2, 4-D.

This herbicide is rapidly absorbed via oral and inhalation routes but is not well absorbed through the skin. Dermal exposure may be of some significance for herbicide workers who are exposed to high concentrations of 2,4-D or are exposed for prolonged periods. Once absorbed, 2,4-D distributes widely in the body and is eliminated predominantly unchanged in the urine, with an elimination half-life ranging from 10 hours to 33 hours (Kohli et al., 1974b; Sauerhoff et al., 1977). Direct skin contact may have irritant effects. Chlorophenoxyacetic acid herbicides have been associated with weakness, headache, dizziness, nausea, and abdominal pain as a result of overexposure in occupational settings. IARC considers the chlorophenoxyacetic acids group of chemicals as possibly carcinogenic to humans.

Interpreting Levels of Urinary 2,4-D Reported in the Tables

Urinary levels of 2,4-D were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. The 95th percentile of the 2001-2002 subsample is similar to the

Table 287. 2,4-Dichlorophenoxyacetic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1977
	01-02	*	< LOD	.230 (<LOD-.320)	.690 (.550-.890)	1.27 (1.02-1.37)	2413
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	1.30 (<LOD-1.50)	477
	01-02	*	< LOD	.300 (<LOD-.400)	.740 (.550-1.13)	1.55 (1.00-2.21)	546
12-19 years	99-00	*	< LOD	< LOD	< LOD	1.00 (<LOD-1.60)	677
	01-02	*	< LOD	.250 (<LOD-.380)	.660 (.440-1.16)	1.24 (.690-1.66)	797
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	823
	01-02	*	< LOD	.210 (<LOD-.310)	.690 (.530-.910)	1.27 (.930-1.49)	1070
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	1.10 (<LOD-1.60)	962
	01-02	*	< LOD	.320 (.230-.480)	.930 (.680-1.22)	1.51 (1.27-2.08)	1135
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1015
	01-02	*	< LOD	< LOD	.480 (.370-.640)	.890 (.670-1.22)	1278
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	695
	01-02	*	< LOD	.250 (<LOD-.340)	.730 (.600-.910)	1.18 (.960-1.36)	659
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	1.20 (<LOD-1.70)	520
	01-02	*	< LOD	< LOD	.610 (.420-.890)	1.06 (.810-1.48)	668
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	589
	01-02	*	< LOD	.240 (<LOD-.410)	.760 (.560-1.10)	1.32 (1.05-2.03)	892

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

95th percentile value from a nonrandom subsample from NHANES III (1988-1994) (Hill et al., 1995).

Levels in children in the 2001-2002 NHANES subsample were similar to values previously reported among children from a community in Arkansas (Hill et al., 1989). In contrast, higher levels of 2,4-D have been measured in herbicide applicators. Mean urinary levels of 2,4-D among workers involved in mixing, loading, and applying this herbicide ranged 5-837 µg /L (Frank et al., 1985). Another study of farmers who reported applying 2,4-D found a geometric mean urinary concentration of 5.36 µg /L (Arbuckle et al., 2002).

Finding a measurable amount of 2,4-D in urine does not mean that the level of the 2,4-D will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to 2,4-D and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of 2,4-D than levels found in the general population.

Table 288. 2,4-Dichlorophenoxyacetic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1977
	01-02	*	< LOD	.378 (.326-.412)	.667 (.583-.737)	1.08 (.926-1.26)	2412
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	1.32 (.785-2.24)	477
	01-02	*	< LOD	.485 (.378-.679)	1.13 (.825-1.35)	1.40 (1.27-1.73)	546
12-19 years	99-00	*	< LOD	< LOD	< LOD	.570 (.333-1.05)	677
	01-02	*	< LOD	.274 (.209-.376)	.476 (.326-.646)	.662 (.517-.918)	796
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	823
	01-02	*	< LOD	.378 (.326-.412)	.667 (.575-.770)	1.04 (.789-1.27)	1070
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	.667 (.447-1.16)	962
	01-02	*	< LOD	.336 (.268-.412)	.640 (.564-.789)	1.14 (.893-1.39)	1135
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1015
	01-02	*	< LOD	< LOD	.700 (.609-.778)	1.06 (.809-1.26)	1277
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	695
	01-02	*	< LOD	.344 (.311-.386)	.720 (.562-.853)	1.10 (.778-1.56)	659
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	.570 (.393-1.19)	520
	01-02	*	< LOD	< LOD	.438 (.325-.560)	.778 (.520-.906)	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	589
	01-02	*	< LOD	.405 (.368-.452)	.737 (.609-.875)	1.14 (.933-1.39)	892

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

2,4-Dichlorophenol

CAS No. 120-83-2

General Information

The chemical 2,4-dichlorophenol is a minor metabolite of the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) that can also result from the metabolism of several other environmental chemicals or can be formed as a byproduct during the manufacture of many chemicals.

A lipid-soluble chemical, 2,4-dichlorophenol is well absorbed via dermal, inhalation, and ingestion routes. Studies in other countries have frequently detected 2,4-dichlorophenol in urine samples obtained from the general population (Angerer et al., 1992). IARC considers the polychlorophenol class of chemicals, including 2,4-dichlorphenol, as possibly carcinogenic to humans.

Interpreting Levels of Urinary 2,4-Dichlorophenol Reported in the Tables

Urinary levels of 2,4-dichlorophenol were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. Urinary levels of 2,4-dichlorophenol from the NHANES 2001-2002 and NHANES 1999-2000 subsamples are lower than levels obtained from a nonrandom sample of NHANES III (1988-1994) participants. In NHANES III, the mean concentration of 2,4-dichlorophenol was 9.3 µg/g creatinine, and the 95th percentile value was 45 µg/g creatinine (Hill et al., 1995). The geometric mean level of 2,4 dichlorphenol for the group aged 20-59 years in the NHANES 2001-2002 was about two-fold higher than the geometric mean reported by Becker et al. (2003) for adults aged 18-69 years in a German study.

Table 289. 2,4-Dichlorophenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**1.11** (.858-1.44)	**.750** (.620-.980)	**2.90** (1.50-5.30)	**11.0** (6.00-18.0)	**22.0** (16.0-31.0)	1990
	01-02	*	< LOD	**3.43** (2.79-4.58)	**12.0** (8.65-16.5)	**23.9** (15.3-35.5)	2503
Age group							
6-11 years	99-00	**1.27** (.847-1.90)	**.820** (.570-1.30)	**3.30** (1.40-7.80)	**17.0** (6.10-27.0)	**29.0** (11.0-91.0)	481
	01-02	*	< LOD	**2.94** (1.41-5.60)	**10.9** (7.53-17.1)	**27.8** (14.6-50.7)	574
12-19 years	99-00	**1.30** (.892-1.89)	**.950** (.680-1.50)	**3.50** (1.70-5.97)	**11.0** (5.20-23.0)	**21.6** (11.0-43.0)	679
	01-02	*	< LOD	**4.36** (3.16-5.21)	**13.6** (9.41-18.4)	**25.9** (20.9-37.7)	820
20-59 years	99-00	**1.05** (.830-1.34)	**.700** (.570-.900)	**2.50** (1.40-4.80)	**9.40** (5.20-17.0)	**21.0** (15.0-31.0)	830
	01-02	*	< LOD	**3.40** (2.52-4.75)	**11.8** (8.18-16.5)	**24.0** (14.2-38.0)	1109
Gender							
Males	99-00	**1.35** (.933-1.95)	**1.00** (.640-1.70)	**3.80** (1.90-7.20)	**12.0** (6.30-18.0)	**21.0** (14.0-31.0)	971
	01-02	*	**.510** (<LOD-1.07)	**4.71** (3.33-5.82)	**13.2** (10.1-17.0)	**23.9** (15.2-38.0)	1178
Females	99-00	**.920** (.739-1.15)	**.590** (.490-.730)	**2.20** (1.22-3.50)	**8.30** (3.90-19.0)	**25.0** (11.0-34.0)	1019
	01-02	*	< LOD	**2.59** (1.83-3.40)	**9.55** (6.43-18.5)	**24.5** (15.3-37.7)	1325
Race/ethnicity							
Mexican Americans	99-00	**1.80** (1.20-2.71)	**1.00** (.700-2.00)	**5.90** (3.50-10.0)	**23.0** (15.0-31.0)	**50.0** (28.0-70.0)	695
	01-02	*	**.800** (<LOD-2.37)	**5.88** (3.68-9.52)	**18.6** (13.7-28.9)	**40.1** (22.5-82.8)	677
Non-Hispanic blacks	99-00	**2.24** (1.37-3.65)	**1.60** (.810-2.80)	**8.80** (2.30-18.0)	**22.0** (11.7-59.0)	**39.0** (18.0-140)	518
	01-02	*	**2.35** (1.62-3.15)	**10.7** (8.09-14.2)	**34.2** (25.0-52.7)	**74.5** (39.8-105)	696
Non-Hispanic whites	99-00	**.892** (.688-1.16)	**.620** (.470-.740)	**2.00** (1.10-4.30)	**7.20** (3.50-15.0)	**17.0** (8.20-29.0)	603
	01-02	*	< LOD	**2.31** (1.71-2.96)	**8.04** (5.66-11.1)	**15.0** (10.0-24.0)	931

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Comparing Adjusted Geometric Means

Geometric mean levels of urinary 2,4-dichlorphenol levels could not be calculated for the 2001-2002 subsample due to the insufficient rate of detection. Geometric mean levels for the previous 1999-2000 subsample were compared after adjusting for the covariates of race/ethnicity, age, gender, and urine creatinine (data not shown). Non-Hispanic whites had a lower adjusted geometric mean levels of urinary 2,4-dichlorphenol than Mexican Americans. It is unknown whether these differences associated with race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of 2,4-dichlorophenol in urine does not mean that the level of the 2,4-dichlorophenol will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to 2,4-dichlorophenol and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of 2,4-dichlorophenol than levels found in the general population.

Table 290. 2,4-Dichlorophenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.994** (.790-1.25)	**.794** (.645-.917)	**2.15** (1.31-3.64)	**6.79** (4.68-10.6)	**13.9** (9.89-23.7)	1990
	01-02	*	< LOD	**2.62** (2.09-3.17)	**8.24** (6.06-12.1)	**18.0** (12.5-26.2)	2502
Age group							
6-11 years	99-00	**1.37** (.932-2.01)	**.966** (.605-1.36)	**3.15** (1.82-6.79)	**12.8** (6.12-26.2)	**25.3** (11.5-76.9)	481
	01-02	*	< LOD	**3.01** (1.75-5.49)	**11.0** (7.88-16.5)	**26.4** (12.5-58.4)	574
12-19 years	99-00	**.877** (.629-1.22)	**.645** (.438-1.09)	**2.19** (1.22-4.19)	**5.70** (3.55-10.5)	**10.3** (5.19-20.8)	679
	01-02	*	< LOD	**2.59** (1.89-3.54)	**8.72** (6.40-12.9)	**17.7** (14.6-22.5)	819
20-59 years	99-00	**.967** (.784-1.19)	**.795** (.654-.909)	**1.95** (1.23-3.42)	**6.36** (4.35-8.84)	**11.6** (8.70-26.5)	830
	01-02	*	< LOD	**2.58** (1.95-3.20)	**7.77** (5.41-12.5)	**17.2** (10.6-26.8)	1109
Gender							
Males	99-00	**1.04** (.742-1.44)	**.819** (.577-1.11)	**2.51** (1.27-4.77)	**7.55** (4.81-11.2)	**12.3** (8.98-27.9)	971
	01-02	*	**.658** (.481-.840)	**2.82** (2.45-3.23)	**8.25** (5.70-12.5)	**15.6** (11.1-24.9)	1178
Females	99-00	**.955** (.791-1.15)	**.735** (.613-.870)	**1.91** (1.36-2.67)	**6.66** (4.12-10.2)	**15.3** (8.84-28.9)	1019
	01-02	*	< LOD	**2.37** (1.50-3.36)	**9.02** (6.23-12.5)	**19.1** (12.5-33.8)	1324
Race/ethnicity							
Mexican Americans	99-00	**1.62** (1.11-2.37)	**1.15** (.798-1.90)	**4.00** (2.61-7.14)	**19.8** (10.2-47.6)	**48.7** (26.7-65.9)	695
	01-02	*	**.779** (.500-1.63)	**4.28** (2.96-7.15)	**15.6** (11.3-29.9)	**41.5** (23.1-54.5)	677
Non-Hispanic blacks	99-00	**1.52** (.923-2.51)	**1.16** (.636-2.15)	**5.12** (1.62-8.82)	**12.7** (6.06-46.8)	**28.9** (8.60-161)	518
	01-02	*	**1.44** (.970-2.02)	**6.68** (4.47-8.57)	**23.9** (17.2-32.8)	**53.3** (31.0-85.5)	695
Non-Hispanic whites	99-00	**.843** (.666-1.07)	**.663** (.562-.840)	**1.58** (1.14-2.39)	**5.00** (3.06-9.33)	**10.7** (6.00-21.3)	603
	01-02	*	< LOD	**1.91** (1.36-2.57)	**5.49** (4.55-6.86)	**11.0** (6.64-17.4)	931

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Figure 37. 2,4-Dichlorophenol (creatinine corrected)

Selected percentiles with 95% confidence intervals of urine concentrations (in μg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

ª Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Atrazine Mercapturate

Metabolite of Atrazine, CAS No. 1912-24-9

General Information

Atrazine, one of the most widely used herbicides in the United States, inhibits photosynthesis in broadleaf and some grassy weeds. An estimated of 65-75 million pounds of atrazine are applied in the United States each year. It is used in agricultural and forestry applications and on recreational turfs. Atrazine is registered for use on corn, sorghum, sugarcane, and certain other agricultural commodities. Use on corn accounts for 86% of its use. Atrazine is also registered for use on golf courses and, in some regions of the United States, on residential lawns (U.S. EPA, 2003*a*). Atrazine takes several days to months to break down in the environment, depending on conditions. Hydroxylated metabolites of atrazine are formed in plants and chlorinated metabolites and

dealkylated degradates formed in animal tissues and the environment.

The general population may be exposed to atrazine from consuming foods or drinking water that contain this herbicide or from using it on lawns or crops. In people, atrazine is metabolized predominantly to atrazine mercapturate. Results of studies of adults occupationally exposed to atrazine have shown that it is rapidly eliminated from the body (Perry et al., 2000). Animal studies have shown that atrazine has low acute toxicity, but atrazine has been associated with adverse developmental and reproductive outcomes in animals when exposed over long periods (Hayes et al., 2002; U.S. EPA, 2003*b*). It is unclear whether or not this association is a causal relationship. The chlorinated metabolites may

Table 291. Atrazine mercapturate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1878
	01-02	*	< LOD	< LOD	< LOD	< LOD	2477
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	449
	01-02	*	< LOD	< LOD	< LOD	< LOD	568
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	639
	01-02	*	< LOD	< LOD	< LOD	< LOD	809
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	790
	01-02	*	< LOD	< LOD	< LOD	< LOD	1100
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1162
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	959
	01-02	*	< LOD	< LOD	< LOD	< LOD	1315
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	676
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	498
	01-02	*	< LOD	< LOD	< LOD	< LOD	684
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	550
	01-02	*	< LOD	< LOD	< LOD	< LOD	918

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

have toxicity similar to atrazine. Atrazine is listed as "not classifiable" by IARC and as "not likely to be a human carcinogen" by the U.S. EPA.

Interpreting Levels of Urinary Atrazine Mercapturate Reported in the Tables

Urinary levels of atrazine mercapturate were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population.

In the both NHANES 1999-2000 and 2001-2002 subsamples, urinary levels of atrazine mercapturate were below the limit of detection. A low frequency of detection for atrazine mercapturate in urine was previously reported in the U.S. population (Macintosh et

al., 1999) and in a study of children 3-13 years of age (Adgate et al., 2001). In contrast, atrazine has been detected more frequently among farmers who apply this herbicide. For example, atrazine was detected at a mean concentration of 14.2 µg/L in a study of farmers (Perry et al., 2000).

Finding a measurable amount of atrazine mercapturate in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to atrazine and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of atrazine mercapturate than levels found in the general population.

Table 292. Atrazine mercapturate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1878
	01-02	*	< LOD	< LOD	< LOD	< LOD	2476
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	449
	01-02	*	< LOD	< LOD	< LOD	< LOD	568
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	639
	01-02	*	< LOD	< LOD	< LOD	< LOD	808
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	790
	01-02	*	< LOD	< LOD	< LOD	< LOD	1100
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1162
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	959
	01-02	*	< LOD	< LOD	< LOD	< LOD	1314
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	676
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	498
	01-02	*	< LOD	< LOD	< LOD	< LOD	683
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	550
	01-02	*	< LOD	< LOD	< LOD	< LOD	918

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Alachlor Mercapturate

Metabolite of Alachlor, CAS No. 15972-60-8

General Information

Alachlor is a restricted-use herbicide that is used for weed control on certain agricultural commodities including corn, soybeans, sorghum, peanuts, and beans. In animal studies, alachlor has generally been shown to be of low acute toxicity. The U.S. EPA has classified alachlor as not likely to be carcinogenic in humans at low doses.

Interpreting Levels of Urinary Alachlor Mercapturate Reported in the Tables

Urinary levels of alachlor mercapturate were measured in a subsample of NHANES participants aged 6-59 years. Note that data are not available for 2001-2002. Participants were selected within the specified age range

to be a representative sample of the U.S. population. In the NHANES 1999-2000 subsample, urinary levels of alachlor mercapturate were generally not detectable. A study of herbicide applicators detected alachlor mercapturate in 60% of urine samples at concentrations ranging from 1.98-9.1 µg/L (Hines et al., 2003).

Finding a measurable amount of alachlor mercapturate in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to alachlor and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of alachlor mercapturate than levels found in the general population.

Table 293. Alachlor mercapturate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1942
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	463
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	662
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	817
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	950
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	992
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	679
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	507
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	586

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 294. Alachlor mercapturate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1942
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	463
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	662
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	817
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	950
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	992
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	679
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	507
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	586

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Acetochlor Mercapturate

Metabolite of Acetochlor, CAS No. 34256-82-1

General Information

Acetochlor is a selective herbicide for controlling annual grasses and broadleaf weeds in cornfields. It degrades in the environment over a period of days to weeks. In animal studies, acetochlor generally has been shown to be of low acute toxicity. The U.S. EPA has classified acetochlor as likely to be carcinogenic to humans.

Interpreting Levels of Urinary Acetochlor Mercapturate Reported in the Tables

Urinary levels of acetochlor mercapturate were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S.

population. In the NHANES 2001-2002 subsample, urine acetochlor mercapturate levels were below the limit of detection. Note that measurements were not made in 1999-2000.

Finding a measurable amount of acetochlor mercapturate in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to acetochlor and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of acetochlor mercapturate than levels found in the general population.

Table 295. Acetochlor mercapturate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2501
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	576
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	820
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1105
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1178
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1323
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	678
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	673
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	952

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 296. Acetochlor mercapturate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2500
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	576
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	819
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1105
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1178
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1322
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	678
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	672
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	952

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Metolachlor Mercapturate

Metabolite of Metolachlor, CAS No. 51218-45-2

General Information

Metolachlor is a broad-spectrum herbicide used for general weed control on many agricultural crops, lawns, turf, rights-of-way, and in forests. This herbicide degrades in the environment over a period of weeks to months. In animal studies, metolachlor mercapturate generally has been shown to be of low acute toxicity. It is listed by the U.S. EPA as a possible human carcinogen.

Interpreting Levels of Urinary Metolachlor Mercapturate Reported in the Tables

Urinary levels of metolachlor mercapturate were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the

U.S. population. In the NHANES 2001-2002 subsample, urinary levels of metolachlor mercapturate were mostly below the limit of detection. A study of herbicide applicators detected metolachlor mercapturate in 60% of urine samples, at concentrations ranging from 2-9 µg/L (Hines et al., 2003).

Finding a measurable amount of metolachlor mercapturate in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to metolachlor and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of metolachlor than levels found in the general population.

Table 297. Metolachlor mercapturate

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2538
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	831
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1127
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	.200 (<LOD-.210)	1192
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1346
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	679
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	701
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 298. Metolachlor mercapturate (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2537
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	830
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1127
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	.424 (.389-.467)	1192
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1345
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	679
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	700
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Results by Chemical Group

Pyrethroid Pesticides

Pyrethroids Pesticides

General Information

Pyrethroid pesticides are synthetic analogues of pyrethrins, which are natural chemicals found in chrysanthemum flowers. Pyrethroid pesticides are used to control a wide range of insects on agricultural fields, and in residences, public and commercial buildings, animal facilities, warehouses, and greenhouses. Certain pyrethroid insecticides (such as permethrin, resmethrin, and sumithrin) are also registered for use in mosquito-control programs in the United States. Pyrethroids are generally formulated as a complex mixture of different chemical isomers. National estimates for amounts of pyrethroids applied in the United States range from approximately 175,000 pounds (cyfluthrin, cypermethrin) to 1 million pounds (permethrin) (ATSDR, 2003).

Exposure of the general population to pyrethroid insecticides occurs primarily from the ingestion of food or from residential use. Permethrin is also used in skin lotion and shampoo to treat lice and scabies and has limited systemic absorption through the skin. Pesticide applicators can be exposed to pyrethroid pesticides via dermal and inhalation routes from powders and liquid formulations.

The average daily intake of permethrin (the most frequently used pyrethroid in the United States) for a man weighing 70 kilograms is estimated at about 3.2 micrograms per day. This value is about 1,000 times lower than the acceptable daily intake of permethrin derived by the United Nations' Food and Agriculture Organization and the World Health Organization. The U.S. FDA and USDA, the U.S. EPA, and OSHA have developed criteria on allowable levels of pyrethroids in foods, the environment, and the workplace, respectively.

Pyrethroid insecticides are currently undergoing regulatory review for a re-registration eligibility decision by the U.S. EPA.

Pyrethroids are not well absorbed through the skin. After a person inhales or ingests pyrethroids, the chemicals are rapidly metabolized and eliminated from the body. Elimination half-lives ranging from 5 to 8 hours have been measured for certain pyrethroids after human exposure (Kuhn et al., 1999). Researchers in other countries have frequently detected specific and nonspecific pyrethroid metabolites in urine samples obtained from adults and children in the general population (Heudorf and Angerer, 2001*d*).

Compared with other classes of insecticides (including organochlorines, organophosphates, and carbamates), pyrethroids have less toxicity in animals and people. Most adverse effects are related to the action of pyrethroids on the nervous system, where these chemicals open sodium channels when a nerve cell is excited (Soderlund et al., 2002). This effect can result in abnormal skin sensations (paresthesias) after dermal exposure, a transient symptom which is most commonly reported among pesticide applicators after direct contact with certain types of pyrethroid insecticides. Cases of systemic poisoning are rare and usually result from accidental or intentional ingestion of pyrethroid insecticides. Signs and symptoms of acute pyrethroid poisoning include tremor, salivation, choreoathetosis, and seizures (Ray et al., 2000).

Information about external exposure (i.e., environmental levels) and health effects of specific pyrethroids insecticides is available from ATSDR's Toxicological Profiles at http://www.atsdr.cdc.gov/toxprofiles and from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris.

Table 299. Pyrethroid pesticides and their metabolites

Pyrethroid (CAS number)	Urine metabolite (CAS number)
Cyfluthrin (68359-37-5)	4-Fluoro-3-phenoxybenzoic acid (77279-89-1)
cis-Permethrin (61949-76-6) Cyfluthrin (68359-37-5) and *cis*-Cypermethrin (52315-07-8)	*cis*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (55701-05-8)
trans-Permethrin (61949-77-7) Cyfluthrin (68359-37-5) and *trans*-Cypermethrin (65732-07-2)	*trans*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (55701-03-6)
Deltamethrin (52918-63-5)	*cis*-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid
Cypermethrin (52315-07-8) Deltamethrin (52918-63-5) Permethrin (52645-53-1)	3-Phenoxybenzoic acid (3739-38-6)

4-Fluoro-3-phenoxybenzoic Acid

CAS No. 77279-89-1

Metabolite of Cyfluthrin, CAS No.68359-37-5

General Information

The chemical 4-fluoro-3-phenoxybenzoic acid is a specific metabolite of the pyrethroid insecticide cyfluthrin. Exposure to cyfluthrin may occur from the diet (including from certain fruits, vegetables, and grains), residential applications in homes and gardens, and from other indoor or outdoor locations where this pesticide is used.

Cyfluthrin is rapidly metabolized and eliminated from the body. The mean elimination half-life of cyfluthrin was 16 hours after an indoor application of this pesticide (Williams et al., 2003).

Interpreting Levels of Urinary 4-Fluoro-3-Phenoxybenzoic Acid Reported in the Tables

Urinary levels of 4-fluoro-3-phenoxybenzoic acid were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample,

urinary levels of 4-fluoro-3-phenoxybenzoic acid were below the limit of detection. In a previous analysis of 217 urine specimens from a nonrandom sample of individuals in the United States that included cases of suspected residential insecticide exposure, the geometric mean concentration of 4-fluoro-3-phenoxybenzoic acid was 0.95 µg/L (Baker et al., 2004). In an investigation of adults and children in the general population in Germany, researchers detected 4-fluoro-3-phenoxybenzoic acid in 16% of urine samples (Heudorf and Angerer, 2001*d*), with adults and children having similar metabolite levels.

Finding a measurable amount of 4-fluoro-3-phenoxybenzoic acid in urine does not mean that the level of the 4-fluoro-3-phenoxybenzoic acid will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to cyfluthrin and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of cyfluthrin than levels found in the general population.

Table 300. 4-Fluoro-3-phenoxybenzoic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2539
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	831
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1128
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1193
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1346
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	701
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Table 301. 4-Fluoro-3-phenoxybenzoic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2538
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	830
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1128
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1193
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1345
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	700
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

cis-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane Carboxylic Acid

CAS No. 55701-05-8

Metabolite of cis-*Permethrin, CAS No.61949-76-6; Cyfluthrin, CAS No.68359-37-5; and*
cis-*Cypermethrin, CAS No. 52315-07-8*

General Information

Cis-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid is a metabolite of *cis*-permethrin and other pyrethroid insecticides. *Cis*-permethrin is an isomer that is commonly present in insecticide formulations containing permethrin as an active ingredient. Permethrin is the most commonly used pyrethroid on agricultural crops in the United States, and it is the most commonly detectable pyrethroid in foods. Permethrin is also used in residences to control home and garden pests and in public health programs to control mosquitos. The *cis*-isomer of permethrin has more potent insecticidal activity than *trans*-permethrin. The metabolic transformation of *cis*-permethrin to *cis*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid can also occur in the environment (George, 1985). Thus, in addition to reflecting exposure to *cis*-permethrin and other pyrethroids, the detection of *cis*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxyclic acid in the urine may also reflect exposure to the metabolite if it was present in the person's food or environment.

The chemical *cis*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid is also a metabolite of other pyrethroids, including cypermethrin and cyfluthrin (Kuhn et al., 1999). Thus, the detection of *cis*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid in the urine may reflect multiple sources of environmental exposure to different pyrethroid insecticides.

Interpreting Levels of Urinary *cis*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane Carboxylic Acid Reported in the Tables

Urinary levels of *cis*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. The 95th percentile values in the 2001-2002 subsample are similar to the corresponding 95th percentile values reported in a study of children and adults in Germany (Schettgen, et al., 2002*a*). Other investigators in Germany detected *cis*-3-(2,2-

Table 302. *cis*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	.160 (.120-.200)	.490 (.380-.670)	.890 (.740-1.10)	2539
Age group							
6-11 years	01-02	*	< LOD	.110 (<LOD-.170)	.360 (.280-.590)	.730 (.490-.870)	580
12-19 years	01-02	*	< LOD	.150 (<LOD-.210)	.430 (.300-.630)	.720 (.630-.920)	831
20-59 years	01-02	*	< LOD	.160 (.120-.220)	.510 (.390-.720)	.960 (.790-1.28)	1128
Gender							
Males	01-02	*	< LOD	.140 (.100-.200)	.470 (.370-.610)	.880 (.650-1.35)	1193
Females	01-02	*	< LOD	.180 (.120-.240)	.500 (.360-.740)	.880 (.790-1.08)	1346
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	.130 (.100-.180)	.290 (.250-.380)	.510 (.380-.580)	680
Non-Hispanic blacks	01-02	*	< LOD	.270 (.220-.350)	.640 (.570-.700)	.840 (.710-1.24)	701
Non-Hispanic whites	01-02	*	< LOD	.130 (<LOD-.200)	.500 (.330-.790)	.890 (.670-1.28)	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid in 30% of urine samples obtained from adults and children in the general population (Heudorf and Angerer, 2001*d*). In that study, urinary metabolite levels in adults and children were similar. Higher levels of *cis*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (up to 12.8 µg/L) have been measured in urine samples obtained from pyrethroid insecticide applicators (Leng et al., 2003).

Finding a measurable amount of *cis*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to pyrethroid insecticides and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of pyrethroids than levels found in the general population.

Table 303. *cis*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	**.219** (.198-.248)	**.436** (.373-.521)	**.778** (.629-1.03)	2538
Age group							
6-11 years	01-02	*	< LOD	**.250** (.184-.318)	**.596** (.430-.703)	**.745** (.636-.886)	580
12-19 years	01-02	*	< LOD	**.154** (.123-.200)	**.303** (.250-.382)	**.500** (.367-.778)	830
20-59 years	01-02	*	< LOD	**.227** (.210-.255)	**.444** (.386-.556)	**.891** (.640-1.08)	1128
Gender							
Males	01-02	*	< LOD	**.171** (.149-.189)	**.350** (.302-.412)	**.675** (.449-1.03)	1193
Females	01-02	*	< LOD	**.263** (.226-.304)	**.500** (.432-.564)	**.920** (.745-1.11)	1345
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	**.165** (.148-.189)	**.297** (.263-.350)	**.535** (.373-.636)	680
Non-Hispanic blacks	01-02	*	< LOD	**.179** (.143-.219)	**.385** (.292-.545)	**.837** (.545-1.11)	700
Non-Hispanic whites	01-02	*	< LOD	**.242** (.206-.269)	**.444** (.389-.563)	**.837** (.583-1.14)	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

trans-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane Carboxylic Acid

CAS No. 55701-03-6

Metabolite of trans-*Permethrin, CAS No. 61949-77-7; Cyfluthrin, CAS No.68359-37-5; and*
trans-*Cypermethrin, CAS No. 65732-07-2*

General Information

The chemical *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid is a metabolite of *trans*-permethrin and other pyrethroid insecticides. *trans*-Permethrin is an isomer that is commonly present in insecticide formulations containing permethrin as an active ingredient. Permethrin is the most commonly used pyrethroid on agricultural crops in the United States, and it is the most commonly detectable pyrethroid in foods. Permethrin is also used in residences to control home and garden pests and in public health programs to control mosquitos. The *trans*- isomer of permethrin has less potent insecticidal activity than cis-permethrin. The metabolic transformation of *trans*-permethrin to *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid can also occur in the environment (George, 1985). Thus, in addition to reflecting exposure to *trans*-permethrin, the detection of *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid in the urine may also reflect exposure to the metabolite if it were present in the person's food or environment.

Trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid is also a metabolite of other pyrethroids, including cypermethrin and cyfluthrin (Kuhn et al., 1999). Thus, the detection of detection of *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid in the urine may reflect multiple sources of environmental exposure to different pyrethroid insecticides.

Interpreting Levels of Urinary *trans*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane Carboxylic Acid Reported in the Tables

Urinary levels of *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. The 95th percentile values in the 2001-2002 subsample are similar to the corresponding 95th percentile values reported in a study of children and

Table 304. *trans*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	.410 (<LOD-.550)	1.20 (.910-1.77)	2.50 (1.68-3.70)	2525
Age group							
6-11 years	01-02	*	< LOD	.470 (<LOD-.680)	1.39 (1.03-1.68)	2.50 (1.55-3.49)	576
12-19 years	01-02	*	< LOD	.490 (<LOD-.670)	1.17 (.780-1.58)	1.94 (1.49-3.77)	826
20-59 years	01-02	*	< LOD	< LOD	1.16 (.850-1.85)	2.56 (1.64-4.66)	1123
Gender							
Males	01-02	*	< LOD	.400 (<LOD-.490)	1.09 (.810-1.63)	2.37 (1.55-4.48)	1184
Females	01-02	*	< LOD	.430 (<LOD-.640)	1.26 (.920-1.95)	2.56 (1.76-3.58)	1341
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	.410 (<LOD-.500)	.900 (.680-1.16)	1.59 (1.11-2.01)	680
Non-Hispanic blacks	01-02	*	< LOD	.570 (.460-.730)	1.26 (1.03-1.68)	1.94 (1.68-2.95)	690
Non-Hispanic whites	01-02	*	< LOD	.400 (<LOD-.610)	1.19 (.840-1.90)	2.60 (1.60-4.66)	954

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

adults in Germany (Schettgen et al., 2002*a*). Other investigators in Germany detected *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid in 65% of urine samples obtained from adults and children in the general population (Heudorf and Angerer, 2001*d*) with adults and children having similar levels of urinary metabolite. Higher levels (up to 13.4 µg/L) of *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid have been reported in pesticide applicators following the application of pyrethroid insecticides (Leng et al., 2003).

Finding a measurable amount of *trans*-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to pyrethroid insecticides and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of pyrethroids than levels found in the general population.

Table 305. *trans*-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	.718 (.636-.778)	1.45 (1.22-1.88)	2.55 (2.07-2.98)	2524
Age group							
6-11 years	01-02	*	< LOD	.903 (.697-1.13)	2.16 (1.40-2.61)	2.80 (2.34-3.44)	576
12-19 years	01-02	*	< LOD	.528 (.431-.651)	.966 (.778-1.12)	1.56 (1.07-2.60)	825
20-59 years	01-02	*	< LOD	< LOD	1.47 (1.20-1.98)	2.47 (2.07-3.11)	1123
Gender							
Males	01-02	*	< LOD	.519 (.475-.571)	1.04 (.875-1.32)	2.20 (1.45-2.57)	1184
Females	01-02	*	< LOD	.875 (.789-1.00)	1.68 (1.47-2.15)	2.81 (2.30-3.19)	1340
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	.569 (.509-.622)	1.08 (.933-1.22)	1.87 (1.27-2.15)	680
Non-Hispanic blacks	01-02	*	< LOD	.475 (.413-.537)	1.12 (.800-1.37)	1.98 (1.20-2.68)	689
Non-Hispanic whites	01-02	*	< LOD	.772 (.700-.848)	1.48 (1.27-2.07)	2.48 (2.15-3.02)	954

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

cis-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane Carboxylic Acid
CAS No. 63597-73-9

Metabolite of Deltamethrin, CAS No. 52918-63-5

General Information

Cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid is a specific metabolite of the pyrethroid insecticide deltamethrin. Exposure to deltamethrin may occur from the diet and its application in indoor or outdoor locations, including homes and gardens.

The metabolic transformation of deltamethrin to *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid can also occur in the environment (International Programme on Chemical Safety, 1990). Thus, in addition to reflecting exposure to deltamethrin, the detection of *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid in the urine may also reflect exposure to the metabolite if it was present in a person's food or environment. Deltamethrin is not considered a persistent pesticide in the body.

Interpreting Levels of Urinary cis-3-(2,2-Dibromovinyl)-2,2-Dimethylcyclopropane Carboxylic Acid Reported in the Tables

Urinary levels of *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, urinary levels of *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid were below the limit of detection. In a previous analysis of 217 urine specimens from a nonrandom sample of individuals in the United States that included cases of possible exposure to residential insecticides, the geometric mean concentration of *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid was 0.39 µg/L (Baker et al., 2004). Results of a study of German children and adults showed that the mean urinary concentration of *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid was 0.08 µg/gram creatinine (Heudorf and Angerer, 2001*d*). In another German study, *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid was detected in 19% of urine samples obtained from adults and children in the general population (Heudorf and Angerer, 2001*d*) with adults and children having similar levels of urinary metabolite.

Table 306. cis-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2539
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	831
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1128
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1193
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1346
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	701
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Finding a measurable amount of *cis*-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to deltamethrin and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of deltamethrin than levels found in the general population.

Table 307. *cis*-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	*	< LOD	< LOD	< LOD	< LOD	2538
Age group							
6-11 years	01-02	*	< LOD	< LOD	< LOD	< LOD	580
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	830
20-59 years	01-02	*	< LOD	< LOD	< LOD	< LOD	1128
Gender							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1193
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1345
Race/ethnicity							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	700
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	957

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

3-Phenoxybenzoic Acid

CAS No. 3739-38-6

Metabolite of Cypermethrin, CAS No.52315-07-8, Deltamethrin, CAS No. 52918-63-5; and Permethrin, CAS No. 52645-53-1

General Information

The chemical 3-phenoxybenzoic acid is a metabolite of cypermethrin, deltamethrin, permethrin, and possibly other pyrethroid insecticides. Thus, the detection of this metabolite in the urine may reflect multiples sources of environmental exposure to different pyrethroid insecticides. The metabolic transformation of certain pyrethroids to 3-phenoxybenzoic acid occurs in the body as well as in the environment. Thus, in addition to reflecting exposure to certain pyrethroids, so detecting 3-phenoxybenzoic acid in the urine may also reflect exposure to the metabolite if it was present in a person's food or environment.

Interpreting Levels of Urinary 3-Phenoxybenzoic Acid Reported in the Tables

Urinary levels of 3-phenoxybenzoic acid were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population.

In the NHANES 2001-2002 subsample, the median concentration 3-phenoxybenzoic acid in urine was similar to measurements reported in a study of German adults aged 17-61 years (Schettgen et al., 2002*b*). In a previous analysis of 217 urine specimens from a nonrandom sample of individuals in the United States that included cases of possible exposure to residential insecticides, geometric mean levels of 3-phenoxybenzoic acid were approximately six-fold higher than levels in the NHANES 2001-2002 subsample (Baker et al., 2004).

A previous study of adults and children in the United States reported the detection of 3-phenoxybenzoic acid in 12% of urine samples at concentrations of up to 30 µg/g creatinine (Baker et al., 2000). In a study by Leng et al. (2003), 3-phenoxybenzoic acid was detected in 25% of urine samples obtained from adult pest-control operators applying pyrethroid insecticides, and metabolite concentrations were observed to increase during the first 48 hours after an application. In that study, 3-phenoxybenzoic acid levels in urine ranged 0.1-11.5 µg/L.

Table 308. 3-Phenoxybenzoic acid

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**.321** (.276-.374)	**.280** (.220-.340)	**.690** (.560-.810)	**1.69** (1.41-2.33)	**3.32** (2.52-5.25)	2539
Age group							
6-11 years	01-02	**.325** (.260-.406)	**.300** (.200-.410)	**.750** (.560-1.03)	**1.81** (1.34-2.69)	**3.28** (2.25-4.12)	580
12-19 years	01-02	**.353** (.288-.434)	**.290** (.250-.390)	**.800** (.560-1.13)	**1.85** (1.48-2.35)	**3.45** (2.14-6.69)	831
20-59 years	01-02	**.314** (.271-.364)	**.270** (.210-.340)	**.670** (.530-.780)	**1.64** (1.27-2.34)	**3.25** (2.51-6.16)	1128
Gender							
Males	01-02	**.328** (.277-.387)	**.290** (.230-.370)	**.680** (.560-.750)	**1.55** (1.26-2.16)	**3.23** (2.56-5.78)	1193
Females	01-02	**.315** (.266-.373)	**.250** (.210-.320)	**.730** (.530-.920)	**1.76** (1.47-2.35)	**3.28** (2.34-6.16)	1346
Race/ethnicity							
Mexican Americans	01-02	**.297** (.238-.369)	**.250** (.190-.340)	**.650** (.480-.810)	**1.30** (.830-2.26)	**2.71** (1.51-3.44)	680
Non-Hispanic blacks	01-02	**.507** (.428-.601)	**.510** (.430-.630)	**.950** (.840-1.12)	**2.00** (1.65-2.28)	**3.25** (2.52-4.62)	701
Non-Hispanic whites	01-02	**.298** (.246-.362)	**.230** (.180-.320)	**.590** (.470-.800)	**1.72** (1.27-2.46)	**3.38** (2.25-7.64)	957

Comparing Adjusted Geometric Means

Geometric mean levels of urinary 3-phenoxybenzoic acid for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine. For NHANES 2001-2002, children aged 6-11 years had slightly higher adjusted geometric mean levels of urinary 3-phenoxybenzoic acid than the group aged 12-19 years. Females had slightly higher levels than males. In addition, non-Hispanic blacks had slightly higher levels than Mexican Americans or non-Hispanic whites. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of 3-phenoxybenzoic acid in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to pyrethroid insecticides and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of pyrethroids than levels found in the general population.

Table 309. 3-Phenoxybenzoic acid (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	01-02	**.316** (.274-.365)	**.283** (.243-.333)	**.582** (.490-.721)	**1.46** (1.13-1.91)	**3.10** (2.21-4.88)	2538
Age group							
6-11 years	01-02	**.423** (.335-.534)	**.382** (.296-.500)	**.859** (.594-1.35)	**2.20** (1.61-2.95)	**3.32** (2.64-5.40)	580
12-19 years	01-02	**.274** (.229-.328)	**.236** (.189-.313)	**.539** (.424-.730)	**1.10** (.864-1.63)	**2.35** (1.36-6.19)	830
20-59 years	01-02	**.311** (.271-.357)	**.282** (.245-.328)	**.550** (.444-.673)	**1.44** (1.02-1.91)	**3.10** (1.91-4.92)	1128
Gender							
Males	01-02	**.264** (.226-.309)	**.238** (.200-.280)	**.490** (.413-.571)	**1.17** (.955-1.60)	**2.75** (1.60-4.00)	1193
Females	01-02	**.378** (.321-.446)	**.333** (.283-.391)	**.716** (.534-.932)	**1.66** (1.25-2.37)	**3.34** (2.25-5.19)	1345
Race/ethnicity							
Mexican Americans	01-02	**.275** (.230-.329)	**.241** (.206-.316)	**.512** (.404-.650)	**1.03** (.750-1.67)	**1.83** (1.15-2.74)	680
Non-Hispanic blacks	01-02	**.362** (.300-.437)	**.350** (.283-.415)	**.636** (.526-.757)	**1.36** (1.17-1.83)	**2.82** (1.63-3.80)	700
Non-Hispanic whites	01-02	**.312** (.261-.372)	**.279** (.233-.333)	**.554** (.438-.811)	**1.52** (1.09-2.35)	**3.43** (1.88-5.48)	957

Results by Chemical Group

Other Pesticides

N,N-Diethyl-3-methylbenzamide

CAS No. 134-62-3

General Information

N,N-diethyl-3-methylbenzamide (DEET) is an insect repellent that was first marketed in 1957. Commonly used to prevent mosquito bites, DEET can be applied to clothing and the skin. Insect repellents containing DEET are widely used by the general population. Commercial formulations of repellents containing DEET range in concentration from 4% to 100%. DEET is also used in combination with dermal sun screens. There are no registered uses of DEET on agricultural commodities.

The general population may be exposed to DEET from application to the skin and from inhalation of aerosol-repellent formulations. Eating food touched by hands that have been treated with DEET can also result in exposure. Absorption of DEET through the skin is limited, depending on the concentration and the presence of other

chemicals in the formulation. After absorption, DEET is eliminated in the urine within approximately 24 hours (Selim et al., 1995). Bioaccumulation of DEET in the human body does not occur. People working in outdoor occupations may apply DEET more frequently or use higher concentration formulations resulting in higher levels of exposure.

Most reports of adverse effects from overexposure to DEET involve skin reactions (Bell et al., 2002). Neurological effects, including seizures, have been reported in a small number of studies involving human overexposure by ingestion or excessive dermal application, although it is unclear whether these effects have been caused by DEET (U.S. EPA, 1998). The toxicological mechanisms resulting in adverse effects from overexposure to DEET are not well understood. DEET is not rated by IARC or NTP with respect to

Table 310. N,N-Diethyl-3-methylbenzamide (DEET)

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1977
	01-02	*	< LOD	< LOD	.100 (<LOD-.110)	.170 (.140-.220)	2535
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	480
	01-02	*	< LOD	< LOD	.120 (.100-.180)	.200 (.120-.560)	580
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	672
	01-02	*	< LOD	< LOD	.120 (.110-.160)	.220 (.130-.460)	829
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	825
	01-02	*	< LOD	< LOD	.100 (<LOD-.110)	.160 (.120-.210)	1126
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	964
	01-02	*	< LOD	< LOD	.100 (<LOD-.110)	.180 (.130-.250)	1191
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1013
	01-02	*	< LOD	< LOD	.100 (<LOD-.120)	.160 (.120-.200)	1344
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	688
	01-02	*	< LOD	< LOD	.110 (<LOD-.130)	.120 (.100-.150)	678
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	518
	01-02	*	< LOD	< LOD	< LOD	.130 (.100-.230)	700
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	598
	01-02	*	< LOD	< LOD	.100 (<LOD-.110)	.170 (.130-.250)	956

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

carcinogenicity.

Interpreting Levels of Urinary DEET Reported in the Tables

Urinary levels of DEET were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. Urinary levels of DEET were characterized at the 90th and 95th percentiles in this 2001-2002 subsample at an improved limit of detection as compared with the NHANES 1999-2000 subsample for which measurements of DEET were usually not detectable. In a small study by Smallwood et

al. (1992), urinary DEET levels as high as 5,690 µg/L were measured in eight park employees who applied 71% DEET once a day.

Finding a measurable amount of DEET in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to DEET and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of DEET than levels found in the general population.

Table 311. N,N-Diethyl-3-methylbenzamide (DEET) (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1977
	01-02	*	< LOD	< LOD	.269 (.233-.300)	.412 (.350-.500)	2534
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	480
	01-02	*	< LOD	< LOD	.333 (.219-.608)	.632 (.280-1.93)	580
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	672
	01-02	*	< LOD	< LOD	.190 (.148-.241)	.241 (.175-.333)	828
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	825
	01-02	*	< LOD	< LOD	.267 (.229-.304)	.407 (.368-.500)	1126
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	964
	01-02	*	< LOD	< LOD	.194 (.163-.250)	.314 (.250-.440)	1191
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1013
	01-02	*	< LOD	< LOD	.327 (.292-.368)	.500 (.400-.543)	1343
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	688
	01-02	*	< LOD	< LOD	.185 (.163-.219)	.280 (.226-.350)	678
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	518
	01-02	*	< LOD	< LOD	< LOD	.187 (.140-.269)	699
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	598
	01-02	*	< LOD	< LOD	.304 (.259-.333)	.481 (.389-.545)	956

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

ortho-Phenylphenol

CAS No. 90-43-7

General Information

Ortho-phenylphenol (OPP) and its water-soluble salt, sodium *o*-phenylphenate (SOPP), are antimicrobial pesticides used in agriculture to control fungal and bacterial growth on stored crops, such as fruits and vegetables. These agents came into use in the mid 1930s. SOPP is applied topically to the crop and then rinsed off, leaving the chemical residue, *o*-phenylphenol. OPP offers additional protection to the crop from infection at scarred or injured sites (Johnson et al., 2001). OPP is also used as a disinfectant fungicide for industrial applications and at one time was used for applications inside the home.

The general population may be exposed to these chemicals via dermal, inhalational, or oral routes from residential use and by ingesting treated food or contaminated ground water. OPP has been detected in carpet dust in residential environments (Immerman and Shaum, 1990). Workers who manufacture, formulate, or apply these chemicals may have higher levels of exposure than other people.

OPP is not effectively absorbed through the skin but is efficiently absorbed from the gastrointestinal tract. Animal studies show that OPP appears to be eliminated rapidly from the body. The major urinary metabolites from SOPP exposure are OPP glucuronide and sulfate conjugates. The available evidence does not suggest that OPP accumulates in the body; however, OPP has been measured in human adipose tissue (Onstot and Stanley, 1989). After dermal exposure, OPP is rapidly eliminated in the urine within 24 hours (Timchalk et al., 1998). IARC has classified SOPP as a possible human carcinogen and OPP as not classifiable as a human carcinogen. The NTP conducted a 2-year experimental

Table 312. *ortho*-Phenylphenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.494** (.387-.630)	**.490** (<LOD-.600)	**.850** (.600-1.30)	**1.46** (1.01-1.90)	**2.00** (1.50-2.80)	1991
	01-02	*	< LOD	< LOD	**.570** (.360-.830)	**1.27** (.710-2.85)	2529
Age group							
6-11 years	99-00	**.507** (.399-.643)	**.490** (<LOD-.630)	**.890** (.610-1.50)	**1.80** (1.30-2.10)	**2.20** (1.80-3.90)	480
	01-02	*	< LOD	< LOD	**1.17** (.730-2.02)	**2.28** (1.28-3.61)	577
12-19 years	99-00	**.506** (.369-.695)	**.490** (<LOD-.660)	**.890** (.570-1.50)	**1.60** (1.10-2.10)	**2.00** (1.40-6.30)	681
	01-02	*	< LOD	< LOD	**.740** (.470-1.25)	**2.05** (.800-3.09)	827
20-59 years	99-00	**.490** (.385-.623)	**.490** (<LOD-.600)	**.810** (.600-1.20)	**1.41** (1.10-1.80)	**1.90** (1.50-2.90)	830
	01-02	*	< LOD	< LOD	**.440** (<LOD-.670)	**.930** (.540-2.23)	1125
Gender							
Males	99-00	**.495** (.386-.635)	**.460** (<LOD-.600)	**.820** (.600-1.30)	**1.60** (1.20-1.90)	**1.90** (1.50-3.20)	973
	01-02	*	< LOD	< LOD	**.610** (.350-1.03)	**1.27** (.750-2.85)	1190
Females	99-00	**.493** (.383-.634)	**.480** (<LOD-.590)	**.860** (.580-1.30)	**1.50** (1.00-2.00)	**2.10** (1.50-4.50)	1018
	01-02	*	< LOD	< LOD	**.520** (.370-.780)	**1.22** (.590-2.91)	1339
Race/ethnicity							
Mexican Americans	99-00	**.548** (.360-.834)	**.410** (<LOD-.950)	**1.10** (.490-1.90)	**2.20** (1.40-4.80)	**3.80** (2.30-7.10)	695
	01-02	*	< LOD	< LOD	**1.11** (<LOD-3.88)	**2.92** (.560-8.22)	680
Non-Hispanic blacks	99-00	**.564** (.428-.742)	**.560** (.410-.780)	**.970** (.690-1.50)	**1.60** (1.30-1.70)	**1.90** (1.60-2.20)	520
	01-02	*	< LOD	< LOD	**.770** (.570-.890)	**1.19** (.840-1.76)	695
Non-Hispanic whites	99-00	**.463** (.347-.619)	**.440** (<LOD-.600)	**.770** (.550-1.20)	**1.40** (.860-1.90)	**1.80** (1.40-5.10)	603
	01-02	*	< LOD	< LOD	**.430** (<LOD-.710)	**1.07** (.570-2.23)	953

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

dermal study in animals using OPP and found no evidence of carcinogenicity.

Interpreting Levels of Urinary *ortho*-Phenylphenol Reported in the Tables

Urinary OPP levels were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. Levels in this *Report* are less than levels measured following experimental dermal application in humans (Timchalk et al., 1998).

Comparing Adjusted Geometric Means

Geometric mean levels of urinary OPP could not be calculated for the 2001-2002 subsample due to an insufficient detection rate. Geometric mean levels in the demographic groups for the previous 1999-2000 subsample were compared after adjustment for the covariates of age, race/ethnicity, gender and urinary

creatinine. No differences between the demographic groups were observed.

Finding a measurable amount of OPP in urine does not mean that the level of the OPP will result in an adverse health effect. These data will help scientists plan and conduct research about exposure to OPP and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of OPP than levels found in the general population.

Table 313. *ortho*-Phenylphenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**.442** (.351-.556)	**.413** (.313-.554)	**.840** (.619-1.11)	**1.84** (1.24-2.33)	**2.93** (2.04-4.29)	1991
	01-02	*	< LOD	< LOD	**.982** (.808-1.17)	**1.75** (1.21-2.33)	2528
Age group							
6-11 years	99-00	**.547** (.452-.663)	**.504** (.402-.667)	**1.02** (.800-1.27)	**1.96** (1.43-2.59)	**2.61** (2.09-3.58)	480
	01-02	*	< LOD	< LOD	**1.91** (1.08-2.53)	**2.53** (1.96-4.01)	577
12-19 years	99-00	**.342** (.247-.472)	**.319** (.198-.497)	**.691** (.460-.913)	**1.14** (.867-1.96)	**1.96** (1.09-6.32)	681
	01-02	*	< LOD	< LOD	**.750** (.643-1.21)	**1.52** (.937-2.32)	826
20-59 years	99-00	**.450** (.358-.566)	**.420** (.313-.562)	**.861** (.618-1.12)	**1.89** (1.24-2.47)	**3.28** (2.06-4.93)	830
	01-02	*	< LOD	< LOD	**.913** (.778-1.05)	**1.44** (1.05-2.30)	1125
Gender							
Males	99-00	**.380** (.299-.482)	**.353** (.239-.471)	**.752** (.548-.994)	**1.43** (1.08-1.93)	**2.07** (1.51-3.29)	973
	01-02	*	< LOD	< LOD	**.750** (.583-1.11)	**1.61** (.750-2.43)	1190
Females	99-00	**.512** (.400-.654)	**.459** (.382-.588)	**.909** (.646-1.46)	**2.04** (1.37-3.28)	**3.78** (2.06-5.96)	1018
	01-02	*	< LOD	< LOD	**1.11** (.913-1.35)	**1.75** (1.25-2.30)	1338
Race/ethnicity							
Mexican Americans	99-00	**.493** (.307-.789)	**.420** (.221-.808)	**1.11** (.548-2.14)	**2.99** (1.25-6.08)	**4.61** (2.40-13.4)	695
	01-02	*	< LOD	< LOD	**1.28** (.525-4.26)	**3.00** (.778-14.0)	680
Non-Hispanic blacks	99-00	**.382** (.287-.509)	**.375** (.259-.549)	**.672** (.509-.897)	**1.21** (.897-1.62)	**1.69** (1.43-2.13)	520
	01-02	*	< LOD	< LOD	**.669** (.477-.966)	**1.16** (.739-2.12)	694
Non-Hispanic whites	99-00	**.438** (.326-.588)	**.410** (.280-.608)	**.861** (.595-1.20)	**1.86** (1.12-2.59)	**2.93** (1.88-4.81)	603
	01-02	*	< LOD	< LOD	**.982** (.808-1.11)	**1.52** (1.11-1.91)	953

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

2,5-Dichlorophenol

CAS No. 583-78-8

Metabolite of para-*Dichlorobenzene, CAS No. 106-47-7*

General Information

The chemical 2,5-dichlorophenol is a metabolite of *para*-dichlorobenzene (*p*-dichlorobenzene), which is used in moth balls, some room deodorizers, and previously as an insecticidal fumigant. *Para*-dichlorobenzene can be absorbed through oral, dermal, or pulmonary exposure. Absorbed *p*-dichlorobenzene can be excreted unchanged in the urine. Once metabolized in the body to 2,5-dichlorophenol, it is conjugated to glutathione and excreted in the urine.

Eye and respiratory irritation may occur at air levels higher than levels encountered with normal uses. Liver necrosis has been observed in workers after prolonged heavy applications of *p*-dichlorobenzene (Cotter, 1953).

The NTP considers *p*-dichlorobenzene as possibly carcinogenic to humans, and IARC considers *p*-dichlorobenzene as reasonably anticipated to be a human carcinogen. Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at http://www.epa.gov/iris and from ATSDR's Toxicological Profiles at http://www.atsdr.cdc. gov/toxprofiles.

Interpreting Levels of Urinary 2,5-Dichlorophenol Reported in the Tables

Urinary levels of 2,5-dichlorophenol were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population.

Table 314. 2,5-Dichlorophenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**6.01** (4.19-8.64)	**6.50** (5.00-9.10)	**37.8** (24.0-47.0)	**144** (88.0-240)	**440** (290-620)	1989
	01-02	*	**2.04** (<LOD-6.48)	**28.8** (20.5-40.2)	**194** (115-255)	**657** (301-1150)	2502
Age group							
6-11 years	99-00	**7.57** (4.62-12.4)	**9.00** (4.70-12.0)	**46.0** (27.0-90.8)	**240** (130-610)	**630** (400-750)	480
	01-02	*	**1.62** (<LOD-11.5)	**34.5** (19.6-107)	**265** (151-536)	**683** (326-1790)	574
12-19 years	99-00	**5.85** (3.80-9.00)	**4.80** (4.10-6.80)	**32.0** (18.0-45.0)	**130** (66.0-280)	**382** (150-950)	680
	01-02	*	**3.51** (<LOD-12.4)	**32.9** (21.6-56.3)	**194** (106-323)	**733** (389-1140)	820
20-59 years	99-00	**5.82** (4.05-8.37)	**6.60** (5.30-9.30)	**36.7** (24.0-45.0)	**130** (86.0-200)	**420** (240-590)	829
	01-02	*	**1.86** (<LOD-6.09)	**27.3** (16.9-42.0)	**186** (99.7-281)	**641** (256-1190)	1108
Gender							
Males	99-00	**6.84** (4.73-9.89)	**7.90** (5.70-11.0)	**37.0** (21.0-55.0)	**150** (88.0-280)	**440** (210-550)	970
	01-02	*	**2.41** (<LOD-8.94)	**31.9** (24.7-44.8)	**189** (108-316)	**663** (251-1210)	1178
Females	99-00	**5.30** (3.34-8.42)	**5.40** (3.80-7.90)	**37.8** (23.0-46.0)	**150** (82.0-260)	**490** (250-740)	1019
	01-02	*	**1.41** (<LOD-5.78)	**24.6** (14.6-40.8)	**194** (95.5-278)	**624** (256-1320)	1324
Race/ethnicity							
Mexican Americans	99-00	**14.3** (5.24-38.8)	**13.0** (7.90-26.0)	**110** (24.0-500)	**660** (210-1200)	**1100** (510-2800)	695
	01-02	*	**12.7** (5.02-27.3)	**97.7** (53.2-195)	**532** (300-1040)	**1550** (641-2980)	677
Non-Hispanic blacks	99-00	**15.8** (9.92-25.2)	**19.0** (11.0-29.0)	**110** (61.0-160)	**460** (290-620)	**770** (470-1200)	517
	01-02	*	**31.5** (24.2-40.2)	**242** (145-404)	**1210** (774-1680)	**2520** (1600-4500)	696
Non-Hispanic whites	99-00	**3.81** (2.38-6.09)	**4.40** (3.00-5.80)	**19.0** (13.0-24.0)	**75.0** (55.0-100)	**170** (120-320)	603
	01-02	*	**< LOD**	**15.2** (7.54-25.1)	**67.9** (40.8-103)	**194** (109-289)	930

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Levels of 2,5-dichlorophenol in a nonrandom subsample of NHANES III (1988-1994) participants were 5-15 times higher than the levels published in this *Report* (Hill et al., 1995). In the 1999 German Environmental Survey for people aged 16-69 years, median 2,5-dichlorophenol levels were similar to the median in the 2001-2002 subsample, but the 90th percentile was 17-fold lower than the NHANES 2001-2002 value, possibly indicating a wider range of exposures in the United States. Urinary levels of 2,5-dichlorophenol have been shown to correlate with environmental air-exposure levels in a convenience sample of Japanese citizens (Yoshida et al., 2002).

Worker exposure to p-dichlorobenzene has resulted in urinary 2,5-dichlorophenol levels that are much higher than levels in either of the two NHANES subsamples. At a mean air concentration of 25 parts per million (ppm), the corresponding urinary level of 2,5-dichlorophenol was 50 mg (50,000 µg)/gram of creatinine (Pagnotto and Walkley, 1965).

Comparing Adjusted Geometric Means

Geometric mean levels of urinary 2,5-dichlorphenol could not be calculated on the 2001-2002 subsample due to an insufficient detection rate. Geometric mean levels of 2,5-dichlorophenol for the demographic groups in the 1999-2000 subsample were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). The group aged 6-11 years had higher adjusted geometric mean levels of urinary 2,5-dichlorophenol than the group aged 12-19 years. Non-Hispanic whites had lower levels than either non-Hispanic blacks or Mexican Americans. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of 2,5-dichlorophenol in urine does not mean that the level will result in an adverse health effect. These data will help scientists plan

Table 315. 2,5-Dichlorophenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	**5.38** (3.76-7.68)	**5.60** (4.30-7.54)	**26.0** (19.6-34.5)	**125** (72.8-213)	**299** (238-426)	1989
	01-02	*	**1.56** (.333-5.00)	**23.9** (15.9-31.8)	**133** (97.0-238)	**527** (268-860)	2501
Age group							
6-11 years	99-00	**8.17** (4.79-13.9)	**11.3** (6.00-16.4)	**47.7** (29.4-78.0)	**247** (100-458)	**516** (267-762)	480
	01-02	*	**2.00** (.250-11.4)	**38.9** (20.6-100)	**248** (150-508)	**729** (361-1880)	574
12-19 years	99-00	**3.95** (2.50-6.24)	**4.11** (2.60-5.72)	**19.4** (12.1-30.0)	**64.7** (46.9-211)	**233** (112-424)	680
	01-02	*	**1.92** (.146-6.69)	**25.6** (14.6-35.7)	**132** (81.0-256)	**541** (280-631)	819
20-59 years	99-00	**5.36** (3.82-7.52)	**5.60** (4.30-7.55)	**24.5** (18.4-32.9)	**115** (69.0-179)	**280** (216-482)	829
	01-02	*	**1.38** (.365-4.47)	**20.8** (12.9-33.0)	**120** (82.5-238)	**514** (207-915)	1108
Gender							
Males	99-00	**5.25** (3.66-7.55)	**5.44** (4.11-7.34)	**24.1** (14.9-32.9)	**96.8** (65.9-208)	**289** (225-394)	970
	01-02	*	**1.99** (.280-5.84)	**24.0** (15.8-33.2)	**128** (88.5-207)	**500** (248-783)	1178
Females	99-00	**5.50** (3.52-8.61)	**6.15** (4.10-9.38)	**28.9** (20.1-43.2)	**136** (72.8-216)	**352** (228-509)	1019
	01-02	*	**1.10** (.333-4.45)	**23.9** (14.7-34.5)	**136** (88.8-291)	**589** (262-1050)	1323
Race/ethnicity							
Mexican Americans	99-00	**12.9** (4.92-33.7)	**12.7** (6.36-30.2)	**72.7** (26.6-337)	**515** (134-1270)	**1170** (516-2810)	695
	01-02	*	**9.92** (4.16-21.3)	**82.2** (40.1-150)	**475** (225-1190)	**1500** (715-2170)	677
Non-Hispanic blacks	99-00	**10.7** (6.92-16.7)	**13.5** (7.65-22.5)	**57.8** (38.5-92.1)	**241** (138-311)	**433** (245-746)	517
	01-02	*	**20.6** (13.8-28.7)	**137** (84.2-248)	**829** (563-1210)	**2030** (1100-2650)	695
Non-Hispanic whites	99-00	**3.60** (2.27-5.71)	**3.81** (2.64-5.22)	**14.4** (11.5-18.9)	**57.4** (44.1-97.4)	**202** (97.4-299)	603
	01-02	*	**< LOD**	**11.7** (5.84-20.7)	**50.3** (35.0-88.5)	**131** (101-248)	930

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

and conduct research about the relation between exposure to *p*-dichlorobenzene and health effects. These data also provide physicians with a reference range so that they can determine whether or not other people have been exposed to higher levels of *p*-dichlorobenzene than those levels found in the general population.

Figure 38. 2,5-Dichlorophenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

a Estimate is less than the limit of detection (LOD). See Appendix A for LODs.

Results by Chemical Group

Carbamate Insecticides

Carbamate Insecticides

General Information

N-methyl carbamate insecticides are widely used as insecticides in the United States and throughout the world. The estimated annual worldwide use for all carbamates ranged from 20,000 to 35,000 tons (International Programme on Chemical Safety, 1986). In the United States, uses of carbamate insecticides include agricultural crops, residential lawns and gardens, nurseries, and golf courses. Carbamate insecticides do not persist long in the environment, so they have a low potential for bioaccumulation. Some thiocarbamates and dithiocarbamates are used as herbicides and fungicides, and were not measured in this *Report*.

Exposure of the general population to these insecticides occurs primarily from ingestion of food products or from residential use. Other potential exposures to these chemicals occur during aerial spraying of these chemicals and during the manufacture, formulation, or application of these chemicals. Exposure may also occur among agricultural workers re-entering areas that have recently been treated with these chemicals. Carbamates can be absorbed through the skin, via inhalation, or by ingestion. Criteria on allowable levels of these chemicals in food, the environment, and the workplace have been developed by the U.S. FDA, U.S. EPA, and OSHA, respectively.

After acute overexposure, carbamate insecticides inhibit acetylcholinesterase enzymes. This inhibition leads to an increase of acetylcholine in the nervous system, resulting in symptoms including nausea, vomiting, cholinergic signs, weakness, paralysis, and seizures. The mechanism of toxicity of carbamate insecticides is similar to that of the organophosphate pesticides. Generally, carbamate insecticides inhibit acetylcholinesterase activity for a shorter amount of time than do organophosphate pesticides. Carbamate insecticides are rapidly eliminated from the body.

This *Report* provides measurements for the urinary metabolites derived from five carbamate insecticides. Table 316 shows the various metabolites measured in this *Report* and their parent carbamate pesticides. For example, propoxur is metabolized to 2-isopropoxyphenol. The presence of these chemicals generally reflects recent exposure to carbamate insecticides. In addition to reflecting exposure to the parent insecticide, the level of the metabolite in a person's urine may reflect exposure to the metabolite itself if it was present in their food or environment.

Table 316. Carbamate insecticides and their metabolites

Carbamate insecticide (CAS number)	Primary urinary metabolite (CAS number)
Propoxur (114-26-1)	2-Isopropoxyphenol (4812-20-8)
Carbofuran (1563-66-2)	Carbofuranphenol (1563-38-8)
Benfuracarb (82560-54-1)	Carbofuranphenol (1563-38-8)
Carbosulfan (55285-14-8)	Carbofuranphenol (1563-38-8)
Furathiocarb (65907-30-4)	Carbofuranphenol (1563-38-8)

2-Isopropoxyphenol

CAS No. 4812-20-8

Metabolite of Propoxur, CAS No. 114-26-1

General Information

The chemical 2-isopropoxyphenol is a metabolite of propoxur. Propoxur is a carbamate insecticide used in and around residences and commercial food-handling establishments. Propoxur may remain in the environment for weeks to months, longer than most carbamate insecticides.

Propoxur is effectively absorbed through the skin and from inhalation and ingestion pathways of exposure. Propoxur does not accumulate in blood or tissues in people and is eliminated rapidly from the body. The detection of 2-isopropoxyphenol in people's urine may reflect exposure to propoxur as well as to the metabolite itself if it was present in their food or environment.

Results of experimental studies in animals have shown that propoxur is of moderate acute toxicity. In contrast to propoxur, 2-isopropoxyphenol is not an inhibitor of acetylcholinesterase enzymes. The carcinogenic potential of propoxur has not been evaluated by either IARC or NTP.

Interpreting Levels of Urinary 2-Isopropoxyphenol Reported in the Tables

Urinary 2-isopropoxyphenol levels were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, most 2-isopropoxyphenol levels in urine were below the limit of

Table 317. 2-Isopropoxyphenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1917
	01-02	*	< LOD	< LOD	< LOD	< LOD	2503
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	456
	01-02	*	< LOD	< LOD	< LOD	< LOD	574
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	655
	01-02	*	< LOD	< LOD	< LOD	< LOD	820
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	806
	01-02	*	< LOD	< LOD	< LOD	< LOD	1109
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	936
	01-02	*	< LOD	< LOD	< LOD	< LOD	1178
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	981
	01-02	*	< LOD	< LOD	< LOD	< LOD	1325
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	664
	01-02	*	< LOD	< LOD	< LOD	< LOD	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	500
	01-02	*	< LOD	< LOD	< LOD	< LOD	696
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	585
	01-02	*	< LOD	< LOD	< LOD	< LOD	931

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

detection, which is lower than the limit of detection used in the previous NHANES 1999-2000 subsample. In a nonrandom subsample from NHANES III (1988-1994), the 95th percentile level of 2-isopropoxyphenol was 1.7 µg/L (Hill et al., 1995). Higher urinary levels of 2-isopropoxyphenol have been measured in pesticide applicators, ranging 45-306 µg/gram creatinine (Hardt and Angerer, 1999).

Finding a measurable amount of 2-isopropoxyphenol in urine does not mean that the level of the 2-isopropoxyphenol will result in an adverse health effect. These data will help scientists plan and conduct research about the relation of exposure to propoxur and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of propoxur than levels found in the general population.

Table 318. 2-Isopropoxyphenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1917
	01-02	*	< LOD	< LOD	< LOD	< LOD	2502
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	456
	01-02	*	< LOD	< LOD	< LOD	< LOD	574
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	655
	01-02	*	< LOD	< LOD	< LOD	< LOD	819
20-59 years	99-00	*	< LOD	< LOD	< LOD	< LOD	806
	01-02	*	< LOD	< LOD	< LOD	< LOD	1109
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	936
	01-02	*	< LOD	< LOD	< LOD	< LOD	1178
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	981
	01-02	*	< LOD	< LOD	< LOD	< LOD	1324
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	664
	01-02	*	< LOD	< LOD	< LOD	< LOD	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	500
	01-02	*	< LOD	< LOD	< LOD	< LOD	695
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	585
	01-02	*	< LOD	< LOD	< LOD	< LOD	931

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Carbofuranphenol

CAS No. 1563-38-8

Metabolite of Benfuracarb, Carbofuran, Furathiocarb, and Carbosulfan

General Information

Carbofuranphenol is a metabolite of the carbamate insecticides benfuracarb, carbofuran, furathiocarb, and carbosulfan. Only carbofuran is registered for use in the United States. Carbofuran is a broad-spectrum carbamate insecticide that has limited applications for use on certain agricultural commodities in the United States.

The detection of carbofuranphenol in people's urine may reflect exposure to carbofuran as well as to the metabolite itself if it was present in their food or environment. For example, benfuracarb undergoes metabolism in the environment to form carbofuran.

Interpreting Levels of Urinary Carbofuranphenol Reported in the Tables

Urinary carbofuranphenol levels were measured in a subsample of NHANES participants aged 6-59 years. Participants were selected within the specified age range to be a representative sample of the U.S. population.

In the NHANES 2001-2002 subsample, most urine levels of carbofuranphenol were below the limit of detection. In the NHANES 1999-2000 subsample, levels slightly above the limit of detection allowed characterization of the 95th percentile. In a nonrandom subsample from NHANES III (1988-1994), the 99th percentile level of carbofuranphenol was 2.1 µg/L (Hill et al., 1995). In a previous study of U.S. farmers and their families,

Table 319. Carbofuranphenol

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	.740 (<LOD-1.30)	1994
	01-02	*	< LOD	< LOD	< LOD	< LOD	2530
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	.430 (<LOD-2.20)	482
	01-02	*	< LOD	< LOD	< LOD	< LOD	578
12-19 years	99-00	*	< LOD	< LOD	< LOD	.570 (<LOD-1.20)	681
	01-02	*	< LOD	< LOD	< LOD	< LOD	827
20-59 years	99-00	*	< LOD	< LOD	< LOD	.840 (<LOD-1.50)	831
	01-02	*	< LOD	< LOD	< LOD	< LOD	1125
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	.740 (<LOD-1.30)	973
	01-02	*	< LOD	< LOD	< LOD	< LOD	1190
Females	99-00	*	< LOD	< LOD	< LOD	.840 (<LOD-1.50)	1021
	01-02	*	< LOD	< LOD	< LOD	< LOD	1340
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	.570 (<LOD-2.00)	1.90 (<LOD-4.90)	696
	01-02	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	.430 (<LOD-1.60)	521
	01-02	*	< LOD	< LOD	< LOD	< LOD	696
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	.740 (<LOD-1.30)	603
	01-02	*	< LOD	< LOD	< LOD	< LOD	953

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

carbofuranphenol was detected in 6.7% of urine samples (Shealy et al., 1997). The 95th percentile value in that study was 0.73 µg/L.

Finding a measurable amount of carbofuranphenol in urine does not mean that the level of carbofuranphenol will result in an adverse health effect. These data will help scientists plan and conduct research about the relation between exposure to these carbamate pesticides and health effects. These data also provide physicians with a reference range so that they can determine whether other people have been exposed to higher levels of carbofuran than those levels found in the general population.

Table 320. Carbofuranphenol (creatinine corrected)

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6-59 years, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
Total, age 6 and older	99-00	*	< LOD	< LOD	< LOD	.777 (.636-1.00)	1994
	01-02	*	< LOD	< LOD	< LOD	< LOD	2529
Age group							
6-11 years	99-00	*	< LOD	< LOD	< LOD	.988 (.432-2.80)	482
	01-02	*	< LOD	< LOD	< LOD	< LOD	578
12-19 years	99-00	*	< LOD	< LOD	< LOD	.472 (.311-.853)	681
	01-02	*	< LOD	< LOD	< LOD	< LOD	826
20-59 years	99-00	*	< LOD	< LOD	< LOD	.824 (.638-1.06)	831
	01-02	*	< LOD	< LOD	< LOD	< LOD	1125
Gender							
Males	99-00	*	< LOD	< LOD	< LOD	.655 (.452-1.08)	973
	01-02	*	< LOD	< LOD	< LOD	< LOD	1190
Females	99-00	*	< LOD	< LOD	< LOD	.875 (.667-1.13)	1021
	01-02	*	< LOD	< LOD	< LOD	< LOD	1339
Race/ethnicity							
Mexican Americans	99-00	*	< LOD	< LOD	.778 (.350-1.94)	1.83 (.560-4.16)	696
	01-02	*	< LOD	< LOD	< LOD	< LOD	680
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	.645 (.318-1.08)	521
	01-02	*	< LOD	< LOD	< LOD	< LOD	695
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	.717 (.636-.881)	603
	01-02	*	< LOD	< LOD	< LOD	< LOD	953

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Third National Report on Human Exposure to Environmental Chemicals

References

Aberg B, Ekman L, Falk R, Greitz U, Persson G, Snihs JO. Metabolism of methyl mercury (^{203}Hg) compounds in man. Arch Environ Health 1969;19:478-84.

Adgate JL, Barr DB, Clayton CA, Eberly LE, Freeman, NCG, Lioy, PJ, et al. Measurement of children's exposure to pesticides: analysis of urinary metabolite levels in a probability-based sample. Environ Health Perspect 2001;109(6):583-90.

Adibi JJ, Perera FP, Jedrychowski W, Camann DE, Barr D, Jacek R, et al. Prenatal exposures to phthalates among women in New York City and Krakow, Poland. Environ Health Perspect 2003;111(14):1719-22.

Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, Hamalainen EK, et al. Soybean phytoestrogens intake and cancer risk. J Nutr 1995*a*;125(3 Suppl):757S-70s.

Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G, et al. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens in urine of women on various habitual diets. J Steroid Biochem 1986;25:791-7.

Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, et al. Urinary excretion of lignans and isoflavone phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991;54:1093-1100.

Adlercreutz H, van der Wildt J, Kinzel J, Attalla H, Wahala K, Makela T, et al. Lignan and isoflavonoid conjugates in human urine. J Steroid Biochem Mol Biol 1995*b*;52(1) 97-103.

Adonis M, Martinez V, Riquelme R, Ancic P, Gonzalez G, Tapia R, et al. Susceptibility and exposure biomarkers in people exposed to PAHs from diesel exhaust. Toxicol Lett 2003;144(1):3-15.

Agency for Toxic Substances and Disease Registry (ATSDR) . Toxicological profile for Cadmium [online]. 1999. Available from URL: http://www.atsdr.cdc.gov/toxprofiles/tp5.html, 4/7/05.

Agency for Toxic Substances and Disease Registry (ATSDR) . Toxicological profile for Colbalt [online]. 2004. Available from URL: http://www.atsdr.cdc.gov/toxprofiles/tp33.html, 4/7/05.

Agency for Toxic Substances and Disease Registry (ATSDR). 2002 Sept. Toxicological profile for di(2-ethylhexyl) phthalate [online]. 2002. Available from URL: http://www.atsdr.cdc.gov/toxprofiles/tp9.html, 03/09/05.

Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for diethyl phthalate [online]. 1995. Available from URL: http://www.atsdr.cdc.gov/toxprofiles/tp73.html, 03/17/05.

Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for di-n-butyl phthalate [online]. 2001. Available from URL: http://www.atsdr.cdc.gov/toxprofiles/tp135.html, 03/17/05

Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for di-n-octyl phthalate [online]. 1997. Available from URL: http://www.atsdr.cdc.gov/toxprofiles/tp95.html, 03/17/05.

Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for pyrethrins and pyrethroids [online]. 2003. Available from URL: http://www.atsdr.cdc.gov/toxprofiles/tp155.html, 03/17/05.

Ahlborg UG, Lindgren JE, Mercier M. Metabolism of pentachlorophenol. Arch Toxicol 1974;32(4):271-81.

Akkina JE, Reif JS, Keefe TJ, Bachand AM. Age at natural menopause and exposure to organochlorine pesticides in Hispanic women. J Toxicol Environ Health 2004;67:1407-22.

Albertazzi P, Pansini F, Bottazi M, Bonaccorsi G, De Aloysio D, Morton MS. Dietary soy supplementation and phytoestrogen levels. Obstet Gynecol 1999;94(2):229-31.

Albro PW, Moore B. Identification of the metabolites of simple phthalate diesters in rat urine. J Chromatogr. 1974;94:209-18.

Albro PW, Corbett JT, Schroeder JL, Jordan S, Matthews HB. Pharmacokinetics, interactions with macromolecules and species differences in metabolism of DEHP. Environ Health Perspect 1982;45:19-25.

Albro PW and Lavenhar SR. Metabolism of di(2-ethylhexyl) phthalate. Drug Metab Rev 1989;21:13-34.

Alexander BH, Checkoway H, van Netten C, Muller CH, Ewers TG, Kaufman JD, et al. Semen quality of men employed at a lead smelter. Occup Environ Med 1996;53:411-6.

Alexander CS. Cobalt-beer cardiomyopathy. A clinical and pathological study of twenty-eight cases. Am J Med 1972;53:395-417.

Alexandersson R. Blood and urinary concentrations as estimators of cobalt exposure. Arch Environ Health 1988;43(4):299-303.

Alexandrie AK, Warholm M, Carstensen U, Axmon A, Hagmar L, Levin JO, et al. CYP1A1 and GSTM1 polymorphisms affect urinary 1-hydroxypyrene levels after PAH exposure. Carcinogenesis 2000;21(4):669-76.

References

Alfven T, Jarup L, Elinder CG. Cadmium and lead in blood in relation to low bone mineral density and tubular proteinuria. Environ Health Perspect 2002;110:699-702.

Allain P, Berre S, Premel-Cabic A, Mauras Y, Cledes A, Cournot A. Urinary elimination of molybdenum by healthy subjects as determined by inductively coupled plasma mass spectrometry. Magnesium and Trace Elements 1991-1992;10(1):47-50.

Ambrose AM, Yost DH. Pharmacologic and toxicologic studies of N,N-diethyltoluamide. II. N,N-Diethyl-o-toluamide and N,N-diethyl-p-toluamide. Toxicol Appl Pharmacol 1965; 7(6):772-80.

American Conference of Government Industrial Hygienists (ACGIH). Documentation of biological exposure indices. 7th edition. Cincinnati (OH): ACGIH Worldwide; 2001.

Anderson HA, Falk C, Hanrahan L, Olson J, Burse VW, Needham LL, et al. Profiles of Great Lakes critical pollutants: a sentinel analysis of human blood and urine. The Great Lakes Consortium. Environ Health Perspect 1998;106(5):279-89.

Anderson WA, Castle L, Scotter MJ, Massey RC, Springall C. A biomarker approach to measuring human dietary exposure to certain phthalate diesters. Food Addit Contam 2001;18(12):1068-74.

Angerer J, Heinzow B, Schaller K H, Weltle D, Lehnert G. Determination of environmentally caused chlorophenol levels in urine of the general population. Fresenius' Journal of Analytical Chemistry 1992;342(4-5):433-8.

Angerer J, Maass R, Heinrich R. Occupational exposure to hexachlorocyclohexane. VI. Metabolism of gamma-hexachlorocyclohexane in man. Int Arch Occup Environ Health 1983;52(1):59-67.

Angerer J, Ritter A. Determination of metabolites of pyrethroids in human urine using solid-phase extraction and gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1997;695(2):217-26.

Apostoli P, Baj A, Bavazzano P, Ganzi A, Neri A, Ronchi L, et al. Blood lead reference values: the results of an Italian polycentric study. Sci Total Environ 2002*a*;287:1-11.

Apostoli P, Cortesi I, Mangili A, Elia G, Drago I, Gagliardi T, et al. Assessment of reference values for mercury in urine: the results of an Italian polycentric study. Sci Total Environ 2002*b*;289:13-24.

Apostoli P, Schaller KH. Urinary beryllium--a suitable tool for assessing occupational and environmental beryllium exposure. Int Arch Occup Environ Health 2001;74:162-6.

Aprea C, Betta A, Catenacci G, Lotti A, Magnaghi S, Barisano A, et al. Reference values of urinary 3,5,6-trichloro-2-pyridinol in the Italian population--validation of analytical method and preliminary results (multicentric study). J AOAC Int 1999;82:305-12.

Aprea C, Sciarra G, Orsi D, Boccalon P, Sartorelli P, Sartorelli E. Urinary excretion of alkylphosphates in the general population (Italy). Sci Total Environ 1996;177:37-41.

Aprea C, Strambi M, Novelli MT, Lunghini L, Bozzi N. Biologic monitoring of exposure to organophosphorus pesticides in 195 Italian children. Environ Health Perspect 2000;108:521-5.

Arai Y, Uehara M, Sato Y, Kimura M, Eboshida A, Adlercreutz H, et al. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 2000;10:127-35.

Araki S, Sato H, Yokoyama K, Murata K. Subclinical neurophysiological effects of lead: a review on peripheral, central, and autonomic nervous system effects in lead workers. Am J Ind Med 2000;37(2):193-204.

Arbuckle TE, Burnett R, Cole D, Teschke K, Dosemeci M, Bencej C, et al. Predictors of herbicide exposure in farm applicators. Int Arch Occup Environ Health 2002;75(6):406-14.

Arisawa K, Matsumura T, Tohyama C, Saito H, Satoh H, Nagai M, et al. Fish intake, plasma omega-3 polyunsaturated fatty acids, and polychlorinated dibenzo-*p*-dioxins/ polychlorinated dibenzo-furans and co-planar polychlorinated biphenyls in the blood of the Japanese population. Int Arch Occup Environ Health 2003;76(3):205-15.

Armitage AK, Dollery CT, George CF, Houseman TH, Lewis PJ, Turner DM. Absorption and metabolism of nicotine from cigarettes. BMJ 1975;4:313-6.

Armstrong B, Hutchinson E, Unwin J, Fletcher T. Lung cancer risk after exposure to polycyclic aromatic hydrocarbons: a review and meta-analysis. Environ Health Perspect 2004;112(9):970-8.

Aylward LL, Hays SM. Temporal trends in human TCDD body burden: decreases over three decades and implications for exposure levels. J Expo Anal Environ Epidemiol 2002;12(5):319-28.

Baccarelli A, Mocarelli P, Patterson DG Jr, Bonzini M, Pesatori AC, Caporaso N, et al. Immunologic effects of dioxin: new results from Seveso and comparison with other studies. Environ Health Perspect 2002;110:1169-73.

Bachthaler M, Lenhart M, Paetzel C, Feuerbach S, Link J, Manke C. Corrosion of tungsten coils after peripheral vascular embolization therapy: influence on outcome and tungsten load. Catheterization and Cardiovascular Interventions 2004;62:380-84.

Bailly R, Lauwerys R, Buchet JP, Mahieu P, Konings J. Experimental and human studies on antimony metabolism: their relevance for the biological monitoring of workers exposed to inorganic antimony. British Journal of Industrial Medicine 1991;48:93-7.

Baker DB, Loo S, Barker J. Evaluation of human exposure to the heptachlor epoxide contamination of milk in Hawaii. Hawaii Med J 1991;50(3):108-12,118.

Baker SE, Barr DB, Driskell WJ, Beeson MD, Needham LL. Quantification of selected pesticide metabolites in human urine using isotope dilution high-performance liquid chromatography/tandem mass spectrometry. J Expo Anal Environ Epidemiol 2000;10:789-98.

Baker SE, Olsson AO, Barr DB. Isotope dilution high-performance liquid chromatography-tandem mass spectrometry method for quantifying urinary metabolites of synthetic pyrethroid insecticides. Arch Environ Contam Toxicol 2004;46:281-8.

Balluz L, Philen R, Ortega L, Rosales C, Brock J, Barr D, et al. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am J Epidemiol 2001;154(11):1029-36.

Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005;113(2):192-200.

Barr DB, Silva MJ, Kato K, Reidy JA, Malek NA, Hurtz D, et al. Assessing human exposure to phthalates using monoesters and their oxidized metabolites as biomarkers. Environ Health Perspect 2003;111(9):1148-51.

Barr DB, Turner WE, DiPietro E, McClure PC, Baker SE, Barr JR, et al. Measurement of p-nitrophenol in the urine of residents whose homes were contaminated with methyl parathion. Environ Health Perspect Suppl 2002;110(6):1085-91.

Barregard L, Sallsten G, Conradi N. Tissue levels of mercury determined in a deceased worker after occupational exposure. Int Arch Occup Environ Health 1999;72:169-73.

Barregard L, Sallsten G, Schutz A, Attewell R, Skerfving S, Jarvholm B. Kinetics of mercury in blood and urine after brief occupational exposure. Arch Environ Health 1992;7(3):176-84.

Bartels MJ, Kastl PE. Analysis of 3,5,6-trichloropyridinol in human urine using negative-ion chemical ionization gas chromatography-mass spectrometry. J Chromatogr 1992;575(1):69-74.

Bates MN, Buckland SJ, Garrett N, Ellis H, Needham LL, Patterson DG Jr, et al. Persistent organochlorines in the serum of the non-occupationally exposed New Zealand population. Chemosphere 2004b;54:1431-43.

Bates MN, Fawcett J, Garrett N, Cutress T, Kjellstrom T. Health effects of dental amalgam exposure: a retrospective cohort study. Int J Epidemiol 2004a;33:1-9.

Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138(11):891-7.

Beck H, Dross A, Mathar W. PCDD and PCDF exposure and levels in humans in Germany. Environ Health Perspect 1994;102 Suppl 1:173-85.

Becker K, Kaus S, Krause C, Lepom P, Schulz C, Seiwert M, et al. German Environmental Survey 1998 (GerES III): environmental pollutants in blood of the German population. International Journal of Hygiene and Environmental Health 2002;205:297-308.

Becker K, Seiwert M, Angerer J, Heger W, Koch HM, Nagorka R, et al. DEHP metabolites in urine of children and DEHP in house dust. International Journal of Hygiene and Environmental Health 2004;207(5):409-17.

Becker K, Schulz C, Kaus S, Seiwert M, Seifert B. German environmental survey 1998 (GerES III): environmental pollutants in the urine of the German population. International Journal of Hygiene and Environmental Health 2003; 206:15-24.

Bell JW, Veltri JC, Page BC. Human exposures to N,N-diethyl-m-toluamide insect repellents reported to the American Association of Poison Control Centers, 1993-1997. International Journal of Toxicology 2002;2:341-52.

Benes B, Spevackova V, Smid J, Cejchanova M, Cerna M, Subrt P, et al. The concentration levels of Cd, Pb, Hg, Cu, Zn, and Se in blood of the population in the Czech Republic. Cent Eur J Public Health 2000;8(2):117-9.

Benes B, Spevackova V, Smid J, Cejchanova M, Kaplanova E, Cerna M, et al. Determination of normal concentrations of Cd, Pb, Hg, Cu, Zn, and Se in urine of the population of the Czech Republic. Cent Eur J Public Health 2002;10:3-5.

Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol Rev 1996;18:188-204.

Benowitz NL, Jacob P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994;56:483-93.

Berman JD. Chemotherapy for leishmaniasis: Biochemical mechanisms, clinical efficacy, and future strategies. Reviews in Infectious Diseases 1988;10(3):560-86.

Bertram HP, Kemper FH, Muller C. Hexachlorobenzene content in human whole blood and adipose tissue: experiences in environmental specimen banking. IARC Sci Publ 1986;77:173-82.

Bhatnagar VK, Kashyap R, Zaidi SS, Kulkarni PK, Saiyed HN. Levels of DDT, HCH, and HCB residues in human blood in Ahmedabad, India. Bull Environ Contam Toxicol 2004;72:261-5.

Bhattacharyya MH, Breitenstein BD, Metivier H, Muggenburg, BA, Stradling GN, Volf V. Guidebook for the treatment of accidental internal radionuclide contamination of workers. In: Gerber GB, Thomas RG, eds. Radiation protection dosimetry. Vol. 41 (1). Kent (England): Nuclear Technology Publishing; 1992. p. 1-49.

Bidstrup PL, Bonnell JA, Harvey DG, Locket S. Chronic mercury poisoning in men repairing direct-current meters. Lancet 1951;2:856-61.

Bittner AC Jr, Echeverria D, Woods JS, Aposhian HV, Naleway C, Martin MD, et al. Behavioral effects of low-level exposure to Hg^0 among dental professionals: a cross-study evaluation of psychomotor effects. Neurotoxicol Teratol 1998;20(4):429-39.

Bjornberg KA, Vahter M, Petersson-Grawe K, Glynn A, Cnattingius S, Darnerud PO, et al. Methyl mercury and inorganic mercury in Swedish pregnant women and in cord blood: influence of fish consumption. Environ Health Perspect 2003;111(4):637-41.

Bloom MS, Vena JE, Swanson MK, Moysich KB, Olson JR. Profiles of ortho-polychlorinated biphenyl congeners, dichlorodiphenyldichloroethylene, hexachlorobenzene, and mirex among male Lake Ontario sportfish consumers: the New York State Angler Cohort Study. Environ Res 2005;97:178-94.

Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL, Sampson EJ, et al. Levels of seven urinary phthalate metabolites in a human reference population. Environ Health Perspect 2000;108(10)979-82.

Boffetta P, Hjourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997;8(3):444-72.

Borja-Aburto VH, Hertz-Picciotto I, Rojas LM, Farias P, Rios C, Blanco J. Blood lead levels measured prospectively and risk of spontaneous abortion. Am J Epidemiol 1999;150(6):590-7.

Bostrom CE, Gerde P, Hanberg A, Jernstrom B, Johansson C, Kyrklund T, et al. Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air. Environ Health Perspect 2002;110Suppl 3:451-88.

Botella B, Crespo J, Rivas A, Cerrillo I, Olea-Serrano MF, Olea N. Exposure of women to organochlorine pesticides in Southern Spain. Environ Res 2004;96:34-40.

Bradberry, SM, Watt BE, Proudfoot AT, Vale JA. Mechanisms of toxicity, clinical features, and management of acute chlorophenoxy herbicide poisoning: a review. J Toxicol Clin Toxicol 2000;38:111-22.

Braun WH, Blau GE, Chenoweth MB. The metabolism/pharmacokinetics of pentachlorophenol in man and a comparison with the rat and monkey. Developments in Toxicology and Environmental Science 1979;4:289-96.

Brenniman GR, Levy, PS. Epidemiological study of barium in Illinois drinking water supplies. In: Calabrese EJ, ed. Advances in modern toxicology. Princeton (NJ): Princeton Scientific Publications; 1984. p. 231-49.

Briegner H, Semisch CW, Stasney J, Piatnek DA. Industrial antimony poisoning. Industrial Medicine and Surgery (Dec.)1954;521-3.

Brockhaus A, Dolger R, Ewers U, Kramer U, Soddemann H, Wiegand H. Intake and health effects of thallium among a population living in the vicinity of a cement plant emitting thallium-containing dust. Int Arch Occup Environ Health 1981;48(4):375-89.

Brokopp CD, Wyatt Jl, Gabica J. Dialkyl phosphates in urine samples from pesticide formulators exposed to disulfoton and phorate. Bull Environ Contam Toxicol 1981;26(4):524-9.

Bucher JR, Hailey JR, Roycroft JR, Haseman JK, Sills RC, Grumbein SL, et al. Inhalation toxicity and carcinogenicity studies of cobalt sulfate. Toxicol Sci 1999;49:56-67.

Budavari S, ed. The Merck index. 11th ed. Rahway (NJ): Merck & Co., Inc; 1989. p. 308-9.

Burns JE. Pesticides in people: organochlorine pesticide and polychlorinated biphenyl residues in biopsied human adipose tissue—Texas 1969-1972. Pesticides Monitoring Journal 1974;7:122-6.

Byrne AR, Benedik L. Uranium content of blood, urine and hair of exposed and non-exposed persons determined by radiochemical neutron activation analysis, with emphasis on quality control. Sci Total Environ 1991;107:143-57.

Byrne SL, Shurdut BA, Saunders DG. Potential chlorpyrifos exposure to residents following standard crack and crevice treatment. Environ Health Perspect 1998;106(11):725-31.

Cabral J, Hall R, Rossi L, Bronczyk SA, Shubik P. Effects of long-term intake of DDT on rats. Tumori 1982;68:11-7.

Calafat, AM, Needham LL, Silva MJ, Lambert G. Exposure to di-(2-ethylhexyl) phthalate among premature neonates in a neonatal intensive care unit. Pediatrics 2004;113:e429-e434.

Calvert GM, Wille KK, Sweeney MH, Fingerhut MA, Halperin WE. Evaluation of serum lipid concentrations among U.S. workers exposed to 2,3,7,8-tetrachloro-dibenzo-p-dioxin. Arch Environ Health 1996;51(2):100-7.

Canfield RL, Henderson CR, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 µg/dL. N Engl J Med 2003;348:1517-26.

Caraballo R, Giovino G, Pechacek TF, Mowery PD, Richter PA, Strauss WJ, et al. Racial/ethnic differences in serum cotinine levels among adult U.S. cigarette smokers: the Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 1998;280:135-40.

Cardenas A, Roels H, Bernard AM, Barbon R, Buchet JP, Lauwerys RR, et al. Markers of early renal changes induced by industrial pollutants. I. Application to workers exposed to mercury vapour. British Journal of Industrial Medicine 1993;50:17-27.

Cassidy A, Bingham S, Setchell KDR. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 1994;60(3):333-40.

Center for the Evaluation of Risks to Human Reproduction. National Toxicology Program. National Institute of Environmental Health Sciences. [online]. 2000. Available from URL: http://cerhr.niehs.nih.gov/news/phthalates/monographs.html, 4/7/05.

Centers for Disease Control. Preventing lead poisoning in young children: a statement by the Centers for Disease Control. Atlanta (GA): CDC; 1991.

Centers for Disease Control and Prevention. Surveillance for elevated blood lead levels among children – United States, 1997-2001. MMWR CDC Surveill Summ September 12, 2003a;52(No. SS-10):1-21.

Centers for Disease Control and Prevention. National Center for Environmental Health. Cancer Clusters. Churchill County (Fallon). Nevada Exposure Asssessment. [online] 2003b. http://www.cdc.gov/nceh/clusters/Fallon/study.htm, 4/17/05.

Chapman LJ, Sauter SL, Henning RA, Dodson VN, Reddan WG, Matthews CG. Differences in frequency of finger tremor in otherwise asymptomatic mercury workers. British Journal of Industrial Medicine 1990;47:838-43.

Charles MJ, Schell MJ, Willman E, Gross HB, Lin Y, Sonnenberg S, et al. Organochlorines and 8-hydroxy-2-deoxyguanosine in cancerous and noncancerous breast tissue: do the data support the hypothesis that oxidative DNA damage caused by organochlorines affects breast cancer? Arch Environ Contam Toxicol 2001;41:386-95.

Charlier C, Pitance F, Piomteux G. PCB residues in a breast cancer patient population. Bull Environ Contam Toxicol 2003;71:887-91.

Chen Z, Zheng W, Custer LJ, Dai Q, Shu X, Jin F, et al. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer 1999;33:82-7.

Choudhury H, Harvey T, Thayer W, Lockwood T, Stiteler WM, Goodrum PE, et al. Urinary cadmium elimination as a biomarker of exposure for evaluating a cadmium dietary exposure – biokinetics model. J Toxicol Environ Health 2001;63(Pt A):321-50.

Christensen JM, Poulsen OM. A 1982-1992 surveillance programme on Danish pottery painters. Biological levels and health effects following exposure to soluble or insoluble cobalt compounds in cobalt blue dyes. Sci Total Environ 1994;50(1-3):95-104.

Chuang JC, Callahan PJ, Lyu CW, Wilson NK. Polycyclic aromatic hydrocarbon exposures of children in low-income families. J Expo Anal Environ Epidemiol 1999;9(2):85-98.

Chuang CY, Lee CC, Chang YK, Sung FC. Oxidative DNA damage estimated by urinary 8-hydroxydeoxyguanosine: influence of taxi driving, smoking and areca chewing. Chemosphere 2003;52(7):1163-71.

Cianciola ME, Echeverria D, Martin MD, Aposian HV, Woods JS. Epidemiologic assessment of measures used to indicate low-level exposure to mercury vapor (Hg^o). J Toxicol Environ Health 1997; 52:19-33.

Clement J, Okey A. Reproduction in female rats born to DDT-treated parents. Bull Environ Contam Toxicol 1974;12(3):373-7.

Coldham NG, Dave M, Silvapathasundaram S, McDonnell DP, Connor C, Sauer MJ. Evaluation of a recombinant yeast cell estrogen screening assay. Environ Health Perspect 1997; 105:734-42.

Cordasco EM, Stone FD. Pulmonary edema of environmental origin. Chest 1973;64(2):182-5.

Cornwell T, Cohick W, Raskin I. Dietary phytoestrogens and health. Phytochemistry 2004;65(8):995-1016.

Cotter LH. Paradichlorobenzene poisoning from insecticides. New York State Journal of Medicine 1953;53:1690-2.

Cugell DW, Morgan WKC, Perkins DG, Rubin A. The respiratory effects of cobalt. Arch Intern Med 1990;150:177-83.

Curl CL, Fenske RA, Kissel JC, Shirai JH, Moate TF, Griffith W, et al. Evaluation of take-home organophosphorus pesticide exposure among agricultural workers and their children. Environ Health Perspect 2002;110(12):787-92.

Czerczak S, Gromiec JP. Nickel, ruthenium, rhodium, palladium, osmium, and platinum. In: Bingham E, Cohrssen B, Powell CH, eds. Patty's toxicology. 5th ed. New York: John Wiley & Sons; 2000. p. 289-380.

Dang HS, Pullat VR, Pillai KC. Determining the normal concentration of uranium in urine and application of the data to its biokinetics. Health Phys 1992;62:562-6.

Das YT, Taskar PK, Brown HD, Chattopadhyay SK. Exposure of professional pest control operator to dichlorvos (DDVP) and residue on house structures. Toxicol Lett 1983;17(1-2):95-9.

Davies JE, Peterson JC. Surveillance of occupational, accidental, and incidental exposure to organophosphate pesticides using urine alkyl phosphate and phenolic metabolite measurements. Ann NY Acad Sci 1997;837:257-68.

Davies JE, Freed VH, Enos HF, Duncan RC, Barquet A, Morgade C, et al. Reduction of pesticide exposure with protective clothing for applicators and mixers. J Occup Med 1982;24(6):464-68.

Davison AG, Fayers PM, Taylor AJ, Venables KM, Darbyshire J, Pickering CA, et al. Cadmium fume inhalation and emphysema. Lancet 1988 Mar 26;1(8587):663-7.

De Boeck M, Kirsch-Volders M, Lison D. Cobalt and antimony: genotoxicity and carcinogenicity. Mutation Res 2003;533:135-52.

Dejmek J, Solansky I, Benes I, Lenicek J, Sram RJ. The impact of polycyclic aromatic hydrocarbons and fine particles on pregnancy outcome. Environ Health Perspect 2000;108(12):1159-64.

den Tonkelaar I, Keinan-Boker L, Van't Veer P, Arts CJM, Adlercreutz H, Thijssen JHH, et al. Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers and Prev 2001;10:223-8.

Dernehl CU, Stead FM, Nau CA. Arsine, stibine, and hydrogen sulfide. Industrial Medicine 1944;13:361-2.

Deutsche Forschungsgemeinschaft (DFG). List of MAK and BAT values, 2000. Report No. 35, Commission for the Investigation of Health Hazards of Chemical Compounds in the work area. Weinheim (Germany): Wiley-VCH; 2000.

Dewailly E, Ayotte P, Bruneau S, Lebel G, Levallois P, Weber JP. Exposure of the Inuit population of Nunavik (Arctic Quebec) to lead and mercury. Arch Environ Health 2001;56(4):350-7.

Diamond GL, Thayer WC, Choudhury H. Pharmacokinetic/pharmacodynamics (PK/PD) modeling of risks of kidney toxicity from exposure to cadmium: estimates of dietary risks in the U.S. population. J Toxicol Environ Health 2003;66(Pt A):2141-64.

Dickel H, Radulescu M, Weyher I, Diepgen TL. Occupationally-induced "isolated cobalt sensitization." Contact Dermatitis 2001;45:246-7.

Dirven HA, van der Broek PH, Jongeneelen FJ. Determination of four metabolites of the plasticizer di (2-ethylhexyl) phthalate in human urine samples. Int Arch Occup Environ Health 1993;64(8):555-60.

Dixon RA, Ferreira D. Genistein. Phytochemistry 2002;60(3):205-11.

Dorgan JF, Brock JW, Rothman N, Needham LL, Miller R, Stephenson HE Jr, et al. Serum organochlorine pesticides and PCBs and breast cancer risk: results from a prospective analysis (USA). Cancer Causes Control 1999;10(1):1-11.

Draper WM, Street JC. Applicator exposure to 2,4-D, dicamba, and a dicamba isomer. J Environ Sci Health B 1982;17(4):321-39.

Droste JHJ, Weyler JJ, Van Meerbeeck JP, Vermeire PA, van Sprundel MP. Occupational risk factors of lung cancer: a hospital based case-control study. Occup Environ Med 1999; 56:322-7.

Dua VK, Pant CS, Sharma VP. Determination of levels of HCH and DDT in soil, water and whole blood from bioenvironmental and insecticide-sprayed areas of malaria control. Indian J Malariol 1996;33(1):7-15.

Duggan RE, Corneliussen PE. Dietary intake of pesticide chemicals in the United States. 3. June 1968–April 1970. Pesticide Monitoring Journal 1972;5(4):331-41.

Durakovic A, Horan P, Dietz LA, Zimmerman I. Estimate of the time zero lung burden of depleted uranium in Persian Gulf War veterans by the 24-hour urinary excretion and exponential decay analysis. Mil Med 2003;168(8):600-5.

Durham WF, Armstrong JF, Quinby GE. DDT and DDE content of complete prepared meals. Arch Environ Health 1965;11(5):641-7.

Duty SM, Silva MJ, Barr DB, Brock JW, Ryan L, Chen ZY, Herrick RF, Christiani DC, Hauser R. Phthalate exposure and human semen parameters. Epidemiology 2003;14:269-277

Duty SM, Calafat AM, Silva MJ, Brock JW, Ryan L, Chen Z, et al. The relationship between environmental exposure to phthalates and computer-aided sperm analysis motion parameters. J Androl 2004;25(2):293-302.

Duty SM, Calafat AM, Silva MJ, Ryan L, Hauser R. Phthalate exposure and reproductive hormones in adult men. Hum Reprod 2005;20(3):604-10.

Eisner MD. Environmental tobacco smoke exposure and pulmonary function among adults in NHANES III: impact on the general population and adults with current asthma. Environ Health Perspect 2002;110:765-70.

Ejnik JW, Carmichael AJ, Hamilton MM, McDiarmid M, Squibb K, Boyd P, et al. Determination of the isotopic composition of uranium in urine by inductively coupled plasma mass spectrometry. Health Phys 2000;78:143-6.

Elinder CG, Friberg L. Antimony. In: Friberg L, Nordberg GF, Vouk VB, eds. Handbook on the toxicology of metals. 2nd ed. New York: Elsevier; 1986. p. 26-42.

Ensslin AS, Huber R, Pethran A, Rommelt H, Schierl R, Kulka U, et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetic studies. Int Arch Occup Environ Health 1997;70(3):205-8.

Eriksson P, Archer T, Fredriksson A. Altered behaviour in adult mice exposed to a single low dose of DDT and its fatty acid conjugate as neonates. Brain Res 1990;514(1):141-2.

Eskenazi B, Mocarelli P, Warner M, Samuels S, Vercellini P, Olive D, et al. Serum dioxin concentrations and endometriosis: a cohort study in Seveso, Italy. Environ Health Perspect 2002;110(7):629-34.

Eskenazi B, Harley K, Bradman A, Weltzien E, Jewell NP, Barr DB, et al. Association of in utero organophosphate pesticide exposure and fetal growth and length of gestation in an agricultural population. Environ Health Perspect 2004;112(10):1116-24.

Esteban E, Rubin C, Hill R, Olson D, Pearce K. Association between indoor residential contamination with methyl parathion and urinary para-nitrophenol. J Expo Anal Environ Epidemiol 1996;6(3):375-87.

European Commission. Scientific Committee for Toxicity, Ecotoxicity and the Environment (CSTEE). Opinion on the results of a second risk assessment of: Bis(2-ethylhexyl) phthalate (DEHP) human health part [online]. 2004. Available from URL: http://europa.eu.int/comm/health/ph_risk/committees/sct/documents/out214_en.pdf, 03/17/05.

Ewers U, Krause C, Schulz C, Wilhelm M. Reference values and human biological monitoring values for environmental toxins. Report on the work and recommendations of the Commission on Human Biological Monitoring of the German Federal Environmental Agency. Int Arch Occup Environ Health 1999;72(4):255-60.

Ezaki T, Tsukahara T, Moriguchi J, Furuki K, et al. No clear-cut evidence for cadmium-induced renal tubular dysfunction among over 10,000 women in the Japanese general population: a nationwide large-scale survey. Int Arch Occup Environ Health 2003;76:186-96.

Fabro S, McLachlan JA, Dames NM. Chemical exposure of embryos during the preimplantation stages of pregnancy: mortality rate and intrauterine development. Am J Obstet Gynecol 1984;148(7):929-38.

Factor-Litvak P, Hasselgren G, Jacobs D, Begg M, Kline J, Geier J, et al. Mercury derived from dental amalgams and neuropsychologic function. Environ Health Perspect 2003;111:719-23.

Falk C, Hanrahan L, Anderson HA, Kanarek MS, Draheim L, Needham LL. Body burden levels of dioxin, furans, and PCBs among frequent consumers of Great Lakes sport fish. The Great Lakes Consortium. Environ Res 1999;80(2 Pt 2):S19-S25.

Farago ME, Kavanagh P, Blanks R, Kelly J, Kazantzis G, Thornton I, et al. Platinum concentrations in urban road dust and soil, and in blood and urine in the United Kingdom. Analyst 1998;123(3):451-4.

Fenske RA, Lu C, Barr D, Needham L. Children's exposure to chlorpyrifos and parathion in an agricultural community in central Washington State. Environ Health Perspect 2002;110(5):549-53.

Fernandez MA, Sanz P, Palomar M, Serra J, Gadea E. Fatal chemical pneumonitis due to cadmium fumes. Occup Med 1996;46:372-4.

Fierens S, Mairesse H, Heilier JF, De Burbure C, Focant JF, Eppe G, et al. Dioxin/polychlorinated biphenyl body burden, diabetes and endometriosis: findings in a population-based study in Belgium. Biomarkers 2003;8(6):529-34.

Finklea J, Priester LE, Creason JP, Hauser T, Hinners T, Hammer DI. Polychlorinated biphenyl residues in human plasma expose a major urban pollution problem. Am J Public Health 1972;62(5):645-51.

Frank R, Campbell RA, Sirons G J. Forestry workers involved in aerial application of 2,4-dichlorophenoxyacetic acid (2,4-D): exposure and urinary excretion. Arch Environ Contam Toxicol 1985;4:427-35.

Franklin CA, Fenske RA, Greenhalgh R, Mathieu L, Denley HV, Leffingwell JT, et al. Correlation of urinary pesticide metabolite excretion with estimated dermal contact in the course of occupational exposure to Guthion. J Toxicol Environ Health 1981;7(5):715-31.

Galletti M, D'Annibale L, Pinto V, Cremisini C. Uranium daily intake and urinary excretion: a preliminary study in Italy. Health Phys 2003;85:228-35.

Garfitt SJ, Jones K, Mason HJ, Cocker J. Exposure to the organophosphate diazinon: data from a human volunteer study with oral and dermal doses. Toxicol Lett 2002;134:105-13.

Geltman PL, Brown MJ, Cochran J. Lead poisoning among refugee children resettled in Massachusetts, 1995 to 1999. Pediatrics 2001;108(1):158-62.

Genter MB. Magnesium, calcium, strontium, barium, and radium In: Bingham A, Cohressen B, Powell C, eds. Patty's

toxicology. 5th ed. New York: John Wiley & Sons, Inc.; 2001. p. 221-52

George DA. Permethrin and its two metabolite residues in seven agricultural crops. J AOAC 1985;68(6):1160-3.

Geyer HJ, Schramm KW, Feicht EA, Behechti A, Steinberg C, Bruggemann R, et al. Half-lives of tetra-, penta-, hexa-, hepta-, and octachlorodibenzo-p-dioxin in rats, monkeys, and humans—a critical review. Chemosphere 2002;48(6):631-44.

Glynn AW, Granath F, Aune M, Atuma S, Darnerud PO, Bjerselius R, et al. Organochlorines in Swedish women: determinants of serum concentrations. Environ Health Perspect 2003;111:349-55.

Glynn AW, Wolk A, Aune M, Atuma S, Zettermark S, Maehle-Schmid M, et al. Serum concentrations of organochlorines in men: a search for markers of exposure. Sci Total Environ 2000; 263(1-3):197-208.

Goen T, Gundel J, Schaller KH, Angerer J. The elimination of 1-hydroxypyrene in the urine of the general population and workers with different occupational exposures to PAH. Sci Total Environ 1995;163(1-3):195-201.

Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988;242:1412-5.

Grace PB, Taylor JI, Low Y, Luben RN, Mulligan AA, Botting NP, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition—Norfolk. Cancer Epidemiol Biomarkers and Prev 2004;13:698-708.

Grandjean P, Weihe P, Needham LL, Burse VW, Patterson DG Jr, Sampson EJ, et al. Relation of a seafood diet to mercury, selenium, arsenic, and polychlorinated biphenyl and other organochlorine concentrations in human milk. Environ Res 1995;71(1):29-38.

Grether JK, Harris JA, Neutra R, Kizer KW: Exposure to aerial malathion application and the occurrence of congenital anomalies and low birthweight. Am J Public Health 1987;77:1009-10.

Grimalt JO, Sunyer J, Moreno V, Amaral OC, Sala M, Rosell A, et al. Risk excess of soft-tissue sarcoma and thyroid cancer in a community exposed to airborne organochlorinated compound mixtures with a high hexachlorobenzene content. Int J Cancer 1994;56(2):200-3.

Guallar E, Sanz-Gallardo MI, van't Veer P, Bode P, Aro A, Gomez-Aracena J, et al. Mercury, fish oils, and the risk of myocardial infarction. New Engl J Med 2002;347(22):1747-54.

Gundel J, Mannschreck C, Buttner K, Ewers U, Angerer J. Urinary levels of 1-hydroxypyrene, 1-, 2-, 3-, and 4-hydroxyphenanthrene in females living in an industrial area of Germany. Arch Environ Contam Toxicol 1996;31(4):585-90.

Gundel J, Schaller KH, Angerer J. Occupational exposure to polycyclic aromatic hydrocarbons in a fireproof stone producing plant: biological monitoring of 1-hydroxypyrene, 1-, 2-, 3- and 4-hydroxyphenanthrene, 3-hydroxybenz(a)anthracene and 3-hydroxybenzo-(a)-pyrene. Int Arch Occup Environ Health 2000;73(4):270-4.

Gwiazda RH, Squibb K, McDiarmid M, Smith D. Detection of depleted uranium in urine of veterans from the 1991 Gulf War. Health Phys 2004;86:12-8.

Halperin W, Vogt R, Sweeney MH, Shopp G, Fingerhut M, Petersen M. Immunological markers among workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Occup Environ Med 1998;55(11):742-9.

Hamilton EI, Sabbioni E, Van der Venne MT. Element reference values in tissues from inhabitants of the European community. VI. Review of elements in blood, plasma and urine and a critical evaluation of reference values for the United Kingdom population. Sci Total Environ 1994;158:165-90.

Hanrahan LP, Falk C, Anderson HA, Draheim L, Kanarek MS, Olson J. Serum PCB and DDE levels of frequent Great Lakes sport fish consumers—a first look. The Great Lakes Consortium. Environ Res 1999;80(2 Pt 2):S26-S37.

Hansen AM, Wallin H, Binderup ML, Dybdahl M, Autrup H, Loft S, et al. Urinary 1-hydroxypyrene and mutagenicity in bus drivers and mail carriers exposed to urban air pollution in Denmark. Mutat Res 2004;557(1):7-17.

Hardt J, Angerer J. Gas chromatographic method with mass-selective detection for the determination of 2-isopropoxyphenol in human urine. J Chromatogr B 1999;723(1&2):139-45.

Harris CA, Henttu P, Park MG, Sumpter JP. The estrogenic activity of phthalate esters in vitro. Environ Health Perspect 1997;105:105-8.

Hattula T, Rahola T. The distribution and biological half-time of ²⁰³Hg in the human body according to a modified whole-body counting technique. Environmental Physiology and Biochemistry 1975;5:252-7.

Hauser R, Meeker JD, Park S, Silva MJ, Calafat AM. Temporal variability of urinary phthalate metabolite levels in men of reproductive age [published erratum appears in Environ Health Perspect 2004;112(17):1740]. Environ Health Perspect 2004;112(17):1734-40.

Hayes TB, Collins A, Lee M, Mendoza M, Noriega N, Stuart AA, et al. Hermaphroditic, demasculinized frogs after

exposure to the herbicide atrazine at low ecologically relevant doses. Proceedings of the National Academy of Sciences USAWashington, DC: PNAS; 2002 Apr 16; 99(8):5476-80.

Hayes WJ Jr. Mortality in 1969 from pesticides, including aerosols. Arch Environ Health 1976;31:61-72.

Hedge AG, Thakker DM, Bhat IS. Long-term clearance of inhaled ^{60}Co. Health Phys 1979;36:732-4.

Hellstrom L, Elinder CG, Dahlberg B, Lundberg M, et al. Cadmium exposure and end-stage renal disease. Am J Kidney Dis 2001;38:1001-8.

Helzlsouer KJ, Alberg AJ, Huang HY, Hoffman SC, Strickland PT, Brock JW, et al. Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8(6):525-32.

Henson MC, Chedrese PJ. Endocrine disruption by cadmium, a common environmental toxicant with paradoxical effects on reproduction. Experimental Biology and Medicine 2004;229:383-92.

Hernandez-Valero MA, Bondy ML, Spitz MR, Zahm SH. Evaluation of Mexican-American migrant farmworker work practices and organochlorine pesticide metabolites. Am J Ind Med 2001;40(5):554-60.

Herr CE, Jankofsky M, Angerer J, Kuster W, Stilianakis NI, Gieler U, et al. Influences on human internal exposure to environmental platinum. J Expo Anal Environ Epidemiol 2003;13(1):24-30.

Herrero C, Ozalla D, Sala M, Otero R, Santiago-Silva M, Lecha M, et al. Urinary porphyrin excretion in a human population highly exposed to hexachlorobenzene. Arch Dermatol 1999;135(4):400-4.

Heudorf U, Angerer J. Internal exposure to PAHs of children and adults living in homes with parquet flooring containing high levels of PAHs in the parquet glue. Int Arch Occup Environ Health 2001a;74(2):91-101.

Heudorf U, Angerer J. Metabolites of organophosphorous insecticides in urine specimens from inhabitants of a residential area. Environ Res 2001c; 86:80-7.

Heudorf U, Angerer J. Metabolites of pyrethroid insecticides in urine specimens: current exposure in an urban population in Germany. Environ Health Perspect 2001d;109(3):213-7.

Heudorf U, Angerer J. Urinary monohydroxylated phenanthrenes and hydroxypyrene--the effects of smoking habits and changes induced by smoking on monooxygenase-mediated metabolism. Int Arch Occup Environ Health. 2001b 74(3):177-83.

Heudorf U, Angerer J, Drexler H. Current internal exposure to pesticides in children and adolescents in Germany: urinary levels of metabolites of pyrethroid and organophosphorus insecticides. Int Arch Occup Environ Health. 2004;77(1):67-72.

Heudorf U, Angerer J, Drexler H. Polychlorinated biphenyls in the blood plasma: current exposure of the population in Germany. Rev Environ Health 2002;17(2):123-34.

Hill RH Jr, Head SL, Baker S, Gregg M, Shealy DB, Bailey SL, et al. Pesticide residues in urine of adults living in the United States: reference range concentrations. Environ Res 1995;71:99-108.

Hill RH Jr, To T, Holler JS, Fast DM, Smith SJ, Needham LL, et al. Residues of chlorinated phenols and phenoxy acid herbicides in the urine of Arkansas children. Arch Environ Contam Toxicol 1989;18(4):469-74.

Hines CJ, Deddens JA. Determinants of chlorpyrifos exposures and urinary 3,5,6-trichloro-2-pyridinol levels among termiticide applicators. Ann Occup Hyg 2001;45:309-21.

Hines CJ, Deddens JA, Striley CA, Biagini RE, Shoemaker DA, Brown KK, et al. Biological monitoring for selected herbicide biomarkers in the urine of exposed custom applications: application of mixed-effect models. Ann Occup Hyg 2003;47(6):503-17.

Hodgert JH, Zacharewski TR, Hammond GL. Interactions between human plasma sex hormone-binding globulin and xenobiotic ligands. J Steroid Biochem Mol Biol 2000;75(2-3):167-76.

Hoppin JA, Brock JW, Davis BJ, Baird DD. Reproducibility of urinary phthalate metabolites in first morning urine samples. Environ Health Perspect 2000;110(5):515-8.

Horiguchi H, Oguma E, Sasaki S, Miyamoto K, Ikeda Y, Machida M, et al. Comprehensive study of the effects of age, iron deficiency, diabetes mellitus, and cadmium burden on dietary cadmium absorption in cadmium-exposed female Japanese farmers. Toxicol Appl Pharmacol 2004a; 196:114-23.

Horiguchi H, Oguma E, Sasaki S, Miyamoto K, Ikeda, Yoko ; Machida, Munehito et al. Dietary exposure to cadmium at close to the current provisional tolerable weekly intake does not affect renal function among female Japanese farmers. Environ Res 2004b;95:20–31.

Horn-Ross PL, Barnes S, Kirk M, Coward L, Parsonnet J, Hiatt RA. Urinary phytoestrogen levels in young women from a multiethnic population. Cancer Epidemiol Biomarkers Prev 1997;6:339-45.

Hotz P, Buchet JP, Bernard A, Lison D, Lauwerys R. Renal effects of low-level environmental cadmium exposure: 5-year follow-up of a subcohort from the Cadmibel study. Lancet 1999;354:1508–13.

References

Howe GR, Hirohata T, Hislop TG, Iscovich JM, Yuan JM, Katsouyanni K, et al. Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst 1990;82:561-9.

Hoyer AP, Grandjean P, Jorgensen T, Brock JW, Hartvig HB. Organochlorine exposure and risk of breast cancer. Lancet 1998;352(9143):1816-20.

Hu H, Aro A, Payton M, Korrick S, Sparrow D, Weiss ST, et al. The relationship of bone and blood lead to hypertension. JAMA 1996;275(15):1171-6.

Hunter DJ, Hankinson SE, Laden F, Colditz GA, Manson JE, Willett WC, et al. Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 1997;337(18):1253-8.

Hursh JB, Greenwood MR, Clarkson TW, Allen J, Demuth S. The effect of ethanol on the fate of mercury vapor inhaled by man. J Pharmacol Exp Ther 1980;214(3):520-7.

Hutchins AM, Lampe JW, Martini MC, Campbell DR, Slavin JL. Vegetables, fruits and legumes: effect on isoflavonoid phytoestrogen and lignan excretion J Am Diet Assoc 1995*a*;95:769-74.

Hutchins AM, Slavin JL, Lampe JW. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc 1995*b*;95(5):545-51.

Iavicoli I, Bocca B, Petrucci F, Senofonte O, Carelli G, Alimonti A, et al. Biomonitoring of traffic police officers exposed to airborne platinum. Occup Environ Med 2004 Jul;61(7):636-9.

Iavicoli I, Caroli S, Alimonti A, Petrucci F, Carelli G. Biomonitoring of a worker population exposed to low antimony trioxide levels. J Trace Elem Med Biol 2002;16: 33-9.

Ichikawa Y, Kusaka Y, Goto S. Biological monitoring of cobalt exposure, based on cobalt concentrations in blood and urine. Int Arch Occup Environ Health 1985;55(4):269-76.

Immerman FW, Schaum JL. Nonoccupational Pesticide Exposure Study (NOPES). Report.[EPA/600/3-90/003; Order No. PB90-152224], U.S. Environmental Protection Agency: Washington (DC); 1990. p. 256.

Ingram D, Sanders K, Kolybaba M, Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997;350(9083):990-4.

Institute of Medicine. Board on Health Promotion and Disease Prevention. Veterans and Agent Orange: update 2002. Washington (DC): National Academy Press; 2003.

Institute of Medicine. Products for tobacco exposure reduction. In: Clearing the smoke: assessing the science base for tobacco

harm reduction. Washington (DC): National Academy Press; 2001*b*. p. 99.

Institute of Medicine. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc: a report of the Panel on Micronutrients. Washington, (DC): National Academy Press; 2001*a*.

International Agency for Research on Cancer (IARC). IARC Monographs. [online]. Available from URL: http://www.iarc.fr, 03/17/05.

International Programme on Chemical Safety. Environmental health criteria monographs. Carbamate pesticides: a general introduction. Vol. 64. Geneva: World Health Organization; 1986. p. 23-43.

International Programme on Chemical Safety. Environmental health criteria 97: deltamethrin. Section 1.1.4. [online] 1990. Available from URL: http://www.inchem.org/documents/ehc/ehc/ehc97.htm#SubSectionNumber:1.1.4, 02/7/05.

Iversen BS, Menne C, White MA, Kristiansen J, Christensen JM, Sabbioni E. Inductively coupled plasma mass spectrometric determination of molybdenum in urine from a Danish population. Analyst 1998;123(1):81-5.

Iwase A, Aiba M, Kira S. Respiratory nicotine absorption in non-smoking females during passive smoking. Int Arch Occup Environ Health 1991;63:139-43.

Jacob J, Seidel A. Biomonitoring of polycyclic aromatic hydrocarbons in human urine. J Chromatogr B 2002;778(1-2):31-47.

Jacobson JL, Jacobson SW. Intellectual impairment in children exposed to polychlorinated biphenyls in utero. N Engl J Med 1996;335:783-9.

James RA, Hertz-Picciotto I, Willman E, Keller JA, Charles MJ. Determinants of serum polychlorinated biphenyls and organochlorine pesticides measured in women from the child health and development study cohort, 1963-1967. Environ Health Perspect 2002;110:617-24.

Jarfelt K, Dalgaard M, Hass U, Borch J, Jacobsen H, Ladefoged O. Antiandrogenic effects in male rats perinatally exposed to a mixture of di(2-ethylhexyl) phthalate and di(2-ethylhexyl) adipate. Reprod Toxicol 2005;19(4):505-15.

Jarup L, Hellstrom L, Alfven T, Carlsson MD, Grubb A, Persson B, et al. Low level exposure to cadmium and early kidney damage: the OSCAR study [published erratum appears in Occup Environ Med 2002;59:497]. Occup Environ Med 2000;57:668-72.

Jarvis JQ, Hammond E, Meier R, Robinson C. Cobalt cardiomyopathy. A report of two cases from mineral assay laboratories and a review of the literature. Journal of Occupational Medicine 1992;34:620-6.

Jauhiainen A, Kangas J, Laitinen S, Savolainen K. Biological monitoring of workers exposed to mevinphos in greenhouses. Bull Environ Contam Toxicol 1992;49(1):37-43.

Jefferson JA, Escudero E, Hurtado ME, Pando J, Tapia R, Swenson ER, et al. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. Lancet 2002;359:407-8.

Jemal A, Graubard BI, Devesa SS, Flegal KM. The association of blood lead level and cancer mortality among whites in the United States. Environ Health Perspect 2002;110(4):325-9.

Jin T, Nordberg G, Ye T, Bo M, Wang H, Zhu G, et al. Osteoporosis and renal dysfunction in a general population exposed to cadmium in China. Environ Res 2004;96:353-9.

Joblin S, Reynolds T, White R, Parker MG, Sumpter JP. A variety of environmentally persistent chemicals including some phthalate plasticizers are weakly estrogenic. Environ Health Perspect 1995;103:582-7.

Johnson E, Shorter C, Bestervelt L, Patterson D, Needham L, Piper W, et al. Serum hormone levels in humans with low serum concentrations of 2,3,7,8-TCDD. Toxicol Ind Health 2001;17(4):105-12.

Johnson GD, Harsy SG, Geronimo J, Wise JM. Ortho-phenylphenol and phenylhydroquinone residues in citrus fruit and processed citrus products after postharvest fungicidal treatments with sodium orthophenylphenate in California and Florida. J Agric Food Chem 2001;49(5):2497-502.

Johnson MD, Kenney N, Stoica A, Hilkivi-Clarke L, Singh B, Chepko G, et al. Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. Nature Med 2003;9:1081-4.

Jones RD, Winter DP, Cooper AJ. Absorption study of pentachlorophenol in persons working with wood preservatives. Hum Toxicol 1986;5(3):189-94.

Jongeneelen FJ. Biological monitoring of environmental exposure to polycyclic aromatic hydrocarbons; 1-hydroxypyrene in urine of people. Toxicol Lett 1994;72(1-3):205-11.

Jonsson F, Sandborgh-Englund G, Johanson G. A compartmental model for the kinetics of mercury vapor in humans. Toxicol Appl Pharmacol 1999;155(2):161-8.

Jonsson HT Jr, Keil JE, Gaddy RG, Loadholt CB, Hennigar GR, Walker EM Jr. Prolonged ingestion of commercial DDT and PCB; effects on progesterone levels and reproduction in the mature female rat. Arch Environ Contam Toxicol 1975-1976;3(4):479-90.

Jourdan S, Moreno B, Pellegrino S, Petrarulo M, Marco R. Suicidal poisoning with barium chloride. Forensic Sci Int 2001;119:263-5.

Jung D, Berg PA, Edler L, Ehrenthal W, Fenner D, Flesch-Janys D, et al. Immunologic findings in workers formerly exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and its congeners. Environ Health Perspect 1998;106(Suppl 2):689-95.

Juhler RK , Larsen SB, Myer O, Jensen ND, Spanò M, Giwercman A, et al. Human semen quality in relation to dietary pesticide exposure and organic diet. Arch Environ Contam Toxicol 1999;37:415-23.

Kaiser R, Henderson AK, Daley WR, Naughton M, Khan MH, Rahman M, et al. Blood lead levels of primary school children in Dhaka, Bangladesh. Environ Health Perspect 2001;109(6):563-6.

Kang D, Tepper A, Patterson DG Jr. Coplanar PCBs and the relative contribution of coplanar PCBs, PCDDs, and PCDFs to the total 2,3,7,8-TCDD toxicity equivalents in human serum. Chemosphere 1997;35(3):503-11.

Kang JW, Cho SH, Kim H, Lee CH. Correlation of urinary 1-hydroxypyrene and 2-naphthol with total suspended particulates in ambient air in municipal middle-school students in Korea. Arch Environ Health 2002;57(4):377-82.

Kanoh T, Fukuda M, Onozuka H, Kinouchi T, Ohnishi Y. Urinary 1-hydroxypyrene as a marker of exposure to polycyclic aromatic hydrocarbons in environment. Environ Res 1993;62(2):230-41.

Karpas Z, Halicz L, Roiz J, Marko R, Katorza E, Lorber A, et al. Inductively coupled plasma mass spectrometry as a simple, rapid, and inexpensive method for determination of uranium in urine and fresh water: comparison with LIF. Health Phys 1996;71(6):879-85.

Karpas Z, Lorber A, Elish E, Kol R, Roiz Y, Marko R, et al. Uptake of ingested uranium after low "acute intake." Health Phys 1998;74(3):337-45.

Karr SC, Lampe JW, Hutchins AM, Slavin JL. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. Am J Clin Nutr 1997;66:46-51.

Kato K, Silva MJ, Reidy JA, Hurtz D, Malek NA, Needham LL, et al. Mono(2-ethyl-5-hydroxyhexyl) phthalate and mono-(2-ethyl-5-oxohexyl) phthalate as biomarkers for human exposure assessment to di-(2-ethylhexyl) phthalate. Environ Health Perspect 2004;112(3):327-30.

Kentner M, Leinemann M, Schaller KH, Weltle D, Lenert G. External and internal antimony exposure in starter battery production. Int Arch Occup Environ Health 1995;67:119-23.

Kerper LE, Ballatori N, Clarkson TW. Methyl mercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol 1992;262:RF 761-RF 5.

Kessler W, Numtip W, Grote K, Csanády G, Chahoud I, Filser J (2004). Blood burden of di(2-ethylhexylphthalate (DEHP) and its primary metabolite mono(2-ethylhexyl) phthalate (MEHP) in pregnant and non-pregnant rats and marmosets. Toxicol Appl Pharmacol 2004;195:142-53.

Kikuchi Y, Nomiyama T, Kumagai N, Dekio F, Uemura T, Takebayashi T, et al. Uptake of cadmium in meals from the digestive tract of young non-smoking Japanese female volunteers. J Occup Health 2003;45:43-52.

Kim MK, Chung BC, Yu VY, Nam JH, Lee HC, Huh KB, et al. Relationships of urinary phyto-oestrogen excretion to BMD in postmenopausal women. Clin Endocrinol (Oxf) 2002;56(3):321-8.

Kim R, Rotnitzky A, Sparrow D, Weiss ST, Wager C, Hu H. A longitudinal study of low-level lead exposure and impairment of renal function: the Normative Aging Study. JAMA 1996;275:1177-81.

Kim YD, Lee CH, Nan HM, Kang JW, Kim H. Effects of genetic polymorphisms in metabolic enzymes on the relationships between 8-hydroxydeoxyguanosine levels in human leukocytes and urinary 1-hydroxypyrene and 2-naphthol concentrations. J Occup Health 2003;45(3):160-7.

Kingman A, Albertini T, Brown LJ. Mercury concentrations in urine and whole blood associated with amalgam exposure in a U.S. military population. J Dent Res 1998;77:461-71.

Kirkman LM, Lampe JW, Campbell D, Martini M, Slavin J. Urinary lignan and isoflavonoid excretion in men and women consuming vegetable and soy diets. Nutr Cancer 1995;24:1-12.

Kisker C, Schindelin H, Rees DC. Molybdenum-cofactor-containing enzymes: structure and mechanism. Annual Review of Biochemistry 1997;66:233-67.

Kitamura K, Kikuchi Y, Watanabe S, Waechter G, Sakurai H, Takada T. Health effects of chronic exposure to polychlorinated dibenzo-P-dioxins (PCDD), dibenzofurans (PCDF) and coplanar PCB of municipal waste incinerator workers. J Epidemiol 2000;10(4):262-70.

Klaassen CD, Liu J, Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annual Review of Pharmacology and Toxicology 1999;39:267-94.

Klein KO. Isoflavones, soy-based infant formulas, and relevance to endocrine function. Nutr Rev 1998;56:193-204.

Knowles LM, Zigrossi DA, Tauber RA, Hightower C, Milner JA. Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer 2000;38(1):116-22.

Koch HM, Drexler H, Angerer J. Internal exposure of nursery-school children and their parents and teachers to di(2-ethylhexyl)phthalate (DEHP). International Journal of Hygiene and Environmental Health 2004;207(1):15-22.

Koch HM, Hardt J, Angerer J. Biological monitoring of exposure of the general population to the organophosphorus pesticides chlorpyrifos and chlorpyrifos-methyl by determination of their specific metabolite 3,5,6-trichloro-2-pyridinol. International Journal of Hygiene and Environmental Health 2001;204:175-80.

Koch HM, Rossbach B, Drexler H, Angerer J. Internal exposure of the general population to DEHP and other phthalates - determination of secondary and primary phthalate monoester metabolites in urine. Environ Res 2003;93:177-85.

Kohli JD, Khanna RN, Gupta BN, Dhar MM, Tandon JS, Sircar KP. Absorption and excretion of 2,4-dichlorophenoxyacetic acid in man. Xenobiotica 1974b;4:97-100.

Kogevinas M. Human health effects of dioxins: cancer, reproductive and endocrine system effects. Hum Reprod Update 2001;7(3):331-9.

Kohli JD, Khanna RN, Gupta BN, Dhar MM, Tandon JS, Sircar KP. Absorption and excretion of 2,4,5-trichlorophenoxy acetic acid in man. Archives of International Pharmacodynamic Therapeutics 1974a; 210:250-5.

Kolmodin-Hedman B, Erne K. Estimation of occupational exposure to phenoxy acids (2,4-D and 2,4,5-T). Arch Toxicol Suppl 1980;4:318-21.

Komaromy-Hiller G, Ash KO, Costa R, Howerton K. Comparison of representative ranges based on U.S. patient population and literature reference intervals for urinary trace elements. Clin Chim Acta 2000;296(1-2):71-90.

Koo JW, Parham F, Kohn MC, Masten SA, Brock JW, Needham LL, et al. The association between biomarker-based exposure estimates for phthalates and demographic factors in a human reference population. Environ Health Perspect 2002;110(4):405-10.

Koopman-Esseboom C, Huisman M, Touwen BC, Boersma ER, Brouwer A, Sauer PJ, et al. Newborn infants diagnosed as neurologically abnormal with relation to PCB and dioxin exposure and their thyroid-hormone status. Dev Med Child Neurol 1997;39(11):785.

Korn EL, Graubard BI. Confidence intervals for proportions with small expected number of positive counts estimated from survey data. Survey Methodology 1998; 24:193-201.

Korrick SA, Hunter DJ, Rotnitzky A, Hu H, Speizer FE. Lead and hypertension in a sample of middle-aged women. Am J Public Health 1999;89:330-5.

Kotsopoulos D, Dalais FS, Liang YL, McGrath BP, Teede HJ. The effects of soy protein-containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric 2000;3(3):161-7.

Koval'skiy GA, Yarovaya GA, Shmavonyan DM. Changes of purine metabolism in man and animals under conditions of molybdenum biogeochemical provinces. Zhurnal Obshchey Biologii 1961;22(3):179-91.

Kozlowski LT, Mehta NY, Sweeney CT, Schwartz SS, Vogler GP, Jarvis MJ, et al. Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom, and the United States. Tob Control 1998;7:369-75.

Kramer RE, Wellman SE, Rockhold RW, Baker RC. Pharmacokinetics of methyl parathion: a comparison following single intravenous, oral or dermal administration. Journal of Biomedical Science 2002;9:311-20.

Kraus T, Schramel P, Schaller KH, Zobelein P, Weber A, Angerer J. Exposure assessment in the hard metal manufacturing industry with special regard to tungsten and its compounds. Occup Environ Med 2001;58(10):631-4.

Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EHF, Aleman A, Lampe JW, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density and plasma lipids in postmenopausal women. JAMA 2004;292:65-74.

Krieger RI, Dinoff TM. Malathion deposition, metabolite clearance, and cholinesterase status of date dusters and harvesters in California. Arch Environ Contam Toxicol 2000;38(4):546-63.

Kriss JP, Carnes WH, Gross RT. Hypothyroidism and thyroid hyperplasia in patients treated with cobalt. JAMA 1955;157:117-21.

Kristiansen J, Christensen JM, Iversen BS, Sabbioni E. Toxic trace element reference levels in blood and urine: influence of gender and lifestyle factors. Sci Total Environ 1997;204:147-60.

Kuhn K, Wieseler B, Leng G, Idel H. Toxicokinetics of pyrethroids in humans: consequences for biological monitoring. Bull Environ Contam Toxicol 1999;62:101-8.

Kuo CT, Chen HW, Chen JL. Determination of 1-hydroxypyrene in children urine using column-switching liquid chromatography and fluorescence detection. J Chromatogr B 2004;805(2):187-93.

Kurttio P, Auvinen A, Salonen L, Saha H, Pekkanen J, Makelainen I, et al. Renal effects of uranium in drinking water. Environ Health Perspect 2002;110(4):337-42.

Kutz FW, Cook BT, Carter-Pokras OD, Brody D, Murphy RS. Selected pesticide residues and metabolites in urine from a survey of the U.S. general population. J Toxicol Environ Health 1992;37(2):277-91.

Kutz FW, Yobs AR, Strassman SC. Racial stratification of organochlorine insecticide residues in human adipose tissue. Journal of Occupational Medicine 1977;19(9):619-22.

Kutz FW, Wood PH, Bottimore DP. Organochlorine pesticides and polychlorinated biphenyls in human adipose tissue. Reviews of Environmental Contamination and Toxicology 1991;120:1-82.

Kuusimaki L, Peltonen Y, Mutanen P, Peltonen K, Savela K. Urinary hydroxy-metabolites of naphthalene, phenanthrene and pyrene as markers of exposure to diesel exhaust. Int Arch Occup Environ Health 2004;77(1):23-30.

Lake BG, Phillips JC, Linnell JC, Gangolli SD. The in vitro hydrolysis of some phthalate diesters by hepatic and intestinal preparations from various species. Toxicol Appl Pharmacol 1977;39:239-48.

Lampe JW, Gustafson DR, Hutchins AM, Martini MG, Li S, Wahala K, et al. Urinary isoflavonoid and lignan excretion on a western diet: relation to soy, vegetable and fruit intake. Cancer Epidemiol Biomarkers and Prev 1999;8:699-707.

Lauwerys RB, Hoet P. Industrial chemical exposure: guidelines for biological monitoring. 3rd ed. Boca Raton (FL): Lewis Publishers; 2001. p. 87-95, 54-68, 500-11.

Lanphear BP, Dietrich K, Auinger P, Cox C. Cognitive deficits with blood lead concentrations < 10 µg/dL in US children and adolescents. Public Health Rep 2000;115:521-9.

Lebel G, Dodin S, Ayotte P, Marcoux S, Ferron LA, Dewailly E. Organochlorine exposure and the risk of endometriosis. Fertil Steril 1998;69(2):221-8.

Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast-cancer risk in Singapore. Lancet 1991;337:1197-1200.

Lee KH, Ichiba M, Zhang J, Tomokuni K, Hong YC, Ha M, et al. Multiple biomarkers study in painters in a shipyard in Korea. Mutat Res 2003;540(1):89-98.

Leggett RW. Age-specific kinetic model of lead metal in humans. Environ Health Perspect 1993;101(7):598-616.

Leng G, Lewalter J. Role of individual susceptibility in risk assessment of pesticides. Occup Environ Med 1999;56(7):449-53.

Leng G, Ranft U, Sugiri D, Hadnagy W, Berger-Preiss, Idel H. Pyrethroids used indoors—biological monitoring of exposure to pyrethroids following an indoor pest control operation. International Journal of Hygiene and Environmental Health 2003;206:85-92.

Lhotka C, Szekeres T, Steffan I, Zhuber K, Zweymuller K. Four-year study of cobalt and chromium blood levels in patients managed with two different metal-on-metal total hip replacements. J Orthop Res 2003;21(2):189-95.

Li N, Hao M, Phalen RF, Hinds WC, Nel AE. Particulate air pollutants and asthma. A paradigm for the role of oxidative stress in PM-induced adverse health effects. Clin Immunol 2003;109(3):250-65.

Life Sciences Research Office (LSRO). Review and analysis of the literature on the potential adverse health effects of dental amalgam. Bethesda (MD): LSRO; July 2004.

Lilis R, Blumberg WE, Fischbein A, Diamond S, Anderson HA, et al. Lead effects among secondary smelter workers with blood lead levels below 80 µg/100 ml. Arch Environ Health 1977;32(6):256-66.

Linna A, Oksa P, Palmroos P, Roto P, Laippala P, Uitti J. Respiratory health of cobalt production workers. American Journal of Industrial Medicine 2003;44:124-32.

Linnainmaa M, Kiilunen M. Urinary cobalt as a measure of exposure in the wet sharpening of hard metal and stellite blades. Int Arch Occup Environ Health 1997;69(3):193-200.

Lisi P. Co-sensitivity between cobalt and other transition metals. Contact Dermatitis 2003;48:172-3.

Lison D, Buchet JP, Swennen B, Molders J, Lauwerys R. Biological monitoring of workers exposed to cobalt metal, salt, oxides, and hard metal dust. Occup Environ Med 1994;51(7):447-50.

Liss GM, Albro PW, Hartle RW, Stringer WT. Urine phthalate determinations as an index of occupational exposure to phthalic anhydride and di (2-ethylhexyl) phthalate. Scand J Work Environ Health 1985;11(5):381-7.

Lloyd J. Long-term mortality study of steelworkers. V. Respiratory cancer in coke plant workers. J Occup Med 1971;13:53-68.

Longnecker MP, Ryan JJ, Gladen BC, Schecter AJ. Correlations among human plasma levels of dioxin-like compounds and polychlorinated biphenyls (PCBs) and implications for epidemiologic studies. Arch Environ Health 2000;55(3):195-200.

Longnecker MP, Wolff MS, Gladen BC, Brock JW, Grandjean P, Jacobson JL, et al. Comparison of polychlorinated biphenyl levels across studies of human neurodevelopment. Environ Health Perspect 2003;111(1):65-70.

Lorber M. A pharmacokinetic model for estimating exposure of Americans to dioxin-like compounds in the past, present, and future. Sci Total Environ 2002;288(1-2):81-95.

Lovekamp-Swan T, Davis BJ. Mechanisms of phthalate ester toxicity in the female reproductive system. Environ Health Perspect 2003;111(2):139-45.

Lu LJ, Grady JJ, Marshall MV, Ramanujam VM, Anderson KE. Altered time course of urinary daidzein and genistein excretion during chronic soya diet in healthy male subjects. Nutr Cancer 1995;24:311-23.

Lu PL, Chen ML, Mao IF. Urinary 1-hydroxypyrene levels in workers exposed to coke oven emissions at various locations in a coke oven plant. Arch Environ Health 2002;57(3):255-61.

Lu C, Bravo R, Caltabiano LM, Irish RM, Weerasekera G, Barr DB. The presence of dialkylphosphates in fresh fruit juices: implication for organophosphorus pesticide exposure and risk assessments. J Toxicol Environ Health A. 2005;68(3):209-27.

Lucena RA, Allam MF, Costabeber IH, Villarejo ML, Navajas RF. Breast cancer risk factors: PCB congeners. Eur J Cancer Prev 2001;10:117-9.

Luedersdorf R, Fuchs A, Mayer P, Skulsukai G, Schacke G. Biological assessment of exposure to antimony and lead in the glass-producing industry. Int Arch Occup Environ Health 1987;59:469-74.

Lundberg C. Effect of DDT on cytochrome P-450 and oestrogen-dependent functions in mice. Environmental Physiology & Biochemistry 1974; 4:200-4.

Luotamo M, Jarvisalo J, Aitio A. Assessment of exposure to polychlorinated biphenyls: analysis of selected isomers in blood and adipose tissue. Environ Res 1991;54(2):121-34.

MacIntosh DL, Needham LL, Hammerstrom KA, Ryan PB. A longitudinal investigation of selected pesticide metabolites in urine. J Expo Anal Environ Epidemiol 1999;9(5):494-501.

Mahaffey KR, Clickner RP, Bodurow CC. Blood organic mercury and dietary mercury intake: National Health and Nutrition Examination Survey, 1999 and 2000. Environ Health Perspect 2004;112(5):562-70.

Mahaffey KR, Mergler D. Blood levels of total and organic mercury in residents of the upper St. Lawrence River Basin, Quebec: association with age, gender, and fish consumption. Environ Res 1998;77(2):104-14.

Mannino DM, Holguin F, Greves HM, Savage-Brown A, Stock AL, Jones RL. Urinary cadmium levels predict lower lung function in current and former smokers: data from the Third National Health and Nutrition Examination Survey. Thorax 2004;59:194-8.

Mantere P, Hänninen H, Hernberg S, Luukkonen R. A prospective follow-up study on psychological effects in workers exposed to low levels of lead. Scand J Work Environ Health 1984;10:43-50.

Marcus RL. Investigation of a working population exposed to thallium. Journal for the Society of Occupational Medicine. 1985;35(1):4-9.

Martin SA Jr, Harlow SD, Sowers MF, Longnecker MP, Garabrant D, Shore DL, et al. DDT metabolite and androgens in African-American farmers. Epidemiology 2002;1:454-8.

Mascagni P, Consonni D, Bregante G, Chiappino G, Toffoletto F. Olfactory function in workers exposed to moderate airborne cadmium levels. Neurotoxicology 2003;24:717-24.

Maskarinec G, Singh S, Meng L, Franke AA. Dietary soy intake and urinary isoflavone excretion among women from a multiethnic population. Cancer Epidemiol Biomarkers and Prev 1998;7:613-9.

Masuda Y. Fate of PCDF/PCB congeners and change of clinical symptoms in patients with Yusho PCB poisoning for 30 years. Chemosphere 2001:43(4-7):925-30.

Masuda Y, Schecter A, Papke O. Concentrations of PCBs, PCDFs and PCDDs in the blood of Yusho patients and their toxic equivalent contribution. Chemosphere 1998;37(9-12):1773-80.

Matsuura N, Uchiyama T, Tada H, Nakamura Y, Kondo N, Morita M. Effects of dioxins and polychlorinated biphenyls (PCBs) on thyroid function in infants born in Japan–the second report from research on environmental health. Chemosphere 2001;45(8):1167-71.

McDiarmid MA, Squibb K, Engelhardt SM. Biologic monitoring for urinary uranium in Gulf War I veterans. Health Phys 2004;87:51-6.

McDowell MA, Dillon CF, Osterloh J, Bolger PM, Pellizzari E, Fernando R, et al. Hair mercury levels in U.S. children and women of childbearing age: reference range data from NHANES 1999-2000. Environ Health Perspect 2004;112(11):1165-71.

McKee RH, Butala JH, David RM, Gans G. NTP center for the evaluation of risks to human reproduction reports on phthalates: addressing the data gaps [review]. Reprod Toxicol 2004;18(1):1-22.

McKee RH, El Hawari M, Stoltz M, Pallas F, Lington AW. Absorption, disposition and metabolism of Di-isononyl phthalate (DINP) in F-344 rats. J Appl Toxicol 2002;22:293-302.

Melnick RL. Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di (2-ethylhexyl) phthalate (DEHP)? Environ Health Perspect 2001;109(5):437-42.

Merlo F, Andreassen A, Weston A, Pan CF, Haugen A, Valerio F, et al. Urinary excretion of 1-hydroxypyrene as a marker for exposure to urban air levels of polycyclic aromatic hydrocarbons. Cancer Epidemiol Biomarkers Prev 1998;7(2):147-55.

Michalek JE, Akhtar FZ, Arezzo JC, Garabrant DH, Albers JW. Serum dioxin and peripheral neuropathy in veterans of Operation Ranch Hand. Neurotoxicology 2001;22:479-90.

Michalek JE, Akhtar FZ, Kiel JL. Serum dioxin, insulin, fasting glucose, and sex hormone-binding globulin in veterans of Operation Ranch Hand. J Clin Endocrinol Metab 1999;84(5):1540-3.

Miettinen JK, Rahola T, Hattula T, Rissanen K, Tillander M. Elimination of ^{203}Hg-methyl mercury in man. Annals of Clinical Research 1971;3(2):116-22.

Milligan SR, Balasubramanian AV, Kalita JC. Relative potency of xenobiotic estrogens in an acute in vivo mammalian assay. Environ Health Perspect 1998;106(1):23-6.

Ming-Hsin H, Shao-Chi C, Ju-Sun P, Kuo-Juie Y, Cheng-Wei L, Chia-Yu H, et al. Mechanism and treatment of cardiac arrhythmias in tartar emetic intoxication. Chin Med J 1958;76(2):103-15.

Minoia C, Gatti A, Aprea C, Ronchi A, Sciarra G, Turci R, et al. Inductively coupled plasma mass spectrometric determination of molybdenum in urine. Rapid Comm Mass Spectrom 2002; 16:1313-9.

Minoia C, Sabbioni E, Apostoli P, Pietra R, Pozzoli L, Gallorini M, et al. Trace element reference values in tissues from inhabitants of the European community I. A study of 46 elements in urine, blood, and serum of Italian subjects. Sci Total Environ 1990;95:89-105.

Misra UK, Gawdi G, Pizzo SV. Induction of mitogenic signaling in the 1LN prostate cell line on exposure to submicromolar concentrations of cadmium. Cell Signal 2003;15:1059-70.

Mocarelli P, Needham LL, Marocchi A, Patterson DG Jr, Brambilla P, Gerthoux PM, et al. Serum concentrations of 2,3,7,8-tetrachlorodibenzo-p-dioxin and test results from selected residents of Seveso, Italy. J Toxicol Environ Health 1991;32(4):357-66.

Morgan DP, Hetzler HL, Slach EF, Lin LI. Urinary excretion of paranitrophenol and alkyl phosphates following ingestion of methyl or ethyl parathion by human subjects. Arch Environ Contam Toxicol 1977;6(2-3):159-73.

Morgan DP, Roberts RJ, Walter AW, Stockdale EM. Anemia associated with exposure to lindane. Arch Environ Health 1980;35(5):307-10.

Morgan MK, Sheldon LS, Croghan CW, Jones PA, Robertson GL, Chuang JC, et al. Exposures of preschool children to chlorpyrifos and its degradation product 3,5,6-trichloro-2-pyridinol in their everyday environments. J Expo Anal Environ

Epidemiol. 2004 Sep 15; [Epub ahead of print] doi:10.1038/sj.jea.7500406

Moriguchi J, Ezaki T, Tsukahara T, Furuki K, Fukui Y, Okamoto S, et al. Alpha1-Microglobulin as a promising marker of cadmium-induced tubular dysfunction, possibly better than beta2-microglobulin. Toxicol Lett. 2004;148(1-2):11-20.

Mosconi G, Bacis M, Vitali MT, Leghissa P, Sabbioni E. Cobalt excretion in urine: results of a study on workers producing diamond grinding tools and on a control group. Sci Total Environ 1994;150(1-3):133-9.

Moulin JJ, Wild P, Romazini S, Lasfargues G, Peltier A, Bozec C, et al. Lung cancer risk in hard-metal workers. Am J Epidemiol 1998;148:241-8.

Mukherjee S, Palmer LJ, Kim JY, Aeschliman DB, Houk RS, Woodin MA, et al. Smoking status and occupational exposure affects oxidative DNA injury in boilermakers exposed to metal fume and residual oil fly ash. Cancer Epidemiol Biomarkers Prev 2004;13(3):454-60.

Muntner P, Vupputyuri S, Coresh J, Batuman V. Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 2003;63:104-50.

Murkies A, Dalais FS, Briganti EM, Burger HG, Healy DL, Wahlqvist ML. Phytoestrogens and breast cancer in postmenopausal women: a case control study. Menopause 2000;7(5):289-96.

Nachlas MM, Seligman AM. Evidence for the specificity of esterase and lipase by the use of three chromogenic substrates. J Biol Chem 1949;181:343-55.

Nagel SC, vom Saal FS, Welshons WV. The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: physiology of delivery modifies estrogenic activity. Proc Soc Exp Biol Med 1998;217:300-9.

Nan HM, Kim H, Lim HS, Choi JK, Kawamoto T, Kang JW, et al. Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations. Carcinogenesis 2001;22(5):787-93.

Nash D, Magder L, Lustberg M, Sherwin R, Rubin R, Kaufmann R, et al. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 2003;289(12):1523-31.

National Research Council. Committee on Measuring Lead in Critical Populations. Measuring lead exposure in infants, children and other sensitive populations. Washington (DC): National Academy Press; 1993. p. 31-98.

National Research Council (Platinum Group Metals). Medical and biologic effects of environmental pollutants. Washington (DC): National Academy of Sciences; 1977. p. 232.

National Research Council. Toxicologic effects of methylmercury. Washington (DC): National Academy of Sciences; 2000.

National Toxicology Program. Lead and lead compounds. In: Report on carcinogens. 11th ed. [online]. 2004. Available from URL: http://ntp.niehs.nih.gov/ntp/roc/eleventh/ profiles/s101lead.pdf, 02/27/05.

National Toxicology Program. Report on carcinogens. 10th ed. Washington (DC): U.S. Department of Health and Human Services, Public Health Service; December 2002.

National Toxicology Program. Report on Carcinogens. 11th ed. [online]. 2004. Available from URL: http://ntp.niehs.nih. gov/ntp/roc/toc11.html, 02/18/05.

National Toxicology Program. TR-301. Toxicology and carcinogenesis studies of o-phenylphenol alone and with 7,12-dimethylbenz(a)anthracene in Swiss CD-1 mice (dermal studies) [online]. 1986. Available at URL: http://ntp.niehs.nih. gov/index.cfm?objectid=07078EB9-E19D-AC1B-07D4A27130861AC1, 03/17/05.

National Toxicology Program. TR-462. Toxicology and carcinogenesis studies of molybdenum trioxide (CAS No. 1313-27-5) in F344 Rats and B6C3F1 Mice (inhalation studies) [online]. 1997. Available from URL: http://ntp.niehs. nih.gov/index.cfm?objectid=070A72C6-E9C1-AE67-4BFAB97AD0F427E8, 03/17/05.

Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004;279(23):23847-50.

Needham LL, Burse VW, Head SL, Korver MP, McClure PC, Andrews JS Jr, et al. Adipose tissue/serum partitioning of chlorinated hydrocarbon pesticides in humans. Chemosphere 1990;20:975-80.

Negri E, Bosetti C, Fattore E, La Vecchia C. Environmental exposure to polychlorinated biphenyls (PCBs) and breast cancer: a systemic review of the epidemiological evidence. Eur J Cancer Prev 2003;12:509-16.

Nesbitt PD, Lam Y, Thompson LU. Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am J Clin Nutr 1999;69(3):549-55.

Nicholls J, Lasley BL, Nakajima ST, Setchell KD, Schneeman BO. Effects of soy consumption on gonadotropin secretion and acute pituitary responses to gonadotropin-releasing hormone in women. J Nutr 2002;132(4):708-14.

Nicolaou G, Pietra R, Sabioni E, Mosconi G, Cassina G, Seghizzi P. Multielement determination of metals in biological specimens of hard-metal workers: a study carried out by neutron activation analysis. Journal of Trace Elements and Electrolytes in Health and Disease 1987;(2):73-7.

Nielsen J, Akesson B, Skerfving S. Phthalate ester exposure—air levels and health of workers processing polyvinylchloride. American Industrial Hygiene Association Journal 1985;46(11):643-7.

Nigam SK, Karnik AB, Majumder SK, Visweswariah K, Raju GS, Bai KM, et al. Serum hexachlorocyclohexane residues in workers engaged at a HCH manufacturing plant. Int Arch Occup Environ Health 1986;57(4):315-20.

Nikov GN, Eshete M, Rajnarayanan RV, Alworth WL. Interactions of synthetic estrogens with human estrogen receptors. J Endocrinol 2001;170(1):137-45.

Nishijo M, Nakagawa H, Honda R, Tanebe K, et al. Effects of maternal exposure to cadmium on pregnancy outcome and breast milk. Occup Environ Med 2002;59:394-7.

Nolan RJ, Rick DL, Freshour NL, Saunders JH. Chlorpyrifos: pharmacokinetics in human volunteers. Toxicol Appl Pharmacol 1984;73:8-15.

Noonan CW, Sarasua SM, Campagna D, Kathman SJ, Lybarger JA, Mueller PW. Effects of exposure to low levels of environmental cadmium on renal biomarkers. Environ Health Perspect 2002;110:151-5.

Nordberg GF, Nordberg M. Biological monitoring of cadmium. In: Clarkson TW, Friberg L, Nordberg GF, Sager PR, eds. Biological monitoring of toxic metals. New York: Plenum Press; 2001. p. 151-68.

Occupational Safety and Health Administration. 29 CFR 1910.1025. Washington, D.C. Available from URL: http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10033, 4/07/05.

Occupational Safety and Health Administration. 29 CFR 1910.1027. Washington, D.C. Available from URL: http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10035, 4/7/05.

Occupational Safety and Health Administration [online]. Available from URL: http://www.osha.gov/comp-links.html, 03/17/05.

O'Flaherty EJ. Physiologically based models for bone-seeking elements. IV. Kinetics of lead disposition in humans. Tox Appl Pharmacol 1993;118:16-29.

Olsson AO, Nguyen JV, Sadowski MA, Barr DB. A liquid chromatography/electrospray ionization-tandem mass spectrometry method for quantification of specific organophosphorus pesticide biomarkers in human urine. Analytical and Bioanalytical Chemistry 2003;376:808-15.

Olsson IM, Bensryd I, Lundh T, Ottosson H, Skerfving S, Oskarsson A. Cadmium in blood and urine – impact of sex, age, dietary intake, iron status, and former smoking – association of renal effects. Environ Health Perspect 2002;110:1185-90.

Okubo T, Suzuki T, Yokoyama Y, Kano K, Kano I. Estimation of estrogenic and anti-estrogenic activities of some phthalate diesters and monoesters by MCF-7 cell proliferation assay in vitro. Biol Pharm Bull 2003;26(8):1219-24.

Onstot JD, Stanley JS. Identification of SARA compounds in adipose tissue. U.S. Environmental Protection Agency (U.S. EPA), Office of Toxic Substances; 1989. EPA-560/5-89-003.

Orloff KG, Mistry K, Charp P, Metcalf S, Marino R, Shelly T, et al. Human exposure to uranium in groundwater. Environ Res 2004;94:319-26.

Oskarsson A, Schultz A, Skerfving S, Hallen IP, Ohlin B, Lagerkvist BJ. Total and inorganic mercury in breast milk and blood in relation to fish consumption and amalgam fillings in lactating women. Arch Environ Health 1996;51(3):234-41.

Otake T, Yoshinaga J, Yanagisawa Y. Exposure to phthalate esters from indoor environment. J Expo Anal Environ Epidemiol 2004;14(7):524-8.

Pagnotto LD, Walkley JE. Urinary dichlorophenol as an index of para-dichlorobenzene exposure. American Journal of Industrial Hygiene 1965;26;137-42.

Papke O. PCDD/PCDD: human background data for Germany, a 10-year experience. Environ Health Perspect 1998;106 (Suppl 2):723-31.

Parkinson A, Safe SH, Robertson LW, Thomas PE, Ryan DE, Reik LM, et al. Immunochemical quantitation of cytochrome P-450 isozymes and epoxide hydrolase in liver microsomes from polychlorinated or polybrominated biphenyl-treated rats. A study of structure-activity relationships. J Biol Chem 1983;258(9):5967-76.

Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, et al. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicol Sci 2000;58:339-49.

Paschal DC, Burse V, Gunter EW, Pirkle JL, Sampson EJ, Miller DT, et al. Exposure of the U.S. population aged 6 years and older to cadmium: 1988-1994. Arch Environ Contam Toxicol 2000;38:377-83.

Paschal DC, Ting BG, Morrow JC, Pirkle JL, Jackson RJ, Sampson EJ, et al. Trace metals in urine of United States

residents: reference range concentrations. Environ Res 1998;76(1):53-9.

Patterson DG, Holler HS, Smith SJ, Liddle JA, Sampson EJ, Needham LL. Human adipose data for 2,3,7,8-tetrachlorodibenzo-p-dioxin in certain U.S. samples. Chemosphere1986;15:2055-60.

Patterson DG Jr, Todd GD, Turner WE, Maggio V, Alexander LR, Needham LL. Levels of non-ortho-substituted (coplanar), mono- and di-ortho-substituted polychlorinated biphenyls, dibenzo-p-dioxins, and dibenzofurans in human serum and adipose tissue. Environ Health Perspect 1994;102 (Suppl 1):195-204.

Pavuk M, Cerhan JR, Lynch CF, Kocan A, Petrik J, Chovancova J. Case-control study of PCBs, other organochlorines and breast cancer. J Expo Anal Environ Epidemiol 2003;13:267-75.

Pavuk M, Cerhan JR, Lynch CF, Schecter A, Petrik J, Chovancova J, et al. Environmental exposure to PCBs and cancer incidence in eastern Slovakia. Chemosphere 2004;54:1509-20.

Payton M, Hu H, Sparrow D, Weiss ST. Low-level lead exposure and renal function in the Normative Aging Study. Am J Epidemiol 1994;140:821-29.

Peck CC, Albro PW. Toxic potential of the plasticizer di (2-ethylhexyl) phthalate in the context of its disposition and metabolism in primates and man. Environ Health Perspect 1982;45:11-7.

Perera FP, Rauh V, Tsai WY, Kinney P, Camann D, Barr D, et al. Effects of transplacental exposure to environmental pollutants on birth outcomes in a multiethnic population. Environ Health Perspect 2003;111(2):201-5.

Perry MJ, Christiani DC, Mathew J, Degenhardt D, Tortorelli J, Strauss J, et al. Urinalysis of atrazine exposure in farm pesticide applicators. Toxicology and Industrial Health 2000;16(7-8): 285-90.

Pesch A, Wilhelm M, Rostek U, Schmitz N, Weishoff-Houben M, Ranft U, et al. Mercury concentrations in urine, scalp hair, and saliva in children from Germany. J Expo Anal Environ Epidemiol 2002;12(4):252-8.

Peters HA, Gocmen A, Cripps DJ, Bryan GT, Dogramaci I. Epidemiology of hexachlorobenzene-induced porphyria in Turkey: clinical and laboratory follow-up after 25 years. Arch Neurol 1982;39(12):744-9.

Pethran A, Schierl R, Hauff K, Grimm CH, Boos KS, Nowak D. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health 2003;76(1):5-10

Pirkle JL, Flegal KM, Bernert JT, Brody DJ, Etzel RA, Maurer KR. Exposure of the U.S. population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 1996;275:1233-40.

Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter EW, Paschal DC. Exposure of the U.S. population to lead: 1991-1994. Environ Health Perspect 1998;106:745-50.

Pisati G, Zedda S. Outcome of occupational asthma due to cobalt hypersensitivity. Sci Total Environ. 1994;150(1-3):167-71.

Porta M, Zumeta E. Implementing the Stockholm Treaty on Persistent Organic Pollutants. Occup Environ Med 2002;59:651-3.

Radomski JL, Astolfi E, Deichmann WB, Rey AA. Blood levels of organochlorine pesticides in Argentina: occupationally and nonoccupationally exposed adults, children and newborn infants. Toxicol Appl Pharmacol 1971;20(2):186-93.

Rahola T, Hattula T, Korolainen A, Miettinen JK. Elimination of free and protein-bound ionic mercury ($^{203}Hg^{2+}$) in man. Annals of Clinical Research 1973;5:214-9.

Ramesh A, Walker SA, Hood DB, Guillen MD, Schneider K, Weyand EH. Bioavailability and risk assessment of orally ingested polycyclic aromatic hydrocarbons. International Journal of Toxicology 2004;23(5):301-33.

Ray DE, Forshaw PJ. Pyrethroid insecticides: poisoning syndromes, synergies, and therapy. J Toxicol Clin Toxicol 2000;38:95-101.

Redmond CK, Strobino BR, Cypess RH. Cancer experience among coke by-product workers. Ann N Y Acad Sci 1976;271:102-15.

Renes LE. Antimony poisoning in industry. Industrial Hygiene and Occupational Medicine 1953;99-108.

Rice DC, Schoeny R, Mahaffey K. Methods and rationale for derivation of a reference dose for methyl mercury by the U.S. EPA. Risk Anal 2003; 23(1):107-15.

Rice DC. The US EPA reference dose for methyl mercury: sources of uncertainty. Environ Res 2004;95:406-13.

Richter ED, Kowalski M, Leventhal A, Grauer F, Marzouk J, Brenner S, et al. Illness and excretion of organophosphate metabolites four months after household pest extermination. Arch Environ Health 1992;47(2):135-8.

Rier S, Foster WG. Environmental dioxins and endometriosis. Seminars in Reproductive Medicine 2003;21:145-54.

Ritchie KA, Gilmour WH, Macdonald EB, Burke FJ, McGowan DA, Dale IM, et al. Health and neuropsychological functioning of dentists exposed to mercury. Occup Environ Med 2002;59(5):287-93.

Robbins PJ, Cherniack MG. Review of the biodistribution and toxicity of the insect repellent N,N-diethyl-m-toluamide (DEET). J Toxicol Environ Health 1986;18(4):503-25.

Roels HA, Boeckx M, Ceulemans E, Lauwerys RR. Urinary excretion of mercury after occupational exposure to mercury vapor and influence of the chelating agent meso-2,3-dimercaptosuccinic acid (DMSA). British Journal of Industrial Medicine 1991;48:247-53.

Roels HA, Hoet P, Lison D. Usefulness of biomarkers of exposure to inorganic mercury, lead, or cadmium in controlling occupational and environmental risks of nephrotoxicity. Ren Fail 1999;21(3-4):251-62.

Roggi C, Minoia C, Sciarra GF, Apostoli P, Maccarini L, Magnaghi S, et al. Urinary 1-hydroxypyrene as a marker of exposure to pyrene: an epidemiological survey on a general population group. Sci Total Environ 1997;199(3):247-54.

Rugman FP. Aplastic anaemia associated with organochlorine pesticide: case reports and review of evidence. J Clin Pathol 1990;42(3):98-101.

Safe SH, Pallaroni L, Yoon K, Gaido K, Ross S, Saville B, et al. Toxicology of environmental estrogens. Reprod Fertil Dev 2001;13(4):307-15.

Sala M, Ribas-Fito N, Cardo E, de Muga ME, Marco E, Mazon C, et al. Levels of hexachlorobenzene and other organochlorine compounds in cord blood: exposure across placenta. Chemosphere 2001;43:895-901.

Sala M, Sunyer J, Otero R, Santiago-Silva M, Camps C, Grimalt J. Organochlorine in the serum of inhabitants living near an electrochemical factory. Occup Environ Med 1999;56(3):152-8.

Sallsten G, Barregard L, Schutz A. Decrease in mercury concentration in blood after long term exposure: a kinetic study of chloralkali workers. British Journal of Industrial Medicine 993;50(9):814-21.

Sanchez-Sicilia L, Seto DS, Nakamoto S, Kolff WJ. Acute mercurial intoxication treated by hemodialysis. Ann Intern Med 1963;59(5):692-706.

Sandborgh-Englund G, Elinder CG, Langworth S, Schutz A, Ekstrand J. Mercury in biological fluids after amalgam removal. J Dent Res 1998;77(4):615-24.

Sanzo JM, Dorronsoro M, Amiano P, Amurrio A, Aguinagalde FX, Azpiri MA. Estimation and validation of mercury intake associated with fish consumption in an EPIC cohort of Spain. Public Health Nutr 2001;4(5):981-8.

SAS Institute, Inc. SAS/STAT User's Guide. Version 8. Cary, NC: SAS Institute, Inc.; 1999.

Satarug S, Baker JR, Reilly PE, Moore MR, Williams DJ. Cadmium levels in the lung, liver, kidney cortex, and urine samples from Australians without occupational exposure to metals. Arch Environ Health 2002;57(1):69-77.

Sauerhoff MW, Braun WH, Blau GE, Gehring PJ. The fate of 2,4-dichlorophenoxyacetic acid (2,4-D) following oral administration to man. Toxicology 1977;8:3-11.

Schaller KH, Manke G, Raithel HJ, Buhlmeyer G, Schmidt M, Valentin H. Investigations of thallium-exposed workers in cement factories. Int Arch Occup Environ Health 1980;47(3):223-31.

Scheepers PT, Coggon D, Knudsen LE, Anzion R, Autrup H, Bogovski S, et al. Biomarkers for occupational diesel exhaust exposure monitoring (BIOMODEM)—a study in underground mining. Toxicol Lett 2002;134(1-3):305-17.

Schettgen T, Heudorf U, Drexler H, Angerer J. Pyrethroid exposure of the general population—is this due to diet? Toxicology Lett 2002a;134(1-3):141-5.

Schettgen T, Koch HM, Drexler H, Angerer J. New gas chromatographic-mass spectrometric method for the determination of urinary pyrethroid metabolites in environmental medicine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2002b;778(1-2):121-30.

Schierl R. Urinary platinum levels associated with dental gold alloys. Arch Environ Health 2001;56(3):283-6.

Schierl R, Fries HG, van de Weyer C, Fruhmann G. Urinary excretion of platinum from platinum-industry workers. Occup Environ Med 1998;55(2):138-4.

Schnorr TM, Lawson CC, Whelan EA, Dankovic DA, Deddens JA, Piacitelli LA, et al. Spontaneous abortion, sex ratio, and paternal occupational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Environ Health Perspect 2001;109(11):1127-32.

Schober SE, Sinks TH, Jones RL, Bolger PM, McDowell M, Osterloh J. Blood mercury levels in US children and women of childbearing age, 1999-2000. JAMA 2003; 289:1667-74.

Schramel P, Wendler I, Angerer J. The determination of metals (antimony, bismuth, lead, cadmium, mercury, palladium, platinum, tellurium, thallium, tin and tungsten) in urine samples by inductively coupled plasma-mass spectrometry. Int Arch Occup Environ Health 1997;69(3):219-23.

Schwartz BS, Lee BK, Lee GS, Stewar WF, Lee SS, Hwang KY, et al. Association of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. Am J Epidemiol 2001;153(5):453-64.

Schwartz J. Lead, blood pressure and cardiovascular disease in men. Arch Environ Health 1995; 50:31-7.

Schwartz J, Landrigan PJ, Baker EL, Orenstein WA, von Lindern IH. Lead induced anemia: dose-response relationships and evidence for a threshold. Am J Public Health 1990;80:165-8.

Seifert B, Becker K, Helm D, Krause C, Schulz C, Seiwert M. The German Environmental Survey 1990/1992 (GerES II): reference concentrations of selected environmental pollutants in blood, urine, hair, house dust, drinking water and indoor air. J Expo Anal Environ Epidemiol 2000;10:552-65.

Selim S, Hartnagel RE Jr, Osimitz TG, Gabriel KL, Schoenig GP. Absorption, metabolism, and excretion of N,N-diethyl-m-toluamide following dermal application to human volunteers. Fundam Appl Toxicol 1995;25:95-100.

Seow A, Shi CY, Franke AA, Hankin JH, Lee H, Yu MC. Isoflavonoid levels in spot urine are associated with frequency of dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore. Cancer Epidemiol Biomarkers Prev 1998;7:135-40.

Serdar B, Waidyanatha S, Zheng Y, Rappaport SM. Simultaneous determination of urinary 1- and 2-naphthols, 3- and 9-phenanthrols, and 1-pyrenol in coke oven workers. Biomarkers 2003*a*;8(2):93-109.

Serdar B, Egeghy PP, Waidyanatha S, Gibson R, Rappaport SM. Urinary biomarkers of exposure to jet fuel (JP-8). Environ Health Perspect 2003*b*;111(14):1760-4.

Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131(4 Suppl):1362S-75S.

Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol—a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132(12):3577-84.

Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999;129(3):758S-67S.

Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 1997;350(9070):23-7.

Shealy DB, Barr JR., Ashley DL, Patterson DG Jr, Camann DE, Bond AE. Correlation of environmental carbaryl measurements with serum and urinary 1-naphthol measurements in a farmer applicator and his family. Environ Health Perspect 1997;105:510-3.

Shealy DB, Bonin MA, Wooten JV, Ashley DL, Needham LL. Application of an improved method for the analysis of pesticides and their metabolites in the urine of farmer

applicators and their families. Environment International 2004; 22:661-75.

Sherlock J, Hislop D, Newton G, Topping G, Whittle K. Elevation of mercury in human blood from controlled ingestion of methyl mercury in fish. Human Toxicology 1984;2:117-31.

Shirakawa T, Kusaka Y, Fujimura N, Goto S, Kato M, Heki S, et al. Occupational asthma from cobalt sensitivity in workers exposed to hard metal dust. Chest 1989;95:29-37.

Sievers E, Schleyerbach U, Schaub J. Molybdenum in infancy: methodical investigation of urinary excretion. J Trace Elem Med Biol 2001;15(2-3):149-54.

Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000 [published erratum appears in Environ Health Perspect 2004; 112(5):A270]. Environ Health Perspect 2004;112(3):331-8.

Simpson GR, Higgins V, Chapman J, Bermingham S. Exposure of council and forestry workers to 2,4,5-T. Med J Aust 1978;18;2(11):536-7.

Siwinska E, Mielzynska D, Bubak A, Smolik E. The effect of coal stoves and environmental tobacco smoke on the level of urinary 1-hydroxypyrene. Mutat Res 1999;445(2):147-53.

Siwinska E, Mielzynska D, Kapka L. Association between urinary 1-hydroxypyrene and genotoxic effects in coke oven workers. Occup Environ Med. 2004;61(3):e10.

Slavin JL, Karr SC, Hutchins AM, Lampe JW. Influence of soybean processing, habitual diet, and soy dose on urinary isoflavonoid excretion. Am J Clin Nutr 1998;68(6 Suppl):1492S-5S.

Smallwood AW, DeBord KE, Lowry LK. N,N'-diethyl-m-toluamide (m-DET): analysis of an insect repellent in human urine and serum by high-performance liquid chromatography. J Anal Toxicol 1992;16(1):10-3.

Smith JC, Allen PV, Turner MD, Most B, Fisher HL, Hall LL. The kinetics of intravenously administered methyl mercury in man. Toxicol Appl Pharmacol 1994;128(2):251-6.

Smith JC, Farris FF. Methyl mercury pharmacokinetics in man: a reevaluation. Toxicol Appl Pharmacol 1996;37:245-52.

Smith PJ, Langolf GD, Goldberg J. Effects of occupational exposure to elemental mercury on short term memory. British Journal of Industrial Medicine 1983;40:413-9.

Smith RG, Vorwald AJ, Patil LS, Mooney TF. Effects of exposure to mercury in the manufacture of chlorine. American Industrial Hygiene Association Journal 1970;31:687-700.

Smith T, Edmonds CJ, Barnaby CF. Absorption and retention of cobalt in man by whole-body counting. Health Phys 1972;22:359-67.

Soderlund DM, Clark JM, Sheets LP, Mullin LS, Piccirillo VJ, Sargent D, et al. Mechanisms of pyrethroid neurotoxicity: implications for cumulative risk assessment. Toxicology 2002;171:3-59.

Soldin OP, Hanak B, Soldin SJ. Blood lead concentrations in children: new ranges. Clin Chim Acta 2003;327:109-13.

Staessen JA, Buchet JP, Ginucchio G, Lauwerys R, Lijnen P, Roels H, et al. Public health implications of environmental exposure to cadmium and lead: an overview of epidemiological studies in Belgium. J Cardiovasc Risk 1996;3:26-41.

Staessen J, Roels HA, Emelianov D, Kuznetsova T, Thijs L, Vangronsveld J, et al. Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study. Lancet 1999;353:1140-4.

Staessen JA, Roels H, Lauwerys RR, Amery A. Low-level lead exposure and blood pressure. J Hum Hypertens 1995;9:303-27.

Stattin P, Adlercreutz H, Tenkanen L, Jellum E, Lumme S, Hallmans G, et al. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 2002;99(1):124-9.

Stehr-Green, PA. Demographic and seasonal influences on human serum pesticide residue levels. J Toxicol Environ Health 1989;27:405-21.

Stern AH, Smith AE. An assessment of the cord blood: maternal blood methyl mercury ratio: implications for risk assessment. Environ Health Perspect 2003;111(12):1465-70.

Strom BL, Schinnar R, Ziegler EE, Barnhart KT, Sammel MD, Macones GA, et al. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. JAMA 2001;286:807-14.

Sturgeon SR, Brock JW, Potischman N, Needham LL, Rothman N, Brinton LA, et al. Serum concentrations of organochlorine compounds and endometrial cancer risk (United States). Cancer Causes Control 1998;9(4):417-24.

SUDAAN User's Manual, Release 8.0, Research Triangle Park (NC): Research Triangle Institute; 2001.

Suwazono Y, Kobayashi E, Okubo Y, Nogawa K, Kido T, Nakagawa H. Renal effects of cadmium exposure in cadmium nonpolluted areas in Japan. Environ Res 2000;84 (Section A):44-55.

Suzuki T, Hongo T, Yoshinaga J, Imai H, Nakazawa M, Matsuo N, et al. The hair-organ relationship in mercury concentration in contemporary Japanese. Arch Environ Health 1993;48(4):221-9.

Swennen B, Buchet JP, Stanescu D, Lison D, Lauwerys R. Epidemiological survey of workers exposed to cobalt oxides, cobalt salts, and cobalt metal. British Journal of Industrial Medicine1993;50(9):835-42.

Szaniszlo J, Ungvary G. Polycyclic aromatic hydrocarbon exposure and burden of outdoor workers in Budapest. J Toxicol Environ Health A 2001;62(5):297-306.

Takahashi W, Parks LH. Organochlorine pesticide residues in human tissues, Hawaii, 1968-1980. Hawaii Med J 1982; 41(9):250-1.

Takamiya K. Monitoring of urinary alkyl phosphates in pest-control operators exposed to various organophosphorus insecticides. Bull Environ Contam Toxicol 1994;52(2):190-5.

Taylor JK. Quality assurance of chemical measurements. Chelsea (MI): Lewis Publishing; 1987.

Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 2001;86(7):3053-60.

Telisman S, Cvitkovic P, Jurasovic J, Pizent A, Gavella M, Rocic B. Semen quality and reproductive endocrine function in relation to biomarkers of lead, cadmium, zinc, and copper in men. Environ Health Perspect. 2000;108(1):45-53.

Tepper A, Burt S, Piacitelli L, Patterson DG Jr. Coplanar PCBs and the relative contribution of coplanar PCBs, PCDDs, and PCDFs to the total 2,3,7,8-TCDD toxicity equivalents in human serum. Chemosphere 1997;35(3):503-11.

Thomas D, Goldhaber M, Petitti D, Swan SH, Rappaport E, Hertz-Picciotto I. Reproductive outcome in women exposed to malathion. Am J Epidemiol 1990;132(4):794-5.

Thomssen H. Hoffmann B. Schank M. Hohler T. Thabe H. Meyer zum Buschenfelde KH, et al. Cobalt-specific T lymphocytes in synovial tissue after an allergic reaction to a cobalt alloy joint prosthesis. J Rheumatol 2001;28(5):1121-8.

Timchalk C, Selim S, Sangha G, Bartels MJ. The pharmacokinetics and metabolism of 14C/13C-labeled ortho-phenylphenol formation following dermal application to human volunteers. Hum Exp Toxicol. 1998;17(8):411-7.

Ting BG, Paschal DC, Jarrett JM, Pirkle JL, Jackson RJ, Sampson EJ, et al. Uranium and thorium in urine of United States residents: reference range concentrations. Environ Res 1999;81:45-51.

Toriba A, Chetiyanukornkul T, Kizu R, Hayakawa K. Quantification of 2-hydroxyfluorene in human urine by

column-switching high performance liquid chromatography with fluorescence detection. Analyst 2003;128(6):605-10.

To-Figueras J, Sala M, Otero R, Barrot C, Santiago-Silva M, Rodamilans M, et al. Metabolism of hexachlorobenzene in humans: association between serum levels and urinary metabolites in a highly exposed population. Environ Health Perspect 1997;105(1):78-83.

Tsai HT, Wu MT, Hauser R, Rodrigues E, Ho CK, Liu CL, et al. Exposure to environmental tobacco smoke and urinary 1-hydroxypyrene levels in preschool children. Kaohsiung J Med Sci 2003;19(3):97-104.

Tsai PJ, Shih TS, Chen HL, Lee WJ, Lai CH, Liou SH. Urinary 1-hydroxypyrene as an indicator for assessing the exposures of booth attendants of a highway toll station to polycyclic aromatic hydrocarbons. Environ Sci Technol 2004;38(1):56-61.

Tsongas TA, Meglen RR, Walravens PA, Chappell WR. Molybdenum in the diet: an estimate of average daily intake in the United States. Am J Clin Nutr 1980;33(5):1103-7.

Tunnessen WW, McMahon KJ, Baser M. Acrodynia: exposure to mercury from fluorescent light bulbs. Pediatrics 1987;79:786-9.

Turnlund JR, Keyes WR, Peiffer GL. Molybdenum absorption, excretion, and retention studied with stable isotopes in young men at five intakes of dietary molybdenum. Am J Clin Nutr 1995;62(4):790-6.

Uehara M, Lapcik O, Hampl R, Al-maharik N, Makela T, Wahala K, et al. Rapid analysis of phytoestrogens in human by time-resolved fluoroimmunoassay. Journal of Steroid Biochemistry and Molecular Biology (Oxford) 2000*b*;72:273-82.

Uehara M, Arai Y, Watanabe S, Adlercreutz H. Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors 2000*a*;12:217-25.

Umweltbundesamt [Federal Environmental Agency]. German Environmental Survey 1998 (GerES III). Federal Ministry for the Environment, Nature Conservation and Nuclear Safety. Germany. 2002 [online]. 2002. Available from URL: http://www.umweltbundesamt.de/survey-e/us98/blut.htm, 02/22/05.

U.S. Department of Health and Human Services (U.S. DHHS). Public Health Service. Subcommittee on Risk Management. Dental amalgam: a scientific review and recommended Public Health Service strategy for research, education, and regulation. Washington (DC): DHHS; January 1993.

U.S. Environmental Protection Agency (U.S. EPA). Deposition of air pollutants to the Great Waters – 3rd Report to Congress,

2000 [online]. Available from URL: http://www.epa.gov/air/oaqps/gr8water/2ndrpt/chap2.pdf, 2/22/05.

U.S. Environmental Protection Agency (U.S. EPA). Hexachlorobenzene health advisory. EPA/820K87110. Washington (DC): U.S. EPA; March 1987.

U. S. Environmental Protection Agency (U.S. EPA). Methyl mercury. Integrated Risk Information System (IRIS). Revised 07/27/2001 [online]. Available from URL: www.epa.gov/iris/subst/0073.htm, 3/03/05.

U. S. Environmental Protection Agency (U.S. EPA). Cadmium compounds . Hazards summary. [online]. 1992. http://www.epa.gov/ttn/atw/hlthef/cadmium.html, 4/26/05.

U.S. Environmental Protection Agency (U.S. EPA). Molybdenum [online]. 1993. Available from URL; http://www.epa.gov/iris/subst/0425.htm, 03/18/05.

U.S. Environmental Protection Agency (U.S. EPA). Nonoccupational Pesticide Exposure Study (NOPES). EPA/600/3-90/003. Washington (DC): U.S. EPA; January 1990.

U.S. Environmental Protection Agency (U.S. EPA). Office of Pesticide Programs. EPA R.E.D. Facts: Alachlor. Washington (DC): U.S. EPA; December 1998.

U.S. Environmental Protection Agency (U.S. EPA). Office of Pesticide Programs. Interim Re-Registration Eligibility Decision: Atrazine. Case No. 0062. Washington (DC): U.S. EPA; January 2003*a*.

U.S. Environmental Protection Agency (U.S. EPA). Office of Prevention, Pesticides and Toxic Substances, EPA Office of Pesticide Programs, Environmental Fate and Effects Division. White paper on potential developmental effects of atrazine on amphibians. Washington (DC): U.S. EPA; May 2003*b*.

U.S. Environmental Protection Agency (U.S. EPA). Office of Pesticide Programs. EPA R.E.D. Facts: Metolachlor. Washington (DC): U.S. EPA; April 1995.

U. S. Environmental Protection Agency (U.S. EPA). Office of Prevention Pesticides and Toxic Substances. Reregistration Eligibility Decision (RED): DEET. EPA 738-R-98-010. Washington (DC): U.S. EPA; September 1998. p. 1-118.

U.S. Environmental Protection Agency (U.S. EPA), Office of Pesticide Programs. Status summary of the organophosphate review process [online]. Available from URL: http://www.epa.gov/pesticides/op/status.htm, 4/8/05.

U. S. Environmental Protection Agency (U.S. EPA). Office of Prevention Pesticides and Toxic Substances. Pesticide industry sales and usage - 2000 and 2001 market estimates. Washington (DC): U.S. EPA; May, 2004 [also online] http://www.epa.gov/oppbead1/pestsales/01pestsales/market_estimates2001.pdf, 5/16/05.

U.S. Geological Survey (U.S.GS). Cadmium. Mineral commodity summary [online]. 2004. Available from URL: http://minerals.usgs.gov/minerals/pubs/commodity/cadmium/cadmimcs04.pdf,03/18/05.

U.S. Nuclear Regulatory Commission (U.S. NRC). U.S. Nuclear Regulatory Commission (NRC) Guide 8.22–Bioassay at uranium mills. Washington (DC): NRC; July 1978.

Vahter M, Mottet NK, Friberg L, Lind B, Shen DD, Burbacher T. Speciation of mercury in the primate blood and brain following long-term exposure to methyl mercury. Tox Appl Pharmacol 1994;124:221-9.

Valentin-Blasini L, Blount B, Caudill S, ,Needham L. Urinary and serum concentrations of seven phytoestrogens in a human reference population subset. J Expos Anal Environ Epidemiol 2003;13:276-82.

Van Oostdam JC, Dewailly E, Gilman A, Hansen JC, Odland JO, Chashchin V, et al. Circumpolar maternal blood contaminant survey, 1994-1997 organochlorine compounds. Sci Total Environ 2004;330:55-70.

van Wijnen JH, Slob R, Jongmans-Liedekerken G, van de Weerdt RH, Woudenberg F. Exposure to polycyclic aromatic hydrocarbons among Dutch children. Environ Health Perspect 1996;104(5):530-4.

Vaughan GT, Florence TM. Platinum in the human diet, blood, hair and excreta. Sci Total Environ 1992;111(1):47-58. Waalkes MP. Cadmium carcinogenesis. Mutat Res 2003;533:107-20.

Waliszewski SM, Pardio VT, Chantiri JN, Infanzon RM, Rivera J. Organochlorine pesticide residues in adipose tissue of Mexicans. Sci Total Environ 1996;181(2):125-31.

Walker KC, Goette MB, Batchelor GS. Pesticide residues in foods: dichlorodiphenyltrichloroethane and dichlorodiphenyldichloroethylene content of prepared meals. J Agric Food Chem 1954;2:1034-7.

Ward EM, Schulte P, Grajewski B, Andersen A, Patterson DG Jr, Turner W, et al. Serum organochlorine levels and breast cancer: a nested case-control study of Norwegian women. Cancer Epidemiol Biomarkers Prev 2000;9:1357-67.

Wariishi M, Suzuki Y, Nishiyama K. Chlordane residues in normal human blood. Bull Environ Contam Toxicol 1986; 36(5):635-43.

Warner M, Eskenazi B, Mocarelli P, Gerthoux PM, Samuels S, Needham, et al. Serum dioxin concentrations and breast cancer risk in the Seveso womens's health study. Environ Health Persp 2002;110(7):625-8.

Werrin M. Chemical food poisoning. Quarterly Bulletin of the Association of Food and Drug Officials 1962; 27:38-45.

Whincup PH, Gilg JA, Emberson JR, Jarvis MJ, Feyerabend C, Bryant A, et al. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ 2004;329(7459):200-5.

White MA, Sabbioni E. Trace element reference values in tissues from inhabitants of the European Union. X. A study of 13 elements in blood and urine of a United Kingdom population. Sci Total Environ 1998;216:253-70.

Whitemore RW, Immerman FW, Camann DE, Bond AE, Lewis RG, Schaum JL. Non-occupational exposures to pesticides for residents of two U.S. cities. Arch Environ Contam Toxicol 1994;26(1):47-59.

Wilhelm M, Ewers U, Schulz C. Revised and new reference values for some persistent organic pollutants (POPs) in blood for human biomonitoring in environmental medicine. Int J Hyg Environ Health 2003;206:223-9.

Wilhelm M, Ewers U, Schulz C. Revised and new reference values for some trace elements in blood and urine for human biomonitoring in environmental medicine. Int J Hyg Environ Health 2004;207(1):69-73.

Williams RL, Bernard CE, Krieger RI. Human exposure to indoor residential cyfluthrin residues during a structured activity program. J Expos Anal Environ Epidemiol 2003;13(2):112-9.

Wilson HK. Related biological monitoring values for occupational exposure: a United Kingdom perspective. Int Arch Occup Environ Health 1999;72(4):274-8.

Wilson NK, Chuang JC, Lyu C, Menton R, Morgan MK. Aggregate exposures of nine preschool children to persistent organic pollutants at day care and at home. J Expo Anal Environ Epidemiol 2003;13(3):187-202.

Wolff MS, Berkowitz GS, Brower S, Senie R, Bleiweiss IJ, Tartter P, et al. Organochlorine exposures and breast cancer risk in New York City women. Environ Res 2000;84:151-61.

Wones RG, Stadler BL, Frohman, LA. Lack of effect of drinking water barium on cardiovascular risk factor. Environ Health Perspect 1990;85:355-9.

World Health Organization (WHO). International Agency for Research on Cancer (IARC). Polychlorinated dibenzo-para-dioxins and dibenzofurans. In: IARC monographs on the evaluation of carcinogenic risk to humans. Vol. 69. Geneva: WHO; 1997.

World Health Organization (WHO). International Programme on Chemical Safety [online]. Available from URL: http://www.inchem.org, 03/18/05.

World Health Organization (WHO). International Programme on Chemical Safety. Environmental Health Criteria 134. [online]. 1992. http://www.inchem.org/documents/ehc/ehc/ehc134.htm .

References

World Health Organization (WHO). Molybdenum. In: Trace elements in human nutrition and health. Geneva: WHO; 1996. p. 144-54.

Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000;9(8):781-6.

Yang M, Kim S, Lee E, Cheong HK, Chang SS, Kang D, et al. Sources of polycyclic aromatic hydrocarbon exposure in non-occupationally exposed Koreans. Environ Mol Mutagen 2003;42(4):250-7.

Yoshida T, Andoh K, Fukuhara M. Urinary 2,5-dichlorophenol as biological index for p-dichlorobenzene exposure in the general population. Arch Environ Contam Toxicol. 2002;43(4):481-5.

Zacharewski TR, Meek MD, Clemons JH, Wu ZF, Fielden MR, Matthews JB. Examination of the in vitro and in vivo estrogenic activities of eight commercial phthalate esters. Toxicological Sci 1998;46:282-93.

Zeitz P, Orr MF, Kaye WE. Public health consequences of mercury spills: hazardous substances emergency events surveillance system, 1993-1998. Environ Health Perspect 2002;110:129-32.

Zhang YL, Zhao YC, Wang JX, Zhu HD, Liu QF, Fan YG, et al. Effect of environmental exposure to cadmium on pregnancy outcome and fetal growth: a study on healthy pregnant women in China. J Environ Sci Health B 2004;39:2507-15.

Zheng W, Dai Q, Custer LJ, Shu XO, Wen WQ, Jin F, et, al. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8(1):35-40.

Zschiesche W, Schaller KH, Weltle D. Exposure to soluble barium compounds: an interventional study in arc welders. Int Arch Occup Environ Health 1992;64(1):13-23.

Appendix A. Limit of Detection Table

The analytical limit of detection (LOD) for each of the different chemical measurements is presented in the table below. The LOD is the level at which the measurement has a 95% probability of being greater than zero (Taylor, 1987). For most chemicals, the LOD is constant for each sample analyzed. However, for dioxins, furans, PCBs, organochlorine pesticides, and some other pesticides, each individual sample has its own LOD. These analyses have an individual LOD for each sample, mostly because the sample volume available for analysis differed for each sample. A higher sample volume results in a lower LOD and a better ability to detect low levels.

For chemicals with sample-specific LODs, we report in the table the maximum LOD among the samples analyzed. In general, the average LOD for these samples is about 40-50% of the maximum LOD. If a geometric mean or percentile estimate is less than the maximum LOD, it is noted in the results tables, and we do not report a number for that estimate. This conservative approach is to assure high confidence in all numbers reported in the results tables.

As analytical methods improve, LODs will often improve. For this reason, LOD results are reported by survey periods (e.g., 1999-2000, 2001-2002). Therefore, it is possible that the same chemical levels may be less than the LOD in 1999-2000 and greater than the LOD in 2001-2002.

Table A1. Limit of Detection for Chemicals Measured in the *Second* and *Third Reports*

Chemical	Matrix	Units	1999-2000	2001-2002
Metals				
Antimony	urine	µg/L	0.04	0.04
Barium	urine	µg/L	0.12	0.12
Beryllium	urine	µg/L	0.13	0.13
Cadmium	whole blood	µg/L	0.3	0.3
Cadmium	urine	µg/L	0.06	0.06
Cesium	urine	µg/L	0.14	0.14
Cobalt	urine	µg/L	0.07	0.07
Lead	whole blood	µg/dL	0.3	0.3
Lead	urine	µg/L	0.1	0.1
Mercury	whole blood	µg/L	0.14	0.14
Mercury	urine	µg/L	0.14	0.14
Molybdenum	urine	µg/L	0.8	0.8
Platinum	urine	µg/L	0.04	0.04
Thallium	urine	µg/L	0.02	0.02
Tungsten	urine	µg/L	0.04	0.04
Uranium	urine	µg/L	0.004	0.004
Tobacco Smoke				
Cotinine	serum	ng/mL	0.05	0.05
Polycyclic Aromatic Hydrocarbons				
1-Hydroxybenz[a]anthracene	urine	ng/L	4.7	3.9
3-Hydroxybenz[a]anthracene and 9-Hydroxybenz[a]anthracene	urine	ng/L	5.4	10.4
1-Hydroxybenzo[c]phenanthrene	urine	ng/L	5.7	3.4
2-Hydroxybenzo[c]phenanthrene	urine	ng/L	6.8	5.4
3-Hydroxybenzo[c]phenanthrene	urine	ng/L	4.9	5.4
1-Hydroxychrysene	urine	ng/L		5
2-Hydroxychrysene	urine	ng/L		5
3-Hydroxychrysene	urine	ng/L	9.9	8.3
4-Hydroxychrysene	urine	ng/L		2.8
6-Hydroxychrysene	urine	ng/L	3.4	2.4
3-Hydroxyfluoranthene	urine	ng/L	3.5	
2-Hydroxyfluorene	urine	ng/L	9.5	3.6
3-Hydroxyfluorene	urine	ng/L	15.1	2
9-Hydroxyfluorene	urine	ng/L		2.8
1-Hydroxyphenanthrene	urine	ng/L	15	3.5
2-Hydroxyphenanthrene	urine	ng/L	11.2	3.2
3-Hydroxyphenanthrene	urine	ng/L	15.3	3.6
4-Hydroxyphenanthrene	urine	ng/L		5.7
9-Hydroxyphenanthrene	urine	ng/L		3.1
1-Hydroxypyrene	urine	ng/L	2	3.3
3-Hydroxybenzo[a]pyrene	urine	ng/L		10.5
1-Hydroxynapthalene	urine	ng/L		6.2
2-Hydroxynapthalene	urine	ng/L		2.4

Chemical	Matrix	Units	1999-2000	2001-2002
Polychlorinated Dibenzo-p-dioxins, Dibenzofurans, Coplanar and Mono-Ortho-Substituted Biphenyls				
1,2,3,4,6,7,8,9-Octachlorodibenzo-*p*-dioxin (OCDD)	serum	pg/g of lipid	329*	319*
1,2,3,4,6,7,8-Heptachlorodibenzo-*p*-dioxin (HpCDD)	serum	pg/g of lipid	55.9*	10.3*
1,2,3,4,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD)	serum	pg/g of lipid		9.00*
1,2,3,6,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD)	serum	pg/g of lipid	20.1*	9.10*
1,2,3,7,8,9-Hexachlorodibenzo-*p*-dioxin (HxCDD)	serum	pg/g of lipid	20.3*	9.30*
1,2,3,7,8-Pentachlorodibenzo-*p*-dioxin (PeCDD)	serum	pg/g of lipid	14.2*	6.00*
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD)	serum	pg/g of lipid	12.1*	5.80*
1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF)	serum	pg/g of lipid	35.6*	21.0*
1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF)	serum	pg/g of lipid	13.5*	7.00*
1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF)	serum	pg/g of lipid		7.00*
1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF)	serum	pg/g of lipid	12.7*	6.50*
1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF)	serum	pg/g of lipid	12.6*	6.10*
1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF)	serum	pg/g of lipid	12.7*	6.00*
1,2,3,7,8-Pentachlorodibenzofuran (PeCDF)	serum	pg/g of lipid	13.2*	5.80*
2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF)	serum	pg/g of lipid	12.9*	5.80*
2,3,4,7,8-Pentachlorodibenzofuran (PeCDF)	serum	pg/g of lipid	12.7*	5.50*
2,3,7,8-Tetrachlorodibenzofuran (TCDF)	serum	pg/g of lipid	11.9*	5.20*
2,4,4'-Trichlorobiphenyl (PCB 28)	serum	ng/g of lipid	32.4*	
2,3',4,4'-Tetrachlorobiphenyl (PCB 66)	serum	ng/g of lipid	12.4*	12.4*
2,4,4',5-Tetrachlorobiphenyl (PCB 74)	serum	ng/g of lipid	12.4*	10.5*
3,4,4',5-Tetrachlorobiphenyl (PCB 81)	serum	pg/g of lipid	68.4*	26.8*
2,3,3',4,4'-Pentachlorobiphenyl (PCB 105)	serum	ng/g of lipid	12.4*	10.5*
2,3',4,4',5-Pentachlorobiphenyl (PCB 118)	serum	ng/g of lipid	12.5*	10.5*
3,3',4,4',5-Pentachlorobiphenyl (PCB 126)	serum	pg/g of lipid	23.2*	10.8*
2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156)	serum	ng/g of lipid	12.5*	10.5*
2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157)	serum	ng/g of lipid	12.5*	10.5*
2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167)	serum	ng/g of lipid	12.4*	10.5*
3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169)	serum	pg/g of lipid	27.0*	11.0*
2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189)	serum	ng/g of lipid		10.5*
Non-dioxin-like Polychlorinated Biphenyls				
2,2',5,5'-Tetrachlorobiphenyl (PCB 52)	serum	ng/g of lipid	12.5*	12.4*
2,2',3,4,5'-Pentachlorobiphenyl (PCB 87)	serum	ng/g of lipid		10.5*
2,2',4,4',5-Pentachlorobiphenyl (PCB 99)	serum	ng/g of lipid	12.5*	10.5*
2,2',4,5,5'-Pentachlorobiphenyl (PCB 101)	serum	ng/g of lipid	25.7*	10.5*
2,3,3',4',6-Pentachlorobiphenyl (PCB 110)	serum	ng/g of lipid		10.5*
2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128)	serum	ng/g of lipid	12.4*	10.5*
2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138&158)	serum	ng/g of lipid	41.1*	10.5*
2,2',3,4,5,5'-Hexachlorobiphenyl (PCB 146)	serum	ng/g of lipid	12.4*	10.5*
2,2',3,4',5',6-Hexachlorobiphenyl (PCB 149)	serum	ng/g of lipid		10.5*
2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151)	serum	ng/g of lipid		10.5*
2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153)	serum	ng/g of lipid	55.6*	10.5*
2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170)	serum	ng/g of lipid	17.2*	10.5*
2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172)	serum	ng/g of lipid	12.5*	10.5*
2,2',3,3',4,5,6'-Heptachlorobiphenyl (PCB 177)	serum	ng/g of lipid	12.5*	10.5*
2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178)	serum	ng/g of lipid	12.4*	10.5*
2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180)	serum	ng/g of lipid	28.2*	10.5*
2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183)	serum	ng/g of lipid	12.4*	10.5*
2,2',3,4,5,5',6-Heptachlorobiphenyl (PCB 187)	serum	ng/g of lipid	12.4*	10.5*
2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194)	serum	ng/g of lipid		10.5*
2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195)	serum	ng/g of lipid		28.1*
2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB196&203)	serum	ng/g of lipid		10.5*
2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199)	serum	ng/g of lipid		10.5*
2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206)	serum	ng/g of lipid		28.1*
Phytoestrogens				
Daidzein	urine	µg/L	0.5	1.6
Enterodiol	urine	µg/L	0.8	1.5
Enterolactone	urine	µg/L	0.6	1.9
Equol	urine	µg/L	3	3.3
Genistein	urine	µg/L	0.3	0.8
O-Desmethylangolensin	urine	µg/L	0.2	0.4

* Maximum LOD. Each person's sample has its own LOD. See text at beginning of Appendix for details.

Chemical	Matrix	Units	1999-2000	2001-2002
Phthalates				
Mono-methyl phthalate	urine	µg/L		0.2
Mono-ethyl phthalate	urine	µg/L	1.2	0.9
Mono-n-butyl phthalate	urine	µg/L	0.9	1.1
Mono-isobutyl phthalate	urine	µg/L		1
Mono-benzyl phthalate	urine	µg/L	0.8	0.3
Mono-cyclohexyl phthalate	urine	µg/L	0.9	0.3
Mono-2-ethylhexyl phthalate	urine	µg/L	1.2	1
Mono-(2-ethyl-5-oxohexyl) phthalate	urine	µg/L		1.1
Mono-(2-ethyl-5-hydroxyhexyl) phthalate	urine	µg/L		1
Mono-n-octyl phthalate	urine	µg/L	0.9	1
Mono-(3-carboxypropyl) phthalate	urine	µg/L		0.4
Mono-isononyl phthalate	urine	µg/L	0.8	0.8
Organochlorine Pesticides				
Hexachlorobenzene	serum	ng/g of lipid	118*	31.4*
Beta-hexachlorocyclohexane	serum	ng/g of lipid	9.36*	6.76*
Gamma-hexachlorocyclohexane	serum	ng/g of lipid	14.5*	10.5*
Pentachlorophenol	urine	µg/L	0.25	0.5
2,4,5-Trichlorophenol	urine	µg/L	0.9	0.9
2,4,6-Trichlorophenol	urine	µg/L	1	1.3
p,p'-DDT	serum	ng/g of lipid	20.7*	17.4*
p,p'-DDE	serum	ng/g of lipid	18.6*	8.3*
o,p'-DDT	serum	ng/g of lipid	20.7*	17.4*
Oxychlordane	serum	ng/g of lipid	14.5*	10.5*
trans-Nonachlor	serum	ng/g of lipid	14.5*	10.5*
Heptachlor Epoxide	serum	ng/g of lipid	14.6*	10.5*
Mirex	serum	ng/g of lipid	14.6*	10.5*
Aldrin	serum	ng/g of lipid		5.94*
Dieldrin	serum	ng/g of lipid		10.5*
Endrin	serum	ng/g of lipid		5.09*
Organophosphate Insecticides: Dialkyl Phosphate Metabolites				
Dimethylphosphate	urine	µg/L	0.58	0.5
Dimethylthiophosphate	urine	µg/L	0.18	0.4
Dimethyldithiophosphate	urine	µg/L	0.08	0.1
Diethylphosphate	urine	µg/L	0.2	0.2
Diethylthiophosphate	urine	µg/L	0.09	0.1
Diethyldithiophosphate	urine	µg/L	0.05	0.1
Organophosphate Insecticides: Specific Metabolites				
Malathion dicarboxylic acid	urine	µg/L	2.64*	
para-Nitrophenol	urine	µg/L	0.80*	0.1
3,5,6-Trichloro-2-pyridinol	urine	µg/L	0.4	0.4
2-Isopropyl-4-methyl-6-hydroxypyrimidine	urine	µg/L	7.21*	0.7
2-(diethylamino)-6-methylpyrimidin-4-ol/one	urine	µg/L		0.2
3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol	urine	µg/L		0.2
Herbicides				
2,4,5-Trichlorophenoxyacetic acid	urine	µg/L	1.20*	0.1
2,4-Dichlorophenoxyacetic acid	urine	µg/L	0.952*	0.2
2,4-Dichlorophenol	urine	µg/L	0.3	0.3
Alachlor mercapturate	urine	µg/L	1.18*	
Atrazine mercapturate	urine	µg/L	0.791*	0.3
Acetochlor mercapturate	urine	µg/L		0.1
Metolachlor mercapturate	urine	µg/L		0.2
Pyrethroid Pesticides				
4-Fluoro-3-phenoxybenzoic acid	urine	µg/L		0.2
Cis-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid	urine	µg/L		0.1
Trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid	urine	µg/L		0.4
Cis-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid	urine	µg/L		0.1
3-Phenoxybenzoic acid	urine	µg/L		0.1
Other Pesticides				
N,N-diethyl-3-methylbenzamide	urine	µg/L	0.449	0.1
ortho-Phenylphenol	urine	µg/L	0.3	0.3
2,5-Dichlorophenol	urine	µg/L	0.1	0.1
Carbamate Pesticides				
2-Isopropoxyphenol	urine	µg/L	1.1	0.4
Carbofuranphenol	urine	µg/L	0.4	0.4

* Maximum LOD. Each person's sample has its own LOD. See text at beginning of Appendix for details.

Appendix B. References for Biomonitoring Analytical Methods

Dioxins, Furans, PCBs, Organochlorine Pesticides

Barr JB, Maggio VL, Barr DB, Turner WE, Sjodin A, Sandau CD, et al. New high-resolution mass spectrometric approach for the measurement of polychlorinated biphenyls and organochlorine pesticides in human serum. J Chromatog B 2003;794:137-48.

Patterson DG Jr., Alexander LR, Turner WE, Isaacs SG, Needham LL. The development and application of a high resolution mass spectrometry method for measuring polychlorinated dibenzo-p-dioxins and dibenzofurans in serum. In: Clement RE, Sui KM, Hill HH Jr., editors. Instrumentation for trace organic monitoring. Chelsea, MI: Lewis Publishers; 1990. p. 119-53.

Patterson DG Jr., Hampton L, Lapeza CR Jr., Belser WT, Green V, Alexander L, et al. High resolution gas chromatographic/high resolution mass spectrometric analysis of human serum on a whole weight and lipid basis for 2,3,7,8 TCDD. Anal Chem 1987;59:2000-5.

Turner WE, DiPietro E, Cash TP, McClure PC, Patterson DG Jr., Shirkhan H. An improved SPE extraction and automated sample cleanup method for serum PCDDs, PCDFs, and coplanar PCBs. Organohalogen Compounds 1994;19:31-5.

Turner WE, DiPietro E, Lapeza CR, Jr., Green V, Gill J, Patterson DG Jr., et al. Universal automated cleanup system for the isotope-dilution high-resolution mass spectrometric analysis of PCDDs, PCDFs, coplanar PCBs, PCB congeners, and persistent pesticides from the same serum sample. Organohalogen Compounds 1997;31:26-31.

Metals

Caldwell KL, Hartel J, Jarrett J, Jones RL. Inductively coupled plasma mass spectrometry to measure multiple toxic elements in urine in NHANES 1999-2000. Atomic Spectroscopy. 2005;26(1):1-7.

Chen HP, Paschal DC, Miller DT, Morrow JC. Determination of total and inorganic mercury in whole blood by on-line digestion with flow injection. Atomic Spectroscopy 1998;19:176-9.

Miller, DT, Paschal DC, Gunter EW, Stroud PE, D'Angelo J. Determination of lead in blood using electrothermal atomization atomic absorption spectrometry with a L'vov platform and matrix modifier. Analyst 1987;112:1701-4.

Paschal DC, Ting BG, Morrow JC, Pirkle JL, Jackson RJ, Sampson EJ, et al. Trace metals in urine of United States residents: reference range concentrations. Environ Res 1998;76:53-9.

Stoeppler M, Brandt K. Determination of cadmium in whole blood and urine by electrothermal atomic-absorption spectrophotometry. Fresnius A Anal Chem 1980;300:372-80.

Pesticide Metabolites

Bravo R, Caltabiano LM, Fernandez C, Smith KD, Gallegos M, Whitehead RD, et al. Quantification of phenolic metabolites of environmental chemicals in human urine using gas chromatography-tandem mass spectrometry and isotope dilution quantification. J Chromatog B. In press 2005. Available online: 26 April 2005, doi:10.1016/j.jchromb.2005.03.012.

Bravo R, Caltabiano LM, Weerasekera G, Whitehead RD, Fernandez C, Needham LL, et al. Measurement of dialkyl phosphate metabolites of organophosphorus pesticides in human urine using lyophilization with gas chromatography-tandem mass spectrometry and isotope dilution quantification. J Expo Anal Environ Epidemiol 2004;14:249-59.

Bravo R, Driskell WJ, Whitehead RD Jr, Needham LL, Barr DB. Quantitation of dialkyl phosphate metabolites of organophosphate pesticides in human urine using GC-MS-MS with isotopic internal standards. J Anal Toxicol 2002;26:245-52.

Hill RH Jr, Shealy DB, Head SL, Williams CC, Bailey SL, Gregg M, et al. Determination of pesticide metabolites in human urine using isotope dilution technique and tandem mass spectrometry. J Anal Toxicol 1995;19(5):323-9.

Olsson AO, Baker SE, Nguyen JV, Romanoff LC, Udunka SO, Walker RD, et al. A liquid chromatography-tandem mass spectrometry multiresidue method for quantification of specific metabolites of organophosphorus pesticides, synthetic pyrethroids, selected herbicides, and DEET in human urine. Anal Chem 2004;76(9):2453-61.

Polycyclic Aromatic Hydrocarbons

Smith CJ, Huang WL, Walcott CJ, Turner WE, Grainger J, Patterson DG Jr. Quantification of monohydroxy-PAH metabolites in urine by solid-phase extraction with isotope dilution GC-HRMS. Analytical and Bioanalytical Chemistry 2002;372:216-20.

Li Z, Romanoff LC, Young KJ, Blakely NC III, Wei RW, Needham LL, et al. Biomonitoring of human exposure to polycyclic aromatic hydrocarbons (PAH) and diesel exhaust by measurement of urinary biomarkers. Epidemiology 2004;15(4):S75.

Phthalate Metabolites

Blount BC, Milgram KE, Silva M, Malek N, Reidy J, Needham LL, et al. Quantitative detection of eight phthalate metabolites in human urine using HPLC-APCI-MS/MS. Anal Chem 2000;72:4127-34.

Silva MJ, Malek NA, Hodge CC, Reidy JA, Kato K, Barr DB, et al. Improved quantitative detection of 11 urinary phthalate metabolites in humans using liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatog B 2003;789:393-404.

Silva MJ, Slakman AR, Reidy JA, Preau JLJ, Herbert AR, Samandar E, et al. Analysis of human urine for 15 phthalate metabolites using automated solid-phase extraction. J Chromatog B 2004;805:161-7.

Phytoestrogens

Valentin-Blasini L, Blount BC, Rogers HS, Needham LL. HPLC-MS/MS method for the measurement of seven phytoestrogens in human serum and urine. J Expo Anal Environ Epidemiol 2000;10:799-807.

Kuklenyik Z, Ye X, Reich JA, Needham LL, Calafat AM. Automated on-line and off-line solid phase extraction methods for measuring isoflavones and lignans in urine. J Chromatogr Sci 2004; 42:495-500.

Tobacco Smoke (Cotinine)

Bernert JT, Turner WE, Pirkle JL, Sosnoff CS, Akins JR, Waldrep MK, et al. Development and validation of a sensitive measurement of serum cotinine in both smokers and nonsmokers by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Clin Chem 1997;43:2281-91.

Bernert JT, McGuffey JE, Morrison MA, Pirkle JL. Comparison of serum and salivary cotinine measurements by a sensitive high-performance liquid chromatography/tandem mass spectrometry method as an indicator of exposure to tobacco smoke among smokers and nonsmokers. J Anal Toxicol 2000;24:333-9.

Appendix C. Confidence Interval Estimation for Percentiles

A common practice to calculate confidence intervals from survey data is to use large-sample normal approximations. Ninety-five percent confidence intervals on point estimates of percentiles are often computed by adding and subtracting from the point estimate a quantity equal to twice its standard error. This normal approximation method may not be adequate, however, when estimating the proportion of subjects above or below a selected value (especially when the proportion is near 0.0 or 1.0 or when the effective sample size is small).

In addition, confidence intervals on proportions deviating from 0.5 are not theoretically expected to be symmetric around the point estimate. Further, adding and subtracting a multiple of the standard error to an estimate near 0.0 or 1.0 can lead to impossible confidence limits (i.e., proportion estimates below 0.0 or above 1.0).

We used the method of Korn and Graubard (1998) to compute Clopper-Pearson 95% confidence intervals about percentile estimates. We describe the method below, using SAS Proc Univariate and SUDAAN. SAS code for calculating these confidence intervals can be downloaded from http://www.cdc.gov/exposurereport.

Procedure to calculate confidence intervals about percentiles

Step 1: Use SAS (SAS Institute Inc., 1999) Proc Univariate to obtain a point estimate of the percentile of a chemical's results for the demographic group of interest (e.g., the 90th percentile of blood lead results for children aged 1-5 years). Use the Freq option to assign the correct sample weight for each chemical result.

Step 2: Use SUDAAN (SUDAAN Users Manual, 2001) Proc Descript with Taylor Linearization DESIGN = WR (i.e., sampling with replacement) and the proper sampling weight to estimate the proportion (p) of subjects with results below the percentile estimate obtained in Step 1 and to obtain the standard error (se_p) associated with this proportion estimate. Compute the degrees-of-freedom adjusted effective sample size

$$n_{df} = ((t_{num}/t_{denom})^2)p(1 - p)/(se_p^2) \tag{1}$$

where t_{num} and t_{denom} are 0.975 critical values of the Student's t distribution with degrees of freedom equal to the sample size minus 1 and the number of PSUs minus the number of strata, respectively. Note: the degrees of freedom for t_{denom} can vary with the demographic sub-group of interest (e.g., males).

Step 3: After obtaining an estimate of p (i.e., the proportion obtained in Step 2), compute the Clopper-Pearson 95% confidence interval ($P_L(x,n_{df})$, $P_U(x,n_{df})$) as follows:

$$P_L(x,n_{df}) = v_1 F_{v1,v2}(0.025)/(v_2 + v_1 F_{v1,v2}(0.025)) \quad \& \quad P_U(x,n_{df}) = v_3 F_{v3,v4}(0.975)/(v_4 + v_3 F_{v3,v4}(0.975)) \tag{2}$$

where x is equal to p times n_{df}, $v_1 = 2x$, $v_2 = 2(n_{df} - x + 1)$, $v_3 = 2(x + 1)$, $v_4 = 2(n_{df} - x)$, and $F_{d1,d2}(\beta)$ is the β quantile of an F distribution with d_1 and d_2 degrees of freedom. (Note: If n_{df} is greater than the actual sample size or if p is equal to zero, then the actual sample size should be used.) This step will produce a lower and an upper limit for the estimated proportion obtained in Step 2.

Step 4: Use SAS Proc Univariate (again using the Freq option to assign weights) to determine the chemical values that correspond to the proportion obtained in Step 2 and the lower and upper limits on this proportion obtained in Step 3.

Example:

To estimate the 75th percentile, use SAS Proc Univariate with the Freq option to get a weighted point estimate of the chemical value that corresponds to the 75th percentile. Then use SUDAAN to estimate the weighted proportion of subjects with results below the 75th percentile (which should be very near 0.75). Next, obtain a confidence interval on this proportion by computing the weighted Clopper-Pearson 95% confidence limits using the degrees-of-freedom adjusted effective sample size. Suppose these confidence limits are 0.67 and 0.81, then use SAS Proc Univariate with the Freq option to determine the chemical values corresponding to the weighted 67th and 81st percentiles. These point estimates are the lower and upper confidence limits on the 75th percentile.

Appendix D. Abbreviations and Acronyms

ACGIH	American Conference of Governmental Industrial Hygienists
ANCOVA	Analysis of covariance
ATSDR	Agency for Toxic Substances and Disease Registry
BAT	Biologischen arbeitsstoff-toleranz [German] or biological tolerance level
BEI	Biological exposure index
BLL	Blood lead level
CAS	Chemical Abstract Service
CDC	Centers for Disease Control and Prevention
CPSC	United States Consumer Product Safety Commission
IARC	International Agency for Research on Cancer
IUPAC	International Union of Pure and Applied Chemistry
LOD	Limit of detection
MSDS	Material Safety Data Sheets
NCEH	National Center for Environmental Health
NCHS	National Center for Health Statistics
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIH	National Institutes of Health
NIOSH	National Institute for Occupational Safety and Health
NTP	National Toxicology Program
OSHA	Occupational Safety and Health Administration
TEF	Toxic equivalency factor
TEQ	Toxic equivalency
TLV	Threshold limit value
USDA	United States Department of Agriculture
U.S. DHHS	United States Department of Health and Human Services
U.S. DOE	United States Department of Energy
U.S. DOT	United States Department of Transportation
U.S. EPA	United States Environmental Protection Agency
U.S. FDA	United States Food and Drug Administration
U.S. HUD	United States Department of Housing and Urban Development
U.S. NRC	United States Nuclear Regulatory Commission
WHO	World Health Organization